Also O
, O
the O
potential O
for O
hepatic O
injury O
should O
be O
considered O
when O
Rebif B-brand
is O
used O
in O
combination O
with O
other O
products O
associated O
with O
hepatic O
injury O
, O
or O
when O
new O
agents O
are O
added O
to O
the O
regimen O
of O
patients O
already O
on O
Rebif B-brand
. O

- O
a O
steroid B-group
medicine I-group
such O
as O
prednisone B-drug
( O
Deltasone B-brand
, O
Orasone B-brand
, O
others O
) O
, O
methylprednisolone B-drug
( O
Medrol B-brand
, O
others O
) O
, O
prednisolone B-drug
( O
Prelone B-brand
, O
Pediapred B-brand
, O
others O
) O
, O
and O
others O
; O

also O
, O
concurrent O
use O
of O
this O
medication O
may O
antagonise O
the O
anti-glaucoma O
and O
miotic O
actions O
of O
ophthalmic O
cholinesterase B-group
inhibitors I-group
. O

If O
any O
signs O
or O
symptoms O
occur O
physicians O
should O
consider O
discontinuation O
of O
either O
one O
or O
both O
agents O
( O
ZYVOX B-brand
or O
concomitant O
serotonergic B-group
agents I-group
) O
. O

This O
time O
window O
is O
different O
than O
for O
other O
oral O
formulations O
of O
ciprofloxacin B-drug
, O
which O
are O
usually O
administered O
2 O
hours O
before O
or O
6 O
hours O
after O
antacids B-group
. O

Lithium B-drug
: O
NSAIDs B-group
have O
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
. O

No O
pharmacokinetic O
data O
are O
available O
. O

pregnancies O
have O
been O
reported O
. O

On O
the O
basis O
of O
the O
estimated O
number O
of O
regular O
users O
of O
intravenous O
amphetamine B-drug
in O
Ontario O
, O
the O
mortality O
rate O
in O
such O
users O
is O
at O
least O
four O
times O
as O
high O
as O
in O
the O
general O
population O
of O
the O
same O
age O
, O
and O
is O
comparable O
to O
that O
in O
alcoholics O
and O
heroin B-drug_n
addicts O
. O

The O
effects O
of O
L-CCG-1 B-drug_n
were O
not O
so O
strong O
. O

A O
400 O
mg O
once-daily O
dose O
was O
not O
studied O
but O
would O
be O
expected O
to O
increase O
aliskiren B-drug
blood O
levels O
further O
. O

SSRIs B-group
: O
Weakness O
hyperreflexia O
, O
and O
incoordination O
have O
been O
reported O
rarely O
when O
5-HT1 B-group
agonists I-group
have O
been O
co-administered O
with O
SSRIs B-group
( O
e. O
g O
. O

Because O
moderate O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
diltiazem B-drug
) O
result O
in O
2-fold O
increase O
in O
plasma O
concentrations O
of O
aprepitant B-drug
, O
concomitant O
administration O
should O
also O
be O
approached O
with O
caution O
. O

Exemestane B-drug
is O
extensively O
metabolized O
by O
CYP O
3A4 O
, O
but O
coadministration O
of O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
CYP O
3A4 O
, O
has O
no O
significant O
effect O
on O
exemestane B-drug
pharmacokinetics O
. O

Phenytoin B-drug
: O
Altered O
serum O
levels O
of O
phenytoin B-drug
( O
increased O
and O
decreased O
) O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
ciprofloxacin B-drug
. O

Since O
iloprost B-drug
inhibits O
platelet O
function O
, O
there O
is O
a O
potential O
for O
increased O
risk O
of O
bleeding O
, O
particularly O
in O
patients O
maintained O
on O
anticoagulants B-group
. O

Therefore O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
loxapine B-drug
and O
CNS-active O
drugs O
is O
required O
. O

Consequently O
, O
drugs O
with O
a O
low O
therapeutic O
margin O
, O
such O
as O
vitamin B-group
K I-group
antagonists I-group
, O
phenytoin B-drug
, O
and O
theophylline B-drug
, O
could O
have O
a O
delayed O
elimination O
and O
increases O
in O
their O
serum O
half-life O
leading O
to O
a O
toxic O
level O
. O

Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O

Phenytoin B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenytoin B-drug
; O

Anticoagulants B-group
: O
Flurbiprofen B-drug
like O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
has O
been O
shown O
to O
affect O
bleeding O
parameters O
in O
patients O
receiving O
anti-coagulants B-group
, O
and O
serious O
clinical O
bleeding O
has O
been O
reported O
. O

propranolol B-drug
to O
healthy O
volunteers O
under O
steady-state O
conditions O
had O
no O
relevant O
effect O
on O
either O
drug O
s O
bioavailability O
, O
AUC O
and O
Cmax O
, O
differences O
were O
20 O
% O
between O
isradipine B-drug
given O
singly O
and O
in O
combination O
with O
propranolol B-drug
, O
and O
between O
propranolol B-drug
given O
singly O
and O
in O
combination O
with O
isradipine B-drug
. O

ocular O
effects O
; O

The O
concomitant O
administration O
of O
bosentan B-drug
and O
cyclosporine B-drug
A I-drug
is O
contraindicated O
. O

This O
oxidation O
, O
which O
is O
catalyzed O
by O
xanthine O
oxidase O
, O
inactivates O
mercaptopurine B-drug
. O

Ethinyl B-drug
estradiol I-drug
: O
Substrate O
of O
CYP3A4 O
( O
major O
) O
, O
3A5-7 O
( O
minor O
) O
; O

4 O
. O

The O
mean O
clearances O
of O
dofetilide B-drug
were O
16 O
% O
and O
15 O
% O
lower O
in O
patients O
on O
thiazide B-group
diuretics I-group
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
respectively O
. O

In O
addition O
, O
levetiracetam B-drug
does O
not O
affect O
the O
in O
vitro O
glucuronidation O
of O
valproic B-drug
acid I-drug
. O

Specifically O
, O
they O
have O
focused O
on O
aspects O
of O
learning O
and O
memory O
that O
are O
impaired O
( O
vs. O
spared O
) O
by O
lesions O
of O
the O
hippocampal O
formation O
. O

The O
concentrations O
of O
SN38 B-drug_n
, O
the O
active O
metabolite O
of O
irinotecan B-drug
, O
were O
on O
average O
33 O
% O
higher O
in O
patients O
receiving O
bolus-IFL O
in O
combination O
with O
AVASTIN B-brand
when O
compared O
with O
bolus-IFL O
alone O
. O

All O
vasopressors B-group
should O
be O
used O
cautiously O
in O
patients O
taking O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
. O

If O
an O
alternative O
treatment O
is O
unavailable O
, O
a O
TARCEVA B-brand
dose O
greater O
than O
150 O
mg O
should O
be O
considered O
for O
NSCLC O
patients O
, O
and O
greater O
than O
100 O
mg O
considered O
for O
pancreatic O
cancer O
patients O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues I-group
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

Check O
serum O
potassium O
levels O
at O
frequent O
intervals O
; O

Twenty-four O
healthy O
male O
subjects O
were O
randomized O
to O
one O
of O
two O
cohorts O
. O

Androgens B-group
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O

The O
serum O
concentration O
of O
phenytoin B-drug
increased O
dramatically O
from O
16.6 O
to O
49.1 O
microg/mL O
when O
fluvoxamine B-drug
was O
coadministered O
, O
although O
the O
daily O
dosage O
of O
phenytoin B-drug
and O
other O
drugs B-drug
had O
not O
changed O
. O

Acetazolamide B-drug
may O
increase O
the O
effects O
of O
other O
folic B-group
acid I-group
antagonists I-group
. O

If O
replacing O
clonidine B-drug
by O
beta-blocker B-group
therapy O
, O
the O
introduction O
of O
beta B-group
blockers I-group
should O
be O
delayed O
for O
several O
days O
after O
clonidine B-drug
administration O
has O
stopped O
. O

Grapefruit O
juice O
Co-administration O
of O
felodipine B-drug
with O
grapefruit O
juice O
resulted O
in O
more O
than O
2-fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
but O
no O
prolongation O
in O
the O
half- O
life O
of O
felodipine B-drug
. O

Renal O
clearance O
measurements O
of O
PAH B-drug
can O
not O
be O
made O
with O
any O
significant O
accuracy O
in O
patients O
receiving O
sulfonamides B-group
, O
procaine B-drug
, O
or O
thiazolesulfone B-drug
. O

Co-administration O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
3A4 O
( O
e.g. O
, O
indinavir B-drug
, O
erythromycin B-drug
) O
may O
increase O
their O
clearance O
, O
resulting O
in O
decreased O
plasma O
concentration O
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
As O
a O
result O
of O
administration O
of O
Keflex B-brand
, O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O

Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-group
channel I-group
blockers I-group
and O
organic O
nitrates B-group
were O
used O
in O
combination O
. O

There O
were O
no O
clinically O
relevant O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

MAO B-group
inhibitors I-group
: O
MAOI B-group
antidepressants I-group
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-drug
, O
slow O
amphetamine B-group
metabolism O
. O

A O
host O
of O
other O
medical O
considerations O
are O
discussed O
in O
chapter O
8 O
, O
including O
persistent O
ovarian O
follicles O
; O

Aprepitant B-drug
increased O
the O
AUC O
of O
midazolam B-drug
by O
25 O
% O
on O
Day O
4 O
and O
decreased O
the O
AUC O
of O
midazolam B-drug
by O
19 O
% O
on O
Day O
8 O
relative O
to O
the O
dosing O
of O
Aprepitant B-drug
on O
Days O
1 O
through O
3 O
. O

1 O
. O

Drug O
Interactions O
: O
a O
. O
Drugs O
Enhancing O
Heparin B-drug
Effect O
: O
Oral O
anticoagulants B-group
: O
Heparin B-drug
sodium I-drug
may O
prolong O
the O
one-stage O
prothrombin O
time O
. O

Seventeen O
percent O
of O
CHOP-HAART O
patients O
developed O
severe O
autonomic O
neurotoxicity O
, O
whereas O
none O
of O
the O
CHOP O
patients O
developed O
neurotoxicity O
( O
P O
= O
0.002 O
) O
. O

metabolic O
interference O
has O
sometimes O
been O
observed O
and O
the O
behaviour O
of O
the O
biological O
indicators O
differs O
from O
what O
would O
be O
expected O
. O

The O
different O
responses O
in O
locomotor O
activity O
induced O
by O
cocaine B-drug
suggest O
that O
genetic O
factors O
may O
play O
a O
role O
in O
determining O
the O
magnitude O
of O
response O
to O
this O
drug O
. O

Acetylcysteine B-drug
interference O
with O
urine O
ketone O
test O
. O

Patients O
with O
renal O
insufficiency O
or O
renal O
failure O
may O
be O
at O
risk O
for O
further O
kidney O
damage O
as O
well O
as O
complications O
related O
to O
interactions O
of O
herbal O
remedies O
with O
complex O
renal O
therapy O
regimens O
. O

nitrosourea B-group
AUC O
, O
with O
the O
extent O
of O
the O
reduction O
depending O
on O
the O
minimum O
effective O
concentration O
( O
MEC O
) O
chosen O
. O

Probenecid B-drug
: O
Probenecid B-drug
interferes O
with O
renal O
tubular O
secretion O
of O
ciprofloxacin B-drug
and O
produces O
an O
increase O
in O
the O
level O
of O
ciprofloxacin B-drug
in O
serum O
. O

Cholinesterase B-group
Inhibitors I-group
: O
Dipyridamole B-drug
may O
counteract O
the O
anticholinesterase O
effect O
of O
cholinesterase B-group
inhibitors I-group
, O
thereby O
potentially O
aggravating O
myasthenia O
gravis O
. O

At O
steady O
state O
, O
VIOXX B-brand
50 O
mg O
once O
daily O
had O
no O
effect O
on O
the O
anti-platelet O
activity O
of O
low-dose O
( O
81 O
mg O
once O
daily O
) O
aspirin B-brand
, O
as O
assessed O
by O
ex O
vivo O
platelet O
aggregation O
and O
serum O
TXB2 O
generation O
in O
clotting O
blood O
. O

Cardiovascular O
: O
Hypotension O
( O
0-9 O
% O
) O
. O

antihistamines B-group
; O

No O
significant O
drug-drug O
pharmacokinetic O
( O
or O
pharmacodynamic O
) O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
and O
nifedipine B-drug
. O

WelChol B-brand
decreased O
the O
Cmax O
and O
AUC O
of O
sustained-release O
verapamil B-drug
( O
Calan B-brand
SR I-brand
) O
by O
approximately O
31 O
% O
and O
11 O
% O
, O
respectively O
. O

Pharmacokinetic O
profile O
of O
etodolac B-drug
in O
special O
populations O
. O

- O
Lithium B-drug
: O
Lithium B-drug
should O
generally O
not O
be O
given O
with O
diuretics B-group
( O
such O
as O
bumetanide B-drug
) O
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Alternatives O
to O
clarithromycin B-drug
, O
such O
as O
azithromycin B-drug
, O
should O
be O
considered O
. O

Administration O
of O
eplerenone B-drug
with O
other O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
erythromycin B-drug
500 O
mg O
BID O
, O
verapamil B-drug
240 O
mg O
QD O
, O
saquinavir B-drug
1200 O
mg O
TID O
, O
fluconazole B-drug
200 O
mg O
QD O
) O
resulted O
in O
increases O
in O
Cmax O
of O
eplerenone B-drug
ranging O
from O
1.4- O
to O
1.6- O
fold O
and O
AUC O
from O
2.0- O
to O
2.9- O
fold O
. O

These O
alterations O
in O
digoxin B-drug
pharmacokinetics O
produced O
by O
amiodarone B-drug
explain O
the O
increase O
in O
serum O
digoxin B-drug
level O
that O
has O
been O
observed O
when O
this O
drug O
combination O
has O
been O
used O
clinically O
. O

co-administration O
of O
phenobarbital B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

Carbamazepine B-drug
: O
Steady-state O
trough O
plasma O
carbamazepine B-drug
and O
carbamazepine B-drug_n
10 I-drug_n
, I-drug_n
11 I-drug_n
epoxide I-drug_n
concentrations O
were O
not O
affected O
by O
concomitant O
gabapentin B-drug
( O
400 O
mg O
TID O
; O

Restoration O
of O
female O
fertility O
to O
values O
similar O
to O
controls O
was O
evident O
following O
a O
29-day O
withdrawal O
period O
after O
dosing O
at O
2 O
mg/kg/day O
( O
twice O
the O
human O
dose O
based O
on O
BSA O
) O
. O

Cardiac B-group
glycosides I-group
could O
exaggerate O
the O
depression O
of O
AV O
nodal O
conduction O
observed O
with O
bepridil B-drug
hydrochloride I-drug
. O

The O
harmonic O
mean O
elimination O
half-life O
was O
45.7 O
and O
43.4 O
hours O
for O
rofecoxib B-drug
+ O
digoxin B-drug
and O
placebo O
+ O
digoxin B-drug
treatments O
, O
respectively O
. O

Most O
who O
take O
EPA B-drug
supplements O
and O
the O
above O
drugs O
or O
herbs O
do O
not O
suffer O
from O
these O
problems O
and O
if O
they O
occur O
, O
they O
are O
rare O
. O

Rifampin B-drug
: O
Coadministration O
of O
rifampin B-drug
and O
VIRACEPT B-brand
resulted O
in O
an O
82 O
% O
decrease O
in O
nelfinavir B-drug
plasma O
A.C O
. O

Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
two O
drugs O
are O
given O
concomitantly O
. O

and O
overdose O
. O

Tadalafil B-drug
dose O
should O
not O
exceed O
a O
maximum O
of O
10 O
mg O
in O
a O
72- O
hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-drug
therapy O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
be O
used O
. O

The O
uptake O
inhibitors O
cocaine B-drug
and O
desipramine B-drug
( O
3 O
mumol/liter O
) O
potentiated O
the O
positive O
inotropic O
effects O
of O
norepinephrine B-drug
in O
nonfailing O
myocardium O
( O
p O
< O
0.05 O
) O
but O
not O
in O
functional O
class O
IV O
myocardium O
. O

In O
clinical O
studies O
performed O
with O
Fondaparinux B-drug
, O
the O
concomitant O
use O
of O
oral O
anticoagulants B-group
( O
warfarin B-drug
) O
, O
platelet B-group
inhibitors I-group
( O
acetylsalicylic B-drug
acid I-drug
) O
, O
NSAIDs B-group
( O
piroxicam B-drug
) O
, O
and O
digoxin B-drug
did O
not O
significantly O
affect O
the O
pharmacokinetics/pharmacodynamics O
of O
fondaparinux B-drug
sodium I-drug
. O

The O
half-life O
of O
ketamine B-drug
in O
plasma O
and O
brain O
was O
longer O
in O
the O
presence O
of O
halothane B-drug
than O
when O
ketamine B-drug
was O
given O
alone O
. O

Tacrolimus B-drug
: O
Co-administration O
of O
tacrolimus B-drug
and O
bosentan B-drug
has O
not O
been O
studied O
in O
man O
. O

Animal O
studies O
indicate O
that O
dobutamine B-drug
may O
be O
ineffective O
if O
the O
patient O
has O
recently O
received O
a O
b-blocking B-group
drug I-group
. O

Avoid O
dong O
quai O
and O
black O
cohosh O
( O
have O
estrogen O
activity O
) O
. O

Administration O
of O
reserpine B-drug
during O
therapy O
with O
a O
tricyclic B-group
antidepressant I-group
has O
been O
shown O
to O
produce O
a O
stimulating O
effect O
in O
some O
depressed O
patients O
. O

Nonetheless O
, O
they O
have O
been O
observed O
with O
macrolide B-group
products I-group
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
with O
CRIXIVAN B-brand


Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-group
with O
potent O
diuretics B-group
such O
as O
furosemide B-drug
. O

Drug/Laboratory O
Interactions O
No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Campath B-brand
. O

Drug O
interaction O
studies O
were O
performed O
with O
azithromycin B-drug
and O
other O
drugs O
likely O
to O
be O
co-administered O
. O

No O
dosage O
adjustment O
of O
either O
drug O
is O
recommended O
when O
azithromycin B-drug
is O
co O
administered O
with O
any O
of O
the O
above O
agents O
. O

Naproxen B-drug
, O
naproxen B-drug
sodium I-drug
and O
other O
NSAIDs B-group
have O
been O
reported O
to O
reduce O
the O
tubular O
secretion O
of O
methotrexate B-drug
in O
an O
animal O
model O
, O
possibly O
increasing O
the O
toxicity O
of O
methotrexate B-drug
. O

Adrenergic B-group
blockers I-group
: O
Adrenergic B-group
blockers I-group
are O
inhibited O
by O
amphetamines B-group
. O

+109 O
% O

Warfarin B-drug
: O
A O
single O
125-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
to O
healthy O
subjects O
who O
were O
stabilized O
on O
chronic O
warfarin B-drug
therapy O
. O

RESULTS O
: O
Bombesin B-drug_n
significantly O
increased O
the O
incidence O
of O
intestinal O
tumors O
and O
cancer O
metastasis O
to O
the O
peritoneum O
. O

The O
gastrointestinal O
absorption O
of O
digoxin B-drug
also O
appears O
to O
be O
inhibited O
. O

. O

The O
physician O
should O
be O
cautious O
when O
administering O
flurbiprofen B-drug
to O
patients O
taking O
anticoagulants B-group
. O

Interactions O
may O
occur O
with O
the O
following O
: O
adrenocorticoids O
( O
cortisone-like O
medicine O
) O
, O
anticoagulants B-group
( O
blood B-group
thinners O
) O
, O
carbamazepine B-drug
, O
corticotropin B-drug
( O
barbiturates B-group
may O
decrease O
the O
effects O
of O
these O
medicines O
) O
, O
central B-group
nervous I-group
system I-group
( I-group
CNS I-group
) I-group
depressants I-group
( O
using O
these O
medicines O
with O
barbiturates B-group
may O
result O
in O
increased O
CNS O
depressant O
effects O
) O
, O
divalproex B-drug
sodium I-drug
, O
valproic B-drug
acid I-drug
( O
using O
these O
medicines O
with O
barbiturates B-group
may O
change O
the O
amount O
of O
either O
medicine O
that O
you O
need O
to O
take O
) O
, O
and O
oral O
contraceptives B-group
containing O
estrogens B-group
( O
barbiturates B-group
may O
decrease O
the O
effectiveness O
of O
these O
oral O
contraceptives B-group
, O
and O
you O
may O
need O
to O
change O
to O
a O
different O
type O
of O
birth O
control O
) O
. O


Other O
CNS B-group
depressant I-group
drugs I-group
( O
e.g O
. O
barbiturates B-group
, O
tranquilizers B-group
, O
opioids B-group
and O
general O
anesthetics B-group
) O
have O
additive O
or O
potentiating O
effects O
with O
INAPSINE B-brand
. O

Because O
of O
the O
small O
effect O
on O
half-life O
, O
the O
coadministration O
with O
probenecid B-drug
to O
extend O
the O
half-life O
of O
ertapenem B-drug
is O
not O
recommended O
. O

[ O
The O
effect O
of O
sandimmune B-brand
on O
the O
activity O
of O
mixed-function O
mono-oxidases O
in O
the O
liver O
microsomes O
] O
The O
effects O
of O
the O
immunodepressant B-group
-- O
the O
drug O
sandimmune B-brand
-- O
on O
hepatic O
microsomal O
monooxygenase O
activities O
were O
studied O
. O

In O
large O
, O
well O
controlled O
trials O
in O
patients O
with O
schizophrenia O
or O
related O
psychoses O
, O
olanzapine B-drug
5 O
to O
20 O
mg/day O
was O
significantly O
superior O
to O
haloperidol B-drug
5 O
to O
20 O
mg/day O
in O
overall O
improvements O
in O
psychopathology O
rating O
scales O
and O
in O
the O
treatment O
of O
depressive O
and O
negative O
symptoms O
, O
and O
was O
comparable O
in O
effects O
on O
positive O
psychotic O
symptoms O
. O

In O
vitro O
studies O
have O
shown O
that O
the O
metabolism O
of O
docetaxel B-drug
may O
be O
modified O
by O
the O
concomitant O
administration O
of O
compounds O
that O
induce O
, O
inhibit O
, O
or O
are O
metabolized O
by O
cytochrome O
P450 O
3A4 O
, O
such O
as O
cyclosporine B-drug
, O
terfenadine B-drug
, O
ketoconazole B-drug
, O
erythromycin B-drug
, O
and O
troleandomycin B-drug
. O

Maximal O
exercise O
testing O
, O
a O
maneuver O
often O
applied O
to O
cardiac O
patients O
, O
does O
not O
significantly O
alter O
the O
serum O
digoxin B-drug
level O
. O

Potential O
interactions O
between O
TAXOL B-brand
, O
a O
substrate O
of O
CYP3A4 O
, O
and O
protease B-group
inhibitors I-group
( O
ritonavir B-drug
, O
saquinavir B-drug
, O
indinavir B-drug
, O
and O
nelfinavir B-drug
) O
, O
which O
are O
substrates O
and/or O
inhibitors O
of O
CYP3A4 O
, O
have O
not O
been O
evaluated O
in O
clinical O
trials O
. O

( O
41 O
) O
but O
returned O
to O
normal O
levels O
when O
the O
nerves O
were O
rewarmed O
. O

Animal O
experience O
indicates O
that O
clorazepate B-drug
dipotassium I-drug
prolongs O
the O
sleeping O
time O
after O
hexobarbital B-drug
or O
after O
ethyl B-drug
alcohol I-drug
, O
increases O
the O
inhibitory O
effects O
of O
chlorpromazine B-drug
, O
but O
does O
not O
exhibit O
monoamine O
oxidase O
inhibition O
. O

and O
calcium B-group
channel I-group
antagonists I-group
e.g. O
, O
verapamil B-drug
) O
, O
CYP1A2 O
inducers O
( O
omeprazole B-drug
) O
and O
CYP1A2 O
inhibitors O
( O
furafylline B-drug
and O
clarithromycin B-drug
) O
. O

Digoxin B-drug
and O
verapamil B-drug
use O
may O
be O
rarely O
associated O
with O
ventricular O
fibrillation O
when O
combined O
with O
Adenocard B-brand
. O

Nelfinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
increased O
by O
12 O
% O
, O
15 O
% O
, O
and O
14 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O


Phase O
II O
clinical O
trial O
data O
, O
where O
IRESSA B-brand
and O
vinorelbine B-drug
have O
been O
used O
concomitantly O
, O
indicate O
that O
IRESSA B-brand
may O
exacerbate O
the O
neutropenic O
effect O
of O
vinorelbine B-drug
. O

Weak O
inhibitory O
effects O
toward O
other O
isoforms O
( O
CYP2C8 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
) O
were O
found O
, O
but O
Ki O
values O
were O
in O
excess O
of O
plasma O
concentrations O
achieved O
following O
dosing O
. O

- O
Drugs O
that O
may O
decrease O
plasma O
phenytoin B-drug
concentrations O
include O
: O
carbamazepine B-drug
, O
chronic O
alcohol B-drug
abuse O
, O
reserpine B-drug

The O
majority O
of O
patients O
in O
RA O
clinical O
studies O
received O
one O
or O
more O
of O
the O
following O
concomitant O
medications O
with O
ORENCIA B-brand
: O
MTX B-drug
, O
NSAIDs B-group
, O
corticosteroids B-group
, O
TNF B-group
blocking I-group
agents I-group
, O
azathioprine B-drug
, O
chloroquine B-drug
, O
gold B-drug
, O
hydroxychloroquine B-drug
, O
leflunomide B-drug
, O
sulfasalazine B-drug
, O
and O
anakinra B-drug
. O

Indinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
decreased O
by O
22 O
% O
, O
38 O
% O
, O
and O
27 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O

In O
contrast O
, O
the O
potency O
of O
norepinephrine B-drug
was O
increased O
in O
failing O
hearts O
( O
New O
York O
Heart O
Association O
functional O
class O
IV O
) O
in O
relation O
to O
the O
concentrations O
producing O
50 O
% O
of O
the O
maximal O
effect O
( O
EC50 O
) O
. O

No O
clinically O
significant O
adverse O
interactions O
with O
commonly O
used O
preanesthetic O
drugs O
, O
or O
drugs O
used O
during O
anesthesia O
( O
muscle B-group
relaxants I-group
, O
intravenous O
agents O
, O
and O
local O
anesthetic B-group
agents I-group
) O
were O
reported O
in O
clinical O
trials O
. O

Monitor O
prothrombin O
levels O
and O
adjust O
anticoagulant B-group
dosage O
accordingly O
. O

Further O
, O
if O
guanfacine B-drug
is O
to O
be O
discontinued O
in O
such O
patients O
, O
careful O
tapering O
of O
the O
dosage O
may O
be O
necessary O
in O
order O
to O
avoid O
rebound O
phenomena O
. O

Activation O
of O
an O
effector O
immediate-early O
gene O
arc O
by O
methamphetamine B-drug
. O

CYP450 O
Metabolized O
Drugs O
Results O
from O
in O
vitro O
and O
in O
vivo O
studies O
suggest O
that O
enfuvirtide B-drug
is O
unlikely O
to O
have O
significant O
drug O
interactions O
with O
concomitantly O
administered O
drugs O
metabolized O
by O
CYP450 O
enzymes O
. O

The O
antihypertensive O
effects O
of O
methyldopa B-drug
, O
mecamylamine B-drug
, O
reserpine B-drug
, O
and O
veratrum B-drug
alkaloids I-drug
may O
be O
reduced O
by O
sympathomimetics B-group
. O

The O
clinical O
relevance O
of O
these O
increases O
is O
not O
known O
. O

Omeprazole B-drug
should O
be O
taken O
as O
directed O
and O
Proquin B-brand
XR I-brand
should O
be O
taken O
with O
a O
main O
meal O
of O
the O
day O
, O
preferably O
the O
evening O
meal.. O

Certain O
drugs O
, O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
NSAIDs B-group
) O
, O
salicylates B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
non-selective B-group
beta-adrenergic-blocking I-group
agents I-group
may O
potentiate O
the O
hypoglycemic O
action O
of O
Starlix B-brand
and O
other O
oral O
antidiabetic B-group
drugs I-group
. O

Corticosteroids B-group
: O
Concomitant O
administration O
with O
aspirin B-brand
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
and O
may O
reduce O
serum O
salicylate O
levels O
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Concomitant O
treatment O
with O
potassium-sparing B-group
diuretics I-group
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O

Valproate B-drug
500 O
mg O
twice O
daily O
did O
not O
modify O
the O
rate O
or O
extent O
of O
levetiracetam B-drug
absorption O
or O
its O
plasma O
clearance O
or O
urinary O
excretion O
. O

However O
, O
in O
a O
follow-up O
study O
in O
normal O
subjects O
, O
single-dose O
administration O
of O
colestipol B-drug
hydrochloride I-drug
and O
propranolol B-drug
and O
twice-a-day O
administration O
for O
5 O
days O
of O
both O
agents O
did O
not O
affect O
the O
extent O
of O
propranolol B-drug
absorption O
, O
but O
had O
a O
small O
yet O
statistically O
significant O
effect O
on O
its O
rate O
of O
absorption O
; O

Sexual O
intercourse O
with O
a O
steady O
partner O
causes O
no O
more O
cardiovascular O
risk O
than O
normal O
daily O
activities O
such O
as O
ironing O
, O
2 O
kilometers O
of O
walking O
without O
climbing O
, O
paperhanging O
, O
playing O
golf O
or O
gardening O
. O

Probenecid B-drug
may O
decrease O
renal O
tubular O
secretion O
of O
cephalosporins B-group
when O
used O
concurrently O
, O
resulting O
in O
increased O
and O
more O
prolonged O
cephalosporin B-group
blood O
levels O
. O

Warfarin B-drug
: O
In O
subjects O
receiving O
warfarin B-drug
, O
no O
significant O
change O
in O
clotting O
time O
was O
observed O
when O
grepafloxacin B-drug
was O
coadministered O
. O

Bismuth B-drug
: O
Bismuth B-drug
subsalicylate I-drug
, O
given O
concomitantly O
with O
enoxacin B-drug
or O
60 O
minutes O
following O
enoxacin B-drug
administration O
, O
decreased O
enoxacin B-drug
bioavailability O
by O
approximately O
25 O
% O
. O

hepatotoxic O
drugs O
; O

For O
the O
calcium-entry B-group
blocking I-group
agents I-group
now O
available O
in O
the O
United O
States O
( O
verapamil B-drug
, O
nifedipine B-drug
and O
diltiazem B-drug
) O
, O
these O
data O
appeared O
well O
after O
clinical O
patterns O
of O
use O
evolved O
. O

However O
, O
prudent O
evaluation O
of O
individual O
cases O
is O
warranted O
in O
the O
clinical O
setting O
. O

When O
used O
concurrently O
with O
such O
drugs O
, O
the O
dose O
of O
butorphanol B-drug
should O
be O
the O
smallest O
effective O
dose O
and O
the O
frequency O
of O
dosing O
reduced O
as O
much O
as O
possible O
when O
administered O
concomitantly O
with O
drugs O
that O
potentiate O
the O
action O
of O
opioids B-group
. O

Most O
events O
were O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
within O
4 O
weeks O
after O
the O
last O
dose O
of O
interleukin-2 B-drug
. O

Cimetidine B-drug
: O
Cimetidine B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
fosfomycin B-drug
when O
coadministered O
with O
MONUROL B-brand
. O

C57BL/6N O
demonstrated O
large O
numbers O
of O
two O
of O
the O
three O
types O
of O
liver O
tumors O
seen O
in O
livers O
of O
genetically O
predisposed O
mice O
, O
one O
of O
which O
required O
the O
additional O
stimulus O
of O
dietary O
phenobarbital B-drug
for O
growth O
. O

May O
interact O
with O
thyroid O
medication O
( O
e.g. O
, O
levothyroxine B-drug
) O
, O
iodine-containing B-drug
products O
, O
antacids B-group
, O
H2-antagonists B-group
( O
e.g. O
, O
famotidine B-drug
, O
ranitidine B-drug
) O
, O
and O
proton B-group
pump I-group
inhibitors I-group
( O
e.g. O
, O
lansoprazole B-drug
, O
omeprazole B-drug
) O
. O

Photic O
evoked O
potentials O
were O
recorded O
from O
the O
visual O
cortex O
of O
chronically O
implanted O
albino O
rats O
. O

SETTING O
: O
Clinical O
research O
center O
. O

Concomitant O
medications O
were O
grouped O
as O
ACE B-group
inhibitors I-group
, O
oral O
anticoagulants B-group
, O
calcium B-group
channel I-group
blockers I-group
, O
beta B-group
blockers I-group
, O
cardiac B-group
glycosides I-group
, O
inducers O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
P-glycoprotein O
, O
nitrates B-group
, O
sulphonylureas B-group
, O
loop B-group
diuretics I-group
, O
potassium B-group
sparing I-group
diuretics I-group
, O
thiazide B-group
diuretics I-group
, O
substrates O
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
and O
QTc-prolonging O
drugs O
. O

Recombinant O
shuttle O
vectors O
containing O
a O
vanH O
promoter-vanA O
antisense O
gene O
cassette O
fully O
restored O
vancomycin B-drug
susceptibility O
through O
a O
combined O
transcriptional O
activator O
binding O
domain O
decoy O
and O
inducible O
vanA O
antisense O
RNA O
effect O
. O

3 O
. O

A O
single O
tonic O
convulsion O
was O
seen O
in O
each O
of O
2 O
male O
dogs O
( O
one O
treated O
at O
10 O
mg/kg/day O
and O
one O
at O
120 O
mg/kg/day O
) O
in O
a O
2-year O
study O
. O

+82 O
% O

Gemfibrozil B-drug
Other O
fibrates B-group
Niacin B-drug
( O
nicotinic B-drug
acid I-drug
) O
( O
=1 O
g/day O
) O

Angiomax B-brand
does O
not O
exhibit O
binding O
to O
plasma O
proteins O
( O
other O
than O
thrombin O
) O
or O
red O
blood O
cells O
. O

therefore O
, O
doses O
greater O
than O
the O
normal O
antiasthmatic O
dose O
of O
beta-agonist B-group
bronchodilator I-group
drugs I-group
may O
be O
required O
. O

Co-administration O
of O
ketoconazole B-drug
, O
a O
strong O
inhibitor O
of O
CYP3A4 O
, O
increased O
cinacalcet B-drug
exposure O
following O
a O
single O
90 O
mg O
dose O
of O
Sensipar B-brand
by O
2.3 O
fold O
. O

If O
resumed O
during O
captopril B-drug
therapy O
, O
such O
agents O
should O
be O
administered O
cautiously O
, O
and O
perhaps O
at O
lower O
dosage O
. O

allopurinol B-drug
; O

Certain O
antibiotic B-group
, O
cisplatin B-drug
, O
cyclosporine B-drug
, O
diuretic B-group
, O
foscarnet B-drug
, O
and O
vaccines B-group
. O

With O
some O
agents O
, O
the O
metabolism O
may O
be O
induced O
, O
resulting O
in O
decreased O
concentrations O
. O

Beta-blockers B-group
, O
clonidine B-drug
, O
lithium B-drug
salts O
, O
and O
alcohol B-drug
may O
either O
potentiate O
or O
weaken O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
. O

Antimicrobial O
activity O
of O
Ganoderma B-drug_n
lucidum I-drug_n
extract I-drug_n
alone O
and O
in O
combination O
with O
some O
antibiotics B-group
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

Due O
to O
the O
possibility O
of O
antagonism O
in O
vivo O
, O
particularly O
when O
bactericidal O
activity O
is O
desired O
, O
this O
drug O
combination O
should O
be O
avoided O
. O

If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
should O
be O
reduced O
and O
the O
patient O
should O
be O
observed O
closely O
for O
several O
hours O
following O
an O
initial O
dose O
and O
until O
blood O
pressure O
has O
stabilized O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Cyclosporin B-drug
: O
Reports O
indicate O
that O
cyclosporine B-drug
levels O
may O
be O
increased O
during O
concomitant O
treatment O
with O
allopurinol B-drug
sodium I-drug
for O
injection O
. O

Adequate O
monitoring O
of O
theophylline B-drug
plasma O
concentrations O
should O
be O
considered O
when O
therapy O
with O
VIOXX B-brand
is O
initiated O
or O
changed O
in O
patients O
receiving O
theophylline B-drug
. O

If O
midazolam B-drug
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O

The O
effect O
of O
Keppra B-brand
on O
probenecid B-drug
was O
not O
studied O
. O

Lopinavir/ritonavir B-drug

It O
is O
structurally O
distinct O
from O
the O
other O
currently O
available O
HMGCoA B-group
reductase I-group
inhibitors I-group
( O
lovastatin B-drug
, O
simvastatin B-drug
, O
and O
pravastatin B-drug
) O
, O
leading O
to O
unique O
biopharmaceutical O
properties O
relative O
to O
the O
other O
agents O
of O
this O
class O
. O

Digoxin B-drug
: O
In O
patients O
with O
hypercholesterolemia O
, O
concomitant O
administration O
of O
lovastatin B-drug
and O
digoxin B-drug
resulted O
in O
no O
effect O
on O
digoxin B-drug
plasma O
concentrations O
. O

There O
have O
been O
isolated O
reports O
of O
patients O
experiencing O
increases O
in O
their O
prothrombin O
times O
when O
etidronate B-drug
was O
added O
to O
warfarin B-drug
therapy O
. O

ulcerans O
infection O
. O

isoflurane B-drug
; O

INDOCIN B-brand
has O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-drug
and O
to O
potentiate O
its O
toxicity O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O

The O
behavioral O
changes O
of O
mice O
induced O
by O
acute O
and O
repeated O
i.p O
. O

An O
intravenous O
injection O
of O
perchlorate B-drug_n
given O
later O
also O
produces O
a O
complete O
and O
immediately O
beginning O
depletion O
of O
pertechnetate B-drug
already O
accumulated O
in O
the O
thyroid O
, O
within O
a O
period O
of O
195 O
min O
after O
99m-TcO-4-injection O
with O
a O
corresponding O
increase O
in O
blood O
levels O
. O

The O
development O
of O
clinical O
vancomycin-resistant O
strains O
of O
enterococci O
( O
VRE O
) O
is O
a O
major O
cause O
for O
concern O
. O

In O
human O
heart O
failure O
, O
there O
is O
a O
presynaptic O
defect O
in O
the O
sympathetic O
nervous O
system O
, O
leading O
to O
reduced O
uptake-1 O
activity O
. O

Administering O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
together O
with O
RR B-drug_n
( O
100-500 O
microM O
) O
inhibited O
InsP O
( O
3 O
) O
-induced O
responses O
( O
both O
Ca O
( O
2+ O
) O
and O
current O
responses O
) O
in O
a O
dose-dependent O
fashion O
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
metabolized O
by O
one O
( O
or O
more O
) O
of O
these O
enzymes O
. O

Seizure O
, O
associated O
with O
increased O
lidocaine B-drug
concentrations O
, O
has O
been O
reported O
with O
concomitant O
administration O
of O
intravenous O
amiodarone B-drug
. O

Evaluation O
of O
its O
efficacy O
and O
toxicity O
. O

Azithromycin B-drug
did O
not O
affect O
the O
prothrombin O
time O
response O
to O
a O
single O
dose O
of O
warfarin B-drug
. O

Preliminary O
investigations O
indicate O
that O
icodextrin B-drug
and O
its O
metabolites O
interfere O
with O
enzymatic-based O
amylase O
assays O
, O
resulting O
in O
inaccurately O
low O
values O
. O

Drugs O
That O
Inhibit O
CYP3A4 O
CYP3A4 O
is O
a O
minor O
metabolic O
pathway O
for O
the O
elimination O
of O
zaleplon B-drug
because O
the O
sum O
of O
desethylzaleplon O
( O
formed O
via O
CYP3A4 O
in O
vitro O
) O
and O
its O
metabolites O
, O
5-oxo-desethylzaleplon B-drug_n
and O
5-oxo-desethylzaleplon B-drug_n
glucuronide I-drug_n
, O
account O
for O
only O
9 O
% O
of O
the O
urinary O
recovery O
of O
a O
zaleplon B-drug
dose O
. O

Blood O
samples O
also O
were O
taken O
before O
morning O
doses O
on O
the O
3rd O
, O
4th O
, O
and O
5th O
days O
of O
phases O
1 O
and O
3 O
. O

Elevated O
International O
Normalized O
Ratio O
and O
Potential O
Bleeding O
International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and O
infrequent O
reports O
of O
bleeding O
events O
including O
gastrointestinal O
and O
non-gastrointestinal O
bleedings O
have O
been O
reported O
in O
clinical O
studies O
, O
some O
associated O
with O
concomitant O
warfarin B-drug
administration O
. O

Cimetidine B-drug
has O
been O
shown O
to O
increase O
the O
bioavailability O
of O
labetalol B-drug
HCl I-drug
. O

indomethacin B-drug
; O

- O
In O
isolated O
cases O
, O
a O
pronounced O
though O
reversible O
, O
impairment O
of O
renal O
function O
( O
accompanied O
by O
a O
corresponding O
increase O
in O
the O
serum O
creatinine O
level O
) O
has O
been O
reported O
in O
organ O
transplant O
patients O
receiving O
immuno-suppressant B-group
therapy O
and O
concomitant O
bezafibrate B-drug
. O

Methadonea O

Patients O
taking O
disopyramide B-drug
phosphate I-drug
and O
hepatic O
enzyme O
inhibitors O
concomitantly O
should O
be O
closely O
monitored O
. O

Observe O
the O
patient O
for O
possible O
diminished O
effect O
of O
steroid B-group
and O
increase O
the O
steroid B-group
dosage O
accordingly O
. O

This O
defect O
is O
not O
related O
to O
acute O
insulin O
release O
or O
the O
presence O
of O
glucose B-drug
. O

In O
vitro O
studies O
have O
demonstrated O
that O
efavirenz B-drug
inhibits O
2C9 O
, O
2C19 O
, O
and O
3A4 O
isozymes O
in O
the O
range O
of O
observed O
efavirenz B-drug
plasma O
concentrations O
. O

At O
a O
higher O
dose O
and O
a O
shorter O
withdrawal O
period O
( O
20 O
mg/kg O
, O
daily O
for O
7 O
days O
followed O
by O
a O
3-day O
withdrawal O
) O
, O
the O
SST O
mice O
showed O
behavioral O
sensitization O
similar O
to O
the O
RBC O
mice O
, O
but O
the O
LST O
mice O
did O
not O
develop O
sensitization O
. O

the O
fourth O
group O
served O
as O
control O
and O
received O
an O
equivalent O
volume O
of O
an O
isocaloric O
solution O
of O
dextrose B-drug
. O

When O
the O
dose O
of O
picrotoxin B-drug_n
is O
minimized O
to O
0.5 O
mg/kg O
such O
an O
effect O
is O
not O
observed O
. O

They O
should O
be O
observed O
closely O
, O
particularly O
if O
renal O
function O
is O
impaired O
. O

In O
addition O
, O
the O
frequency O
of O
monitoring O
serum O
lithium B-drug
concentration O
should O
be O
increased O
at O
the O
outset O
of O
such O
combination O
drug O
treatment O
. O


Dose-response O
curves O
( O
derived O
from O
the O
results O
of O
using O
the O
tablets O
as O
well O
as O
pure O
powders O
) O
showed O
that O
tripelennamine B-drug
was O
responsible O
for O
the O
inhibitory O
activity O
, O
which O
was O
partially O
antagonized O
by O
pentazocine B-drug
. O

When O
CANCIDAS B-brand
is O
co-administered O
with O
inducers O
of O
drug O
clearance O
, O
such O
as O
efavirenz B-drug
, O
nevirapine B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
or O
carbamazepine B-drug
, O
use O
of O
a O
daily O
dose O
of O
70 O
mg O
of O
CANCIDAS B-brand
should O
be O
considered O

Antidiabetics B-group
: O
Because O
corticosteroids B-group
may O
increase O
blood O
glucose O
concentrations O
, O
dosage O
adjustments O
of O
antidiabetic B-group
agents I-group
may O
be O
required O
. O

Sulfapyridine B-drug
may O
interact O
with O
any O
of O
the O
following O
: O
- O
Acetaminophen B-drug
( O
e.g. O
, O
Tylenol B-brand
) O
( O
with O
long-term O
, O
high-dose O
use O
) O
or O

Patients O
receiving O
beta-blockers B-group
should O
be O
warned O
of O
this O
potential O
hazard O
. O

Diltiazem B-drug
is O
both O
a O
substrate O
and O
an O
inhibitor O
of O
the O
cytochrome O
P-450 O
3A4 O
enzyme O
system O
. O

Recommendations O
were O
to O
avoid O
administration O
of O
diffusible O
anti-helminthic B-group
treatment O
during O
the O
cure O
, O
and O
to O
improve O
the O
general O
conditions O
of O
patients O
before O
the O
cure O
of O
melarsoprol B-drug
. O

Estrogen-containing B-group
therapies O
should O
not O
be O
used O
with O
ARIMIDEX B-brand
as O
they O
may O
diminish O
its O
pharmacologic O
action O
. O

If O
CEFOTAN B-brand
and O
an O
aminoglycoside B-group
are O
used O
concomitantly O
, O
renal O
function O
should O
be O
carefully O
monitored O
, O
because O
nephrotoxicity O
may O
be O
potentiated O
. O

Anticoagulants B-group
: O
Coagulation O
parameters O
should O
be O
tested O
more O
frequently O
and O
monitored O
regularly O
during O
simultaneous O
administration O
of O
high O
doses O
of O
heparin B-drug
, O
oral O
anticoagulants B-group
, O
or O
other O
drugs O
that O
may O
affect O
the O
blood O
coagulation O
system O
or O
the O
thrombocyte O
function O
. O

Amprenavir B-drug
significantly O
increased O
the O
area O
under O
the O
curve O
at O
steady O
state O
( O
AUC O
( O
ss O
) O
) O
of O
rifabutin B-drug
by O
2.93-fold O
and O
the O
AUC O
( O
ss O
) O
of O
25-O-desacetylrifabutin B-drug_n
by O
13.3-fold O
. O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

The O
concomitant O
administration O
of O
Exjade B-brand
and O
aluminum-containing B-drug
antacid B-group
preparations I-group
has O
not O
been O
formally O
studied O
. O

Clinical O
experience O
in O
the O
concurrent O
administration O
of O
ECT O
and O
antidepressant B-group
drugs I-group
is O
limited O
. O

Pharmacokinetic O
Interaction O
between O
amprenavir B-drug
and O
rifabutin B-drug
or O
rifampin B-drug
in O
healthy O
males O
. O

Therefore O
, O
we O
investigated O
the O
effects O
of O
biocytin O
inclusion O
on O
opioid B-group
responses O
and O
other O
membrane O
properties O
during O
whole-cell O
, O
tight O
seal O
recordings O
of O
these O
neurons O
. O

Probenecid B-drug
: O
May O
decrease O
renal O
tubular O
secretion O
of O
ampicillin B-drug
resulting O
in O
increased O
blood O
levels O
and/or O
ampicillin B-drug
toxicity O
. O

Tricyclic B-group
antidepressants I-group
may O
potentiate O
the O
cardiovascular O
effects O
of O
adreneric O
agents O
. O

4 O
. O

Many O
drugs O
used O
in O
dentistry O
can O
not O
be O
taken O
concomitantly O
with O
these O
medications O
. O

Fluvastatin B-drug
is O
the O
first O
synthetic B-group
3-hydroxy-3-methylglutaryl I-group
coenzyme I-group
A I-group
( I-group
HMGCoA I-group
) I-group
reductase I-group
inhibitor I-group
to O
be O
approved O
for O
clinical O
use O
, O
and O
has O
been O
studied O
extensively O
in O
humans O
since O
1986 O
. O

Endogenous O
respiration O
was O
unaffected O
by O
the O
drug O
at O
a O
concentration O
as O
high O
as O
100 O
mug/ml O
, O
whereas O
exogenous O
respiration O
was O
markedly O
sensitive O
and O
inhibited O
to O
an O
extent O
of O
85 O
% O
. O

Nonsteroidal B-group
Anti-Inflammatory I-group
Drugs I-group
: O
The O
administration O
of O
diflunisal B-drug
to O
normal O
volunteers O
receiving O
indomethacin B-drug
decreased O
the O
renal O
clearance O
and O
significantly O
increased O
the O
plasma O
levels O
of O
indomethacin B-drug
. O

Analgesic/anti-inflammatory B-group
( O
e.g. O
, O
acetaminophen B-drug
, O
aspirin B-brand
, O
codeine B-drug
and O
codeine B-drug
combinations O
, O
ibuprofen B-drug
, O
indomethacin B-drug
) O
. O

Drugs O
which O
induce O
CYP3A4 O
activity O
( O
eg O
, O
phenobarbital B-drug
, O
rifampin B-drug
, O
rifabutin B-drug
) O
would O
be O
expected O
to O
increase O
the O
clearance O
of O
efavirenz B-drug
resulting O
in O
lowered O
plasma O
concentrations O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
digoxin B-drug
increases O
the O
serum O
digoxin B-drug
concentration O
by O
70 O
% O
after O
one O
day O
. O

Haloperidol B-drug
reduced O
or O
eliminated O
the O
increases O
in O
FI O
responding O
produced O
by O
intermediate O
doses O
of O
either O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
in O
pigeons O
, O
but O
did O
not O
antagonize O
the O
decreases O
in O
FI O
or O
FR O
responding O
produced O
by O
high O
doses O
of O
PCP O
or O
either O
stereoisomer O
of O
NANM B-drug_n
. O

WelChol B-brand
has O
been O
studied O
in O
several O
human O
drug O
interaction O
studies O
in O
which O
it O
was O
administered O
with O
a O
meal O
and O
the O
test O
drug O
. O

Propoxyphene B-drug
: O
In O
cases O
of O
propoxyphene B-drug
overdosage O
, O
amphetamine B-group
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O

No O
drug O
interaction O
studies O
have O
been O
conducted O
for O
COLAZAL B-brand
, O
however O
the O
use O
of O
orally O
administered O
antibiotics B-group
could O
, O
theoretically O
, O
interfere O
with O
the O
release O
of O
mesalamine B-drug
in O
the O
colon O
. O

T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O

Local O
and O
some O
general O
anesthetics B-group
, O
antiarrhythmic B-group
agents I-group
and O
other O
drugs O
that O
interfere O
with O
neuromuscular O
transmission O
should O
be O
used O
cautiously O
, O
if O
at O
all O
, O
in O
patients O
with O
myasthenia O
gravis O
; O

The O
clinical O
significance O
of O
this O
finding O
is O
not O
clear O
. O

If O
intravenous O
pentamidine B-drug
is O
required O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
, O
treatment O
with O
HIVID B-drug
should O
be O
interrupted O
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
block O
morphine-induced B-drug
and O
nicotine-induced B-drug
dopamine O
release O
in O
the O
nucleus O
accumbens O
; O

Tetracyclines B-group
: O
Since O
both O
acitretin B-drug
and O
tetracyclines B-group
can O
cause O
increased O
intracranial O
pressure O
, O
their O
combined O
use O
is O
contraindicated O
. O

In O
vitro O
, O
buspirone B-drug
may O
displace O
less O
firmly O
bound O
drugs O
like O
digoxin B-drug
. O

Death O
in O
amphetamine B-drug
users O
: O
causes O
and O
rates O
. O

The O
following O
drug O
interactions O
have O
been O
reported O
with O
erythromycin B-drug
products O
. O

The O
goal O
of O
enhancing O
selective O
tumor O
cell O
killing O
relative O
to O
the O
normal O
cells O
that O
are O
dose O
limiting O
may O
be O
achieved O
either O
by O
overcoming O
tumor O
cell O
resistance O
or O
by O
protecting O
normal O
cells O
. O

this O
phenomenon O
was O
not O
observed O
in O
North O
American O
clinical O
trials O
. O

Acetazolamide B-drug
reduces O
urinary O
excretion O
of O
quinidine B-drug
and O
may O
enhance O
its O
effect O
. O

Agents O
that O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Fondaparinux B-drug
therapy O
. O

The O
absorption O
of O
lymecycline B-drug
may O
be O
affected O
by O
the O
simultaneous O
administration O
of O
indigestion O
remedies O
, O
iron B-drug
or O
zinc B-drug
supplements O
. O

RESULTS O
: O
Sildenafil B-drug
has O
demonstrated O
effectiveness O
in O
men O
with O
erectile O
dysfunction O
associated O
with O
prostatectomy O
, O
radiation O
therapy O
, O
diabetes O
mellitus O
, O
certain O
neurologic O
disorders O
, O
and O
drug O
therapy O
( O
eg O
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
[ O
SSRIs B-group
] O
) O
. O

Beta-Blockers B-group
: O
In O
controlled O
clinical O
studies O
, O
adrenergic B-group
beta-receptor I-group
blockers I-group
have O
been O
frequently O
administered O
concomitantly O
with O
nicardipine B-drug
HCl I-drug
. O

Metoprolol B-drug
- O
Administration O
of O
20 O
mg/day O
LEXAPRO B-brand
for O
21 O
days O
in O
healthy O
volunteers O
resulted O
in O
a O
50 O
% O
increase O
in O
Cmax O
and O
82 O
% O
increase O
in O
AUC O
of O
the O
beta-adrenergic B-group
blocker I-group
metoprolol B-drug
( O
given O
in O
a O
single O
dose O
of O
100 O
mg O
) O
. O

Histamine B-group
H2-receptor I-group
antagonists I-group
: O
Histamine B-group
H2-receptor I-group
antagonists I-group
appear O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
ciprofloxacin B-drug
. O

( O
200 O
mg O
Q12h O
) O

Usually O
, O
such O
inactivation O
of O
the O
aminoglycoside B-group
is O
clinically O
significant O
only O
in O
patients O
with O
severely O
impaired O
renal O
function.. O

Liver O
Function O
Tests O
: O
Elevations O
of O
AST O
( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O
or O
LDH O
were O
experienced O
by O
approximately O
1 O
in O
3 O
patients O
treated O
with O
Soriatane B-brand
. O

Phenytoin B-drug

Concomitant O
administration O
of O
Robinul B-brand
Injection O
and O
potassium B-drug
chloride I-drug
in O
a O
wax O
matrix O
may O
increase O
the O
severity O
of O
potassium O
chloride-induced O
gastrointestinal O
lesions O
as O
a O
result O
of O
a O
slower O
gastrointestinal O
transit O
time O
. O

There O
are O
no O
significant O
effects O
on O
cefdinir B-drug
pharmacokinetics O
if O
the O
antacid B-group
is O
administered O
2 O
hours O
before O
or O
2 O
hours O
after O
cefdinir B-drug
. O

Acarbose B-drug
has O
been O
shown O
to O
change O
the O
bioavailabillty O
digoxin B-drug
when O
they O
are O
co-administered O
, O
which O
may O
require O
digoxin B-drug
dose O
adjustment O
. O

In O
such O
cases O
, O
the O
unbound O
( O
free O
) O
hormone O
should O
be O
measured O
. O

- O
Procainamide B-drug
( O
e.g. O
, O
Pronestyl B-brand
) O
or O

4 O
microg O
mL O
( O
-1 O
) O
in O
the O
presence O
of O
galangin B-drug
( O
12.5 O
microg O
mL O
( O
-1 O
) O
) O
or O
3,7-dihydroxyflavone O
( O
6.25 O
microg O
mL O
( O
-1 O
) O
) O
. O

Aspirin B-brand
: O
CELEBREX B-brand
can O
be O
used O
with O
low O
dose O
aspirin B-brand
. O

however O
, O
no O
deleterious O
interactions O
were O
seen O
when O
ROMAZICON B-brand
was O
administered O
after O
narcotics B-group
, O
inhalational O
anesthetics B-group
, O
muscle B-group
relaxants I-group
and O
muscle O
relaxant O
antagonists O
administered O
in O
conjunction O
with O
sedation O
or O
anesthesia O
. O

Opioid B-group
analgesics I-group
Decreased O
antinociceptive O
action O

Both O
digoxin B-drug
and O
COREG B-brand
slow O
AV O
conduction O
. O

Patients O
with O
HACA O
titers O
may O
have O
allergic O
or O
hypersensitivity O
reactions O
when O
treated O
with O
other O
diagnostic B-group
or O
therapeutic B-group
monoclonal I-group
antibodies I-group
. O

Acute O
dosing O
with O
clozapine B-drug
failed O
to O
alter O
the O
behavioral O
effects O
of O
PCP B-drug_n
in O
either O
procedure O
even O
when O
tested O
up O
to O
doses O
that O
produced O
pharmacological O
effects O
alone O
. O

Pharmacodynamic O
Interactions O
: O
The O
CNS-depressant O
action O
of O
the O
benzodiazepine B-group
class I-group
of O
drugs O
may O
be O
potentiated O
by O
alcohol B-drug
, O
narcotics B-group
, O
barbiturates B-group
, O
nonbarbiturate B-group
hypnotics I-group
, O
antianxiety B-group
agents I-group
, O
the O
phenothiazines O
, O
thioxanthene O
and O
butyrophenone B-group
classes I-group
of I-group
antipsychotic I-group
agents I-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
and O
the O
tricyclic B-group
antidepressants I-group
, O
and O
by O
other O
anticonvulsant B-group
drugs I-group
. O

Massive O
seizures O
may O
be O
encountered O
with O
this O
combination O
. O

This O
article O
reviews O
the O
impact O
of O
renal O
disease O
on O
the O
pharmacokinetics O
of O
cardiovascular O
drugs O
and O
identifies O
clinically O
important O
interactions O
between O
these O
and O
other O
drugs O
commonly O
used O
in O
the O
management O
of O
chronic O
renal O
disease O
. O

In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-group
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-drug
requirements O
. O

Some O
early O
studies O
indicated O
that O
EPA B-drug
supplements O
might O
have O
detrimental O
effects O
in O
those O
groups O
. O

Exacerbation O
or O
the O
initial O
presentation O
of O
a O
number O
of O
autoimmune O
and O
inflammatory O
disorders O
has O
been O
observed O
following O
concurrent O
use O
of O
interferon-alfa B-drug
and O
PROLEUKIN B-brand
, O
including O
crescentic O
IgA O
glomerulonephritis O
, O
oculo-bulbar O
myasthenia O
gravis O
, O
inflammatory O
arthritis O
, O
thyroiditis O
, O
bullous O
pemphigoid O
, O
and O
Stevens-Johnson O
syndrome O
. O

3 O
. O

In O
female O
rats O
, O
fulvestrant B-drug
administered O
at O
doses O
0.01 O
mg/kg/day O
( O
approximately O
one-hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
, O
for O
2 O
weeks O
prior O
to O
and O
for O
1 O
week O
following O
mating O
, O
caused O
a O
reduction O
in O
fertility O
and O
embryonic O
survival O
. O

indinavir I-drug
concentration O

DOXIL B-brand
may O
interact O
with O
drugs O
known O
to O
interact O
with O
the O
conventional O
formulation O
of O
doxorubicin B-drug
HCl I-drug
. O

Ethosuximide B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
ethosuximide B-drug
. O

In O
situations O
in O
which O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O

This O
interference O
has O
resulted O
in O
significant O
increases O
in O
half-life O
and O
AUC O
. O

suppression O
of O
midcycle O
gonadotropin O
peaks O
; O

However O
, O
caution O
should O
be O
used O
when O
administering O
CELEBREX B-brand
with O
warfarin B-drug
since O
these O
patients O
are O
at O
increased O
risk O
of O
bleeding O
complications O
. O

Gentamicin B-drug
- O
Methionine B-drug
may O
protect O
against O
the O
ototoxic O
effects O
of O
gentamicin B-drug
. O

Atracurium B-drug
was O
again O
given O
by O
infusion O
to O
maintain O
40 O
% O
twitch O
for O
a O
second O
hour O
, O
then O
2 O
mg O
gentamycin/kg B-drug
bwt O
were O
given O
i.v O
. O

conversely O
, O
diethylpropion B-drug
may O
interfere O
with O
antihypertensive B-group
drugs I-group
( O
i.e. O
, O
guanethidine B-drug
, O
a-methyldopa B-drug
) O
. O

Co-treatment O
with O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-drug
increases O
erlotinib B-drug
AUC O
by O
2/3 O
. O

Platelet B-group
inhibitors I-group
: O
Drugs O
such O
as O
acetylsalicylic B-drug
acid I-drug
, O
dextran B-drug
, O
phenylbutazone B-drug
, O
ibuprofen B-drug
, O
indomethacin B-drug
, O
dipyridamole B-drug
, O
hydroxychloroquine B-drug
and O
others O
that O
interfere O
with O
platelet-aggregation O
reactions O
( O
the O
main O
hemostatic O
defense O
of O
heparinized O
patients O
) O
may O
induce O
bleeding O
and O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
heparin B-drug
sodium I-drug
. O

It O
is O
not O
known O
whether O
the O
concurrent O
use O
of O
these O
agents O
with O
apraclonidine B-drug
can O
lead O
to O
a O
reduction O
in O
IOP O
lowering O
effect O
. O

The O
approach O
is O
applicable O
across O
a O
wide O
variety O
of O
settings O
commonly O
associated O
with O
joint O
action O
data O
, O
including O
continuous O
and O
discrete O
responses O
, O
alternative O
error O
structures O
, O
and O
nonzero O
background O
response O
. O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

Methotrexate B-drug
: O
Ibuprofen B-drug
, O
as O
well O
as O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
probably O
reduces O
the O
tubular O
secretion O
of O
methotrexate B-drug
based O
on O
in O
vitro O
studies O
in O
rabbit O
kidney O
slices O
. O

Inducers O
of O
CYP3A4 O

Because O
of O
the O
potential O
for O
additive O
or O
synergistic O
depressant O
effects O
on O
the O
SA O
and O
AV O
nodes O
, O
however O
, O
Adenocard B-brand
should O
be O
used O
with O
caution O
in O
the O
presence O
of O
these O
agents O
. O

Food O
: O
Isoniazid B-drug
should O
not O
be O
administered O
with O
food O
. O

Postoperatively O
, O
45 O
patients O
were O
randomly O
assigned O
in O
a O
double-blind O
fashion O
to O
receive O
ADL B-drug
8-2698 I-drug
( O
4 O
mg O
) O
or O
placebo O
and O
intravenous O
morphine B-drug
( O
0.15 O
mg/kg O
) O
or O
to O
receive O
oral O
and O
intravenous O
placebo O
. O

No O
information O
available O
. O

An O
increased O
incidence O
of O
benign O
ovarian O
granulosa O
cell O
tumors O
and O
testicular O
Leydig O
cell O
tumors O
was O
evident O
, O
in O
females O
dosed O
at O
10 O
mg/rat/15 O
days O
and O
males O
dosed O
at O
15 O
mg/rat/30 O
days O
, O
respectively O
. O

Behavioral O
responses O
to O
repeated O
cocaine B-drug
exposure O
in O
mice O
selectively O
bred O
for O
differential O
sensitivity O
to O
pentobarbital B-drug
. O

Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-drug
, O
dextromethorphan B-drug
, O
the O
tricyclic B-group
antidepressants I-group
, O
and O
clozapine B-drug
. O

Steady-state O
plasma O
felbamate B-drug
concentrations O
were O
found O
to O
be O
29 O
% O
lower O
than O
the O
mean O
concentrations O
of O
a O
group O
of O
newly O
diagnosed O
subjects O
with O
epilepsy O
also O
receiving O
2400 O
mg O
of O
felbamate B-drug
a O
day O
. O

Cevimeline B-drug
should O
be O
used O
with O
caution O
in O
individuals O
known O
or O
suspected O
to O
be O
deficient O
in O
CYP2D6 O
activity O
, O
based O
on O
previous O
experience O
, O
as O
they O
may O
be O
at O
a O
higher O
risk O
of O
adverse O
events O
. O

see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Dasatinib B-drug
and O
its O
metabolites O
are O
minimally O
excreted O
via O
the O
kidney O
. O

Other O
CYP3A4 O
inducers O
include O
, O
but O
are O
not O
limited O
to O
, O
rifabutin B-drug
, O
rifapentine B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
and O
St. O
Johns O
Wort O
. O

. O

Co-medications O
that O
induce O
CYP O
3A4 O
( O
e.g. O
, O
rifampicin B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
, O
or O
St. O
John O
s O
wort O
) O
may O
significantly O
decrease O
exposure O
to O
exemestane B-drug
. O

Among O
the O
risk O
factors O
studied O
, O
two O
appear O
to O
increase O
the O
risk O
of O
ARE O
: O
the O
prescription O
of O
thiabendazole B-drug
to O
treat O
strongyloidiasis O
during O
the O
melarsoprol B-drug
cure O
and O
the O
bad O
general O
clinical O
conditions O
of O
patients O
. O

The O
effects O
of O
nonbenzodiazepine O
agonists O
at O
benzodiazepine O
receptors O
, O
such O
as O
zopiclone B-drug
, O
triazolopyridazines O
and O
others O
, O
are O
also O
blocked O
by O
ROMAZICON B-brand
. O

. O

When O
administered O
with O
food O
or O
milk O
, O
there O
is O
more O
rapid O
absorption O
; O

Read O
circulars O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O

indinavir I-drug
concentration O

= O
decrease O

No O
change O
in O
dose O
of O
either O
drug O
is O
recommended O
. O

INH B-drug
( O
Isoniazid B-drug
) O
is O
also O
reported O
to O
affect O
ketoconazole B-drug
concentrations O
adversely O
. O

In O
vitro O
studies O
demonstrated O
that O
the O
plasma O
protein O
binding O
of O
des-ciclesonide B-drug
was O
not O
affected O
by O
warfarin B-drug
or O
salicylic B-drug
acid I-drug
, O
indicating O
no O
potential O
for O
protein O
binding-based O
drug O
interactions O
. O

The O
following O
drug O
interactions O
have O
been O
identified O
involving O
NIZORAL B-brand
Tablets O
and O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
: O
Ketoconazole B-drug
tablets O
inhibit O
the O
metabolism O
of O
terfenadine B-drug
, O
resulting O
in O
an O
increased O
plasma O
concentration O
of O
terfenadine B-drug
and O
a O
delay O
in O
the O
elimination O
of O
its O
acid O
metabolite O
. O

Cmax O
and O
t1/2 O
were O
increased O
1.4-fold O
and O
1.3-fold O
, O
respectively O
. O


Pharmacokinetic O
interactions O
between O
nisoldipine B-drug
and O
beta-blockers B-group
( O
atenolol B-drug
, O
propranolol B-drug
) O
were O
variable O
and O
not O
significant O
. O

Theophylline-related B-drug
adverse O
effects O
have O
occurred O
in O
patients O
when O
theophylline B-drug
and O
enoxacin B-drug
were O
coadministered O
. O


Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Example O
inhibitors O
include O
azole B-group
antifungals I-group
, O
ciprofloxacin B-drug
, O
clarithromycin B-drug
, O
diclofenac B-drug
, O
doxycycline B-drug
, O
erythromycin B-drug
, O
imatinib B-drug
, O
isoniazid B-drug
, O
nefazodone B-drug
, O
nicardipine B-drug
, O
propofol B-drug
, O
protease B-group
inhibitors I-group
, O
quinidine B-drug
, O
and O
verapamil B-drug
. O

Effect O
of O
diazepam B-drug
and O
midazolam B-drug
on O
the O
antinociceptive O
effect O
of O
morphine B-drug
, O
metamizol B-drug
and O
indomethacin B-drug
in O
mice O
. O

When O
encountered O
, O
such O
arrhythmias O
may O
respond O
to O
administration O
of O
a O
beta-adrenergic B-group
blocking I-group
drug I-group
. O

The O
clinical O
significance O
is O
unknown O
. O

Cytochrome O
P-450 O
inducers O
, O
such O
as O
phenytoin B-drug
, O
carbamazepine B-drug
and O
phenobarbital B-drug
, O
induce O
clonazepam B-drug
metabolism O
, O
causing O
an O
approximately O
30 O
% O
decrease O
in O
plasma O
clonazepam B-drug
levels O
. O

Binding O
to O
plasma O
protein O
is O
not O
significantly O
altered O
by O
diazepam B-drug
, O
diphenylhydantoin B-drug
, O
or O
phenylbutazone B-drug
. O

Immunogenicity/Re-exposure O
: O
In O
in O
vitro O
studies O
, O
Angiomax B-brand
exhibited O
no O
platelet O
aggregation O
response O
against O
sera O
from O
patients O
with O
a O
history O
of O
HIT/HITTS O
. O

Concomitant O
administration O
of O
other O
sympathomimetic B-group
agents I-group
may O
potentiate O
the O
undesirable O
effects O
of O
FORADIL B-brand
. O

Doxylamine B-drug
may O
enhance O
the O
effects O
of O
epinephrine B-drug
. O

Rare O
instances O
of O
dyspnea O
, O
palpitation O
, O
chest O
pain O
, O
syncope O
. O

Nevertheless O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
monitored O
when O
warfarin B-drug
or O
its O
derivatives O
and O
enoxacin B-drug
are O
given O
concomitantly O
. O

These O
agents O
should O
not O
be O
taken O
within O
4 O
hours O
before O
or O
4 O
hours O
after O
grepafloxacin B-drug
administration O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
quinidine B-drug
increases O
quinidine B-drug
serum O
concentration O
by O
33 O
% O
after O
two O
days O
. O

If O
antacid B-group
therapy O
is O
needed O
, O
the O
antacid O
dose O
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
or O
2 O
hours O
after O
the O
dose O
of O
SPRYCEL B-brand
. O

Although O
17-hydroxy-corticosteroid O
measurements O
( O
Porter-Silber O
test O
) O
do O
not O
appear O
to O
be O
artifactually O
altered O
, O
it O
is O
suggested O
that O
therapy O
with O
naproxen B-drug
be O
temporarily O
discontinued O
72 O
hours O
before O
adrenal O
function O
tests O
are O
performed O
if O
the O
Porter-Silber O
test O
is O
to O
be O
used O
. O

Rifampin B-drug
, O
an O
inducer O
of O
drug O
metabolism O
, O
decreased O
the O
concentrations O
of O
losartan B-drug
and O
its O
active O
metabolite O
. O

Drugs O
Whose O
Absorption O
Can O
Be O
Affected O
by O
the O
Level O
of O
Acidity O
in O
the O
Stomach O
: O
Drugs O
such O
as O
ketoconazole B-drug
and O
itraconazole B-drug
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
dosing O
with O
VIDEX B-brand
. O

Vaccinations O
with O
attenuated O
live O
bacteria O
should O
therefore O
be O
completed O
at O
least O
3 O
days O
before O
the O
first O
dose O
of O
Mefloquine B-drug
. O

Additional O
reductions O
in O
blood O
pressure O
may O
occur O
when O
FLOLAN B-brand
is O
administered O
with O
diuretics B-group
, O
antihypertensive B-group
agents I-group
, O
or O
other O
vasodilators B-group
. O

The O
inhibitor O
, O
on O
the O
other O
hand O
, O
promoted O
significant O
decrease O
of O
nucleolin/C23 O
in O
NIH-3T3 O
cells O
during O
serum O
deprivation O
. O

Candida O
albicans O
, O
one O
of O
the O
pathogenic O
species O
, O
was O
totally O
inhibited O
at O
a O
concentration O
of O
approximately O
10 O
mug/ml O
. O

certain O
antibiotics B-group
, O
especially O
the O
aminoglycosides B-group
and O
polymyxins B-group
; O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

The O
AUC O
of O
eszopiclone B-drug
was O
increased O
2.2-fold O
by O
coadministration O
of O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
400 O
mg O
daily O
for O
5 O
days O
. O

Lopinavir I-drug

Particular O
caution O
is O
necessary O
when O
using O
ROMAZICON B-brand
in O
cases O
of O
mixed O
drug O
overdosage O
since O
the O
toxic O
effects O
( O
such O
as O
convulsions O
and O
cardiac O
dysrhythmias O
) O
of O
other O
drugs O
taken O
in O
overdose O
( O
especially O
cyclic B-group
antidepressants I-group
) O
may O
emerge O
with O
the O
reversal O
of O
the O
benzodiazepine B-group
effect O
by O
flumazenil B-drug
. O

The O
second O
response O
is O
due O
to O
a O
release O
of O
norepinephrine O
from O
nerves O
and O
was O
potentiated O
by O
ouabain B-drug
through O
the O
increase O
in O
the O
norepinephrine O
release O
, O
whereas O
the O
first O
response O
was O
not O
due O
to O
the O
norepinephrine O
release O
but O
presumably O
to O
a O
direct O
action O
on O
smooth O
muscle O
cell O
and O
was O
inhibited O
by O
ouabain B-drug
. O

Oral O
contraceptives B-group
and O
other O
hormonalmethods O
of O
birth O
control O
should O
not O
be O
usedas O
the O
sole O
method O
of O
contraception O
inwomen O
taking O
nevirapine B-drug
, O
since O
nevirapinemay O
lower O
the O
plasma O
levels O
of O
thesemedications O
. O

Therefore O
, O
the O
potential O
for O
such O
drug O
interactions O
should O
be O
considered O
in O
patients O
receiving O
dorzolamide B-drug
. O

Human I-drug
growth I-drug
hormone I-drug
- O
Concomitant O
use O
of O
L-glutamine B-drug
and O
human B-drug
growth I-drug
hormone I-drug
may O
enhance O
nutrient O
absorption O
in O
those O
with O
severe O
short O
bowel O
syndrome O
. O

No O
effects O
on O
plasma O
concentrations O
of O
cimetidine B-drug
or O
ketoconazole B-drug
were O
observed O
. O

amphotericin B-drug
B I-drug
, O
however O
, O
is O
useful O
in O
therapy O
of O
human O
fungal O
infections O
because O
it O
is O
less O
toxic O
. O

Administration O
of O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
concomitantly O
with O
cyclosporine B-drug
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine-induced B-drug
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O

No O
studies O
have O
been O
performed O
with O
other O
NNRTIs B-group
. O

Nicotine B-drug
: O
Nicotine B-drug
may O
provoke O
vasoconstriction O
in O
some O
patients O
, O
predisposing O
to O
a O
greater O
ischemic O
response O
to O
ergot B-drug
therapy O
. O

8 O
. O

Because O
of O
the O
broadening O
indications O
for O
immunosuppressive B-group
drugs I-group
, O
and O
the O
prolonged O
survival O
in O
conditions O
for O
which O
they O
are O
being O
used O
, O
many O
patients O
on O
immunosuppression O
are O
now O
cared O
for O
in O
the O
community O
or O
seen O
in O
non-specialist O
hospitals O
, O
usually O
in O
close O
collaboration O
with O
a O
specialist O
. O

A O
causal O
relationship O
has O
not O
been O
established O

Therefore O
, O
there O
is O
a O
potential O
for O
an O
in O
vivo O
drug O
interaction O
with O
drugs O
that O
are O
metabolized O
by O
P450 O
2D6 O
. O

Verapamil B-drug
: O
Concomitant O
use O
of O
verapamil B-drug
is O
contraindicated O
. O

( O
500 O
mg O
Q8h O
) O

Duloxetine B-drug
May O
Have O
a O
Clinically O
Important O
Interaction O
with O
the O
Following O
Other O
Drugs O
: O
Alcohol B-drug
: O
When O
Duloxetine B-drug
and O
ethanol B-drug
were O
administered O
several O
hours O
apart O
so O
that O
peak O
concentrations O
of O
each O
would O
coincide O
, O
Duloxetine B-drug
did O
not O
increase O
the O
impairment O
of O
mental O
and O
motor O
skills O
caused O
by O
alcohol B-drug
. O

On O
the O
basis O
of O
the O
metabolism O
of O
bexarotene B-drug
by O
cytochrome O
P450 O
3A4 O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
gemfibrozil B-drug
, O
grapefruit O
juice O
, O
and O
other O
inhibitors O
of O
cytochrome O
P450 O
3A4 O
would O
be O
expected O
to O
lead O
to O
an O
increase O
in O
plasma O
bexarotene B-drug
concentrations O
. O

- O
Decreased O
pregnanediol O
excretion O

The O
incidence O
of O
upper O
gastrointestinal O
events O
in O
patients O
concomitantly O
taking O
aspirin B-brand
or O
NSAIDs B-group
was O
similar O
in O
patients O
taking O
ibandronate B-drug
2.5 O
mg O
daily O
( O
21.7 O
% O
) O
and O
150 O
mg O
once O
monthly O
( O
22.0 O
% O
) O
. O

Oral O
Contraceptive B-group
: O
Based O
on O
AUC O
and O
half-life O
, O
multiple-dose O
pharmacokinetic O
profiles O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
following O
administration O
of O
tablets O
containing O
2.5 O
mg O
of O
norethindrone B-drug
acetate I-drug
and O
50 O
mcg O
of O
ethinyl B-drug
estradiol I-drug
were O
similar O
with O
and O
without O
coadministration O
of O
gabapentin B-drug
( O
400 O
mg O
TID O
; O

Drugs O
That O
Are O
Mainly O
Metabolized O
by O
CYP3A4 O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
quinolone B-group
use O
. O

Because O
lithium B-drug
may O
enhance O
the O
serotonergic O
effects O
of O
escitalopram B-drug
, O
caution O
should O
be O
exercised O
when O
LEXAPRO B-brand
and O
lithium B-drug
are O
coadministered O
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
VIRACEPT B-brand
Antiarrhythmics B-group
: O
amiodarone B-drug
, O
quinidine B-drug
Antihistamines B-group
: O
astemizole B-drug
, O
terfenadine B-drug
Antimigraine O
: O
ergot B-group
derivatives I-group
Antimycobacterial I-group
agents I-group
: O
rifampin B-drug
Benzodiazepines B-group
midazolam B-drug
, O
triazolam B-drug
GI O
motility O
agents O
: O
cisapride B-drug

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

Cercarial O
encystment O
at O
concentrations O
of O
25000 O
microg/l O
or O
higher O
was O
significantly O
impaired O
by O
all O
test O
metals O
; O

Hyperpyrexia O
has O
been O
reported O
when O
amitriptyline B-drug
HCl I-drug
is O
administered O
with O
anticholinergic B-drug
agents O
or O
with O
neuroleptic B-drug
drugs O
, O
particularly O
during O
hot O
weather O
. O

Some O
clinicians O
have O
noted O
that O
these O
reactions O
resemble O
the O
immediate O
side O
effects O
caused O
by O
interleukin-2 B-drug
administration O
, O
however O
the O
cause O
of O
contrast O
reactions O
after O
interleukin-2 O
therapy O
is O
unknown O
. O

The O
anxiogenic O
effects O
of O
theophylline B-drug
were O
reduced O
by O
pretreatment O
with O
CGS B-drug_n
21680 I-drug_n
, O
an O
A2-selective O
agonist O
, O
but O
not O
by O
N6-cyclopentyladenosine B-drug_n
( O
CPA B-drug_n
) O
, O
an O
A1-selective O
agonist O
. O

CNS O
vascular O
lesions O
, O
characterized O
by O
perivascular O
hemorrhages O
, O
edema O
, O
and O
mononuclear O
cell O
infiltration O
of O
perivascular O
spaces O
, O
have O
been O
observed O
in O
dogs O
treated O
with O
other O
members O
of O
this O
class O
. O

Ketamine B-drug
is O
clinically O
compatible O
with O
the O
commonly O
used O
general O
and O
local O
anesthetic B-group
agents I-group
when O
an O
adequate O
respiratory O
exchange O
is O
maintained O
. O

Erythromycin B-drug

increased O
plasminogen O
antigen O
and O
activity O
. O

Although O
there O
was O
no O
clinical O
evidence O
in O
the O
vehicle-controlled O
studies O
of O
drug O
interactions O
with O
systemic O
antiretroviral B-group
agents I-group
, O
including O
protease B-group
inhibitors I-group
, O
macrolide B-group
antibiotics I-group
, O
and O
azole B-group
antifungals I-group
, O
the O
effect O
of O
Panretin B-brand
gel O
on O
the O
steady-state O
concentrations O
of O
these O
drugs O
is O
not O
known O
. O

In O
contrast O
, O
acute O
toxicity O
tests O
showed O
that O
oral O
CCNU B-drug
was O
1.45 O
times O
less O
toxic O
to O
normal O
tissue O
, O
although O
the O
dose-limiting O
organ O
may O
be O
different O
for O
the O
two O
routes O
. O

Levodopa B-drug
and O
Amantadine B-drug
: O
Limited O
clinical O
data O
suggest O
a O
higher O
incidence O
of O
adverse O
experiences O
in O
patients O
receiving O
bupropion B-drug
concurrently O
with O
either O
levodopa B-drug
or O
amantadine B-drug
. O

In O
patients O
receiving O
another O
serotonin B-group
reuptake I-group
inhibitor I-group
drug I-group
in O
combination O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOI B-group
) O
, O
there O
have O
been O
reports O
of O
serious O
, O
sometimes O
fatal O
, O
reactions O
including O
hyperthermia O
, O
rigidity O
, O
myoclonus O
, O
autonomic O
instability O
with O
possible O
rapid O
fluctuations O
of O
vital O
signs O
, O
and O
mental O
status O
changes O
that O
include O
extreme O
agitation O
progressing O
to O
delirium O
and O
coma O
. O

In O
addition O
, O
several O
AED B-group
s O
that O
are O
cytochrome O
P450 O
inducers O
can O
decrease O
plasma O
concentrations O
of O
oxcarbazepine B-drug
and O
MHD B-drug_n
. O

Administer O
LEVSIN B-brand
before O
meals O
; O

No O
studies O
have O
been O
conducted O
at O
intermediate O
doses O
of O
cimetidine B-drug
. O

Inhibition O
of O
metabolism O
may O
produce O
significant O
increases O
in O
circulating O
phenytoin B-drug
concentrations O
and O
enhance O
the O
risk O
of O
drug O
toxicity O
. O

The O
mechanism O
for O
this O
interaction O
is O
not O
known O
. O

In O
ewes O
given O
40 O
mg O
of O
phenobarbital B-drug
sodium/kg O
for O
5 O
days O
intraperitoneally O
( O
IP O
) O
, O
the O
anticholinesterase O
effect O
of O
4 O
mg O
of O
coumaphos/kg B-drug_n
was O
significantly O
reduced O
and O
signs O
of O
toxicity O
were O
not O
present O
. O

There O
also O
was O
no O
effect O
on O
exposure O
to O
and O
the O
excretion O
of O
the O
primary O
metabolite O
, O
ucb O
L057 O
. O

Chlorthalidone B-drug
may O
add O
to O
or O
potentiate O
the O
action O
of O
other O
antihypertensive B-group
drugs I-group
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

OBJECTIVE O
: O
Our O
objective O
was O
to O
characterize O
the O
steady-state O
pharmacokinetics O
of O
everolimus B-drug
and O
cyclosporine B-drug
( O
INN O
, O
ciclosporin B-drug
) O
when O
coadministered O
in O
de O
novo O
kidney O
allograft O
recipients O
during O
the O
first O
year O
after O
transplantation O
. O

Adrenocorticoids O
: O
Metabolic O
clearance O
of O
adrenocorticoids O
is O
decreased O
in O
hypothyroid O
patients O
and O
increased O
in O
hyperthyroid O
patients O
, O
and O
may O
therefore O
change O
with O
changing O
thyroid O
status O
. O

The O
physician O
should O
be O
notified O
immediately O
if O
any O
of O
the O
following O
situations O
occur O
, O
which O
may O
be O
a O
sign O
of O
seriously O
worsening O
asthma O
: O
Decreased O
effectiveness O
of O
short-acting B-group
, I-group
inhaled I-group
beta2-agonists I-group
; O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

The O
steady-state O
Cmin O
concentration O
increased O
to O
17.8 O
micrograms/mL O
when O
2400 O
mg/day O
of O
felbamate B-drug
was O
coadministered O
for O
one O
week O
. O

Lithium B-drug
- O
Coadministration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
10 O
days O
) O
and O
lithium B-drug
( O
30 O
mmol/day O
for O
5 O
days O
) O
had O
no O
significant O
effect O
on O
the O
pharmacokinetics O
of O
citalopram B-drug
or O
lithium B-drug
. O

Avoid O
the O
use O
of O
preparations O
such O
as O
decongestants B-group
and O
local O
anesthetics B-group
which O
contain O
any O
sympathomimetic B-group
amine I-group
( O
e.g. O
, O
epinephrine B-drug
, O
norepinephrine B-drug
) O
, O
since O
it O
has O
been O
reported O
that O
tricyclic B-group
antidepressants I-group
can O
potentiate O
the O
effects O
of O
catecholamines O
. O

The O
para-aminobenzoic O
acid O
metabolite O
of O
chloroprocaine O
inhibits O
the O
action O
of O
sulfonamides B-group
. O

Lithium B-drug
: O
Increased O
serum O
lithium B-drug
levels O
and O
symptoms O
of O
lithium B-drug
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-group
inhibitors I-group
during O
therapy O
with O
lithium B-drug
. O

Use O
with O
caution O
and O
be O
prepared O
to O
treat O
hypertension O
, O
if O
necessary O
. O

Gastrointestinal O
agents O
( O
e.g. O
, O
antacids B-group
) O
. O

- O
Daunorubicin B-drug
( O
e.g. O
, O
Cerubidine B-brand
) O
or O

Pediatric O
Use O
The O
safety O
and O
effectiveness O
of O
PEGASYS B-brand
, O
alone O
or O
in O
combination O
with O
COPEGUS B-brand
in O
patients O
below O
the O
age O
of O
18 O
years O
have O
not O
been O
established O
. O

Prolonged O
menstrual O
cycles O
and/or O
amenorrhea O
were O
observed O
in O
female O
cynomolgus O
monkeys O
given O
sc O
injections O
of O
600 O
m O
g/kg/dose O
( O
7200 O
m O
g/m2/dose O
) O
of O
PEGASYS B-brand
every O
other O
day O
for O
one O
month O
, O
at O
approximately O
180 O
times O
the O
recommended O
weekly O
human O
dose O
for O
a O
60 O
kg O
person O
( O
based O
on O
body O
surface O
area O
) O
. O

Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O
. O

Alternatives O
to O
rifampin B-drug
should O
be O
considered O
during O
the O
course O
of O
PCP O
treatment O
with O
MEPRON B-brand
. O

Component O
P2 O
, O
however O
, O
was O
increased O
in O
amplitude O
. O

In O
utero O
, O
serum O
levels O
of O
exposure O
in O
these O
monkeys O
were O
23 O
% O
of O
maternal O
serum O
levels O
. O

Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-group
hormone I-group
. O

Coadministration O
of O
LEXAPRO B-brand
and O
metoprolol B-drug
had O
no O
clinically O
significant O
effects O
on O
blood O
pressure O
or O
heart O
rate O
. O

NaCMC B-drug_n
at O
1 O
% O
( O
m/v O
) O
in O
the O
presence O
of O
free O
cysteine B-drug
had O
no O
significant O
effect O
on O
the O
R-value O
of O
NaFlu B-drug
compared O
to O
NaCMC B-drug_n
alone O
. O

It O
is O
recommended O
that O
these O
tests O
be O
performed O
prior O
to O
initiation O
of O
Soriatane B-brand
therapy O
, O
at O
1- O
to O
2-week O
intervals O
until O
stable O
and O
thereafter O
at O
intervals O
as O
clinically O
indicated O
. O

24.9 O
% O
( O
95 O
% O
CI O
, O
+/- O
4.5 O
) O
were O
PICR O
, O
detected O
in O
11.7 O
% O
( O
95 O
% O
CI O
, O
+/- O
2.5 O
) O
of O
the O
MAC O
. O

Data O
beyond O
10 O
days O
are O
not O
available O
. O

Each O
month O
of O
therapy O
, O
the O
patient O
must O
have O
a O
negative O
result O
from O
a O
urine O
or O
serum O
pregnancy O
test O
. O

When O
intravenous O
morphine B-drug
and O
BREVIBLOC B-brand
were O
concomitantly O
administered O
in O
normal O
subjects O
, O
no O
effect O
on O
morphine B-drug
blood O
levels O
was O
seen O
, O
but O
BREVIBLOC B-brand
steady-state O
blood O
levels O
were O
increased O
by O
46 O
% O
in O
the O
presence O
of O
morphine B-drug
. O

Because O
of O
the O
pronounced O
intersubject O
variability O
in O
the O
extent O
of O
the O
sirolimus-diltiazem B-drug
interaction O
, O
whole O
blood O
sirolimus B-drug
concentrations O
should O
be O
monitored O
closely O
in O
patients O
treated O
with O
the O
two O
drugs O
. O

Effect O

Therefore O
, O
patients O
receiving O
probenecid B-drug
will O
have O
erroneously O
low O
ERPF O
and O
Tm O
PAH B-drug
values O
. O

Drug-Drug O
Interactions O
: O
No O
clinically O
significant O
drug O
interactions O
have O
been O
found O
with O
theophylline B-drug
at O
a O
low O
dose O
, O
azithromycin B-drug
, O
pseudoephedrine B-drug
, O
ketoconazole B-drug
, O
or O
erythromycin B-drug
. O

Drug O
and O
Laboratory O
Test O
Interactions O
1 O
. O

Drug O
interactions O
with O
SUSTIVA B-brand
are O
summarized O
in O
Table O
5 O
. O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Inhibitors O
of O
the O
CYP3A4 O
isoenzyme O
could O
increase O
systemic O
dofetilide B-drug
exposure O
. O

Furosemide B-drug
has O
a O
tendency O
to O
antagonize O
the O
skeletal O
muscle O
relaxing O
effect O
of O
tubocurarine B-drug
and O
may O
potentiate O
the O
action O
of O
succinylcholine B-drug
. O

The O
concomitant O
use O
of O
diflunisal B-drug
tablets O
and O
other O
NSAIDs B-group
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O

Therefore O
, O
a O
slower O
onset O
can O
be O
anticipated O
if O
STADOL B-brand
NS I-brand
is O
administered O
concomitantly O
with O
, O
or O
immediately O
following O
, O
a O
nasal B-group
vasoconstrictor I-group
. O


Smokers O
have O
an O
increased O
clearance O
of O
benzodiazepines B-group
as O
compared O
to O
nonsmokers O
; O

In O
post-marketing O
experience O
there O
have O
been O
reports O
of O
increases O
in O
plasma O
lithium B-drug
levels O
. O

periodic O
monitoring O
of O
anticonvulsant B-group
plasma O
levels O
should O
be O
conducted O
. O

Patients O
receiving O
azathioprine B-drug
and O
allopurinol B-drug
concomitantly O
should O
have O
a O
dose O
reduction O
of O
azathioprine B-drug
, O
to O
approximately O
1/3 O
to O
1/4 O
the O
usual O
dose O
. O

These O
stimulants O
are O
commonly O
found O
in O
coffee O
and O
tea O
, O
respectively O
. O

The O
pharmacodynamic O
effects O
can O
be O
explained O
by O
a O
combination O
of O
the O
increase O
in O
dofetilide B-drug
exposure O
and O
the O
reductions O
in O
serum O
potassium O
. O

In O
about O
30 O
% O
of O
patients O
, O
the O
dose O
of O
cyclosporine B-drug
had O
to O
be O
reduced O
in O
order O
to O
maintain O
cyclosporine B-drug
concentrations O
within O
the O
therapeutic O
range O
, O
while O
in O
the O
remainder O
no O
adjustment O
was O
needed O
. O

The O
pharmacokinetics O
of O
fluvastatin B-drug
have O
also O
been O
assessed O
in O
various O
demographic O
groups O
. O


Potential O
drug O
interactions O
between O
Mentax B-brand
( O
butenafine B-drug
HCl I-drug
cream O
) O
Cream O
, O
1 O
% O
, O
and O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

( O
Thiazides B-group
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-drug
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
with O
aminoglycoside B-group
antibiotics I-group
or O
potent O
diuretics B-group
such O
as O
furosemide B-drug
. O

. O

Lithium-A B-drug
drug O
interaction O
study O
of O
eplerenone B-drug
with O
lithium B-drug
has O
not O
been O
conducted O
. O

The O
acid-catalyzed O
ethanol-drug B-drug
reaction O
is O
a O
relatively O
unexplored O
area O
and O
may O
alter O
the O
pharmacological O
action O
of O
some O
drugs O
. O

Immunosuppressants B-group

Intestinal B-group
adsorbents I-group
( O
e. O
g. O
, O
charcoal B-drug
) O
and O
digestive B-group
enzyme I-group
preparations I-group
containing O
carbohydrate-splitting O
enzymes O
( O
e. O
g. O
, O
amylase B-drug
, O
pancreatin B-drug
) O
may O
reduce O
the O
effect O
of O
Acarbose B-drug
and O
should O
not O
be O
taken O
concomitantly O
. O

The O
augmentation O
persisted O
even O
after O
carbachol B-drug
was O
washed O
out O
and O
was O
resistant O
to O
chelated O
extracellular O
Ca O
( O
2+ O
) O
and O
to O
inhibitors O
of O
either O
protein O
kinase O
C O
or O
calmodulin O
kinase O
II O
. O

Much O
higher O
changes O
were O
observed O
in O
liver O
, O
increasing O
from O
a O
level O
of O
60 O
% O
at O
4 O
h O
up O
to O
nearly O
4 O
times O
the O
control O
at O
24 O
h O
for O
single O
dose O
. O

BACKGROUND O
: O
The O
effects O
of O
combined O
administration O
of O
bombesin B-drug_n
and O
verapamil B-drug
hydrochloride I-drug
( O
verapamil B-drug
) O
, O
a O
calcium B-group
channel I-group
blocker I-group
, O
on O
the O
incidence O
of O
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-drug_n
( O
AOM B-drug_n
) O
and O
the O
labeling O
index O
of O
intestinal O
cancers O
were O
investigated O
in O
male O
Wistar O
rats O
. O

Exjade B-brand
tablets O
for O
oral O
suspension O
can O
be O
dispersed O
in O
water O
, O
orange O
juice O
, O
or O
apple O
juice O
. O

Since O
apraclonidine B-drug
may O
reduce O
pulse O
and O
blood O
pressure O
, O
caution O
in O
using O
drugs O
such O
as O
beta-blockers B-group
( O
ophthalmic O
and O
systemic O
) O
, O
antihypertensives B-group
, O
and O
cardiac B-group
glycosides I-group
is O
advised O
. O

The O
administration O
of O
lower O
doses O
of O
Vardenafil B-drug
with O
alpha-blockers B-group
has O
not O
been O
completely O
evaluated O
to O
determine O
if O
they O
can O
be O
safely O
administered O
together O
. O

Ascorbic B-drug
acid I-drug
: O
Doses O
of O
ascorbic B-drug
acid I-drug
( O
vitamin B-drug
C I-drug
) O
1 O
g/day O
have O
been O
reported O
to O
increase O
plasma O
concentration O
of O
synthetic B-group
estrogens I-group
by O
~47 O
% O
, O
possibly O
by O
inhibiting O
conjugation O
; O

In O
patients O
with O
impaired O
cardiac O
function O
, O
simultaneous O
use O
should O
be O
avoided O
altogether O
. O

Investigations O
into O
the O
effect O
of O
acitretin B-drug
on O
the O
protein O
binding O
of O
anticoagulants B-group
of I-group
the I-group
coumarin I-group
type I-group
( O
warfarin B-drug
) O
revealed O
no O
interaction O
. O

In O
order O
to O
avoid O
lithium B-drug
intoxication O
, O
lithium B-drug
plasma O
levels O
should O
be O
monitored O
closely O
. O

2 O
. O

THE O
DOSAGE O
OF O
THE O
ANTICOAGULANTS B-group
SHOULD O
BE O
REDUCED O
TO O
MAINTAIN O
THE O
PROTHROMBIN O
TIME/INR O
AT O
THE O
DESIRED O
LEVEL O
TO O
PREVENT O
BLEEDING O
COMPLICATIONS O
. O

The O
literature O
provides O
considerable O
evidence O
indicating O
that O
several O
, O
but O
not O
all O
antihistaminics B-group
, O
are O
indeed O
analgesic B-group
agents I-group
and O
some O
are O
analgesic B-group
adjuvants I-group
as O
well O
. O

Two O
of O
16 O
subjects O
dosed O
simultaneously O
with O
Vardenafil B-drug
10 O
mg O
and O
tamsulosin B-drug
0.4 O
mg O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

Thirty O
male O
rats O
of O
the O
Fischer-344 O
strain O
were O
divided O
into O
three O
equal O
groups O
and O
were O
given O
injections O
of O
trimethyl B-drug_n
lead I-drug_n
( O
TML B-drug_n
) O
( O
8.0 O
or O
17.0 O
mg/kg/ml O
SC O
) O
or O
the O
saline O
vehicle O
. O

Antacids B-group
and O
sucralfate B-drug
: O
Sucralfate B-drug
and O
antacids B-group
containing O
magnesium B-drug
or O
aluminum B-drug
, O
as O
well O
as O
formulations O
containing O
divalent O
and O
trivalent O
cations O
such O
as O
Videx B-brand
( O
didanosine B-drug
) O
, O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
can O
form O
chelation O
complexes O
with O
lomefloxacin B-drug
and O
interfere O
with O
its O
bioavailability O
. O

Flecainide B-drug
is O
not O
extensively O
bound O
to O
plasma O
proteins O
. O

In O
well-controlled O
patients O
undergoing O
concurrent O
therapy O
with O
cimetidine B-drug
, O
a O
decrease O
in O
the O
steady-state O
serum O
concentrations O
of O
tricyclic B-group
antidepressants I-group
may O
occur O
when O
cime-tidine O
therapy O
is O
discontinued O
. O

When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Other O
: O
Concomitant O
alcohol B-drug
or O
hot O
drinks O
may O
increase O
the O
side O
effects O
of O
flushing O
and O
pruritus O
and O
should O
be O
avoided O
at O
the O
time O
of O
drug O
ingestion O
. O

Furosemide B-drug
: O
TORADOL B-brand
IV/IM O
reduced O
the O
diuretic B-group
response O
to O
furosemide B-drug
in O
normovolemic O
healthy O
subjects O
by O
approximately O
20 O
% O
( O
mean O
sodium O
and O
urinary O
output O
decreased O
17 O
% O
) O
. O

After O
the O
coadministration O
of O
200 O
mg O
oral O
ketoconazole B-drug
twice O
daily O
and O
one O
20 O
mg O
dose O
of O
loratadine B-drug
to O
11 O
subjects O
, O
the O
AUC O
and O
Cmax O
of O
loratadine B-drug
averaged O
302 O
% O
( O
142 O
S.D O
. O
) O
and O
251 O
% O
( O
68 O
S.D O
. O
) O
, O
respectively O
, O
of O
those O
obtained O
after O
co-treatment O
with O
placebo O
. O

Warfarin B-drug
: O
Atorvastatin B-drug
had O
no O
clinically O
significant O
effect O
on O
prothrombin O
time O
when O
administered O
to O
patients O
receiving O
chronic O
warfarin B-drug
treatment O
. O

The O
combination O
is O
well O
tolerated O
. O

Acetazolamide B-drug
decreases O
urinary O
excretion O
of O
amphetamine B-drug
and O
may O
enhance O
the O
magnitude O
and O
duration O
of O
their O
effect O
. O

Theoretically O
, O
fenoprofen B-drug
could O
likewise O
be O
displaced O
. O

Oral O
Contraceptives B-group

It O
is O
concluded O
that O
ketamine B-drug
is O
not O
a O
short-acting O
drug O
and O
that O
concomitant O
use O
with O
halothane B-drug
would O
be O
expected O
to O
prolong O
further O
the O
duration O
of O
its O
action O
on O
the O
central O
nervous O
system O
. O

therefore O
it O
is O
not O
expected O
to O
affect O
the O
plasma O
concentrations O
of O
other O
drugs O
metabolized O
by O
CYP3A4 O
. O

However O
, O
since O
aspirin B-brand
, O
NSAIDs B-group
, O
and O
bisphosphonates B-group
are O
all O
associated O
with O
gastrointestinal O
irritation O
, O
caution O
should O
be O
exercised O
in O
the O
concomitant O
use O
of O
aspirin B-brand
or O
NSAIDs B-group
with O
Ibandronate B-drug
. O

Warfarin B-drug
: O
Quinolones B-group
have O
been O
reported O
to O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
or O
its O
derivatives O
. O

No O
clinically O
significant O
effect O
of O
famotidine B-drug
, O
valproate B-drug
, O
or O
lithium B-drug
was O
seen O
on O
the O
pharmacokinetics O
of O
aripiprazole B-drug
( O
see O
CLINICAL O
PHARMACOLOGY O
: O
Drug- O
Drug O
Interactions O
) O
. O

Carbamazepine B-drug
: O
Coadministration O
of O
carbamazepine B-drug
( O
200 O
mg O
BID O
) O
, O
a O
potent O
CYP3A4 O
inducer O
, O
with O
aripiprazole B-drug
( O
30 O
mg O
QD O
) O
resulted O
in O
an O
approximate O
70 O
% O
decrease O
in O
Cmax O
and O
AUC O
values O
of O
both O
aripiprazole B-drug
and O
its O
active O
metabolite O
, O
dehydro-aripiprazole B-drug_n
. O

Certain O
antibiotics B-group
, O
especially O
neomycin B-drug
, O
streptomycin B-drug
and O
kanamycin B-drug
, O
have O
a O
mild O
but O
definite O
nondepolarizing O
blocking O
action O
which O
may O
accentuate O
neuromuscular O
block O
. O

Loratadine B-drug
Descarboethoxyloratadine I-drug

. O

Drug/Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
APOKYN B-brand
and O
laboratory O
tests O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

In O
one O
study O
, O
following O
chronic O
administration O
of O
bupropion B-drug
, O
100 O
mg O
3 O
times O
daily O
to O
8 O
healthy O
male O
volunteers O
for O
14 O
days O
, O
there O
was O
no O
evidence O
of O
induction O
of O
its O
own O
metabolism O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Cetrotide B-brand
. O

Since O
hydroxyurea B-drug
may O
raise O
the O
serum O
uric O
acid O
level O
, O
dosage O
adjustment O
of O
uricosuric B-group
medication I-group
may O
be O
necessary O

Physiological O
changes O
resulting O
from O
smoking O
cessation O
, O
with O
or O
without O
nicotine B-drug
replacement O
, O
may O
alter O
the O
pharmacokinetics O
of O
certain O
concomitant O
medications O
, O
such O
as O
tricyclic B-group
antidepressants I-group
and O
theophylline B-drug
. O

The O
effect O
of O
administering O
different O
botulinum B-group
neurotoxin I-group
serotypes O
at O
the O
same O
time O
or O
within O
less O
than O
4 O
months O
of O
each O
other O
is O
unknown O
. O

Established O
Drug O
Interactions O

Non-nucleoside B-group
reverse I-group
transcriptase I-group
inhibitors I-group

Lithium B-drug
toxicity O
was O
usually O
reversible O
upon O
discontinuation O
of O
lithium B-drug
and O
the O
ACE B-group
inhibitor I-group
. O

The O
in O
vitro O
anti-cryptosporidial O
activity O
of O
buforin B-drug_n
II I-drug_n
alone O
and O
in O
combination O
with O
azithromycin B-drug
and O
minocycline B-drug
was O
investigated O
. O

Although O
this O
effect O
was O
noted O
even O
when O
cholestyramine B-drug
was O
given O
4 O
hours O
prior O
to O
fluvastatin B-drug
, O
this O
regimen O
did O
not O
result O
in O
diminished O
efficacy O
. O

Drug/Laboratory O
Test O
Interactions O
Cephalosporins B-group
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Perioperative O
administration O
of O
drugs O
affecting O
hepatic O
blood O
flow O
or O
enzyme O
function O
may O
reduce O
plasma O
clearance O
and O
prolong O
recovery O
. O

CONCLUSIONS O
: O
Macrolide B-group
antibiotics I-group
inhibit O
the O
metabolism O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
that O
are O
metabolized O
by O
CYP3A4 O
( O
i.e. O
, O
atorvastatin B-drug
, O
cerivastatin B-drug
, O
lovastatin B-drug
, O
simvastatin B-drug
) O
. O

CNS O
depression O
producing O
medications O
- O
concurrent O
use O
may O
potentiate O
the O
effects O
of O
either O
these O
medications O
or O
diphenidol B-drug
; O

Nicardipine B-drug
HCl I-drug
usually O
does O
not O
alter O
the O
plasma O
levels O
of O
digoxin B-drug
, O
however O
, O
serum O
digoxin B-drug
levels O
should O
be O
evaluated O
after O
concomitant O
therapy O
with O
nicardipine B-drug
HCl I-drug
is O
initiated O
. O

Sirolimus B-drug
works O
differently O
from O
the O
immunosuppressants B-group
currently O
available O
, O
and O
except O
for O
increased O
lipid O
levels O
, O
the O
adverse O
reaction O
profile O
of O
sirolimus B-drug
does O
not O
appear O
to O
overlap O
to O
any O
great O
extent O
with O
that O
associated O
with O
cyclosporine B-drug
or O
tacrolimus B-drug
. O

When O
carbamazepine B-drug
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-drug
dose O
should O
then O
be O
reduced O
. O

A O
common O
phenotypic O
subset O
of O
the O
serotype O
O11 O
strains O
from O
drug O
addicts O
was O
especially O
resistant O
to O
the O
inhibitory O
effects O
. O

Because O
there O
are O
no O
data O
on O
the O
compatibility O
of O
NovoLog B-brand
and O
crystalline O
zinc B-drug
insulin I-drug
preparations O
, O
NovoLog B-brand
should O
not O
be O
mixed O
with O
these O
preparations O
. O

In O
this O
paper O
lists O
of O
multiple O
exposure O
in O
which O
the O
doses O
of O
the O
substances O
, O
the O
types O
of O
interferences O
and O
the O
behaviour O
of O
the O
biological O
levels O
have O
been O
drawn O
up O
and O
proposed O
as O
a O
tool O
for O
easy O
consultation O
. O

Administration O
of O
WELLBUTRIN B-brand
Tablets O
to O
patients O
receiving O
either O
levodopa B-drug
or O
amantadine B-drug
concurrently O
should O
be O
undertaken O
with O
caution O
, O
using O
small O
initial O
doses O
and O
small O
gradual O
dose O
increases O
. O

consideration O
should O
be O
given O
to O
possible O
CNS O
and O
other O
effects O
of O
alcohol B-drug
. O

Agents O
Causing O
Renin O
Release O
: O
The O
antihypertensive O
effect O
of O
enalapril B-drug
and O
enalapril B-drug
IV O
is O
augmented O
by O
antihypertensive B-group
agents I-group
that O
cause O
renin O
release O
( O
e.g. O
, O
diuretics B-group
) O
. O

Serum O
lithium B-drug
levels O
should O
be O
monitored O
frequently O
if O
INSPRA B-brand
is O
administered O
concomitantly O
with O
lithium B-drug
. O

Increased O
hepatotoxicity O
of O
acetaminophen B-drug
by O
concomitant O
administration O
of O
caffeine B-drug
in O
the O
rat O
. O

Digoxin B-drug
: O
Supraventricular O
arrhythmias O
may O
mask O
the O
cardiotoxicity O
associated O
with O
excessive O
digoxin B-drug
levels O
. O

Since O
falsely O
elevated O
glucose O
levels O
have O
been O
observed O
with O
blood O
glucose O
monitoring O
devices O
and O
test O
strips O
that O
use O
glucose O
dehydrogenase O
pyrroloquinolinequinone O
( O
GDH O
PQQ O
) O
-based O
methods O
, O
GDH O
PQQ-based O
methods O
should O
not O
be O
used O
to O
measure O
glucose O
levels O
in O
patients O
administered O
EXTRANEAL.. B-brand

Both O
the O
magnitude O
and O
duration O
of O
central O
nervous O
system O
and O
cardiovascular O
effects O
may O
be O
enhanced O
when O
ALFENTA B-brand
is O
administered O
in O
combination O
with O
other O
CNS B-group
depressants I-group
such O
as O
barbiturates B-group
, O
tranquilizers B-group
, O
opioids B-group
, O
or O
inhalation O
general O
anesthetics B-group
. O

However O
, O
co O
administration O
of O
fexofenadine B-drug
hydrochloride I-drug
with O
either O
ketoconazole B-drug
or O
erythromycin B-drug
led O
to O
increased O
plasma O
concentrations O
of O
fexofenadine B-drug
. O

A O
single O
dose O
of O
pravastatin B-drug
had O
no O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
fenofibric B-drug_n
acid I-drug_n
. O

The O
drug O
interaction O
studies O
with O
valdecoxib B-drug
were O
performed O
both O
with O
valdecoxib B-drug
and O
a O
rapidly O
hydrolyzed O
intravenous O
prodrug O
form O
. O

Usually O
, O
severe O
abdominal O
symptoms O
appear O
before O
there O
is O
such O
a O
fall O
in O
the O
blood O
pressure O
. O

Determinations O
of O
serum O
digoxin B-drug
levels O
utilizing O
commercially O
available O
kits O
with O
an O
125I-labelled O
antigen O
were O
precise O
and O
not O
materially O
different O
from O
results O
obtained O
with O
a O
3H-labelled O
antigen O
. O

At O
least O
3 O
weeks O
should O
elapse O
between O
discontinuation O
of O
dexfenfluramine B-drug
and O
initiation O
of O
treatment O
with O
a O
MAO B-group
inhibitor I-group
. O

The O
lower O
rate O
of O
absorption O
in O
the O
groups O
receiving O
446 O
mg O
Fe B-drug
instead O
of O
48 O
mg O
of O
Fe B-drug
per O
kg O
diet O
resulted O
in O
a O
decreased O
renal O
excretion O
of O
cobalt B-drug
. O

Etofibrate B-drug
elicited O
62 O
% O
enhancement O
of O
post-heparin B-drug
lipolytic O
activity O
and O
100 O
% O
increase O
of O
3H-triglyceride O
fractional O
clearance O
rate O
compared O
with O
placebo O
treatment O
. O

Recovery O
from O
50 O
% O
twitch O
to O
75 O
% O
fade O
recovery O
took O
13.8 O
+/- O
0.8 O
min O
for O
atracurium B-drug
alone O
and O
13.7 O
+/- O
1.2 O
min O
for O
atracurium B-drug
plus O
gentamycin B-drug
. O

This O
increase O
is O
due O
to O
the O
inhibition O
of O
celecoxib B-drug
metabolism O
via O
P450 O
2C9 O
by O
fluconazole B-drug
( O
see O
CLINICAL O
PHARMACOLOGY O
- O
Pharmacokinetics O
: O
Metabolism O
) O
. O

Non-pegylated B-drug
interferon I-drug
alfa-2a I-drug
treatment O
of O
pregnant O
Rhesus O
monkeys O
at O
approximately O
20 O
to O
500 O
times O
the O
human O
weekly O
dose O
resulted O
in O
a O
statistically O
significant O
increase O
in O
abortions O
. O

In O
monkeys O
, O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
but O
not O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
, O
were O
antagonized O
by O
naloxone B-drug
; O

In O
monkeys O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
was O
about O
10 O
times O
more O
potent O
than O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
in O
decreasing O
responding O
, O
whereas O
in O
pigeons O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
was O
about O
equipotent O
with O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
. O

Increased O
toxicity O
( O
CNS O
depression O
) O
: O
CNS B-group
depressants I-group
, O
MAO B-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
, O
phenothiazines B-group
. O

Transient O
delirium O
has O
been O
reported O
in O
patients O
who O
were O
treated O
with O
one O
gram O
of O
ethchlorvynol B-drug
and O
75 O
- O
150 O
mg O
of O
amitriptyline B-drug
HCl I-drug
. O

In O
such O
patients O
, O
the O
mean O
area O
under O
the O
felodipine B-drug
plasma O
concentration-time O
curve O
was O
also O
reduced O
to O
approximately O
6 O
% O
of O
that O
observed O
in O
healthy O
volunteers O
. O

Several O
clinically O
important O
interactions O
have O
previously O
been O
reported O
for O
other O
immunosuppressive B-group
drugs I-group
that O
are O
metabolized O
by O
the O
same O
enzyme O
and O
for O
calcium B-group
antagonists I-group
. O

Clarithromycin B-drug

Alteration O
of O
pH O
may O
affect O
absorption O
of O
certain O
drugs O
( O
e.g. O
, O
ketoconazole B-drug
) O
. O

Both O
the O
toxicity O
of O
filipin B-drug_n
and O
the O
therapeutic O
value O
of O
amphotericin B-drug
B I-drug
can O
be O
rationalized O
at O
the O
cellular O
and O
molecular O
level O
by O
the O
following O
observations O
: O
( O
i O
) O
these O
polyene B-group
antibiotics I-group
showed O
differential O
effects O
on O
cells O
; O

Multivitamins B-group
, O
or O
other O
products O
containing O
iron B-drug
or O
zinc B-drug
, O
antacids B-group
or O
sucralfate B-drug
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-drug
, O
because O
they O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-drug
. O

In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta-blockers B-group
, O
clonidine B-drug
, O
guanethidine B-drug
, O
and O
reserpine B-drug
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O

Valproic B-drug
acid I-drug

May O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
CRIXIVAN B-brand
or O
to O
the O
class O
of O
protease B-group
inhibitors I-group
or O
other O
coadministered O
antiretroviral B-group
agents I-group
. O

The O
risk O
of O
myopathy O
during O
treatment O
with O
drugs O
of O
this O
class O
is O
increased O
with O
concurrent O
administration O
of O
cyclosporine B-drug
, O
fibric B-group
acid I-group
derivatives I-group
, O
niacin B-drug
( O
nicotinic B-drug
acid I-drug
) O
, O
erythromycin B-drug
, O
azole B-group
antifungals I-group
. O

In O
this O
formal O
interaction O
study O
, O
TAMBOCOR B-brand
and O
propranolol B-drug
were O
each O
found O
to O
have O
negative O
inotropic O
effects O
; O

This O
slowing O
potentiates O
amphetamines B-group
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O

Physiological O
oral O
magnesium B-drug
supplementation O
( O
5 O
mg/kg/day O
) O
is O
easy O
and O
can O
be O
carried O
out O
in O
the O
diet O
or O
with O
magnesium B-drug
salts O
, O
with O
practically O
only O
one O
contra-indication O
: O
overt O
renal O
failure O
. O

Rifampin B-drug

Influence O
of O
AED B-group
On O
MHD B-drug_n
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O

- O
Drugs O
with O
nephrotoxic O
potential O
: O
There O
has O
been O
no O
experience O
on O
the O
concurrent O
use O
of O
bumetanide B-drug
with O
drugs O
known O
to O
have O
a O
nephrotoxic O
potential O
. O

In O
this O
setting O
, O
cardioselective B-group
beta-blockers I-group
could O
be O
considered O
, O
although O
they O
should O
be O
administered O
with O
caution O
. O

Before O
taking O
glimepiride B-drug
, O
tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
medicines O
: O
- O
aspirin B-brand
or O
another O
salicylate B-group
such O
as O
magnesium/choline B-drug
salicylate I-drug
( O
Trilisate B-brand
) O
, O
salsalate B-drug
( O
Disalcid B-brand
, O
others O
) O
, O
choline B-drug
salicylate I-drug
( O
Arthropan B-drug
) O
, O
magnesium B-drug
salicylate I-drug
( O
Magan B-brand
) O
, O
or O
bismuth B-drug
subsalicylate I-drug
( O
Pepto-Bismol B-brand
) O
; O

It O
is O
postulated O
that O
some O
of O
the O
observed O
training-induced O
neurobiological O
alterations O
might O
reflect O
the O
interaction O
between O
two O
( O
or O
more O
) O
competing O
memory O
systems O
at O
the O
hippocampal O
level O
. O

These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
the O
NSAID B-group
. O

Many O
people O
use O
both O
alcohol B-drug
and O
nicotine B-drug
( O
i.e. O
, O
cigarettes O
and O
other O
tobacco O
products O
) O
. O


In O
addition O
, O
reduced O
kidney O
and O
liver O
function O
secondary O
to O
PROLEUKIN B-brand
treatment O
may O
delay O
elimination O
of O
concomitant O
medications O
and O
increase O
the O
risk O
of O
adverse O
events O
from O
those O
drugs O
. O

Drugs O
That O
Induce O
CYP3A4 O
Rifampin B-drug
: O
CYP3A4 O
is O
ordinarily O
a O
minor O
metabolizing O
enzyme O
of O
zaleplon B-drug
. O

Atovaquone B-drug
is O
highly O
bound O
to O
plasma O
protein O
( O
99.9 O
% O
) O
. O

and O
Videx B-brand
, O
( O
Didanosine B-drug
) O
, O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
may O
substantially O
interfere O
with O
the O
absorption O
of O
quinolones B-group
, O
resulting O
in O
systemic O
levels O
considerably O
lower O
than O
desired O
. O

No O
specific O
pharmacokinetic O
or O
other O
formal O
drug O
interaction O
studies O
were O
conducted O
. O

Methylprednisolone B-drug

Vaccines B-group
neurological O
complications O
and O
lack O
of O
antibody O
response O
. O

Because O
of O
reports O
of O
prolongation O
of O
the O
prothrombin O
time O
beyond O
the O
therapeutic O
range O
in O
patients O
taking O
concurrent O
levamisole B-drug
and O
warfarin B-drug
sodium I-drug
, O
it O
is O
suggested O
that O
the O
prothrombin O
time O
be O
monitored O
carefully O
, O
and O
the O
dose O
of O
warfarin B-drug
sodium I-drug
or O
other O
coumarin-like B-group
drugs O
should O
be O
adjusted O
accordingly O
, O
in O
patients O
taking O
both O
drugs O
. O

Therefore O
, O
it O
can O
prolong O
bleeding O
time O
by O
approximately O
3 O
to O
4 O
minutes O
from O
baseline O
values O
. O

Time O
to O
reach O
Cmax O
is O
also O
prolonged O
by O
1 O
hour O
. O

There O
may O
remain O
some O
indications O
of O
the O
laxative O
and O
antacid O
properties O
of O
non O
soluble O
magnesium B-drug
, O
particularly O
during O
intermittent O
haemodialysis O
. O

Increased O
plasma O
levels O
of O
diazepam B-drug
were O
observed O
12 O
hours O
after O
dosing O
and O
onwards O
. O

Because O
of O
possible O
clinical O
significance O
, O
these O
two O
drugs O
should O
not O
be O
administered O
concurrently O
. O

increased O
thyroid O
binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
, O
as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O

Whether O
an O
alteration O
in O
norepinephrine B-drug
uptake-1 O
occurs O
is O
still O
unresolved O
. O

The O
possibility O
of O
altered O
safety O
and O
efficacy O
should O
be O
considered O
when O
Ponstel B-brand
is O
used O
concomitantly O
with O
these O
drugs O
. O

Interactions O
for O
vitamin B-group
D I-group
analogues I-group
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Immunosuppressives B-drug
: O
Cyclosporine B-drug
( O
CYP3A4 B-drug
substrate O
) O
administered O
in O
combination O
with O
oral O
amiodarone B-drug
has O
been O
reported O
to O
produce O
persistently O
elevated O
plasma O
concentrations O
of O
cyclosporine B-drug
resulting O
in O
elevated O
creatinine O
, O
despite O
reduction O
in O
dose O
of O
cyclosporine B-drug
. O

In O
addition O
, O
results O
from O
regression O
analyses O
of O
patient O
pharmacokinetic O
data O
suggest O
that O
co-administration O
of O
other O
inducers O
of O
drug O
clearance O
( O
efavirenz B-drug
, O
nevirapine B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
or O
carbamazepine B-drug
) O
with O
CANCIDAS B-brand
may O
result O
in O
clinically O
meaningful O
reductions O
in O
caspofungin B-drug
concentrations O
. O

Concomitant O
administration O
of O
drugs O
known O
to O
inhibit O
the O
activity O
of O
cytochrome O
P450 O
isozymes O
may O
increase O
the O
plasma O
levels O
of O
clozapine B-drug
. O

Insulin O
parameters O
were O
not O
affected O
. O

Specific O
and O
aspecific O
treatments O
of O
magnesium B-drug
depletion O
are O
tricky O
using O
for O
example O
magnesium B-group
sparing I-group
diuretics I-group
, O
pharmacological O
doses O
of O
vitamin B-drug
B6 I-drug
, O
physiological O
doses O
of O
vitamin B-group
D I-group
and O
of O
selenium B-drug
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

The O
effects O
of O
Mefloquineuine O
on O
the O
compromised O
cardiovascular O
system O
have O
not O
been O
evaluated O
. O

The O
clinical O
relevance O
of O
this O
difference O
is O
unknown O
. O

Caution O
is O
therefore O
advised O
in O
the O
coadministration O
of O
ATROVENT B-brand
Inhalation O
Aerosol O
with O
other O
anticholinergic-containing B-group
drugs O
. O

Amphotericin B-drug
B I-drug
injection O
and O
potassium-depleting O
agents O
: O
When O
corticosteroids B-group
are O
administered O
concomitantly O
with O
potassium-depleting O
agents O
( O
e.g. O
, O
amphotericin B-drug
B I-drug
, O
diuretics B-group
) O
, O
patients O
should O
be O
observed O
closely O
for O
development O
of O
hypokalemia O
. O

No O
clinically O
relevant O
pharmacokinetic O
interactions O
between O
anagrelide B-drug
and O
acetylsalicylic B-drug
acid I-drug
were O
observed O
. O

SETTING O
: O
Rural O
primary O
care O
centre O
. O

Cyclosporine B-drug
: O
Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-drug
with O
other O
members O
of O
the O
quinolone B-group
class I-group
. O

Wait O
2 O
weeks O
after O
stopping O
an O
MAO B-group
inhibitor I-group
before O
starting O
escitalopram B-drug
. O

Tolbutamide B-drug
: O
Aprepitant B-drug
, O
when O
given O
as O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
, O
decreased O
the O
AUC O
of O
tolbutamide B-drug
( O
a O
CYP2C9 O
substrate O
) O
by O
23 O
% O
on O
Day O
4 O
, O
28 O
% O
on O
Day O
8 O
, O
and O
15 O
% O
on O
Day O
15 O
, O
when O
a O
single O
dose O
of O
tolbutamide B-drug
500 O
mg O
was O
admini O
, O
stered O
orally O
prior O
to O
the O
administration O
of O
the O
3-day O
regimen O
of O
Aprepitant B-drug
and O
on O
Days O
4,8 O
, O
and O
15 O
. O

increased O
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII-X O
complex O
, O
II-VII-X O
complex O
, O
and O
beta-thromboglobulin O
; O

There O
is O
one O
report O
of O
cardiopulmonary O
arrest O
, O
with O
full O
recovery O
, O
in O
a O
patient O
who O
was O
taking O
a O
beta B-group
blocker I-group
( O
propranolol B-drug
) O
. O

Such O
agents O
must O
be O
discontinued O
at O
least O
seven O
days O
prior O
to O
starting O
therapy O
with O
VISTIDE B-brand
. O

Ephedrine B-drug
: O
Ephedrine B-drug
may O
enhance O
the O
metabolic O
clearance O
of O
corticosteroids B-group
, O
resulting O
in O
decreased O
blood O
levels O
and O
lessened O
physiologic O
activity O
, O
thus O
requiring O
an O
increase O
in O
corticosteroid B-group
dosage O
. O

- O
Anabolic B-group
steroids I-group
( O
nandrolone B-drug
[ O
e.g. O
, O
Anabolin B-brand
] O
, O
oxandrolone B-drug
[ O
e.g. O
, O
Anavar B-brand
] O
, O
oxymetholone B-drug
[ O
e.g. O
, O
Anadrol B-brand
] O
, O
stanozolol B-drug
[ O
e.g. O
, O
Winstrol B-brand
] O
) O
or O

When O
given O
concomitantly O
with O
felodipine B-drug
, O
the O
tacrolimus B-drug
blood O
concentration O
should O
be O
followed O
and O
the O
tacrolimus O
dose O
may O
need O
to O
be O
adjusted O
. O

Increased O
anticoagulation O
effects O
due O
to O
a O
drug O
interaction O
with O
erythromycin B-drug
may O
be O
more O
pronounced O
in O
the O
elderly O
. O

A O
specific O
treatment O
for O
extravasation O
reactions O
is O
unknown O
at O
this O
time O
. O

An O
interval O
of O
at O
least O
two O
hours O
between O
intake O
of O
this O
agent O
and O
chloroquine B-drug
should O
be O
observed O
. O

Amphetamines B-group
may O
decrease O
the O
hypotensive O
effect O
of O
antihypertensives B-group
. O

Although O
one O
study O
tentatively O
supports O
the O
hypothesis O
that O
such O
doses O
of O
ascorbic B-drug
acid I-drug
may O
be O
efficacious O
, O
a O
second O
study O
by O
the O
same O
group O
did O
not O
confirm O
the O
significant O
findings O
, O
and O
no O
clear O
, O
reproducible O
pattern O
of O
efficacy O
has O
emerged O
from O
the O
review O
of O
all O
the O
evidence O
. O

This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
and O
also O
with O
Clinitest O
tablets O
. O

Therefore O
, O
dose O
adjustments O
of O
concomitant O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
have O
a O
narrow O
therapeutic O
index O
( O
e.g. O
, O
flecainide B-drug
, O
vinblastine B-drug
, O
thioridazine B-drug
and O
most O
tricyclic B-group
antidepressants I-group
) O
may O
be O
required O
. O

Plasma O
concentrations O
of O
quinolone B-group
antibiotics I-group
are O
decreased O
when O
administered O
with O
antacids B-group
containing O
magnesium B-drug
, O
calcium B-drug
, O
or O
aluminum B-drug
. O

However O
, O
patients O
receiving O
infusions O
of O
FLOLAN B-brand
in O
clinical O
trials O
were O
maintained O
on O
anticoagulants B-group
without O
evidence O
of O
increased O
bleeding O
. O

Monitoring O
of O
cyclosporine B-drug
levels O
and O
possible O
adjustment O
of O
cyclosporine B-drug
dosage O
should O
be O
considered O
when O
these O
drugs O
are O
co-administered O
. O

Since O
amiodarone B-drug
is O
a O
substrate O
for O
CYP3A4 B-drug
, O
there O
is O
the O
potential O
that O
the O
use O
of O
St. O
John O
s O
Wort O
in O
patients O
receiving O
amiodarone B-drug
could O
result O
in O
reduced O
amiodarone B-drug
levels O
. O

However O
, O
decreases O
in O
exposure O
were O
as O
much O
as O
56 O
% O
and O
66 O
% O
, O
respectively O
, O
in O
individual O
subjects O
. O

Drug O
Class O

High O
concentrations O
of O
cefoxitin B-drug
in O
the O
urine O
may O
interfere O
with O
measurement O
of O
urinary O
17-hydroxy-corticosteroids O
by O
the O
Porter-Silber O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
reported O
. O

Based O
on O
total O
ertapenem B-drug
concentrations O
, O
probenecid B-drug
increased O
the O
AUC O
by O
25 O
% O
and O
reduced O
the O
plasma O
and O
renal O
clearances O
by O
20 O
% O
and O
35 O
% O
, O
respectively O
. O

CASE O
SUMMARY O
: O
A O
64-year-old O
African-American O
man O
was O
admitted O
to O
the O
hospital O
for O
worsening O
renal O
failure O
, O
elevated O
creatine O
phosphokinase O
, O
diffuse O
muscle O
pain O
, O
and O
severe O
muscle O
weakness O
. O

Allopurinol B-drug
: O
Increased O
possibility O
of O
skin O
rash O
, O
particularly O
in O
hyperuricemic O
patients O
may O
occur O
. O

Effects O
of O
xanthine B-group
derivatives I-group
in O
a O
light/dark O
test O
in O
mice O
and O
the O
contribution O
of O
adenosine O
receptors O
. O

Therefore O
, O
patients O
on O
propranolol B-drug
should O
be O
observed O
when O
COLESTID B-brand
Tablets O
are O
either O
added O
or O
deleted O
from O
a O
therapeutic O
regimen O
. O

Phenothiazines B-group
and O
butyrophenones B-group
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-drug
. O

There O
were O
no O
reports O
of O
skeletal O
myopathy O
in O
a O
placebo-controlled O
Phase O
I O
trial O
in O
which O
10 O
healthy O
subjects O
on O
stable O
simvastatin B-drug
therapy O
were O
treated O
concurrently O
with O
daptomycin B-drug
( O
4 O
mg/kg O
once O
every O
24 O
hours O
) O
for O
14 O
days O
. O

METHODS O
: O
We O
carried O
out O
two O
different O
3-way O
crossover O
studies O
in O
healthy O
subjects O
( O
each O
, O
n O
= O
9 O
) O
. O

In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta-blockers B-group
, O
clonidine B-drug
, O
guanethidine B-drug
, O
and O
reserpine B-drug
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O


Since O
barbiturates B-group
are O
potentiated O
by O
the O
anticholinesterases B-group
, O
they O
should O
be O
used O
cautiously O
in O
the O
treatment O
of O
convulsions O
. O

Patients O
receiving O
medications O
that O
interfere O
with O
platelet O
function O
or O
coagulation O
should O
have O
more O
frequent O
laboratory O
monitoring O
for O
thrombocytopenia O
. O

Pre-treatment O
with O
the O
CYP3A4 O
inducer O
rifampicin B-drug
decreased O
erlotinib B-drug
AUC O
by O
about O
2/3 O
. O

These O
doses O
are O
lower O
than O
the O
therapeutic O
doses O
for O
both O
drugs O
. O

Should O
not O
be O
used O
as O
sole O
protease B-group
inhibitor I-group
in O
combination O
with O
SUSTIVA B-brand
. O

In O
vitro O
studies O
: O
Studies O
in O
human O
liver O
microsomes O
showed O
that O
vardenafil B-drug
is O
metabolized O
primarily O
by O
cytochrome O
P450 O
( O
CYP O
) O
isoforms O
3A4/5 O
, O
and O
to O
a O
lesser O
degree O
by O
CYP2C9 O
. O

Careful O
observation O
is O
required O
when O
amantadine B-drug
is O
administered O
concurrently O
with O
central B-group
nervous I-group
system I-group
stimulants I-group
. O

Accutane B-brand
use O
is O
associated O
with O
depression O
in O
some O
patients O
. O

Antiretroviral B-group
regimens O
consisted O
of O
two O
reverse B-group
transcriptase I-group
inhibitors I-group
and O
one O
protease B-group
inhibitor I-group
. O

If O
concomitant O
treatment O
with O
AXERT B-brand
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

Fenbufen B-drug
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O

weaker O
inhibitors O
( O
erythromycin B-drug
, O
grapefruit O
juice O
) O
have O
not O
been O
studied O
. O

The O
risk O
of O
using O
loxapine B-drug
in O
combination O
with O
CNS-active O
drugs O
has O
not O
been O
systematically O
evaluated O
. O

In O
practice O
, O
the O
greatest O
value O
of O
the O
thioether O
assay O
appears O
to O
lie O
in O
its O
signal O
function O
. O

Renal O
clearance O
of O
ucb O
L057 O
in O
the O
presence O
of O
probenecid B-drug
decreased O
60 O
% O
, O
probably O
related O
to O
competitive O
inhibition O
of O
tubular O
secretion O
of O
ucb O
L057 O
. O

Fat O
redistribution O
: O
Redistribution/accumulation O
of O
body O
fat O
including O
central O
obesity O
, O
dorsocervical O
fat O
enlargement O
( O
buffalo O
hump O
) O
, O
peripheral O
wasting O
, O
facial O
wasting O
, O
breast O
enlargement O
, O
and O
cushingoid O
appearance O
have O
been O
observed O
in O
patients O
receiving O
antiretroviral B-group
therapy O
. O

In O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
PEGASYS B-brand
in O
combination O
with O
COPEGUS B-brand
, O
PEGASYS B-brand
treatment O
did O
not O
affect O
ribavirin B-drug
distribution O
or O
clearance O
. O

In O
addition O
, O
several O
cardiovascular O
drugs O
directly O
affect O
renal O
function O
and O
the O
management O
of O
patients O
with O
renal O
disease O
. O

FREQUENT O
PROTHROMBIN O
TIME/INR O
DETERMINATIONS O
ARE O
ADVISABLE O
UNTIL O
IT O
HAS O
BEEN O
DEFINITELY O
DETERMINED O
THAT O
THE O
PROTHROMBIN O
TIME/INR O
HAS O
STABILIZED O
. O

PEGASYS B-brand
and O
COPEGUS B-brand
are O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic O
reactions O
to O
this O
therapy O
may O
be O
greater O
in O
patients O
with O
impaired O
renal O
function O
. O

Volatile O
Anesthetic B-drug
Agents O
: O
. O

Lansoprazole B-drug
is O
metabolized O
through O
the O
cytochrome O
P450 O
system O
, O
specifically O
through O
the O
CYP3A O
and O
CYP2C19 O
isozymes O
. O

Cholinergic O
role O
in O
alcohol B-drug
's O
effects O
on O
evoked O
potentials O
in O
visual O
cortex O
of O
the O
albino O
rat O
. O

alopecia O

Use O
in O
Ambulatory O
Patients O
The O
effects O
of O
ROMAZICON B-brand
may O
wear O
off O
before O
a O
long-acting B-group
benzodiazepine I-group
is O
completely O
cleared O
from O
the O
body O
. O

Therefore O
, O
it O
is O
critically O
important O
for O
women O
of O
childbearing O
potential O
to O
select O
and O
commit O
to O
use O
2 O
forms O
of O
effective O
contraception O
simultaneously O
, O
at O
least O
1 O
of O
which O
must O
be O
a O
primary O
form O
, O
unless O
absolute O
abstinence O
is O
the O
chosen O
method O
, O
or O
the O
patient O
has O
undergone O
a O
hysterectomy O

Pharmacokinetics O
were O
assessed O
in O
two O
of O
these O
trials O
. O

increased O
serum O
digoxin B-drug
concentrations O
may O
result O
. O

monoamine B-group
oxidase I-group
inhibitors I-group
; O

There O
does O
not O
appear O
to O
be O
an O
increase O
in O
adverse O
events O
in O
subjects O
who O
received O
oral O
contraceptives B-group
and O
loratadine B-drug
. O

However O
, O
numerous O
potentiation O
effects O
have O
frequently O
been O
reported O
for O
combined O
exposure O
to O
substances O
of O
widespread O
use O
. O

Because O
of O
its O
lack O
of O
platelet O
effects O
, O
VIOXX B-brand
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

Monoamine B-drug
Oxidase I-drug
Inhibitors I-drug
: O
Guanethidine B-drug
or O
similarly O
acting O
compounds O
; O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post-marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Caution O
should O
be O
exercised O
when O
taking O
this O
medicine O
certain O
antibiotics B-group
, O
such O
as O
erythromycin B-drug
, O
clarithromycin B-drug
, O
or O
azithromycin B-drug
. O

Drugs O
Metabolized O
by O
Cytochrome O
P450IID6 O
( O
CYP2D6 O
) O
: O
Many O
drugs O
, O
including O
most O
antidepressants B-group
( O
SSRIs O
, O
many O
tricyclics B-group
) O
, O
beta-blockers B-group
, O
antiarrhythmics B-drug
, O
and O
antipsychotics B-group
are O
metabolized O
by O
the O
CYP2D6 O
isoenzyme O
. O

Moreover O
, O
each O
task O
induced O
significant O
alterations O
in O
hippocampal O
adenylate O
cyclase O
activity O
but O
in O
opposite O
directions O
. O

Registered O
trademark O
of O
Ames O
Company O
, O
Division O
of O
Miles O
Laboratories O
, O
Inc O
. O

Twenty O
four O
male O
Wistar O
rats O
were O
divided O
into O
four O
groups O
. O

Quinidine B-drug
: O
Immediate O
Release O
Capsules O
: O
There O
have O
been O
rare O
reports O
of O
an O
interaction O
between O
quinidine B-drug
and O
nifedipine B-drug
( O
with O
a O
decreased O
plasma O
level O
of O
quinidine B-drug
) O
. O

There O
is O
no O
known O
drug O
interference O
with O
standard O
clinical O
laboratory O
tests O
. O

The O
absorption O
of O
oral O
gemifloxacin B-drug
is O
significantly O
reduced O
by O
the O
concomitant O
administration O
of O
an O
antacid B-group
containing O
aluminum B-drug
and O
magnesium B-drug
. O

- O
Phenytoin B-drug
( O
e.g. O
, O
Dilantin B-brand
) O
Use O
of O
phenytoin B-drug
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and/or O
the O
side O
effects O
of O
phenytoin B-drug

Multivalent O
Cation-Containing O
Products O
: O
Concurrent O
administration O
of O
a O
quinolone B-group
, O
including O
ciprofloxacin B-drug
, O
with O
multivalent O
cation-containing O
products O
such O
as O
magnesium B-drug
or O
aluminum B-drug
antacids B-group
, O
sucralfate B-drug
, O
VIDEX B-brand
chewable/buffered O
tablets O
or O
pediatric O
powder O
, O
or O
products O
containing O
calcium B-drug
, O
iron B-drug
, O
or O
zinc B-drug
may O
substantially O
decrease O
the O
absorption O
of O
ciprofloxacin B-drug
, O
resulting O
in O
serum O
and O
urine O
levels O
considerably O
lower O
than O
desired O
. O

Compounds O
that O
have O
been O
tested O
in O
man O
include O
antipyrine B-drug
, O
digoxin B-drug
, O
propranolol B-drug
, O
theophylline B-drug
, O
and O
warfarin B-drug
and O
no O
clinically O
meaningful O
interactions O
were O
found O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
PEGASYS B-brand
in O
pregnant O
women O
. O

cholestyramine B-drug
; O

cases O
of O
rhabdomyolysis O
have O
been O
reported O
in O
seriously O
ill O
patients O
. O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
quinolones B-group
and O
theophylline B-drug
. O

. O

Use O
with O
Other O
Agents O
Affecting O
Myelopoesis O
: O
Drugs O
which O
may O
affect O
leukocyte O
production O
, O
including O
co-trimoxazole B-brand
, O
may O
lead O
to O
exaggerated O
leukopenia O
, O
especially O
in O
renal O
transplant O
recipients O
. O

Together O
with O
previous O
findings O
, O
these O
results O
suggest O
that O
the O
hippocampus O
is O
involved O
in O
both O
the O
so-called O
" O
hippocampal-dependent O
" O

A O
clinical O
interaction O
study O
was O
also O
conducted O
with O
alosetron B-drug
and O
the O
CYP3A4 O
substrate O
cisapride B-drug
. O

In O
addition O
, O
drugs O
that O
are O
actively O
secreted O
via O
this O
route O
( O
e.g. O
, O
triamterene B-drug
, O
metformin B-drug
and O
amiloride B-drug
) O
should O
be O
co-administered O
with O
care O
as O
they O
might O
increase O
dofetilide B-drug
levels O
. O

Endothelium-intact O
aortic O
rings O
from O
high-estradiol B-drug
rats O
were O
supersensitive O
to O
noradrenaline B-drug
when O
compared O
to O
vehicle- O
, O
progesterone- B-drug
and O
progesterone B-drug
+ O
high-estradiol-treated O
rats O
( O
pD2 O
values O
= O
7.77+/-0.12 O
, O
7.21+/-0.13 O
, O
6.93+/-0.04 O
and O
7.22+/-0.18 O
, O
respectively O
) O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
some O
quinolones B-group
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
controlled O
clinical O
trials O
and O
studies O
involving O
otherwise O
healthy O
adults O
with O
epilepsy O
. O

decreased O
antithrombin B-drug
3 I-drug
; O

The O
hypoglycemic O
action O
of O
sulfonylureas B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

The O
AUC O
and O
Cmax O
of O
both O
the O
( O
R O
) O
and O
( O
S O
) O
isomers O
of O
warfarin B-drug
were O
unaffected O
by O
concurrent O
dosing O
of O
0.3 O
mg O
cerivastatin B-drug
sodium I-drug
. O

Clinical O
studies O
with O
celecoxib B-drug
have O
identified O
potentially O
significant O
interactions O
with O
fluconazole B-drug
and O
lithium B-drug
. O

Rifabutin B-drug

Digitalis B-group

Coadministration O
of O
digoxin B-drug
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

The O
mechanism O
and O
long-term O
consequences O
of O
these O
events O
are O
currently O
unknown O
. O

- O
Estrogens B-group
( O
female O
hormones O
) O
or O

Administration O
of O
phenytoin B-drug
to O
patients O
receiving O
dopamine B-drug
HCl I-drug
has O
been O
reported O
to O
lead O
to O
hypotension O
and O
bradycardia O
. O

As O
immediate-early O
genes O
( O
IEGs O
) O
are O
thought O
to O
play O
a O
critical O
role O
in O
mediating O
stimulus-induced O
neural O
plasticity O
, O
IEG O
response O
induced O
by O
methamphetamine B-drug
( O
METH B-drug
) O
has O
been O
characterized O
to O
define O
the O
changes O
in O
gene O
expression O
that O
may O
underlie O
its O
long-lasting O
behavioral O
effects O
. O

In O
seven O
experiments O
reactions O
to O
norepinephrine B-drug
and O
oxytocin B-drug
were O
PGF2alpha B-drug
. O

Both O
itraconazole B-drug
and O
its O
major O
metabolite O
, O
hydroxyitraconazole B-drug_n
, O
are O
inhibitors O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O

Prothrombin O
times O
were O
measured O
four O
times O
weekly O
during O
five O
long-term O
experiments O
. O

Caution O
should O
be O
used O
when O
alosetron B-drug
and O
ketoconazole B-drug
are O
administered O
concomitantly O
. O

Caution O
is O
therefore O
advised O
when O
administering O
PEGANONE B-brand
to O
patients O
receiving O
coumarin B-group
anticoagulants I-group
. O

In O
vitro O
studies O
indicate O
CYP3A4 O
isoform O
and O
CYP1A2 O
isoform O
mediate O
the O
metabolism O
of O
levobupivacaine B-drug
to O
desbutyl B-drug_n
levobupivacaine I-drug_n
and O
3-hydroxy B-drug_n
levobupivacaine I-drug_n
, O
respectively O
. O

3 O
. O

Venlafaxine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-drug
10 O
mg O
and O
multiple O
doses O
of O
venlafaxine B-drug
ER O
( O
extended O
release O
) O
150 O
mg O
did O
not O
result O
in O
any O
significant O
changes O
in O
the O
pharmacokinetics O
of O
either O
zaleplon B-drug
or O
venlafaxine B-drug
. O

Amprenavir B-drug
does O
not O
inhibit O
CYP2D6 O
, O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2E1 O
, O
or O
uridine O
glucuronosyltransferase O
( O
UDPGT O
) O
. O

Co-administration O
of O
single O
25-mg O
dose O
warfarin B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
total O
lenalidomide B-drug
. O

Advantages O
offered O
by O
this O
class O
of O
antibiotics B-group
include O
optimal O
pharmacokinetics O
, O
effectiveness O
against O
multidrug-resistant O
organisms O
, O
and O
oral O
administration O
even O
when O
parenteral O
antibiotics B-drug
are O
generally O
used O
. O

- O
Amiodarone B-drug
( O
e.g. O
, O
Cordarone B-brand
) O
or O

Coadministration O
of O
Itraconazole B-drug
with O
oral O
midazolam B-drug
or O
triazolam B-drug
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O

Ritonavir B-drug
( O
600 O
mg O
b.i.d O
. O
) O
co-administered O
with O
Vardenafil B-drug
5 O
mg O
resulted O
in O
a O
49-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
13-fold O
increase O
in O
vardenafil B-drug
Cmax O
. O

Drug/Laboratory O
Test O
Interactions O
The O
administration O
of O
ceftazidime B-drug
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
when O
using O
CLINITEST O
tablets O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O

In O
addition O
, O
olanzapine B-drug
is O
not O
associated O
with O
a O
risk O
of O
agranulocytosis O
as O
seen O
with O
clozapine B-drug
or O
clinically O
significant O
hyperprolactinaemia O
as O
seen O
with O
risperidone B-drug
or O
prolongation O
of O
the O
QT O
interval O
. O

Ethinyl I-drug
estradiol I-drug
Norethindrone I-drug

Clinical O
trials O
have O
indicated O
that O
Pulmozyme B-brand
can O
be O
effectively O
and O
safely O
used O
in O
conjunction O
with O
standard O
cystic O
fibrosis O
therapies O
including O
oral O
, O
inhaled O
and/or O
parenteral O
antibiotics B-group
, O
bronchodilators B-group
, O
enzyme O
supplements O
, O
vitamins B-group
, O
oral O
or O
inhaled O
corticosteroids B-group
, O
and O
analgesics B-group
. O

Drug/Laboratory O
Test O
Interaction O
Captopril B-drug
may O
cause O
a O
false-positive O
urine O
test O
for O
acetone O
. O

Tolbutamide B-drug
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
tolbutamide B-drug
at O
concentrations O
in O
the O
clinical O
range O
. O

Interactions O
between O
COPAXONE B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

Therefore O
, O
patients O
without O
a O
functioning O
thyroid B-group
gland O
who O
are O
on O
thyroid O
replacement O
therapy O
may O
need O
to O
increase O
their O
thyroid O
dose O
if O
estrogens B-group
or O
estrogen-containing B-group
oral O
contraceptives B-group
are O
given O
. O

These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
. O

Serum O
samples O
from O
patients O
treated O
with O
cefoxitin B-drug
should O
not O
be O
analyzed O
for O
creatinine O
if O
withdrawn O
within O
2 O
hours O
of O
drug O
administration O
. O

- O
Gold B-drug
salts O
( O
medicine O
for O
arthritis O
) O
or O

Calcium B-group
channel I-group
blockers I-group
may O
also O
have O
an O
additive O
effect O
when O
given O
with O
TENORMIN B-brand
. O

Fluvoxamine B-drug
has O
also O
been O
shown O
to O
inhibit O
P450 O
1A2 O
, O
an O
isoform O
also O
involved O
in O
TCAmetabolism B-group
. O

Coadminstration O
with O
agents O
that O
induce O
3A4 O
activity O
may O
reduce O
the O
efficacy O
of O
DURAGESIC B-brand
. O

1 O
. O

Antiarrhythmics B-group
: O
amiodarone B-drug

Digitalis B-group
: O
Vitamin B-group
D I-group
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-group
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O

Administration O
of O
0.1-mg/kg O
( O
2 O
x O
ED95 O
) O
NIMBEX B-brand
at O
10 O
% O
or O
95 O
% O
recovery O
following O
an O
intubating O
dose O
of O
succinylcholine B-drug
( O
1 O
mg/kg O
) O
produced O
95 O
% O
neuromuscular O
block O
. O

There O
have O
been O
reports O
of O
interactions O
of O
erythromycin B-drug
with O
carbamazepine B-drug
, O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
hexobarbital B-drug
, O
phenytoin B-drug
, O
alfentanil B-drug
, O
cisapride B-drug
, O
disopyramide B-drug
, O
lovastatin B-drug
, O
bromocriptine B-drug
, O
valproate B-drug
, O
terfenadine B-drug
, O
and O
astemizole B-drug
. O

( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O

However O
, O
10 O
patients O
who O
switched O
from O
therapy O
with O
Interferon B-drug
beta I-drug
to O
COPAXONE B-brand
did O
not O
report O
any O
serious O
and O
unexpected O
adverse O
reactions O
thought O
to O
be O
related O
to O
treatment O
. O

Therefore O
, O
esomeprazole B-drug
may O
interfere O
with O
the O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
bioavailability O
( O
eg O
, O
ketoconazole B-drug
, O
iron B-drug
salts O
and O
digoxin B-drug
) O
. O

In O
a O
similar O
study O
, O
attempting O
to O
replicate O
this O
finding O
, O
no O
interactive O
effect O
on O
hepatic O
transaminases O
was O
identified O
. O

inhalation O
anesthetics B-group
; O

Because O
of O
its O
lack O
of O
platelet O
effects O
, O
CELEBREX B-brand
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

Paroxetine B-drug
( O
20 O
mg O
QD O
) O
increased O
the O
concentration O
of O
duloxetine B-drug
( O
40 O
mg O
QD O
) O
by O
about O
60 O
% O
, O
and O
greater O
degrees O
of O
inhibition O
are O
expected O
with O
higher O
doses O
of O
paroxetine B-drug
. O

Thus O
, O
when O
NSAIDs B-group
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

These O
findings O
suggest O
that O
intracellular O
Ca O
( O
2+ O
) O
release O
by O
cholinergic O
stimulation O
is O
critical O
for O
determining O
synergism O
with O
cAMP O
in O
parietal O
cell O
activation O
and O
that O
functional O
coupling O
between O
the O
Ca O
( O
2+ O
) O
store O
and O
the O
receptor O
is O
maintained O
by O
actin O
microfilaments O
. O

Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

Serum O
concentration O
of O
digoxin B-drug
and O
digitoxin B-drug
may O
increase O
when O
patients O
take O
antithyroid B-group
agents I-group
. O

The O
administration O
of O
naratriptan B-drug
with O
other O
5-HT1 B-group
agonists I-group
has O
not O
been O
evaluated O
in O
migraine O
patients O
. O

Molecular O
basis O
for O
the O
selective O
toxicity O
of O
amphotericin B-drug
B I-drug
for O
yeast O
and O
filipin B-drug_n
for O
animal O
cells O
. O

Estazolam B-drug
: O
Interaction O
with O
Other O
Drugs O
that O
are O
Metabolized O
by O
Cytochrome O
P450 O
( O
CYP O
) O
: O
At O
clinically O
relevant O
concentrations O
, O
in O
vitro O
studies O
indicate O
that O
estazolam B-drug
( O
0.6 O
M O
) O
was O
not O
inhibitory O
towards O
the O
major O
cytochrome O
P450 O
isoforms O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A O
. O

However O
, O
when O
the O
thioether O
concentration O
ranges O
within O
the O
limits O
of O
the O
normal O
value O
, O
one O
must O
not O
conclude O
that O
there O
is O
no O
, O
or O
negligible O
, O
exposure O
. O

- O
Naltrexone B-drug
( O
e.g. O
, O
Trexan B-brand
) O
( O
with O
long-term O
, O
high-dose O
use O
) O
or O

Drugs O
that O
reportedly O
may O
increase O
oral O
anticoagulant B-group
response O
, O
ie O
, O
increased O
prothrombin O
response O
, O
in O
man O
include O
: O
alcohol* B-drug
; O

Again O
, O
sertraline B-drug
neutralized O
the O
increase O
in O
glycemia O
after O
glucose B-drug
overload O
both O
in O
diabetic O
and O
non-diabetic O
rats O
. O

Coadministration O
of O
phenytoin B-drug
with O
40 O
mg O
SULAR B-brand
tablets O
in O
epileptic O
patients O
lowered O
the O
nisoldipine B-drug
plasma O
concentrations O
to O
undetectable O
levels O
. O

The O
effects O
of O
coadministration O
of O
BARACLUDE B-brand
with O
other O
drugs O
that O
are O
renally O
eliminated O
or O
are O
known O
to O
affect O
renal O
function O
have O
not O
been O
evaluated O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
adverse O
events O
when O
BARACLUDE B-brand
is O
coadministered O
with O
such O
drugs O
. O

Garlic O
Capsules O
Garlic O
capsules O
should O
not O
be O
used O
while O
taking O
saquinavir B-drug
( O
FORTOVASE B-brand
) O
as O
the O
sole O
protease B-group
inhibitor I-group
due O
to O
the O
risk O
of O
decreased O
saquinavir B-drug
plasma O
concentrations O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O

Mylotarg B-brand
is O
not O
known O
to O
interfere O
with O
any O
routine O
diagnostic O
tests O
. O

pyrazolones B-group
; O

. O

Oral O
Hypoglycemics B-group
: O
Bepridil B-drug
has O
been O
safely O
used O
in O
diabetic O
patients O
without O
significantly O
lowering O
their O
blood O
glucose O
levels O
or O
altering O
their O
need O
for O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
. O

however O
, O
patients O
with O
moderate O
to O
severe O
cardiovascular O
disease O
or O
those O
taking O
nitrate B-group
therapy O
are O
at O
increased O
risk O
for O
potentially O
serious O
cardiovascular O
adverse O
effects O
with O
sildenafil B-drug
therapy O
. O

A O
dose O
increase O
of O
lopinavir/ritonavir B-drug
to O
533/133 O
mg O
( O
4 O
capsules O
or O
6.5 O
mL O
) O
twice O
daily O
taken O
with O
food O
is O
recommended O
when O
used O
in O
combination O
with O
SUSTIVA B-brand
. O

Systemic O
antibiotic B-group
agents I-group
. O

Currently O
, O
it O
is O
conceived O
that O
a O
number O
of O
events O
, O
or O
hits O
, O
are O
required O
for O
the O
induction O
of O
tumors O
by O
chemical O
agents O
. O

In O
contrast O
, O
in O
Ontario O
alone O
, O
in O
1972 O
and O
1973 O
there O
were O
26 O
deaths O
in O
amphetamine B-drug
users O
, O
of O
which O
16 O
were O
due O
to O
accident O
suicide O
or O
homicide O
. O

These O
effects O
have O
been O
observed O
with O
co-administration O
of O
itraconazole B-drug
( O
a O
potent O
CYP3A4 B-drug
inhibitor O
) O
. O

Thus O
patients O
receiving O
oral O
anticoagulants B-group
and O
Fluvoxamine B-drug
Tablets O
should O
have O
their O
prothrombin O
time O
monitored O
and O
their O
anticoagulant B-group
dose O
adjusted O
accordingly O
. O

We O
compared O
indinavir B-drug
pharmacokinetics O
and O
gastric O
pH O
in O
12 O
human O
immunodeficiency O
virus-positive O
patients O
by O
use O
of O
800 O
mg O
of O
indinavir B-drug
alone O
versus O
800 O
mg O
of O
indinavir B-drug
administered O
1 O
h O
after O
didanosine B-drug
administration O
. O

3 O
. O

The O
possible O
adverse O
effects O
of O
ZINECARD B-brand
on O
the O
fertility O
of O
humans O
and O
experimental O
animals O
, O
male O
or O
female O
, O
have O
not O
been O
adequately O
studied O
. O

Terfenadine B-drug
, O
astemizole B-drug
and O
cisapride B-drug
are O
all O
metabolized O
by O
the O
cytochrome O
P450IIIA4 O
isozyme O
, O
and O
it O
has O
been O
demonstrated O
that O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
IIIA4 O
, O
blocks O
the O
metabolism O
of O
these O
drugs O
, O
resulting O
in O
increased O
plasma O
concentrations O
of O
parent O
drug O
. O

Loperamide B-drug
and O
morphine B-drug
( O
0.1 O
and O
1.0 O
mg/kg O
, O
s.c. O
) O
inhibited O
the O
dmPGE2 B-drug_n
( O
0.3 O
mg/kg O
, O
p.o O
. O
) O
-induced O
diarrhea O
in O
cecectomized O
rats O
. O

In O
geriatric O
subjects O
( O
n=7 O
) O
there O
was O
a O
reduction O
in O
the O
rate O
but O
not O
the O
extent O
of O
flurbiprofen B-drug
absorption O
. O

Influence O
of O
coadministration O
of O
fluoxetine B-drug
on O
cisapride B-drug
pharmacokinetics O
and O
QTc O
intervals O
in O
healthy O
volunteers O
. O

Coadministration O
of O
esomeprazole B-drug
30 O
mg O
and O
diazepam B-drug
, O
a O
CYP2C19 O
substrate O
, O
resulted O
in O
a O
45 O
% O
decrease O
in O
clearance O
of O
diazepam B-drug
. O

. O

SIDE O
EFFECTS O
( O
KEMSTRO B-brand
) O
The O
most O
common O
adverse O
reaction O
during O
treatment O
with O
baclofen B-drug
is O
transient O
drowsiness O
( O
10-63 O
% O
) O
. O

Coadministration O
of O
CRIXIVAN B-brand
and O
drugs O
primarily O
metabolized O
by O
CYP3A4 O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
other O
drug O
, O
which O
could O
increase O
or O
prolong O
its O
therapeutic O
and O
adverse O
effects O
. O

The O
relevance O
of O
this O
finding O
to O
humans O
is O
not O
known O
at O
this O
time O
. O

Effect O
of O
Sensipar B-brand
on O
other O
drugs O
: O
Drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
: O
Sensipar B-brand
is O
a O
strong O
in O
vitro O
inhibitor O
of O
CYP2D6 O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
pharmacokinetic O
basis O
of O
this O
interaction O
in O
10 O
normal O
subjects O
. O

In O
uninfected O
volunteers O
, O
46 O
% O
developed O
rash O
while O
receiving O
SUSTIVA B-brand
and O
clarithromycin B-drug
. O

Interactions O
for O
Vitamin B-drug
B3 I-drug
( O
Niacin B-drug
) O
: O
Antihypertensive B-group
Therapy O
: O
Nicotinic B-drug
acid I-drug
may O
potentiate O
the O
effects O
of O
ganglionic B-group
blocking I-group
agents I-group
and O
vasoactive O
drugs O
resulting O
in O
postural O
hypotension O
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Following O
oral O
administration O
of O
two O
150-mg O
sustained-release O
tablets O
with O
and O
without O
800 O
mg O
of O
cimetidine B-drug
, O
the O
pharmacokinetics O
of O
bupropion B-drug
and O
hydroxybupropion B-drug_n
were O
unaffected O
. O

In O
addition O
, O
most O
macrolides B-group
are O
contraindicated O
in O
patients O
receiving O
terfenadine B-drug
therapy O
who O
have O
pre-existing O
cardiac O
abnormalities O
( O
arrhythmia O
, O
bradycardia O
, O
QT O
c O
interval O
prolongation O
, O
ischemic O
heart O
disease O
, O
congestive O
heart O
failure O
, O
etc O
. O
) O
or O
electrolyte O
disturbances O
. O

OBJECTIVE O
: O
This O
paper O
reviews O
recent O
studies O
of O
the O
efficacy O
of O
sildenafil B-drug
, O
its O
adverse O
effects O
and O
drug O
interactions O
, O
and O
socioeconomic O
factors O
involved O
in O
its O
use O
, O
with O
a O
focus O
on O
specific O
patient O
populations O
( O
prostate O
cancer O
, O
diabetes O
mellitus O
, O
ischemic O
heart O
disease O
, O
spinal O
cord O
injuries O
, O
neurologic O
disorders O
) O
. O

Drug/Laboratory O
Test O
Interactions O
: O
Measurement O
of O
serum O
creatinine O
levels O
should O
be O
determined O
by O
the O
Jaffe O
reaction O
, O
since O
Ancobon B-brand
does O
not O
interfere O
with O
the O
determination O
of O
creatinine O
values O
by O
this O
method O
. O

Other O
strong O
selective O
CYP3A4 O
inhibitors O
such O
as O
ketoconazole B-drug
can O
also O
be O
expected O
to O
increase O
the O
exposure O
of O
zaleplon B-drug
. O

Phenobarbital B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-drug
; O

In O
two O
combined O
12-week O
placebo O
controlled O
trials O
that O
included O
BROVANA B-brand
doses O
of O
15 O
mcg O
twice O
daily O
, O
25 O
mcg O
twice O
daily O
, O
and O
50 O
mcg O
once O
daily O
, O
54 O
of O
873 O
BROVANA B-brand
-treated O
subjects O
received O
concomitant O
theophylline B-drug
at O
study O
entry O
. O

Limited O
comparative O
data O
in O
patients O
with O
high O
viral O
loads O
treated O
with O
nevirapine- B-drug
or O
delavirdine-based B-drug
regimens O
currently O
exist O
. O

Norepinephrine B-drug
: O
Amphetamines B-group
enhance O
the O
adrenergic O
effect O
of O
norepinephrine B-drug
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
400 O
mg O
daily O
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
rofecoxib B-drug
. O

) O

paraldehyde B-drug
; O

*Not O
administered O
, O
but O
an O
active O
metabolite O
of O
carbamazepine B-drug
. O

Clinical O
studies O
have O
shown O
increased O
sedation O
with O
concurrent O
hypnotic B-group
medications I-group
. O

The O
digoxin B-drug
median O
tmax O
was O
0.5 O
hours O
for O
both O
treatments O
. O

No O
pharmacokinetic O
interactions O
between O
dexmedetomidine B-drug
and O
isoflurane B-drug
, O
propofol B-drug
, O
alfentanil B-drug
, O
and O
midazolam B-drug
have O
been O
demonstrated O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
the O
dosage O
are O
required O
when O
nortriptyline B-drug
hydrochloride I-drug
is O
used O
with O
other O
anticholinergic B-group
drugs I-group
or O
sympathomimetic B-group
drugs I-group
. O

Also O
flucytosine B-drug
. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Theophylline B-drug
serum O
levels O
should O
be O
monitored O
and O
appropriate O
dose O
adjustments O
considered O
for O
patients O
given O
both O
theophylline B-drug
and O
PEGASYS B-brand
. O

AXERT B-brand
is O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

Bosentan B-drug
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
statins B-group
that O
have O
significant O
metabolism O
by O
CYP3A4 O
, O
such O
as O
lovastatin B-drug
and O
atorvastatin B-drug
. O

No O
clinically O
relevant O
interactions O
with O
drugs O
metabolized O
by O
these O
CYP O
enzymes O
would O
be O
expected O
. O

therefore O
, O
nitroglycerin B-drug
or O
other O
nitrates B-group
( O
as O
used O
for O
management O
of O
angina O
) O
or O
other O
drugs O
having O
vasodilator O
activity O
should O
, O
if O
possible O
, O
be O
discontinued O
before O
starting O
captopril B-drug
. O

( O
Thiazide B-group
drugs I-group
may O
increase O
the O
responsiveness O
to O
tubocurarine B-drug
. O
) O

DISULFIRAM B-drug
SHOULD O
BE O
USED O
WITH O
CAUTION O
IN O
THOSE O
PATIENTS O
REVEIVING O
PHENYTOIN B-drug
AND O
ITS O
CONGENERS O
. O

These O
increased O
exposures O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
should O
be O
taken O
into O
consideration O
when O
selecting O
an O
oral O
contraceptive B-group
for O
women O
taking O
valdecoxib B-drug
. O

Patients O
receiving O
narrow O
therapeutic O
ratio O
drugs O
or O
other O
drugs O
that O
require O
careful O
titration O
should O
be O
followed O
closely O
; O

Evidence O
supporting O
the O
conclusion O
that O
it O
is O
inadvisable O
to O
co-administer O
fluvoxamine B-drug
and O
diazepam B-drug
is O
derived O
from O
a O
study O
in O
which O
healthy O
volunteers O
taking O
150 O
mg/day O
of O
fluvoxamine B-drug
were O
administered O
a O
single O
oral O
dose O
of O
10 O
mg O
of O
diazepam B-drug
. O

Inhibition O
of O
these O
isoenzymes O
may O
increase O
the O
plasma O
concentration O
of O
bosentan B-drug
. O

These O
results O
are O
consistent O
with O
the O
in O
vitro O
finding O
that O
neither O
isotretinoin B-drug
nor O
its O
metabolites O
induce O
or O
inhibit O
the O
activity O
of O
the O
CYP O
2C9 O
human O
hepatic O
P450 O
enzyme O
. O

Although O
clinical O
studies O
have O
not O
been O
conducted O
, O
in O
vitro O
studies O
of O
iloprost B-drug
indicate O
that O
no O
relevant O
inhibition O
of O
cytochrome O
P450 O
drug O
metabolism O
would O
be O
expected O
. O

Quinolone B-group
Antibiotics O
: O
VIDEX B-brand
should O
be O
administered O
at O
least O
2 O
hours O
after O
or O
6 O
hours O
before O
dosing O
with O
ciprofloxacin B-drug
because O
plasma O
concentrations O
of O
ciprofloxacin B-drug
are O
decreased O
when O
administered O
with O
antacids B-group
containing O
magnesium B-drug
, O
calcium B-drug
, O
or O
aluminum B-drug
. O

Thyroid B-group
administration O
to O
a O
digitalized O
, O
hypothyroid O
patient O
may O
increase O
the O
dose O
requirement O
of O
digoxin B-drug
. O

Similarly O
, O
diazepam B-drug
decreased O
the O
antinociceptive O
effect O
of O
metamizol B-drug
( O
only O
in O
the O
tail-flick O
test O
) O
and O
indomethacin B-drug
. O

The O
following O
are O
examples O
of O
substances O
that O
may O
increase O
the O
blood-glucose-lowering O
effect O
and O
susceptibility O
to O
hypoglycemia O
: O
oral O
antidiabetes O
products O
, O
ACE B-group
inhibitors I-group
, O
disopyramide B-drug
, O
fibrates B-group
, O
fluoxetine B-drug
, O
MAO B-group
inhibitors I-group
, O
propoxyphene B-drug
, O
salicylates B-group
, O
somatostatin B-group
analog I-group
( O
e.g. O
, O
octreotide B-drug
) O
, O
sulfonamide B-group
antibiotics I-group
. O

Patients O
should O
be O
monitored O
for O
signs O
of O
withdrawal O
and O
their O
methadone B-drug
dose O
increased O
as O
required O
to O
alleviate O
withdrawal O
symptoms O
. O

Therefore O
, O
positive O
test O
results O
in O
patients O
receiving O
piperacillin B-drug
should O
be O
interpreted O
cautiously O
and O
confirmed O
by O
other O
diagnostic O
methods O
. O

Concomitant O
use O
of O
cimetidine B-drug
should O
be O
avoided O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
antacids B-group
may O
reduce O
plasma O
levels O
of O
diflunisal B-drug
. O

In O
patients O
who O
have O
been O
reported O
to O
be O
well O
controlled O
on O
tricyclic B-group
antidepressants I-group
receiving O
concurrent O
cimetidine B-drug
therapy O
, O
discontinuation O
of O
cimetidine B-drug
has O
been O
reported O
to O
decrease O
established O
steady-state O
serum O
tricyclic B-group
antidepressant I-group
levels O
and O
compromise O
their O
therapeutic O
effects O
. O

Insulin B-drug
requirements O
in O
diabetic O
patients O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O

at O
high O
doses O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
decreased O
FI O
and O
FR O
responding O
. O

The O
pharmacokinetics O
of O
terfenadine B-drug
and O
its O
acid O
metabolite O
and O
the O
electrocardiographic O
QT O
c O
interval O
were O
measured O
during O
both O
periods O
: O
with O
terfenadine B-drug
alone O
, O
and O
with O
terfenadine B-drug
plus O
dirithromycin B-drug
. O

Thus O
, O
if O
such O
treatment O
is O
essential O
, O
the O
possibility O
of O
increased O
risk O
relative O
to O
benefits O
should O
be O
considered O
. O

In O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
phenytoin B-drug
, O
the O
steadystate O
trough O
( O
Cmin O
) O
phenytoin B-drug
plasma O
concentration O
was O
17 O
5 O
micrograms/mL O
. O

Antiretroviral B-group
Agents I-group
: O
No O
drug O
interactions O
with O
other O
antiretroviral B-group
medications I-group
have O
been O
identified O
that O
would O
warrant O
alteration O
of O
either O
the O
enfuvirtide B-drug
dose O
or O
the O
dose O
of O
the O
other O
antiretroviral B-group
medication I-group
. O

Toxicology O
studies O
of O
heroin-related B-drug_n
deaths O
reveal O
frequent O
involvement O
of O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
including O
alcohol B-drug
, O
benzodiazepines B-group
such O
as O
diazepam B-drug
( O
Valium B-brand
) O
, O
and O
, O
to O
a O
rising O
degree O
, O
methadone B-drug
. O

Aprepitant B-drug
has O
been O
shown O
to O
induce O
the O
metabolism O
of O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
and O
tolbutamide B-drug
, O
which O
are O
metabolized O
through O
CYP2C9 O
. O

5 O
. O

Although O
increased O
plasma O
concentrations O
( O
C O
max O
and O
AUC O
0-24 O
hrs O
) O
of O
desloratadine B-drug
and O
3-hydroxydesloratadine B-drug_n
were O
observed O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
desloratadine B-drug
, O
as O
assessed O
by O
electrocardiographic O
parameters O
( O
including O
the O
corrected O
QT O
interval O
) O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O

Plasma O
exposure O
of O
diazepam B-drug
( O
10 O
mg O
BID O
) O
was O
increased O
by O
28 O
% O
following O
administration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
) O
for O
12 O
days O
, O
while O
plasma O
exposure O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
) O
was O
not O
substantially O
increased O
following O
administration O
of O
diazepam B-drug
( O
10 O
mg O
BID O
) O
for O
12 O
days O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
ampicillin B-drug
. O

Concomitant O
treatment O
with O
methylxanthines B-group
( O
aminophylline B-drug
, O
theophylline B-drug
) O
, O
steroids B-group
, O
or O
diuretics B-group
may O
potentiate O
any O
hypokalemic O
effect O
of O
adrenergic B-group
agonists I-group
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Drug/LaboratoryTest O
Interactions O
Dactinomycin B-drug
may O
interfere O
with O
bioassay O
procedures O
for O
the O
determination O
of O
antibacterial B-group
drug I-group
levels O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p.o O
. O

Intravenous O
Adenocard B-brand
( O
adenosine B-drug
) O
has O
been O
effectively O
administered O
in O
the O
presence O
of O
other O
cardioactive O
drugs O
, O
such O
as O
quinidine B-drug
, O
beta-adrenergic B-group
blocking I-group
agents I-group
, O
calcium B-group
channel I-group
blocking I-group
agents I-group
, O
and O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
, O
without O
any O
change O
in O
the O
adverse O
reaction O
profile O
. O

8 O
. O

At O
24 O
hours O
postdose O
, O
a O
similar O
proportion O
of O
patients O
treated O
with O
methotrexate B-drug
alone O
( O
94 O
% O
) O
and O
subsequently O
treated O
with O
methotrexate B-drug
co-administered O
with O
75 O
mg O
of O
rofecoxib B-drug
( O
88 O
% O
) O
had O
methotrexate B-drug
plasma O
concentrations O
below O
the O
measurable O
limit O
( O
5 O
ng/mL O
) O
. O

In O
a O
p53 O
( O
+/- O
) O
mouse O
carcinogenicity O
study O
at O
doses O
up O
to O
the O
maximum O
tolerated O
dose O
of O
100 O
mg/kg/day O
ribavirin B-drug
was O
not O
oncogenic O
. O

Results O
of O
studies O
in O
multiple O
sclerosis O
patients O
taking O
TYSABRI B-brand
and O
concomitant O
interferon B-drug
beta-1a I-drug
( O
AVONEX B-brand
30 O
mcg O
IM O
once O
weekly O
) O
or O
glatiramer B-drug
acetate I-drug
were O
inconclusive O
with O
regard O
to O
the O
need O
for O
dose O
adjustment O
of O
the O
beta-interferon B-drug
or O
glatiramer B-drug
acetate I-drug
. O

Laboratory O
Test O
Interactions O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
Caucasian O
population O
( O
about O
7-10 O
% O
of O
Caucasians O
are O
so-called O
poor O
metabolizers O
) O
; O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450IID6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

In O
general O
, O
any O
added O
antiarrhythmic B-drug
drug I-drug
should O
be O
initiated O
at O
a O
lower O
than O
usual O
dose O
with O
careful O
monitoring O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
rhabdomyolysis O
, O
some O
associated O
with O
strenuous O
physical O
activity O
. O

The O
effects O
of O
concomitant O
administration O
of O
TAMBOCOR B-brand
and O
propranolol B-drug
on O
the O
PR O
interval O
were O
less O
than O
additive O
. O

Influence O
of O
calcium-channel B-group
blockers I-group
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
. O

Amphetamines B-group
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

Studies O
have O
shown O
that O
lansoprazole B-drug
does O
not O
have O
clinically O
significant O
interactions O
with O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
such O
as O
warfarin B-drug
, O
antipyrine B-drug
, O
indomethacin B-drug
, O
ibuprofen B-drug
, O
phenytoin B-drug
, O
propranolol B-drug
, O
prednisone B-drug
, O
diazepam B-drug
, O
clarithromycin B-drug
, O
or O
terfenadine B-drug
in O
healthy O
subjects O
. O

We O
report O
the O
case O
of O
an O
adolescent O
with O
altered O
consciousness O
caused O
by O
carbamazepine B-drug
overdose O
with O
a O
positive O
tricyclic B-group
antidepressant I-group
level O
to O
alert O
clinicians O
to O
the O
cross-reactivity O
of O
carbamazepine B-drug
with O
a O
toxicology O
screen O
for O
tricyclic B-group
antidepressants I-group
. O

nc1 O
18 O
% O
decrease O
[ O
CI O
: O
13 O
% O
decrease O
, O
40 O
% O
decrease O
] O

Trough O
plasma O
enoxacin B-drug
levels O
were O
also O
20 O
% O
higher O
when O
caffeine B-drug
and O
enoxacin B-drug
were O
administered O
concomitantly O
. O

In O
contrast O
, O
preliminary O
results O
from O
an O
8-week O
controlled O
study O
suggested O
risperidone B-drug
2 O
to O
6 O
mg/day O
was O
superior O
to O
olanzapine B-drug
5 O
to O
20 O
mg/day O
against O
positive O
and O
anxiety/depressive O
symptoms O
( O
p O
< O
0.05 O
) O
, O
although O
consistent O
with O
the O
first O
study O
, O
both O
agents O
demonstrated O
similar O
efficacy O
on O
measures O
of O
overall O
psychopathology O
. O

The O
goal O
of O
this O
review O
was O
to O
cite O
primary O
sources O
for O
virtually O
all O
research O
specific O
to O
POPs O
since O
1975 O
. O

Then O
, O
the O
effects O
of O
metabotropic O
glutamate O
receptor O
( O
mGluR O
) O
agonists O
, O
DCG-IV B-drug_n
and O
L-CCG-1 B-drug_n
, O
on O
the O
above O
behavioral O
changes O
induced O
by O
PCP B-drug_n
were O
found O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

Patients O
treated O
with O
proton B-group
pump I-group
inhibitors I-group
and O
warfarin B-drug
concomitantly O
may O
need O
to O
be O
monitored O
for O
increases O
in O
INR O
and O
prothrombin O
time O
. O

Both O
hypo- O
and O
hyperglycemic O
effects O
have O
been O
reported O
. O

There O
were O
no O
clinically O
significant O
changes O
in O
corrected O
QT O
intervals O
during O
administration O
of O
cisapride B-drug
alone O
or O
with O
fluoxetine B-drug
. O

A O
rare O
, O
but O
serious O
, O
constellation O
of O
symptoms O
, O
termed O
serotonin O
syndrome O
, O
has O
been O
reported O
with O
the O
concomitant O
use O
of O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
and O
agents O
for O
migraine O
therapy O
, O
such O
as O
Imitrex B-brand
( O
sumatriptan B-drug
succinate I-drug
) O
and O
dihydroergotamine B-drug
. O

Concomitant O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
vincristine B-drug
, O
and O
prednisone B-drug
chemotherapy O
plus O
highly B-group
active I-group
antiretroviral I-group
therapy O
in O
patients O
with O
human O
immunodeficiency O
virus-related O
, O
non-Hodgkin O
lymphoma O
. O

Most O
automated O
equipment O
for O
measurement O
of O
creatinine O
makes O
use O
of O
the O
Jaffe O
reaction O
. O

Some O
quinolones B-group
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

vii O
. O

No O
inhibition O
of O
deferasirox B-drug
metabolism O
by O
hydroxyurea B-drug
is O
expected O
based O
on O
the O
results O
of O
an O
in O
vitro O
study O
. O

Since O
aminotransferase O
determinations O
are O
important O
in O
the O
differential O
diagnosis O
of O
myocardial O
infarction O
, O
liver O
disease O
and O
pulmonary O
emboli O
, O
rises O
that O
might O
be O
caused O
by O
drugs O
( O
heparin B-drug
sodium I-drug
) O
should O
be O
interpreted O
with O
caution O
. O

This O
product O
can O
affect O
the O
results O
of O
certain O
lab O
tests O
. O

The O
mean O
QT O
c O
interval O
( O
msec O
) O
was O
369 O
with O
terfenadine B-drug
alone O
and O
367 O
with O
terfenadine B-drug
plus O
dirithromycin B-drug
. O

Therefore O
you O
may O
need O
to O
take O
a O
vitamin B-drug
B12 I-drug
supplement O
while O
taking O
aminosalicylic B-drug
acid I-drug
. O

Beta B-group
Blockers I-group

Atorvastatin B-drug
: O
Atorvastatin B-drug
increases O
the O
AUC O
for O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
. O

Combinations O
of O
clindamycin B-drug
and O
gentamicin B-drug
were O
indifferent O
for O
29 O
strains O
and O
synergistic O
for O
33 O
strains O
. O

Agents O
Causing O
Renin O
Release O
Captopril B-drug
's O
effect O
will O
be O
augmented O
by O
antihypertensive B-group
agents I-group
that O
cause O
renin O
release O
. O

Amprenavir B-drug
inhibits O
the O
ERMBT O
, O
and O
rifampin B-drug
and O
rifabutin B-drug
are O
equipotent O
inducers O
of O
the O
ERMBT O
. O

Concomitant O
use O
of O
zalcitabine B-drug
and O
lamivudine B-drug
is O
not O
recommended O
. O

Although O
activation O
of O
several O
transcription O
factor O
IEGs O
has O
been O
described O
, O
little O
is O
known O
about O
effector O
IEGs O
. O

Clostridium B-drug_n
difficile I-drug_n
toxin I-drug_n
A I-drug_n
displays O
both O
cytotoxic O
and O
enterotoxic O
activities O
. O

It O
is O
likely O
that O
experience O
significantly O
underestimates O
the O
degree O
of O
accumulation O
that O
might O
occur O
with O
repealed O
diazepam B-drug
administration O
. O

The O
use O
of O
dexfenfluramine B-drug
with O
other O
CNS-active O
drugs O
has O
not O
been O
systematically O
evaluated O
; O

NSAIDs B-group
may O
decrease O
the O
hemodynamic O
effects O
of O
hydralazine B-drug
; O

therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
, O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
when O
Tagamet B-brand
is O
administered O
concomitantly O
. O

Genetic O
variation O
also O
occurs O
in O
proteins O
interacting O
with O
drugs O
, O
which O
may O
change O
the O
effect O
of O
e.g O
. O

Before O
using O
this O
medication O
, O
tell O
your O
doctor O
or O
pharmacist O
of O
all O
prescription O
and O
nonprescription O
products O
you O
may O
use O
, O
especially O
of O
: O
aminoglycosides B-group
( O
e.g. O
, O
gentamicin B-drug
, O
amikacin B-drug
) O
, O
amphotericin B-drug
B I-drug
, O
cyclosporine B-drug
, O
non-steroidal B-group
anti-inflammatory I-group
drugs O
( O
e.g. O
, O
ibuprofen B-drug
) O
, O
tacrolimus B-drug
, O
vancomycin B-drug
. O

- O
a O
diuretic B-group
( O
water O
pill O
) O
such O
as O
hydrochlorothiazide B-drug
( O
HCTZ B-drug
, O
Hydrodiuril B-brand
) O
, O
chlorothiazide B-drug
( O
Diuril B-brand
) O
, O
and O
others O
; O

Diuretics B-group
: O
Etodolac O
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
furosemide B-drug
or O
hydrochlorothiazide B-drug
. O

Interaction O
studies O
have O
been O
performed O
with O
fluvastatin B-drug
and O
several O
drugs O
with O
which O
it O
might O
be O
coadministered O
. O

As O
with O
other O
antihypertensive B-group
agents I-group
, O
the O
antihypertensive O
effect O
of O
losartan B-drug
may O
be O
blunted O
by O
the O
non-steroidal B-group
anti-inflammatory I-group
drug I-group
indomethacin B-drug

Erythromycin O
Co-administration O
of O
felodipine B-drug
( O
PLENDIL B-drug
) O
with O
erythromycin B-drug
resulted O
in O
approximately O
2.5- O
fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
and O
about O
2- O
fold O
prolongation O
in O
the O
half- O
life O
of O
felodipine B-drug
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
VELCADE B-brand
. O

If O
SPRYCEL B-brand
must O
be O
administered O
with O
a O
CYP3A4 O
inducer O
, O
a O
dose O
increase O
in O
SPRYCEL B-brand
should O
be O
considered O
. O

In O
a O
multiple-dose O
study O
, O
enoxacin B-drug
caused O
a O
dose-related O
increase O
in O
the O
mean O
elimination O
half-life O
of O
caffeine B-drug
, O
thereby O
decreasing O
the O
clearance O
of O
caffeine B-drug
by O
up O
to O
80 O
% O
and O
leading O
to O
a O
five-fold O
increase O
in O
the O
AUC O
and O
the O
half-life O
of O
caffeine B-drug
. O

Interaction O
between O
exogenous O
and O
endogenous O
oxytocin B-drug
and O
vasopressin O
was O
found O
to O
affect O
the O
mechanism O
of O
milk O
ejection O
by O
the O
alveoli O
of O
the O
mammary O
gland O
in O
lactating O
rats O
. O

Administration O
of O
ELLENCE B-brand
after O
previous O
radiation O
therapy O
may O
induce O
an O
inflammatory O
recall O
reaction O
at O
the O
site O
of O
the O
irradiation O
. O

[ O
The O
effect O
of O
cimetidine B-drug
on O
the O
renal O
excretion O
of O
verografin B-drug
and O
iodamide B-drug
in O
dogs O
] O
The O
intravenous O
injection O
of O
cimetidine B-drug
in O
a O
dose O
of O
20 O
mg/kg O
enhanced O
verografine B-drug
and O
iodamide B-drug
excretion O
in O
chronic O
canine O
experiments O
. O

An O
adjustment O
in O
the O
diltiazem B-drug
dose O
may O
be O
warranted O
. O

The O
concomitant O
use O
of O
heparin B-drug
or O
aspirin B-brand
during O
the O
first O
24 O
hours O
following O
symptom O
onset O
were O
prohibited O
in O
The O
NINDS O
t-PA O
Stroke O
Trial O
. O

The O
effects O
of O
concomitant O
administration O
of O
cimetidine B-drug
on O
the O
pharmacokinetics O
of O
bupropion B-drug
and O
its O
active O
metabolites O
were O
studied O
in O
24 O
healthy O
young O
male O
volunteers O
. O

Gleevec B-brand
will O
increase O
plasmaconcentration O
of O
other O
CYP3A4 O
metabolized O
drugs O
( O
e.g. O
, O
triazolo-benzodiazepines B-group
, O
dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
, O
certain O
HMG-CoA B-group
reductase I-group
inhibitors I-group
, O
etc O
. O
) O
. O

Pharmacokinetics O
of O
levetiracetam B-drug
were O
also O
not O
affected O
by O
phenytoin B-drug
. O

Fulvestrant B-drug
is O
metabolized O
by O
CYP O
3A4 O
in O
vitro O
. O

The O
results O
of O
assays O
using O
red O
cells O
from O
healthy O
subjects O
to O
determine O
whether O
ceftibuten B-drug
would O
cause O
direct O
Coombs O
reactions O
in O
vitro O
showed O
no O
positive O
reaction O
at O
ceftibuten B-drug
concentrations O
as O
high O
as O
40 O
g/mL O
. O

Theophylline B-drug
: O
Enoxacin B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P-450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-group
. O

Lithium B-drug
Reversible O
increases O
in O
serum O
lithium B-drug
concentrations O
and O
toxicity O
have O
been O
reported O
during O
concomitant O
administration O
of O
lithium B-drug
with O
ACE B-group
inhibitors I-group
, O
and O
with O
some O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
. O

Adjustment O
of O
adenosine B-drug
dosage O
may O
be O
necessary O
. O

The O
proposed O
mechanisms O
of O
analgesic O
action O
of O
antihistaminics B-group
are O
reviewed O
and O
discussed O
. O

PGF2alpha B-drug
produced O
significantly O
increased O
vasoconstriction O
after O
a O
single O
administration O
of O
oxytocin B-drug
. O

For O
these O
reasons O
, O
it O
is O
felt O
that O
, O
in O
most O
subjects O
who O
have O
had O
an O
unsatisfactory O
lipid O
response O
to O
either O
drug O
alone O
, O
the O
possible O
benefits O
of O
combined O
therapy O
with O
lovastatin B-drug
and O
a O
fibrate B-group
do O
not O
outweigh O
the O
risks O
of O
severe O
myopathy O
, O
rhabdomyolysis O
, O
and O
acute O
renal O
failure O
. O

The O
risk O
of O
hypoglycemia O
secondary O
to O
this O
mechanism O
may O
be O
increased O
if O
allopurinol B-drug
and O
chlorpropamide B-drug
are O
given O
concomitantly O
in O
the O
presence O
of O
renal O
insufficiency O
. O

When O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

As O
noted O
below O
, O
a O
sub- O
for O
fluvoxamine B-drug
in O
combination O
with O
alprazolam B-drug
, O
a O
drug O
that O
is O
known O
to O
be O
metabolized O
by O
the O
IIIA4 O
isozyme O
. O

In O
a O
clinical O
pharmacology O
study O
, O
indomethacin B-drug
or O
sulindac B-drug
was O
administered O
to O
hypertensive O
patients O
receiving O
VASOTEC B-brand
. O

Concomitant O
administration O
of O
alosetron B-drug
and O
moderate O
CYP1A2 O
inhibitors O
, O
including O
quinolone B-group
antibiotics I-group
and O
cimetidine B-drug
, O
has O
not O
been O
evaluated O
, O
but O
should O
be O
avoided O
unless O
clinically O
necessary O
because O
of O
similar O
potential O
drug O
interactions O
. O

This O
effect O
may O
be O
mediated O
by O
the O
ability O
of O
rifampin B-drug
to O
induce O
microsomal O
enzymes O
and O
, O
thus O
, O
the O
catabolism O
of O
warfarin B-drug
. O

NSAIDs B-group
should O
be O
used O
with O
caution O
in O
patients O
taking O
cyclosporine B-drug
, O
and O
renal O
function O
should O
be O
carefully O
monitored O
. O

The O
reddish O
color O
is O
due O
to O
the O
formation O
of O
a O
nonabsorbable O
complex O
between O
cefdinir B-drug
or O
its O
breakdown O
products O
and O
iron B-drug
in O
the O
gastrointestinal O
tract O
. O

On O
administration O
of O
oral O
amiodarone B-drug
, O
the O
need O
for O
digitalis B-group
therapy O
should O
be O
reviewed O
and O
the O
dose O
reduced O
by O
approximately O
50 O
% O
or O
discontinued O
. O

Anagrelide B-drug
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e.g O
. O

In O
vitro O
studies O
indicate O
that O
celecoxib B-drug
is O
not O
an O
inhibitor O
of O
cytochrome O
P450 O
2C9 O
, O
2C19 O
or O
3A4 O
. O

The O
metabolism O
of O
TAXOL B-brand
is O
catalyzed O
by O
cytochrome O
P450 O
isoen-zymes O
CYP2C8 O
and O
CYP3A4 O
. O

In O
order O
to O
maintain O
phenytoin B-drug
levels O
, O
limit O
adverse O
experiences O
, O
and O
achieve O
the O
felbamate B-drug
dose O
of O
3600 O
mg/day O
, O
a O
phenytoin B-drug
dose O
reduction O
of O
approximately O
40 O
% O
was O
necessary O
for O
eight O
of O
these O
10 O
subjects O
. O

Rare O
cases O
of O
a O
disulfiram-like O
reaction O
to O
alcohol B-drug
have O
been O
reported O
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased O
renal O
function O
, O
care O
should O
be O
taken O
in O
dose O
selection O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O

diet O
high O
in O
vitamin B-group
K I-group
; O

Oral O
Contraceptives B-group
: O
Valdecoxib B-drug
( O
40 O
mg O
BID O
) O
did O
not O
induce O
the O
metabolism O
of O
the O
combination O
oral O
contraceptive B-group
norethindrone/ethinyl B-drug
estradiol I-drug
( O
1 O
mg O
/35 O
mcg O
combination O
, O
Ortho-Novum B-brand
1/35 O
) O
. O

Ketoconazole B-drug

In O
vitro O
studies O
: O
Vardenafil B-drug
and O
its O
metabolites O
had O
no O
effect O
on O
CYP1A2 O
, O
2A6 O
, O
and O
2E1 O
( O
Ki O
100uM O
) O
. O

MAO B-group
inhibitors I-group
MAOI I-group
antidepressants I-group
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-drug
, O
slow O
amphetamine B-drug
metabolism O
. O

Occasionally O
TAXOL B-brand
infusions O
must O
be O
interrupted O
or O
discontinued O
because O
of O
initial O
or O
recurrent O
hypertension O
. O

Because O
their O
vasospastic O
effects O
may O
be O
additive O
, O
coadministration O
of O
naratriptan B-drug
and O
other O
5-HT1 B-group
agonists I-group
within O
24 O
hours O
of O
each O
other O
is O
not O
recommended O
. O

Drugs O
that O
are O
contraindicated O
specifically O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
adverse O
events O
are O
listed O
CONTRAINDICATIONS O
. O

It O
has O
not O
been O
as O
effective O
in O
women O
with O
sexual O
dysfunction O
, O
with O
the O
exception O
of O
SSRI-associated B-group
sexual O
dysfunction O
. O

Corticosteroids B-group
. O

Ethopropazine B-drug
can O
interact O
with O
chlorpromazine B-drug
, O
increasing O
the O
metabolism O
of O
chlorpromazine B-drug
. O

In O
1992 O
and O
1993 O
, O
two O
outbreaks O
of O
arsenical O
reactive O
encephalopathy O
( O
ARE O
) O
occurred O
in O
the O
sleeping O
sickness O
center O
of O
Adjumani O
. O

Herbal O
products O
: O
St. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O

Selegiline B-drug
: O
Combination B-group
hormonal I-group
contraceptives I-group
may O
increase O
the O
serum O
concentration O
of O
selegiline B-drug
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
BEXTRA B-brand
concomitantly O
with O
ACE-inhibitors B-group
. O

Ventricular O
tachycardia O
induced O
by O
ouabain B-drug
was O
generally O
converted O
to O
sinus O
rhythm O
following O
administration O
of O
Innovar B-brand
, O
ketamine B-drug
, O
or O
droperidol B-drug
but O
not O
after O
administration O
of O
fentayl B-drug
alone O
or O
after O
pentobarbital B-drug
. O

The O
most O
common O
adverse O
effects O
reported O
with O
olanzapine B-drug
are O
bodyweight O
gain O
, O
somnolence O
, O
dizziness O
, O
anticholinergic O
effects O
( O
constipation O
and O
dry O
mouth O
) O
and O
transient O
asymptomatic O
liver O
enzyme O
elevations O
. O

Lymphocytopenia O
has O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-brand
, O
and O
it O
is O
possible O
that O
the O
administration O
of O
dexamethasone B-drug
as O
antiemetic O
prophylaxis O
may O
have O
enhanced O
the O
likelihood O
of O
this O
effect O
. O

Because O
alosetron B-drug
is O
metabolized O
by O
a O
variety O
of O
hepatic O
CYP O
drug-metabolizing O
enzymes O
, O
inducers O
or O
inhibitors O
of O
these O
enzymes O
may O
change O
the O
clearance O
of O
alosetron B-drug
. O

Dual O
effect O
of O
ouabain B-drug
on O
the O
palytoxin-induced B-drug_n
contraction O
and O
norepinephrine O
release O
in O
the O
guinea-pig O
vas O
deferens O
. O

Aspirin B-brand
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids B-group
in O
hypoprothrombinemia O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
magnesium B-drug
hydroxide I-drug
and O
aluminum B-drug
hydroxide I-drug
does O
not O
interfere O
with O
the O
rate O
or O
extent O
of O
the O
absorption O
of O
ketoprofen B-drug
administered O
as O
Orudis B-brand
. O

Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
tricyclic B-drug
antidepressants I-drug
when O
used O
concomitantly O
with O
cimetidine B-drug
. O

Sildenafil B-drug
citrate I-drug
: O
a O
therapeutic O
update O
. O

Oral O
doses O
of O
Antizol B-brand
( O
10-20 O
mg/kg O
) O
, O
via O
alcohol O
dehydrogenase O
inhibition O
, O
significantly O
reduced O
the O
rate O
of O
elimination O
of O
ethanol B-drug
( O
by O
approximately O
40 O
% O
) O
given O
to O
healthy O
volunteers O
in O
moderate O
doses O
. O

Monitor O
salicylate B-group
levels O
or O
the O
therapeutic O
effect O
for O
which O
aspirin B-brand
is O
given O
; O

The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O

Cyclosporine O
, O
Digoxin O
, O
Methotrexate O
Lodine B-brand
, O
like O
other O
NSAIDs B-group
, O
through O
effects O
on O
renal O
prostaglandins O
, O
may O
cause O
changes O
in O
the O
elimination O
of O
these O
drugs O
leading O
to O
elevated O
serum O
levels O
of O
cyclosporine B-drug
, O
digoxin B-drug
, O
methotrexate B-drug
, O
and O
increased O
toxicity O
. O

Caution O
should O
be O
used O
when O
NSAIDs B-group
are O
administered O
concomitantly O
with O
methotrexate B-drug
. O

If O
the O
dose O
of O
lovastatin B-drug
is O
changed O
, O
the O
same O
procedure O
should O
be O
repeated O
. O

Although O
no O
clinical O
studies O
have O
been O
conducted O
, O
it O
is O
likely O
that O
the O
metabolism O
of O
levobupivacaine B-drug
may O
be O
affected O
by O
the O
known O
CYP3A4 O
inducers O
( O
such O
as O
phenytoin B-drug
, O
phenobarbital B-drug
, O
rifampin B-drug
) O
, O
CYP3A4 O
inhibitors O
( O
azole O
antimycotics O
e.g. O
, O
ketoconazole B-drug
; O

Salicylic B-drug
acid I-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
salicylic B-drug
acid I-drug
. O

When O
such O
drugs O
are O
withdrawn O
from O
patients O
receiving O
Acarbose B-drug
in O
combination O
with O
sulfonylureas B-group
or O
insulin B-drug
, O
patients O
should O
be O
observed O
closely O
for O
any O
evidence O
of O
hypoglycemia O
. O

Only O
with O
knowledge O
of O
the O
interaction O
can O
the O
therapeutic O
regimen O
be O
altered O
so O
as O
to O
provide O
therapeutic O
levels O
of O
necessary O
drugs O
while O
avoiding O
toxicity O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-drug
. O

Additionally O
, O
anti-malarial B-group
drugs I-group
, O
such O
as O
chloroquine B-drug
and O
mefloquine B-drug
, O
may O
antagonize O
the O
activity O
of O
carbamazepine B-drug
. O

Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
, O
or O
vaginal O
preparations O
of O
miconazole B-drug
is O
not O
known O
. O

. O

Agents O
Increasing O
Serum O
Potassium O
Since O
captopril B-drug
decreases O
aldosterone O
production O
, O
elevation O
of O
serum O
potassium O
may O
occur O
. O

In O
the O
first O
double-blind O
comparative O
study O
( O
28-week O
) O
of O
olanzapine B-drug
and O
risperidone B-drug
, O
olanzapine B-drug
10 O
to O
20 O
mg/day O
proved O
to O
be O
significantly O
more O
effective O
than O
risperidone B-drug
4 O
to O
12 O
mg/day O
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
but O
not O
on O
overall O
psychopathology O
symptoms O
. O

Secondary O
prevention O
of O
atherosclerotic O
risk O
factors O
is O
also O
important O
: O
regulation O
of O
blood O
pressure O
and O
blood O
sugar O
level O
, O
hyperlipidaemia O
and O
obesity O
, O
as O
well O
as O
a O
change O
of O
lifestyle O
( O
giving O
up O
smoking O
, O
adapting O
of O
diet O
and O
more O
physical O
exertion O
) O
. O

Drug/Laboratory O
Test O
Interactions O
FROVA B-brand
is O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O


By O
decreasing O
the O
gastrointestinal O
absorption O
of O
primidone B-drug
, O
DIAMOX B-brand
may O
decrease O
serum O
concentrations O
of O
primidone B-drug
and O
its O
metabolites O
, O
with O
a O
consequent O
possible O
decrease O
in O
anticonvulsant O
effect O
. O

Other O
plasma O
proteins O
may O
be O
increased O
( O
angiotensinogen/renin O
substrate O
, O
alpha-1-antitrypsin O
, O
ceruloplasmin O
) O
. O

These O
models O
are O
typically O
nonlinear O
in O
the O
parameters O
, O
and O
as O
such O
, O
a O
nonlinear O
weighted O
least O
squares O
approach O
can O
be O
employed O
for O
the O
purpose O
of O
designing O
experiments O
. O

Fluvoxamine B-drug
inhibits O
the O
CYP2C9 O
catalyzed O
biotransformation O
of O
tolbutamide B-drug
. O

Norepinephrine B-drug

Oral O
anticoagulants B-group
decreased O
prothrombin O
time O
response O
. O

No O
adjustment O
of O
dosage O
is O
recommended O
in O
such O
patients O
. O

In O
a O
placebo-controlled O
trial O
in O
normal O
volunteers O
, O
the O
administration O
of O
a O
single O
1 O
mg O
dose O
of O
doxazosin B-drug
on O
day O
1 O
of O
a O
four-day O
regimen O
of O
oral O
cimetidine B-drug
( O
400 O
mg O
twice O
daily O
) O
resulted O
in O
a O
10 O
% O
increase O
in O
mean O
AUC O
of O
doxazosin B-drug
( O
p=0.006 O
) O
, O
and O
a O
slight O
but O
not O
statistically O
significant O
increase O
in O
mean O
Cmax O
and O
mean O
half-life O
of O
doxazosin B-drug
. O

RESULTS O
. O

Similar O
decreases O
in O
Cmax O
and O
AUC O
were O
seen O
after O
the O
first O
dose O
. O

No O
in O
vitro O
metabolism O
studies O
were O
performed O
. O

If O
concomitant O
treatment O
with O
naratriptan B-drug
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

- O
Other O
anti-infectives B-group
by O
mouth O
or O
by O
injection O
( O
medicine O
for O
infection O
) O
or O

[ O
Multiple O
occupational O
exposure O
to O
solvents O
] O
This O
article O
review O
papers O
published O
over O
the O
last O
20 O
years O
on O
multiple O
occupational O
exposure O
to O
solvents O
. O

Drug O
exposure O
in O
rodent O
pups O
from O
fulvestrant-treated B-drug
lactating O
dams O
was O
estimated O
as O
10 O
% O
of O
the O
administered O
dose O
. O

If O
rifampicin B-drug
therapy O
is O
required O
, O
isradipine B-drug
concentrations O
and O
therapeutic O
effects O
are O
likely O
to O
be O
markedly O
reduced O
or O
abolished O
as O
a O
consequence O
of O
increased O
metabolism O
and O
higher O
clearance O
of O
isradipine B-drug
. O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Subsequent O
adjustment O
of O
doses O
of O
mercaptopurine B-drug
or O
azathioprine B-drug
should O
be O
made O
on O
the O
basis O
of O
therapeutic O
response O
and O
the O
appearance O
of O
toxic O
effects O
. O

All O
drugs O
were O
injected O
intraperitoneally O
. O

Glyburide B-drug
: O
Etodolac B-drug
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
glyburide B-drug
. O

Concomitant O
administration O
of O
fenofibrate B-drug
( O
equivalent O
to O
145 O
mg O
TRICOR B-brand
) O
with O
atorvastatin B-drug
( O
20 O
mg O
) O
once O
daily O
for O
10 O
days O
resulted O
in O
approximately O
17 O
% O
decrease O
( O
range O
from O
67 O
% O
decrease O
to O
44 O
% O
increase O
) O
in O
atorvastatin B-drug
AUC O
values O
in O
22 O
healthy O
males O
. O

Drug/Food O
Interactions O
The O
bioavailability O
( O
AUC O
) O
of O
deferasirox B-drug
was O
variably O
increased O
when O
taken O
with O
a O
meal O
. O

Pharmacokinetic O
data O
from O
these O
patients O
demonstrated O
a O
decrease O
in O
paclitaxel B-drug
clearance O
of O
approximately O
33 O
% O
when O
TAXOL B-brand
was O
administered O
following O
cisplatin B-drug
. O

In O
secretions O
such O
as O
colostrum O
, O
IgA O
is O
the O
only O
protein O
precipitated O
by O
jacalin B-drug_n
. O

Trecator B-brand
has O
been O
found O
to O
temporarily O
raise O
serum O
concentrations O
of O
isoniazid B-drug
. O

Therefore O
, O
when O
MIDAMOR B-brand
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

Omeprazole B-drug
: O
The O
rate O
and O
extent O
of O
absorption O
of O
ciprofloxacin B-drug
was O
bioequivalent O
when O
Proquin B-brand
XR I-brand
was O
given O
alone O
or O
when O
Proquin B-brand
XR I-brand
was O
given O
2 O
hours O
after O
omeprazole B-drug
at O
the O
dose O
that O
maximally O
suppresses O
gastric O
acid O
secretion O
. O

Chlorotrianisene B-drug
may O
interact O
with O
antidepressants B-group
, O
aspirin B-brand
, O
barbiturates B-group
, O
bromocriptine B-drug
, O
calcium B-drug
supplements O
, O
corticosteroids B-group
, O
corticotropin B-drug
, O
cyclosporine B-drug
, O
dantrolene B-drug
, O
nicotine B-drug
, O
somatropin B-drug
, O
tamoxifen B-drug
, O
and O
warfarin B-drug
. O

Therefore O
, O
co-administration O
of O
clozapine B-drug
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
antidepressants B-group
, O
phenothiazines B-group
, O
carbamazepine B-drug
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
and O
encainide B-drug
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
e.g. O
, O
quinidine B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

There O
is O
a O
significant O
increase O
in O
exposure O
to O
imatinib B-drug
when O
Gleevec B-brand
is O
coadministered O
with O
ketoconazole B-drug
( O
CYP3A4 O
inhibitor O
) O
. O

There O
is O
one O
report O
suggesting O
that O
the O
concomitant O
use O
of O
trazodone B-drug
hydrochloride I-drug
( O
Desyrel B-brand
) O
and O
buspirone B-drug
HCl I-drug
may O
have O
caused O
3- O
to O
6-fold O
elevations O
on O
SGPT O
( O
ALT O
) O
in O
a O
few O
patients O
. O

An O
alternative O
or O
additional O
method O
of O
contraception O
is O
recommended O
. O

- O
rifampin B-drug
( O
Rifadin B-brand
, O
Rifamate B-brand
) O
; O

ACE B-group
inhibitors I-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
Angiotensin B-group
Converting I-group
Enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
. O

Cimetidine B-drug
: O
Atorvastatin B-drug
plasma O
concentrations O
and O
LDL-C O
reduction O
were O
not O
altered O
by O
coadministration O
of O
cimetidine B-drug
. O

In O
vivo O
studies O
: O
Nitrates B-group
: O
The O
blood O
pressure O
lowering O
effects O
of O
sublingual O
nitrates B-group
( O
0.4 O
mg O
) O
taken O
1 O
and O
4 O
hours O
after O
vardenafil B-drug
and O
increases O
in O
heart O
rate O
when O
taken O
at O
1 O
, O
4 O
and O
8 O
hours O
were O
potentiated O
by O
a O
20 O
mg O
dose O
of O
Vardenafil B-drug
in O
healthy O
middle-aged O
subjects O
. O

aeruginosa O
serotype O
O11 O
strains O
, O
but O
not O
S O
. O

Eprosartan B-drug
has O
been O
shown O
to O
have O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
and O
the O
pharmacodynamics O
of O
warfarin B-drug
and O
glyburide B-drug
. O

Neither O
subject O
demonstrated O
clinical O
evidence O
of O
allergic O
or O
anaphylactic O
reactions O
and O
repeat O
testing O
was O
not O
performed O
. O

No O
specific O
information O
available O

METHODS O
: O
Healthy O
subjects O
who O
were O
20 O
to O
43 O
years O
old O
participated O
in O
an O
open O
, O
three-period O
, O
randomized O
, O
crossover O
study O
of O
the O
pharmacokinetics O
of O
a O
single O
10-mg O
oral O
dose O
of O
sirolimus B-drug
, O
a O
single O
oral O
120-mg O
dose O
of O
diltiazem B-drug
, O
and O
the O
two O
drugs O
given O
together O
. O

These O
lines O
showed O
variable O
degrees O
of O
locomotor O
activities O
in O
response O
to O
cocaine B-drug
. O

An O
adequate O
period O
of O
observation O
must O
be O
provided O
for O
any O
patient O
in O
whom O
either O
long-acting B-group
benzodiazepines I-group
( O
such O
as O
diazepam B-drug
) O
or O
large O
doses O
of O
short-acting B-group
benzodiazepines I-group
( O
such O
as O
10 O
mg O
of O
midazolam B-drug
) O
have O
been O
used O
. O

The O
vasodilating O
effects O
of O
isosorbide B-drug
dinitrate I-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

In O
the O
Duloxetine B-drug
clinical O
trials O
database O
, O
three O
Duloxetine-treated B-drug
patients O
had O
liver O
injury O
as O
manifested O
by O
ALT O
and O
total O
bilirubin O
elevations O
, O
with O
evidence O
of O
obstruction O
. O

Stavudine B-drug
and O
Zidovudine B-drug
Ribavirin I-drug
can O
antagonize O
the O
in O
vitro O
antiviral O
activity O
of O
stavudine B-drug
and O
zidovudine B-drug
against O
HIV O
. O

No O
reported O
interactions O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
low O
and O
high O
doses O
of O
estradiol B-drug
, O
and O
of O
progesterone B-drug
on O
the O
response O
to O
noradrenaline B-drug
in O
rat O
thoracic O
aorta O
. O

The O
similarity O
of O
the O
TYSABRI B-brand
-associated O
adverse O
event O
profile O
between O
Study O
1 O
( O
without O
co-administered O
AVONEX B-brand
) O
and O
Study O
2 O
( O
with O
co-administered O
AVONEX B-brand
) O
indicates O
that O
this O
alteration O
in O
clearance O
does O
not O
necessitate O
reduction O
of O
the O
TYSABRI B-brand
dose O
to O
maintain O
safety O
, O
General O
) O
. O

Haloperidol B-drug
: O
Haloperidol B-drug
blocks O
dopamine O
and O
norepinephrine O
reuptake O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
. O

Patients O
on O
oral O
antidiabetic B-group
agents I-group
receiving O
VELCADE B-brand
treatment O
may O
require O
close O
monitoring O
of O
their O
blood O
glucose O
levels O
and O
adjustment O
of O
the O
dose O
of O
their O
antidiabetic B-group
medication I-group
. O

Concurrent O
administration O
of O
cimetidine B-drug
and O
tricyclic B-group
antidepressants I-group
can O
produce O
clinically O
significant O
increases O
in O
the O
plasma O
levels O
of O
the O
tricyclic B-group
antidepressants I-group
. O

Haemodynamic O
effects O
of O
glucose B-drug
and O
insulin B-drug
were O
additive O
when O
somatostatin B-drug
was O
co-administered O
but O
not O
under O
basal O
conditions O
. O

Inhibits O
CYP1A2 O
( O
weak O
) O
, O
2B6 O
( O
weak O
) O
, O
2C19 O
( O
weak O
) O
, O
3A4 O
( O
weak O
) O
. O

Subjects O
who O
do O
not O
metabolize O
losartan B-drug
to O
active O
metabolite O
have O
been O
shown O
to O
have O
a O
specific O
, O
rare O
defect O
in O
cytochrome O
P450 O
2C9 O
. O

This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O

Thus O
, O
probenecid B-drug
should O
not O
be O
administered O
concurrently O
with O
bumetanide B-drug
. O

A O
3-fold O
increase O
was O
seen O
in O
another O
5 O
patients O
. O

However O
, O
the O
systemic O
administration O
of O
some O
quinolones B-group
has O
been O
shown O
to O
elevate O
plasma O
concentrations O
of O
theophylline B-drug
, O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
, O
and O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
and O
its O
derivatives O
, O
and O
has O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
systemic O
cyclosporine B-drug
concomitantly O
. O

Other O
Agents O

Coumarin B-group
Anticoagulants I-group
: O
There O
have O
been O
rare O
reports O
of O
increased O
prothrombin O
time O
in O
patients O
taking O
coumarin B-group
anticoagulants I-group
to O
whom O
nifedipine B-drug
was O
administered O
. O

In O
a O
pharmacokinetic O
study O
, O
40 O
healthy O
female O
subjects O
received O
fluvoxamine B-drug
in O
escalating O
doses O
from O
50 O
to O
200 O
mg O
per O
day O
for O
16 O
days O
, O
with O
coadministration O
of O
alosetron B-drug
1 O
mg O
on O
the O
last O
day O
. O

Anakinra B-drug
: O
Concurrent O
administration O
of O
anakinra B-drug
( O
an O
interleukin-1 B-group
antagonist I-group
) O
and O
another O
TNF-blocking B-group
agent I-group
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
an O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O

Some O
of O
the O
CNS O
and O
genitourinary O
symptoms O
may O
be O
related O
to O
the O
underlying O
disease O
rather O
than O
to O
drug O
therapy O
. O

This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
but O
not O
with O
the O
glucose O
enzymatic O
test O
. O

If O
co-administration O
is O
essential O
, O
conduct O
close O
clinical O
and O
laboratory O
monitoring O

Using O
this O
technique O
, O
it O
was O
possible O
to O
escalate O
the O
cisplatin B-drug
dose O
to O
225 O
mg/m2 O
before O
dose-limiting O
toxicities O
were O
encountered O
. O

Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta-blocker B-group
is O
administered O
to O
patients O
receiving O
catecholamine-depleting O
drugs O
such O
as O
reserpine B-drug
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and/or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
or O
postural O
hypotension O
. O

primidone B-drug
; O

Physiological O
oral O
magnesium B-drug
load O
constitutes O
the O
best O
tool O
for O
diagnosis O
of O
magnesium B-drug
deficiency O
and O
the O
first O
step O
of O
its O
treatment O
. O

sildenafil I-drug
concentration O

Concomitant O
administration O
of O
Kerlone B-brand
with O
the O
oral O
anticoagulant B-group
warfarin B-drug
has O
been O
shown O
not O
to O
potentiate O
the O
anticoagulant O
effect O
of O
warfarin B-drug
. O

Free O
hormone O
concentrations O
may O
be O
decreased O
. O

2 O
. O

Diazepam B-drug
at O
doses O
of O
0.25 O
mg/kg O
and O
2.5 O
mg/kg O
injected O
with O
morphine B-drug
was O
found O
to O
decrease O
the O
antinociceptive O
effect O
of O
morphine B-drug
. O

Mutagenesis O
Impairment O
of O
Fertility O
PEGASYS B-brand
may O
impair O
fertility O
in O
women O
. O

Caution O
should O
be O
used O
if O
ibuprofen B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

However O
, O
antacids B-group
can O
decrease O
the O
peak O
concentration O
reached O
by O
15 O
% O
to O
20 O
% O
but O
have O
no O
detectable O
effect O
on O
the O
time-to-peak O
. O

The O
anesthesiologist O
should O
be O
informed O
when O
a O
patient O
is O
receiving O
labetalol B-drug
HCl I-drug
. O

Interactions O
with O
Other O
Antiretroviral B-group
Drugs I-group
: O
Significant O
decreases O
in O
the O
AUC O
of O
delavirdine B-drug
( O
20 O
% O
) O
and O
indinavir B-drug
( O
84 O
% O
) O
occurred O
following O
simultaneous O
administration O
of O
these O
agents O
with O
VIDEX B-brand
. O

Other O
Drugs O
: O
Drugs O
such O
as O
quinidine B-drug
, O
disopyramide B-drug
, O
procainamide B-drug
, O
phenothiazines B-group
, O
antihistamines B-group
, O
and O
tricyclic B-group
antidepressants I-group
may O
be O
associated O
with O
QT-interval O
prolongation O
and O
an O
increased O
risk O
of O
ventricular O
arrhythmia O
. O

Cyclophosphamide B-drug
treatment O
, O
which O
causes O
a O
marked O
and O
persistent O
inhibition O
of O
cholinesterase O
activity O
, O
potentiates O
the O
effect O
of O
succinylcholine B-drug
chloride I-drug
. O

Chloral B-drug
hydrate I-drug
may O
cause O
an O
increased O
prothrombin O
response O
by O
displacing O
the O
anticoagulant B-group
from O
protein O
binding O
sites O
or O
a O
diminished O
prothrombin O
response O
through O
increased O
metabolism O
of O
the O
unbound O
drug O
by O
hepatic O
enzyme O
induction O
, O
thus O
leading O
to O
inter-patient O
variation O
in O
ultimate O
prothrombin O
effect O
. O

The O
plasma O
concentration O
of O
imipramine B-drug
may O
increase O
when O
the O
drug O
is O
given O
concomitantly O
with O
hepatic O
enzyme O
inhibitors O
( O
e.g. O
, O
cimetidine B-drug
, O
fluoxetine B-drug
) O
and O
decrease O
by O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e.g. O
, O
barbiturates B-group
, O
phenytoin B-drug
) O
, O
and O
adjustment O
of O
the O
dosage O
of O
imipramine B-drug
may O
therefore O
be O
necessary O
. O

Lomefloxacin B-drug
is O
unlikely O
to O
have O
a O
significant O
effect O
on O
phenytoin B-drug
metabolism O
. O

Hemodynamic O
and O
electrophysiologic O
interactions O
have O
also O
been O
observed O
after O
concomitant O
administration O
with O
propranolol B-drug
, O
diltiazem B-drug
, O
and O
verapamil B-drug
. O

Therefore O
, O
appropriate O
dose O
adjustments O
may O
be O
necessary O
for O
these O
drugs O
. O

- O
Perhexiline B-drug
hydrogen I-drug
maleate I-drug
or O
MAO-inhibitors B-group
( O
with O
hepatotoxic O
potential O
) O
must O
not O
be O
administered O
together O
with O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
. O

These O
data O
suggest O
that O
the O
conversion O
of O
losartan B-drug
to O
its O
active O
metabolite O
is O
mediated O
primarily O
by O
P450 O
2C9 O
and O
not O
P450 O
3A4 O
. O

Analgesia O
and O
pupil O
constriction O
were O
measured O
. O

Effects O
on O
in O
vitro O
excystment O
rates O
over O
a O
2 O
h O
period O
demonstrated O
widespread O
effects O
for O
cercariae-exposed O
P O
. O

In O
a O
single O
subject O
given O
one O
dose O
of O
ciprofloxacin B-drug
2 O
hours O
after O
a O
dose O
of O
didanosine-placebo B-drug
tablets O
, O
a O
greater O
than O
50 O
% O
reduction O
in O
the O
AUC O
of O
ciprofloxacin B-drug
was O
observed O
. O

If O
you O
are O
also O
using O
a O
steroid B-group
inhaler O
, O
take O
bitolterol B-drug
first O
and O
then O
wait O
about O
15 O
minutes O
before O
using O
the O
steroid B-group
inhaler O
. O

Urinary O
acidifying O
agents O
These O
agents O
( O
ammonium B-drug
chloride I-drug
, O
sodium B-drug
acid I-drug
phosphate I-drug
, O
etc O
. O
) O
increase O
the O
concentration O
of O
the O
ionized O
species O
of O
the O
amphetamine B-drug
molecule O
, O
thereby O
increasing O
urinary O
excretion O
. O

6 O
. O

In O
vitro O
, O
nilutamide B-drug
has O
been O
shown O
to O
inhibit O
the O
activity O
of O
liver O
cytochrome O
P-450 O
isoenzymes O
and O
therefore O
, O
may O
reduce O
the O
metabolism O
of O
compounds O
requiring O
these O
systems O
. O

Both O
of O
these O
effects O
were O
endothelium-dependent O
. O

Although O
clinical O
studies O
have O
not O
established O
a O
cause O
and O
effect O
relationship O
, O
physicians O
should O
be O
aware O
that O
variable O
effects O
an O
blood O
coagulation O
have O
been O
reported O
very O
rarely O
in O
patients O
receiving O
oral O
anticoagulants B-group
and O
chlordiazepoxide B-drug
. O

There O
was O
no O
evidence O
in O
clinical O
trials O
of O
drug O
interactions O
with O
concurrent O
medications O
. O

Erythromycin B-drug
use O
in O
patients O
who O
are O
receiving O
high O
doses O
of O
theophylline B-drug
may O
be O
associated O
with O
an O
increase O
in O
serum O
theophylline B-drug
levels O
and O
potential O
theophylline B-drug
toxicity O
. O

If O
concomitant O
use O
can O
not O
be O
avoided O
, O
serum O
levels O
of O
theophylline B-drug
should O
be O
monitored O
and O
dosage O
adjustments O
made O
as O
appropriate O
. O

In O
a O
study O
in O
normal O
volunteers O
, O
it O
was O
found O
that O
chronic O
concurrent O
administration O
of O
3.6 O
g O
of O
aspirin B-brand
per O
day O
decreases O
indomethacin B-drug
blood O
levels O
approximately O
20 O
% O
. O

The O
safety O
and O
efficacy O
of O
concomitant O
use O
of O
REVIA B-brand
and O
disulfiram B-drug
is O
unknown O
, O
and O
the O
concomitant O
use O
of O
two O
potentially O
hepatotoxic O
medications O
is O
not O
ordinarily O
recommended O
unless O
the O
probable O
benefits O
outweigh O
the O
known O
risks O
. O

Propranolol B-drug
increases O
hydralazines B-drug
serum O
concentrations O
. O

Uricosuric B-group
Agents I-group
: O
Since O
the O
excretion O
of O
oxipurinol B-drug
is O
similar O
to O
that O
of O
urate O
, O
uricosuric B-group
agents I-group
, O
which O
increase O
the O
excretion O
of O
urate O
, O
are O
also O
likely O
to O
increase O
the O
excretion O
of O
oxipurinol B-drug
and O
thus O
lower O
the O
degree O
of O
inhibition O
of O
xanthine O
oxidase O
. O

No O
data O
for O
delavirdine B-drug
; O

All O
elevations O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-drug
. O

Reports O
of O
fatal O
hepatic O
failure O
, O
as O
well O
as O
peripheral O
neuropathy O
, O
pancreatitis O
, O
and O
symptomatic O
hyperlactatemia/lactic O
acidosis O
have O
been O
reported O
in O
clinical O
trials O
. O

There O
is O
thus O
an O
enhancement O
effect O

Systemic O
exposure O
to O
substrates O
of O
CYP2D6 O
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec O
. O

If O
chlorprothixene B-drug
is O
given O
concomitantly O
with O
opioids B-group
, O
the O
opioid B-group
dose O
should O
be O
reduced O
( O
by O
approx O
. O
50 O
% O
) O
, O
because O
chlorprothixene B-drug
amplifies O
the O
therapeutic O
actions O
and O
side-effects O
of O
opioids B-group
massively O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
is O
required O
when O
this O
drug O
is O
administered O
concomitantly O
with O
anticholinergic B-group
drugs I-group
. O

Sucralfate B-drug
and O
antacids B-group
: O
Quinolones B-group
form O
chelates O
with O
metal O
cations O
. O

These O
doses O
correspond O
to O
approximately O
1- O
, O
3- O
, O
and O
5-fold O
( O
in O
females O
) O
and O
1.3- O
, O
1.3- O
, O
and O
1.6-fold O
( O
in O
males O
) O
the O
systemic O
exposure O
[ O
AUC0-30 O
days O
] O
] O
achieved O
in O
women O
receiving O
the O
recommended O
dose O
of O
250 O
mg/month O
. O

Antibiotics B-group
: O
Macrolide B-group
antibiotics I-group
have O
been O
reported O
to O
cause O
a O
significant O
decrease O
in O
corticosteroid B-group
clearance O
. O

Digoxin O
When O
given O
concomitantly O
with O
PLENDIL B-drug
the O
pharmacokinetics O
of O
digoxin B-drug
in O
patients O
with O
heart O
failure O
were O
not O
significantly O
altered O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes-Tape O
) O
be O
used O
. O

Potassium-sparing B-group
diuretics I-group
( O
spironolactone B-drug
, O
amiloride B-drug
, O
triamterene B-drug
, O
and O
others O
) O
or O
potassium B-drug
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O

Valproate B-drug
: O
Available O
data O
suggest O
that O
there O
is O
no O
significant O
effect O
of O
valproate B-drug
on O
the O
clearance O
of O
Felbatol B-brand
at O
steady O
state O
, O
Therefore O
, O
the O
addition O
of O
valproate B-drug
is O
not O
expected O
to O
cause O
a O
clinically O
important O
effect O
on O
Felbatol B-brand
( O
felbamate B-drug
) O
plasma O
concentrations O
. O

Ascorbic B-drug
acid I-drug
and O
the O
common O
cold O
. O

CYP3A4 O
Interactions O

Methotrexate B-drug
: O
Ketoprofen B-drug
, O
like O
other O
NSAIDs B-group
, O
may O
cause O
changes O
in O
the O
elimination O
of O
methotrexate B-drug
leading O
to O
elevated O
serum O
levels O
of O
the O
drug O
and O
increased O
toxicity O
. O

The O
clinical O
significance O
of O
these O
observations O
is O
unknown O
. O

Antacids B-group
containing O
magnesium B-drug
, O
aluminum B-drug
, O
or O
calcium B-drug
; O

Tinnitus O
and O
decreased O
hearing O
have O
been O
reported O
in O
patients O
concomitantly O
receiving O
Itraconazole B-drug
and O
quinidine B-drug
. O

No O
significant O
effects O
were O
noted O
with O
other O
drug O
combinations O
or O
with O
the O
addition O
of O
ethanol B-drug
. O

Drug/Laboratory O
Tests O
Interactions O
There O
are O
no O
known O
clinically O
significant O
interactions O
of O
CLOLAR B-brand
with O
other O
medications O
or O
laboratory O
tests O
. O

Dicumarol B-drug
and O
warfarin B-drug
may O
decrease O
hypoprothrombinemic O
effect O
. O

apomorphine B-drug
- O
prior O
ingestion O
of O
diphenidol B-drug
may O
decrease O
the O
emetic B-group
response O
to O
apomorphine B-drug
in O
the O
treatment O
of O
poisoning O
. O

Dosing O
recommendations O
for O
SUSTIVA B-brand
and O
atazanavir B-drug
in O
treatment-experienced O
patients O
have O
not O
been O
established O
. O

Toxicity O
associated O
with O
concomitant O
use O
of O
aerosolized O
pentamidine B-drug
has O
not O
been O
reported O
. O

Lithium B-drug
carbonate I-drug
: O
The O
stimulatory O
effects O
of O
amphetamines B-group
may O
be O
inhibited O
by O
lithium B-drug
carbonate I-drug
. O

The O
treatment O
of O
depression O
in O
diabetic O
patients O
must O
take O
into O
account O
variations O
of O
glycemic O
levels O
at O
different O
times O
and O
a O
comparison O
of O
the O
available O
antidepressant B-group
agents I-group
is O
important O
. O

Caution O
should O
be O
exercised O
when O
administering O
ETOPOPHOS B-brand
with O
drugs O
that O
are O
known O
to O
inhibit O
phosphatase O
activities O
( O
e.g. O
, O
levamisole B-drug
hydrochloride I-drug
) O
. O

Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
naratriptan B-drug
within O
24 O
hours O
is O
contraindicated O
. O

This O
suggests O
that O
interactions O
between O
the O
two O
elements O
only O
take O
place O
at O
the O
site O
of O
absorption O
. O

Aminoglycosides B-group
: O
The O
mixing O
of O
piperacillin B-drug
with O
an O
aminoglycoside B-group
in O
vitro O
can O
result O
in O
substantial O
inactivation O
of O
the O
aminoglycoside B-group
. O

A O
dose O
adjustment O
is O
not O
needed O
when O
zidovudine B-drug
is O
administered O
with O
VIRACEPT B-brand
. O

HIV B-group
Protease I-group
Inhibitors I-group
: O
Indinavir B-drug
( O
800 O
mg O
t.i.d O
. O
) O
co-administered O
with O
Vardenafil B-drug
10 O
mg O
resulted O
in O
a O
16-fold O
increase O
in O
vardenafil B-drug
AUC O
, O
a O
7-fold O
increase O
in O
vardenafil B-drug
Cmax O
and O
a O
2-fold O
increase O
in O
vardenafil B-drug
half-life O
. O

AED B-group
Co-administered O

Antiarrhythmic B-drug
agents I-drug
, I-drug
class I-drug
I I-drug
( O
such O
as O
flecainide B-drug
, O
lidocaine B-drug
, O
or O
quinidine B-drug
) O
: O
concurrent O
use O
with O
arbutamine B-drug
may O
have O
a O
proarrhythmic O
effect O
. O

Antitubercular O
drugs O
: O
Serum O
concentrations O
of O
isoniazid B-drug
may O
be O
decreased O
. O

No O
information O
available O
. O

Other O
Potentially O
Important O
Drug O
Interactions O
: O
Benzodiazepines B-group
: O
Benzodiazepines B-group
metabolized O
by O
hepatic O
oxidation O
( O
e.g. O
, O
alprazolam B-drug
, O
midazolam B-drug
, O
triazolam B-drug
elc O
. O
) O
should O
be O
used O
with O
caution O
because O
the O
clearance O
of O
these O
drugs O
is O
likely O
to O
be O
reduced O
by O
fluvoxamine B-drug
. O

Fluoxetine B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
clonazepam B-drug
. O

In O
a O
drug O
interaction O
study O
, O
co-administration O
of O
orally O
inhaled O
ciclesonide B-drug
and O
oral O
erythromycin B-drug
, O
an O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
des-ciclesonide B-drug
or O
erythromycin B-drug
. O

In O
vitro O
data O
in O
human O
plasma O
indicate O
that O
doxazosin B-drug
mesylate I-drug
has O
no O
effect O
on O
protein O
binding O
of O
digoxin B-drug
, O
warfarin B-drug
, O
phenytoin B-drug
or O
indomethacin B-drug
. O

Herbal O
Products O
: O
St. O
John O
s O
wort O
( O
hypericum O
perforatum O
) O
WARNING O
coadministration O
may O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
INVIRASE B-brand
or O
to O
the O
class O
of O
protease O
inhibitors O
. O

The O
action O
of O
nondepolarizing O
relaxants O
is O
augmented O
by O
Enflurane B-drug
. O

Theophylline B-drug
VIOXX B-brand
12.5 O
, O
25 O
, O
and O
50 O
mg O
administered O
once O
daily O
for O
7 O
days O
increased O
plasma O
theophylline B-drug
concentrations O
( O
AUC O
( O
0- O
) O
) O
by O
38 O
to O
60 O
% O
in O
healthy O
subjects O
administered O
a O
single O
300-mg O
dose O
of O
theophylline B-drug
. O

If O
bupropion B-drug
is O
added O
to O
the O
treatment O
regimen O
of O
a O
patient O
already O
receiving O
a O
drug O
metabolized O
by O
CYP2D6 O
, O
the O
need O
to O
decrease O
the O
dose O
of O
the O
original O
medication O
should O
be O
considered O
, O
particularly O
for O
those O
concomitant O
medications O
with O
a O
narrow O
therapeutic O
index O
. O

Consequently O
, O
TRACLEER B-brand
is O
not O
expected O
to O
increase O
the O
plasma O
concentrations O
of O
drugs O
metabolized O
by O
these O
enzymes O
. O

Each O
subject O
received O
an O
individualized O
fixed O
daily O
dose O
of O
warfarin B-drug
and O
served O
as O
his O
own O
pre- O
and O
postsedative O
treatment O
control O
. O

Warfarin B-drug
: O
Multiple O
oral O
doses O
of O
Sonata B-brand
( O
20 O
mg O
q24h O
for O
13 O
days O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-drug
( O
R+ O
) O
- O
or O
( O
S- O
) O
-enantiomers O
or O
the O
pharmacodynamics O
( O
prothrombin O
time O
) O
following O
a O
single O
25-mg O
oral O
dose O
of O
warfarin B-drug
. O

The O
hypoglycemic O
action O
of O
sulfonylurea B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

Rates O
of O
patients O
with O
maximum O
potassium O
levels O
5.5 O
mEq/L O
were O
similar O
regardless O
of O
the O
use O
of O
ACEI/ARB B-group
. O

SUBSEQUENT O
TO O
INITIATION O
OF O
DISULFIRAM B-drug
THERAPY O
. O

Lithium B-drug
: O
Increased O
serum O
lithium B-drug
levels O
and O
symptoms O
of O
lithium B-drug
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-group
inhibitors I-group
during O
therapy O
with O
lithium B-drug
. O

Phenytoin B-drug
is O
known O
to O
cause O
osteomalacia O
. O

The O
beneficial O
effects O
on O
arterial O
thrombus O
formation O
from O
combined O
therapy O
with O
antiplatelet O
and O
anticoagulant B-group
medication I-group
must O
be O
weighed O
against O
an O
increased O
risk O
of O
inducing O
hemorrhage O
. O

Sulfacetamide B-drug
preparations O
are O
incompatible O
with O
silver B-drug
preparations O
. O

antibody O

Cimetidine B-drug
: O
Albendazole B-drug
sulfoxide I-drug
concentrations O
in O
bile O
and O
cystic O
fluid O
were O
increased O
( O
about O
2-fold O
) O
in O
hydatid O
cyst O
patients O
treated O
with O
cimetidine B-drug
( O
10 O
mg/kg/day O
) O
( O
n=7 O
) O
compared O
with O
albendazole B-drug
( O
20 O
mg/kg/day O
) O
alone O
( O
n=12 O
) O
. O

Omeprazole B-drug
: O
Omeprazole B-drug
is O
a O
CYP O
3A4 O
substrate O
and O
CYP O
2C19 O
substrate O
and O
inhibitor O
. O

It O
was O
observed O
that O
MPTP B-drug_n
induced O
long O
lasting O
depletions O
of O
striatal O
dopamine O
concentrations O
and O
this O
neurotoxic O
effect O
could O
be O
prevented O
by O
pargyline B-drug
pretreatment O
. O

Patients O
treated O
concurrently O
with O
BREVIBLOC B-brand
( O
esmolol B-drug
HCl I-drug
) O
and O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
result O
in O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

Other O
Concomitant O
Therapy O
In O
healthy O
subjects O
there O
were O
no O
clinically O
significant O
interactions O
when O
felodipine B-drug
was O
given O
concomitantly O
with O
indomethacin B-drug
or O
spironolactone B-drug
. O

vasopressors B-group
, O
such O
as O
dopamine B-drug
and O
isoproterenol B-drug
; O

Decreasing O
the O
concentration O
of O
CMC-Cys B-drug_n
, O
exhibiting O
7.3 O
% O
( O
m/m O
) O
of O
immobilised O
cysteine B-drug
( O
CMC-Cys7.3 O
) O
from O
1 O
% O
( O
m/v O
) O
to O
0.5 O
% O
( O
m/v O
) O
decreased O
the O
R-value O
of O
NaFlu B-drug
from O
1.8 O
to O
1.2 O
. O

Antidepressants B-group
, O
tricyclic B-group
Amphetamines I-group
may O
enhance O
the O
activity O
of O
tricyclic B-drug
antidepressants I-drug
or O
sympathomimetic B-group
agents I-group
; O

. O

However O
, O
modification O
abolished O
the O
'cold O
' O
binding O
of O
toxin O
to O
bovine O
thyroglobulin O
in O
an O
ELISA O
and O
reduced O
ligand O
binding O
activity O
in O
a O
rabbit O
erythrocyte O
haemagglutination O
assay O
. O

However O
, O
at O
that O
time O
, O
the O
plasma O
levels O
of O
diazepam B-drug
were O
below O
the O
therapeutic O
interval O
, O
and O
thus O
this O
interaction O
is O
unlikely O
to O
be O
of O
clinical O
relevance O
. O

In O
simultaneous O
treatment O
with O
imidazole B-group
drugs I-group
and O
coumarin B-group
drugs I-group
, O
the O
anticoagulant O
effect O
should O
be O
carefully O
titrated O
and O
monitored O
. O

There O
was O
no O
evidence O
of O
drug O
interactions O
in O
clinical O
studies O
in O
which O
dobutamine B-drug
was O
administered O
concurrently O
with O
other O
drugs O
, O
including O
digitalis B-group
preparations I-group
, O
furosemide B-drug
, O
spironolactone B-drug
, O
lidocaine B-drug
, O
glyceryl B-drug
trinitrate I-drug
, O
isosorbide B-drug
dinitrate I-drug
, O
morphine B-drug
, O
atropine B-drug
, O
heparin B-drug
, O
protamine B-drug
, O
potassium B-drug
chloride I-drug
, O
folic B-drug
acid I-drug
, O
and O
acetaminophen B-drug
. O

halothane B-drug
; O

Olanzapine B-drug
: O
an O
updated O
review O
of O
its O
use O
in O
the O
management O
of O
schizophrenia O
. O

We O
assessed O
the O
ability O
of O
gene O
transfer O
to O
reverse O
vancomycin B-drug
resistance O
in O
class O
A O
( O
VanA O
) O
glycopeptide-resistant O
Enterococcus O
faecalis O
. O

Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
laboratory O
test O
interactions O
. O

Cell O
permeable O
caspase-3 O
inhibitor O
added O
in O
the O
medium O
blocked O
the O
decrease O
of O
nucleophosmin/B23 O
and O
apoptosis O
induced O
by O
serum O
deprivation O
in O
NIH-3T3 O
cells O
. O

Therefore O
, O
co-administration O
of O
Duloxetine B-drug
with O
other O
drugs O
that O
are O
extensively O
metabolized O
by O
this O
isozyme O
and O
which O
have O
a O
narrow O
therapeutic O
index O
, O
including O
certain O
antidepressants B-group
( O
tricyclic B-group
antidepressants I-group
[ O
TCAs B-group
] O
, O
such O
as O
nortriptyline B-drug
, O
amitriptyline B-drug
, O
and O
imipramine B-drug
) O
, O
phenothiazines B-group
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

aureus O
to O
P O
. O

gestational O
trophoblastic O
disease O
; O

While O
only O
a O
limited O
number O
of O
in O
vivo O
drug-drug O
interactions O
with O
amiodarone B-drug
have O
been O
reported O
, O
chiefly O
with O
the O
oral O
formulation O
, O
the O
potential O
for O
other O
interactions O
should O
be O
anticipated O
. O

Discontinuing O
colestipol B-drug
hydrochloride I-drug
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
that O
is O
significantly O
bound O
to O
the O
resin B-group
has O
been O
titrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
colestipol B-drug
hydrochloride I-drug
. O

DEA O
concentrations O
were O
not O
affected O
. O

thrombocytopenia O

Since O
there O
is O
a O
high O
degree O
of O
variability O
in O
the O
bioavailability O
of O
verapamil B-drug
, O
the O
clinical O
significance O
of O
this O
finding O
is O
unclear O
. O

Nevirapine B-drug

Therefore O
, O
caffeine B-drug
has O
the O
potential O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
CYP1A2 O
, O
inhibit O
CYP1A2 O
, O
or O
induce O
CYP1A2 O
. O

Conversely O
, O
decreases O
in O
plasma O
levels O
of O
the O
tricyclic B-group
antidepressants I-group
have O
been O
reported O
upon O
discontinuation O
of O
cimetidine B-drug
which O
may O
result O
in O
the O
loss O
of O
the O
therapeutic O
efficacy O
of O
the O
tricyclic B-group
antidepressant I-group
6 O
. O

Prothrombin O
time O
was O
increased O
by O
5 O
% O
, O
the O
clinical O
significance O
of O
which O
is O
unknown O
. O

Iron B-drug
salts O
may O
reduce O
the O
bioavailability O
of O
carbidopa B-drug
and O
levodopa B-drug
. O

Monoamine O
Oxidase O
Inhibition O
: O
Linezolid B-drug
is O
a O
reversible O
, O
nonselective O
inhibitor O
of O
monoamine O
oxidase O
. O

Patients O
in O
clinical O
studies O
were O
prohibited O
from O
receiving O
growth O
factor O
treatment O
for O
2 O
weeks O
prior O
to O
the O
ZEVALIN B-brand
therapeutic O
regimen O
as O
well O
as O
for O
2 O
weeks O
following O
completion O
of O
the O
regimen O
. O

It O
is O
believed O
that O
the O
toxicity O
may O
have O
resulted O
from O
a O
previously O
unrecognized O
interaction O
between O
isoniazid B-drug
and O
acetaminophen B-drug
and O
a O
molecular O
basis O
for O
this O
interaction O
has O
been O
proposed O
. O

Vesselinovitch O
et O
al O
. O

Patients O
taking O
these O
drugs O
with O
LODOSYN B-brand
and O
levodopa B-drug
or O
carbidopa-levodopa B-drug
combination O
products O
should O
be O
carefully O
observed O
for O
loss O
of O
therapeutic O
response O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p.o O
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

- O
Drugs O
with O
ototoxic O
potential O
: O
Especially O
in O
the O
presence O
of O
impaired O
renal O
function O
, O
the O
use O
of O
parenterally O
administered O
bumetanide B-drug
in O
patients O
to O
whom O
aminoglycoside B-group
antibiotics I-group
are O
also O
being O
given O
should O
be O
avoided O
, O
except O
in O
life-threatening O
conditions O
. O

However O
, O
severe O
reactions O
, O
such O
as O
hypotension O
requiring O
treatment O
, O
dyspnea O
requiring O
bronchodilators B-group
, O
angioedema O
, O
or O
generalized O
urticaria O
require O
immediate O
discontinuation O
of O
TAXOL B-brand
and O
aggressive O
symptomatic O
therapy O
. O

A O
30 O
to O
45 O
% O
increase O
in O
AUC O
and O
Cmax O
of O
nisoldipine B-drug
was O
observed O
with O
concomitant O
administration O
of O
cimetidine B-drug
400 I-drug
mg I-drug
twice O
daily O
. O

Drug O
interaction O
studies O
with O
other O
anticonvulsants B-group
have O
not O
been O
conducted O
. O

In O
the O
same O
study O
it O
was O
shown O
that O
didanosine B-drug
and O
stavudine B-drug
had O
no O
significant O
effect O
on O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-drug
in O
peripheral O
blood O
mononuclear O
cells O
. O

A O
study O
of O
interaction O
between O
BREVIBLOC B-brand
and O
warfarin B-drug
showed O
that O
concomitant O
administration O
of O
BREVIBLOC B-brand
and O
warfarin B-drug
does O
not O
alter O
warfarin B-drug
plasma O
levels O
. O

In O
a O
study O
involving O
12 O
adult O
volunteers O
, O
TORADOLORAL O
was O
coadministered O
with O
a O
single O
dose O
of O
25 O
mg O
warfarin B-drug
, O
causing O
no O
significant O
changes O
in O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-drug
. O

Patients O
receiving O
both O
indomethacin B-drug
and O
furosemide B-drug
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and/or O
antihypertensive O
effect O
of O
furosemide B-drug
is O
achieved O
. O

Nonsteroidal B-group
Anti-inflammatory I-group
Drugs I-group
( O
NSAIDs B-group
) O
: O
The O
concomitant O
administration O
of O
a O
nonsteroidal B-group
anti I-group
inflammatory I-group
drug I-group
with O
a O
quinolone B-group
may O
increase O
the O
risks O
of O
CNS O
stimulation O
and O
convulsions O
. O

The O
effect O
of O
induction O
or O
inhibition O
of O
other O
pathways O
on O
exposure O
to O
alosetron B-drug
and O
its O
metabolites O
is O
not O
known O
. O

Drugs O
such O
as O
troleandomycin B-drug
and O
ketoconazole B-drug
may O
inhibit O
the O
metabolism O
of O
corticosteroids B-group
and O
thus O
decrease O
their O
clearance O
. O

In O
some O
patients O
, O
this O
may O
lead O
to O
reduced O
clearance O
, O
prolongation O
of O
plasma O
half-life O
, O
and O
enhanced O
effects O
of O
caffeine B-drug
and O
theobromine B-drug
. O

Effect O
of O
aprepitant B-drug
on O
the O
pharmacokinetics O
of O
other O
agents O

Hydrochlorothiazide B-drug
( O
HCTZ B-drug
) O
Alone O
or O
in O
Combination O
with O
Triamterene B-drug
: O
Concomitant O
use O
of O
HCTZ B-drug
alone O
or O
in O
combination O
with O
triamterene B-drug
is O
contraindicated O
. O

Salicylate B-group
levels O
have O
been O
found O
to O
be O
falsely O
elevated O
with O
some O
assay O
methods O
. O

Little O
or O
no O
change O
in O
the O
pharmacokinetics O
of O
either O
drug O
was O
observed O
when O
VIRACEPT B-brand
was O
coadministered O
with O
lamivudine B-drug
or O
stavudine B-drug
. O

Each O
group O
took O
either O
150 O
mg O
or O
75 O
mg O
of O
fluvoxamine B-drug
a O
day O
for O
5 O
days O
( O
day O
-3 O
to O
day O
2 O
) O
. O

- O
Chloroquine B-drug
( O
e.g. O
, O
Aralen B-brand
) O
or O

Indinavir B-drug
has O
been O
shown O
to O
increase O
plasma O
levels O
of O
combination B-group
hormonal I-group
contraceptives I-group
. O

In O
one O
controlled O
clinical O
study O
, O
the O
ureidopenicillins O
, O
including O
piperacillin B-drug
, O
were O
reported O
to O
prolong O
the O
action O
of O
vecuronium B-drug
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Thalidomide B-drug
: O
Co-administration O
with O
thalidomide B-drug
should O
be O
employed O
cautiously O
, O
as O
toxic O
epidermal O
necrolysis O
has O
been O
reported O
with O
concomitant O
use O
. O

In O
addition O
, O
studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-brand
does O
not O
affect O
the O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-drug
, O
or O
the O
pharmacokinetics O
of O
propranolol B-drug
( O
40 O
mg O
twice O
daily O
) O
, O
phenytoin B-drug
, O
theophylline B-drug
, O
or O
oral O
contraceptives B-group
. O

- O
Medicinal O
or O
dietary O
iodine B-group
interferes O
with O
all O
in O
vivo O
tests O
of O
radio-iodine O
uptake O
producing O
low O
uptakes O
which O
may O
not O
be O
reflective O
of O
a O
true O
decrease O
in O
hormone O
synthesis O

The O
pressor O
effects O
of O
diethylpropion B-drug
and O
those O
of O
other O
drugs O
may O
be O
additive O
when O
the O
drugs O
are O
used O
concomitantly O
; O

Previous O
studies O
have O
demonstrated O
a O
significant O
reduction O
in O
the O
oral O
bioavailability O
of O
trovafloxacin B-drug
and O
ciprofloxacin B-drug
when O
administered O
concomitantly O
with O
an O
intravenous O
opiate B-group
such O
as O
morphine B-drug
. O

Digoxin B-drug
volume O
of O
distribution O
was O
not O
significantly O
changed O
. O

free O
T4 O
concentration O
is O
unaltered O

Serious O
anticholinergic O
symptoms O
( O
i.e. O
, O
severe O
dry O
mouth O
, O
urinary O
retention O
and O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-group
antidepressant I-group
when O
cimetidine B-drug
therapy O
is O
initiated O
. O

there O
was O
no O
alteration O
in O
the O
pharmacokinetics O
of O
either O
drug O
. O

Patients O
taking O
disopyramide B-drug
phosphate I-drug
and O
erythromycin B-drug
concomitantly O
may O
develop O
increased O
serum O
concentrations O
of O
disopyramide B-drug
resulting O
in O
excessive O
widening O
of O
the O
QRS O
complex O
and/or O
prolongation O
of O
the O
Q-T O
interval O
. O

Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-drug
levels O
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-drug
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

Valdecoxib B-drug
did O
not O
have O
a O
statistically O
significant O
effect O
on O
the O
pharmacokinetics O
of O
phenytoin B-drug
( O
a O
CYP O
2C9 O
and O
CYP O
2C19 O
substrate O
) O
. O

certain O
protease B-group
inhibitors I-group
e.g. O
, O
ritanovir O
; O

Three O
clinical O
trials O
have O
investigated O
Simulect B-brand
use O
in O
combination O
with O
triple-therapy O
regimens O
. O

adjust O
dosage O
of O
antidiabetic B-group
drug I-group
accordingly O
. O

Potent O
inhibitors O
of O
CYP3A4 O
( O
below O
) O
increase O
the O
risk O
of O
myopathy O
by O
reducing O
the O
elimination O
of O
lovastatin B-drug
. O

There O
have O
been O
inconsistent O
reports O
regarding O
the O
effects O
of O
other O
drugs O
( O
e.g. O
, O
quinine B-drug
, O
penicillamine B-drug
) O
on O
serum O
digoxin B-drug
concentration O
. O

Therefore O
, O
cyclosporine B-drug
serum O
levels O
should O
be O
monitored O
and O
appropriate O
cyclosporine B-drug
dosage O
adjustments O
made O
when O
these O
drugs O
are O
used O
concomitantly O
. O

These O
include O
probenecid B-drug
, O
cholestyramine B-drug
, O
and O
some O
antibiotics B-group
( O
e.g O
. O
erythromycin B-drug
, O
rifamipicin O
, O
ampicillin B-drug
and O
chloramphenicol B-drug
) O
. O

Thyroid O
Physiology O
: O
The O
following O
agents O
may O
alter O
thyroid O
hormone O
or O
TSH O
levels O
, O
generally O
by O
effects O
on O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
metabolism O
, O
hormone O
action O
, O
or O
elimination O
, O
or O
altered O
TSH O
secretion O
: O
aminoglutethimide B-drug
, O
p-aminosalicylic B-drug
acid I-drug
, O
amiodarone B-drug
, O
androgens B-group
and O
related O
anabolic O
hormones O
, O
complex O
anions O
( O
thiocyanate B-drug
, O
perchlorate B-drug
, O
pertechnetate B-drug
) O
, O
antithyroid B-group
drugs I-group
, O
b-adrenergic B-group
blocking I-group
agents I-group
, O
carbamazepine B-drug
, O
chloral B-drug
hydrate I-drug
, O
diazepam B-drug
, O
dopamine B-drug
and O
dopamine B-group
agonists I-group
, O
ethionamide B-drug
, O
glucocorticoids B-group
, O
heparin B-drug
, O
hepatic O
enzyme O
inducers O
, O
insulin B-drug
, O
iodinated O
cholestographic O
agents O
, O
iodine-containing B-group
compounds I-group
, O
levodopa B-drug
, O
lovastatin B-drug
, O
lithium B-drug
, O
6-mercaptopurine B-drug
, O
metoclopramide B-drug
, O
mitotane B-drug
, O
nitroprusside B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
resorcinol B-drug
, O
rifampin B-drug
, O
somatostatin B-group
analogs I-group
, O
sulfonamides B-group
, O
sulfonylureas B-group
, O
thiazide B-group
diuretics I-group
. O

Given O
the O
possibility O
of O
extravasation O
, O
it O
is O
advisable O
to O
closely O
monitor O
the O
infusion O
site O
for O
possible O
infiltration O
during O
drug O
administration O
. O

Since O
INVIRASE B-brand
is O
coadministered O
with O
ritonavir B-drug
, O
the O
ritonavir B-drug
label O
should O
be O
reviewed O
for O
additional O
drugs O
that O
should O
not O
be O
coadministered O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O

Sixty-two O
( O
94 O
% O
) O
of O
66 O
strains O
of O
Enterobacteriaceae O
and O
Pseudomonas O
aeruginosa O
were O
inhibited O
by O
6.2 O
mug O
or O
less O
of O
gentamicin B-drug
per O
ml O
. O

Anticonvulsants B-group
: O
carbamazepine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug

Resveratrol B-drug_n
has O
been O
shown O
to O
induce O
vasorelaxation O
. O

prolonged B-group
narcotics I-group
; O

Risk O
of O
Anaphylactic O
Reaction O
: O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

Epinephrine B-drug
should O
not O
be O
administered O
concomitantly O
with O
other O
sympathomimetic B-group
drugs I-group
( O
such O
as O
isoproterenol B-drug
) O
because O
of O
possible O
additive O
effects O
and O
increased O
toxicity O
. O

Clinical O
studies O
have O
shown O
that O
INDOCIN B-brand
does O
not O
influence O
the O
hypoprothrombinemia O
produced O
by O
anticoagulants B-group
. O

Effect O
of O
other O
drugs O
on O
Sensipar B-brand
: O
Sensipar B-brand
is O
metabolized O
by O
multiple O
cytochrome O
P450 O
enzymes O
, O
primarily O
CYP3A4 O
, O
CYP2D6 O
, O
and O
CYP1A2 O
. O

therefore O
, O
drug O
interactions O
mediated O
by O
inhibition O
of O
hepatic O
metabolism O
are O
not O
expected O
to O
occur O
. O

In O
rheumatoid O
arthritis O
, O
concomitant O
medications O
besides O
MTX B-drug
were O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
folic B-drug
acid I-drug
, O
corticosteroids B-group
and/or O
narcotics B-group
. O

Therefore O
, O
when O
Hydrochlorothiazide B-drug
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

In O
addition O
, O
steady O
state O
levels O
of O
racemic O
citalopram B-drug
were O
not O
significantly O
different O
in O
poor O
metabolizers O
and O
extensive O
CYP2D6 O
metabolizers O
after O
multiple-dose O
administration O
of O
citalopram B-drug
, O
suggesting O
that O
coadministration O
, O
with O
escitalopram B-drug
, O
of O
a O
drug O
that O
inhibits O
CYP2D6 O
, O
is O
unlikely O
to O
have O
clinically O
significant O
effects O
on O
escitalopram B-drug
metabolism O
. O

May O
interact O
anticoagulants B-group
( O
altered O
hypo-prothrombinemic O
effect O
) O
, O
barbiturates B-group
, O
rifampin B-drug
and O
other O
inducers O
of O
hepatic O
microsomal O
enzyme O
oxidation O
system O
( O
decreased O
effect O
of O
diethylstilbestrol B-drug
) O
, O
corticosteroids B-group
( O
increased O
effect O
of O
corticosteroids B-group
) O
. O

Effects O
of O
other O
Antiepilepsy O
Drugs O
( O
AEDs B-group
) O
on O
GABITRIL B-brand
: O
Carbamazepine B-drug
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
carbamazepine B-drug
with O
or O
without O
other O
enzyme- O
inducing O
AEDs B-group
. O

Diphenhydramine B-drug
: O
Diphenhydramine B-drug
is O
reported O
to O
be O
a O
weak O
inhibitor O
of O
aldehyde O
oxidase O
in O
rat O
liver O
, O
but O
its O
inhibitory O
effects O
in O
human O
liver O
are O
not O
known O
. O

Verapamil B-drug
produced O
a O
decrease O
of O
20 O
% O
[ O
90 O
% O
CI O
: O
18-27 O
] O
of O
the O
plasma O
levels O
of O
MHD B-drug_n
. O

serum O
magnesium O
levels O
may O
increase O
in O
uremic O
patients O
) O
Serum O
protein-bound O
iodine O
( O
PBI O
) O
levels O
( O
may O
be O
decreased O
) O
Thiazides B-group
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

It O
is O
not O
known O
if O
fulvestrant B-drug
is O
excreted O
in O
human O
milk O
. O

Doses O
of O
vitamin B-drug
C I-drug
up O
to O
200 O
mg O
were O
allowed O
in O
clinical O
studies O
without O
negative O
consequences O
. O

- O
Drugs O
whose O
efficacy O
is O
impaired O
by O
phenytoin B-drug
include O
: O
anticoagulants B-group
, O
corticosteroids B-group
, O
coumarin B-group
, O
digitoxin B-drug
, O
doxycycline B-drug
, O
estrogens B-group
, O
furosemide B-drug
, O
oral O
contraceptives B-group
, O
rifampin B-drug
, O
quinidine B-drug
, O
theophylline B-drug
, O
vitamin B-group
D I-group
. O

Here O
we O
show O
that O
a O
combination O
of O
galangin B-drug
or O
3,7-dihydroxyflavone O
with O
vancomycin B-drug
may O
be O
used O
to O
sensitize O
resistant O
strains O
of O
Enterococcus O
faecalis O
and O
Enterococcus O
faecium O
to O
the O
level O
of O
vancomycin-sensitive O
strains O
. O

In O
vitro O
studies O
with O
human O
liver O
microsomes O
indicate O
that O
bortezomib B-drug
is O
primarily O
a O
substrate O
for O
cytochrome O
P450 O
3A4 O
, O
2C19 O
, O
and O
1A2 O
. O

Additionally O
, O
there O
is O
no O
evidence O
of O
circulating O
active O
metabolites O
or O
accumulation O
during O
chronic O
dosing O
. O

Therefore O
, O
there O
is O
a O
potential O
for O
an O
interaction O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
1A2 O
( O
e.g. O
, O
amitriptyline B-drug
, O
tacrine B-drug
, O
and O
zileuton B-drug
) O
. O

In O
vitro O
activity O
of O
KRM-1648 B-drug_n
, O
either O
singly O
or O
in O
combination O
with O
ofloxacin B-drug
, O
against O
Mycobacterium O
ulcerans O
. O

Coadministration O
of O
ethoxzolamide B-drug
with O
other O
diuretics B-group
, O
amphotericin B-drug
B I-drug
, O
and O
corticosteroids B-group
may O
cause O
hypokalemia O
. O

However O
, O
norepinephrine B-drug
may O
still O
be O
used O
effectively O
. O

haloperidol B-drug
; O

Absorption O
of O
fluvastatin B-drug
is O
virtually O
complete O
across O
all O
species O
, O
including O
man O
, O
and O
is O
not O
affected O
by O
the O
presence O
of O
food O
. O

. O

decreased O
pregnanediol O
excretion O
; O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

ritonavir I-drug
concentration O

Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-group
hormone I-group
. O

Enoxacin B-drug
interferes O
with O
the O
metabolism O
of O
theophylline B-drug
resulting O
in O
a O
42 O
% O
to O
74 O
% O
dose-related O
decrease O
in O
theophylline B-drug
clearance O
and O
a O
subsequent O
260 O
% O
to O
350 O
% O
increase O
in O
serum O
theophylline O
levels O
. O

Prostatic O
epithelium O
proliferates O
in O
a O
defined O
medium O
consisting O
of O
basal O
medium O
RPMI1640 O
containing O
transferrin B-drug_n
( O
1 O
microgram/ml O
) O
, O
EGF B-drug_n
( O
10 O
ng/ml O
) O
, O
and O
insulin B-drug
( O
3.7 O
micrograms/ml O
or O
0.1 O
IU/ml O
) O
. O

Amantadine B-drug
, O
tricyclic B-group
antidepressants I-group
, O
and O
MAOIs B-group
may O
increase O
anticholinergic O
effect O
of O
clidinium B-drug
. O

In O
these O
patients O
whose O
hypertension O
was O
controlled O
with O
nifedipine B-drug
, O
Vardenafil B-drug
20 O
mg O
produced O
mean O
additional O
supine O
systolic/diastolic O
blood O
pressure O
reductions O
of O
6/5 O
mm O
Hg O
compared O
to O
placebo O
. O

- O
Oral O
contraceptives B-group
( O
birth O
control O
pills O
) O
containing O
estrogen B-group
or O

meprobamate B-drug
; O

Morphine B-drug
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
.005 O
) O
; O

Hematopoietic O

It O
is O
unknown O
how O
the O
effect O
seen O
in O
these O
in O
vitro O
studies O
translates O
into O
clinical O
consequences O
. O

Corticosteroids B-group
: O
Dexamethasone B-drug
: O
Aprepitant B-drug
, O
when O
given O
as O
a O
regimen O
of O
125mg O
with O
dexamethasone B-drug
coadministered O
orally O
as O
20 O
mg O
on O
Day O
1 O
, O
and O
Aprepitant B-drug
when O
given O
as O
80 O
mg/day O
with O
dexamethasone B-drug
coadministered O
orally O
as O
8 O
mg O
on O
Days O
2 O
through O
5 O
, O
increased O
the O
AUC O
of O
dexamethasone B-drug
, O
a O
CYP3A4 O
substrate O
by O
2.2-fold O
, O
on O
Days O
1 O
and O
5 O
. O

ii O
. O

Drug/Laboratory O
Test O
Interactions O
The O
following O
drugs O
or O
moieties O
are O
known O
to O
interfere O
with O
laboratory O
tests O
performed O
in O
patients O
on O
thyroid B-group
hormone I-group
therapy O
: O
androgens B-group
, O
corticosteroids B-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
containing O
estrogens B-group
, O
iodine-containing B-group
preparations O
and O
the O
numerous O
preparations O
containing O
salicylates B-group
. O

Ketamine B-drug
: O
Marked O
hypertension O
and O
tachycardia O
have O
been O
reported O
in O
association O
with O
concomitant O
administration O
of O
levothyroxine B-drug
sodium I-drug
and O
ketamine B-drug
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

There O
have O
been O
greater O
than O
2-fold O
increases O
in O
previously O
stable O
plasma O
levels O
of O
other O
antidepressants B-group
, O
including O
nortriptyline B-drug
, O
when O
fluoxetine B-drug
hydrochloride I-drug
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O

No O
confirmed O
interactions O
have O
been O
reported O
between O
ZOLADEX B-brand
and O
other O
drugs O

Strong O
inducers O
of O
cytochrome O
P450 O
enzymes O
( O
i.e O
. O
carbamazepine B-drug
, O
phenytoin B-drug
and O
phenobarbital B-drug
) O
have O
been O
shown O
to O
decrease O
the O
plasma O
levels O
of O
MHD B-drug_n
( O
29-40 O
% O
) O
. O

Tolbutamides B-drug
conversion O
to O
inactive O
metabolites O
has O
been O
shown O
to O
be O
catalyzed O
by O
xanthine O
oxidase O
from O
rat O
liver O
. O

For O
example O
, O
since O
cholestyramine B-drug
may O
reduce O
the O
gastrointestinal O
absorption O
of O
both O
the O
oral O
anticoagulants B-group
and O
vitamin B-group
K I-group
, O
the O
net O
effects O
are O
unpredictable O
. O

It O
is O
recommended O
that O
if O
CASODEX B-brand
is O
started O
in O
patients O
already O
receiving O
coumarin B-group
anticoagulants I-group
, O
prothrombin O
times O
should O
be O
closely O
monitored O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
. O

Anticonvulsants B-group
( O
Phenytoin B-drug
) O
: O
Steady O
state O
plasma O
exposure O
( O
AUC O
) O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
for O
12 O
days O
) O
was O
decreased O
by O
27 O
% O
when O
co-administered O
with O
multiple O
doses O
( O
300 O
mg O
QD O
for O
12 O
days O
) O
of O
phenytoin B-drug
( O
a O
CYP O
3A4 O
inducer O
) O
. O

Quinolones B-group
, O
including O
norfloxacin B-drug
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-group
, O
including O
warfarin B-drug
or O
its O
derivatives O
or O
similar O
agents O
. O

Felbamate B-drug
treatment O
resulted O
in O
a O
42 O
% O
decrease O
in O
the O
gestodene B-drug
AUC O
0-24 O
, O
but O
no O
clinically O
relevant O
effect O
was O
observed O
on O
the O
pharmacokinetic O
parameters O
of O
ethinyl B-drug
estradiol I-drug
. O

Drug/Laboratory O
Test O
Interactions O
As O
with O
cephalothin B-drug
, O
high O
concentrations O
of O
cefoxitin B-drug
( O
100 O
micrograms/mL O
) O
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
the O
Jaff O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
of O
creatinine O
reported O
. O

aureus O
, O
to O
survive O
in O
pentazocine B-drug
and O
tripelennamine B-drug
may O
explain O
in O
part O
a O
shift O
from O
S O
. O

In O
addition O
to O
the O
interactions O
noted O
above O
, O
chronic O
( O
2 O
weeks O
) O
oral O
Cordarone B-drug
administration O
impairs O
metabolism O
of O
phenytoin B-drug
, O
dextromethorphan B-drug
, O
and O
methotrexate B-drug
. O

. O

A O
review O
is O
presented O
of O
some O
of O
the O
problems O
that O
may O
arise O
in O
association O
with O
anaesthesia O
for O
epileptic O
patients O
. O

Special O
care O
is O
required O
if O
this O
drug O
is O
given O
to O
patients O
receiving O
ganglion B-group
blocking I-group
compounds I-group
because O
a O
critical O
fall O
in O
blood O
pressure O
may O
occur O
. O

Tetracyclines B-group
: O
Concomitant O
treatment O
with O
Accutane B-brand
and O
tetracyclines B-group
should O
be O
avoided O
because O
Accutane B-brand
use O
has O
been O
associated O
with O
a O
number O
of O
cases O
of O
pseudotumor O
cerebri O
( O
benign O
intracranial O
hypertension O
) O
, O
some O
of O
which O
involved O
concomitant O
use O
of O
tetracyclines B-group

No O
drug O
interaction O
data O
are O
available O
on O
concomitant O
administration O
of O
Panretin B-brand
gel O
and O
systemic O
anti-KS O
agents O
. O

A O
drug-drug O
interaction O
study O
with O
rifampin B-drug
in O
healthy O
volunteers O
has O
shown O
a O
30 O
% O
decrease O
in O
caspofungin B-drug
trough O
concentrations O
. O

To O
find O
out O
whether O
this O
observation O
is O
related O
to O
the O
increased O
regional O
perfusion O
in O
diabetes O
longitudinal O
studies O
on O
patients O
with O
Type O
I O
( O
insulin-dependent O
) O
diabetes O
mellitus O
are O
needed O
. O

Carbamazepine B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
14 O
days O
) O
and O
carbamazepine B-drug
( O
titrated O
to O
400 O
mg/day O
for O
35 O
days O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
carbamazepine B-drug
, O
a O
CYP3A4 O
substrate O
. O

Levetiracetam B-drug
circulates O
largely O
unbound O
( O
10 O
% O
bound O
) O
to O
plasma O
proteins O
; O

Therefore O
, O
when O
INSPRA B-brand
and O
NSAIDs B-group
are O
used O
concomitantly O
, O
patients O
should O
be O
observed O
to O
determine O
whether O
the O
desired O
effect O
on O
blood O
pressure O
is O
obtained O
. O

Caution O
should O
be O
exercised O
when O
treating O
patients O
with O
either O
of O
these O
drugs O
or O
other O
highly O
protein-bound O
drugs O
and O
Atromid-S B-brand
. O

The O
clinical O
relevance O
of O
this O
finding O
is O
unclear O
. O

Carbamazepine B-drug
: O
Carbamazepine B-drug
causes O
an O
approximate O
50 O
% O
increase O
in O
the O
clearance O
of O
Felbatol B-brand
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
carbamazepine B-drug
results O
in O
an O
approximate O
40 O
% O
decrease O
in O
the O
steady-state O
trough O
concentrations O
of O
Felbatol B-brand
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-brand
given O
as O
monotherapy O
. O

Saquinavir B-drug

Less O
than O
the O
usual O
amounts O
of O
these O
medicines O
should O
be O
used O
. O

In O
clinical O
studies O
, O
Tilade B-brand
has O
been O
co-administered O
with O
other O
anti-asthma O
medications O
, O
including O
inhaled O
and O
oral O
bronchodilators B-group
, O
and O
inhaled O
corticosteroids B-group
, O
with O
no O
evidence O
of O
increased O
frequency O
of O
adverse O
events O
or O
laboratory O
abnormalities O
. O

- O
Methyldopa B-drug
( O
e.g. O
, O
Aldomet B-brand
) O
Use O
of O
methyldopa B-drug
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and/or O
the O
blood O

Consideration O
should O
be O
taken O
in O
patients O
being O
treated O
with O
antidiabetic B-drug
agents O
. O

However O
, O
the O
pharmacodynamic O
effect O
increased O
by O
197 O
% O
( O
QTc O
increase O
over O
time O
) O
and O
by O
95 O
% O
( O
maximum O
QTc O
increase O
) O
. O

No O
drug/drug O
interaction O
studies O
have O
been O
performed O
. O

Insulin B-drug
or O
Oral O
Hypoglycemics B-group
: O
Initiating O
thyroid O
replacement O
therapy O
may O
cause O
increases O
in O
insulin B-drug
or O
oral O
hypoglycemic B-group
requirements O
. O

Although O
the O
occurrence O
has O
not O
been O
reported O
with O
Cefizox B-brand
, O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-group
and O
aminoglycosides B-group
. O

Serotonin O
release O
by O
platelets O
plays O
an O
important O
role O
in O
hemostasis O
. O

. O

Sumatriptan B-drug
- O
There O
have O
been O
rare O
postmarketing O
reports O
describing O
patients O
with O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
following O
the O
use O
of O
a O
selective B-group
serotonin I-group
reuptake I-group
inhibitor I-group
( O
SSRI B-group
) O
and O
sumatriptan B-drug
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Fluoxetine B-drug
and O
moclobemide B-drug
increased O
blood O
glucose B-drug
at O
different O
times O
after O
the O
glucose O
overload O
. O

Cyclosporine B-drug
, O
tacrolimus B-drug
and O
digoxin B-drug
concentrations O
should O
be O
monitored O
at O
the O
initiation O
of O
Itraconazole B-drug
therapy O
and O
frequently O
thereafter O
, O
and O
the O
dose O
of O
these O
three O
drug O
products O
adjusted O
appropriately O
. O

Probenecid B-drug
: O
Concomitant O
administration O
of O
TORADOL B-brand
ORAL O
and O
probenecid B-drug
resulted O
in O
decreased O
clearance O
of O
ketorolac B-drug
and O
significant O
increases O
in O
ketorolac B-drug
plasma O
levels O
( O
total O
AUC O
increased O
approximately O
threefold O
from O
5.4 O
to O
17.8 O
m O
g/h/mL O
) O
and O
terminal O
half-life O
increased O
approximately O
twofold O
from O
6.6 O
to O
15.1 O
hours O
. O

Therefore O
, O
it O
is O
advisable O
to O
be O
particularly O
cautious O
in O
patients O
whose O
plasma O
digoxin B-drug
levels O
are O
above O
or O
suspected O
to O
be O
above O
the O
usual O
therapeutic O
range O
. O

Pediatric O
Use O

Thus O
, O
the O
interaction O
observed O
between O
erythromycin B-drug
and O
terfenadine B-drug
is O
not O
expected O
for O
dirithromycin B-drug
. O

The O
reported O
dose O
used O
for O
L-glutamine B-drug
was O
21 O
grams O
daily O
taken O
in O
divided O
doses O
three O
times O
a O
day O
. O

Due O
to O
its O
potential O
to O
cause O
neutropenia O
and O
lymphopenia O
, O
proper O
monitoring O
of O
patients O
is O
required O
if O
Rebif B-brand
is O
given O
in O
combination O
with O
myelosuppressive O
agents O
. O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Most O
of O
the O
above O
effects O
concerning O
diuretics B-group
have O
been O
attributed O
, O
at O
least O
in O
part O
, O
to O
mechanisms O
involving O
inhibition O
of O
prostaglandin O
synthesis O
by O
INDOCIN B-brand
. O

Warfarin B-drug
- O
Administration O
of O
40 O
mg/day O
racemic O
citalopram B-drug
for O
21 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-drug
, O
a O
CYP3A4 O
substrate O
. O

Concomitant O
use O
of O
bromocriptine B-drug
mesylate I-drug
with O
other O
ergot B-group
alkaloids I-group
is O
not O
recommended O
. O

Antifungals B-group
: O
Itraconazole B-drug
Ketoconazole I-drug

Blood O
samples O
were O
drawn O
at O
0 O
, O
0.5 O
, O
1 O
, O
1.5 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
, O
18 O
, O
and O
24 O
hours O
for O
Cmax O
, O
tmax O
, O
and O
AUC O
determinations O
. O

In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic B-group
, I-group
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-group
diuretics I-group
. O

These O
facts O
should O
be O
considered O
when O
evaluating O
plasma O
renin O
activity O
in O
hypertensive O
patients O
. O

Onset O
of O
the O
interaction O
began O
within O
five O
days O
of O
beginning O
concurrent O
therapy O
. O

Antacids B-group
: O
Enteric O
Coated O
Aspirin B-brand
should O
not O
be O
given O
concurrently O
with O
antacids B-group
, O
since O
an O
increase O
in O
the O
pH O
of O
the O
stomach O
may O
effect O
the O
enteric O
coating O
of O
the O
tablets O
. O

Naproxen B-drug
had O
no O
effect O
on O
plasma O
levels O
of O
diflunisal B-drug
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
coadministered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

To O
study O
the O
pancreatic O
effects O
of O
other O
agents O
, O
dynamic O
insulin O
and O
glucagon O
release O
was O
measured O
from O
the O
in O
vitro O
perfused O
pancreases O
of O
normal O
and O
diabetic O
Chinese O
hamsters O
in O
response O
to O
various O
combinations O
of O
arginine B-drug
( O
20mM O
) O
, O
glucose B-drug
( O
100 O
or O
150 O
mg. O
per O
100 O
ml O
. O
) O
, O
and O
theophylline B-drug
( O
10 O
mM O
) O
. O

MAO B-group
Inhibitors I-group
: O
Studies O
in O
animals O
demonstrate O
that O
the O
acute O
toxicity O
of O
bupropion B-drug
is O
enhanced O
by O
the O
MAO B-group
inhibitor I-group
phenelzine B-drug
. O

Ethopropazine B-drug
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
, O
causing O
increased O
sedative O
effects O
. O

The O
blood O
pressure O
effect O
of O
SULAR B-brand
tended O
to O
be O
greater O
in O
patients O
on O
atenolol B-drug
than O
in O
patients O
on O
no O
other O
antihypertensive B-group
therapy O
. O

Digoxin B-drug
: O
In O
controlled O
studies O
in O
healthy O
volunteers O
, O
bepridil B-drug
hydrochloride I-drug
either O
had O
no O
effect O
( O
one O
study O
) O
or O
was O
associated O
with O
modest O
increases O
, O
about O
30 O
% O
( O
two O
studies O
) O
in O
steady-state O
serum O
digoxin B-drug
concentrations O
. O

Four O
educational O
messages O
advise O
on O
over O
60 O
% O
of O
the O
PICR O
detected O
. O

Racemic O
citalopram B-drug
did O
not O
alter O
the O
mean O
AUC O
or O
Cmax O
of O
pimozide B-drug
. O

Antigout B-group
medications I-group

Because O
warfarin B-drug
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
, O
patients O
who O
require O
anticoagulation O
should O
receive O
low-molecular O
weight O
or O
standard O
heparin B-drug
. O

Lupus-like O
syndrome O

Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
i.e. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone-binding O
globulin O
( O
SHBG O
) O
, O
leading O
to O
increased O
total O
circulating O
corticosteroids B-group
and O
sex B-group
steroids I-group
, O
respectively O
. O

Toxicity O
of O
cadmium O
and O
zinc B-drug
to O
encystment O
and O
in O
vitro O
excystment O
of O
Parorchis O
acanthus O
( O
Digenea O
: O
Philophthalmidae O
) O
. O

Although O
clinical O
evidence O
to O
date O
has O
not O
demonstrated O
renal O
precipitation O
of O
oxypurines O
in O
patients O
either O
on O
allopurinol B-drug
alone O
or O
in O
combination O
with O
uricosuric B-group
agents I-group
, O
the O
possibility O
should O
be O
kept O
in O
mind O
. O

( O
Concurrent O
use O
with O
thiazide B-group
diuretics I-group
may O
intensify O
electrolyte O
imbalance O
, O
particularly O
hypokalemia O
. O
) O

Diphenoxylate B-drug
HCl I-drug
and O
atropine B-drug
sulfate I-drug
may O
interact O
with O
MAO B-group
inhibitors I-group
In O
studies O
with O
male O
rats O
, O
diphenoxylate B-drug
hydrochloride I-drug
was O
found O
to O
inhibit O
the O
hepatic O
microsomal O
enzyme O
system O
at O
a O
dose O
of O
2 O
mg/kg/day O
. O

The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-group
: O
- O
Increased O
sulfobromophthalein O
retention O

Corticosteroids B-group
, O
ACTH B-drug
: O
intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O
. O

Flucytosine B-drug
: O
while O
a O
synergistic O
relationship O
with O
amphotericin B-drug
B I-drug
has O
been O
reported O
, O
concomitant O
use O
may O
increase O
the O
toxicity O
of O
flucytosine B-drug
by O
possibly O
increasing O
its O
cellular O
uptake O
and/or O
impairing O
its O
renal O
excretion O
. O

reduced O
response O
to O
metyrapone O
test O
; O

Quinidine B-drug
, O
verapamil B-drug
, O
amiodarone B-drug
, O
propafenone B-drug
, O
indomethacin B-drug
, O
itraconazole B-drug
, O
alprazolam B-drug
, O
and O
spironolactone B-drug
raise O
the O
serum O
digoxin B-drug
concentration O
due O
to O
a O
reduction O
in O
clearance O
and/or O
in O
volume O
of O
distribution O
of O
the O
drug O
, O
with O
the O
implication O
that O
digitalis B-group
intoxication O
may O
result O
. O

Aminoglutethimide B-drug
: O
May O
increase O
CYP O
metabolism O
of O
progestins B-group
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O

There O
are O
case O
reports O
of O
patients O
who O
developed O
increased O
BUN O
, O
serum O
creatinine O
and O
serum O
potassium O
levels O
, O
and O
weight O
gain O
when O
furosemide B-drug
was O
used O
in O
conjunction O
with O
NSAIDs B-group
. O

A O
drug O
interaction O
study O
was O
performed O
in O
which O
ERBITUX B-brand
was O
administered O
in O
combination O
with O
irinotecan B-drug
. O

Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
warfarin B-group
anticoagulants I-group
; O

Phenobarbital B-drug
or O
Primidone B-drug
: O
No O
formal O
pharmacokinetic O
studies O
have O
been O
performed O
examining O
the O
addition O
of O
tiagabine B-drug
to O
regimens O
containing O
phenobarbital B-drug
or O
primidone B-drug
. O

. O

Interconversion O
between O
caffeine B-drug
and O
theophylline B-drug
has O
been O
reported O
in O
preterm O
neonates O
. O

therefore O
, O
the O
use O
of O
dofetilide B-drug
does O
not O
necessitate O
an O
adjustment O
in O
digoxin B-drug
dose O
to O
maintain O
therapeutic O
digoxin O
levels O
. O

Spermine B-drug
promotes O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
cytosol O
to O
the O
microsomal O
fraction O
of O
rat O
liver O
and O
it O
enhances O
the O
effects O
of O
oleate O
in O
this O
respect O
. O

The O
steady O
state O
plasma O
concentrations O
of O
imipramine B-drug
and O
desipramine B-drug
have O
been O
reported O
to O
be O
increased O
an O
average O
of O
31 O
% O
and O
20 O
% O
, O
respectively O
, O
by O
the O
concomitant O
administration O
of O
alprazolam B-drug
tablets O
in O
doses O
up O
to O
4 O
mg/day O
. O

There O
is O
insufficient O
experience O
to O
assess O
the O
safety O
and O
efficacy O
of O
ORENCIA B-brand
administered O
concurrently O
with O
anakinra B-drug
, O
and O
therefore O
such O
use O
is O
not O
recommended O
. O

however O
, O
it O
adversely O
affected O
response O
duration O
suggesting O
that O
pyridoxine B-drug
should O
not O
be O
administered O
with O
HEXALEN B-brand
and/or O
cisplatin.1 B-drug

Nursing O
Mothers O
It O
is O
not O
known O
whether O
peginterferon B-drug
or O
ribavirin B-drug
or O
its O
components O
are O
excreted O
in O
human O
milk O
. O

Antiretroviral B-group
plasma O
and O
urine O
sampling O
were O
conducted O
on O
Days O
1 O
, O
7 O
, O
and O
21 O
for O
zidovudine B-drug
and O
on O
Days O
7 O
and O
21 O
for O
dideoxyinosine B-drug
. O

. O

In O
order O
to O
provide O
information O
for O
the O
appropriate O
package O
insert O
labeling O
of O
progestin-only B-group
oral I-group
contraceptives I-group
( O
POC B-group
) O
in O
the O
US O
, O
a O
comprehensive O
review O
was O
made O
of O
norgestrel B-drug
( O
0.075 O
mg O
) O
and O
norethindrone B-drug
( O
0.35 O
mg O
) O
, O
with O
the O
clinical O
differences O
indicated O
where O
applicable O
. O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
ELLENCE B-brand
and O
laboratory O
tests O
. O

None O
known O
. O

Valproate B-drug
: O
The O
addition O
of O
tiagabine B-drug
to O
patients O
taking O
valproate B-drug
chronically O
had O
no O
effect O
on O
tiagabine B-drug
pharmacokinetics O
, O
but O
valproate B-drug
significantly O
decreased O
tiagabine B-drug
binding O
in O
vitro O
from O
96.3 O
to O
94.8 O
% O
, O
which O
resulted O
in O
an O
increase O
of O
approximately O
40 O
% O
in O
the O
free O
tiagabine O
concentration O
. O

The O
successive O
application O
of O
glycine B-drug
( O
5 O
or O
10 O
mg/kg O
egg O
weight O
( O
e.w O
. O
) O
and O
glutamate B-drug
( O
15 O
mg/kg O
e.w O
. O
) O
in O
a O
10 O
min O
interval O
significantly O
increased O
the O
activation O
of O
spontaneous O
motility O
of O
17-day-old O
chick O
embryos O
in O
comparison O
with O
the O
effect O
of O
glutamate B-drug
alone O
. O

Propranolol B-drug
: O
May O
decrease O
aspirins B-brand
anti-inflammatory O
action O
by O
competing O
for O
the O
same O
receptors O
. O

with O
sucralfate B-drug
; O

Some O
quinolones B-group
, O
including O
ciprofloxacin B-drug
, O
have O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
cyclosporine B-drug
concomitantly O
. O

twice O
the O
human O
dose O
on O
BSA O
) O
and O
non-ossification O
of O
the O
odontoid O
and O
ventral O
tubercle O
of O
the O
first O
cervical O
vertebra O
at O
doses O
0.1 O
mg/kg/day O
IM O
( O
approximately O
one-tenth O
of O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O

Thus O
there O
was O
a O
tendency O
toward O
a O
more O
pronounced O
inhibition O
of O
the O
4-hydroxylation O
during O
treatment O
with O
150 O
mg/d O
of O
fluvoxamine B-drug
compared O
with O
75 O
mg/d O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O

Amiodarone B-drug
is O
also O
known O
to O
be O
an O
inhibitor O
of O
CYP3A4 O
. O

Concomitant O
administration O
of O
Mefloquine B-drug
and O
other O
related O
compounds O
( O
eg O
, O
quinine B-drug
, O
quinidine B-drug
and O
chloroquine B-drug
) O
may O
produce O
electrocardiographic O
abnormalities O
and O
increase O
the O
risk O
of O
convulsions O
. O

Clinical O
studies O
of O
the O
effect O
of O
strong O
CYP O
3A4 O
inhibitors O
on O
the O
pharmacokinetics O
of O
fulvestrant B-drug
have O
not O
been O
performed O
. O

The O
natriuretic O
effect O
of O
furosemide B-drug
has O
been O
reported O
to O
be O
inhibited O
by O
some O
drugs O
of O
this O
class O
. O

Interference O
of O
biocytin O
with O
opioid-evoked B-group
hyperpolarization O
and O
membrane O
properties O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
. O

tricyclic B-group
antidepressants I-group
. O

Coadministration O
of O
digoxin B-drug
did O
not O
have O
effects O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-drug
in O
the O
clinical O
trials O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

In O
an O
effort O
to O
screen O
compounds O
for O
antipsychotic O
activity O
, O
preclinical O
researchers O
have O
investigated O
whether O
these O
compounds O
block O
PCP-induced B-drug_n
behaviors O
in O
animals O
. O

Other O
compounds O
that O
are O
substrates O
of O
CYP3A4 O
may O
have O
decreased O
plasma O
concentrations O
when O
coadministered O
with O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
. O

Only O
at O
the O
highest O
concentration O
tested O
( O
171 O

No O
carcinogenicity O
or O
fertility O
studies O
were O
conducted O
. O

Estazolam B-drug
: O
Interaction O
with O
Drugs O
that O
Inhibit O
Metabolism O
via O
Cytochrome O
P450 O
3A O
( O
CYP3A O
) O
: O
The O
metabolism O
of O
estazolam B-drug
to O
the O
major O
circulating O
metabolite O
4-hydroxy-estazolam B-drug_n
and O
the O
metabolism O
of O
other O
triazolobenzodiazepines B-group
is O
catalyzed O
by O
CYP3A O
. O

A O
daily O
dose O
of O
2 O
mg O
of O
coumaphos/kg B-drug_n
of O
body O
weight O
for O
6 O
days O
did O
not O
affect O
the O
plasma O
enzymes O
or O
the O
antiprothrombinemic O
effect O
of O
bishydroxy-coumarin B-drug
in O
wethers O
. O

The O
incidence O
of O
cardiovascular O
morbidity O
and O
mortality O
is O
not O
higher O
among O
users O
of O
sildenafil B-drug
. O

- O
Primaquine B-drug
or O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
norfloxacin B-drug
and O
theophylline B-drug
. O

Since O
entecavir B-drug
is O
primarily O
eliminated O
by O
the O
kidneys O
, O
coadministration O
of O
BARACLUDE B-brand
with O
drugs O
that O
reduce O
renal O
function O
or O
compete O
for O
active O
tubular O
secretion O
may O
increase O
serum O
concentrations O
of O
either O
entecavir B-drug
or O
the O
coadministered O
drug O
. O

Naproxen B-drug
: O
Coadministration O
( O
N=18 O
) O
of O
naproxen B-drug
sodium I-drug
capsules O
( O
250 O
mg O
) O
with O
Neurontin B-brand
( O
125 O
mg O
) O
appears O
to O
increase O
the O
amount O
of O
gabapentin B-drug
absorbed O
by O
12 O
% O
to O
15 O
% O
. O

Therefore O
, O
COLESTlD B-brand
Tablets O
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
. O

PEGANONE B-brand
used O
in O
combination O
with O
other O
drugs O
known O
to O
adversely O
affect O
the O
hematopoietic O
system O
should O
be O
avoided O
if O
possible O
. O

Drug O
Interactions O
with O
Antacids B-group
Administration O
of O
120 O
mg O
of O
fexofenadine B-drug
hydrochloride I-drug
( O
2 O
x O
60 O
mg O
capsule O
) O
within O
15 O
minutes O
of O
an O
aluminum B-drug
and O
magnesium B-drug
containing O
antacid B-group
( O
Maalox B-brand
) O
decreased O
fexofenadine B-drug
AUC O
by O
41 O
% O
and O
cmax O
by O
43 O
% O
. O

Somatrem/Somatropin B-drug
: O
Excessive O
concurrent O
use O
of O
thyroid B-group
hormone I-group
may O
accelerate O
epiphyseal O
closure O
. O

Drugs O
whose O
absorption O
is O
sensitive O
to O
pH O
may O
be O
negatively O
impacted O
by O
concomitant O
administration O
of O
omeprazole B-drug
and O
valdecoxib B-drug
. O

No O
information O
available O
. O

Arginine B-drug
, O
in O
the O
absence O
of O
glucose B-drug
or O
theophylline B-drug
, O
caused O
excessive O
glucagon O
release O
in O
the O
diabetics O
and O
undetectable O
insulin O
release O
in O
either O
diabetics O
or O
normals O
. O

These O
agents O
should O
not O
be O
taken O
for O
8 O
hours O
before O
or O
for O
2 O
hours O
after O
enoxacin B-drug
administration O
. O

During O
amiodarone B-drug
administration O
, O
systemic O
clearance O
of O
digoxin B-drug
was O
reduced O
from O
234 O
+/- O
72 O
ml/min O
( O
mean O
+/- O
standard O
deviation O
) O
to O
172 O
+/- O
33 O
ml/min O
( O
p O
less O
than O
0.01 O
) O
. O

Drug O
interactions O
: O
How O
to O
identify O
them O
. O

. O

injection O
of O
vehicle O
( O
corn O
oil O
, O
0.1 O
mL/day O
) O
, O
estradiol B-drug
( O
10 O
microg/kg/day O
or O
4 O
mg/kg/day O
) O
and/or O
progesterone B-drug
( O
20 O
mg/kg/day O
) O
, O
for O
eight O
days O
. O

This O
may O
indicate O
that O
they O
could O
enhance O
the O
toxicity O
of O
methotrexate B-drug
. O

Inhibitors O
of O
CYP3A4 O
( O
eg O
, O
ketoconazole B-drug
) O
or O
CYP2D6 O
( O
eg O
, O
quinidine B-drug
, O
fluoxetine B-drug
, O
or O
paroxetine B-drug
) O
can O
inhibit O
aripiprazole B-drug
elimination O
and O
cause O
increased O
blood O
levels O
. O

The O
mechanism O
underlying O
many O
of O
these O
events O
is O
unknown O
, O
but O
may O
represent O
increased O
hypotension O
. O

It O
is O
therefore O
necessary O
to O
be O
well O
acquainted O
with O
the O
clinical O
and O
paraclinical O
pattern O
of O
magnesium B-drug
deficit O
and O
to O
discriminate O
between O
magnesium B-drug
deficiency O
due O
to O
an O
insufficient O
magnesium B-drug
intake O
which O
only O
requires O
oral O
physiological O
supplementation O
and O
magnesium B-drug
depletion O
related O
to O
a O
dysregulation O
of O
the O
control O
mechanisms O
of O
magnesium B-drug
status O
which O
requires O
more O
or O
less O
specific O
regulation O
of O
its O
causal O
dysregulation O
. O

Therefore O
, O
the O
concomitant O
administration O
of O
TRACLEER B-brand
and O
glyburide B-drug
is O
contraindicated O
, O
and O
alternative O
hypoglycemic B-group
agents I-group
should O
be O
considered O
. O

Phenytoin B-drug
: O
Serum O
phenytoin B-drug
levels O
may O
be O
increased O
by O
aspirin B-brand
. O

Pharmacologic O
studies O
indicate O
that O
there O
may O
be O
additive O
effects O
in O
prolonging O
AV O
conduction O
when O
using O
beta-blockers B-group
or O
digitalis B-group
concomitantly O
with O
Tiazac B-brand
. O

Amprenavir B-drug

No O
abortifacient O
or O
teratogenic O
effects O
were O
observed O
in O
cynomolgus O
monkeys O
following O
intravenous O
bolus O
injections O
of O
AMEVIVE B-brand
administered O
weekly O
during O
the O
period O
of O
organogenesis O
to O
gestation O
. O

Therefore O
, O
concomitant O
use O
of O
TORADOL B-brand
and O
probenecid B-drug
is O
contraindicated O
. O

( O
54 O
) O
microtubules O
per O
axon O
. O

Primary O
and O
secondary O
magnesium B-drug
deficiencies O
constitute O
the O
sole O
indication O
of O
physiological O
oral O
magnesium B-drug
therapy O
. O

Antacid B-group
: O
The O
effect O
of O
an O
aluminum B-drug
hydroxide- O
and O
magnesium B-drug
hydroxide-containing O
antacid B-group
( O
Maalox B-brand
) O
* O
on O
the O
pharmacokinetics O
of O
capecitabine B-drug
was O
investigated O
in O
12 O
cancer O
patients O
. O

Antacids B-group
, O
kaolin-pectin B-drug
, O
sulfasalazine B-drug
, O
neomycin B-drug
, O
cholestyramine B-drug
, O
certain O
anticancer O
drugs O
, O
and O
metoclopramide B-drug
may O
interfere O
with O
intestinal O
digoxin B-drug
absorption O
, O
resulting O
in O
unexpectedly O
low O
serum O
concentrations O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
this O
drug O
is O
given O
concomitantly O
with O
anticholinergic B-group
or O
sympathomimetic B-group
drugs I-group
. O

Acetaminophen B-drug
diminished O
the O
binding O
of O
theophylline B-drug
to O
human O
serum O
by O
a O
net O
change O
of O
5.7 O
% O
( O
percentage O
increase O
in O
free O
drug O
fraction O
[ O
FDF O
] O
, O
11.0 O
% O
) O
at O
662 O
micromol/L O
and O
by O
a O
net O
change O
of O
7.1 O
% O
( O
percentage O
increase O
in O
FDF O
, O
13.7 O
% O
) O
at O
1324 O
micromol/L O
. O

This O
paper O
attempts O
to O
provide O
a O
basis O
for O
the O
understanding O
and O
identifications O
of O
important O
drug O
interactions O
. O

Effects O
of O
etofibrate B-drug
upon O
the O
metabolism O
of O
chylomicron-like O
emulsions O
in O
patients O
with O
coronary O
artery O
disease O
. O

Hypersensitivity O
Reactions O
: O
Patients O
with O
a O
history O
of O
severe O
hypersensitivity O
reactions O
to O
products O
containing O
Cremophor O
EL O
( O
eg O
, O
cyclosporin B-drug
for O
injection O
concentrate O
and O
teniposide B-drug
for O
injection O
concentrate O
) O
should O
not O
be O
treated O
with O
TAXOL B-brand
. O

Rare O
reports O
of O
more O
severe O
events O
such O
as O
phlebitis O
, O
cellulitis O
, O
induration O
, O
skin O
exfoliation O
, O
necrosis O
, O
and O
fibrosis O
have O
been O
received O
as O
part O
of O
the O
continuing O
surveillance O
of O
TAXOL B-brand
safety O
. O

Cocaine B-drug
sometimes O
proves O
to O
be O
fatal O
when O
used O
in O
combination O
with O
heroin B-drug_n
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
aminoglycoside B-group
antibiotics I-group
and O
cephalosporin B-group
antibiotics I-group
. O

Of O
the O
229 O
patients O
who O
had O
potassium B-group
depleting I-group
diuretics I-group
added O
to O
their O
concomitant O
medications O
in O
the O
DIAMOND O
trials O
, O
the O
patients O
on O
TIKOSYN B-brand
had O
a O
non-significantly O
reduced O
relative O
risk O
for O
death O
of O
0.68 O
( O
95 O
% O
CI O
0.376 O
, O
1.230 O
) O
. O

Azlocillin B-drug
should O
not O
be O
administered O
concomitantly O
with O
amikacin B-drug
, O
ciprofloxacin B-drug
, O
gentamicin B-drug
, O
netilmicin B-drug
, O
or O
tobramycin B-drug
. O

Itraconazole B-drug
plasma O
concentrations O
should O
be O
monitored O
when O
Itraconazole B-drug
and O
isoniazid B-drug
are O
coadministered O
. O

Moreover O
, O
its O
activity O
was O
enhanced O
when O
it O
was O
combined O
with O
either O
azithromycin B-drug
or O
minocycline B-drug
with O
90 O
% O
parasite O
reduction O
at O
the O
highest O
concentration O
tested O
. O

Whether O
abnormal O
topoisomerase O
quantity O
and O
specific O
activity O
are O
associated O
with O
resistance O
or O
sensitivity O
to O
topoisomerase-targeted O
chemotherapy O
in O
the O
clinic O
is O
now O
being O
studied O
. O

Cardiac B-group
glycosides I-group

The O
color O
reverses O
when O
the O
test O
sample O
is O
acidified O
in O
vitro O
to O
a O
pH O
below O
4 O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

Amiodarone B-drug
or O
Verapamil B-drug
: O
The O
risk O
of O
myopathy/rhabdomyolysis O
is O
increased O
when O
either O
amiodarone B-drug
or O
verapamil B-drug
is O
used O
concomitantly O
with O
a O
closely O
related O
member O
of O
the O
HMG-CoA B-group
reductase I-group
inhibitor I-group
class I-group
( O
see O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
) O
. O

Lithium B-drug
: O
Diclofenac B-drug
decreases O
lithium B-drug
renal O
clearance O
and O
increases O
lithium B-drug
plasma O
levels O
. O

- O
Probenecid B-drug
: O
Pretreatment O
with O
probenecid B-drug
reduces O
both O
the O
natriuresis O
and O
hyperreninemia O
produced O
by O
bumetanide B-drug
. O

The O
interaction O
was O
pharmacodynamic O
; O

Dose O
of O
AED B-group
( O
mg/day O
) O

Concomitantly O
administered O
iron-fortified B-drug_n
infant O
formula O
( O
2.2 O
mg O
elemental O
iron/6 B-drug_n
oz O
) O
has O
no O
significant O
effect O
on O
cefdinir B-drug
pharmacokinetics O
. O

No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-drug
Tablets O
. O

Coadministration O
of O
Itraconazole B-drug
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O

Buforin B-drug_n
II I-drug_n
may O
be O
active O
in O
inhibiting O
Cryptosporidium O
parvum O
growth O
in O
vitro O
upon O
combination O
with O
either O
azithromycin B-drug
or O
minocycline B-drug
. O

Lovastatin B-drug
is O
metabolized O
by O
CYP3A4 O
but O
has O
no O
CYP3A4 O
inhibitory O
activity O
; O

The O
effects O
of O
chlordiazepoxide B-drug
, O
amphetamine B-drug
and O
cocaine B-drug
on O
bar-press O
behavior O
in O
normal O
and O
genetically O
nervous O
dogs O
. O

Hydrocodone B-drug
: O
Coadministration O
of O
Neurontin B-brand
( O
125 O
to O
500 O
mg O
; O

There O
are O
a O
number O
of O
steps O
physicians O
can O
take O
to O
ensure O
that O
their O
patients O
are O
not O
being O
undertreated O
. O

Digitalis B-group
: O
Thyroid B-group
preparations I-group
may O
potentiate O
the O
toxic O
effects O
of O
digitalis B-group
. O

Studies O
with O
ACE B-group
inhibitors I-group
in O
combination O
with O
diuretics B-group
indicate O
that O
the O
dose O
of O
the O
ACE B-group
inhibitor I-group
can O
be O
reduced O
when O
it O
is O
given O
with O
a O
diuretic B-group
. O

Monitoring O
of O
liver O
enzymes O
is O
recommended O
when O
SUSTIVA B-brand
is O
used O
in O
combination O
with O
ritonavir B-drug
. O

Severe O
allergic O
reactions O
including O
anaphylaxis O
have O
been O
reported O
in O
patients O
exposed O
to O
a O
variety O
of O
allergens O
either O
by O
repeated O
challenge O
, O
or O
accidental O
contact O
, O
and O
with O
diagnostic O
or O
therapeutic O
agents O
while O
receiving O
beta-blockers B-group
. O

Ketoconazole B-drug
: O
Sensipar B-brand
is O
metabolized O
in O
part O
by O
CYP3A4 O
. O

Erythromycin B-drug
( O
500 O
mg O
every O
8 O
hrs O
) O

In O
the O
present O
study O
, O
evoked O
potentials O
were O
recorded O
at O
5 O
, O
20 O
, O
and O
40 O
min O
following O
IP O
injections O
of O
saline O
, O
ethanol B-drug
( O
2.0 O
g/kg O
) O
, O
physostigmine B-drug
( O
0.6 O
mg/kg O
) O
or O
atropine B-drug
( O
15.0 O
mg/kg O
) O
on O
separate O
days O
. O

There O
is O
little O
if O
any O
clinically O
significant O
interaction O
between O
Acarbose B-drug
and O
metformin B-drug
. O

Edema O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
Itraconazole B-drug
and O
dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
. O

Thyroid O
hormonal O
replacement O
increases O
metabolic O
rate O
, O
which O
requires O
an O
increase O
in O
digitalis B-group
dosage O
. O

No O
dose O
adjustment O
is O
necessary O
. O

Antihypertensives B-group
: O
Amphetamines B-group
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-group
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Caution O
should O
be O
exercised O
if O
LEUSTATIN B-brand
Injection O
is O
administered O
before O
, O
after O
, O
or O
in O
conjunction O
with O
other O
drugs O
known O
to O
cause O
immunosuppression O
or O
myelosuppression O
. O

As O
a O
false-negative O
result O
may O
occur O
in O
the O
ferricyanide O
test O
, O
it O
is O
recommended O
that O
either O
the O
glucose O
oxidase O
or O
hexokinase O
method O
be O
used O
to O
determine O
blood/plasma O
glucose O
levels O
in O
patients O
receiving O
cefditoren B-drug
pivoxil I-drug
. O

No O
significant O
interactions O
with O
digoxin B-drug
, O
hydrochlorothiazide B-drug
, O
hydralazine B-drug
, O
sulfinpyrazone B-drug
, O
oral O
contraceptives B-group
, O
tolbutamide B-drug
, O
or O
warfarin B-drug
have O
been O
observed O
. O

The O
high O
acquisition O
cost O
of O
olanzapine B-drug
is O
offset O
by O
reductions O
in O
other O
treatment O
costs O
( O
inpatient O
and/or O
outpatient O
services O
) O
of O
schizophrenia O
. O

The O
daily O
dose O
of O
ENABLEX B-brand
should O
not O
exceed O
7.5 O
mg O
when O
coadministered O
with O
potent O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
ritonavir B-drug
, O
nelfinavir B-drug
, O
clarithromycin B-drug
and O
nefazadone O
) O
. O

Treatment O
of O
the O
glands O
with O
cytochalasin B-drug_n
D I-drug_n
redistributed O
type O
3 O
inositol O
1,4,5-trisphosphate O
receptor O
( O
the O
major O
subtype O
in O
the O
parietal O
cell O
) O
from O
the O
fraction O
containing O
membranes O
of O
large O
size O
to O
the O
microsomal O
fraction O
, O
suggesting O
a O
dissociation O
of O
the O
store O
from O
the O
plasma O
membrane O
. O

diuretics* B-group
; O

It O
is O
presently O
not O
known O
whether O
these O
same O
drug O
interactions O
occur O
with O
dirithromycin B-drug
. O

Doxazosin B-drug
mesylate I-drug
has O
been O
administered O
without O
any O
evidence O
of O
an O
adverse O
drug O
interaction O
to O
patients O
receiving O
thiazide B-group
diuretics I-group
, O
beta-blocking B-group
agents O
, O
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
. O

Viable O
counts O
for O
type O
culture O
E O
. O

The O
concurrent O
use O
of O
drugs O
from O
these O
groups O
is O
decreasing O
according O
to O
a O
survey O
of O
200 O
hospital O
medical O
records O
. O

Nephrotoxicity O
associated O
with O
cyclosporine B-drug
may O
also O
be O
enhanced O
. O

Pretreatment O
of O
megakaryocytes O
with O
extracellular O
RR B-drug_n
( O
50 O
microM O
) O
also O
inhibited O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-induced O
responses O
. O

Dopamine B-group
Antagonists I-group
: O
Since O
apomorphine B-drug
is O
a O
dopamine B-group
agonist I-group
, O
it O
is O
possible O
that O
dopamine B-group
antagonists I-group
, O
such O
as O
the O
neuroleptics B-group
( O
phenothiazines B-group
, O
butyrophenones B-group
, O
thioxanthenes B-group
) O
or O
metoclopramide B-drug
, O
may O
diminish O
the O
effectiveness O
of O
APOKYN B-brand
. O

If O
such O
drugs O
are O
needed O
, O
their O
dose O
should O
be O
reassessed O
and O
, O
where O
appropriate O
, O
plasma O
concentration O
measured O
. O

The O
AUC O
of O
midazolam B-drug
on O
Day O
15 O
was O
similar O
to O
that O
observed O
at O
baseline O
. O

5 O
. O

Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
indinavir B-drug
may O
be O
required O
. O

They O
are O
part O
of O
the O
treatment O
of O
patients O
with O
organ O
transplants O
, O
malignancy O
, O
and O
increasingly O
those O
with O
conditions O
such O
as O
psoriasis O
, O
rheumatoid O
arthritis O
, O
and O
liver O
and O
bowel O
disease O
in O
which O
inflammation O
is O
an O
aetiological O
factor O
. O

Phenytoin B-drug
: O
Etodolac B-drug
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
phenytoin B-drug
. O

Concomitant O
use O
of O
HIVID B-drug
with O
didanosine B-drug
is O
not O
recommended O
. O

Under O
similar O
conditions O
, O
bexarotene B-drug
concentrations O
were O
not O
affected O
by O
concomitant O
atorvastatin B-drug
administration O
. O

Increased O
stability O
of O
nucleophosmin/B23 O
in O
anti-apoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O

H2 B-group
Receptor I-group
Antagonists I-group
: O
Cimetidine B-drug
coadministration O
leads O
to O
an O
increased O
peak O
plasma O
concentration O
and O
AUC O
of O
cisapride B-drug
, O
there O
is O
no O
effect O
on O
cisapride B-drug
absorption O
when O
it O
is O
coadministered O
with O
ranitidine B-drug
. O

Pentamidine B-drug
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O

However O
, O
concomitant O
administration O
of O
aspirin B-brand
with O
CELEBREX B-brand
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
CELEBREX B-brand
alone O
. O

Another O
investigator O
found O
no O
increase O
in O
digoxin B-drug
levels O
in O
13 O
patients O
with O
coronary O
artery O
disease O
. O

If O
additional O
adrenergic B-group
drugs I-group
are O
to O
be O
administered O
by O
any O
route O
, O
they O
should O
be O
used O
with O
caution O
because O
the O
pharmacologically O
predictable O
sympathetic O
effects O
of O
BROVANA B-brand
may O
be O
potentiated O
. O

Based O
on O
this O
reported O
activity O
, O
they O
should O
not O
be O
given O
concomitantly O
with O
Coly-Mycin B-brand
M I-brand
Parenteral O
except O
with O
the O
greatest O
caution O
. O

No O
changes O
were O
observed O
in O
the O
degree O
of O
anticoagulation O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

However O
, O
because O
higher O
doses O
( O
up O
to O
360 O
mg O
QD O
) O
of O
omeprazole B-drug
are O
tolerated O
in O
Zollinger-Ellison O
( O
ZE O
) O
patients O
, O
no O
dose O
adjustment O
for O
omeprazole B-drug
is O
recommended O
at O
current O
doses O
. O

After O
14 O
days O
of O
co-administration O
, O
mean O
trough O
concentrations O
of O
clozapine B-drug
and O
its O
metabolites O
, O
N-desmethylclozapine B-drug_n
and O
clozapine B-drug_n
N-oxide I-drug_n
, O
were O
elevated O
with O
fluvoxamine B-drug
by O
about O
three-fold O
compared O
to O
baseline O
concentrations O
. O

In O
a O
study O
involving O
healthy O
subjects O
receiving O
TAMBOCOR B-brand
and O
propranolol B-drug
concurrently O
, O
plasma O
flecainide B-drug
levels O
were O
increased O
about O
20 O
% O
and O
propranolol B-drug
levels O
were O
increased O
about O
30 O
% O
compared O
to O
control O
values O
. O

Because O
of O
its O
lack O
of O
anti-platelet O
effect O
valdecoxib B-drug
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

The O
management O
of O
infection O
is O
dealt O
with O
as O
a O
separate O
section O
. O

diuretics* B-group
; O

Patients O
should O
be O
advised O
against O
the O
simultaneous O
use O
of O
other O
CNS B-group
depressant I-group
drugs I-group
, O
and O
cautioned O
that O
the O
effect O
of O
alcohol B-drug
may O
be O
increased O
. O

OTHER O
CONCOMITANT O
THERAPY O
: O
Although O
specific O
interaction O
studies O
were O
not O
performed O
, O
in O
clinical O
studies O
, O
cerivastatin B-drug
sodium I-drug
was O
used O
concomitantly O
with O
angiotensin- B-group
converting I-group
enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
, O
betablockers B-group
, O
calcium-channel B-group
blockers I-group
, O
diuretics B-group
, O
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
( O
NSAIDs B-group
) O
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

Known O
drug O
interactions O
include O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
alcohol B-drug
. O

Concurrent O
administration O
of O
drugs O
possessing O
nephrotoxic O
( O
e.g. O
, O
aminoglycosides B-group
, O
indomethacin B-drug
) O
, O
myelotoxic O
( O
e.g. O
, O
cytotoxic B-group
chemotherapy O
) O
, O
cardiotoxic O
( O
e.g. O
, O
doxorubicin B-drug
) O
or O
hepatotoxic O
( O
e.g. O
, O
methotrexate B-drug
, O
asparaginase B-drug
) O
effects O
with O
PROLEUKIN B-brand
may O
increase O
toxicity O
in O
these O
organ O
systems O
. O

PCP B-drug_n
produced O
distinctive O
effects O
in O
each O
task O
: O
it O
substituted O
for O
the O
training O
dose O
in O
PCP B-drug_n
discrimination O
and O
it O
increased O
the O
number O
of O
responses O
with O
short O
( O
< O
3 O
s O
) O
interresponse O
times O
as O
well O
as O
increasing O
overall O
response O
rates O
in O
the O
DRL O
schedule O
. O

Eprosartan B-drug
( O
up O
to O
400 O
mg O
b.i.d O
. O
or O
800 O
mg O
q.d O
. O
) O
doses O
have O
been O
safely O
used O
concomitantly O
with O
a O
thiazide B-group
diuretic I-group
( O
hydrochlorothiazide B-drug
) O
. O

clinical O
significance O
unknown O
. O

Because O
candesartan B-drug
is O
not O
significantly O
metabolized O
by O
the O
cytochrome O
P450 O
system O
and O
at O
therapeutic O
concentrations O
has O
no O
effects O
on O
P450 O
enzymes O
, O
interactions O
with O
drugs O
that O
inhibit O
or O
are O
metabolized O
by O
those O
enzymes O
would O
not O
be O
expected O
. O

The O
AUC O
and O
Cmax O
of O
descarboethoxyloratadine B-drug_n
, O
an O
active O
metabolite O
, O
averaged O
155 O
% O
( O
27 O
S.D O
. O
) O
and O
141 O
% O
( O
35 O
S.D O
. O
) O
, O
respectively O
. O

No O
significant O
difference O
was O
found O
between O
the O
mean O
values O
of O
the O
volume O
of O
distribution O
of O
cloxacillin B-drug
with O
and O
without O
probenecid B-drug
( O
13.0 O
and O
12.6 O
liters O
, O
respectively O
) O
. O

Toxicity O
of O
cadmium O
and O
zinc B-drug
to O
miracidia O
of O
Schistosoma O
mansoni O
. O

Rifampicin B-drug
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
a O
six-day O
course O
of O
rifampicin B-drug
at O
600 O
mg/day O
followed O
by O
a O
single O
5 O
mg O
dose O
of O
isradipine B-drug
resulted O
in O
a O
reduction O
in O
isradipine B-drug
levels O
to O
below O
detectable O
limits O
. O

and O
, O
rarely O
, O
euphoria O
, O
excitement O
, O
depression O
, O
hallucinations O
, O
paresthesia O
, O
muscle O
pain O
, O
tinnitus O
, O
slurred O
speech O
, O
coordination O
disorder O
, O
tremor O
, O
rigidity O
, O
dystonia O
, O
ataxia O
, O
blurred O
vision O
, O
nystagmus O
, O
strabismus O
, O
miosis O
, O
mydriasis O
, O
diplopia O
, O
dysarthria O
, O
epileptic O
seizure O
. O

Cholecystokinin O
octapeptide O
is O
a O
necessary O
factor O
for O
realization O
of O
this O
action O
of O
neuroleptics B-group
. O

Menstrual O
cycle O
irregularities O
were O
accompanied O
by O
both O
a O
decrease O
and O
delay O
in O
the O
peak O
17b O
-estradiol O
and O
progesterone O
levels O
following O
administration O
of O
PEGASYS B-brand
to O
female O
monkeys O
. O

HMG-CoA B-group
Reductase I-group
Inhibitors I-group
: O
Inhibitors B-group
of I-group
HMG-CoA I-group
reductase I-group
may O
cause O
myopathy O
, O
which O
is O
manifested O
as O
muscle O
pain O
or O
weakness O
associated O
with O
elevated O
levels O
of O
CPK O
. O

Although O
the O
clinical O
significance O
of O
these O
effects O
is O
not O
known O
, O
caution O
is O
advised O
in O
the O
co-administration O
of O
beta-agonists B-group
with O
non-potassium B-group
sparing I-group
diuretics I-group
. O

Since O
animal O
studies O
suggest O
that O
the O
action O
of O
barbiturates B-group
may O
be O
prolonged O
by O
therapy O
with O
chlorpropamide B-drug
, O
barbiturates B-group
should O
be O
employed O
with O
caution O
. O

Antihistamines B-group
may O
have O
additive O
effects O
with O
alcohol B-drug
and O
other O
CNS B-group
depressants I-group
, O
e.g. O
, O
hypnotics B-group
, O
sedatives B-group
, O
tranquilizers B-group
, O
antianxiety B-group
agents I-group
. O

Upon O
administration O
of O
10 O
mg O
of O
Vardenafil B-drug
with O
800 O
mg O
TID O
indinavir B-drug
, O
the O
Cmax O
and O
AUC O
of O
indinavir B-drug
were O
reduced O
by O
40 O
% O
and O
30 O
% O
, O
respectively O
. O

Interaction O
of O
clindamycin B-drug
and O
gentamicin B-drug
in O
vitro O
. O

Anafranil B-brand
should O
not O
be O
used O
with O
MAO B-group
inhibitors I-group
. O

Respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
or O
coma O
may O
occur O
. O

Therefore O
, O
monitoring O
of O
theophylline B-drug
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-drug
adjusted O
as O
required O
. O

These O
results O
suggest O
that O
oral O
administration O
of O
dmPGE2 B-drug_n
induces O
a O
more O
pronounced O
secretory O
diarrhea O
in O
cecectomized O
than O
in O
control O
rats O
, O
probably O
due O
to O
the O
lack O
of O
the O
reservoir O
function O
of O
the O
cecum O
in O
the O
operated O
animals O
. O

Caution O
should O
be O
used O
when O
CYP3A4 B-drug
inhibitors O
are O
co-administered O
with O
felodipine B-drug
. O

The O
actions O
of O
the O
benzodiazepines B-group
may O
be O
potentiated O
by O
barbiturates B-group
, O
narcotics B-group
, O
phenothiazines B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
other O
antidepressants B-group
. O

Effects O
of O
Erythromycin B-drug
on O
Felbatol B-brand
The O
coadministration O
of O
erythromycin B-drug
( O
1000 O
mg/day O
) O
for O
10 O
days O
did O
not O
alter O
the O
pharmacokinetic O
parameters O
of O
Cmax O
, O
Cmin O
, O
AUC O
, O
CI/kg O
or O
tmax O
at O
felbamate B-drug
daily O
doses O
of O
3000 O
or O
3600 O
mg/day O
in O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
. O

Small O
differences O
in O
sensitivity O
to O
chemotherapy O
can O
have O
a O
dramatic O
effect O
on O
cure O
rates O
, O
and O
therefore O
subtle O
cell O
type-specific O
differences O
may O
be O
important O
determinants O
of O
drug O
sensitivity O
. O

Potassium O
sparing O
agents O
should O
generally O
not O
be O
used O
in O
patients O
with O
heart O
failure O
who O
are O
receiving O
PRINIVIL B-brand
. O

Methotrexate B-drug
: O
Valdecoxib B-drug
10 I-drug
mg I-drug
BID O
did O
not O
show O
a O
significant O
effect O
on O
the O
plasma O
exposure O
or O
renal O
clearance O
of O
methotrexate B-drug
. O

Medications O
that O
interfere O
with O
your O
bodys O
ability O
to O
use O
folate O
may O
also O
increase O
the O
need O
for O
this O
vitamin B-group
. O

Effect O
of O
estradiol B-drug
on O
endotoxin-induced B-drug_n
changes O
in O
steroid O
hormone O
levels O
and O
lethality O
in O
male O
rats O
. O

In O
noradrenaline-precontracted B-drug
arteries O
from O
dietary-obese O
rats O
, O
responses O
to O
resveratrol B-drug_n
were O
not O
attenuated O
by O
endothelial O
denudation O
, O
indicating O
an O
action O
independent O
of O
the O
endothelium O
. O

Nelfinavir I-drug
M8 O

Drug/Laboratory O
Test O
Interactions O

d-amphetamine B-drug
with O
desipramine B-drug
or O
protriptyline B-drug
and O
possibly O
other O
tricyclics B-group
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d-amphetamine B-drug
in O
the O
brain O
; O

In O
vitro O
studies O
were O
conducted O
to O
investigate O
the O
potential O
of O
gabapentin B-drug
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A4 O
) O
that O
mediate O
drug O
and O
xenobiotic O
metabolism O
using O
isoform O
selective O
marker O
substrates O
and O
human O
liver O
microsomal O
preparations O
. O

Careful O
supervision O
of O
diabetic O
patients O
under O
treatment O
with O
Soriatane B-brand
is O
recommended O
. O

The O
potential O
for O
clinically O
significant O
drug-drug O
interactions O
posed O
by O
dolasetron B-drug
and O
hydrodolasetron B-drug_n
appears O
to O
be O
low O
for O
drugs O
commonly O
used O
in O
chemotherapy O
or O
surgery O
, O
because O
hydrodolasetron B-drug_n
is O
eliminated O
by O
multiple O
routes O
. O

Aspirin B-brand
: O
Concomitant O
aspirin B-brand
may O
decrease O
the O
metabolic O
clearance O
of O
nicotinic B-drug
acid I-drug
. O

During O
clinical O
trials O
, O
hypoglycemia O
and O
hyperglycemia O
were O
reported O
in O
diabetic O
patients O
receiving O
oral O
hypoglycemics B-group
. O

use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Administration O
of O
a O
5 O
g O
bolus O
followed O
by O
1 O
to O
1.25 O
g/hr O
should O
achieve O
and O
sustain O
plasma O
levels O
of O
0.13 O
mg/mL O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
. O

Therefore O
, O
a O
starting O
daily O
dose O
of O
25 O
mg O
of O
VIOXX B-brand
should O
be O
considered O
for O
the O
treatment O
of O
osteoarthritis O
when O
VIOXX B-brand
is O
co-administered O
with O
potent O
inducers O
of O
hepatic O
metabolism O
. O

Influence O
of O
Trileptal B-brand
on O
AED B-group
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O

Although O
these O
results O
do O
not O
indicate O
a O
significant O
interaction O
between O
TORADOL B-brand
and O
warfarin B-drug
or O
heparin B-drug
, O
the O
administration O
of O
TORADOL B-brand
to O
patients O
taking O
anticoagulants B-group
should O
be O
done O
extremely O
cautiously O
, O
and O
patients O
should O
be O
closely O
monitored O
. O

The O
decision O
to O
prescribe O
this O
agent O
should O
include O
such O
considerations O
as O
the O
cost-risk-benefit O
balance O
, O
patient O
access O
, O
drug O
distribution O
pathways O
, O
and O
prescription O
drug O
coverage O
. O

Aspirin/Acetaminophen B-brand
: O
Pharmacokinetic O
or O
pharmacodynamic O
drug-drug O
interactions O
have O
not O
been O
demonstrated O
between O
Argatroban B-drug
and O
concomitantly O
administered O
aspirin B-brand
( O
162.5 O
mg O
orally O
given O
26 O
and O
2 O
hours O
prior O
to O
initiation O
of O
Argatroban B-drug
1 O
g/kg/min O
. O
over O
4 O
hours O
) O
or O
acetaminophen B-drug
( O
1000 O
mg O
orally O
given O
12 O
, O
6 O
and O
0 O
hours O
prior O
to O
, O
and O
6 O
and O
12 O
hours O
subsequent O
to O
, O
initiation O
of O
Argatroban B-drug
1.5 O
g/kg/min O
. O
over O
18 O
hours O
) O
. O

Pregnancy O
Pregnancy O
: O
Category O
C O
PEGASYS B-brand
has O
not O
been O
studied O
for O
its O
teratogenic O
effect O
. O

Intravenous O
ranitidine B-drug
was O
shown O
to O
double O
the O
bioavailability O
of O
oral O
alendronate B-drug
. O

Caution O
is O
advised O
if O
patients O
receive O
large O
doses O
of O
ethchlorvynol B-drug
concurrently O
. O

Chlorprothixene B-drug
may O
increase O
the O
plasma-level O
of O
concomitantly O
given O
lithium B-drug
. O

Genetic O
variation O
in O
metabolism O
may O
result O
in O
high O
concentrations O
of O
drugs O
and O
an O
increased O
risk O
of O
adverse O
effects O
in O
slow O
metabolizers O
, O
which O
is O
important O
when O
using O
for O
example O
antidepressants B-group
or O
chemotherapy O
. O

Ampicillin/Amoxicillin B-drug
: O
An O
increase O
in O
the O
frequency O
of O
skin O
rash O
has O
been O
reported O
among O
patients O
receiving O
ampicillin B-drug
or O
amoxicillin B-drug
concurrently O
with O
allopurinol B-drug
compared O
to O
patients O
who O
are O
not O
receiving O
both O
drugs O
. O

Hyperglycemia O
has O
also O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-brand
. O

Until O
further O
data O
are O
developed O
regarding O
drug O
interactions O
when O
azithromycin B-drug
and O
these O
drugs O
are O
used O
concomitantly O
, O
careful O
monitoring O
of O
patients O
is O
advised O
: O
Digoxin B-drug
elevated O
digoxin B-drug
concentrations O
. O

Oral O
Contraceptives B-group
Multiple O
doses O
of O
cefditoren B-drug
pivoxil I-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-drug
estradiol I-drug
, O
the O
estrogenic O
component O
in O
most O
oral O
contraceptives B-group
. O

When O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
used O
at O
the O
same O
time O
as O
other O
medicines O
or O
substances O
the O
following O
interactions O
must O
be O
taken O
into O
account O
: O
- O
Bezalip B-brand
and O
Bezalip B-brand
retard I-brand
may O
enhance O
the O
action O
of O
anticoagulants B-group
of I-group
the I-group
coumarin I-group
type I-group
. O

Oral O
Contraceptives B-group
: O
The O
effect O
of O
oral O
contraceptives B-group
on O
the O
pharmacokinetics O
of O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
has O
not O
been O
studied O
. O

Reduced O
response O
to O
metyrapone O
test O
. O

About O
three O
weeks O
prior O
to O
admission O
, O
the O
patient O
was O
started O
on O
clarithromycin B-drug
for O
sinusitis O
. O

The O
unrestricted O
use O
of O
ascorbic B-drug
acid I-drug
for O
these O
purposes O
can O
not O
be O
advocated O
on O
the O
basis O
of O
the O
evidence O
currently O
available O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

Nonsteroidal B-group
anti-inflammatory I-group
agents I-group

Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-group
response O
, O
ie O
, O
decreased O
prothrom-bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-group
steroids I-group
; O
alcohol* B-drug
; O
antacids B-group
; O
antihistamines B-group
; O
barbiturates B-group
; O
carbamazepine B-drug
; O
chloral B-drug
hydrate* O
; O
chlordiazepoxide B-drug
; O
cholestyramine B-drug
; O
diet O
high O
in O
vitamin B-group
K I-group
; O
diuretics* B-group
; O
ethchlorvynol B-drug
; O
glutethimide B-drug
; O
griseofulvin B-drug
; O
haloperidol B-drug
; O
meprobamate B-drug
; O
oral O
contraceptives B-group
; O
paraldehyde B-drug
; O
primidone B-drug
; O
ranitidine* B-drug
; O
rifampin B-drug
; O
unreliable O
prothrombin O
time O
determinations O
; O
vitamin B-drug
C I-drug
; O
warfarin B-drug
sodium I-drug
under-dosage O
. O

This O
transient O
hypotensive O
response O
is O
not O
a O
contraindication O
to O
further O
doses O
which O
can O
be O
given O
without O
difficulty O
once O
the O
blood O
pressure O
has O
increased O
after O
volume O
expansion O
. O

Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-drug
potently O
inhibits O
the O
metabolism O
of O
cisapride B-drug
resulting O
in O
an O
eight-fold O
increase O
in O
the O
mean O
AUC O
of O
cisapride B-drug
. O

Increasing O
the O
felbamate B-drug
dose O
to O
1800 O
mg/day O
in O
six O
of O
these O
subjects O
increased O
the O
steady-state O
phenytoin B-drug
Cmin O
to O
25 O
7 O
micrograms/mL O
. O

Literature O
reports O
suggest O
that O
oral O
calcium B-group
antagonists I-group
may O
be O
used O
in O
combination O
with O
beta-adrenergic B-group
blocking I-group
agents I-group
when O
heart O
function O
is O
normal O
, O
but O
should O
be O
avoided O
in O
patients O
with O
impaired O
cardiac O
function O
. O

The O
effect O
of O
temperature O
changes O
on O
the O
number O
of O
microtubules O
in O
non-myelinated O
axons O
has O
been O
studied O
in O
cat O
inferior O
mesenteric O
ganglion/hypogastric O
nerve O
preparations O
incubated O
at O
various O
temperatures O
in O
Eagles O
minimal O
essential O
tissue O
culture O
medium O
in O
vitro O
. O

Administration O
of O
thiazide B-group
diuretics I-group
to O
hypoparathyroid O
patients O
who O
are O
concurrently O
being O
treated O
with O
ergocalciferol B-drug
may O
cause O
hypercalcemia O
. O

Until O
further O
data O
are O
available O
regarding O
the O
potential O
interaction O
of O
dirithromycin B-drug
with O
these O
compounds O
, O
caution O
should O
be O
used O
during O
coadministration O
. O

Restoration O
of O
vancomycin B-drug
susceptibility O
in O
Enterococcus O
faecalis O
by O
antiresistance O
determinant O
gene O
transfer O
. O

Other O
common O
adverse O
reactions O
are O
dizziness O
( O
5-15 O
% O
) O
, O
weakness O
( O
5-15 O
% O
) O
and O
fatigue O
( O
2-4 O
% O
) O
. O

Interactions O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
could O
potentially O
occur O
. O

Further O
, O
designs O
can O
be O
expressed O
in O
terms O
of O
proportionate O
responses O
associated O
with O
the O
individual O
compounds O
rather O
than O
dose O
levels O
, O
thereby O
providing O
for O
results O
that O
are O
applicable O
across O
compounds O
. O

therefore O
, O
the O
disposition O
of O
zaleplon B-drug
is O
not O
expected O
to O
be O
sensitive O
to O
alterations O
in O
protein O
binding O
. O

The O
potential O
for O
drug-drug O
interaction O
with O
drugs O
affected O
by O
cytochrome O
P450 O
enzymes O
may O
not O
be O
ruled O
out O
. O

dermatitis O

Lithium B-drug
: O
In O
a O
study O
conducted O
in O
healthy O
subjects O
, O
mean O
steady-state O
lithium B-drug
plasma O
levels O
increased O
approximately O
17 O
% O
in O
subjects O
receiving O
lithium B-drug
450 O
mg O
BID O
with O
CELEBREX B-brand
200 O
mg O
BID O
as O
compared O
to O
subjects O
receiving O
lithium B-drug
alone O
. O

In O
situations O
when O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O

Phosphate-Binding O
Agents O
: O
Since O
vitamin B-group
D I-group
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate-binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O

or O
with O
multivitamins B-group
containing O
zinc B-drug
may O
substantially O
interfere O
with O
drug O
absorption O
and O
result O
in O
insufficient O
plasma O
and O
tissue O
quinolone B-group
concentrations O
. O

Similarly O
, O
patients O
receiving O
the O
drug O
and O
a O
hydantoin B-group
, O
sulfonamide B-group
or O
sulfonylurea B-group
should O
be O
observed O
for O
signs O
of O
toxicity O
to O
these O
drugs O
. O

Antipyrine B-drug
: O
Antipyrine B-drug
pharmacokinetics O
were O
not O
significantly O
different O
before O
and O
after O
tiagabine B-drug
multiple-dose O
regimens O
. O

Phenytoin B-drug
: O
In O
a O
single O
( O
400 O
mg O
) O
and O
multiple O
dose O
( O
400 O
mg O
TID O
) O
study O
of O
Neurontin B-brand
in O
epileptic O
patients O
( O
N=8 O
) O
maintained O
on O
phenytoin B-drug
monotherapy O
for O
at O
least O
2 O
months O
, O
gabapentin B-drug
had O
no O
effect O
on O
the O
steady-state O
trough O
plasma O
concentrations O
of O
phenytoin B-drug
and O
phenytoin B-drug
had O
no O
effect O
on O
gabapentin B-drug
pharmacokinetics O
. O

Zidovudine B-drug
should O
either O
be O
temporarily O
discontinued O
or O
decreased O
by O
50 O
% O
when O
coadministered O
with O
probenecid B-drug
on O
the O
day O
of O
VISTIDE B-brand
infusion O
. O

This O
interaction O
appears O
to O
be O
related O
both O
to O
pressor O
activity O
and O
to O
beta-adrenergic O
stimulating O
properties O
of O
these O
catecholamines B-group
and O
may O
produce O
ventricular O
arrhythmias O
and O
hypertension O
. O

Jacalin B-drug_n
: O
an O
IgA-binding O
lectin O
. O

It O
is O
desirable O
to O
monitor O
TCAplasma B-group
levels O
whenever O
an O
agent O
of O
the O
tricyclic B-group
antidepressant I-group
class I-group
including O
Anafranil B-brand
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
( O
and/or O
P450 O
1A2 O
) O
. O

The O
effect O
of O
cyclosporine B-drug
on O
diltiazem B-drug
plasma O
concentrations O
has O
not O
been O
evaluated O
. O

ERGAMISOL B-brand
( O
levamisole B-drug
hydrochloride I-drug
) O
has O
been O
reported O
to O
produce O
ANTABUSE-like O
side O
effects O
when O
given O
concomitantly O
with O
alcohol B-drug
. O

During O
the O
above O
experiments O
we O
noted O
a O
massive O
precipitation O
in O
cell O
cultures O
stimulated O
with O
greater O
than O
or O
equal O
to O
100 O
micrograms O
of O
lectin O
. O

Other O
drugs O
metabolized O
by O
C.P.A O
. O

Cytochalasin B-drug_n
D I-drug_n
inhibited O
the O
carbachol-stimulated B-drug
intracellular O
Ca O
( O
2+ O
) O
concentration O
( O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
) O
increase O
due O
to O
release O
from O
the O
Ca O
( O
2+ O
) O
store O
. O

There O
was O
a O
reduction O
that O
reached O
borderline O
statistical O
significance O
in O
the O
group O
that O
received O
150 O
mg/d O
of O
tolbutamide B-drug
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

glutethimide B-drug
; O

For O
patients O
receiving O
both O
therapies O
, O
standard O
monitoring O
of O
tacrolimus B-drug
blood O
concentrations O
and O
appropriate O
tacrolimus B-drug
dosage O
adjustments O
are O
recommended O
. O

Patients O
on O
rifampin B-drug
should O
receive O
70 O
mg O
of O
CANCIDAS B-brand
daily O
. O

Sodium B-drug
Iodide I-drug
( O
123I O
and O
131I O
) O
, O
Sodium B-drug
Pertechnetate I-drug
Tc99m I-drug
: O
Uptake O
of O
radiolabeled O
ions O
may O
be O
decreased O
. O

Nevirapine B-drug
is O
principally O
metabolized O
by O
the O
liver O
via O
the O
cytochrome O
P450 O
isoenzymes O
, O
3A4 O
and O
2B6 O
. O

CNS O
Toxicity O
Brain O
hemorrhage O
was O
seen O
in O
a O
female O
dog O
treated O
for O
3 O
months O
at O
120 O
mg/kg/day O
. O

This O
allows O
bitolterol B-drug
to O
open O
air O
passages O
, O
increasing O
the O
effectiveness O
of O
the O
steroid B-group
. O

It O
is O
known O
that O
CYP1A2 O
is O
inhibited O
by O
several O
medicinal O
products O
, O
including O
fluvoxamine B-drug
, O
and O
such O
medicinal O
products O
could O
theoretically O
adversely O
influence O
the O
clearance O
of O
anagrelide B-drug
. O

The O
present O
work O
involved O
the O
administration O
of O
both O
ethynyl B-drug
estradiol I-drug
and O
levonorgestrel B-drug
to O
groups O
of O
rats O
, O
followed O
by O
determination O
of O
the O
homocysteine O
excretion O
rate O
in O
urine O
. O

Theoretically O
, O
the O
naproxen B-drug
anion O
itself O
could O
likewise O
be O
displaced O
. O

Indinavir B-drug
: O
Coadministration O
of O
indinavir B-drug
with O
VIRACEPT B-brand
resulted O
in O
an O
83 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
51 O
% O
increase O
in O
indinavir B-drug
plasma O
A.C O
. O

Pharmacokinetics O
of O
calcium-entry B-group
blockers I-group
. O

Coumarin-Type B-group
Anticoagulants I-group
: O
Several O
short-term O
controlled O
studies O
failed O
to O
wshow O
that O
ibuprofen B-drug
significantly O
affected O
prothrombin O
times O
or O
a O
variety O
of O
other O
clotting O
factors O
when O
administered O
to O
individuals O
on O
coumarin-type B-group
anticoagulants I-group
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

Flavoridin B-drug_n
alone O
was O
found O
to O
have O
no O
effect O
on O
CAS O
, O
but O
can O
completely O
block O
contortrostatin-induced B-drug_n
phosphorylation O
of O
this O
protein O
in O
MDA-MB-435 O
cells O
. O

If O
a O
patient O
is O
truly O
hypothyroid O
, O
it O
is O
likely O
that O
a O
reduction O
in O
anticoagulant B-group
dosage O
will O
be O
required O
. O

Methenamine B-drug

Therefore O
, O
OMNICEF B-brand
for O
Oral O
Suspension O
can O
be O
administered O
with O
iron-fortified B-drug_n
infant O
formula O
. O

Both O
CRIXIVAN B-brand
and O
atazanavir B-drug
are O
associated O
with O
indirect O
( O
unconjugated O
) O
hyperbilirubinemia O
. O

Alkalinizing O
agents O
: O
Gastrointestinal O
alkalinizing O
agents O
( O
sodium B-drug
bicarbonate I-drug
, O
etc O
. O
) O
increase O
absorption O
of O
amphetamines B-drug
. O

Patients O
taking O
REVIA B-brand
may O
not O
benefit O
from O
opioid B-group
containing O
medicines O
, O
such O
as O
cough O
and O
cold O
preparations O
, O
antidiarrheal O
preparations O
, O
and O
opioid B-group
analgesics I-group
. O

Hormonal B-group
Contraceptives I-group
, O
Including O
Oral O
, O
Injectable O
, O
Transdermal O
, O
and O
Implantable O
Contraceptives B-group
: O
An O
interaction O
study O
demonstrated O
that O
co-administration O
of O
bosentan B-drug
and O
the O
oral O
hormonal B-group
contraceptive I-group
Ortho-Novum B-brand
produced O
average O
decreases O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
levels O
of O
14 O
% O
and O
31 O
% O
, O
respectively O
. O

macrolide B-group
antibiotics I-group
e.g. O
, O
erythromycin B-drug
; O

Radioligand O
binding O
experiments O
using O
the O
uptake O
inhibitor O
hydrogen-3 O
mazindol B-drug
revealed O
a O
significant O
decrease O
by O
approximately O
30 O
% O
in O
norepinephrine B-drug
uptake-1 O
carrier O
density O
in O
functional O
classes O
II O
to O
III O
and O
IV O
myocardium O
versus O
nonfailing O
myocardium O
( O
p O
< O
0.05 O
) O
. O

However O
, O
the O
pharmacodynamics O
of O
coadministration O
of O
zaleplon B-drug
and O
promethazine B-drug
have O
not O
been O
evaluated O
. O

AIM O
AND O
BACKGROUND O
: O
The O
pharmacokinetic O
interaction O
between O
sirolimus B-drug
, O
a O
macrolide B-group
immunosuppressant I-group
metabolized O
by O
CYP3A4 O
, O
and O
the O
calcium B-group
channel I-group
blocker I-group
diltiazem B-drug
was O
studied O
in O
18 O
healthy O
subjects O
. O

only O
ibogaine B-drug_n
enhances O
cocaine-induced B-drug
increases O
in O
accumbal O
dopamine O
. O

Behavioral O
mechanisms O
underlying O
the O
link O
between O
smoking O
and O
drinking O
. O

John O
s O
wort O
) O
may O
increase O
the O
formation O
of O
dapsone B-drug_n
hydroxylamine I-drug_n
, O
a O
metabolite O
of O
dapsone B-drug
associated O
with O
hemolysis O
. O

Like O
ibogaine B-drug_n
( O
40 O
mg/kg O
) O
, O
18-MC B-drug_n
( O
40 O
mg/kg O
) O
decreases O
the O
intravenous O
self-administration O
of O
morphine B-drug
and O
cocaine B-drug
and O
the O
oral O
self-administration O
of O
ethanol B-drug
and O
nicotine B-drug
in O
rats O
; O

increased O
plasminogen O
antigen O
and O
activity O
. O

Permeation O
studies O
were O
performed O
on O
guinea O
pig O
small O
intestinal O
mucosa O
mounted O
in O
Ussing-type O
chamber O
. O

Other O
macrolide B-group
antibiotics I-group
, O
such O
as O
erythromycin B-drug
, O
have O
not O
been O
studied O
in O
combination O
with O
SUSTIVA B-brand
. O


Compounds O
tested O
in O
man O
include O
warfarin B-drug
, O
theophylline B-drug
, O
phenytoin B-drug
, O
diazepam B-drug
, O
aminopyrine B-drug
and O
antipyrine B-drug
. O

Reported O
examples O
include O
the O
following O
: O
Protease B-group
Inhibitors I-group
: O
Protease B-group
inhibitors I-group
are O
known O
to O
inhibit O
CYP3A4 O
to O
varying O
degrees O
. O

therefore O
, O
patients O
who O
may O
be O
adversely O
affected O
by O
such O
an O
action O
should O
be O
carefully O
observed O
. O

In O
patients O
given O
very O
high O
doses O
( O
3900 O
mg O
) O
of O
aspirin B-brand
daily O
, O
increases O
in O
serum O
salicylate B-group
levels O
were O
seen O
when O
nizatidine B-drug
, O
150 O
mg O
b.i.d. O
, O
was O
administered O
concurrently O
. O

Nicotine B-drug
Transdermal O
System O
: O
. O

Rabbits O
failed O
to O
maintain O
pregnancy O
when O
dosed O
with O
1 O
mg/kg/day O
fulvestrant B-drug
IM O
( O
twice O
the O
human O
dose O
on O
BSA O
) O
during O
the O
period O
of O
organogenesis O
. O

- O
Other O
antihypertensive B-group
drugs I-group
: O
Additive O
effect O
or O
potentiation O

The O
physician O
is O
advised O
to O
monitor O
the O
plasma O
concentrations O
of O
itraconazole B-drug
when O
any O
of O
these O
drugs O
is O
taken O
concurrently O
, O
and O
to O
increase O
the O
dose O
of O
Itraconazole B-drug
if O
necessary O
. O

The O
concurrent O
administration O
of O
CAMPTOSAR B-brand
with O
irradiation O
has O
not O
been O
adequately O
studied O
and O
is O
not O
recommended O
. O

Indomethacin B-drug
- O
Concomitant O
use O
of O
L-glutamine B-drug
and O
indomethacin B-drug
may O
ameliorate O
increased O
intestinal O
permeability O
caused O
by O
indomethacin B-drug
. O

Prospective O
studies O
on O
the O
potential O
for O
hydroxyurea B-drug
to O
interact O
with O
other O
drugs O
have O
not O
been O
performed O
. O

There O
is O
, O
however O
, O
currently O
no O
data O
on O
the O
effect O
of O
combined O
hyperglycaemia O
and O
hyperinsulinaemia O
on O
the O
renal O
and O
ocular O
blood O
flow O
seen O
in O
diabetic O
patients O
on O
insulin O
therapy O
. O

Animals O
dosed O
with O
1,3-difluoroacetone B-drug_n
did O
not O
display O
the O
2-3 O
hour O
lag O
phase O
in O
either O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
synthesis O
or O
in O
citrate O
and O
fluoride O
accumulation O
characteristic O
of O
animals O
dosed O
with O
1,3-difluoro-2-propanol B-drug_n
. O

In O
clinical O
trials O
, O
antacids B-group
were O
administered O
concomitantly O
with O
lansoprazole B-drug
delayed-release O
capsules O
; O

DISCUSSION O
: O
Clarithromycin B-drug
is O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
the O
major O
enzyme O
responsible O
for O
simvastatin B-drug
metabolism O
. O

Sodium B-drug
thiosulfate I-drug
is O
a O
neutralizing O
agent O
for O
cisplatin B-drug
that O
protects O
against O
renal O
damage O
. O

Digitalis B-group
glycosides I-group
: O
Patients O
on O
digitalis B-group
glycosides I-group
may O
be O
at O
increased O
risk O
of O
arrhythmias O
due O
to O
hypokalemia O
. O

Phenytoin B-drug
: O
Accutane B-brand
has O
not O
been O
shown O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-drug
in O
a O
study O
in O
seven O
healthy O
volunteers O
. O

The O
average O
increase O
was O
45 O
% O
. O

There O
was O
an O
increasing O
incidence O
of O
transient O
thrombocytopenia O
( O
or O
=100 O
x O
10 O
( O
9 O
) O
/L O
) O
with O
increasing O
everolimus B-drug
AUC O
( O
P O
= O
.03 O
) O
. O

MAO B-group
Inhibitors I-group
: O
Serious O
side O
effects O
and O
even O
death O
have O
been O
reported O
following O
the O
concomitant O
use O
of O
certain O
drugs O
with O
MAO B-group
inhibitors I-group
. O

This O
should O
be O
taken O
into O
account O
when O
evaluating O
serum O
amylase O
levels O
for O
diagnosis O
or O
monitoring O
of O
pancreatitis O
in O
patients O
using O
EXTRANEAL B-brand
. O

No O
change O
in O
phase O
was O
detected O
, O
although O
the O
aerosol O
particles O
appeared O
to O
contain O
residual O
solvent B-group
. O

Sympathomimetic B-group
amines I-group
may O
reduce O
the O
antihypertensive O
effects O
of O
reserpine B-drug
, O
veratrum B-group
alkaloids I-group
, O
methyldopa B-drug
and O
mecamylamine B-drug
. O

CYP3A4 O
and O
-2C19 O
Inhibitors O
- O
In O
vitro O
studies O
indicated O
that O
CYP3A4 O
and O
-2C19 O
are O
the O
primary O
enzymes O
involved O
in O
the O
metabolism O
of O
escitalopram B-drug
. O

this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O

Celecoxib B-drug
metabolism O
is O
predominantly O
mediated O
via O
cytochrome O
P450 O
2C9 O
in O
the O
liver O
. O

Digitalis B-group
glycosides I-group
: O
amphotericin B-drug
B-induced O
hypokalemia O
may O
potentiate O
digitalis B-group
toxicity O
. O

Potential O
effect O
on O
anticoagulation O
. O

Androgens B-group
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O

SERUM O
LEVELS O
OF O
PHENYTOIN B-drug
SHOULD O
BE O
DETERMINED O
ON O
DIFFERENT O
DAYS O
FOR O
EVIDENCE O
OF O
AN O
INCREASE O
OR O
FOR O
A O
CONTINUING O
RISE O
IN O
LEVELS O
. O

Absorption O
of O
tetracyclines B-group
is O
impaired O
by O
antacids B-group
containing O
aluminum B-drug
, O
calcium B-drug
, O
or O
magnesium B-drug
, O
and O
iron-containing B-drug
preparations O
. O

The O
effects O
of O
adenosine B-drug
are O
antagonized O
by O
methylxanthines B-group
such O
as O
caffeine B-drug
and O
theophylline B-drug
. O

Oral O
contraceptives B-group
: O
Aprepitant B-drug
, O
when O
given O
once O
daily O
for O
14 O
days O
as O
a O
100-mg O
capsule O
with O
an O
oral O
contraceptive B-group
containing O
35 O
mcg O
of O
ethinyl B-drug
estradiol I-drug
and O
1 O
mg O
of O
norethindrone B-drug
, O
decreased O
the O
AUC O
of O
ethinyl B-drug
estradiol I-drug
by O
43 O
% O
, O
and O
decreased O
the O
AUC O
of O
norethindrone B-drug
by O
8 O
% O
; O

Particular O
caution O
should O
be O
exercised O
in O
using O
preparations O
containing O
sulfur B-drug
, O
resorcinol B-drug
, O
or O
salicylic B-drug
acid I-drug
in O
combination O
with O
DIFFERIN B-brand
Gel O
. O

Ketoconazole B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg O
) O
and O
ketoconazole B-drug
( O
200 O
mg O
) O
decreased O
the O
Cmax O
and O
AUC O
of O
ketoconazole B-drug
by O
21 O
% O
and O
10 O
% O
, O
respectively O
, O
and O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
citalopram B-drug
. O

Terfenadine B-drug
: O
In O
a O
prospective O
study O
involving O
six-healthy-male O
volunteers O
, O
dirithromycin B-drug
did O
not O
affect O
the O
metabolism O
of O
terfenadine B-drug
. O

The O
existence O
of O
PI O
was O
related O
to O
the O
number O
of O
drugs O
prescribed O
to O
each O
patient O
( O
p O
< O
0.01 O
) O
. O

No O
Information O
Provided O

. O

Certain O
other O
antibiotics B-group
( O
aminoglycosides B-group
and O
polymyxin B-group
) O
have O
also O
been O
reported O
to O
interfere O
with O
the O
nerve O
transmission O
at O
the O
neuromuscular O
junction O
. O

Likewise O
, O
gabapentin B-drug
pharmacokinetics O
were O
unaltered O
by O
carbamazepine B-drug
administration O
. O

atorvastatin I-drug
concentration O

Controlled O
and O
uncontrolled O
domestic O
studies O
suggest O
that O
concomitant O
use O
of O
diltiazem B-drug
hydrochloride I-drug
and O
beta-blockers B-group
is O
usually O
well O
tolerated O
, O
but O
available O
data O
are O
not O
sufficient O
to O
predict O
the O
effects O
of O
concomitant O
treatment O
in O
patients O
with O
left O
ventricular O
dysfunction O
or O
cardiac O
conduction O
abnormalities O
. O

It O
is O
recommended O
that O
buspirone B-drug
hydrochloride I-drug
not O
be O
used O
concomitantly O
with O
MAO B-group
inhibitors I-group
Because O
the O
effects O
of O
concomitant O
administration O
of O
buspirone B-drug
HCl I-drug
with O
most O
other O
psychotropic B-group
drugs I-group
have O
not O
been O
studied O
, O
the O
concomitant O
use O
of O
buspirone B-drug
HCl I-drug
with O
other O
CNS-active O
drugs O
should O
be O
approached O
with O
caution O
. O

No O
interaction O
trials O
have O
been O
conducted O
with O
MEPRON B-brand
and O
rifabutin B-drug
. O

Fluconazole B-drug
and O
Ketoconazole B-drug
: O
Ketoconazole B-drug
and O
fluconazole B-drug
are O
predominantly O
CYP O
3A4 O
and O
2C9 O
inhibitors O
, O
respectively O
. O

These O
observations O
strongly O
suggest O
that O
the O
homodimeric O
structure O
of O
contortrostatin B-drug_n
functionally O
distinguishes O
it O
from O
other O
monomeric O
members O
of O
the O
disintegrin O
family O
. O

- O
Impaired O
glucose O
tolerance O

If O
a O
diuretic B-group
is O
also O
used O
, O
it O
may O
increase O
the O
risk O
of O
lithium B-drug
toxicity O
. O

The O
most O
significant O
drug O
interactions O
following O
administration O
of O
Cerebyx B-brand
are O
expected O
to O
occur O
with O
drugs O
that O
interact O
with O
phenytoin B-drug
. O

Corticosteroids B-group
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-group
D I-group
analogues I-group
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-group
, O
which O
inhibit O
calcium O
absorption O
. O

Keys O
to O
maximizing O
benefit O
while O
avoiding O
adverse O
drug O
effects O
. O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-group
diuretics I-group
. O

Other O
Drug O
Interactions O
: O
No O
pharmacokinetic O
interactions O
were O
observed O
between O
vardenafil B-drug
and O
the O
following O
drugs O
: O
glyburide B-drug
, O
warfarin B-drug
, O
digoxin B-drug
, O
Maalox B-brand
, O
and O
ranitidine B-drug
. O

Drug/Laboratory O
Test O
Interactions O
: O
Amphetamines B-group
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid B-group
levels O
. O

When O
cocaine B-drug
is O
the O
primary O
addiction O
, O
after O
withdrawal O
the O
most O
effective O
treatment O
is O
group O
therapy O
with O
other O
recovering O
cocaine O
abusers O
. O

Today O
pharmacological O
magnesium B-drug
therapy O
mainly O
concerns O
the O
obstetrical O
, O
cardiological O
and O
anaesthesiological O
fields O
. O

Compared O
with O
conventional B-group
antipsychotics I-group
, O
it O
has O
greater O
affinity O
for O
serotonin O
5-HT2A O
than O
for O
dopamine O
D2 O
receptors O
. O

Due O
to O
a O
theoretical O
risk O
of O
a O
pharmacodynamic O
interaction O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
FROVA B-brand
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
( O
see O
a O
href= O
frova_od.htm O
# O
CI O
CONTRAINDICATIONS O
) O
. O

Drug O
Name O

The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-group
: O
Increased O
sulfobromophthalein O
retention O
; O

Due O
to O
high O
inter-patient O
variability O
and O
limited O
sampling O
, O
the O
extent O
of O
the O
increase O
in O
SN38 B-drug_n
levels O
in O
patients O
receiving O
concurrent O
irinotecan B-drug
and O
AVASTIN B-brand
is O
uncertain O
. O

Hypoglycemics B-group

http O
: O
//www.rxlist.com/cgi/generic3/guanethidine_od.htm O

The O
authors O
examined O
the O
effect O
of O
the O
cyclooxygenase-2 O
( O
COX-2 O
) O
inhibitor O
, O
rofecoxib B-drug
, O
at O
steady O
state O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
following O
a O
single O
dose O
in O
healthy O
subjects O
. O

WelChol B-brand
was O
found O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
digoxin B-drug
, O
lovastatin B-drug
, O
metoprolol B-drug
, O
quinidine B-drug
, O
valproic B-drug
acid I-drug
, O
and O
warfarin B-drug
. O

Such O
interactions O
might O
be O
manifested O
by O
increased O
susceptibility O
to O
bruising O
, O
nosebleeds O
, O
hemoptysis O
, O
hematemesis O
, O
hematuria O
and O
blood O
in O
the O
stool O
. O

There O
is O
a O
single O
case O
report O
, O
which O
suggests O
that O
sucralfate B-drug
may O
interfere O
with O
anagrelide B-drug
absorption O
. O

Spontaneous O
reports O
of O
serotonin O
syndrome O
associated O
with O
co-administration O
of O
ZYVOX B-brand
and O
serotonergic B-group
agents I-group
, O
including O
antidepressants B-group
such O
as O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
have O
been O
reported O
. O

Therefore O
, O
4 O
to O
5 O
hours O
should O
elapse O
between O
administration O
of O
cholestyramine B-drug
and O
thyroid B-group
hormones I-group
. O

It O
is O
not O
known O
whether O
alosetron B-drug
might O
induce O
other O
enzymes O
. O

The O
use O
of O
ROMAZICON B-brand
is O
not O
recommended O
in O
epileptic O
patients O
who O
have O
been O
receiving O
benzodiazepine O
treatment O
for O
a O
prolonged O
period O
. O

Caution O
should O
be O
used O
when O
administering O
or O
taking O
TARCEVA B-brand
with O
ketoconazole B-drug
and O
other O
strong O
CYP3A4 O
inhibitors O
such O
as O
, O
but O
not O
limited O
to O
, O
atazanavir B-drug
, O
clarithromycin B-drug
, O
indinavir B-drug
, O
itraconazole B-drug
, O
nefazodone B-drug
, O
nelfinavir B-drug
, O
ritonavir B-drug
, O
saquinavir B-drug
, O
telithromycin B-drug
, O
troleandomycin B-drug
( O
TAO B-drug
) O
, O
and O
voriconazole B-drug
. O

The O
clinical O
significance O
, O
if O
any O
, O
of O
these O
observations O
is O
unknown O
. O

Oral O
Anticoagulants B-group
: O
Thyroid B-group
hormones I-group
appear O
to O
increase O
catabolism O
of O
vitamin O
K-dependent O
clotting O
factors O
. O

Medroxyprogesterone B-drug
Acetate I-drug
- O
L-histidine B-drug
was O
observed O
to O
enhance O
( O
in O
tissue O
culture O
) O
the O
effect O
of O
medroxyprogesterone B-drug
acetate I-drug
in O
reducing O
the O
number O
of O
human O
breast O
cancer O
cells O
that O
were O
in O
the O
S O
phase O
. O

Other O
Drugs O
: O
Based O
on O
the O
results O
of O
drug O
interaction O
studies O
, O
no O
dosage O
adjustment O
is O
recommended O
when O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
is O
given O
with O
the O
following O
: O
aluminum/magnesium B-group
hydroxide I-group
antacids I-group
, O
azithromycin B-drug
, O
cetirizine B-drug
, O
famotidine B-drug
, O
fluconazole B-drug
, O
lamivudine B-drug
, O
lorazepam B-drug
, O
nelfinavir B-drug
, O
paroxetine B-drug
, O
and O
zidovudine B-drug
. O

The O
concurrent O
use O
of O
intravenously O
or O
orally O
administered O
methylxanthines B-group
( O
e.g. O
, O
aminophylline B-drug
, O
theophylline B-drug
) O
by O
patients O
receiving O
BROVANA B-brand
has O
not O
been O
completely O
evaluated O
. O

74.1 O
% O
( O
95 O
% O
CI O
, O
+/- O
9.3 O
) O
of O
the O
total O
PICR O
could O
be O
avoided O
by O
simple O
recommendations O
; O

The O
data O
do O
not O
suggest O
the O
need O
for O
dose O
adjustment O
of O
either O
HUMIRA B-brand
or O
MTX B-drug
. O

Diphenhydramine B-drug
hydrochloride I-drug
has O
additive O
effects O
with O
alcohol B-drug
and O
other O
CNS B-group
depressants I-group
( O
hypnotics B-group
, O
sedatives B-group
, O
tranquilizers B-group
, O
etc O
) O
. O

g/mL O
; O

If O
the O
treatment O
is O
continued O
, O
these O
patients O
should O
be O
particularly O
carefully O
monitored O
for O
adverse O
effects O
, O
especially O
conduction O
disturbances O
and O
exacerbation O
of O
tachyarrhythmias O
, O
as O
amiodarone B-drug
is O
continued O
. O

Probenecid B-drug
Prolonged O
action O
of O
etomidate B-drug

The O
first O
phase O
of O
this O
sequence O
, O
initiation O
, O
is O
considered O
to O
result O
from O
at O
least O
one O
event O
in O
the O
genetic O
apparatus O
. O

Concomitant O
use O
of O
prophylactic O
low O
dose O
heparin B-drug
did O
not O
appear O
to O
affect O
safety O
, O
however O
, O
its O
effects O
on O
the O
efficacy O
of O
Xigris B-brand
have O
not O
been O
evaluated O
in O
an O
adequate O
and O
well-controlled O
clinical O
trial O
. O

Amphotericin B-drug
B I-drug
or O
potassium-depleting B-group
diuretics I-group
( O
benzothiadiazines B-group
and O
related O
drugs O
, O
ethacrynic B-drug
acid I-drug
and O
furosemide B-drug
) O
enhanced O
hypokalemia O
. O

Aspirin B-brand
: O
As O
with O
other O
NSAIDs B-group
, O
concomitant O
administration O
of O
Ponstel B-brand
and O
aspirin B-brand
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O

Calcium B-group
Antagonists O
: O
After O
repeated O
co-administration O
of O
Trileptal B-brand
, O
the O
AUC O
of O
felodipine B-drug
was O
lowered O
by O
28 O
% O
[ O
90 O
% O
CI O
: O
20-33 O
] O
. O


Patients O
with O
Crohn O
s O
disease O
who O
received O
immunosuppressants B-group
tended O
to O
experience O
fewer O
infusion O
reactions O
compared O
to O
patients O
on O
no O
immunosuppressants B-group
. O

There O
have O
been O
a O
number O
of O
reports O
in O
the O
post-marketing O
experience O
of O
coma O
and O
death O
associated O
with O
the O
concomitant O
intravenous O
misuse O
of O
buprenorphine B-drug
and O
benzodiazepines B-drug
by O
addicts O
. O

The O
regulation O
of O
the O
level O
of O
the O
glucocorticoid-induced O
gene O
expression O
by O
the O
antioxidative O
gallates O
is O
of O
great O
interest O
from O
a O
therapeutic O
point O
of O
view O
. O

If O
concomitant O
treatment O
with O
frovatriptan B-drug
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

Quinolones B-group
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metals O
. O

Beta-adrenergic B-group
Blocking I-group
Agents I-group
: O
Experience O
in O
over O
1400 O
patients O
in O
a O
non-comparative O
clinical O
trial O
has O
shown O
that O
concomitant O
administration O
of O
nifedipine B-drug
and O
beta-blocking B-group
agents I-group
is O
usually O
well O
tolerated O
, O
but O
there O
have O
been O
occasional O
literature O
reports O
suggesting O
that O
the O
combination O
may O
increase O
the O
likelihood O
of O
congestive O
heart O
failure O
, O
severe O
hypotension O
or O
exacerbation O
of O
angina O
. O

Moreover O
, O
as O
noted O
with O
alprazolam B-drug
, O
the O
effect O
of O
fluvoxamine B-drug
may O
even O
be O
more O
pronounced O
when O
it O
is O
administered O
at O
higher O
doses O
. O

In O
vitro O
studies O
indicate O
that O
ertapenem B-drug
does O
not O
inhibit O
P-glycoprotein-mediated O
transport O
of O
digoxin B-drug
or O
vinblastine B-drug
and O
that O
ertapenem B-drug
is O
not O
a O
substrate O
for O
P-glycoprotein-mediated O
transport O
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

Thus O
, O
when O
NSAIDs B-group
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

( O
Read O
circulars O
for O
lithium B-drug
preparation O
before O
use O
of O
such O
concurrent O
therapy O
) O
. O

When O
atropine B-drug
and O
pralidoxime B-drug
are O
used O
together O
, O
the O
signs O
of O
atropinization O
( O
flushing O
, O
mydriasis O
, O
tachycardia O
, O
dryness O
of O
the O
mouth O
and O
nose O
) O
may O
occur O
earlier O
than O
might O
be O
expected O
than O
when O
atropine B-drug
is O
used O
alone O
because O
pralidoxime B-drug
may O
potentiate O
the O
effect O
of O
atropine B-drug
. O

Diuretic B-group
agents I-group
may O
decrease O
vascular O
response O
to O
pressor O
drugs O
such O
as O
epinephrine B-drug
. O

- O
Nitrofurantoin B-drug
( O
e.g. O
, O
Furadantin B-brand
) O
or O

Effect O
of O
AEDs B-group
in O
Pediatric O
Patients O
There O
was O
about O
a O
22 O
% O
increase O
of O
apparent O
total O
body O
clearance O
of O
levetiracetam B-drug
when O
it O
was O
co-administered O
with O
enzyme-inducing O
AEDs B-group
. O

Disulfiram B-drug
appears O
to O
decrease O
the O
rate O
at O
which O
certain O
drugs O
are O
metabolized O
and O
therefore O
may O
increase O
the O
blood O
levels O
and O
the O
possibility O
of O
clinical O
toxicity O
of O
drugs O
given O
concomitantly O
. O

Coadministration O
of O
thioridazine B-drug
has O
been O
reported O
to O
worsen O
the O
tremor O
in O
elderly O
patients O
with O
Parkinsons O
disease O
; O

Antihistamines B-group
: O
Amphetamines B-group
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-group
. O

Changes O
in O
urinary O
homocysteine O
following O
synthetic B-group
steroidal I-group
estrogen I-group
and O
progestogen O
administration O
to O
rats O
. O

Plasma O
concentrations O
of O
azole B-group
antifungal I-group
agents I-group
are O
reduced O
when O
given O
concurrently O
with O
isoniazid B-drug
. O

Hitherto O
unrecognized O
interactions O
between O
homopolyribonucleotides O
and O
complexes O
thereof O
are O
suggested O
by O
interferon O
induction O
data O
obtained O
in O
a O
highly O
sensitive O
assay O
system O
of O
primary O
rabbit O
kidney O
cell O
cultures O
superinduced O
by O
metabolic O
inhibitors O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

Isoflurane B-drug
potentiates O
the O
muscle O
relaxant O
effect O
of O
all O
muscle B-group
relaxants I-group
, O
most O
notably O
nondepolarizing B-group
muscle I-group
relaxants I-group
, O
and O
MAC O
( O
minimum O
alveolar O
concentration O
) O
is O
reduced O
by O
concomitant O
administration O
of O
N O
2O O
. O

Concurrent O
administration O
of O
etanercept B-drug
( O
another O
TNF O
-blocking O
agent O
) O
and O
anakinra B-drug
( O
an O
interleukin-1 B-group
antagonist I-group
) O
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
and O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O

The O
conversion O
of O
6-deoxy B-drug_n
penciclovir I-drug_n
to O
penciclovir B-drug
is O
catalyzed O
by O
aldehyde O
oxidase O
. O

In O
patients O
receiving O
coumarin-type B-group
anticoagulants I-group
, O
the O
addition O
of O
Nalfon B-brand
to O
therapy O
could O
prolong O
the O
prothrombin O
time O
. O

5 O
. O

. O

Caution O
is O
advised O
in O
patients O
receiving O
concomitant O
high-dose O
aspirin B-brand
and O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
as O
anorexia O
, O
tachypnea O
, O
lethargy O
and O
coma O
have O
been O
rarely O
reported O
due O
to O
a O
possible O
drug O
interaction O
. O

Tricyclic B-group
antidepressants I-group
may O
block O
the O
antihypertensive O
action O
of O
guanethidine B-drug
and O
similarly O
acting O
compounds O
. O

The O
rats O
treated O
with O
the O
highest O
dose O
of O
TML B-drug_n
manifested O
significantly O
longer O
latencies O
to O
lose O
the O
righting O
reflex O
and O
shorter O
durations O
of O
sleep O
than O
did O
controls O
. O

High-dose O
cyclosporin B-drug
A I-drug
resulting O
in O
concentrations O
above O
2000 O
ng/mL O
administered O
with O
oral O
etoposide B-drug
has O
led O
to O
an O
80 O
% O
increase O
in O
etoposide B-drug
exposure O
with O
a O
38 O
% O
decrease O
in O
total O
body O
clearance O
of O
etoposide B-drug
compared O
to O
etoposide B-drug
alone O
. O

Since O
a O
clinically O
significant O
interaction O
may O
be O
anticipated O
, O
alternative O
antihypertensive B-drug
therapy O
should O
be O
considered O
in O
these O
patients O
. O

The O
clinical O
significance O
of O
these O
changes O
has O
not O
been O
adequately O
studied O
. O

It O
is O
suggested O
that O
there O
is O
a O
minor O
contribution O
of O
adenosine O
receptors O
to O
these O
effects O
, O
although O
theophylline-induced B-drug
anxiogenic O
effects O
were O
antagonized O
by O
an O
A2 O
receptor O
agonist O
. O

Drug/ O
Laboratory O
Test O
Interactions O
: O
It O
is O
not O
known O
if O
MEPRON B-brand
interferes O
with O
clinical O
laboratory O
test O
or O
assay O
results O
. O

These O
levels O
then O
remained O
stable O
for O
up O
to O
1 O
year O
of O
therapy O
. O

Indomethacin B-drug
may O
also O
affect O
plasma O
renin O
levels O
, O
aldosterone O
excretion O
, O
and O
renin O
profile O
evaluation O
. O

The O
extent O
of O
interaction O
depends O
on O
the O
variability O
of O
effect O
on O
CYP2D6 O
. O

Drugs O
that O
Inhibit O
Drug O
Transport O
Systems O
Lapatinib B-drug
is O
a O
substrate O
of O
the O
efflux O
transporter O
P-glycoprotein O
( O
Pgp O
, O
ABCB1 O
) O
. O

Ultimately O
however O
, O
up O
to O
80 O
% O
of O
type O
2 O
diabetics O
die O
from O
macrovascular O
cardiovascular O
disease O
. O

Furthermore O
, O
caution O
should O
be O
exercised O
when O
combining O
digoxin B-drug
with O
any O
drug O
that O
may O
cause O
a O
significant O
deterioration O
in O
renal O
function O
, O
since O
a O
decline O
in O
glomerular O
filtration O
or O
tubular O
secretion O
may O
impair O
the O
excretion O
of O
digoxin B-drug
. O

Effect O

CONCLUSION O
: O
Cisapride B-drug
can O
be O
administered O
safely O
to O
patients O
receiving O
low O
therapeutic O
dosages O
of O
fluoxetine B-drug
. O

The O
optimal O
dose O
of O
indinavir B-drug
, O
when O
given O
in O
combination O
with O
SUSTIVA B-brand
, O
is O
not O
known O
. O

Drug/Laboratory O
Test O
Interactions O
Cephalosporins B-group
, O
including O
cefotaxime B-drug
sodium I-drug
, O
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

OBJECTIVES O
. O

Metoclopramide B-drug
: O
Bioavailability O
is O
mildly O
reduced O
( O
approximately O
10 O
% O
) O
when O
zalcitabine B-drug
and O
metoclopramide B-drug
are O
coadministered O
. O

In O
our O
laboratory O
, O
preliminary O
whole-cell O
, O
tight O
seal O
recordings O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
including O
biocytin O
in O
the O
patch O
pipette O
yielded O
a O
significantly O
smaller O
proportion O
of O
neurons O
hyperpolarized O
by O
selective B-group
opioid I-group
agonists I-group
compared O
with O
recordings O
without O
biocytin O
. O

Nonetheless O
, O
the O
range O
of O
individual O
Simulect B-brand
clearance O
values O
in O
the O
presence O
of O
azathioprine B-drug
( O
12-57 O
mL/h O
) O
or O
mycophenolate B-drug
mofetil I-drug
( O
7-54 O
mL/h O
) O
did O
not O
extend O
outside O
the O
range O
observed O
with O
dual O
therapy O
( O
10-78 O
mL/h O
) O
. O

In O
vivo O
interaction O
studies O
in O
humans O
have O
demonstrated O
that O
digoxin B-drug
and O
warfarin B-drug
do O
not O
affect O
the O
PK O
properties O
of O
anagrelide B-drug
, O
nor O
does O
anagrelide B-drug
affect O
the O
PK O
properties O
of O
digoxin B-drug
or O
warfarin B-drug
. O

Diltiazem B-drug
plasma O
levels O
were O
not O
significantly O
affected O
by O
lovastatin B-drug
or O
pravastatin B-drug
. O

Metabolism O
of O
dasatinib B-drug
is O
mainly O
hepatic O
. O

Cimetidine B-drug
, O
Ranitidine B-drug
: O
In O
normal O
volunteers O
( O
n=9 O
) O
, O
pretreatment O
with O
cimetidine B-drug
or O
ranitidine B-drug
did O
not O
affect O
flurbiprofen B-drug
pharmacokinetics O
except O
that O
a O
small O
( O
13 O
% O
) O
but O
statistically O
significant O
increase O
in O
the O
area O
under O
the O
serum O
concentration O
curve O
of O
flurbiprofen B-drug
resulted O
with O
cimetidine B-drug
. O

Using O
in O
situ O
hybridization O
, O
we O
observed O
that O
METH B-drug
caused O
a O
rapid O
and O
transient O
dose-dependent O
increase O
in O
arc O
mRNA O
level O
in O
the O
striatum O
and O
cortex O
that O
was O
abolished O
by O
pretreatment O
with O
the O
specific O
dopamine O
D1 O
receptor O
antagonist O
SCH-23390 B-drug_n
but O
not O
by O
an O
atypical B-group
neuroleptic I-group
clozapine B-drug
. O

Consider O
additive O
sedative O
effects O
and O
confusional O
states O
to O
emerge O
, O
if O
chlorprothixene B-drug
is O
given O
with O
benzodiazepines B-group
or O
barbituates B-group
. O

Aminophylline B-drug
Etomidate I-drug
antagonism O

Coumarin B-group
Anticoagulants O
: O
In O
a O
small O
clinical O
trial O
in O
which O
lovastatin B-drug
was O
administered O
to O
warfarin B-drug
treated O
patients O
, O
no O
effect O
on O
prothrombin O
time O
was O
detected O
. O

Coadministration O
of O
single O
, O
oral O
doses O
of O
zaleplon B-drug
with O
erythromycin B-drug
( O
10 O
mg O
and O
800 O
mg O
, O
respectively O
) O
, O
a O
strong O
, O
selective O
CYP3A4 O
inhibitor O
produced O
a O
34 O
% O
increase O
in O
zaleplons B-drug
maximal O
plasma O
concentrations O
and O
a O
20 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
. O

Other O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
e.g. O
, O
aspirin B-brand
) O
may O
also O
have O
this O
effect O
. O

iii O
. O

The O
clinical O
relevance O
is O
unclear O
. O

alcohol* B-drug
; O

In O
vitro O
studies O
have O
shown O
that O
fenoprofen B-drug
, O
because O
of O
its O
affinity O
for O
albumin O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
that O
are O
also O
albumin O
bound O
, O
and O
this O
may O
lead O
to O
drug O
interaction O
. O

[ O
A O
pharmacological O
analysis O
of O
the O
effect O
of O
angiotensin B-drug_n
on O
stimulated O
gastric O
secretion O
] O
Chronic O
experiments O
on O
dogs O
with O
gastric O
fistulas O
were O
carried O
out O
to O
study O
the O
influence O
of O
angiotensin B-drug_n
1 I-drug_n
and O
angiotensin B-drug_n
2 I-drug_n
on O
pentagastrin- B-drug
and O
histamine-induced B-drug
gastric O
acid O
secretion O
. O

changes O
in O
cervical O
mucus O
, O
the O
endometrium O
, O
and O
the O
fallopian O
tubes O
; O

Anticoagulants B-group
including O
coumarin O
derivatives O
, O
indandione O
derivatives O
, O
and O
platelet B-group
aggregation I-group
inhibitors I-group
such O
as O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
( O
NSAIDs B-group
) O
, O
and O
aspirin B-brand
may O
increase O
the O
risk O
of O
bleeding O
when O
administered O
concomitantly O
with O
ardeparin B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
10 O
mg O
BID O
for O
7 O
days O
) O
with O
glyburide B-drug
( O
5 O
mg O
QD O
or O
10 O
mg O
BID O
) O
did O
not O
affect O
the O
pharmacokinetics O
( O
exposure O
) O
of O
glyburide B-drug
. O

Protein O
Binding O
In O
vitro O
, O
diclofenac B-drug
interferes O
minimally O
or O
not O
at O
all O
with O
the O
protein O
binding O
of O
salicylic B-drug
acid I-drug
( O
20 O
% O
decrease O
in O
binding O
) O
, O
tolbutamide B-drug
, O
prednisolone B-drug
( O
10 O
% O
decrease O
in O
binding O
) O
, O
or O
warfarin B-drug
. O

injection O
of O
phencyclidine B-drug_n
( O
PCP B-drug_n
) O
were O
observed O
by O
measuring O
locomotor O
activity O
and O
stereotyped O
behavior O
. O

Thus O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
adjustment O
may O
be O
necessary O
. O

Repeated O
injection O
of O
PCP B-drug_n
for O
20 O
days O
into O
mice O
induced O
lower O
locomotor O
activity O
than O
that O
in O
acutely O
injected O
mice O
. O

Ibogaine B-drug_n
, O
but O
not O
18-MC B-drug_n
, O
decreases O
heart O
rate O
at O
high O
doses O
. O

Similar O
effects O
would O
be O
expected O
with O
other O
potent O
CYP2D6 O
inhibitors O
( O
e.g. O
, O
fluoxetine B-drug
, O
quinidine B-drug
) O
. O

The O
following O
medications O
have O
been O
administered O
in O
clinical O
trials O
with O
Simulect B-brand
with O
no O
increase O
in O
adverse O
reactions O
: O
ATG/ALG O
, O
azathioprine B-drug
, O
corticosteroids B-group
, O
cyclosporine B-drug
, O
mycophenolate B-drug
mofetil I-drug
, O
and O
muromonab-CD3 B-drug
. O

Therefore O
, O
it O
is O
recommended O
that O
Fluvoxamine B-drug
Tablets O
not O
be O
used O
in O
combination O
with O
MAOIs B-group
, O
or O
within O
14 O
days O
of O
discontinuing O
treatment O
with O
a O
MAOI B-group
. O

Midazolam B-drug
used O
at O
doses O
of O
1.25 O
mg/kg O
and O
2.5 O
mg/kg O
decreased O
the O
antinociceptive O
effect O
of O
morphine B-drug
, O
metamizol B-drug
( O
only O
in O
the O
tail-flick O
test O
) O
and O
indomethacin B-drug
. O

Oral O
Contraceptives B-group
Rofecoxib B-drug
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-drug
estradiol I-drug
and O
norethindrone B-drug
. O

The O
continued O
need O
for O
the O
other O
antiarrhythmic B-drug
agent O
should O
be O
reviewed O
after O
the O
effects O
of O
amiodarone B-drug
have O
been O
established O
, O
and O
discontinuation O
ordinarily O
should O
be O
attempted O
. O

Drug-lab O
interactions O
: O
implications O
for O
nutrition O
support O
. O

However O
, O
careful O
attention O
must O
be O
directed O
to B-group
cross O
toxicity O
and O
possible O
pharmacokinetic O
interactions O
between O
antiretroviral O
and O
antineoplastic B-group
drugs I-group
. O

Effect O
of O
other O
agents O
on O
the O
pharmacokinefics O
of O
aprepitant B-drug

Patients O
who O
require O
the O
use O
of O
one O
of O
these O
drugs O
with O
HIVID B-drug
should O
have O
frequent O
clinical O
and O
laboratory O
monitoring O
with O
dosage O
adjustment O
for O
any O
significant O
change O
in O
renal O
function O
. O

however O
, O
150 O
mg O
of O
ranitidine B-drug
q12h O
for O
3 O
days O
increased O
the O
ceftibuten B-drug
C O
max O
by O
23 O
% O
and O
ceftibuten B-drug
AUC O
by O
16 O
% O
. O

Antacid B-group
( O
Maalox B-brand
) O
: O
Maalox B-brand
reduced O
the O
bioavailability O
of O
gabapentin B-drug
( O
N=16 O
) O
by O
about O
20 O
% O
. O

The O
intensity O
, O
uniformity O
and O
time O
course O
of O
anticoagulant B-group
interference O
by O
phenobarbital B-drug
, O
secobarbital B-drug
, O
glutethimide B-drug
, O
chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
were O
systematically O
investigated O
in O
16 O
patients O
receiving O
coumarin B-group
therapy O
. O

Warfarin-Vitamin B-drug
K B-group
can O
antagonize O
the O
effect O
of O
warfarin B-drug

If O
a O
patient O
has O
been O
treated O
with O
cyclophosphamide B-drug
within O
10 O
days O
of O
general O
anesthesia O
, O
the O
anesthesiologist O
should O
be O
alerted O
. O

The O
effect O
of O
alosetron B-drug
on O
monoamine O
oxidases O
and O
on O
intestinal O
first O
pass O
secondary O
to O
high O
intraluminal O
concentrations O
have O
not O
been O
examined O
. O

2 O
. O

Clinical O
implications O
of O
warfarin B-drug
interactions O
with O
five O
sedatives B-group
. O

Table O
5a O
: O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
SUSTIVA B-brand

Clonidine B-drug
: O
Concomitant O
administration O
of O
clonidine B-drug
with O
agents B-group
with I-group
b-blocking I-group
properties I-group
may O
potentiate O
blood-pressure- O
and O
heart-rate-lowering O
effects O
. O

Steady O
state O
plasma O
digitoxin B-drug
concentrations O
did O
not O
appear O
to O
change O
. O

CFUs O
were O
maintained O
at O
low O
levels O
( O
10 O
( O
3 O
) O
CFU O
mL O
( O
-1 O
) O
) O
for O
24 O
h O
by O
vancomycin/flavone B-drug
combinations O
. O

Appropriate O
doses O
for O
this O
combination O
are O
not O
established O
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
cotherapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
may O
be O
required O
. O

Olanzapine B-drug
treatment O
improves O
quality O
of O
life O
in O
patients O
with O
schizophrenia O
and O
related O
psychoses O
to O
a O
greater O
extent O
than O
haloperidol B-drug
, O
and O
to O
broadly O
the O
same O
extent O
as O
risperidone B-drug
. O

Since O
PLETAL B-brand
is O
extensively O
metabolized O
by O
cytochrome O
P-450 O
isoenzymes O
, O
caution O
should O
be O
exercised O
when O
PLETAL B-brand
is O
coadministered O
with O
inhibitors O
of O
C.P.A O
. O
such O
as O
ketoconazole B-drug
and O
erythromycin B-drug
or O
inhibitors O
of O
CYP2C19 O
such O
as O
omeprazole B-drug
. O

On O
the O
average O
for O
the O
group O
, O
the O
dose O
of O
cyclosporine B-drug
was O
reduced O
about O
20 O
% O
in O
these O
patients O
. O

In O
vitro O
studies O
evaluating O
the O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
of O
vancomycin B-drug
, O
cefazolin B-drug
, O
ampicillin B-drug
, O
ampicillin/flucoxacillin B-drug
, O
ceftazidime B-drug
, O
gentamicin B-drug
, O
and O
amphotericin B-drug
demonstrated O
no O
evidence O
of O
incompatibility O
of O
these O
antibiotics B-group
with O
EXTRANEAL B-brand
. O

Fulminant O
rhabdomyolysis O
has O
been O
seen O
as O
early O
as O
three O
weeks O
after O
initiation O
of O
combined O
therapy O
with O
another O
fibrate B-group
and O
lovastatin B-drug
but O
may O
be O
seen O
after O
several O
months O
. O

Although O
it O
has O
not O
been O
definitively O
demonstrated O
that O
fluvoxamine B-drug
is O
a O
potent O
IIIA4 O
inhibitor O
, O
it O
is O
likely O
to O
be O
, O
given O
the O
substantial O
interaction O
of O
fluvoxamine B-drug
with O
alprazolam B-drug
. O

Although O
the O
clinical O
significance O
is O
not O
known O
, O
it O
is O
not O
recommended O
that O
cefditoren B-drug
pivoxil I-drug
be O
taken O
concomitantly O
with O
H2 B-group
receptor I-group
antagonists I-group
. O

The O
administration O
of O
guanfacine B-drug
concomitantly O
with O
known O
microsomal O
enzyme O
inducer O
( O
phenobarbital B-drug
or O
phenytoin B-drug
) O
to O
two O
patients O
with O
renal O
impairment O
reportedly O
resulted O
in O
significant O
reductions O
in O
elimination O
half-life O
and O
plasma O
concentration O
. O

These O
antibiotics B-group
should O
be O
used O
in O
the O
myasthenic O
patient O
only O
where O
definitely O
indicated O
, O
and O
then O
careful O
adjustment O
should O
be O
made O
of O
adjunctive O
anticholinesterase B-group
dosage O
. O

Both O
18-MC B-drug_n
and O
ibogaine B-drug_n
are O
sequestered O
in O
fat O
and O
, O
like O
ibogaine B-drug_n
, O
18-MC B-drug_n
probably O
has O
an O
active O
metabolite O
. O

Theophylline B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
21 O
days O
) O
and O
the O
CYP1A2 O
substrate O
theophylline B-drug
( O
single O
dose O
of O
300 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
theophylline B-drug
. O

Digitalis B-group
Glycosides I-group
: O
Therapeutic O
effects O
of O
digitalis B-group
glycosides I-group
may O
be O
reduced O
. O

However O
, O
other O
published O
reports O
describe O
modest O
elevations O
( O
less O
than O
two-fold O
) O
of O
clozapine B-drug
and O
metabolite O
concentrations O
when O
clozapine B-drug
was O
taken O
with O
paroxetine B-drug
, O
fluoxetine B-drug
, O
and O
sertraline B-drug
. O

These O
results O
suggest O
that O
D1 O
receptors O
are O
coupled O
to O
activation O
of O
arc O
gene O
, O
which O
may O
be O
involved O
in O
functional O
or O
structural O
alterations O
underlying O
neural O
plasticity O
triggered O
by O
METH B-drug
. O

. O

Close O
monitoring O
allows O
physicians O
to O
minimize O
risks O
, O
maximize O
benefits O
, O
and O
get O
the O
most O
out O
of O
what O
modern O
medications O
can O
do O
to O
help O
older O
patients O
. O

Because O
ritonavir B-drug
is O
coadministered O
, O
prescribers O
should O
also O
refer O
to O
the O
prescribing O
information O
for O
ritonavir B-drug
regarding O
drug O
interactions O
associated O
with O
this O
agent O
. O

Exogenous O
estradiol B-drug
also O
appeared O
to O
influence O
the O
percentage O
of O
endotoxin-induced B-drug_n
deaths O
in O
a O
dose-dependent O
manner O
. O

Therefore O
, O
caution O
should O
be O
used O
when O
administering O
MEPRON B-brand
concurrently O
with O
other O
highly O
plasma O
protein- O
bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
. O

Therefore O
, O
the O
potential O
for O
such O
drug O
interaction O
should O
be O
considered O
in O
patients O
receiving O
AZOPT B-brand
( O
brinzolamide B-drug
ophthalmic O
suspension O
) O
1 O
% O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
adrenal B-group
corticosteroids I-group
. O

forms O
of O
memory O
. O

Warfarin B-drug
, O
Digoxin B-drug
, O
Salicylate B-group
, O
and O
Heparin B-drug
The O
in O
vitro O
binding O
of O
warfarin B-drug
to O
plasma O
proteins O
is O
only O
slightly O
reduced O
by O
ketorolac B-drug
tromethamine I-drug
( O
99.5 O
% O
control O
vs O
99.3 O
% O
) O
when O
ketorolac B-drug
plasma O
concentrations O
reach O
5 O
to10 O
m O
g/mL O
. O

Conversely O
, O
at O
exposure O
levels O
close O
to O
the O
" O
limit O
values O
" O

Reduced O
response O
to O
metyrapone O
test O
. O

Subjects O
treated O
with O
200 O
mg O
of O
dideoxyinosine B-drug
twice O
daily O
for O
21 O
days O
received O
1200 O
mg O
of O
azithromycin B-drug
or O
an O
equivalent O
amount O
of O
placebo/day O
for O
Days O
8 O
to O
21 O
. O

Therefore O
, O
caution O
should O
be O
used O
in O
concomitant O
administration O
. O

Use O
of O
barrier O
form O
of O
contraception O
is O
suggested O
while O
on O
griseofulvin B-drug
therapy O
. O

With O
drugs O
inhibiting O
CYP3A O
to O
a O
lesser O
, O
but O
still O
significant O
degree O
, O
estazolam B-drug
should O
be O
used O
only O
with O
caution O
and O
consideration O
of O
appropriate O
dosage O
reduction O
. O

However O
, O
because O
some O
quinolones B-group
have O
been O
reported O
to O
enhance O
the O
anticoagulant O
effects O
of O
warfarin B-drug
or O
its O
derivatives O
in O
patients O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
if O
a O
quinolone B-group
antimicrobial I-group
is O
administered O
concomitantly O
with O
warfarin B-drug
or O
its O
derivatives O
. O

Clinically O
meaningful O
drug O
interactions O
have O
occurred O
with O
concomitant O
medications O
and O
include O
, O
but O
are O
not O
limited O
to O
the O
following O
: O
Agents O
Highly O
Bound O
to O
Plasma O
Protein O
Carbamazepine B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
; O

Clinical O
Laboratory O

Geriatric O
Use O
When O
tumor O
response O
was O
considered O
by O
age O
, O
objective O
responses O
were O
seen O
in O
24 O
% O
and O
22 O
% O
of O
patients O
under O
65 O
years O
of O
age O
and O
in O
16 O
% O
and O
11 O
% O
of O
patients O
65 O
years O
of O
age O
and O
older O
, O
who O
were O
treated O
with O
FASLODEX B-brand
in O
the O
European O
and O
North O
American O
trials O
, O
respectively O
. O

Therefore O
, O
etodolac B-drug
can O
generally O
be O
given O
without O
the O
need O
for O
dosage O
modifications O
in O
special O
populations O
such O
as O
uncompromised O
elderly O
patients O
, O
those O
with O
moderate O
renal O
impairment O
, O
and O
patients O
with O
stable O
hepatic O
disease O
. O

Studies O
of O
the O
effect O
of O
food O
on O
the O
pharmacokinetics O
of O
fluvastatin B-drug
have O
demonstrated O
marked O
reductions O
in O
the O
rate O
of O
bioavailability O
-- O
from O
40 O
% O
to O
60 O
% O
; O

In O
a O
patient O
with O
a O
nonfunctioning O
thyroid O
gland O
who O
is O
receiving O
thyroid O
replacement O
therapy O
, O
free O
levothyroxine B-drug
may O
be O
decreased O
when O
estrogens B-group
are O
started O
thus O
increasing O
thyroid B-group
requirements O
. O

In O
patients O
receiving O
Nalfon B-brand
and O
a O
steroid B-group
concomitantly O
, O
any O
reduction O
in O
steroid B-group
dosage O
should O
be O
gradual O
in O
order O
to O
avoid O
the O
possible O
complications O
of O
sudden O
steroid B-group
withdrawal O
. O

The O
effect O
of O
foods O
highly O
fortified O
with O
elemental O
iron B-drug_n
( O
primarily O
iron-fortified B-drug_n
breakfast O
cereals O
) O
on O
cefdinir B-drug
absorption O
has O
not O
been O
studied O
. O

As O
plasma O
protein O
binding O
of O
decitabine B-drug
is O
negligible O
( O
1 O
% O
) O
, O
interactions O
due O
to O
displacement O
of O
more O
highly O
protein O
bound O
drugs O
from O
plasma O
proteins O
are O
not O
expected O
. O

Although O
specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ALPHAGAN B-brand
P I-brand
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-group
depressants I-group
( O
alcohol B-drug
, O
barbiturates B-group
, O
opiates B-group
, O
sedatives B-group
, O
or O
anesthetics B-group
) O
should O
be O
considered O
. O

Gabapentin B-drug
pharmacokinetic O
parameters O
without O
and O
with O
probenecid B-drug
were O
comparable O
. O

and O
, O
rarely O
, O
dry O
mouth O
, O
anorexia O
, O
taste O
disorder O
, O
abdominal O
pain O
, O
vomiting O
, O
diarrhea O
, O
and O
positive O
test O
for O
occult O
blood O
in O
stool O
. O

Plasma O
levels O
of O
anticonvulsant B-group
agents I-group
may O
become O
subtherapeutic O
during O
cisplatin B-drug
therapy O
. O

Cardiovascular O
agents O
( O
e.g. O
, O
atenolol B-drug
, O
hydrochlorothiazide B-drug
, O
propranolol B-drug
) O
. O

+164 O
% O

vi O
. O

A O
possible O
interaction O
between O
glyburide B-drug
and O
ciprofloxacin B-drug
, O
a O
fluoroquinolone B-group
antibiotic I-group
, O
has O
been O
reported O
, O
resulting O
in O
a O
potentiation O
of O
the O
hypoglycemic O
action O
of O
glyburide B-drug
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

These O
above O
findings O
are O
summarized O
in O
TABLE O
1 O
. O

In O
vitro O
studies O
have O
shown O
that O
, O
because O
of O
its O
affinity O
for O
protein O
, O
6MNA B-drug_n
may O
displace O
other O
protein-bound O
drugs O
from O
their O
binding O
site O
. O

The O
effects O
of O
PEGASYS B-brand
on O
male O
fertility O
have O
not O
been O
studied O
. O

The O
pressor O
effects O
of O
catecholamines B-group
such O
as O
dopamine B-drug
or O
norepinephrine B-drug
are O
enhanced O
by O
Bretylium B-drug
Tosylate I-drug
. O

Because O
dexfenfluramine B-drug
is O
a O
serotonin O
releaser O
and O
reuptake O
inhibitor O
, O
dexfenfluramine B-drug
should O
not O
be O
used O
concomitantly O
with O
a O
MAO B-group
inhibitor I-group
. O

CONCLUSIONS/INTERPRETATION O
: O
Glucose B-drug
and O
insulin B-drug
can O
exert O
additive O
vasodilator O
properties O
on O
renal O
and O
ocular O
circulation O
. O

Dexamethasone B-drug
at O
10 O
( O
-10 O
) O
M O
or O
retinyl B-drug
acetate I-drug
at O
about O
3 O
X O
10 O
( O
-9 O
) O
M O
inhibits O
proliferation O
stimulated O
by O
EGF B-drug_n
. O

Therefore O
, O
concurrent O
administration O
of O
drugs O
that O
induce O
or O
inhibit O
this O
enzyme O
may O
affect O
quetiapine B-drug
pharmacokinetics O
. O

Our O
results O
indicate O
important O
relationships O
among O
ras O
, O
nucleophosmin/B23 O
, O
activation O
of O
caspase-3 O
, O
and O
induction O
of O
apoptosis O
. O

Plasma O
concentrations O
increased O
by O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
; O

Coadministration O
of O
terfenadine B-drug
with O
Itraconazole B-drug
has O
led O
to O
elevated O
plasma O
concentrations O
of O
terfenadine B-drug
, O
resulting O
in O
rare O
instances O
of O
life- O
threatening O
cardiac O
dysrhythmias O
and O
one O
death O
. O

Agents O
that O
are O
CYP O
inducers O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
decrease O
plasma O
levels O
of O
EQUETROTM B-brand
are O
the O
following O
: O
Cisplatin B-drug
, O
doxorubicin B-drug
HCL I-drug
, O
felbamate B-drug
, O
rifampin B-drug
, O
phenobarbital B-drug
, O
Phenytoin B-drug
( O
2 O
) O
, O
primidone B-drug
, O
methsuximide B-drug
, O
and O
theophylline B-drug
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
EQUETROTM B-brand
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
inducers O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
EQUETROTM B-brand
may O
be O
necessary O
. O

The O
Cmax O
of O
norethindrone B-drug
was O
13 O
% O
higher O
when O
it O
was O
coadministered O
with O
gabapentin B-drug
; O

The O
effectiveness O
of O
norepinephrine B-drug
in O
increasing O
the O
force O
of O
contraction O
was O
decreased O
in O
relation O
to O
the O
degree O
of O
heart O
failure O
. O

Cholestyramine B-drug
resin B-group
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
such O
as O
phenylbutazone B-group
, O
warfarin B-drug
, O
thiazide B-group
diuretics I-group
( O
acidic O
) O
or O
propranolol B-drug
( O
basic O
) O
, O
as O
well O
as O
tetracycline B-drug
penicillin I-drug
G I-drug
, O
phenobarbital B-drug
, O
thyroid O
and O
thyroxine B-drug
preparations O
, O
estrogens B-group
and O
progestins B-group
, O
and O
digitalis B-group
. O

- O
Changes O
in O
TBg O
concentration O
should O
be O
taken O
into O
consideration O
in O
the O
interpretation O
of O
T4 O
and O
T3 O
values O
. O

14-OH O
metabolite O
concentration O

No O
data O
from O
prospective O
clinical O
trials O
currently O
exist O
comparing O
the O
3 O
approved O
agents O
( O
efavirenz B-drug
, O
nevirapine B-drug
or O
delavirdine B-drug
) O
. O

A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O

Intracellular O
and O
extracellular O
application O
of O
RR B-drug_n
reduced O
ADP-induced O
increases O
in O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
. O

Imipramine B-drug
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-brand
20 O
mg O
and O
imipramine B-drug
75 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O

Total O
body O
clearance O
of O
Simulect B-brand
was O
reduced O
by O
an O
average O
22 O
% O
and O
51 O
% O
when O
azathioprine B-drug
and O
mycophenolate B-drug
mofetil I-drug
, O
respectively O
, O
were O
added O
to O
a O
regimen O
consisting O
of O
cyclosporine B-drug
, O
USP O
( O
MODIFIED O
) O
and O
corticosteroids B-group
. O

Of O
the O
1357 O
patients O
who O
received O
AMEVIVE B-brand
in O
clinical O
trials O
, O
a O
total O
of O
100 O
patients O
were O

Ibandronate B-drug
should O
be O
taken O
at O
least O
60 O
minutes O
before O
any O
oral O
medications O
containing O
multivalent O
cations O
( O
including O
antacids B-group
, O
supplements O
or O
vitamins B-group
) O
. O

Frequent O
prothrombin O
determinations O
are O
advisable O
until O
it O
has O
been O
determined O
definitely O
that O
the O
prothrombin O
level O
has O
been O
stabilized O
. O

The O
risk O
of O
a O
potential O
interaction O
between O
NovoSeven B-brand
and O
coagulation B-group
factor I-group
concentrates O
has O
not O
been O
adequately O
evaluated O
in O
preclinical O
or O
clinical O
studies O
. O

Probenecid B-drug
: O
Probenecid B-drug
slows O
the O
renal O
elimination O
of O
lome-floxacin O
. O

Among O
the O
polyene B-group
antibiotics I-group
, O
many O
, O
like O
filipin B-drug_n
, O
can O
not O
be O
used O
clinically O
because O
they O
are O
toxic O
; O

Patients O
' O
mean O
age O
was O
69.1 O
( O
95 O
% O
CI O
, O
+/- O
1.2 O
) O
. O

Plasma O
valproate B-drug
concentration O
should O
be O
monitored O
when O
isoniazid B-drug
and O
valproate B-drug
are O
co O
administered O
, O
and O
appropriate O
dosage O
adjustments O
of O
valproate B-drug
should O
be O
made O
. O

Effective O
use O
of O
drugs O
in O
therapy O
depends O
not O
only O
on O
clinical O
acumen O
but O
also O
on O
the O
availability O
of O
relevant O
pharmacokinetic O
and O
pharmacodynamic O
data O
. O

Drug O
Interactions O
. O

salicylates B-group
; O
sulfinpyrazone B-drug
; O

No O
adverse O
effects O
on O
female O
fertility O
and O
embryonic O
survival O
were O
evident O
in O
female O
animals O
dosed O
at O
0.001 O
mg/kg/day O
( O
approximately O
one-thousandth O
of O
the O
human O
dose O
based O
on O
BSA O
) O
. O

These O
agents O
have O
also O
been O
shown O
to O
decrease O
platelet O
nucleotide O
release O
and O
thromboxane O
A2 O
generation O
. O

Do O
not O
start O
or O
stop O
any O
medicine O
without O
doctor O
or O
pharmacist O
approval O
. O

Psychoactive B-group
Drugs I-group
: O
Hallucinations O
have O
been O
reported O
when O
TORADOL B-brand
was O
used O
in O
patients O
taking O
psychoactive B-group
drugs I-group
( O
fluoxetine B-drug
, O
thiothixene B-drug
, O
alprazolam B-drug
) O
. O

Use O
caution O
when O
giving O
these O
drugs O
together O
, O
especially O
in O
patients O
with O
hepatic O
or O
cardiac O
disease O
. O

In O
addition O
, O
Fondaparinux B-drug
neither O
influenced O
the O
pharmacodynamics O
of O
warfarin B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
piroxicam B-drug
, O
and O
digoxin B-drug
, O
nor O
the O
pharmacokinetics O
of O
digoxin B-drug
at O
steady O
state O
. O

Cypermethrin-induced B-drug
oxidative O
stress O
in O
rat O
brain O
and O
liver O
is O
prevented O
by O
vitamin B-drug
E I-drug
or O
allopurinol B-drug
. O

In O
patients O
taking O
diclofenac B-drug
and O
lithium B-drug
concomitantly O
, O
lithium B-drug
toxicity O
may O
develop O
. O

In O
the O
present O
study O
, O
the O
atypical B-group
antipsychotic I-group
clozapine B-drug
was O
tested O
in O
combination O
with O
an O
active O
dose O
of O
PCP B-drug_n
in O
two-lever O
drug O
discrimination O
and O
mixed O
signalled-unsignalled O
differential-reinforcement-of-low-rates O
( O
DRL O
) O
procedures O
. O

The O
vasodilating O
effects O
of O
isosorbide B-drug
mononitrate I-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

In O
vitro O
, O
buspirone B-drug
does O
not O
displace O
tightly O
bound O
drugs O
like O
phenytoin B-drug
, O
propranolol B-drug
, O
and O
warfarin B-drug
from O
serum O
proteins O
. O

No O
evidence O
of O
fetal O
toxicity O
including O
adverse O
effects O
on O
immune O
system O
development O
was O
observed O
in O
any O
of O
these O
animals O
. O

Efavirenz B-drug
has O
demonstrated O
superiority O
over O
nelfinavir B-drug
in O
nucleoside-experienced O
patients O
, O
although O
combining O
these O
2 O
agents O
may O
represent O
the O
best O
approach O
in O
these O
circumstances O
. O

Gold B-group
is O
excreted O
slowly O
from O
the O
body O
. O

When O
ertapenem B-drug
is O
co-administered O
with O
probenecid B-drug
( O
500 O
mg O
p.o O
. O
every O
6 O
hours O
) O
, O
probenecid B-drug
competes O
for O
active O
tubular O
secretion O
and O
reduces O
the O
renal O
clearance O
of O
ertapenem B-drug
. O

METHODS O
: O
All O
patients O
were O
enrolled O
in O
two O
sequential O
trials O
performed O
at O
the O
Aviano O
Cancer O
Center O
, O
Italy O
, O
from O
April O
1988 O
to O
December O
1998 O
. O

There O
was O
no O
effect O
on O
bleeding O
time O
, O
PT O
or O
aPTT O
. O

The O
potential O
for O
drug O
interactions O
with O
EMTRIVA B-brand
has O
been O
studied O
in O
combination O
with O
indinavir B-drug
, O
stavudine B-drug
, O
famciclovir B-drug
, O
and O
tenofovir B-drug
disoproxil I-drug
fumarate I-drug
. O

therefore O
, O
administration O
of O
these O
agents O
should O
precede O
lomefloxacin B-drug
dosing O
by O
4 O
hours O
or O
follow O
lomefloxacin B-drug
dosing O
by O
at O
least O
2 O
hours O
. O

As O
a O
moderate O
inhibitor O
of O
CYP3A4 O
, O
aprepitant B-drug
can O
increase O
plasma O
concentrations O
of O
coadministered O
medicinal O
products O
that O
are O
metabolized O
through O
CYP3A4 O
. O

Medications O
can O
interfere O
with O
folate O
utilization O
, O
including O
: O
anticonvulsant B-group
medications I-group
( O
such O
as O
phenytoin B-drug
, O
and O
primidone B-drug
) O
metformin B-drug
( O
sometimes O
prescribed O
to O
control O
blood O
sugar O
in O
type O
2 O
diabetes O
) O
sulfasalazine B-drug
( O
used O
to O
control O
inflammation O
associated O
with O
Crohns O
disease O
and O
ulcerative O
colitis O
) O
triamterene B-drug
( O
a O
diuretic B-group
) O
Methotrexate B-drug
There O
has O
been O
concern O
about O
the O
interaction O
between O
vitamin B-drug
B12 I-drug
and O
folic B-drug
acid I-drug
. O

Digoxin B-drug
: O
Some O
calcium B-group
blockers I-group
may O
increase O
the O
concentration O
of O
digitalis B-group
preparations I-group
in O
the O
blood O
. O

The O
mechanism O
of O
the O
action O
of O
PTX B-drug_n
was O
discussed O
in O
the O
relation O
with O
Na O
, O
K-ATPase O
. O

Pregnancy O
estrogens B-group
and O
estrogen-containing B-group
oral O
contraceptives B-group
increase O
TBg O
concentrations O
. O

Reformed O
microtubules O
appeared O
to O
function O
normally O
with O
respect O
to O
their O
possible O
role O
in O
the O
transport O
of O
noradrenaline O
storage O
vesicles O
along O
the O
axons O
. O

Free O
hormone O
concentrations O
may O
be O
decreased O
. O

Exposed O
histidines O
on O
toxin B-drug_n
A I-drug_n
are O
available O
for O
zinc B-drug
chelation O
, O
and O
these O
have O
been O
exploited O
in O
the O
development O
of O
a O
novel O
purification O
protocol O
for O
toxin B-drug_n
A I-drug_n
using O
zinc-chelating B-drug
chromatography O
. O

However O
, O
it O
was O
observed O
that O
the O
pharmacokinetics O
of O
ENBREL B-brand
was O
unaltered O
by O
concomitant O
methotrexate B-drug
in O
rheumatoid O
arthritis O
patients O
. O

Ketamine B-drug
: O
When O
administered O
to O
patients O
on O
a O
thyroid B-group
preparation I-group
, O
this O
parenteral O
anesthetic B-group
may O
cause O
hypertension O
and O
tachycardia O
. O

Acetaminophen B-drug
, O
lidocaine B-drug
, O
phenobarbital B-drug
, O
quinidine B-drug
, O
theophylline B-drug
, O
and O
valproic B-drug
acid I-drug
were O
added O
to O
pooled O
human O
serum O
at O
therapeutic O
concentrations O
. O

Metformin B-drug
: O
In O
healthy O
subjects O
given O
single O
500 O
mg O
doses O
of O
cephalexin B-drug
and O
metformin B-drug
, O
plasma O
metformin B-drug
mean O
cmax O
and O
AUC O
increased O
by O
an O
average O
of O
34 O
% O
and O
24 O
% O
, O
respectively O
, O
and O
metformin B-drug
mean O
renal O
clearance O
decreased O
by O
14 O
% O
. O

Therefore O
, O
a O
possible O
lack O
of O
desired O
effect O
of O
treatment O
should O
be O
taken O
into O
consideration O
before O
such O
drugs O
are O
given O
concomitantly O
with O
lactulose B-drug
. O

Nevertheless O
, O
clinical O
studies O
, O
as O
well O
as O
postmarketing O
observations O
have O
shown O
that O
Lodine B-brand
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

MAO B-group
inhibitors I-group
, O
narcotic B-group
analgesics I-group
( O
e.g. O
, O
meperidine B-drug
) O
, O
nitrates B-group
and O
nitrites B-group
, O
sympathomimetic B-group
agents I-group
, O
tricyclic B-group
antidepressants I-group
, O
and O
other O
drugs O
having O
anticholinergic O
activity O
. O

consequently O
, O
caution O
is O
advised O
if O
dexfenfluramine B-drug
and O
such O
drugs O
are O
prescribed O
concurrently O
. O

( O
Effects O
may O
be O
potentiated O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
; O

The O
effectiveness O
of O
progestin-only B-group
pills O
is O
reduced O
by O
hepatic O
enzyme-inducing O
drugs O
such O
as O
the O
anticonvulsants B-group
phenytoin B-drug
, O
carbamazepine B-drug
, O
and O
barbiturates B-group
, O
and O
the O
antituberculosis B-group
drug I-group
rifampin B-drug
. O

Concurrent O
administration O
of O
indinavir B-drug
and O
didanosine B-drug
significantly O
reduces O
the O
level O
of O
exposure O
to O
indinavir B-drug
, O
but O
it O
is O
unclear O
how O
soon O
after O
didanosine B-drug
administration O
indinavir B-drug
may O
be O
given O
safely O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

Drug O
interaction O
studies O
with O
Xigris B-brand
have O
not O
been O
performed O
in O
patients O
with O
severe O
sepsis O
. O

Phenytoin B-drug
, O
nicotine B-drug
, O
and O
rifampin B-drug
may O
decrease O
Clozapine B-drug
plasma O
levels O
, O
resulting O
in O
a O
decrease O
in O
effectiveness O
of O
a O
previously O
effective O
Clozapine B-drug
dose O
. O

Concomitant O
treatment O
of O
four O
patients O
in O
the O
United O
Kingdom O
with O
FOSCAVIR B-brand
and O
intravenous O
pentamidine B-drug
may O
have O
caused O
hypocalcemia O
; O

Tablets O
Simultaneous O
administration O
of O
sucralfate B-drug
and O
furosemide B-drug
tablets O
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2-7 O
) O
) O
with O
glyburide B-drug
( O
5 O
mg O
QD O
) O
did O
not O
affect O
either O
the O
pharmacokinetics O
( O
exposure O
) O
or O
the O
pharmacodynamics O
( O
blood O
glucose O
and O
insulin O
levels O
) O
of O
glyburide B-drug
. O

No O
significant O
effects O
on O
cisapride B-drug
metabolism O
or O
QT O
interval O
were O
noted O
. O

This O
study O
demonstrates O
that O
concurrent O
administration O
of O
thiosulfate B-drug
permits O
at O
least O
a O
twofold O
increase O
in O
dose O
and O
total O
exposure O
to O
cisplatin B-drug
. O

Therefore O
, O
such O
combined O
treatment O
should O
be O
approached O
with O
caution O
and O
patients O
should O
be O
monitored O
closely O
when O
Clozapine B-drug
is O
combined O
with O
these O
drugs O
, O
particularly O
with O
fluvoxamine B-drug
. O

In O
the O
long-term O
safety O
studies O
, O
guanfacine B-drug
was O
given O
concomitantly O
with O
many O
drugs O
without O
evidence O
of O
any O
interactions O
. O

The O
concurrent O
use O
of O
Robinul B-brand
Injection O
with O
other O
anticholinergics B-group
or O
medications O
with O
anticholinergic O
activity O
, O
such O
as O
phenothiazines B-group
, O
antiparkinson B-group
drugs I-group
, O
or O
tricyclic B-group
antidepressants I-group
, O
may O
intensify O
the O
antimuscarinic O
effects O
and O
may O
result O
in O
an O
increase O
in O
anticholinergic O
side O
effects O
. O

They O
are O
weak O
inhibitors O
of O
CYP2C19 O
and O
CYP2A6 O
, O
and O
mild-to-moderate O
inhibitors O
of O
CYP2C9 O
at O
therapeutic O
concentrations O
. O

Because O
fluvoxamine B-drug
reduces O
the O
clearance O
of O
both O
diazepam B-drug
and O
its O
active O
metabolite O
, O
N-desmethyldiazepam B-drug_n
, O
there O
is O
a O
strong O
likelihood O
of O
substantial O
accumulation O
of O
both O
species O
during O
chronic O
co-administration O
. O

Antibiotics B-group
: O
No O
human O
drug O
interaction O
studies O
with O
antibiotics B-group
were O
conducted O
. O

There O
have O
been O
greater O
than O
two-fold O
increases O
of O
previously O
stable O
plasma O
levels O
of O
tricyclic B-group
antidepressants I-group
when O
fluoxetine B-drug
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O

No O
formal O
drug/laboratory O
test O
interaction O
studies O
have O
been O
conducted O
with O
CLOLAR B-brand
. O


In O
patients O
where O
rifampin B-drug
or O
other O
CYP3A4 O
inducers O
are O
indicated O
, O
alternative O
therapeutic O
agents O
with O
less O
enzyme O
induction O
potential O
should O
be O
considered O
. O

As O
with O
all O
drugs O
, O
the O
potential O
exists O
for O
interaction O
with O
other O
drugs O
by O
a O
variety O
of O
mechanisms O
. O

The O
amount O
of O
metformin B-drug
absorbed O
while O
taking O
Acarbose B-drug
was O
bioequivalent O
to O
the O
amount O
absorbed O
when O
taking O
placebo O
, O
as O
indicated O
by O
the O
plasma O
AUC O
values O
. O

All O
the O
animals O
were O
killed O
at O
the O
end O
of O
the O
9th O
week O
of O
the O
experiment O
. O

The O
pharmacokinetics O
of O
etodolac B-drug
in O
healthy O
normal O
volunteers O
has O
been O
extensively O
studied O
and O
is O
well O
described O
. O

Patients O
on O
lithium B-drug
treatment O
should O
be O
closely O
monitored O
when O
CELEBREX B-brand
is O
introduced O
or O
withdrawn O
. O

In O
addition O
, O
administration O
to O
a O
patient O
population O
with O
hepatic O
insufficiency O
resulted O
in O
a O
2.5-fold O
increase O
in O
both O
the O
rate O
and O
extent O
of O
bioavailability O
relative O
to O
controls O
. O

Hydrocodone B-drug
increases O
gabapentin B-drug
AUC O
values O
by O
14 O
% O
. O

Therefore O
, O
Clozapine B-drug
should O
not O
be O
used O
with O
other O
agents O
having O
a O
well-known O
potential O
to O
suppress O
bone O
marrow O
function O
. O

We O
could O
observe O
that O
ginsenosides B-drug_n
inhibited O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
currents O
in O
a O
dose-dependent O
manner O
. O

Selegiline B-drug
- O
L-phenylalanine B-drug
and O
the O
selective B-group
MAO I-group
inhibitor I-group
selegiline B-drug
may O
have O
synergistic O
antidepressant O
activity O
if O
used O
concomitantly O
. O

As O
the O
primary O
effect O
of O
adenosine B-drug
is O
to O
decrease O
conduction O
through O
the O
A-V O
node O
, O
higher O
degrees O
of O
heart O
block O
may O
be O
produced O
in O
the O
presence O
of O
carbamazepine B-drug
. O

The O
effect O
of O
these O
interactions O
on O
mean O
AUCs O
and O
Cmin O
are O
summarized O
in O
Table O
2 O
: O
Table O
2 O
: O
Summary O
of O
AED O
interactions O
with O
Trileptal B-brand

Drugs O
and O
other O
substances O
demonstrated O
to O
be O
CYP O
3A O
inhibitors O
on O
the O
basis O
of O
clinical O
studies O
involving O
benzodiazepines B-group
metabolized O
similarly O
to O
alprazolam B-drug
or O
on O
the O
basis O
of O
in O
vitro O
studies O
with O
alprazolam B-drug
or O
other O
benzodiazepines B-group
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-drug
) O
: O
Available O
data O
from O
clinical O
studies O
of O
benzodiazepines B-group
other O
than O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-drug
for O
the O
following O
: O
diltiazem B-drug
, O
isoniazid B-drug
, O
macrolide B-group
antibiotics I-group
such O
as O
erythromycin B-drug
and O
clarithromycin B-drug
, O
and O
grapefruit O
juice O
. O

Ketorolac B-drug
does O
not O
alter O
digoxin B-drug
protein O
binding O
. O

Tricyclic B-group
antidepressants I-group
may O
enhance O
the O
seizure O
risk O
in O
patients O
taking O
tramadol B-drug

Since O
the O
therapeutic O
range O
of O
theophylline B-drug
is O
narrow O
theophylline B-drug
serum O
levels O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustments O
of O
theophylline B-drug
should O
be O
made O
. O

Combination O
was O
associated O
with O
a O
higher O
frequency O
of O
adverse O
clinical O
experiences O
( O
eg O
, O
dizziness O
, O
nausea O
, O
paresthesia O
) O
and O
laboratory O
abnormalities O
( O
elevated O
liver O
enzymes O
) O
. O

Cimetidine B-drug
: O
Cimetidine B-drug
has O
been O
demonstrated O
to O
interfere O
with O
the O
elimination O
of O
other O
quinolones B-group
. O

Antipyrine B-drug
: O
Because O
atorvastatin B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
antipyrine B-drug
, O
interactions O
with O
other O
drugs B-drug
metabolized O
via O
the O
same O
cytochrome O
isozymes O
are O
not O
expected O
. O

Because O
a O
similar O
interaction O
is O
likely O
, O
VIRACEPT B-brand
should O
also O
not O
be O
administered O
concurrently O
with O
astemizole B-drug
. O

Calcium B-group
channel I-group
blocking I-group
agents I-group
: O
Coadministration O
of O
calcium B-group
channel I-group
blockers I-group
did O
not O
have O
any O
effect O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-drug
in O
the O
clinical O
trials O
. O

Anticoagulants B-drug
: O
Potentiation O
of O
warfarin-type B-drug
( O
CYP2C9 B-drug
and O
CYP3A4 B-drug
substrate O
) O
anticoagulant B-drug
response O
is O
almost O
always O
seen O
in O
patients O
receiving O
amiodarone B-drug
and O
can O
result O
in O
serious O
or O
fatal O
bleeding O
. O

The O
use O
of O
MAO B-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
with O
hydrocodone B-drug
preparations O
may O
increase O
the O
effect O
of O
either O
the O
antidepressant B-group
or O
hydrocodone B-drug
. O

It O
has O
recently O
been O
demonstrated O
that O
toxin B-drug_n
A I-drug_n
exerts O
its O
cytotoxic O
effect O
by O
the O
glucosylation O
of O
the O
small O
GTP-binding O
proteins O
of O
the O
Rho O
family O
. O

Potentiation O
occurs O
with O
ganglionic B-group
peripheral I-group
adrenergic I-group
blocking I-group
drugs I-group
. O

Also O
, O
in O
vitro O
experiments O
demonstrated O
a O
lack O
of O
interaction O
between O
dirithromycin B-drug
and O
terfenadine B-drug
. O


The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O

The O
main O
indications O
are O
eclampsia O
, O
some O
dysrhythmias O
( O
torsades O
de O
pointe O
particularly O
) O
and O
myocardial O
ischaemias O
. O

Also O
, O
there O
were O
no O
clinically O
significant O
differences O
in O
adverse O
events O
when O
loratadine B-drug
was O
administered O
with O
or O
without O
ketoconazole B-drug
. O

To O
determine O
whether O
injection O
of O
thiosulfate B-drug
would O
permit O
larger O
doses O
of O
cisplatin B-drug
to O
be O
administered O
, O
a O
fixed O
9.9-g/m2 O
dose O
of O
thiosulfate B-drug
was O
given O
intravenously O
over O
three O
hours O
concurrently O
with O
escalating O
doses O
of O
cisplatin B-drug
. O

Cytochalasin B-drug_n
D I-drug_n
at O
10 O
microM O
preferentially O
blocked O
the O
secretory O
effect O
of O
carbachol B-drug
and O
its O
synergism O
with O
cAMP O
, O
whereas O
it O
had O
no O
effect O
on O
histamine- O
or O
cAMP-stimulated O
acid O
secretion O
within O
15 O
min O
. O

Omeprazole B-drug
: O
No O
clinically O
significant O
changes O
in O
lomefloxacin B-drug
pharmacokinetics O
( O
AUC O
, O
C O
max O
, O
or O
T O
max O
) O
were O
observed O
when O
a O
single O
dose O
of O
lomefloxacin B-drug
400 O
mg O
was O
given O
after O
multiple O
doses O
of O
omeprazole B-drug
( O
20 O
mg O
qd O
) O
in O
13 O
healthy O
volunteers O
. O

Caution O
is O
indicated O
when O
piperacillin B-drug
is O
used O
perioperatively O
. O

In O
the O
presence O
of O
phentolamine B-drug
( O
10 O
( O
-6 O
) O
M O
) O
, O
the O
second O
contraction O
was O
inhibited O
selectively O
. O

Heparin B-drug
Sodium I-drug
Injection O
should O
not O
be O
mixed O
with O
doxorubicin B-drug
, O
droperidol B-drug
, O
ciprofloxacin B-drug
, O
or O
mitoxantrone B-drug
, O
since O
it O
has O
been O
reported O
that O
these O
drugs O
are O
incompatible O
with O
heparin B-drug
and O
a O
precipitate O
may O
form O
. O

The O
intestinal O
absorption O
of O
arsenate B-drug_n
( O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
) I-drug_n
has O
been O
investigated O
in O
the O
chick O
by O
means O
of O
the O
in O
situ O
ligated O
duodenal O
loop O
technique O
. O

If O
leprosy-associated O
inflammatory O
reactions O
develop O
in O
patients O
being O
treated O
with O
dapsone B-drug
and O
clofazimine B-drug
, O
it O
is O
still O
advisable O
to O
continue O
treatment O
with O
both O
drugs O
. O

Fexofenadine B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
erythromycin B-drug
or O
ketoconazole B-drug
. O

Dofetilide B-drug
is O
metabolized O
to O
a O
small O
extent O
by O
the O
CYP3A4 O
isoenzyme O
of O
the O
cytochrome O
P450 O
system O
. O

Because O
the O
risk O
to O
the O
development O
of O
the O
fetal O
immune O
system O
and O
postnatal O
immune O
function O
in O
humans O
is O
unknown O
, O
AMEVIVE B-brand
should O
be O
used O
during O
pregnancy O
only O
if O
clearly O
needed O
. O

Significant O
pharmacokinetic O
interactions O
mediated O
by O
inhibition O
of O
CYP O
isoenzymes O
therefore O
appear O
unlikely O
. O

Tiagabine B-drug
has O
shown O
no O
clinically O
important O
potentiation O
of O
the O
pharmacodynamic O
effects O
of O
triazo O
lam O
or O
alcohol B-drug
. O

metabolizers O
. O

Population O
pharmacokinetic O
analyses O
were O
conducted O
on O
plasma O
concentration O
data O
from O
1445 O
patients O
in O
clinical O
trials O
to O
examine O
the O
effects O
of O
concomitant O
medications O
on O
clearance O
or O
volume O
of O
distribution O
of O
dofetilide B-drug
. O

Isoproterenol B-drug
hydrochloride I-drug
injection O
and O
epinephrine B-drug
should O
not O
be O
administered O
simultaneously O
because O
both O
drugs O
are O
direct O
cardiac O
stimulants O
and O
their O
combined O
effects O
may O
induce O
serious O
arrhythmias O
. O

Compared O
with O
lean O
rats O
, O
arteries O
from O
dietary-obese O
rats O
showed O
significant O
( O
P O
< O
0.001 O
) O
endothelial O
dysfunction O
, O
as O
indicated O
by O
a O
decrease O
( O
> O
20 O
% O
) O
in O
maximal O
acetylcholine-induced O
vasorelaxation O
. O

Suppression O
by O
verapamil B-drug
of O
bombesin-enhanced B-drug_n
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-drug_n
in O
wistar O
rats O
. O

Glyburide B-drug
: O
In O
a O
randomized O
, O
multiple-dose O
crossover O
study O
, O
patients O
with O
Type O
2 O
diabetes O
were O
administered O
120 O
mg O
Starlix B-brand
three O
times O
a O
day O
before O
meals O
for O
1 O
day O
in O
combination O
with O
glyburide B-drug
10 O
mg O
daily O
. O

This O
might O
increase O
the O
risk O
of O
methotrexate B-drug
toxic O
reactions O
. O

Since O
the O
arrival O
of O
oral O
erection-supporting B-group
medication I-group
, O
patients O
want O
to O
know O
how O
safe O
sexual O
activity O
is O
in O
cardiovascular O
disease O
in O
general O
and O
during O
use O
of O
erection-supporting B-group
medication I-group
in O
particular O
. O

Bile B-group
acid I-group
sequestrants I-group
have O
been O
shown O
to O
bind O
other O
drugs O
given O
concurrently O
. O

Allopurinol B-drug
: O
In O
a O
study O
of O
healthy O
male O
volunteers O
no O
significant O
pharmacokinetic O
interaction O
occurred O
when O
captopril B-drug
and O
allopurinol B-drug
were O
administered O
concomitantly O
for O
6 O
days O
. O

See O
CLINICAL O
PHARMACOLOGY O
. O


Inhibitory O
effects O
of O
ruthenium B-drug_n
red I-drug_n
on O
inositol O
1,4 O
, O
5-trisphosphate-induced O
responses O
in O
rat O
megakaryocytes O
. O

Drugs O
That O
Inhibit O
Both O
Aldehyde O
Oxidase O
and O
CYP3A4 O
Cimetidine B-drug
: O
Cimetidine B-drug
inhibits O
both O
aldehyde O
oxidase O
( O
in O
vitro O
) O
and O
CYP3A4 O
( O
in O
vitro O
and O
in O
vivo O
) O
, O
the O
primary O
and O
secondary O
enzymes O
, O
respectively O
, O
responsible O
for O
zaleplon B-drug
metabolism O
. O

Drug/Laboratory O
Test O
Interactions O
No O
laboratory O
test O
abnormalities O
related O
to O
the O
use O
of O
guanfacine B-drug
have O
been O
identified O
. O

These O
increases O
in O
concentration O
may O
lead O
to O
increased O
effects O
, O
( O
lower O
blood O
pressure O
and O
increased O
heart O
rate O
) O
. O

There O
have O
been O
postmarketing O
reports O
of O
drug O
interactions O
when O
erythromycin B-drug
is O
coadministered O
with O
cisapride B-drug
, O
resulting O
in O
QT O
prolongation O
, O
cardiac O
arrythmias O
, O
ventricular O
tachycardia O
, O
ventricular O
fibrulation O
, O
and O
torsades O
de O
pointes O
, O
most O
like O
due O
to O
inhibition O
of O
hepatic O
metabolism O
of O
cisapride B-drug
by O
erythromycin B-drug
. O

There O
are O
3 O
types O
of O
indications O
: O
specific O
( O
for O
the O
treatment O
of O
some O
forms O
of O
magnesium B-drug
deficit O
i.e O
. O
acute O
) O
, O
pharmacological O
( O
i.e O
. O
without O
alterations O
of O
magnesium B-drug
status O
) O
and O
mixed O
-- O
pharmacological O
and O
aetiopathogenic O
-- O
( O
for O
example O
complications O
of O
chronic O
alcoholism O
) O
. O

decreased O
antithrombin O
3 O
; O


Two O
percent O
of O
patients O
treated O
concurrently O
with O
ENBREL B-brand
and O
anakinra B-drug
developed O
neutropenia O
( O
ANC O
1 O
x O
109/L O
) O
. O

Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Antibiotics B-drug
: O
Rifampin B-drug
is O
a O
potent O
inducer O
of O
CYP3A4 B-drug
. O

The O
resulting O
increase O
in O
free O
drug O
concentration O
may O
lead O
to O
enhanced O
drug O
effect O
in O
vivo O
. O

The O
results O
raise O
the O
possibility O
that O
the O
ethanolysis O
reaction O
may O
occur O
in O
the O
stomach O
of O
people O
who O
consume O
alcohol B-drug
and O
3-hydroxy-1,4-benzodiazepine B-group
on O
a O
regular O
basis O
. O

Patients O
should O
be O
warned O
of O
the O
potential O
danger O
of O
the O
intravenous O
self-administration O
of O
benzodiazepines B-group
while O
under O
treatment O
with O
SUBOXONE B-brand
or O
SUBUTEX B-brand
. O

In O
vitro O
studies O
also O
indicate O
that O
celecoxib B-drug
, O
although O
not O
a O
substrate O
, O
is O
an O
inhibitor O
of O
cytochrome O
P450 O
2D6 O
. O

Acute O
symptoms O
should O
be O
treated O
with O
a O
short-acting O
, O
inhaled O
beta2-agonist B-group
such O
as O
salbutamol B-drug
( O
the O
physician O
should O
provide O
the O
patient O
with O
such O
medication O
and O
instruct O
the O
patient O
in O
how O
it O
should O
be O
used O
) O
. O

Drug O
interaction O
studies O
of O
mefenamic B-drug
acid I-drug
and O
these O
compounds O
have O
not O
been O
conducted O
. O

Cimetidine B-drug
is O
reported O
to O
reduce O
hepatic O
metabolism O
of O
certain O
tricyclic B-drug
antidepressants I-drug
, O
thereby O
delaying O
elimination O
and O
increasing O
steady-state O
concentrations O
of O
these O
drugs B-drug
. O

This O
indicates O
that O
gabapentin B-drug
does O
not O
undergo O
renal O
tubular O
secretion O
by O
the O
pathway O
that O
is O
blocked O
by O
probenecid B-drug
. O

Induction O
of O
such O
tumors O
is O
consistent O
with O
the O
pharmacology-related O
endocrine O
feedback O
alterations O
in O
gonadotropin O
levels O
caused O
by O
an O
antiestrogen B-group
. O

Acid-catalyzed O
ethanolysis O
of O
temazepam B-drug
in O
anhydrous O
and O
aqueous O
ethanol B-drug
solutions O
. O


Concomitant O
use O
of O
calcium B-drug
supplements O
and O
L-lysine B-drug
may O
increase O
calcium B-drug
absorption O

Monitor O
serum O
potassium O
levels O
; O

Digoxin B-drug
: O
In O
a O
study O
in O
12 O
patients O
with O
congestive O
heart O
failure O
where O
ketoprofen B-drug
and O
digoxin B-drug
were O
concomitantly O
administered O
, O
ketoprofen B-drug
did O
not O
alter O
the O
serum O
levels O
of O
digoxin B-drug
. O

Valproate B-drug
Keppra B-brand
( O
1500 O
mg O
twice O
daily O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
valproate B-drug
in O
healthy O
volunteers O
. O

If O
you O
are O
50 O
years O
of O
age O
or O
older O
, O
ask O
your O
physician O
to O
check O
your O
B12 O
status O
before O
you O
take O
a O
supplement O
that O
contains O
folic B-drug
acid I-drug
. O

Vancomycin O
resistance O
reversal O
in O
enterococci O
by O
flavonoids O
. O

route O
. O

Jacalin B-drug_n
is O
a O
D-Gal O
binding O
lectin O
and O
should O
be O
a O
useful O
tool O
for O
studying O
of O
serum O
and O
secretory O
IgA O
. O

The O
increase O
of O
phenobarbital B-drug
level O
, O
however O
, O
is O
small O
( O
15 O
% O
) O
when O
given O
with O
Trileptal B-brand
. O

therefore O
, O
periodic O
liver O
function O
testing O
( O
transaminases O
, O
bilirubin O
, O
and O
alkaline O
phosphatase O
) O
should O
be O
considered O
. O

Until O
specific O
compatibility O
data O
are O
available O
, O
it O
is O
not O
recommended O
that O
DOXIL B-brand
be O
mixed O
with O
other O
drugs O
. O

Anticonvulsants B-group

Pharmacokinetic-related O
Interactions O
: O
Clozapine B-drug
is O
a O
substrate O
for O
many O
CYP O
450 O
isozymes O
, O
in O
particular O
1A2 O
, O
2D6 O
, O
and O
3A4 O
. O

Concomitant O
use O
of O
Isocarboxazid B-drug
and O
other O
psychotropic B-group
agents I-group
is O
generally O
not O
recommended O
because O
of O
possible O
potentiating O
effects O
. O

Methadone B-drug

Table O
9 O

The O
majority O
of O
adverse O
events O
with O
NNRTIs B-group
occur O
within O
the O
first O
month O
, O
and O
are O
predictable O
and O
manageable O
without O
therapy O
interruption O
. O

administration O
1 O
hour O
before O
or O
4 O
hours O
after O
colestipol B-drug
is O
recommended O
. O
) O

Failure O
of O
neomycin B-drug
to O
modify O
ACTH B-group
induced O
hypertension O
in O
sheep O
. O

PATIENTS O
: O
Random O
sample O
of O
626 O
MAC O
out O
of O
a O
total O
of O
1306 O
. O

Monitor O
for O
symptoms O
of O
hyperglycemia O
; O

At O
higher O
than O
recommended O
doses O
, O
VIOXX B-brand
75 O
mg O
administered O
once O
daily O
for O
10 O
days O
increased O
plasma O
concentrations O
by O
23 O
% O
as O
measured O
by O
AUC0-24hr O
in O
patients O
receiving O
methotrexate B-drug
7.5 O
to O
15 O
mg/week O
for O
rheumatoid O
arthritis O
. O

Acitretin B-drug
: O
Interferes O
with O
the O
contraceptive O
effect O
of O
microdosed O
progestin-containing B-group
minipill O
preparations O
. O

Co-administration O
of O
CYP3A4 O
inhibitors O
( O
eg O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
grapefruit O
juice O
, O
cimetidine B-drug
) O
with O
felodipine B-drug
may O
lead O
to O
several- O
fold O
increases O
in O
the O
plasma O
levels O
of O
felodipine B-drug
, O
either O
due O
to O
an O
increase O
in O
bioavailability O
or O
due O
to O
a O
decrease O
in O
metabolism O
. O

Differences O
can O
occur O
in O
therapeutic O
effect O
and O
in O
adverse O
events O
. O

Conversely O
, O
adverse O
effects O
may O
result O
from O
displacement O
of O
protein-bound O
Anafranil B-brand
by O
other O
highly O
bound O
drugs O
. O

The O
recommended O
dosage O
( O
one O
or O
two O
capsules O
twice O
daily O
, O
morning O
and O
evening O
) O
should O
not O
be O
exceeded O
. O

Increases O
in O
sertraline B-drug
dose O
should O
be O
guided O
by O
clinical O
response O
. O

Pharmacokinetic O
studies O
have O
demonstrated O
that O
omeprazole B-drug
and O
erythromycin B-drug
significantly O
increased O
the O
systemic O
exposure O
of O
cilostazol B-drug
and/or O
its O
major O
metabolites O
. O


Brain O
hemorrhage O
and O
optic O
nerve O
vacuolation O
were O
seen O
in O
another O
female O
dog O
that O
was O
sacrificed O
in O
moribund O
condition O
after O
11 O
weeks O
of O
escalating O
doses O
up O
to O
280 O
mg/kg/day O
. O

Warning O
signs O
, O
irrespective O
of O
cause O
, O
are O
: O
dryness O
of O
mouth O
, O
thirst O
, O
weakness O
, O
lethargy O
, O
drowsiness O
, O
restlessness O
, O
muscle O
pains O
or O
cramps O
, O
muscular O
fatigue O
, O
hypotension O
, O
oliguria O
, O
tachycardia O
, O
and O
gastrointestinal O
disturbances O
such O
as O
nausea O
and O
vomiting O
. O

In O
studies O
in O
normal O
volunteers O
, O
there O
was O
no O
pharmacodynamic O
interaction O
between O
intravenous O
iloprost B-drug
and O
either O
nifedipine B-drug
, O
diltiazem B-drug
, O
or O
captopril B-drug
. O

Expected O
to O
substantially O
decrease O
plasma O
levels O
of O
efavirenz B-drug
; O
has O
not O
been O
studied O
in O
combination O
with O
SUSTIVA B-brand
. O

As O
with O
some O
other O
nondepolarizing B-group
neuromuscular I-group
blocking I-group
agents I-group
, O
the O
time O
of O
onset O
of O
neuromuscular O
block O
induced O
by O
NUROMAX B-brand
is O
lengthened O
and O
the O
duration O
of O
block O
is O
shortened O
in O
patients O
receiving O
phenytoin B-drug
or O
carbamazepine B-drug
. O

Uricosuric B-group
drugs I-group
, O
such O
as O
probenecid B-drug
and O
sulfinpyrazone B-drug
, O
can O
inhibit O
renal O
tubular O
secretion O
of O
nitrofurantoin B-drug
. O

Potential O
for O
ABILIFY B-brand
to O
Affect O
Other O
Drugs O
Aripiprazole B-drug
is O
unlikely O
to O
cause O
clinically O
important O
pharmacokinetic O
interactions O
with O
drugs O
metabolized O
by O
cytochrome O
P450 O
enzymes O
. O

Antifungals B-group
: O
In O
vitro O
and/or O
in O
vivo O
data O
indicate O
that O
fluconazole B-drug
, O
itraconazole B-drug
, O
and O
oral O
ketoconazole B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

This O
medicine O
should O
not O
be O
taken O
with O
MAO B-group
inhibitors I-group
. O

Drugs O
that O
inhibit O
cytochrome O
P450IID6 O
, O
such O
as O
quinidine B-drug
, O
might O
increase O
the O
plasma O
concentrations O
of O
flecainide B-drug
in O
patients O
that O
are O
on O
chronic O
flecainide B-drug
therapy O
; O

Methotrexate B-drug
VIOXX B-brand
12.5 O
, O
25 O
, O
and O
50 O
mg O
, O
each O
dose O
administered O
once O
daily O
for O
7 O
days O
, O
had O
no O
effect O
on O
the O
plasma O
concentration O
of O
methotrexate B-drug
as O
measured O
by O
AUC0-24hr O
in O
patients O
receiving O
single O
weekly O
methotrexate B-drug
doses O
of O
7.5 O
to O
20 O
mg O
for O
rheumatoid O
arthritis O
. O

Antacids I-group
: O
Administration O
of O
flurbiprofen B-drug
to O
volunteers O
under O
fasting O
conditions O
, O
or O
with O
antacid B-group
suspension O
yielded O
similar O
serum O
flurbiprofen B-drug
time O
profiles O
in O
young O
subjects O
( O
n=12 O
) O
. O

Effects O
on O
the O
absorption O
of O
other O
beta-blockers B-group
have O
not O
been O
determined O
. O

Therefore O
, O
EXTREME O
CAUTION O
should O
be O
exercised O
when O
administering O
dopamine B-drug
HCl I-drug
to O
patients O
receiving O
cyclopropane B-drug
or O
halogenated B-group
hydrocarbon I-group
anesthetics I-group
. O

Another O
investigator O
found O
no O
increase O
in O
digoxin B-drug
levels O
in O
12 O
patients O
with O
coronary O
artery O
disease O
. O

PEGASYS B-brand
is O
to O
be O
used O
during O
pregnancy O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
to O
the O
fetus O
. O

In O
hematologic O
studies O
or O
in O
transfusion O
cross-matching O
procedures O
when O
anti-globulin O
tests O
are O
performed O
on O
the O
minor O
side O
or O
in O
Coombs O
testing O
of O
newborns O
whose O
mothers O
have O
received O
cephalosporin B-group
antibiotics I-group
before O
parturition O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
may O
be O
due O
to O
the O
drug O
. O

Anticoagulants B-group
. O

Tolbutamide B-drug
: O
In O
diabetic O
patients O
receiving O
diflunisal B-drug
and O
tolbutamide B-drug
, O
no O
significant O
effects O
were O
seen O
on O
tolbutamide B-drug
plasma O
levels O
or O
fasting O
blood O
glucose O
. O


There O
is O
limited O
experience O
with O
concomitant O
antihypertensive B-group
agents I-group
such O
as O
alpha-blockers B-group
, O
calcium B-group
channel-blockers I-group
, O
ACE B-group
inhibitors I-group
, O
and O
diuretics B-group
( O
both O
thiazide-like B-group
and O
loop O
) O
. O

No O
drug O
, O
nutritional O
supplement O
, O
food O
or O
herb O
interactions O
have O
yet O
been O
reported O
. O

Note O
: O
dissolution O
of O
aerosol O
particles O
of O
budesonide B-drug
in O
Survanta B-brand
, O
a O
model O
lung B-group
surfactant I-group
. O

If O
TYKERB B-brand
is O
administered O
with O
drugs O
that O
are O
substrates O
of O
Pgp O
, O
increased O
concentrations O
of O
the O
substrate O
drug O
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O

ETHANOL B-drug
/ O
NUTRITION O
/ O
HERB O
INTERACTIONS O
: O
Food O
: O
CNS O
effects O
of O
caffeine B-drug
may O
be O
enhanced O
if O
combination B-group
hormonal I-group
contraceptives I-group
are O
used O
concurrently O
with O
caffeine B-drug
. O

If O
antacids B-group
are O
required O
during O
OMNICEF B-brand
therapy O
, O
OMNICEF B-brand
should O
be O
taken O
at O
least O
2 O
hours O
before O
or O
after O
the O
antacid B-group
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

It O
is O
not O
known O
if O
the O
effects O
of O
butorphanol B-drug
are O
altered O
by O
concomitant O
medications O
that O
affect O
hepatic O
metabolism O
of O
drugs O
( O
erythromycin B-drug
, O
etc O
. O
) O
, O
but O
physicians O
should O
be O
alert O
to O
the O
possibility O
that O
a O
smaller O
initial O
dose O
and O
longer O
intervals O
between O
doses O
may O
be O
needed O
. O

The O
mean O
C O
max O
, O
T O
max O
, O
and O
AUC O
of O
the O
acid O
metabolite O
of O
terfenadine B-drug
were O
not O
significantly O
changed O
. O

Beta-blocking B-group
Agents I-group
: O
The O
concomitant O
use O
of O
Bepridil B-drug
and O
beta-blocking B-group
agents I-group
has O
been O
well O
tolerated O
in O
patients O
with O
stable O
angina O
. O


The O
possibility O
of O
increased O
interaction O
should O
be O
kept O
in O
mind O
when O
Orudis B-brand
doses O
greater O
than O
50 O
mg O
as O
a O
single O
dose O
or O
200 O
mg O
of O
ketoprofen B-drug
per O
day O
are O
used O
concomitantly O
with O
highly O
bound O
drugs O
. O

Results O
showed O
that O
, O
depending O
on O
the O
task O
considered O
, O
the O
same O
pharmacological O
treatment O
produced O
either O
a O
facilitation O
or O
an O
impairment O
of O
acquisition O
. O

Co-administration O
of O
nelfinavir B-drug
at O
steady-state O
with O
a O
single O
dose O
of O
azithromycin B-drug
. O

TABLE O
1 O
Effects O
on O
Plasma O
Concentrations O
( O
AUC O
0-24 O
hrs O
) O
of O
Loratadine B-drug
and O
Descarboethoxyloratadine B-drug
After O
10 O
Days O
of O
Coadministration O
( O
Loratadine B-drug
10 O
mg O
) O
in O
Normal O
Volunteers O

Serum O
infliximab B-drug
concentrations O
appeared O
to O
be O
unaffected O
by O
baseline O
use O
of O
medications O
for O
the O
treatment O
of O
Crohn O
s O
disease O
including O
corticosteroids B-group
, O
antibiotics B-group
( O
metronidazole B-drug
or O
ciprofloxacin B-drug
) O
and O
aminosalicylates O
. O

Erythromycin B-drug
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam B-drug
and O
midazolam B-drug
and O
thus O
may O
increase O
the O
pharmacologic O
effect O
of O
these O
benzodiazepines B-group
. O

Drugs O
Associated O
With O
Peripheral O
Neuropathy O
: O
The O
concomitant O
use O
of O
HIVID B-drug
with O
drugs O
that O
have O
the O
potential O
to O
cause O
peripheral O
neuropathy O
should O
be O
avoided O
where O
possible O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
. O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
quinolone B-group
use O
. O

HAART O
was O
included O
with O
combination O
therapy O
from O
January O
1997 O
. O

Consequently O
, O
estazolam B-drug
should O
be O
avoided O
in O
patients O
receiving O
ketoconazole B-drug
and O
itraconazole B-drug
, O
which O
are O
very O
potent O
inhibitors O
of O
CYP3A O
. O

trimethoprim/sulfamethoxazole B-drug
; O

We O
conclude O
that O
an O
ability O
of O
some O
P O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O


Drug O
interactions O
caused O
by O
inhibition O
of O
P-glycoprotein-mediated O
drug O
clearance O
or O
CYP-mediated O
drug O
clearance O
with O
the O
listed O
isoforms O
are O
unlikely O
. O

Drugs O
other O
than O
those O
listed O
here O
may O
also O
interact O
with O
glimepiride B-drug
or O
affect O
your O
condition O
. O

In O
a O
clinical O
trial O
of O
217 O
pediatric O
patients O
( O
12 O
to O
17 O
years O
) O
with O
severe O
recalcitrant O
nodular O
acne O
, O
transient O
elevations O
in O
CPK O
were O
observed O
in O
12 O
% O
of O
patients O
, O
including O
those O
undergoing O
strenuous O
physical O
activity O
in O
association O
with O
reported O
musculoskeletal O
adverse O
events O
such O
as O
back O
pain O
, O
arthralgia O
, O
limb O
injury O
, O
or O
muscle O
sprain O
. O

Recent O
, O
better O
designed O
studies O
have O
not O
reported O
these O
adverse O
effects O
. O

Administration O
of O
doxapram B-drug
to O
patients O
who O
are O
receiving O
sympathomimetic B-group
or O
monoamine B-group
oxidase I-group
inhibiting I-group
drugs I-group
may O
result O
in O
an O
additive O
pressor O
effect O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reactions O
. O

Therefore O
, O
proton B-group
pump I-group
inhibitors I-group
should O
be O
taken O
at O
least O
30 O
minutes O
prior O
to O
sucralfate B-drug
. O

Potential O
for O
Interaction O
with O
Drugs O
that O
Affect O
Gastric O
Acidity O
: O
Duloxetine B-drug
has O
an O
enteric O
coating O
that O
resists O
dissolution O
until O
reaching O
a O
segment O
of O
the O
gastrointestinal O
tract O
where O
the O
pH O
exceeds O
5.5 O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Drugs I-group
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-group
diuretics I-group
. O

In O
vitro O
studies O
indicate O
that O
bupropion B-drug
is O
primarily O
metabolized O
to O
hydroxybupropion B-drug_n
by O
the O
CYP2B6 O
isoenzyme O
. O

In O
vitro O
, O
the O
UDP-glucuronyl O
transferase O
level O
was O
increased O
, O
indicating O
induction O
of O
this O
enzyme O
. O

In O
Study O
1 O
, O
patients O
with O
colorectal O
cancer O
were O
given O
irinotecan/5-FU/leucovorin B-drug
( O
bolus-IFL O
) O
with O
or O
without O
AVASTIN B-brand
. O

Avoid O
saw O
palmetto O
, O
red O
clover O
, O
ginseng O
. O

. O

phase O
2 O
( O
days O
14-44 O
) O
: O
fluoxetine B-drug
20 O
mg/day O
; O

In O
study O
one O
, O
hyperglycaemic O
clamps O
( O
5.6 O
mmol/l O
, O
11.1 O
mmol/ O
1 O
, O
16.7 O
mmol/l O
) O
were O
carried O
out O
during O
placebo O
or O
insulin B-drug
( O
dose O
1 O
: O
1 O
mU/kg/min O
; O
dose O
2 O
: O
2 O
mU/kg/min O
) O
infusion O
. O

Omniscan B-brand
interferes O
with O
serum O
calcium O
measurements O
with O
some O
colorimetric O
( O
complexometric O
) O
methods O
commonly O
used O
in O
hospitals O
, O
resulting O
in O
serum O
calcium O
concentrations O
lower O
than O
the O
true O
values O
. O

Appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Drug/ O
Laboratory O
Tests O
Interactions O
Hyperaminotransferasemia O
: O
Significant O
elevations O
of O
aminotransferase O
( O
SGOT O
[ O
S-AST O
] O
and O
SGPT O
[ O
S-ALT O
] O
) O
levels O
have O
occurred O
in O
a O
high O
percentage O
of O
patients O
( O
and O
healthy O
subjects O
) O
who O
have O
received O
heparin B-drug
sodium I-drug
. O

The O
effect O
of O
clofarabine B-drug
on O
the O
metabolism O
of O
cytochrome O
p450 O
substrates O
has O
not O
been O
studied O
. O

The O
effect O
of O
natural O
and O
synthetic O
galloyl O
esters O
on O
glucocorticoid-induced O
gene O
expression O
was O
evaluated O
by O
using O
rat O
fibroblast O
3Y1 O
cells O
stably O
transfected O
with O
a O
luciferase O
reporter O
gene O
under O
the O
transcriptional O
regulation O
of O
the O
mouse O
mammary O
tumor O
virus O
promoter B-drug
. O

The O
ECG O
changes O
and/or O
hypokalemia O
that O
may O
result O
from O
the O
administration O
of O
non-potassium B-group
sparing I-group
diuretics I-group
( O
such O
as O
loop O
or O
thiazide B-group
diuretics I-group
) O
can O
be O
acutely O
worsened O
by O
beta-agonists B-group
, O
especially O
when O
the O
recommended O
dose O
of O
the O
beta-agonist B-group
is O
exceeded O
. O

Corticotropin B-drug
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-group
therapy O
. O

Given O
the O
anticonvulsant O
properties O
of O
carbamazepine B-drug
, O
EQUETROTM B-brand
may O
reduce O
the O
thyroid O
function O
as O
has O
been O
reported O
with O
other O
anticonvulsants B-group
. O

Concomitant O
single O
dose O
administration O
of O
valdecoxib B-drug
20 O
mg O
with O
multiple O
doses O
of O
ketoconazole B-drug
and O
fluconazole B-drug
produced O
a O
significant O
increase O
in O
exposure O
of O
valdecoxib B-drug
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
enhance O
the O
locomotor O
and/or O
stereotypic O
effects O
of O
stimulants O
. O

Protease B-group
inhibitor I-group
: O
atazanavir B-drug

T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O

Therefore O
, O
patients O
with O
COPD O
should O
not O
normally O
be O
treated O
with O
beta-blockers B-group
. O

The O
interaction O
of O
intramuscularly O
injected O
ketamine B-drug
and O
its O
N-demethylated O
metabolite O
( O
metabolite O
I O
) O
with O
halothane B-drug
was O
evaluated O
in O
rats O
. O

It O
is O
recommended O
that O
the O
dose O
of O
rifabutin B-drug
be O
reduced O
to O
one-half O
the O
usual O
dose O
when O
administered O
with O
VIRACEPT B-brand
. O

however O
, O
patients O
receiving O
such O
combined O
therapy O
should O
be O
monitored O
closely O
for O
early O
evidence O
of O
neurological O
toxicity O
and O
treatment O
discontinued O
promptly O
if O
such O
signs O
appear O
. O

During O
phenytoin B-drug
and O
fluvoxamine O
treatment O
, O
ataxia O
, O
a O
typical O
side O
effect O
of O
phenytoin B-drug
, O
was O
observed O
. O

1 O
. O

The O
increased O
plasma O
concentration O
of O
terfenadine B-drug
or O
its O
metabolite O
may O
result O
in O
prolonged O
QT O
intervals O
. O

Phenytoin O
intoxication O
induced O
by O
fluvoxamine B-drug
. O

Clinically O
significant O
interactions O
would O
not O
be O
expected O
since O
the O
NRTIs B-group
are O
metabolized O
via O
a O
different O
route O
than O
efavirenz B-drug
and O
would O
be O
unlikely O
to O
compete O
for O
the O
same O
metabolic O
enzymes O
and O
elimination O
pathways O
. O


In O
a O
pharmacokinetic O
interaction O
study O
with O
warfarin B-drug
, O
bioavailability O
parameters O
, O
the O
degree O
of O
protein O
binding O
, O
and O
the O
anticoagulant O
effect O
( O
measured O
by O
prothrombin O
time O
) O
of O
warfarin B-drug
were O
not O
significantly O
changed O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O

A O
method O
to O
maximize O
the O
therapeutic O
benefit O
of O
gentamicin B-drug
while O
minimizing O
the O
risk O
of O
nephrotoxicity O
and O
the O
appearance O
of O
a O
hot O
kidney O
on O
scintigraphy O
is O
desirable O
. O

Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-brand
include O
: O
enflurane B-drug
; O

Patients O
stabilized O
on O
oral O
anticoagulants B-group
who O
are O
found O
to O
require O
thyroid B-group
replacement O
therapy O
should O
be O
watched O
very O
closely O
when O
thyroid O
is O
started O
. O

The O
second O
study O
was O
identical O
but O
endogenous O
insulin O
secretion O
was O
blocked O
with O
somatostatin B-drug
. O

If O
other O
muscle B-group
relaxants I-group
are O
used O
during O
the O
same O
procedure O
, O
the O
possibility O
of O
a O
synergistic O
or O
antagonist O
effect O
should O
be O
considered O
. O

Magnesium- B-drug
and/or O
aluminum-containing B-drug
antacids B-group
, O
products O
containing O
ferrous B-drug
sulfate I-drug
( O
iron B-drug
) O
, O
multivitamin B-group
preparations I-group
containing O
zinc B-drug
or O
other O
metal O
cations O
, O
or O
Videx B-brand
( O
didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
taken O
within O
3 O
hours O
before O
or O
2 O
hours O
after O
FACTIVE B-brand
. O

The O
concomitant O
administration O
of O
either O
cocaine B-drug
or O
amphetamine B-drug
, O
compounds O
which O
inhibit O
neuronal O
reuptake O
of O
norepinephrine O
, O
disrupts O
the O
behavioral O
response O
of O
the O
genetically O
nervous O
E-strain O
subjects O
to O
a O
far O
greater O
extent O
than O
the O
stable O
A-strain O
subjects O
. O

If O
TYKERB B-brand
is O
administered O
with O
drugs O
that O
inhibit O
Pgp O
, O
increased O
concentrations O
of O
lapatinib B-drug
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O

Because O
changes O
in O
glucose O
concentrations O
with O
valdecoxib B-drug
coadministration O
were O
within O
the O
normal O
variability O
and O
individual O
glucose O
concentrations O
were O
above O
or O
near O
70 O
mg/dL O
, O
dose O
adjustment O
for O
glyburide B-drug
( O
5 O
mg O
QD O
and O
10 O
mg O
BID O
) O
with O
valdecoxib B-drug
coadministration O
( O
up O
to O
40 O
mg O
QD O
) O
is O
not O
indicated O
. O

False-positive O
direct O
Coombs O
tests O
have O
been O
reported O
during O
treatment O
with O
other O
cephalosporins B-group
. O

Impaired O
glucose O
tolerance O
. O

Ketoconazole B-drug
: O
When O
a O
single O
125-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day5 O
of O
a O

In O
four O
subjects O
with O
epilepsy O
ingesting O
valproate B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
valproate B-drug
plasma O
concentration O
was O
63 O
16 O
micrograms/mL O
. O

Anti-HIV B-group
Reverse I-group
Transcriptase I-group
Inhibitors I-group

Clofibric B-drug_n
acid I-drug_n
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
clofibric B-drug_n
acid I-drug_n
. O

No O
specific O
studies O
have O
been O
performed O
and O
caution O
is O
recommended O
. O

rash O

Frequent O
determination O
of O
prothrombin O
time O
and O
close O
monitoring O
of O
the O
patient O
is O
essential O
to O
ascertain O
when O
adjustment O
of O
dosage O
of O
anticoagulant B-group
may O
be O
needed O
. O

A O
21 O
( O
17 O
) O
% O
decrease O
in O
the O
steady-state O
AUC O
of O
ganciclovir B-drug
was O
observed O
when O
VIDEX B-brand
was O
administered O
2 O
hours O
prior O
to O
ganciclovir B-drug
, O
but O
not O
when O
the O
two O
drugs O
were O
administered O
simultaneously O
( O
n O
= O
12 O
) O
. O

Cevimeline B-drug
might O
interfere O
with O
desirable O
antimuscarinic O
effects O
of O
drugs O
used O
concomitantly O
. O

Statistical O
analysis O
: O
Mantel-Haenszel O
( O
alpha O
= O
0.05 O
) O
. O

Cyclosporine B-drug
doses O
, O
trough O
concentrations O
, O
and O
AUC O
exhibited O
similar O
temporal O
patterns O
during O
the O
course O
of O
the O
study O
regardless O
of O
the O
co-administered O
everolimus B-drug
dose O
level O
( O
P O
= O
.13 O
, O
.82 O
, O
and O
.76 O
, O
respectively O
) O
. O

No O
drug O
interactions O
have O
been O
observed O
with O
the O
Vitrasert B-brand
Implant O
. O

No O
interactions O
were O
observed O
. O

An O
interaction O
study O
with O
warfarin B-drug
showed O
no O
clinically O
significant O
effect O
of O
anastrozole B-drug
on O
warfarin B-drug
pharmacokinetics O
or O
anticoagulant O
activity O
. O

Drug/Laboratory O
Test O
Interactions O
Naproxen B-drug
may O
decrease O
platelet O
aggregation O
and O
prolong O
bleeding O
time O
. O

Intestinal O
absorption O
of O
arsenate B-drug_n
in O
the O
chick O
. O

Ethanol B-drug
depressed O
the O
amplitudes O
of O
most O
evoked O
potential O
components O
in O
comparison O
to O
saline O
administration O
. O

alcohol B-drug
, O
barbiturates B-drug
and O
other O
CNS B-drug
depressants I-drug
; O

An O
immune O
response O
to O
Campath B-brand
may O
interfere O
with O
subsequent O
diagnostic O
serum O
tests O
that O
utilize O
antibodies B-group

After O
one O
day O
, O
fecal O
as O
well O
as O
urinary O
excretion O
of O
both O
elements O
had O
already O
responded O
to O
the O
dietary O
treatments O
, O
with O
constant O
values O
being O
reached O
after O
approximately O
three O
days O
. O

Epinephrine B-drug
also O
should O
be O
used O
cautiously O
with O
other O
drugs O
( O
e.g. O
, O
digitalis B-group
, O
glycosides B-group
) O
that O
sensitize O
the O
myocardium O
to O
the O
actions O
of O
sympathomimetic B-group
drugs I-group
. O

Significant O
increases O
In O
AUC O
( O
27 O
% O
) O
and O
Cmax O
( O
58 O
% O
) O
and O
decreases O
in O
tmax O
( O
23 O
% O
) O
of O
propranolol B-drug
were O
noted O
in O
this O
study O
. O

Treatment O
with O
PEGASYS B-brand
once O
weekly O
for O
4 O
weeks O
in O
healthy O
subjects O
was O
associated O
with O
an O
inhibition O
of O
P450 O
1A2 O
and O
a O
25 O
% O
increase O
in O
theophylline B-drug
AUC O
. O

Itraconazole B-drug

Clinical O
Comment O

The O
risks O
of O
using O
Anafranil B-brand
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

- O
Quinidine B-drug
( O
e.g. O
, O
Quinidex B-brand
) O
or O

Drug/Laboratory O
Test O
Interactions O
Increases O
in O
lymphocyte O
counts O
related O
to O
the O
pharmacologic O
mechanism O
of O
action O
are O
frequently O
observed O
during O
RAPTIVA B-brand
treatment O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
there O
exists O
the O
potential O
for O
serious O
adverse O
reactions O
in O
nursing O
infants O
from O
AMEVIVE B-brand
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
while O
taking O
the O
drug O
or O
to O
discontinue O
the O
use O
of O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

Both O
efavirenz B-drug
and O
nevirapine B-drug
have O
been O
compared O
to O
triple O
therapy O
with O
the O
PI B-group
indinavir B-drug
over O
48 O
weeks O
as O
initial O
therapy O
, O
with O
similar O
responses O
being O
observed O
with O
nevirapine B-drug
regimens O
and O
superiority O
observed O
with O
efavirenz B-drug
. O

Several O
drug O
interaction O
studies O
have O
been O
completed O
with O
both O
INVIRASE B-brand
and O
FORTOVASE B-brand
. O

Bexarotene B-drug
oxidative O
metabolites O
appear O
to O
be O
formed O
by O
cytochrome O
P450 O
3A4 O
. O

If O
you O
think O
you O
are O
taking O
an O
MAO B-group
inhibitor I-group
talk O
to O
your O
doctor O
or O
pharmacist O
. O

The O
effect O
of O
a O
pulmonary B-group
surfactant I-group
extract O
from O
bovine O
lung O
, O
Survanta B-brand
, O
on O
the O
dissolution O
rate O
of O
aerosol O
particles O
of O
budesonide B-drug
was O
determined O
. O

In O
a O
single O
study O
, O
rats O
given O
high O
intraperitoneal O
doses O
of O
an O
MAO B-group
inhibitor I-group
plus O
disulfiram B-drug
experienced O
severe O
toxicity O
, O
including O
convulsions O
and O
death O
. O

FACTIVE B-brand
had O
no O
significant O
effect O
on O
the O
anticoagulant O
effect O
of O
warfarin B-drug
in O
healthy O
subjects O
on O
stable O
warfarin B-drug
therapy O
. O

The O
interindividual O
pharmacokinetic O
variability O
for O
AUC O
was O
85.4 O
% O
and O
intraindividual O
, O
interoccasion O
variability O
was O
40.8 O
% O
. O

Excretion O
of O
thioethers O
in O
urine O
after O
exposure O
to O
electrophilic O
chemicals O
. O

Expected O
changes O
in O
laboratory O
assessments O
of O
PT O
and O
INR O
were O
observed O
after O
warfarin B-drug
administration O
, O
but O
these O
changes O
were O
not O
affected O
by O
concomitant O
lenalidomide B-drug
administration O
. O

Propoxyphene B-drug
: O
In O
cases O
of O
propoxyphene B-drug
overdosage O
, O
amphetamine B-drug
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O

Quinolones B-group
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Caution O
should O
be O
exercised O
with O
these O
drugs O
when O
treating O
patients O
receiving O
TAXOTERE B-brand
as O
there O
is O
a O
potential O
for O
a O
significant O
interaction O
. O

Except O
for O
clindamycin-sensitive B-drug
isolates O
, O
synergy O
was O
usually O
observed O
only O
at O
concentrations O
of O
one O
or O
both O
drugs O
which O
are O
not O
readily O
obtainable O
in O
vivo O
. O

- O
Cholestyramine B-drug
and O
colestipol B-drug
resins B-group
: O
Cholestytamine B-drug
and O
colestipol B-drug
resins B-group
have O
the O
potential O
of O
binding O
thiazide B-group
diuretics I-group
and O
reducing O
diuretic B-group
absorption O
from O
the O
gastrointestinal O
tract O

This O
medicine O
should O
not O
be O
taken O
with O
MAO B-group
inhibitors I-group
. O

Patients O
with O
a O
very O
low O
cardiac O
capacity O
should O
be O
advised O
to O
refrain O
from O
treatment O
of O
the O
erection O
disorder O
. O

As O
binding O
of O
MHD B-drug_n
to O
plasma O
proteins O
is O
low O
( O
40 O
% O
) O
, O
clinically O
significant O
interactions O
with O
other O
drugs O
through O
competition O
for O
protein O
binding O
sites O
are O
unlikely O
. O

Adverse O
reactions O
related O
to O
alpha B-drug
interferons O
, O
such O
as O
CNS O
, O
cardiac O
, O
and O
systemic O
( O
eg O
, O
flu-like O
) O
effects O
may O
be O
more O
severe O
in O
the O
elderly O
and O
caution O
should O
be O
exercised O
in O
the O
use O
of O
PEGASYS B-brand
in O
this O
population O
. O

In O
opioid-dependent B-group
patients O
, O
mixed B-group
agonist/antagonist I-group
analgesics I-group
may O
precipitate O
withdrawal O
symptoms O
. O

Chirocaine B-brand
should O
be O
used O
with O
caution O
in O
patients O
receiving O
other O
local O
anesthetics B-group
or O
agents O
structurally O
related O
to O
amide-type O
local O
anesthetics O
since O
the O
toxic O
effects O
of O
these O
drugs O
could O
be O
additive O
. O

Misonidazole B-drug_n
reduced O
the O
antitumour O
activity O
of O
oral O
CCNU B-drug
by O
dose O
modifying O
factors O
( O
DMF O
) O
of O
0.58-0.71 O
. O

An O
association O
between O
prilocaine B-drug
and O
an O
increased O
risk O
of O
methaemoglobinaemia O
, O
particularly O
in O
infants O
, O
has O
specifically O
been O
described O
in O
a O
literature O
case O
report O
. O

Fenfluramine B-drug
may O
increase O
slightly O
the O
effect O
of O
antihypertensive B-group
drugs I-group
, O
e.g. O
, O
guanethidine B-drug
, O
methyldopa B-drug
, O
reserpine B-drug
. O

Cytochrome O
P450 O
1A2 O
( O
CYP1A2 O
) O
is O
known O
to O
be O
the O
major O
enzyme O
involved O
in O
the O
metabolism O
of O
caffeine B-drug
. O

Exposure O
of O
the O
muscle O
to O
ouabain B-drug
( O
10 O
( O
-5 O
) O
M O
) O
markedly O
increased O
the O
PTX-induced B-drug_n
release O
. O

The O
possibility O
of O
hypotensive O
effects O
with O
enalapril B-drug
or O
enalaprilat B-drug
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-drug
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
enalapril B-drug
or O
enalaprilat B-drug
. O

+15 O
% O
+0 O
% O
+17 O
% O
+13 O
% O

When O
phenobarbital B-drug
is O
added O
to O
or O
withdrawn O
from O
treatment O
, O
dosage O
adjustment O
of O
Nalfon B-brand
may O
be O
required O
. O

Digitalis B-group
: O
Immediate O
Release O
Capsules O
: O
Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-drug
levels O
, O
and O
there O
is O
a O
possible O
interaction O
between O
digoxin B-drug
and O
nifedipine B-drug
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-drug
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

Cyclosporin B-drug
, O
tacrolimus B-drug
, O
sirolimus B-drug

Thus O
, O
the O
selective O
regulation O
of O
voltage-dependent O
Ca O
( O
2+ O
) O
subtypes O
by O
ginsenosides B-drug_n
in O
bovine O
chromaffin O
cell O
could O
be O
the O
cellular O
basis O
of O
antistress O
effects O
induced O
by O
ginseng B-drug
. O

It O
has O
been O
reported O
that O
the O
addition O
of O
triamterene B-drug
to O
a O
maintenance O
schedule O
of O
INDOCIN B-brand
resulted O
in O
reversible O
acute O
renal O
failure O
in O
two O
of O
four O
healthy O
volunteers O
. O

As O
with O
other O
drugs O
primarily O
being O
metabolized O
through O
CYP3A4 O
, O
ingestion O
of O
grapefruit O
or O
grapefruit O
juice O
should O
be O
avoided O
in O
connection O
with O
budesonide B-drug
administration O
. O

. O

Dexamethasone B-drug
had O
a O
similar O
effect O
in O
the O
presence O
of O
insulin B-drug
. O

There O
is O
limited O
experience O
with O
use O
of O
retinal O
tamponades O
in O
conjunction O
with O
the O
Vitrasert B-brand
Implant O
. O

Drugs O
which O
inhibit O
CYP2D6 O
and O
CYP3A3/4 O
also O
inhibit O
the O
metabolism O
of O
cevimeline B-drug
. O

Tubocurarine B-drug

Benzyl B-drug_n
alcohol I-drug_n
has O
been O
reported O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
neurological O
and O
other O
complications O
in O
neonates O
and O
infants O
, O
which O
are O
sometimes O
fatal O
. O

+135 O
% O

these O
may O
also O
occur O
in O
neonates O
whose O
mothers O
received O
cephalosporins B-group
before O
delivery O
. O

Blood O
glucose O
concentrations O
should O
be O
carefully O
monitored O
when O
Itraconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
are O
coadministered O
. O

Prednisolone B-drug
: O
Ethinyl B-drug
estradiol I-drug
may O
inhibit O
the O
metabolism O
of O
prednisolone B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
. O

Coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
induce O
CYP3A4 O
activity O
may O
result O
in O
reduced O
plasma O
concentrations O
and O
decreased O
efficacy O
of O
Aprepitant B-drug
. O

Diagnostic O
dip-stick O
methodology O
, O
used O
to O
detect O
ketone O
bodies O
in O
urine O
, O
has O
resulted O
in O
false-positive O
findings O
in O
some O
patients O
treated O
with O
Lodine B-brand
. O

Concomitant O
Administration O
with O
Racemic O
Citalopram B-drug
Citalopram I-drug
- O
Since O
escitalopram B-drug
is O
the O
active O
isomer O
of O
racemic O
citalopram B-drug
( O
Celexa B-brand
) O
, O
the O
two O
agents O
should O
not O
be O
coadministered O
. O

Calcium B-group
channel I-group
blockers I-group

Antihypertensive B-group
medications I-group
, O
other O
, O
especially O
diazoxide B-drug
, O
or O
preanesthetic B-group
and O
anesthetic O
agents O
used O
in O
surgery O
or O
skeletal-muscle B-group
relaxants I-group
, O
nondepolarizing O
, O
used O
in O
surgery O

Clinical O
Comment O

Glyburide B-drug
: O
The O
concomitant O
administration O
of O
ciprofloxacin B-drug
with O
the O
sulfonylurea B-group
glyburide B-drug
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O

However O
, O
theophylline B-drug
plasma O
concentrations O
should O
be O
monitored O
, O
with O
dosage O
adjustment O
as O
appropriate O
, O
in O
patients O
whose O
pulmonary O
disease O
requires O
maintaining O
a O
given O
theophylline B-drug
plasma O
concentration O
for O
optimal O
pulmonary O
function O
or O
in O
patients O
with O
theophylline B-drug
concentrations O
at O
the O
higher O
end O
of O
the O
therapeutic O
range O
. O

Chronic O
administration O
of O
phenobarbital B-drug
, O
a O
known O
enzyme O
inducer O
, O
may O
be O
associated O
with O
a O
decrease O
in O
the O
plasma O
half-life O
of O
fenoprofen B-drug
. O

Similarly O
dialyzed O
were O
phenobarbital B-drug
, O
quinidine B-drug
, O
and O
theophylline B-drug
, O
both O
alone O
at O
therapeutic O
concentrations O
in O
serum O
and O
with O
ethanol B-drug
at O
three O
different O
concentrations O
in O
serum O
. O

Do O
not O
take O
this O
medicine O
with O
St. O
Johns O
Wort O
because O
of O
the O
additive O
effects O
of O
sertonin O
. O

ATROVENT B-brand
Inhalation O
Aerosol O
has O
been O
used O
concomitantly O
with O
other O
drugs O
, O
including O
sympathomimetic B-group
bronchodilators I-group
, O
methylxanthines B-group
, O
and O
steroids B-group
, O
commonly O
used O
in O
the O
treatment O
of O
chronic O
obstructive O
pulmonary O
disease O
. O

This O
drug O
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-drug
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-drug
) O
. O

This O
could O
lead O
to O
decreased O
salicylate B-group
serum O
levels O
or O
increase O
the O
risk O
of O
salicylate B-group
toxicity O
when O
corticosteroid B-drug
is O
withdrawn O
. O

Oral O
Hypoglycemics B-group
: O
Diclofenac B-drug
does O
not O
alter O
glucose O
metabolism O
in O
normal O
subjects O
nor O
does O
it O
alter O
the O
effects O
of O
oral O
hypoglycemic B-group
agents I-group
. O

After O
extensive O
intake O
of O
grapefruit O
juice O
( O
which O
inhibits O
CYP3A4 O
activity O
predominantly O
in O
the O
intestinal O
mucosa O
) O
, O
the O
systemic O
exposure O
for O
oral O
budesonide B-drug
increased O
about O
two O
times O
. O

Drug/Laboratory O
Test O
Interactions O
Blood O
Glucose O
Blood O
glucose O
measurement O
must O
be O
done O
with O
a O
glucose-specific O
method O
to O
prevent O
maltose O
interference O
with O
test O
results O
. O

Interaction O
with O
phenytoin B-drug
, O
lidocaine B-drug
and O
theophylline B-drug
has O
also O
been O
reported O
to O
produce O
adverse O
clinical O
effects O
. O

Carbamazepine B-drug
: O
Elevated O
carbamazepine B-drug
levels O
have O
been O
reported O
in O
postmarketing O
experience O
when O
SUPRAX B-brand
is O
administered O
concomitantly O
. O

Aspirin B-brand
increased O
ulcerogenic O
effect O
; O

Concurrent O
use O
of O
tetracycline B-drug
may O
render O
oral O
contraceptives B-group
less O
effective O
. O

These O
results O
suggest O
that O
KRM-1648 B-drug_n
has O
a O
great O
potential O
in O
the O
treatment O
of O
M O
. O

Two O
different O
types O
of O
therapy O
with O
magnesium B-drug
are O
used O
: O
physiological O
oral O
magnesium B-drug
supplementation O
which O
is O
totally O
atoxic O
since O
it O
palliates O
magnesium B-drug
deficiencies O
by O
simply O
normalizing O
the O
magnesium B-drug
intake O
and O
pharmacological O
magnesium B-drug
therapy O
which O
may O
induce O
toxicity O
since O
it O
creates O
iatrogenic O
magnesium B-drug
overload O
. O

No O
data O
are O
available O
on O
potential O
interactions O
in O
individuals O
who O
consume O
greater O
than O
200 O
mg O
of O
caffeine B-drug
per O
day O
or O
in O
those O
, O
such O
as O
the O
geriatric O
population O
, O
who O
are O
generally O
believed O
to O
be O
more O
susceptible O
to O
the O
development O
of O
drug-induced O
CNS-related O
adverse O
effects O
. O

Theophylline B-drug
: O
Twelve O
healthy O
male O
volunteers O
were O
administered O
one O
200-mg O
ceftibuten B-drug
capsule O
twice O
daily O
for O
6 O
days O
. O

No O
significant O
interactions O
were O
found O
between O
nisoldipine B-drug
and O
warfarin B-drug
or O
digoxin B-drug
. O

It O
was O
concluded O
that O
oral O
oxycodone B-drug
and O
levofloxacin B-drug
can O
be O
administered O
concomitantly O
without O
a O
significant O
decrease O
in O
AUC O
, O
Cmax O
, O
or O
tmax O
. O

The O
cause O
of O
the O
reported O
association O
has O
not O
been O
established O
. O

Phosphate-Binding O
Agents O
: O
Since O
vitamin B-group
D I-group
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate-binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O

vasculitis O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

Antacids B-group
: O
Nonclinical O
data O
demonstrate O
that O
the O
solubility O
of O
dasatinib B-drug
is O
pH O
dependent O
. O

It O
is O
not O
known O
which O
drug O
clearance O
mechanism O
involved O
in O
caspofungin B-drug
disposition O
may O
be O
inducible O
. O

Laboratory O
Tests O
Response O
to O
Plenaxis B-brand
should O
be O
monitored O
by O
measuring O
serum O
total O
testosterone B-drug
concentrations O
just O
prior O
to O
administration O
on O
Day O
29 O
and O
every O
8 O
weeks O
thereafter O
. O

In O
the O
present O
study O
we O
evaluated O
the O
interference O
of O
antidepressants B-group
with O
blood O
glucose O
levels O
of O
diabetic O
and O
non-diabetic O
rats O
. O

In O
two O
clinical O
studies O
, O
cyclosporine B-drug
( O
one O
4 O
mg/kg O
dose O
or O
two O
3 O
mg/kg O
doses O
) O
increased O
the O
AUC O
of O
caspofungin B-drug
by O
approximately O
35 O
% O
. O

dietary O
deficiencies O
; O

Women O
should O
practice O
additional O
methods O
of O
contraception O
and O
not O
rely O
on O
hormonal O
contraception O
alone O
when O
taking O
TRACLEER B-brand
. O

Concomitant O
use O
of O
barbiturates B-group
usually O
depresses O
griseofulvin B-drug
activity O
and O
may O
necessitate O
raising O
the O
dosage O
. O

Tetracycline B-drug
, O
a O
bacteriostatic B-group
antibiotic I-group
, O
may O
antagonize O
the O
bactericidal O
effect O
of O
penicillin B-drug
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

There O
have O
been O
no O
formal O
clinical O
studies O
to O
evaluate O
the O
drug O
interactions O
of O
TAXOTERE B-brand
with O
other O
medications O
. O

Amphetamines B-group
may O
enhance O
the O
effects O
of O
tricyclic B-group
antidepressants I-group
. O

Immunologic O

In O
clinical O
trials O
, O
the O
concomitant O
administration O
of O
sulfadoxine B-drug
and O
pyrimethamine B-drug
did O
not O
alter O
the O
adverse O
reaction O
profile O
. O

Coadministration O
of O
VIRACEPT B-brand
and O
drugs O
that O
induce O
CYP3A O
may O
decrease O
nelfinavir B-drug
plasma O
concentrations O
and O
reduce O
its O
therapeutic O
effect O
. O

CYP3A4 O
inhibitors O
: O
May O
increase O
the O
levels/effects O
of O
chlorpheniramine B-drug
. O

Results O
from O
human O
in O
vitro O
metabolism O
studies O
and O
nonclinical O
studies O
show O
that O
REVLIMID B-brand
( O
lenalidomide B-drug
) O
is O
neither O
metabolized O
by O
nor O
inhibits O
or O
induces O
the O
cytochrome O
P450 O
pathway O
suggesting O
that O
lenalidomide B-drug
is O
not O
likely O
to O
cause O
or O
be O
subject O
to O
P450-based O
metabolic O
drug O
interactions O
in O
man O
. O

The O
effects O
of O
ketamine B-drug
and O
of O
Innovar B-brand
anesthesia O
on O
digitalis B-group
tolerance O
in O
dogs O
. O

The O
potential O
effects O
of O
fulvestrant B-drug
on O
the O
fertility O
of O
male O
animals O
were O
not O
studied O
but O
in O
a O
6-month O
toxicology O
study O
, O
male O
rats O
treated O
with O
intramuscular O
doses O
of O
15 O
mg/kg/30 O
days O
, O
10 O
mg/rat/30 O
days O
, O
or O
10 O
mg/rat/15 O
days O
fulvestrant B-drug
showed O
a O
loss O
of O
spermatozoa O
from O
the O
seminiferous O
tubules O
, O
seminiferous O
tubular O
atrophy O
, O
and O
degenerative O
changes O
in O
the O
epididymides O
. O

Talk O
to O
your O
doctor O
and O
pharmacist O
before O
taking O
any O
prescription O
or O
over-the-counter O
medicines O
, O
including O
herbal O
products O
. O

If O
you O
are O
taking O
medications O
for O
migraines O
such O
as O
Imitrex B-brand
, O
talk O
to O
your O
doctor O
before O
starting O
this O
medicine O
. O

Consequently O
, O
it O
is O
recommended O
that O
fluvoxamine B-drug
not O
be O
used O
in O
combination O
with O
either O
terbinafine B-drug
, O
astemizole B-drug
, O
or O
cisapride B-drug
. O

In O
a O
similar O
study O
with O
tamsulosin B-drug
in O
healthy O
volunteers O
, O
1 O
of O
24 O
subjects O
dosed O
with O
Vardenafil B-drug
20 O
mg O
and O
tamsulosin B-drug
0.4 O
mg O
separated O
by O
6 O
hours O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

Doses O
of O
these O
and O
perhaps O
other O
medications O
may O
need O
to O
be O
adjusted O
in O
patients O
who O
successfully O
quit O
smoking O
. O

However O
, O
no O
related O
changes O
were O
noted O
in O
the O
QT0 O
on O
ECG O
taken O
at O
2 O
, O
6 O
, O
and O
24 O
hours O
after O
the O
coadministration O
. O

The O
effect O
of O
gabapentin B-drug
on O
cimetidine B-drug
was O
not O
evaluated O
. O

However O
, O
in O
clinical O
studies O
the O
consequences O
of O
concomitant O
irbesartan B-drug
on O
the O
pharmacodynamics O
of O
warfarin B-drug
were O
negligible O
. O

When O
patients O
have O
received O
such O
drugs O
, O
the O
dose O
of O
INAPSINE B-brand
required O
will O
be O
less O
than O
usual O
. O

Pyrantel B-drug
( O
e.g. O
, O
Antiminth B-drug
) O
- O
Taking O
piperazine B-drug
and O
pyrantel B-drug
together O
may O
decrease O
the O
effects O
of O
piperazine B-drug
. O

The O
clinical O
significance O
of O
this O
observation O
is O
unknown O
. O

The O
administrative O
arrangements O
in O
an O
area O
of O
Scotland O
were O
accompanied O
by O
a O
300 O
% O
increase O
in O
the O
frequency O
of O
admissions O
for O
mania O
, O
whereas O
in O
an O
area O
of O
the O
West O
Midlands O
, O
a O
large O
decrease O
was O
achieved O
. O

However O
, O
it O
should O
be O
noted O
that O
both O
products O
are O
capable O
of O
producing O
transient O
increases O
in O
blood O
pressure O
. O

Probenecid B-drug
given O
concurrently O
increases O
naproxen B-drug
anion O
plasma O
levels O
and O
extends O
its O
plasma O
half-life O
significantly O
. O

Concomitant O
administration O
of O
ketoconazole B-drug
tablets O
with O
phenytoin B-drug
may O
alter O
the O
metabolism O
of O
one O
or O
both O
of O
the O
drugs O
. O

Adrenergic B-group
blockers I-group
Adrenergic I-group
blockers I-group
are O
inhibited O
by O
amphetamines B-group
. O

Since O
there O
have O
been O
conflicting O
results O
regarding O
the O
effect O
of O
digoxin B-drug
levels O
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
diltiazem B-drug
hydrochloride I-drug
therapy O
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

However O
, O
caution O
must O
be O
exercised O
in O
extrapolating O
these O
findings O
to O
the O
clinical O
situation O
and O
in O
the O
use O
of O
glipizide B-drug
with O
these O
drugs O
. O

The O
daily O
dose O
of O
dexamethasone B-drug
administered O
in O
clinical O
studies O
with O
Aprepitant B-drug
reflects O
an O
approximate O
50 O
% O
reduction O
of O
the O
dose O
of O
dexamethasone B-drug
. O

During O
controlled O
hypotensive O
anesthesia O
using O
labetalol B-drug
HCl I-drug
in O
association O
with O
halothane B-drug
, O
high O
concentrations O
( O
3 O
% O
or O
above O
) O
of O
halothane B-drug
should O
not O
be O
used O
because O
the O
degree O
of O
hypotension O
will O
be O
increased O
and O
because O
of O
the O
possibility O
of O
a O
large O
reduction O
in O
cardiac O
output O
and O
an O
increase O
in O
central O
venous O
pressure O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

Formal O
drug O
interaction O
studies O
with O
Abciximab B-drug
have O
not O
been O
conducted O
. O

Bosentan B-drug
had O
no O
relevant O
inhibitory O
effect O
on O
any O
CYP O
isoenzymes O
tested O
( O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP3A4 O
) O
. O

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
frequently O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

indinavir I-drug
concentration O

- O
Lofexidine B-drug
may O
enhance O
the O
CNS O
depressive O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
and O
other O
sedatives B-group

When O
s.c O
. O

Population O
pharmacokinetic O
analyses O
revealed O
that O
MTX B-drug
, O
NSAIDs B-group
, O
corticosteroids B-group
, O
and O
TNF B-group
blocking I-group
agents I-group
did O
not O
influence O
abatacept B-drug
clearance O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Carcinogenesis O
PEGASYS B-brand
has O
not O
been O
tested O
for O
its O
carcinogenic O
potential O
. O

Alosetron B-drug
also O
does O
not O
appear O
to O
induce O
CYP O
enzymes O
2E1 O
or O
2C19 O
. O

There O
is O
now O
strong O
evidence O
that O
intensive O
control O
of O
blood O
glucose O
can O
significantly O
reduce O
and O
retard O
the O
microvascular O
complications O
of O
retinopathy O
, O
nephropathy O
, O
and O
neuropathy O
. O

20 O
mg O
result O
in O
incomplete O
depletion O
which O
becomes O
complete O
after O
a O
second O
additional O
dose O
. O

Excessive O
widening O
of O
the O
QRS O
complex O
and/or O
prolongation O
of O
the O
Q-T O
interval O
may O
occur O
in O
these O
situations O
. O

These O
effects O
of O
calcium B-group
blockers I-group
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
could O
contribute O
in O
part O
to O
their O
efficacy O
in O
patients O
with O
ischemic O
heart O
disease O
. O

Antithrombotics B-group

pruritus O

Lovastatin B-drug

Palytoxin B-drug_n
( O
PTX B-drug_n
) O
, O
C129H223N3O54 O
, O
isolated O
from O
marine O
coelenterates O
of O
Palythoa O
tuberculosa O
, O
caused O
a O
first O
rapid O
contraction O
followed O
by O
the O
slow O
phasic O
contraction O
of O
guinea-pig O
vas O
deferens O
. O

If O
TRANXENE B-brand
tablets O
are O
used O
to O
treat O
anxiety O
associated O
with O
somatic O
disease O
states O
, O
careful O
attention O
must O
be O
paid O
to O
possible O
drug O
interaction O
with O
concomitant O
medication O
. O

Cancer O
chemotherapy O

Drugs O
Within O
Class O
Not O
To O
Be O
Coadministered O
With O
SUSTIVA B-brand

Every O
other O
day O
dosing O
with O
100m O
g/kg O
( O
1200m O
g/m2 O
) O
PEGASYS B-brand
( O
equivalent O
to O
approximately O
30 O
times O
the O
recommended O
human O
dose O
) O
had O
no O
effects O
on O
cycle O
duration O
or O
reproductive O
hormone O
status O
. O

Symptoms O
resolved O
when O
clonidine B-drug
was O
withdrawn O
and O
recurred O
when O
the O
patient O
was O
rechallenged O
with O
clonidine B-drug
. O

Rearrangements O
of O
genomes O
have O
been O
found O
to O
accompany O
cellular O
aging O
. O

Anagrelide B-drug
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e.g O
. O
theophylline B-drug
. O


Cefuroxime B-drug
does O
not O
interfere O
with O
the O
assay O
of O
serum O
and O
urine O
creatinine O
by O
the O
alkaline O
picrate O
method O
. O

Because O
of O
the O
danger O
of O
a O
potentially O
fatal O
prolongation O
of O
the O
QTc O
interval O
, O
halofantrine B-drug
must O
not O
be O
given O
simultaneously O
with O
or O
subsequent O
to O
Mefloquine B-drug
. O

He O
was O
treated O
aggressively O
with O
intravenous O
hydration O
, O
sodium B-drug
bicarbonate I-drug
, O
and O
hemodialysis O
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

indinavir I-drug
concentration O

Since O
the O
pharmacokinetics O
of O
BUSULFEX B-brand
were O
studied O
in O
patients O
treated O
with O
phenytoin B-drug
, O
the O
clearance O
of O
BUSULFEX B-brand
at O
the O
recommended O
dose O
may O
be O
lower O
and O
exposure O
( O
AUC O
) O
higher O
in O
patients O
not O
treated O
with O
phenytoin B-drug
. O

Effects O
of O
Other O
Antiepileptic B-group
Drugs I-group
on O
Felbatol B-brand
Phenytoin B-drug
: O
Phenytoin B-drug
causes O
an O
approximate O
doubling O
of O
the O
clearance O
of O
Felbatol B-brand
( O
felbamate B-drug
) O
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
phenytoin B-drug
causes O
an O
approximate O
45 O
% O
decrease O
in O
the O
steady-state O
trough O
concentrations O
of O
Felbatol B-brand
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-brand
given O
as O
monotherapy O
. O

[ O
Pharmacologic O
interactions O
in O
chronic O
treatments O
: O
corrective O
measures O
for O
its O
prevention O
in O
a O
basic O
area O
of O
rural O
health O
] O
OBJECTIVES O
: O
To O
identify O
the O
pharmacological O
interactions O
of O
clinical O
relevance O
( O
PICR O
) O
in O
the O
medication O
authorization O
cards O
( O
MAC O
) O
of O
the O
chronically O
ill O
and O
to O
establish O
strategies O
to O
minimise O
their O
appearance O
. O

As O
a O
result O
, O
drugs O
that O
are O
metabolized O
by O
these O
enzyme O
systems O
may O
have O
lower O
than O
expected O
plasma O
levels O
when O
coadministered O
with O
nevirapine B-drug
. O

General O
: O
In O
humans O
, O
valdecoxib B-drug
metabolism O
is O
predominantly O
mediated O
via O
CYP O
3A4 O
and O
2C9 O
with O
glucuronidation O
being O
a O
further O
( O
20 O
% O
) O
route O
of O
metabolism O
. O

International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and/or O
bleeding O
events O
have O
been O
reported O
in O
some O
patients O
taking O
warfarin B-drug
while O
on O
IRESSA B-brand
therapy O
. O

There O
have O
been O
case O
reports O
of O
increased O
steady-state O
levels O
of O
quinidine B-drug
, O
procainamide B-drug
, O
and O
phenytoin B-drug
during O
concomitant O
therapy O
with O
amiodarone B-drug
. O

Since O
1988 O
, O
it O
has O
been O
noted O
that O
incidence O
of O
melarsoprol B-drug
reaction O
had O
increased O
systematically O
between O
June O
and O
October O
of O
each O
year O
, O
indicating O
strong O
seasonal O
variation O
. O

Treatment O
plans O
for O
patients O
taking O
anticoagulants B-group
can O
become O
complicated O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
CLINISTIX O
or O
TES-TAPE O
) O
be O
used O
. O

Saquinavir I-drug

There O
is O
no O
evidence O
in O
animal O
or O
human O
studies O
that O
TORADOL B-brand
induces O
or O
inhibits O
hepatic O
enzymes O
capable O
of O
metabolizing O
itself O
or O
other O
drugs O

Coadministration O
of O
propoxyphene B-drug
decreased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
6 O
% O
, O
decreased O
clearance O
by O
38 O
% O
, O
and O
increased O
half-life O
by O
58 O
% O
. O

No O
formal O
interaction O
studies O
have O
been O
performed O
. O

A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-group
, O
phenyl-butazone O
, O
phenytoin B-drug
sodium I-drug
, O
carbamazepine B-drug
and O
possibly O
with O
griseofulvin B-drug
, O
ampicillin B-drug
, O
and O
tetracyclines B-group
( O
72 O
) O

Pharmacokinetic O
interaction O
between O
single O
oral O
doses O
of O
diltiazem B-drug
and O
sirolimus B-drug
in O
healthy O
volunteers O
. O

Resveratrol B-drug_n
( O
5-35 O
micromol/l O
) O
induced O
concentration-dependent O
relaxation O
of O
mesenteric O
arteries O
preconstricted O
with O
noradrenaline B-drug
( O
8 O
micromol/l O
) O
or O
KCl B-drug
( O
125 O
mmol/l O
) O
from O
both O
lean O
and O
dietary-obese O
rats O
. O

When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
significantly O
reduced O
. O

Clinical O
studies O
have O
shown O
that O
atorvastatin B-drug
does O
not O
reduce O
basal O
plasma O
cortisol O
concentration O
or O
impair O
adrenal O
reserve O
. O

CNS-Active O
Drugs O
Ethanol B-drug
An O
additive O
effect O
on O
psychomotor O
performance O
was O
seen O
with O
coadministration O
of O
eszopiclone B-drug
and O
ethanol B-drug
0.70 O
g/kg O
for O
up O
to O
4 O
hours O
after O
ethanol B-drug
administration O
. O

In O
response O
to O
cocaine B-drug
, O
the O
locomotor O
activities O
of O
the O
SST O
were O
not O
significantly O
different O
from O
the O
RBC O
group O
. O

In O
previous O
reports O
we O
have O
shown O
that O
ginsenosides B-drug_n
inhibit O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
channels O
in O
neuronal O
cells O
. O

oxyphenbutazone B-drug
; O

The O
plasma O
concentrations O
of O
bosentan B-drug
were O
not O
affected O
. O

Hypoglycemics B-group
and O
endocrine O
drugs O
. O

Antiarrhythmics B-group
: O
Amiodarone B-drug
, O
bepridil B-drug
, O
flecainide B-drug
, O
propafenone B-drug
, O
quinidine B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
. O

H2-Receptor B-group
Antagonists I-group
: O
Co-administration O
of O
a O
single O
dose O
of O
intravenously O
administered O
famotidine B-drug
( O
20 O
mg O
) O
reduced O
the O
oral O
absorption O
of O
a O
single O
400 O
mg O
dose O
of O
cefditoren B-drug
pivoxil I-drug
administered O
following O
a O
meal O
, O
as O
evidenced O
by O
a O
27 O
% O
decrease O
in O
mean O
Cmax O
and O
a O
22 O
% O
decrease O
in O
mean O
AUC O
. O

Everolimus B-drug
exposure-response O
relationships O
between O
area O
under O
the O
blood O
concentration-time O
curve O
( O
AUC O
) O
and O
changes O
in O
platelets O
, O
leukocytes O
, O
and O
lipids O
were O
explored O
with O
the O
median-effect O
model O
. O

Thus O
, O
patients O
should O
be O
cautioned O
about O
the O
use O
of O
such O
drugs O
concurrently O
with O
LEXAPRO B-brand
. O

Oils O
may O
enhance O
absorption O
. O

Drugs O
Highly O
Bound O
To O
Plasma O
Protein O
Eszopiclone B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
52-59 O
% O
bound O
) O
; O

however O
, O
a O
comparison O
of O
fluvastatin B-drug
administration O
with O
the O
evening O
meal O
or O
at O
bedtime O
has O
revealed O
no O
significant O
differences O
in O
the O
extent O
of O
bioavailability O
( O
area O
under O
the O
curve O
) O
of O
these O
two O
regimens O
. O

Patients O
receiving O
catecholamine-depleting O
drugs O
, O
such O
as O
reserpine B-drug
or O
guanethidine B-drug
, O
should O
be O
closely O
monitored O
, O
because O
the O
added O
beta-adrenergic O
blocking O
action O
of O
ZEBETA B-brand
may O
produce O
excessive O
reduction O
of O
sympathetic O
activity O
. O

The O
benefits O
and O
risks O
of O
using O
TRICOR B-brand
with O
immunosuppressants B-group
and O
other O
potentially O
nephrotoxic O
agents O
should O
be O
carefully O
considered O
, O
and O
the O
lowest O
effective O
dose O
employed O

The O
16,16-dimethylprostaglandin B-drug_n
E2 I-drug_n
( O
dmPGE2 B-drug_n
) O
-induced O
diarrhea O
was O
analyzed O
in O
cecectomized O
rats O
prepared O
by O
resecting O
the O
cecum O
and O
its O
vasculature O
without O
disturbing O
the O
ileocecal O
junction O
. O

In O
vitro O
studies O
in O
human O
liver O
microsomes O
suggest O
that O
decitabine B-drug
is O
unlikely O
to O
inhibit O
or O
induce O
cytochrome O
P450 O
enzymes O
. O

In O
one O
controlled O
study O
of O
175 O
patients O
, O
transient O
drowsiness O
was O
observed O
in O
63 O
% O
of O
those O
receiving O
baclofen B-drug
tablets O
compared O
to O
36 O
% O
of O
those O
in O
the O
placebo O
group O
. O

HMG-CoA B-drug
Reductase I-drug
Inhibitors I-drug
: O
Simvastatin B-drug
( O
CYP3A4 B-drug
substrate O
) O
in O
combination O
with O
amiodarone B-drug
has O
been O
associated O
with O
reports O
of O
myopathy/rhabdomyolysis O
. O

The O
majority O
of O
patients O
in O
rheumatoid O
arthritis O
or O
Crohn O
s O
disease O
clinical O
studies O
received O
one O
or O
more O
concomitant O
medications O
. O

Danazol B-drug
: O
The O
risk O
of O
myopathy/rhabdomyolysis O
is O
increased O
by O
concomitant O
administration O
of O
danazol B-drug
particularly O
with O
higher O
doses O
of O
lovastatin B-drug
( O
see O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
) O
. O

one-half O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O

Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta-blocker B-group
is O
administered O
to O
patients O
receiving O
catecholamine-depleting O
drugs O
such O
as O
reserpine B-drug
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and/or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

These O
findings O
suggest O
that O
the O
phenotype O
of O
a O
tumor O
that O
results O
from O
a O
pulse O
of O
a O
chemical O
carcinogen O
may O
depend O
upon O
the O
target O
cell O
. O

Ergot B-group
Derivatives I-group
: O
Dihydroergotamine B-drug
, O
ergonovine B-drug
, O
ergotamine B-drug
, O
methylergonovine B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
life-threatening O
reactions O
such O
as O
acute O
ergot B-group
toxicity O
characterized O
by O
peripheral O
vasospasm O
and O
ischemia O
of O
the O
extremities O
and O
other O
tissues O
. O

Measurement O
of O
nociception O
was O
performed O
within O
2 O
h O
after O
benzodiazepine B-group
administration O
. O

Epirubicin B-drug
is O
extensively O
metabolized O
by O
the O
liver O
. O

After O
consumption O
of O
alcohol B-drug
, O
at O
least O
36 O
hours O
should O
elapse O
before O
these O
determinations O
are O
made O
. O

If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-group
, O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
for O
at O
least O
two O
hours O
and O
until O
blood O
pressure O
has O
stabilized O
for O
at O
least O
an O
additional O
hour.. O


The O
magnitude O
of O
these O
effects O
may O
depend O
on O
the O
duration O
of O
administration O
of O
the O
volatile O
agents O
. O

Phenytoin B-drug
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenytoin B-drug
with O
or O
without O
other O
enzyme- O
inducing O
AEDs B-group
. O

In O
addition O
, O
we O
have O
shown O
that O
RR B-drug_n
is O
a O
useful O
pharmacological O
tool O
with O
which O
to O
examine O
the O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-mediated O
responses O
of O
megakaryocytes O
. O

Conversely O
, O
the O
administration O
of O
STADOL B-brand
NS I-brand
( O
1 O
mg O
butorphanol B-drug
QID O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
a O
300-mg O
dose O
of O
cimetidine B-drug
. O

Rifabutin B-drug

The O
clinical O
effects O
of O
this O
combination O
have O
not O
been O
studied O
. O

No O
drug O
interactions O
have O
been O
reported O
. O

The O
next O
chapter O
presents O
information O
on O
efficacy O
and O
pregnancy O
outcomes O
in O
terms O
of O
pregnancy O
rates O
, O
compliance O
and O
efficacy O
, O
ectopic O
pregnancies O
, O
the O
outcome O
of O
pregnancies O
conceived O
while O
using O
POCs B-group
, O
and O
fertility O
following O
discontinuation O
. O

Interactions O
between O
Betaseron B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

There O
have O
been O
no O
reported O
cases O
from O
spontaneous O
reports O
of O
drug O
interaction O
between O
SSRIs B-group
and O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
. O

increased O
bilirubin O

A O
small O
number O
of O
patients O
received O
epirubicin-based B-drug
chemotherapy O
concomitantly O
with O
radiation O
therapy O
but O
had O
chemotherapy O
interrupted O
in O
order O
to O
avoid O
potential O
overlapping O
toxicities O
. O

Laboratory O
Test O
In O
clinical O
trials O
, O
no O
clinically O
relevant O
laboratory O
test O
abnormalities O
were O
identified O
as O
causally O
related O
to O
drug O
during O
short-term O
treatment O
with O
guanfacine B-drug
. O

These O
reactions O
consisted O
of O
erythema O
, O
pruritus O
, O
and O
hypotension O
and O
occurred O
within O
hours O
of O
administration O
of O
chemotherapy O
. O

Although O
much O
statistical O
work O
has O
focused O
on O
developing O
mathematical O
functions O
to O
model O
the O
joint O
dose-response O
curves O
, O
relatively O
little O
work O
exists O
in O
regard O
to O
designing O
experiments O
for O
assessing O
joint O
action O
. O

PEGASYS B-brand
is O
recommended O
for O
use O
in O
women O
of O
childbearing O
potential O
only O
when O
they O
are O
using O
effective O
contraception O
during O
therapy O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

Lithium B-drug
carbonate I-drug
( O
450 O
mg O
BID O
for O
7 O
days O
) O
had O
no O
effect O
on O
valdecoxib B-drug
pharmacokinetics O
. O

Lithium B-drug
salts O

therefore O
, O
these O
combinations O
should O
be O
used O
with O
caution O
. O

Phenobarbital B-drug

Vasospastic O
reactions O
have O
been O
reported O
with O
therapeutic O
doses O
of O
ergotamine-containing B-drug
drugs O
when O
co-administered O
with O
these O
antibiotics B-group
. O

Apparent O
oral O
clearance O
and O
volume O
of O
distribution O
of O
sirolimus B-drug
decreased O
with O
38 O
% O
and O
45 O
% O
, O
respectively O
, O
when O
sirolimus B-drug
was O
given O
with O
diltiazem B-drug
. O

The O
interaction O
of O
prostaglandin B-drug
F2alpha I-drug
and O
synthetic O
oxytocin B-drug
on O
placental O
vessels O
was O
studied O
in O
vitro O
. O

Urinary O
alkalinizing O
agents O
increase O
blood O
levels O
and O
decrease O
excretion O
of O
amphetamines B-group
. O

( O
500 O
mg O
day O
1 O
, O
250 O
mg O
QD O
4 O
days O
) O

METHODS O
: O
Hydrocortisone B-drug
( O
100 O
mg O
) O
and O
d-amphetamine B-drug
( O
20 O
mg O
) O
were O
administered O
orally O
to O
16 O
healthy O
male O
and O
female O
volunteers O
in O
a O
four-session O
, O
placebo-controlled O
, O
within-subject O
, O
crossover O
design O
. O

The O
world O
medical O
literature O
contains O
43 O
reports O
of O
deaths O
associated O
with O
amphetamines B-drug
in O
a O
35-year O
period O
. O

Cardiovasculars O
: O
Cardiac B-drug
glycosides I-drug
: O
In O
patients O
receiving O
digoxin B-drug
therapy O
, O
administration O
of O
oral O
amiodarone B-drug
regularly O
results O
in O
an O
increase O
in O
serum O
digoxin B-drug
concentration O
that O
may O
reach O
toxic O
levels O
with O
resultant O
clinical O
toxicity O
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

New O
oral O
therapies O
for O
type O
2 O
diabetes O
mellitus O
: O
The O
glitazones B-group
or O
insulin O
sensitizers O
. O

CONCLUSIONS O
: O
In O
contrast O
to O
the O
effects O
of O
glucocorticoids B-group
in O
rodent O
studies O
, O
these O
results O
indicate O
that O
an O
acute O
increase O
in O
cortisol O
does O
not O
enhance O
the O
psychostimulant O
effects O
of O
d-amphetamine B-drug
in O
humans O
. O

In O
addition O
, O
ketoconazole B-drug
alone O
can O
inhibit O
adrenal O
corticosteroid B-drug
synthesis O
and O
may O
cause O
adrenal O
insufficiency O
during O
corticosteroid O
withdrawal O
. O

Aspirin B-brand
: O
Concomitant O
administration O
of O
diclofenac B-drug
and O
aspirin B-brand
is O
not O
recommended O
because O
diclofenac B-drug
is O
displaced O
from O
its O
binding O
sites O
during O
the O
concomitant O
administration O
of O
aspirin B-brand
, O
resulting O
in O
lower O
plasma O
concentrations O
, O
peak O
plasma O
levels O
, O
and O
AUC O
values O
. O

The O
clearance O
of O
benzodiazepines B-group
metabolized O
by O
glucuronidation O
( O
e. O
g. O
, O
lorazepam B-drug
, O
oxazepam B-drug
, O
temazepam B-drug
) O
is O
unlikely O
to O
be O
affected O
by O
fluvoxamine B-drug
. O

The O
pharmacokinetics O
of O
benzodiazepines B-group
are O
unaltered O
in O
the O
presence O
of O
flumazenil B-drug
and O
vice O
versa O
. O

however O
, O
the O
clinical O
significance O
is O
unknown O
. O

Other O
: O
Neither O
fosinopril B-drug
sodium I-drug
nor O
its O
metabolites O
have O
been O
found O
to O
interact O
with O
food O
. O

On O
the O
basis O
of O
this O
specificity O
we O
describe O
a O
simple O
and O
reliable O
affinity O
chromatography O
procedure O
for O
the O
purification O
of O
both O
human O
serum O
and O
colostrum O
IgA O
. O

and O
disulfiram B-drug
When O
amitriptyline B-drug
HCl I-drug
is O
given O
with O
anticholinergic B-drug
agents O
or O
sympathomimetic B-drug
drugs O
, O
including O
epinephrine B-drug
combined O
with O
local O
anesthetics B-drug
, O
close O
supervision O
and O
careful O
adjustment O
of O
dosages O
are O
required O
. O

Rifabutin B-drug
: O
Coadministration O
of O
rifabutin B-drug
and O
VIRACEPT B-brand
resulted O
in O
a O
32 O
% O
decrease O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
207 O
% O
increase O
in O
rifabutin B-drug
plasma O
A.C O
. O

while O
no O
formal O
interaction O
studies O
have O
been O
conducted O
, O
no O
interactions O
were O
observed O
. O


Food O
has O
no O
clinically O
significant O
effect O
on O
the O
bioavailability O
of O
anagrelide B-drug
. O

Although O
no O
studies O
have O
been O
conducted O
, O
concomitant O
administration O
of O
Itraconazole B-drug
and O
phenytoin B-drug
may O
alter O
the O
metabolism O
of O
phenytoin B-drug
; O

Established O
Drug O
Interactions O
( O
continued O
) O

Potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
potassium-containing B-drug
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O

This O
observed O
increase O
in O
the O
bioavailability O
of O
fexofenadine B-drug
may O
be O
due O
to O
transport-related O
effects O
, O
such O
as O
p-glycoprotein O
. O
in O
vivo O
animal O
studies O
also O
suggest O
that O
in O
addition O
to O
enhancing O
absorption O
, O
ketoconazole B-drug
decreases O
fexofenadine B-drug
gastrointestinal O
secretion O
, O
while O
erythromycin B-drug
may O
also O
decrease O
biliary O
excretion O
. O

No O
pharmacokinetic O
drug-drug O
interaction O
studies O
were O
conducted O
with O
PERSANTINE B-brand
( O
dipyridamole B-drug
USP O
) O
Tablets O
. O

There O
is O
no O
experience O
with O
co-administration O
of O
Angiomax B-brand
and O
plasma O
expanders O
such O
as O
dextran B-drug
. O

On O
the O
ninth O
day O
, O
the O
rats O
were O
sacrificed O
and O
aortic O
rings O
, O
with O
or O
without O
endothelium O
, O
were O
used O
to O
generate O
concentration-response O
curves O
to O
noradrenaline B-drug
. O

At O
stable O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
concentrations O
greater O
than O
1 O
mM O
, O
fractional O
mucosal O
cell O
accumulation O
of O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
remains O
constant O
, O
while O
fractional O
transfer O
to O
the O
body O
declines O
. O

Although O
there O
is O
little O
published O
information O
on O
concomitant O
administration O
of O
lidocaine B-drug
and O
Bretylium B-drug
Tosylate I-drug
, O
these O
drugs O
are O
often O
administered O
concurrently O
without O
any O
evidence O
of O
interactions O
resulting O
in O
adverse O
effects O
or O
diminished O
efficacy O
. O

Plenaxis B-brand
is O
highly O
bound O
to O
plasma O
proteins O
( O
96 O
to O
99 O
% O
) O
. O

The O
concurrent O
use O
of O
tetracycline B-drug
and O
Penthrane B-brand
( O
methoxyflurane B-drug
) O
has O
been O
reported O
to O
result O
in O
fatal O
renal O
toxicity O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
and O
aminoglycoside B-group
antibiotics I-group
. O

with O
divalent O
or O
trivalent O
cations O
such O
as O
iron B-drug
; O

Patients O
response O
to O
oral O
anticoagulants B-group
may O
be O
affected O
by O
his/her O
thyroid O
and O
metabolic O
status O
. O

However O
, O
the O
relationship O
to O
nifedipine B-drug
therapy O
is O
uncertain O
. O

Cimetidine B-drug
increased O
AUC O
by O
about O
30 O
% O
but O
caused O
no O
change O
in O
Cmax O
. O

Clinically O
significant O
QTc O
prolongation O
has O
not O
been O
found O
with O
Mefloquineuine O
alone O
. O

Acute O
effect O
of O
different O
antidepressants B-group
on O
glycemia O
in O
diabetic O
and O
non-diabetic O
rats O
. O

In O
a O
separate O
study O
, O
baboons O
given O
3 O
doses O
of O
alefacept B-drug
at O
1 O
mg/kg O
every O
8 O
weeks O
were O
found O
to O
have O
centroblast O
proliferation O
in O
B-cell O
dependent O
areas O
in O
the O
germinal O
centers O
of O
the O
spleen O
following O
a O
116-day O
washout O
period O
. O

Nevirapine I-drug

Although O
there O
was O
no O
effect O
of O
Aprepitant B-drug
on O
the O
plasma O
AUC O
of O
R O
( O
+ O
) O
or O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
determined O
on O
Day B-drug
3 I-drug
, I-drug
there O
was O
a O
34 O
% O
decrease O
in O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
( O
a O
CYP2C9 O
substrate O
) O
trough O
concentration O
accompanied O
by O
a O
14 O
% O
decrease O
in O
the O
prothrombin O
time O
( O
reported O
as O
International O
Normalized O
Ratio O
or O
INR O
) O
5 O
days O
after O
completion O
of O
dosing O
with O
Aprepitant B-drug
. O

influenza B-group
virus I-group
vaccine I-group
; O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
a O
prolongation O
of O
its O
plasma O
half-life O
. O

Naproxen B-drug
and O
other O
NSAIDs B-group
can O
reduce O
the O
antihypertensive O
effect O
of O
propranolol B-drug
and O
other O
beta-blockers B-group
. O

Routine O
monitoring O
should O
be O
performed O
when O
therapy O
with O
BEXTRA B-brand
is O
either O
initiated O
or O
discontinued O
in O
patients O
on O
anticonvulsant O
therapy O
. O

These O
cephalosporins B-group
are O
inhibitors O
of O
hepatic O
vitamin O
K O
epoxide O
reductase O
. O

CONCLUSION O
: O
Fluvoxamine B-drug
is O
a O
moderate O
inhibitor O
of O
CYP2C9 O
in O
vivo O
. O

Calcium B-drug
, O
particularly O
if O
administered O
rapidly O
by O
the O
intravenous O
route O
, O
may O
produce O
serious O
arrhythmias O
in O
digitalized O
patients O
. O

Dextromethorphan B-drug
: O
Dextromethorphan B-drug
is O
primarily O
metabolized O
by O
CYP O
2D6 O
and O
to O
a O
lesser O
extent O
by O
3A4 O
. O

Didanosine B-drug

However O
, O
preliminary O
results O
from O
an O
8-week O
trial O
showed O
comparable O
cognitive O
enhancing O
effects O
of O
olanzapine B-drug
and O
risperidone B-drug
treatment O
in O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
. O

The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
ifosfamide B-drug
even O
though O
ifosfamide B-drug
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O

Population O
pharmacokinetic O
studies O
showed O
higher O
concentrations O
of O
cilostazol B-drug
among O
patients O
concurrently O
treated O
with O
diltiazem B-drug
, O
an O
inhibitor O
of O
C.P.A.. O

Lithium B-drug
: O
generally O
should O
not O
be O
given O
with O
diuretics B-group
. O

Antihistamines B-group
: O
Benzodiazepines B-group
GI O
Motility O
Agents O
Anti-Migraine B-group
Antifungal I-group

Cimetidine B-drug
treatment O
should O
be O
stopped O
during O
treatment O
with O
ELLENCE B-brand
. O

Propoxyphene B-drug
: O
The O
concurrent O
administration O
of O
propoxyphene B-drug
hydrochloride I-drug
does O
not O
affect O
the O
bioavailability O
of O
meclofenamate B-drug
sodium I-drug
. O

Alcohol B-drug
, O
barbiturates B-group
, O
or O
narcotics B-group
: O
potentiation O
of O
orthostatic O
hypotension O
may O
occur O
. O

. O

The O
120 O
mg/kg O
dose O
resulted O
in O
a O
systemic O
exposure O
approximately O
16 O
times O
the O
human O
plasma O
area-under-the-curve O
( O
AUC O
, O
0-24 O
hours O
) O
based O
on O
the O
maximum O
human O
dose O
of O
80 O
mg/day O
. O

This O
should O
be O
considered O
whenever O
these O
agents O
are O
prescribed O
concomitantly O
. O

Effect O
of O
rofecoxib B-drug
on O
the O
pharmacokinetics O
of O
digoxin B-drug
in O
healthy O
volunteers O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
renal O
excretion O
of O
loracarbef B-drug
is O
inhibited O
by O
probenecid B-drug
and O
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
the O
AUC O
for O
loracarbef B-drug
. O

Plasma O
exposure O
( O
AUC O
) O
to O
valdecoxib B-drug
was O
increased O
62 O
% O
when O
coadministered O
with O
fluconazole B-drug
and O
38 O
% O
when O
coadministered O
with O
ketoconazole B-drug
. O

Cyclosporine B-drug

vardenafil I-drug
concentration O

Interaction O
with O
central B-group
nervous I-group
system I-group
depressants I-group
other O
than O
benzodiazepines B-group
has O
not O
been O
specifically O
studied O
; O

Ketoconazole B-drug
did O
not O
affect O
the O
conversion O
of O
losartan B-drug
to O
the O
active O
metabolite O
after O
intravenous O
administration O
of O
losartan B-drug
, O
and O
erythromycin B-drug
had O
no O
clinically O
significant O
effect O
after O
oral O
administration O
. O

Antidepressants B-group
, O
tricyclic B-group
: O
Amphetamines B-group
may O
enhance O
the O
activity O
of O
tricyclic B-group
or O
sympathomimetic B-group
agents I-group
; O

Anagrelide B-drug
alone O
had O
no O
effect O
on O
platelet O
aggregation O
, O
but O
did O
slightly O
enhance O
the O
inhibition O
of O
platelet O
aggregation O
by O
aspirin B-brand
. O

Substantial O
intercurrent O
ethanol B-drug
use O
was O
present O
in O
each O
of O
these O
cases O
, O
and O
this O
may O
have O
contributed O
to O
the O
abnormalities O
seen O
. O

Therefore O
, O
concurrent O
use O
of O
aspirin B-brand
and O
ketoprofen B-drug
is O
not O
recommended O
. O

Tablets O
: O
The O
benzodiazepines B-group
, O
including O
lorazepam B-drug
, O
produce O
CNS-depressant O
effects O
when O
administered O
with O
such O
medications O
as O
barbiturates B-group
or O
alcohol B-drug
. O

The O
first O
test O
is O
obtained O
by O
the O
prescriber O
when O
the O
decision O
is O
made O
to O
pursue O
qualification O
of O
the O
patient O
for O
Accutane B-brand
( O
a O
screening O
test O
) O
. O

High O
oral O
magnesium B-drug
doses O
besides O
their O
laxative O
action O
may O
bring O
latent O
complications O
which O
may O
reduce O
lifespan O
. O

phenylbutazone B-drug
; O

Drug/Laboratory O
Test O
Interaction O
Because O
Xigris B-brand
may O
affect O
the O
APTT O
assay O
, O
Xigris B-brand
present O
in O
plasma O
samples O
may O
interfere O
with O
one-stage O
coagulation O
assays O
based O
on O
the O
APTT O
( O
such O
as O
factor O
VIII O
, O
IX O
, O
and O
XI O
assays O
) O
. O

Methenamine B-drug
therapy O
: O
Urinary O
excretion O
of O
amphetamines B-group
is O
increased O
, O
and O
efficacy O
is O
reduced O
, O
by O
acidifying B-group
agents I-group
used O
in O
methenamine B-drug
therapy O
. O

Rifampin B-drug
: O
Rifampin B-drug
increases O
the O
metabolism O
of O
ethinyl B-drug
estradiol I-drug
and O
some O
progestins B-group
( O
norethindrone B-drug
) O
resulting O
in O
decreased O
contraceptive O
effectiveness O
and O
increased O
menstrual O
irregularities O
. O

Potentiation O
of O
coumarin-type B-group
anticoagulants I-group
has O
been O
observed O
with O
prolongation O
of O
the O
prothrombin O
time/INR O
. O

Further O
, O
misoprostol B-drug
is O
reported O
to O
have O
a O
synergistic O
effect O
with O
this O
combination O
in O
ameliorating O
intestinal O
permeability O
. O

Phenothiazines B-group
- O
Taking O
piperazine B-drug
and O
a O
phenothiazine B-group
together O
may O
increase O
the O
risk O
of O
convulsions O
( O
seizures O
) O
. O

However O
, O
cohort O
data O
and O
selected O
patient O
data O
from O
clinical O
trials O
suggest O
comparable O
activity O
to O
PI-based B-group
regimens O
in O
these O
patients O
. O

Dicumarol B-drug
: O
It O
has O
been O
reported O
that O
allopurinol B-drug
prolongs O
the O
half-life O
of O
the O
anticoagulant B-group
, O
dicumarol B-drug
. O

Aspirin B-brand
: O
Concomitant O
administration O
of O
aspirin B-brand
with O
valdecoxib B-drug
may O
result O
in O
an O
increased O
risk O
of O
GI O
ulceration O
and O
complications O
compared O
to O
valdecoxib B-drug
alone O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
the O
changes O
in O
the O
Kd O
of O
D2 O
in O
the O
NAC O
and O
the O
Bmax O
of O
D2 O
in O
the O
STR O
may O
contribute O
to O
the O
differences O
in O
locomotor O
responses O
to O
cocaine B-drug
exposure O
in O
these O
mouse O
lines O
. O

Barbiturates B-group
may O
decrease O
the O
effectiveness O
of O
oral O
contraceptives B-group
, O
certain O
antibiotics B-group
, O
quinidine B-drug
, O
theophylline B-drug
, O
corticosteroids B-group
, O
anticoagulants B-group
, O
and O
beta B-group
blockers I-group
. O

Glucose B-drug
, O
alone O
and O
in O
the O
presence O
of O
theophylline B-drug
, O
caused O
subnormal O
insulin O
release O
and O
less O
suppression O
of O
glucagon O
release O
in O
the O
diabectics O
than O
in O
the O
normals O
. O

Nucleophosmin/B23 O
in O
serum-deprived O
( O
0 O
% O
serum O
) O
NIH-3T3 O
cells O
was O
found O
to O
be O
highly O
unstable O
with O
a O
half-life O
less O
than O
4 O
h O
. O

Although O
deferasirox B-drug
has O
a O
lower O
affinity O
for O
aluminum B-drug
than O
for O
iron B-drug
, O
Exjade B-brand
should O
not O
be O
taken O
with O
aluminum-containing B-drug
antacid B-group
preparations I-group
. O

However O
, O
under O
certain O
circumstances O
, O
e.g. O
, O
as O
prophylaxis O
after O
myocardial O
infarction O
, O
there O
may O
be O
no O
acceptable O
alternatives O
to O
the O
use O
of O
beta-blockers B-group
in O
patients O
with O
COPD O
. O

Concomitant O
use O
of O
clozapine B-drug
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
clozapine B-drug
or O
the O
other O
drug O
. O

increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Digoxin B-drug
: O
Digoxin B-drug
concentrations O
are O
increased O
by O
about O
15 O
% O
when O
digoxin B-drug
and O
carvedilol B-drug
are O
administered O
concomitantly O
. O

This O
drug O
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

Patients O
receiving O
both O
drugs O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and/or O
antihypertensive O
effect O
of O
furosemide B-drug
is O
achieved O
. O

Patients O
should O
not O
be O
re-treated O
with O
subsequent O
cycles O
of O
TAXOL B-brand
until O
neutrophils O
recover O
to O
a O
level O
1500 O
cells/mm3 O
and O
platelets O
recover O
to O
a O
level O
100,000 O
cells/mm3 O
. O

Anabolic B-group
steroids I-group
( O
particularly O
C-17 O
alkylated O
androgens B-group
such O
as O
oxymetholone B-drug
, O
methandrostenolone B-drug
, O
norethandrolone B-drug
, O
and O
similar O
compounds O
) O
enhanced O
tendency O
toward O
edema O
. O

Physicians O
are O
provided O
this O
information O
to O
increase O
awareness O
of O
the O
potential O
for O
serious O
interactions O
when O
cinoxacin B-drug
and O
certain O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
are O
administered O
concomitantly O
. O

Furthermore O
, O
no O
significant O
difference O
in O
pharmacodynamic O
effect O
( O
reduction O
in O
low-density O
lipoprotein O
cholesterol O
levels O
) O
could O
be O
ascertained O
between O
mealtime O
dosing O
and O
bedtime O
dosing O
. O

5 O
. O

In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-group
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-drug
requirements O
. O

The O
incidence O
of O
hypertriglyceridemia O
is O
1 O
patient O
in O
4 O
on O
Accutane B-brand
therapy O

Dexamethasone B-drug
and O
retinyl B-drug
acetate I-drug
similarly O
inhibit O
and O
stimulate O
EGF- B-drug_n
or O
insulin-induced B-drug
proliferation O
of O
prostatic O
epithelium O
. O

Cold O
and O
flu O
remedies O
. O

Diflunisal B-drug
decreased O
the O
hyperuricemic O
effect O
of O
furosemide B-drug
. O

No O
other O
pharmacokinetic O
parameters O
were O
changed O
. O

Use O
of O
Antithrombotics B-group
Aspirin B-brand
and O
heparin B-drug
have O
been O
administered O
concomitantly O
with O
and O
following O
infusions O
of O
Activase B-brand
in O
the O
management O
of O
acute O
myocardial O
infarction O
or O
pulmonary O
embolism O
. O

The O
results O
from O
a O
study O
in O
which O
eight O
HIV-infected O
individuals O
were O
treated O
with O
zidovudine B-drug
, O
8 O
+/- O
0.4 O
mg/kg/day O
, O
showed O
that O
the O
pharmacokinetics O
of O
zidovudine B-drug
were O
not O
affected O
during O
concomitant O
administration O
of O
Itraconazole B-drug
, O
100 O
mg O
b.i.d O
. O

The O
concomitant O
administration O
of O
quinolones B-group
including O
norfloxacin B-drug
with O
glyburide B-drug
( O
a O
sulfonylurea B-group
agent I-group
) O
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O

Phenytoin B-drug
may O
also O
cause O
increased O
serum O
concentrations O
of O
glucose O
, O
alkaline O
phosphatase O
, O
and O
gamma O
glutamyl O
transpeptidase O
( O
GGT O
) O
. O

The O
risk O
of O
metabolic O
interactions O
caused O
by O
an O
effect O
on O
an O
individual O
isoform O
is O
therefore O
minimized O
. O

" O
hippocampal-independent O
" O


Repeated O
doses O
of O
colestipol B-drug
hydrochloride I-drug
given O
prior O
to O
a O
single O
dose O
of O
propranolol B-drug
in O
human O
trials O
have O
been O
reported O
to O
decrease O
propranolol B-drug
absorption O
. O

Acetaminophen B-drug
and O
methotrexate B-drug
- O
L-methionine B-drug
may O
decrease O
hepatic O
toxicity O
in O
those O
with O
acetaminophen B-drug
overdosage O
or O
in O
those O
taking O
methotrexate B-drug
. O

Cholestyramine B-drug
and O
Charcoal B-drug
Administration O
of O
cholestyramine B-drug
or O
activated B-drug
charcoal I-drug
in O
patients O
( O
n=13 O
) O
and O
volunteers O
( O
n=96 O
) O
resulted O
in O
a O
rapid O
and O
significant O
decrease O
in O
plasma O
M1 O
( O
the O
active O
metabolite O
of O
leflunomide B-drug
) O
concentration O
. O

In O
some O
patients O
, O
combined O
use O
of O
INDOCIN B-brand
and O
diflunisal B-drug
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O

- O
Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
may O
reduce O
the O
efficacy O
of O
lofexidine B-drug
. O

Furosemide B-drug
may O
add O
to O
or O
potentiate O
the O
therapeutic O
effect O
of O
other O
antihypertensive B-group
drugs I-group
. O

dosage O
adjustments O
may O
be O
necessary O
. O
) O

Synergism O
was O
observed O
when O
GL B-drug_n
was O
combined O
with O
cefazolin B-drug
against O
Bacillus O
subtilis O
and O
Klebsiella O
oxytoca O
. O

Etonogestrel B-drug
may O
interact O
with O
the O
following O
medications O
: O
acetaminophen B-drug
( O
Tylenol B-brand
) O
, O
antibiotics B-group
such O
as O
ampicillin B-drug
and O
tetracycline B-drug
, O
anticonvulsants B-group
( O
Dilantin B-brand
, O
Phenobarbital B-drug
, O
Tegretol B-brand
, O
Trileptal B-brand
, O
Topamax B-brand
, O
Felbatol B-brand
) O
, O
antifungals B-group
( O
Gris-PEG B-brand
, O
Nizoral B-brand
, O
Sporanox B-brand
) O
, O
atorvastatin B-drug
( O
Lipitor B-brand
) O
, O
clofibrate B-drug
( O
Atromid-S B-brand
) O
, O
cyclosporine B-drug
( O
Neoral B-brand
, O
Sandimmune B-brand
) O
, O
HIV O
drugs O
classified O
as O
protease B-group
inhibitors I-group
( O
Agenerase B-brand
, O
Crixivan B-brand
, O
Fortovase B-brand
, O
Invirase B-brand
, O
Kaletra B-brand
, O
Norvir B-brand
, O
Viracept B-brand
) O
, O
morphine B-drug
( O
Astramorph B-brand
, O
Kadian B-brand
, O
MS B-brand
Contin I-brand
) O
, O
phenylbutazone B-drug
, O
prednisolone B-drug
( O
Prelone B-brand
) O
, O
rifadin B-brand
( O
rifampin B-drug
) O
, O
St. O
Johns O
wort O
, O
temazepam B-drug
, O
theophylline B-drug
( O
Theo-Dur B-brand
) O
, O
and O
vitamin B-drug
C I-drug
. O

The O
three O
study O
periods O
were O
separated O
by O
a O
21-day O
washout O
phase O
. O

Nephrotoxic O
agents O
: O
Concomitant O
administration O
of O
VISTIDE B-brand
and O
agents O
with O
nephrotoxic O
potential O
[ O
e.g. O
, O
intravenous O
aminoglycosides B-group
( O
e.g. O
, O
tobramycin B-drug
, O
gentamicin B-drug
, O
and O
amikacin B-drug
) O
, O
amphotericin B-drug
B I-drug
, O
foscarnet B-drug
, O
intravenous O
pentamidine B-drug
, O
vancomycin B-drug
, O
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
] O
is O
contraindicated O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
aluminum O
and O
magnesium B-drug
hydroxides O
does O
not O
interfere O
with O
absorption B-drug
of O
meclofenamate B-drug
sodium I-drug
. O

Tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
drugs O
: O
blood B-group
thinners O
( O
Coumadin B-brand
) O
other O
antidepressants B-group
metoprolol B-drug
antihistamines B-group
carbamazepine B-drug
( O
Tegretol B-brand
) O
cimetidine B-drug
( O
Tagamet B-brand
) O
estrogens B-group
fluoxetine B-drug
( O
Prozac B-brand
) O
intraconazole O
( O
Sporanox B-brand
) O
ketoconazole B-drug
( O
Nizoral B-brand
) O
levodopa B-drug
lithium I-drug
muscle B-group
relaxants I-group
birth O
control O
pills O
sleeping O
pills O
thyroid O
medications O

and/or O
Drug/Laboratory O
Test O
Interactions O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Drug O
Interactions O
. O

Furosemide B-drug
should O
not O
be O
used O
concomitantly O
with O
ethacrynic B-drug
acid I-drug
because O
of O
the O
possibility O
of O
ototoxicity O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues I-group
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

A O
variety O
of O
neurological O
toxic O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O

No O
information O
is O
available O
about O
the O
interaction O
of O
cephalexin B-drug
and O
metformin B-drug
following O
multiple O
doses O
of O
either O
drug O
. O

The O
groups O
then O
took O
500 O
mg O
of O
tolbutamide B-drug
as O
a O
single O
dose O
( O
day O
0 O
) O
. O

Indinavir B-drug

When O
other O
potent O
parental O
antihypertensive B-group
drugs I-group
, O
such O
as O
diazoxide B-drug
, O
are O
used O
in O
combination O
with O
hydralazine B-drug
, O
patients O
should O
be O
continuously O
observed O
for O
several O
hours O
for O
any O
excessive O
fall O
in O
blood O
pressure O
. O

Agents O
Increasing O
Serum O
Potassium O
: O
PRINIVIL B-brand
attenuates O
potassium O
loss O
caused O
by O
thiazide-type B-group
diuretics I-group
. O

Effects O
were O
already O
seen O
with O
doses O
corresponding O
to O
relevant O
plasma O
levels O
in O
humans O
, O
and O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-drug
to O
its O
three O
metabolites O
( O
including O
the O
active O
zalcitabine O
triphosphate O
metabolite O
) O
was O
significantly O
inhibited O
. O

In O
the O
large O
, O
placebo-controlled O
osteoporosis O
Treatment O
Study O
, O
aspirin B-brand
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
were O
taken O
by O
62 O
% O
of O
the O
2946 O
patients O
. O

Certain O
drugs O
including O
thiazides B-group
, O
corticosteroids B-group
, O
thyroid B-group
products I-group
, O
and O
sympathomimetics B-group
may O
reduce O
the O
hypoglycemic O
action O
of O
Starlix B-brand
and O
other O
oral O
antidiabetic B-group
drugs I-group
. O

Neuromuscular B-group
Blockers I-group
: O
In O
one O
study O
of O
10 O
healthy O
volunteers O
, O
administration O
of O
PRECEDEX B-brand
for O
45 O
minutes O
at O
a O
plasma O
concentration O
of O
1 O
( O
one O
) O
ng/mL O
resulted O
in O
no O
clinically O
meaningful O
increases O
in O
the O
magnitude O
or O
neuromuscular O
blockade O
associated O
with O
rocuronium B-drug
administration O
. O

A O
variety O
of O
parametric O
dose-response O
models O
based O
on O
either O
the O
normal O
or O
logistic O
probability O
distribution O
have O
been O
proposed O
in O
the O
literature O
. O

Drugs O
with O
parasympathomimetic O
effects O
administered O
concurrently O
with O
cevimeline B-drug
can O
be O
expected O
to O
have O
additive O
effects O
. O

Thus O
, O
concomitant O
therapy O
with O
warfarin B-drug
and O
Lodine B-brand
should O
not O
require O
dosage O
adjustment O
of O
either O
drug O
. O

A O
study O
in O
14 O
normal O
male O
and O
female O
volunteers O
suggests O
that O
coadministration O
of O
cisapride B-drug
and O
ketoconazole B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

The O
IC O
( O
50 O
) O
was O
about O
120 O
microgram/ml O
. O

- O
Phenothiazines B-group
( O
acetophenazine B-drug
[ O
e.g. O
, O
Tindal B-brand
] O
, O
chlorpromazine B-drug
[ O
e.g. O
, O
Thorazine B-brand
] O
, O
fluphenazine B-drug
[ O
e.g. O
, O
Prolixin B-brand
] O
, O
mesoridazine B-brand
[ O
e.g. O
, O
Serentil B-brand
] O
, O
perphenazine B-drug
[ O
e.g. O
, O
Trilafon B-brand
] O
, O
prochlorperazine B-drug
[ O
e.g. O
, O
Compazine B-brand
] O
, O
promazine B-drug
[ O
e.g. O
, O
Sparine B-brand
] O
, O
promethazine B-drug
[ O
e.g. O
, O
Phenergan B-brand
] O
, O
thioridazine B-drug
[ O
e.g. O
, O
Mellaril B-brand
] O
, O
trifluoperazine B-drug
[ O
e.g. O
, O
Stelazine B-brand
] O
, O
triflupromazine B-drug
[ O
e.g. O
, O
Vesprin B-brand
] O
, O
trimeprazine B-drug
[ O
e.g. O
, O
Temaril B-brand
] O
) O
or O

Drug/Laboratory O
Test O
Interactions O
Finasteride B-drug
had O
no O
effect O
on O
circulating O
levels O
of O
cortisol O
, O
thyroid-stimulating O
hormone O
, O
or O
thyroxine O
, O
nor O
did O
it O
affect O
the O
plasma O
lipid O
profile O
( O
e.g. O
, O
total O
cholesterol O
, O
low-density O
lipoproteins O
, O
high-density O
lipoproteins O
and O
triglycerides O
) O
or O
bone O
mineral O
density O
. O

Some O
quinolones B-group
, O
including O
ciprofloxacin B-drug
, O
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Simultaneous O
administration O
of O
SPRYCEL B-brand
with O
antacids B-group
should O
be O
avoided O
. O

procainamide B-drug
; O

Your O
doctor O
or O
pharmacist O
can O
give O
you O
more O
information O
on O
MAO B-group
inhibitors I-group
. O

Clonidine B-drug
hydrochloride I-drug
may O
enhance O
the O
CNS-depressive O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
or O
other O
sedatives B-group
. O

Warfarin B-drug
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
no O
clinically O
relevant O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
between O
isradipine B-drug
and O
racemic O
warfarin B-drug
was O
seen O
when O
two O
single O
oral O
doses O
of O
warfarin B-drug
( O
0.7 O
mg/kg O
body O
weight O
) O
were O
administered O
during O
11 O
days O
of O
multipledose O
treatment O
with O
5 O
mg O
b.i.d O
. O
isradipine B-drug
. O

These O
events O
were O
also O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
several O
months O
after O
interleukin-2 B-drug
treatment O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Established O
and O
Other O
Potentially O
Significant O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O
or O
Predicted O
Interaction O

. O

In O
an O
in O
vivo O
metabolic O
probe O
study O
, O
alosetron B-drug
did O
not O
inhibit O
CYP2E1 O
but O
did O
produce O
30 O
% O
inhibition O
of O
both O
CYP1A2 O
and O
N-acetyltransferase O
. O

2 O
. O

Saquinavir B-drug
: O
The O
combination O
of O
HIVID B-drug
, O
saquinavir B-drug
, O
and O
ZDV B-drug
has O
been O
studied O
( O
as O
triple O
combination O
) O
in O
adults O
. O

Serotonergic B-group
Agents I-group
: O
Co-administration O
of O
linezolid B-drug
and O
serotonergic B-group
agents I-group
was O
not O
associated O
with O
serotonin O
syndrome O
in O
Phase O
1 O
, O
2 O
or O
3 O
studies O
. O

In O
an O
analysis O
of O
the O
supraventricular O
arrhythmia O
and O
DIAMOND O
patient O
populations O
, O
the O
concomitant O
administration O
of O
verapamil B-drug
with O
dofetilide B-drug
was O
associated O
with O
a O
higher O
occurrence O
of O
torsade O
de O
pointes O
. O

Digoxin B-drug
, O
Nimodipine B-drug
and O
Losartan B-drug
: O
Bosentan B-drug
has O
no O
significant O
pharmacokinetic O
interactions O
with O
digoxin B-drug
and O
nimodipine B-drug
, O
and O
losartan B-drug
has O
no O
significant O
effect O
on O
plasma O
levels O
of O
bosentan B-drug
. O

In O
general O
, O
if O
a O
patient O
shows O
no O
signs O
of O
sedation O
within O
2 O
hours O
after O
a O
1-mg O
dose O
of O
flumazenil B-drug
, O
serious O
resedation O
at O
a O
later O
time O
is O
unlikely O
. O

Mice O
from O
the O
20th O
generation O
of O
three O
lines O
divergently O
selected O
for O
response O
to O
pentobarbital-induced B-drug
sedation O
times O
[ O
long-sedation O
time O
( O
LST O
) O
, O
short O
sedation O
time O
( O
SST O
) O
, O
and O
randomly O
bred O
control O
( O
RBC O
) O
] O
were O
used O
to O
study O
cocaine-induced B-drug
behavioral O
sensitization O
. O

Bosentan B-drug
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
. O

No O
teratogenic O
effects O
were O
seen O
in O
the O
offspring O
delivered O
at O
term O
. O

Valproate B-drug
: O
Tiagabine B-drug
causes O
a O
slight O
decrease O
( O
about O
10 O
% O
) O
in O
steady-state O
valproate B-drug
concentrations O
. O

The O
risks O
of O
using O
Clozapine B-drug
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

when O
the O
drugs O
were O
administered O
together O
, O
the O
effects O
were O
additive O
. O

It O
is O
suggested O
to O
monitor O
both O
ketoconazole B-drug
and O
phenytoin B-drug
. O

co-administration O
of O
phenytoin B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

Since O
caffeine B-drug
is O
frequently O
co-administered O
with O
acetaminophen B-drug
, O
it O
is O
of O
clinical O
interest O
to O
study O
the O
effect O
of O
caffeine B-drug
on O
the O
hepatotoxicity O
of O
acetaminophen B-drug
. O

Phenytoin B-drug
: O
No O
significant O
differences O
were O
observed O
in O
mean O
phenytoin B-drug
AUC O
, O
C O
max O
, O
C O
min O
or O
T O
max O
( O
although O
C O
max O
increased O
by O
11 O
% O
) O
when O
extended O
phenytoin B-drug
sodium I-drug
capsules O
( O
100 O
mg O
tid O
) O
were O
coadministered O
with O
lomefloxacin B-drug
( O
400 O
mg O
qd O
) O
for O
five O
days O
in O
15 O
healthy O
males O
. O

These O
precautions O
probably O
should O
apply O
to O
digitoxin B-drug
administration O
as O
well O
. O

Phospholine B-drug
Iodide I-drug
potentiates O
other O
cholinesterase B-group
inhibitors I-group
such O
as O
succinylcholine B-drug
or O
organophosphate B-drug_n
and O
carbamate B-drug_n
insecticides O
. O

Carbamazepine B-drug
has O
been O
reported O
to O
increase O
the O
degree O
of O
heart O
block O
produced O
by O
other O
agents O
. O

Avoid O
concomitant O
use O
unless O
necessary O
to O
control O
side O
effects O
of O
amphotericin B-drug
B I-drug
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
( O
MAOIs B-group
) O

Fluoxetine B-drug
, O
OCs B-group
, O
sertraline B-drug
, O
diltiazem B-drug
, O
macrolide B-group
antibiotics I-group
( O
exercise O
caution O
) O
. O

Powder O
x-ray O
diffraction O
, O
differential O
scanning O
calorimetry O
, O
differential O
thermal O
analysis O
, O
and O
scanning O
electron O
microscopy O
were O
used O
to O
characterize O
the O
aerosol O
particles O
and O
starting O
material O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
co-administration O
of O
probenecid B-drug
with O
cefditoren B-drug
pivoxil I-drug
resulted O
in O
an O
increase O
in O
the O
plasma O
exposure O
of O
cefditoren B-drug
, O
with O
a O
49 O
% O
increase O
in O
mean O
Cmax O
, O
a O
122 O
% O
increase O
in O
mean O
AUC O
, O
and O
a O
53 O
% O
increase O
in O
half-life O
. O

The O
hypoglycemic O
effect O
of O
tolbutamide B-drug
has O
been O
reported O
to O
increase O
when O
Atromid-S B-brand
is O
given O
concurrently O
. O

Hepatotoxic O
medications O
, O
such O
as O
high-dose O
methotrexate B-drug
, O
may O
impair O
liver O
function O
and O
increase O
the O
risk O
of O
toxicity O
. O

It O
is O
not O
clear O
whether O
this O
represents O
an O
interaction O
with O
TIKOSYN B-brand
or O
the O
presence O
of O
more O
severe O
structural O
heart O
disease O
in O
patients O
on O
digoxin B-drug
; O

Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

In O
this O
paper O
, O
we O
show O
that O
the O
precipitate O
is O
formed O
after O
the O
interaction O
of O
jacalin B-drug_n
and O
the O
serum O
protein O
added O
to O
the O
culture O
medium O
. O

The O
possibility O
of O
hypotensive O
effects O
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-group
or O
increasing O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
fosinopril B-drug
sodium I-drug
. O

Several O
beta-adrenergic O
neuroeffector O
defects O
occur O
in O
heart O
failure O
. O

The O
clinical O
basis O
of O
this O
drug O
interaction O
has O
not O
been O
established O
but O
should O
be O
noted O
when O
allopurinol B-drug
is O
given O
to O
patients O
already O
on O
dicumarol B-drug
therapy O
. O

Methotrexate B-drug
: O
Piperacillin B-drug
sodium I-drug
may O
reduce O
the O
excretion O
of O
methotrexate B-drug
. O

The O
onset O
of O
80 O
% O
of O
those O
" O
epidemic O
" O

Testicular O
atrophy O
was O
seen O
with O
dexrazoxane B-drug
administration O
at O
doses O
as O
low O
as O
30 O
mg/kg O
weekly O
for O
6 O
weeks O
in O
rats O
( O
1/3 O
the O
human O
dose O
on O
a O
mg/m O
2 O
basis O
) O
and O
as O
low O
as O
20 O
mg/kg O
weekly O
for O
13 O
weeks O
in O
dogs O
( O
approximately O
equal O
to O
the O
human O
dose O
on O
a O
mg/m O
2 O
basis O
) O
. O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium O
toxicity O
. O

Co-medications O
that O
induce O
CYP3A4 O
( O
e.g. O
, O
dexamethasone B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
rifampin B-drug
, O
phenobarbital B-drug
or O
St O
. O

We O
propose O
these O
pharmacokinetic O
changes O
to O
be O
the O
underlying O
mechanism O
for O
the O
reduction O
of O
oral O
CCNU B-drug
cytotoxicity O
by O
misonidazole B-drug_n
. O

General O
Interactions O
: O
Certain O
drugs O
could O
increase O
the O
likelihood O
of O
potentially O
serious O
adverse O
effects O
with O
bepridil B-drug
hydrochloride I-drug
. O

The O
response O
to O
Factrel B-brand
may O
be O
blunted O
by O
phenothiazines B-group
and O
dopamine B-group
antagonists I-group
which O
cause O
a O
rise O
in O
prolactin O
. O

Caution O
is O
advised O
when O
beginning O
, O
discontinuing O
, O
or O
changing O
the O
dose O
of O
DIAMOX B-brand
in O
patients O
receiving O
primidone B-drug
. O

Drugs O
that O
may O
have O
their O
plasma O
concentration O
altered O
by O
Gleevec B-brand
Gleevec I-brand
increases O
the O
mean O
cmax O
and O
AUC O
of O
simvastatin B-drug
( O
CYP3A4 O
substrate O
) O
2- O
and O
3.5-fold O
, O
respectively O
, O
suggesting O
an O
inhibition O
of O
the O
CYP3A4 O
by O
Gleevec B-brand
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
citalopram B-drug
, O
escitalopram B-drug
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

During O
clinical O
trials O
, O
iloprost B-drug
was O
used O
concurrently O
with O
anticoagulants B-group
, O
diuretics B-group
, O
cardiac B-group
glycosides I-group
, O
calcium B-group
channel I-group
blockers I-group
, O
analgesics B-group
, O
antipyretics B-group
, O
nonsteroidal B-group
antiinflammatories I-group
, O
corticosteroids B-group
, O
and O
other O
medications O
. O

Prolonged O
daily O
administration O
of O
picrotoxin B-drug_n
in O
a O
dose O
of O
1 O
mg/kg O
results O
in O
the O
development O
of O
brain O
edema O
. O

The O
superiority O
of O
efavirenz B-drug
over O
indinavir-based B-drug
regimens O
has O
been O
observed O
in O
comparative O
data O
in O
a O
subset O
of O
patients O
with O
high O
viral O
loads O
. O

and O
by O
observations O
now O
appearing O
on O
the O
relation O
between O
plasma O
drug O
levels O
and O
drug O
effects O
, O
both O
therapeutic O
and O
toxic O
. O

Thus O
, O
it O
is O
recommended O
not O
to O
use O
such O
methods O
for O
12-24 O
hours O
after O
administration O
of O
Omniscan B-brand
. O

Cardiovascular O
: O
Hypotension O
, O
bradycardia O
, O
and O
hypertension O
have O
been O
observed O
during O
administration O
of O
TAXOL B-brand
, O
but O
generally O
do O
not O
require O
treatment O
. O


Antidiabetic B-group
drugs I-group
( O
oral O
agents O
and O
insulin B-drug
) O
diminished O
antidiabetic O
effect O
. O

Digitalis B-group
toxicity O
may O
be O
aggravated O
by O
the O
initial O
release O
of O
norepinephrine O
caused O
by O
Bretylium B-drug
Tosylate I-drug
Injection O
. O

The O
dissolution O
rate O
of O
the O
aerosol O
particles O
in O
saline O
was O
low O
and O
variable O
. O

However O
, O
because O
both O
of O
these O
compounds O
have O
CNS O
effects O
, O
an O
additive O
pharmacodynamic O
effect O
is O
possible O
. O

Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
FASLODEX B-brand
in O
pediatric O
patients O
have O
not O
been O
established O
. O

The O
steady-state O
Cmin O
increased O
to O
78 O
14 O
micrograms/mL O
when O
1200 O
mg/day O
of O
felbamate B-drug
was O
coadministered O
. O

In O
order O
to O
examine O
some O
molecular O
mechanisms O
of O
PCP-induced B-drug_n
behavioral O
changes O
, O
Northern O
blot O
analysis O
of O
total O
RNA O
from O
prefrontal O
cortical O
tissues O
of O
mice O
treated O
with O
PCP B-drug_n
, O
DCG-IV B-drug_n
, O
and O
L-CCG-1 B-drug_n
was O
carried O
out O
. O

Clonidine B-drug
therapy O
can O
then O
be O
discontinued O
several O
days O
later O
by O
gradually O
decreasing O
the O
dosage O
. O

However O
, O
administration O
of O
4-methylpyrazole B-drug
( O
90 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
to O
rats O
2 O
hours O
prior O
to O
1,3-difluoroacetone B-drug_n
( O
100 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
was O
ineffective O
in O
preventing O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
synthesis O
and O
did O
not O
diminish O
fluoride O
or O
citrate O
accumulation O
in O
vivo O
. O

When O
Mefloquine B-drug
is O
taken O
concurrently O
with O
oral O
live B-group
typhoid I-group
vaccines I-group
, O
attenuation O
of O
immunization O
can O
not O
be O
excluded O
. O

Therefore O
, O
fenofibrate B-drug
should O
be O
taken O
at O
least O
1 O
hour O
before O
or O
4-6 O
hours O
after O
a O
bile B-group
acid I-group
binding I-group
resin I-group
to O
avoid O
impeding O
its O
absorption O
. O

no O
change O
in O
pravastatin B-drug
AUC O
and O
Cmax O
was O
observed O
during O
diltiazem B-drug
coadministration O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
, O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

There O
is O
no O
clinical O
evidence O
to O
suggest O
that O
anagrelide B-drug
interacts O
with O
any O
of O
these O
compounds O
. O

The O
affinity O
( O
Kd O
) O
of O
D2 O
in O
the O
NAC O
decreased O
significantly O
, O
without O
changes O
in O
density O
( O
Bmax O
) O
, O
in O
the O
cocaine-treated B-drug
SST O
and O
RBC O
mice O
. O

angioedema O

Nonetheless O
, O
individual O
patients O
may O
require O
additional O
titration O
of O
their O
theophylline B-drug
dosage O
when O
lansoprazole B-drug
is O
started O
or O
stopped O
to O
ensure O
clinically O
effective O
blood O
levels O
. O

Chloramphenicol B-drug
has O
been O
shown O
to O
be O
antagonistic O
to O
beta-lactam B-group
antibiotics I-group
, O
including O
ceftazidime B-drug
, O
based O
on O
in O
vitro O
studies O
and O
time O
kill O
curves O
with O
enteric O
gram-negative O
bacilli O
. O

Therefore O
, O
co-administration O
of O
tricyclic B-group
antidepressants I-group
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isoenzyme O
, O
including O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
carbamazepine B-drug
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
eg O
, O
propafenone B-drug
, O
flecainide B-drug
, O
and O
encainide B-drug
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
eg O
, O
quinidine B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

In O
another O
study O
, O
TORADOLIV/IM O
was O
given O
with O
two O
doses O
of O
5000 O
U O
of O
heparin B-drug
to O
11 O
healthy O
volunteers O
, O
resulting O
in O
a O
mean O
template O
bleeding O
time O
of O
6.4 O
minutes O
( O
3.2 O
to O
11.4 O
min O
) O
compared O
to O
a O
mean O
of O
6.0 O
minutes O
( O
3.4 O
to O
7.5 O
min O
) O
for O
heparin B-drug
alone O
and O
5.1 O
minutes O
( O
3.5 O
to O
8.5 O
min O
) O
for O
placebo O
. O

Coadministration O
of O
valdecoxib B-drug
and O
Ortho-Novum B-brand
1/35 O
increased O
the O
exposure O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
by O
20 O
% O
and O
34 O
% O
, O
respectively O
. O

Drug/Laboratory O
Test O
Interactions O
Corticosteroids B-group
may O
affect O
the O
nitrobluetetrazolium O
test O
for O
bacterial O
infection O
and O
produce O
false-negative O
results O

Ketoconazole B-drug
is O
a O
known O
strong O
inhibitor O
of O
CYP3A4 O
. O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
lithiums B-drug
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Thus O
, O
careful O
monitoring O
of O
clinical O
status O
is O
warranted O
when O
rifampin B-drug
is O
administered O
or O
discontinued O
in O
haloperidol-treated B-drug
patients O
. O

On O
the O
other O
hand O
, O
intrathecal O
naloxone B-drug
( O
12-120 O
micrograms O
) O
had O
only O
a O
very O
weak O
effect O
on O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
morphine B-drug
( O
40 O
micrograms O
) O
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
either O
healthy O
subjects O
or O
patients O
with O
epilepsy O
. O

Concomitant O
administration O
of O
diflunisal B-drug
and O
acetaminophen B-drug
in O
dogs O
, O
but O
not O
in O
rats O
, O
at O
approximately O
2 O
times O
the O
recommended O
maximum O
human O
therapeutic O
dose O
of O
each O
( O
40 O
to O
52 O
mg/kg/day O
of O
diflunisal/acetaminophen B-drug
) O
resulted O
in O
greater O
gastrointestinal O
toxicity O
than O
when O
either O
drug O
was O
administered O
alone O
. O

Co-administration O
of O
naltrexone B-drug
with O
Acamprosate B-drug
produced O
a O
25 O
% O
increase O
in O
AUC O
and O
a O
33 O
% O
increase O
in O
the O
Cmax O
of O
acamprosate B-drug
. O

CONCLUSIONS O
: O
Everolimus B-drug
exhibited O
dose-proportional O
, O
stable O
exposure O
during O
the O
first O
post-transplant O
year O
. O

Cholestyramine-Concomitant B-drug
intake O
of O
cholestyramine B-drug
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Morphine B-drug
: O
TORADOLIV/IM O
has O
been O
administered O
concurrently O
with O
morphine B-drug
in O
several O
clinical O
trials O
of O
postoperative O
pain O
without O
evidence O
of O
adverse O
interactions O
. O

At O
low-levels O
of O
exposure O
the O
toxicokinetic O
interferences O
between O
solvents O
have O
generally O
not O
been O
observed O
in O
man O
and O
presumably O
a O
threshold O
limit O
exists O
. O

Antiacid O
, O
clarithromycin B-drug
, O
Didanosine B-drug
, O
Fluconazole B-drug
, O
Fluoxetine B-drug
, O
Indanavir O
, O
Ketoconazole B-drug
, O
Phenytoin B-drug
, O
Phenobarbitol O
, O
carbamazepine B-drug
, O
Rifabutin B-drug
, O
Rifampin B-drug
, O
Ritanovir O
, O
Saquinavir B-drug
. O

disulfiram B-drug
; O

Bentiromide B-drug
may O
interact O
with O
acetaminophen B-drug
( O
e.g. O
, O
Tylenol B-brand
) O
, O
chloramphenicol B-drug
( O
e.g. O
, O
Chloromycetin B-brand
) O
, O
local O
anesthetics B-group
( O
e.g. O
, O
benzocaine B-drug
and O
lidocaine B-drug
) O
, O
para-aminobenzoic B-drug_n
acid I-drug_n
( O
PABA B-drug_n
) O
-containing O
preparations O
( O
e.g. O
, O
sunscreens O
and O
some O
multivitamins B-group
) O
, O
procainamide B-drug
( O
e.g. O
, O
Pronestyl B-brand
) O
, O
sulfonamides B-group
( O
sulfa O
medicines O
) O
, O
thiazide B-group
diuretics I-group
( O
use O
of O
these O
medicines O
during O
the O
test O
period O
will O
affect O
the O
test O
results O
) O
, O
and O
pancreatic O
supplements O
( O
use O
of O
pancreatic O
supplements O
may O
give O
false O
test O
results O
) O
. O

When O
used O
in O
external O
subcutaneous O
infusion O
pumps O
for O
insulin B-drug
, O
NovoLog B-brand
should O
not O
be O
mixed O
with O
any O
other O
insulins B-group
or O
diluent O
. O

Digitalis B-group
: O
Vitamin B-group
D I-group
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-group
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O

Anticholinergic B-group
agents I-group
may O
potentially O
alter O
the O
absorption O
of O
some O
concomitantly O
administered O
drugs O
due O
to O
effects O
on O
gastrointestinal O
motility O
. O

Antacids B-group
or O
H B-group
2 I-group
receptor I-group
antagonists I-group
: O
When O
dirithromycin B-drug
is O
administered O
immediately O
following O
antacids B-group
or O
H B-group
2 I-group
-receptor I-group
antagonists I-group
, O
the O
absorption O
of O
dirithromycin B-drug
is O
slightly O
enhanced O
. O

In O
particular O
, O
convulsions O
have O
been O
reported O
when O
ethionamide B-drug
is O
administered O
with O
cycloserine B-drug
and O
special O
care O
should O
be O
taken O
when O
the O
treatment O
regimen O
includes O
both O
of O
these O
drugs O
. O

Because O
dopamine B-drug
is O
metabolized O
by O
monoamine O
oxidase O
( O
MAO O
) O
, O
inhibition O
of O
this O
enzyme O
prolongs O
and O
potentiates O
the O
effect O
of O
dopamine B-drug
. O

Also O
included O
in O
this O
paper O
is O
a O
study O
which O
confirms O
the O
identity O
of O
the O
HPLC O
peak O
as O
being O
homocysteine O
by O
forming O
a O
radioactive O
derivative O
of O
this O
particular O
sulphydryl-containing O
amino O
acid O
, O
and O
then O
analysing O
the O
resulting O
mixture O
by O
TLC O
. O

Digoxin B-drug
Keppra B-brand
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
and O
pharmacodynamics O
( O
ECG O
) O
of O
digoxin B-drug
given O
as O
a O
0.25 O
mg O
dose O
every O
day O
. O

Azithromycin B-drug
had O
no O
significant O
effect O
on O
dideoxyinosine B-drug
pharmacokinetics O
. O

Macrolide B-group
Antibiotics I-group
( O
e. O
g. O
erythromycin B-drug
and O
troleandomycin B-drug
) O
: O
Agents O
of O
the O
ergot B-group
alkaloid I-group
class I-group
, O
of O
which O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
is O
a O
member O
, O
have O
been O
shown O
to O
interact O
with O
antibiotics B-group
of O
the O
macrolide B-group
class I-group
, O
resulting O
in O
increased O
plasma O
levels O
of O
unchanged O
alkaloids O
and O
peripheral O
vasoconstriction O
. O

Due O
to O
their O
similar O
mechanism O
of O
action O
, O
it O
is O
expected O
that O
the O
neuromuscular O
blockade O
produced O
by O
any O
of O
the O
non-depolarizing B-group
muscle I-group
relaxants I-group
could O
be O
prolonged O
in O
the O
presence O
of O
piperacillin B-drug
. O

In O
the O
DIAMOND O
trials O
, O
1252 O
patients O
were O
treated O
with O
TIKOSYN B-brand
and O
diuretics B-group
concomitantly O
of O
whom O
493 O
died O
compared O
to O
508 O
deaths O
among O
the O
1248 O
patients O
receiving O
placebo O
and O
diuretics B-group
. O

7 O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
and O
aminoglycoside B-group
antibiotics I-group
. O

Inhibitors O
of O
CYP2D6 O
; O

Co-administration O
of O
multiple O
doses O
of O
10 O
mg O
of O
lenalidomide B-drug
had O
no O
effect O
on O
the O
single O
dose O
pharmacokinetics O
of O
R- O
and O
S- B-drug
warfarin I-drug
. O

Nimodipine B-drug
had O
no O
effect O
on O
ginsenosides B-drug_n
response O
. O

Specific O
drug O
interaction O
studies O
, O
including O
interactions O
with O
MTX B-drug
, O
have O
not O
been O
conducted O
. O

Based O
on O
these O
data O
, O
Vardenafil B-drug
should O
not O
be O
used O
in O
patients O
on O
alpha-blocker B-group
therapy O
. O

In O
a O
12-month O
controlled O
trial O
that O
included O
a O
50 O
mcg O
once O
daily O
BROVANA B-brand
dose O
, O
30 O
of O
the O
528 O
BROVANA B-brand
-treated O
subjects O
received O
concomitant O
theophylline B-drug
at O
study O
entry O
. O

Fentanyl B-drug

Phenytoin B-drug
is O
metabolized O
by O
hepatic O
cytochrome O
P450 O
enzymes O
and O
is O
particularly O
susceptible O
to O
inhibitory O
drug O
interactions O
because O
it O
is O
subject O
to O
saturable O
metabolism O
. O

No O
information O
provided O

The O
literature O
suggests O
that O
more O
than O
one O
mechanism O
of O
action O
exists O
for O
them O
. O

In O
view O
of O
the O
long O
and O
variable O
half-life O
of O
amiodarone B-drug
, O
potential O
for O
drug O
interactions O
exists O
not O
only O
with O
concomitant O
medication O
but O
also O
with O
drugs O
administered O
after O
discontinuation O
of O
amiodarone B-drug
. O

Concomitant O
administration O
of O
FACTIVE B-brand
with O
probenecid B-drug
resulted O
in O
a O
45 O
% O
increase O
in O
systemic O
exposure O
to O
gemifloxacin B-drug
. O

Drugs O
Metabolized O
by O
Catechol-O-methyltransferase O
( O
COMT O
) O
: O
Hormone O
levels O
: O
Levodopa B-drug
is O
known O
to O
depress O
prolactin O
secretion O
and O
increase O
growth O
hormone O
levels O
. O

Hepatic O
: O
There O
is O
limited O
evidence O
that O
the O
myelotoxicity O
of O
TAXOL B-brand
may O
be O
exacerbated O
in O
patients O
with O
serum O
total O
bilirubin O
2 O
times O
ULN O
. O

Other O
antiarrhythmic B-group
drugs I-group
( O
eg O
, O
quinidine B-drug
, O
procainamide B-drug
, O
lidocaine B-drug
, O
propranolol B-drug
) O
have O
occasionally O
been O
used O
concurrently O
with O
Norpace B-brand
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
that O
inhibits O
CYP3A4 O
and/or O
epoxide O
hydrolase O
. O

Co-administration O
of O
MYOBLOC B-brand
and O
aminoglycosides B-group
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e.g. O
, O
curare-like B-group
compounds I-group
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-drug
may O
be O
potentiated O
. O

1 O
mM O
) O
was O
a O
slight O
degree O
of O
inhibition O
( O
14 O
% O
-30 O
% O
) O
of O
isoform O
CYP2A6 O
observed O
. O

Cimetidine B-drug
: O
A O
study O
in O
6 O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
nifedipine B-drug
plasma O
levels O
( O
80 O
% O
) O
and O
area-under-the-curve O
( O
74 O
% O
) O
after O
a O
1 O
week O
course O
of O
cimetidine B-drug
at O
1000 O
mg O
per O
day O
and O
nifedipine B-drug
at O
40 O
mg O
per O
day O
. O

Lipids O
: O
In O
clinical O
studies O
, O
the O
incidence O
of O
hypertriglyceridemia O
was O
66 O
% O
, O
hypercholesterolemia O
was O
33 O
% O
and O
that O
of O
decreased O
HDL O
was O
40 O
% O
. O

Alpha-agonists B-group
, O
as O
a O
class O
, O
may O
reduce O
pulse O
and O
blood O
pressure O
. O

Experience O
with O
co-administration O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
and O
Fentanyl B-drug
in O
patients O
is O
limited O
, O
therefore O
, O
consideration O
should O
be O
given O
to O
temporarily O
suspending O
use O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
in O
patients O
receiving O
Fentanyl B-drug
. O

Resistance O
to O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-group
neuromuscular I-group
blocking I-group
agents I-group
has O
been O
demonstrated O
in O
patients O
chronically O
administered O
phenytoin B-drug
or O
carbamazepine B-drug
. O

Drug/ O
Laboratory O
Test O
Interactions O
AMERGE B-brand
Tablets O
are O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

It O
is O
important O
for O
older O
adults O
to O
be O
aware O
of O
the O
relationship O
between O
folic B-drug
acid I-drug
and O
vitamin B-drug
B12 I-drug
because O
they O
are O
at O
greater O
risk O
of O
having O
a O
vitamin O
B12 O
deficiency O
. O

Much O
less O
caspase-3 O
activity O
was O
noted O
in O
the O
lysate O
derived O
from O
serum-deprived O
RAS-3T3 O
cells O
compared O
with O
that O
in O
the O
lysate O
of O
serum-deprived O
NIH-3T3 O
cells O
. O

FORADIL B-brand
is O
not O
meant O
to O
relieve O
acute O
asthma O
or O
COPD O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Nevirapine I-drug
and O
ketoconazole B-drug
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O
ketoconazole B-drug
plasmaconcentrations O
may O
reduce O
the O
efficacy O
of O
the O
drug O
. O

Drug/Laboratory O
Test O
Interactions O
A O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
Benedicts O
solution O
, O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
, O
but O
not O
with O
enzyme-based O
tests O
such O
as O
CLINISTIX O
. O

Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Increased O
By O
Co-administration O
With O
Nevirapine B-drug

Alcohol B-drug
: O
There O
was O
no O
significant O
difference O
between O
aripiprazole B-drug
coadministered O
with O
ethanol B-drug
and O
placebo O
coadministered O
with O
ethanol B-drug
on O
performance O
of O
gross O
motor O
skills O
or O
stimulus O
response O
in O
healthy O
subjects O
. O

Aprepitant B-drug
is O
also O
an O
inducer O
of O
CYP2C9 O
. O

. O

Drug O
Laboratory O
Test O
Interactions O
None O
known O
. O

Although O
specific O
studies O
have O
not O
been O
performed O
, O
coadministration O
with O
drugs O
that O
are O
mainly O
metabolized O
by O
CYP3A4 O
( O
eg O
, O
calcium B-group
channel I-group
blockers I-group
, O
dapsone B-drug
, O
disopyramide B-drug
, O
quinine B-drug
, O
amiodarone B-drug
, O
quinidine B-drug
, O
warfarin B-drug
, O
tacrolimus B-drug
, O
cyclosporine B-drug
, O
ergot B-group
derivatives I-group
, O
pimozide B-drug
, O
carbamazepine B-drug
, O
fentanyl B-drug
, O
alfentanyl B-drug
, O
alprazolam B-drug
, O
and O
triazolam B-drug
) O
may O
have O
elevated O
plasma O
concentrations O
when O
coadministered O
with O
saquinavir B-drug
; O

Drug/Laboratory O
Test O
Interaction O
Fosinopril B-drug
may O
cause O
a O
false O
low O
measurement O
of O
serum O
digoxin B-drug
levels O
with O
the O
Digi- O
Tab O
RIA O
Kit O
for O
Digoxin B-drug
. O

An O
encephalopathic O
syndrome O
( O
characterized O
by O
weakness O
, O
lethargy O
, O
fever O
, O
tremulousness O
and O
confusion O
, O
extrapyramidal O
symptoms O
, O
leukocytosis O
, O
elevated O
serum O
enzymes O
, O
BUN O
, O
and O
FBS O
) O
followed O
by O
irreversible O
brain O
damage O
has O
occurred O
in O
a O
few O
patients O
treated O
with O
lithium B-drug
plus O
HALDOL B-brand
. O

InjectionSite O
Reaction O
: O
Injection O
site O
reactions O
, O
including O
reactions O
secondary O
to O
extravasation O
, O
were O
usually O
mild O
and O
consisted O
of O
erythema O
, O
tenderness O
, O
skin O
discoloration O
, O
or O
swelling O
at O
the O
injection O
site O
. O

In O
patients O
receiving O
treatment O
with O
SPRYCEL B-brand
, O
close O
monitoring O
for O
toxicity O
and O
a O
SPRYCEL B-brand
dose O
reduction O
should O
be O
considered O
if O
systemic O
administration O
of O
a O
potent O
CYP3A4 O
inhibitor O
can O
not O
be O
avoided O
. O

Additional O
dose O
increases O
should O
be O
based O
on O
clinical O
evaluation O
. O

The O
oral O
bioavailability O
of O
enoxacin B-drug
is O
reduced O
by O
60 O
% O
with O
coadministration O
of O
ranitidine B-drug
. O

ranitidine* B-drug
; O

Antimicrobial O
activity O
of O
GL B-drug_n
( O
the O
aqueous O
extract O
from O
the O
carpophores O
of O
Ganoderma O
lucidum O
( O
FR O
) O
KARST O
) O
was O
tested O
in O
vitro O
against O
Gram O
positive O
and O
Gram O
negative O
bacteria O
by O
serial O
broth O
dilution O
method O
, O
and O
the O
antimicrobial O
activity O
was O
expressed O
by O
minimal O
inhibitory O
concentration O
( O
MIC O
) O
. O

Ethanol B-drug
: O
Clinical O
evidence O
has O
shown O
that O
etretinate B-drug
can O
be O
formed O
with O
concurrent O
ingestion O
of O
acitretin B-drug
and O
ethanol B-drug
. O

INTERVENTIONS O
: O
Each O
subject O
was O
treated O
according O
to O
the O
following O
sequence O
: O
baseline O
; O

Cyclosporine B-drug
: O
Administration O
of O
nonsteroial B-group
anti-inflammatory I-group
drugs I-group
concomitantly O
with O
cyclosporine B-drug
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine-induced B-drug
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O

Co-administration O
of O
BOTOX B-brand
and O
aminoglycosides B-group
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e.g. O
, O
curare-like B-group
compounds I-group
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-drug
may O
be O
potentiated O
. O

In O
vitro O
studies O
have O
shown O
no O
binding O
displacement O
between O
entacapone B-drug
and O
other O
highly O
bound O
drugs O
, O
such O
as O
warfarin B-drug
, O
salicylic B-drug
acid I-drug
, O
phenylbutazone B-drug
, O
and O
diazepam B-drug
. O

Compromised O
norepinephrine B-drug
uptake-1 O
in O
functional O
class O
IV O
can O
not O
be O
further O
increased O
by O
cocaine B-drug
and O
desipramine B-drug
. O

SINCE O
CHOLESTYRAMINE B-drug
RESIN B-group
MAY O
BIND O
OTHER O
DRUGS O
GIVEN O
CONCURRENTLY O
, O
IT O
IS O
RECOMMENDED O
THAT O
PATIENTS O
TAKE O
OTHER O
DRUGS O
AT O
LEAST O
1 O
HOUR O
BEFORE O
OR O
4 O
TO O
6 O
HOURS O
AFTER O
CHOLESTYRAMINE B-drug
RESIN B-group
( O
OR O
AT O
AS O
GREAT O
AN O
INTERVAL O
AS O
POSSIBLE O
) O
TO O
AVOID O
IMPEDING O
THEIR O
ABSORPTION O
. O

Lansoprazole B-drug
causes O
a O
profound O
and O
long O
lasting O
inhibition O
of O
gastric O
acid O
secretion O
; O

Therefore O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
could O
be O
due O
to O
the O
drug O
. O

Maalox B-brand
* O
Coadministration O
of O
Maalox B-brand
TC I-brand
had O
no O
effect O
on O
nicardipine B-drug
HCl I-drug
absorption O
. O

Concomitant O
use O
of O
antihistamines B-group
with O
alcohol B-drug
, O
tricyclic B-group
antidepressants I-group
, O
barbiturates B-group
, O
or O
other O
central B-group
nervous I-group
system I-group
depressants I-group
may O
have O
an O
additive O
effect O
. O

Table O
8 O

anabolic B-group
steroids I-group
; O

adjust O
dosage O
of O
antidiabetic B-group
drug I-group
upward O
if O
necessary O
. O

Carbamazepine B-drug
( O
CBZ B-drug
) O

Combinations O
of O
these O
drugs O
have O
not O
been O
studied O
and O
coadministration O
of O
CRIXIVAN B-brand
and O
atazanavir B-drug
is O
not O
recommended O
. O

Amphotericin B-drug
, O
Foscarnet B-drug
, O
and O
Aminoglycosides B-group
: O
Drugs O
such O
as O
amphotericin B-drug
, O
foscarnet B-drug
, O
and O
aminoglycosides B-group
may O
increase O
the O
risk O
of O
developing O
peripheral O
neuropathy O
or O
other O
HIVID-associated B-drug
adverse O
events O
by O
interfering O
with O
the O
renal O
clearance O
of O
zalcitabine B-drug
( O
thereby O
raising O
systemic O
exposure O
) O
. O

Antiepileptic B-group
drugs I-group
: O
Potential O
interactions O
between O
Trileptal B-brand
and O
other O
AEDs B-group
were O
assessed O
in O
clinical O
studies O
. O

Selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HT1 B-group
agonists I-group
. O

Short-term O
pharmacokinetic O
studies O
have O
demonstrated O
that O
concomitant O
administration O
of O
warfarin B-drug
and O
Lodine B-brand
( O
etodolac B-drug
capsules O
and O
tablets O
) O
results O
in O
reduced O
protein O
binding O
of O
warfarin B-drug
, O
but O
there O
was O
no O
change O
in O
the O
clearance O
of O
free O
warfarin B-drug
. O

Antihistamines B-group
may O
enhance O
the O
effects O
of O
tricyclic B-group
antidepressants I-group
, O
barbiturates B-group
, O
alcohol B-drug
, O
and O
other O
CNS B-group
depressants I-group
. O

Skeletal B-group
muscle I-group
relaxants I-group
, O
nondepolarizing O
( O
e.g. O
, O
tubocurarine B-drug
) O
: O
possible O
increased O
responsiveness O
to O
the O
muscle B-group
relaxant I-group
. O

Videx B-brand
( O
Didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-drug
, O
because O
these O
products O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-drug
. O

If O
desipramine B-drug
hydrochloride I-drug
is O
to O
be O
combined O
with O
other O
psychotropic B-group
agents I-group
such O
as O
tranquilizers B-group
or O
sedative/hypnotics B-group
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
employed O
since O
the O
sedative O
effects O
of O
desipramine B-drug
and O
benzodiazepines B-group
( O
e.g. O
, O
chlordiazepoxide B-drug
or O
diazepam B-drug
) O
are O
additive O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
T.A B-group
. I-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

The O
results O
from O
trials O
using O
the O
intravenous O
prodrug O
are O
reported O
in O
this O
section O
as O
they O
relate O
to O
the O
role O
of O
valdecoxib B-drug
in O
drug O
interactions O
. O

ACE B-group
Inhibitors I-group
and O
Angiotensin B-group
II I-group
Receptor I-group
Antagonists I-group
( O
Congestive O
Heart O
Failure O
Post-Myocardial O
Infarction O
) O
- O
In O
EPHESUS O
, O
3020 O
( O
91 O
% O
) O
patients O
receiving O
INSPRA B-brand
25 O
to O
50 O
mg O
also O
received O
ACE B-group
inhibitors I-group
or O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
( O
ACEI/ARB B-group
) O
. O

Furosemide B-drug
may O
increase O
the O
ototoxic O
potential O
of O
aminoglycoside B-group
antibiotics I-group
, O
especially O
in O
the O
presence O
of O
impaired O
renal O
function O
. O

therefore O
, O
coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
inhibit O
CYP3A4 O
activity O
may O
result O
in O
increased O
plasma O
concentrations O
of O
aprepitant B-drug
. O

. O

Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O

Drugs O
that O
are O
known O
to O
prolong O
the O
QTc O
interval O
have O
an O
increased O
risk O
of O
ventricular O
arrhythmias O
. O

Exposure O
from O
the O
proposed O
topical O
dose O
is O
about O
1 O
% O
of O
that O
from O
the O
100 O
mg O
oral O
dose O
, O
even O
when O
co-administered O
with O
TMP/SMX B-drug
. O

Morphine B-drug
: O
A O
literature O
article O
reported O
that O
when O
a O
60-mg O
controlled-release O
morphine B-drug
capsule O
was O
administered O
2 O
hours O
prior O
to O
a O
600-mg O
Neurontin B-brand
capsule O
( O
N=12 O
) O
, O
mean O
gabapentin B-drug
AUC O
increased O
by O
44 O
% O
compared O
to O
gabapentin B-drug
administered O
without O
morphine B-drug
. O

The O
clearance O
of O
theophylline B-drug
was O
decreased O
approximately O
3-fold O
. O

phenyramidol B-drug_n
; O

Auranofin B-drug
should O
be O
avoided O
by O
patients O
with O
a O
history O
of O
serious O
reaction O
to O
any O
gold B-group
medication I-group
, O
including O
Solganal B-brand
and O
Myochrysine B-brand
. O

However O
, O
on O
a O
body O
surface O
area O
basis O
, O
this O
dose O
was O
0.5 O
times O
maximum O
recommended O
human O
24-hour O
dose O
of O
ribavirin B-drug
. O

ANTACID B-group
( O
Magnesium-Aluminum B-drug
Hydroxide I-drug
) O
: O
Cerivastatin B-drug
plasma O
concentrations O
were O
not O
affected O
by O
co-administration O
of O
antacid B-group
. O

Although O
no O
interaction O
between O
MAO B-group
inhibitors I-group
and O
Levo-Dromoran B-brand
has O
been O
observed O
, O
it O
is O
not O
recommended O
for O
use O
with O
MAO B-group
inhibitors I-group
. O

Table O
1 O
Changes O
in O
Desloratadine B-drug
and O
3-Hydroxydesloratadine B-drug_n
Pharmacokinetics O
in O
Healthy O
Male O
and O
Female O
Volunteers O

If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-group
, O
initiate O
therapy O
with O
PRINIVIL B-brand
at O
a O
dose O
of O
5 O
mg O
daily O
, O
and O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
until O
blood O
pressure O
has O
stabilized O
. O

Diabetics O
who O
take O
EPA B-drug
supplements O
should O
be O
monitored O
by O
their O
physicians O
. O

if O
plasma O
levels O
are O
being O
monitored O
, O
they O
should O
be O
reassessed O
. O

In O
adjuvant O
trials O
of O
epirubicin-containing B-drug
CEF-120 O
or O
FEC-100 O
chemotherapies O
, O
breast O
irradiation O
was O
delayed O
until O
after O
chemotherapy O
was O
completed O
. O

Phenytoin B-drug
is O
a O
potent O
inducer O
of O
hepatic O
drug-metabolizing O
enzymes O
. O

Caution O
is O
warranted O
and O
clinical O
monitoring O
of O
patients O
is O
recommended O
. O

In O
both O
species O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
but O
not O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
, O
antagonized O
the O
rate-decreasing O
effects O
of O
morphine B-drug
on O
FI O
and O
FR O
responding O
. O

Glibenclamide B-drug
: O
In O
a O
study O
of O
7 O
healthy O
male O
volunteers O
, O
acitretin B-drug
treatment O
potentiated O
the O
blood O
glucose O
lowering O
effect O
of O
glibenclamide B-drug
( O
a O
sulfonylurea B-group
similar O
to O
chlorpropamide B-drug
) O
in O
3 O
of O
the O
7 O
subjects O
. O

By O
this O
procedure O
, O
it O
was O
observed O
that O
arsenate B-drug_n
is O
rapidly O
and O
essentially O
completely O
absorbed O
( O
80-95 O
% O
) O
from O
the O
lumen O
at O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
concentrations O
up O
to O
5 O
mM O
, O
declining O
to O
about O
50 O
% O
absorption O
at O
50 O
mM O
. O

There O
have O
been O
reports O
of O
QTc O
prolongation O
, O
with O
or O
without O
TdP O
, O
in O
patients O
taking O
amiodarone B-drug
when O
fluoroquinolones B-drug
, O
macrolide B-drug
antibiotics I-drug
, O
or O
azoles O
were O
administered O
concomitantly O
. O

cinchophen B-drug
; O

Cholestyramine B-drug
resin B-group
may O
interfere O
with O
the O
pharmacokinetics O
of O
drugs O
that O
undergo O
enterohepatic O
circulation O
, O
The O
discontinuance O
of O
cholestyramine B-drug
resin B-group
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
such O
as O
digitalis B-group
has O
been O
filtrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
cholestyramine B-drug
resin B-group
. O

Ibuprofen B-drug
- O
L-arginine B-drug
may O
increase O
the O
absorption O
of O
ibuprofen B-drug
if O
taken O
concomitantly O
. O

Prednisone/prednisolone B-drug
: O
Rofecoxib B-drug
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
prednisolone B-drug
or O
prednisone B-drug
. O

Therefore O
smaller O
ALFENTA B-brand
doses O
will O
be O
required O
with O
prolonged O
administration O
and O
the O
duration O
of O
action O
of O
ALFENTA B-brand
my O
be O
extended O
. O

Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg/day O
to O
1200 O
mg/day O
ketoconazole B-drug
for O
a O
week O
to O
healthy O
men O
. O

Methadone B-drug
dose O
was O
increased O
by O
a O
mean O
of O
22 O
% O
to O
alleviate O
withdrawal O
symptoms O
. O

. O

The O
concomitant O
use O
of O
ENABLEX B-brand
with O
other O
anticholinergic B-group
agents I-group
may O
increase O
the O
frequency O
and/or O
severity O
of O
dry O
mouth O
, O
constipation O
, O
blurred O
vision O
and O
other O
anticholinergic O
pharmacological O
effects O
. O

You O
may O
require O
a O
dosage O
adjustment O
or O
special O
monitoring O
if O
you O
are O
taking O
any O
of O
the O
medicines O
listed O
above O
. O

Nateglinide B-drug
is O
highly O
bound O
to O
plasma O
proteins O
( O
98 O
% O
) O
, O
mainly O
albumin O
. O

- O
Lithium B-drug
: O
Generally O
should O
not O
be O
given O
with O
diuretics B-group
. O

Theophylline B-drug
: O
As O
with O
some O
other O
quinolones B-group
, O
concurrent O
administration O
of O
ciprofloxacin B-drug
with O
theophylline B-drug
may O
lead O
to O
elevated O
serum O
concentrations O
of O
theophylline B-drug
and O
prolongation O
of O
its O
elimination O
half-life O
. O

This O
problem O
has O
been O
analysed O
using O
two O
different O
tasks O
in O
mice O
: O
a O
bar-press O
conditioning O
and O
a O
spatial O
discrimination O
task O
. O

Patients O
with O
Hepatic O
Impairment O
In O
vitro O
and O
in O
vivo O
evidence O
suggest O
that O
erlotinib B-drug
is O
cleared O
primarily O
by O
the O
liver O
. O

Of O
over O
3500 O
patients O
enrolled O
in O
the O
Ibandronate B-drug
osteoporosis O
Treatment O
and O
Prevention O
Studies O
, O
15 O
% O
used O
anti-peptic O
agents O
( O
primarily O
H2 B-group
blockers I-group
and O
PPIs B-group
) O
. O

Desloratadine B-drug
3-Hydroxydesloratadine B-drug_n

More O
importantly O
, O
we O
demonstrate O
that O
IgA O
is O
probably O
the O
major O
serum O
constituent O
precipitated O
by O
the O
lectin O
and O
that O
no O
IgG O
or O
IgM O
can O
be O
detected O
in O
the O
precipitates O
. O

The O
effect O
on O
other O
progestational B-group
contraceptives I-group
( O
eg O
, O
implants O
, O
injectables O
) O
is O
unknown O
. O

These O
drugs O
should O
be O
coad-ministered O
with O
caution O
and O
frequent O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
. O

dosage O
adjustment O
of O
antigout B-group
medications I-group
may O
be O
necessary O
to O
control O
hyperuricemia O
and O
gout O
. O
) O

Drug/Laboratory O
Test O
Interactions O
False O
elevations O
of O
urinary O
catecholamine O
levels O
may O
occur O
due O
to O
interference O
with O
the O
fluorescence O
test O
. O

In O
these O
six O
cases O
it O
was O
demonstrated O
that O
the O
neuroleptics B-group
dosage O
was O
inappropriate O
, O
being O
either O
too O
high O
or O
too O
low O
as O
judged O
from O
the O
plasma O
concentrations O
. O

This O
may O
lead O
to O
low O
amiodarone B-drug
serum O
levels O
and O
potential O
decrease O
in O
efficacy O
. O

Vasopressors B-group
: O
Thyroxine B-drug
increases O
the O
adrenergic O
effect O
of O
catecholamines O
such O
as O
epinephrine B-drug
and O
norepinephrine B-drug
. O

Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-brand
include O
: O
enflurane B-drug
; O
isoflurane B-drug
; O
halothane B-drug
; O
certain O
antibiotics B-group
, O
especially O
the O
aminoglycosides B-group
and O
polymyxins B-group
; O
lithium B-drug
; O
magnesium B-drug
salts O
; O
procainamide B-drug
; O
and O
quinidine B-drug
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co-therapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
may O
be O
required O
. O

ACE B-group
Inhibitors I-group
: O
Concomitant O
use O
of O
ACE B-group
inhibitors I-group
may O
increase O
the O
risk O
of O
renal O
impairment O
, O
particularly O
in O
volume-depleted O
patients O
. O

barbiturates B-group
; O

b O
. O

Paroxetine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
Sonata B-brand
20 O
mg O
and O
paroxetine B-drug
20 O
mg O
daily O
for O
7 O
days O
did O
not O
produce O
any O
interaction O
on O
psychomotor O
performance O
. O

ulcerans O
was O
measured O
by O
plate O
counts O
and O
the O
BACTEC O
radiometric O
method O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
there O
is O
a O
pharmacokinetic O
interaction O
when O
amprenavir B-drug
is O
given O
with O
rifabutin B-drug
or O
rifampin B-drug
and O
to O
determine O
the O
effects O
of O
these O
drugs O
on O
the O
erythromycin O
breath O
test O
( O
ERMBT O
) O
. O

Stereoselective O
behavioral O
effects O
of O
N-allylnormetazocine B-drug_n
in O
pigeons O
and O
squirrel O
monkeys O
. O

The O
effect O
on O
CYP1A2 O
was O
explored O
further O
in O
a O
clinical O
interaction O
study O
with O
theophylline B-drug
and O
no O
effect O
on O
metabolism O
was O
observed O
. O

Nabilone I-drug
should O
be O
administered O
with O
caution O
to O
patients O
who O
are O
taking O
other O
psychoactive B-group
drugs I-group
or O
CNS B-group
depressants I-group
, O
including O
alcohol B-drug
, O
barbiturates B-group
and O
narcotic B-group
analgesics I-group
, O
or O
to O
those O
with O
a O
history O
of O
psychiatric O
disorder O
( O
including O
manic-depressive O
illness O
and O
schizophrenia O
) O
. O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
CAMPTOSAR B-brand
and O
laboratory O
tests O
. O

Administration O
of O
lithium B-drug
prophylaxis O
. O

Sedatives/Hypnotics B-group
: O
triazolam B-drug
, O
midazolam B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
prolonged O
or O
increased O
sedation O
or O
respiratory O
depression O
. O

Drug O
Class O
Examples O
of O
Drugs O

Dosage O
adjustment O
of O
concomitant O
medications O
may O
be O
necessary O
. O

In O
the O
current O
study O
, O
the O
nonpredisposed O
strain O
C57BL/6N O
was O
also O
shown O
to O
be O
highly O
susceptible O
to O
diethylnitrosamine O
during O
the O
neonatal O
period O
. O

Phenobarbital B-drug
( O
Primidone B-drug
) O
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenobarbital B-drug
( O
primidone B-drug
) O
with O
or O
without O
other O
enzyme-inducing O
AEDs B-group
. O

BACKGROUND O
: O
Since O
its O
approval O
by O
the O
US O
Food O
and O
Drug O
Administration O
in O
March O
1998 O
, O
sildenafil B-drug
citrate I-drug
has O
been O
used O
by O
millions O
of O
men O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O

unreliable O
prothrombin O
time O
determinations O
; O

Additional O
iron B-drug
significantly O
inhibited O
the O
absorption O
of O
cobalt B-drug
in O
both O
dietary O
cobalt B-drug
treatments O
. O

It O
is O
not O
clear O
whether O
this O
was O
due O
to O
the O
combination O
of O
therapy O
. O

increased O
creatine O

A O
number O
of O
substances O
affect O
glucose O
metabolism O
and O
may O
require O
insulin B-drug
dose O
adjustment O
and O
particularly O
close O
monitoring O
. O

Beta-adrenergic B-group
receptor I-group
antagonists I-group
( O
beta-blockers B-group
) O
and O
BROVANA B-brand
may O
interfere O
with O
the O
effect O
of O
each O
other O
when O
administered O
concurrently O
. O

Based O
on O
the O
chemical O
resemblance O
of O
itraconazole B-drug
and O
ketoconazole B-drug
, O
coadministration O
of O
astemizole B-drug
with O
itraconazole B-drug
is O
contraindicated O
. O

Unless O
really O
needed O
, O
agents O
which O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Lovenox B-brand
Injection O
therapy O
. O

With O
the O
morning O
dose O
of O
ceftibuten B-drug
on O
day O
6 O
, O
each O
volunteer O
received O
a O
single O
intravenous O
infusion O
of O
theophylline B-drug
( O
4 O
mg/kg O
) O
. O

Ways O
of O
improving O
the O
adequacy O
of O
the O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-group
are O
discussed O
. O

May O
interact O
with O
wthionamide O
( O
Trecator-SC B-brand
) O
and O
isoniazid B-drug
( O
Nydrazid B-brand
) O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Methadone B-drug
: O
Coadministration O
of O
amprenavir B-drug
and O
methadone B-drug
can O
decrease O
plasma O
levels O
of O
methadone B-drug
. O

N-methyllevallorphan B-drug_n
( O
5 O
mg/kg O
, O
s.c O
. O
) O

Studies O
showed O
that O
diltiazem B-drug
increased O
the O
AUC O
of O
midazolam B-drug
and O
triazolam B-drug
by O
3-4 O
fold O
and O
the O
Cmax O
by O
2-fold O
, O
compared O
to O
placebo O
. O

AMEVIVE B-brand
is O
not O
indicated O
for O
pediatric O
patients O
. O

If O
pregnancy O
occurs O
in O
a O
patient O
or O
partner O
of O
a O
patient O
during O
treatment O
or O
during O
the O
6 O
months O
after O
treatment O
cessation O
, O
such O
cases O
should O
be O
reported O
to O
the O
COPEGUS B-brand
Pregnancy O
Registry O
at O
1-800-526-6367 O
. O

. O

Steady-state O
bosentan B-drug
plasma O
concentrations O
were O
3- O
to O
4-fold O
higher O
than O
in O
the O
absence O
of O
cyclosporine B-drug
A I-drug
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Therefore O
, O
it O
should O
be O
used O
in O
caution O
in O
patients O
receiving O
such O
agents O
. O

this O
did O
not O
interfere O
with O
its O
effect O
. O

Based O
on O
the O
results O
of O
these O
studies O
, O
it O
is O
concluded O
that O
azithromycin B-drug
may O
be O
safely O
coadministered O
with O
both O
zidovudine B-drug
and O
dideoxyinosine B-drug
. O

Hypotension O
- O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-group
, O
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
PRINIVIL B-brand
. O

Metformin B-drug
: O
In O
a O
single-dose O
interaction O
study O
in O
NIDDM O
subjects O
, O
decreases O
in O
glyburide B-drug
AUC O
and O
Cmax O
were O
observed O
, O
but O
were O
highly O
variable O
. O

. O

The O
bioavailability O
of O
the O
capsule O
formulation O
of O
cefprozil B-drug
was O
not O
affected O
when O
administered O
5 O
minutes O
following O
an O
antacid B-group
. O

Therefore O
, O
when O
using O
these O
blocking O
agents O
to O
treat O
hypertension O
, O
patients O
should O
be O
observed O
carefully O
in O
order O
to O
confirm O
that O
the O
desired O
therapeutic O
effect O
has O
been O
obtained O
. O

This O
interaction O
was O
not O
accompanied O
by O
ECG O
changes O
and O
its O
clinical O
significance O
is O
not O
known O
. O

Veratrum B-group
alkaloids I-group
: O
Amphetamines B-group
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-group
alkaloids I-group
. O

aBased O
on O
reports O
of O
narcotic O
withdrawal O
syndrome O
in O
patients O
treated O
with O
nevirapine B-drug
and O
methadone B-drug
concurrently O
, O
and O
evidence O
of O
decreased O
plasma O
concentrations O
of O
methadone B-drug
. O

The O
administration O
of O
naproxen B-drug
may O
result O
in O
increased O
urinary O
values O
for O
17-ketogenic O
steroids O
because O
of O
an O
interaction O
between O
the O
drug O
and/or O
its O
metabolites O
with O
m-dinitrobenzene O
used O
in O
this O
assay O
. O

these O
enzymes O
would O
therefore O
not O
be O
expected O
to O
be O
inhibited O
in O
clinical O
use O
. O

The O
reduced O
risk O
of O
adverse O
events O
and O
therapeutic O
superiority O
compared O
with O
haloperidol B-drug
and O
risperidone B-drug
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
support O
the O
choice O
of O
olanzapine B-drug
as O
a O
first-line O
option O
in O
the O
management O
of O
schizophrenia O
in O
the O
acute O
phase O
and O
for O
the O
maintenance O
of O
treatment O
response O
. O

In O
a O
study O
of O
12 O
schizophrenic O
patients O
coadministered O
oral O
haloperidol B-drug
and O
rifampin B-drug
, O
plasma O
haloperidol B-drug
levels O
were O
decreased O
by O
a O
mean O
of O
70 O
% O
and O
mean O
scores O
on O
the O
Brief O
Psychiatric O
Rating O
Scale O
were O
increased O
from O
baseline O
. O

Co-administration O
with O
antifungal B-group
agents I-group
such O
as O
ketoconazole B-drug
or O
itraconazole B-drug
is O
not O
recommended O
. O

Leucovorin B-drug
may O
enhance O
the O
toxicity O
of O
5-fluorouracil B-drug
. O

Laboratory O
Tests O
Pregnancy O
Test O
Female O
patients O
of O
childbearing O
potential O
must O
have O
negative O
results O
from O
2 O
urine O
or O
serum O
pregnancy O
tests O
with O
a O
sensitivity O
of O
at O
least O
25 O
mIU/mL O
before O
receiving O
the O
initial O
Accutane B-brand
prescription O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Mineral B-drug
oil I-drug
interferes O
with O
the O
absorption O
of O
fat-soluble B-group
vitamins I-group
, O
including O
vitamin B-group
D I-group
preparations I-group
. O

Digoxin B-drug
half-life O
of O
elimination O
was O
prolonged O
from O
34 O
+/- O
13 O
to O
40 O
+/- O
16 O
hours O
( O
p O
less O
than O
0.05 O
) O
. O

Therefore O
, O
based O
on O
these O
in O
vitro O
data O
, O
estazolam B-drug
is O
very O
unlikely O
to O
inhibit O
the O
biotransformation O
of O
other O
drugs O
metabolized O
by O
these O
CYP O
isoforms O

The O
biochemical O
toxicology O
of O
1,3-difluoroacetone B-drug_n
, O
a O
known O
metabolite O
of O
the O
major O
ingredient O
of O
the O
pesticide O
Gliftor B-drug_n
( O
1,3-difluoro-2-propanol B-drug_n
) O
, O
was O
investigated O
in O
vivo O
and O
in O
vitro O
. O

No O
pharmacokinetic O
interaction O
was O
identified O
. O

Alprazolam B-drug
: O
When O
fluvoxamine B-drug
maleate I-drug
( O
100 O
mg O
qd O
) O
and O
alprazolam B-drug
( O
1 O
mg O
q.d O
. O
were O
co-administered O
to O
steady O
state O
, O
plasma O
concentration O
and O
other O
pharmacokinetics O
parameters O
( O
AUC O
, O
Cmax O
, O
T1/2 O
, O
) O
of O
alprazolam B-drug
were O
approximately O
twice O
those O
observed O
when O
alprazolam B-drug
was O
administered O
alone O
; O

Drug/Laboratory O
Test O
Interactions O
No O
clinically O
significant O
changes O
in O
the O
results O
of O
clinical O
laboratory O
tests O
have O
been O
observed O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
blood O
glucose O
control O
. O

These O
compounds O
are O
metabolized O
through O
various O
cytochrome O
P450 O
isozymes O
including O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
and O
CYP3A O
. O

Efavirenz B-drug

The O
pharmacokinetics O
of O
fenofibric B-drug_n
acid I-drug_n
were O
not O
significantly O
affected O
by O
atorvastatin B-drug

Acebutolol B-drug
, O
atenolol B-drug
, O
and O
nadolol B-drug
( O
low O
hepatic O
clearance O
or O
no O
first-pass O
metabolism O
) O
are O
unlikely O
to O
be O
affected O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Drugs O
Demonstrated O
to O
be O
CYP O
3A O
Inhibitors O
of O
Possible O
Clinical O
Significance O
on O
the O
Basis O
of O
Clinical O
Studies O
Involving O
Alprazolam B-drug
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-drug
) O
: O
Coadministration O
of O
fluoxetine B-drug
with O
alprazolam B-drug
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
46 O
% O
, O
decreased O
clearance O
by O
21 O
% O
, O
increased O
half-life O
by O
17 O
% O
, O
and O
decreased O
measured O
psychomotor O
performance O
. O

The O
serum O
androgen O
concentrations O
of O
estradiol B-drug
+ O
endotoxin-treated B-drug_n
rats O
did O
not O
change O
significantly O
, O
while O
those O
of O
endotoxin-treated B-drug_n
rats O
dropped O
to O
30-40 O
% O

The O
mechanism O
for O
this O
interaction O
is O
unknown O
. O

Sucralfate B-drug
should O
not O
be O
taken O
within O
2 O
hours O
of O
FACTIVE B-brand
. O

Diltiazem B-drug
, O
nifedipine B-drug
, O
verapamil B-drug

In O
contrast O
, O
atropine B-drug
increased O
the O
amplitudes O
of O
components O
P1 O
and O
P2 O
, O
while O
decreasing O
components O
N1 O
, O
N2 O
and O
N3 O
for O
varying O
durations O
of O
time O
. O

Clindamycin B-drug
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-group
blocking I-group
agents I-group
. O

No O
drug O
interactions O
of O
clinical O
importance O
have O
been O
identified O
. O

Prior O
administration O
of O
succinylcholine B-drug
has O
no O
clinically O
important O
effect O
on O
the O
neuromuscular O
blocking O
action O
of O
NUROMAX B-brand
. O

Imipramine B-drug
hydrochloride I-drug
may O
potentiate O
the O
effects O
of O
CNS B-group
depressant I-group
drugs I-group
. O

SUSTIVA B-brand
has O
the O
potential O
to O
decrease O
plasma O
concentrations O
of O
itraconazole B-drug
and O
ketoconazole B-drug
. O

Since O
symptoms O
of O
anticholinesterase O
overdose O
( O
cholinergic O
crisis O
) O
may O
mimic O
underdosage O
( O
myasthenic O
weakness O
) O
, O
their O
condition O
may O
be O
worsened O
by O
the O
use O
of O
this O
drug O
. O

Since O
the O
effect O
of O
AMEVIVE B-brand
on O
pregnancy O
and O
fetal O
development O
, O
including O
immune O
system O
development O
, O
is O
not O
known O
, O
health O
care O
providers O
are O
encouraged O
to O
enroll O
patients O
currently O
taking O
AMEVIVE B-brand
who O
become O
pregnant O
into O
the O
Biogen O
Pregnancy O
Registry O
by O
calling O
1-866-AMEVIVE B-brand
( O
1-866-263-8483 O
) O
. O

Myocardial O
injury O
, O
including O
myocardial O
infarction O
, O
myocarditis O
, O
ventricular O
hypokinesia O
, O
and O
severe O
rhabdomyolysis O
appear O
to O
be O
increased O
in O
patients O
receiving O
PROLEUKIN B-brand
and O
interferon-alfa B-drug
concurrently O
. O

In O
comparison O
to O
saline O
values O
, O
all O
three O
agents O
produced O
reliable O
increases O
in O
peak O
latency O
for O
most O
of O
the O
components O
, O
with O
only O
N3 O
showing O
no O
effects O
. O

Understanding O
the O
breadth O
of O
systemic O
antimicrobial B-group
agents I-group
available O
for O
use O
by O
the O
dermatologist O
and O
their O
associated O
side-effect O
profiles O
and O
drug O
interactions O
allows O
the O
clinician O
to O
offer O
patients O
optimal O
care O
in O
the O
management O
of O
cutaneous O
infectious O
disease O
. O

Studies O
in O
humans O
show O
that O
the O
absorption O
of O
chlorothiazide B-drug
as O
reflected O
in O
urinary O
excretion O
is O
markedly O
decreased O
even O
when O
administered O
one O
hour O
before O
colestipol B-drug
hydrochloride I-drug
. O

Anticoagulants B-group
( O
Oral O
) O
: O
The O
hypoprothrombinemic O
effect O
of O
anticoagulants B-group
may O
be O
potentiated O
, O
apparently O
by O
increased O
catabloism O
of O
vitamin O
K-dependent O
clotting O
factors O
. O

Boric B-drug
acid I-drug
may O
interact O
with O
the O
idoxuridine B-drug
preparation O
causing O
a O
gritty O
substance O
to O
form O
or O
may O
interact O
with O
the O
preservative O
in O
the O
idoxuridine B-drug
preparation O
causing O
a O
toxic O
effect O
in O
the O
eye O
. O

Although O
inhibition O
of O
CYP O
3A4/5 O
by O
OXC B-drug
and O
MHD B-drug_n
did O
occur O
at O
high O
concentrations O
, O
it O
is O
not O
likely O
to O
be O
of O
clinical O
significance O
. O

The O
dosage O
of O
these O
drugs O
or O
others O
with O
a O
similar O
metabolism O
may O
need O
to O
be O
modified O
if O
they O
are O
administered O
concomitantly O
with O
nilutamide B-drug
. O

Lastly O
local O
use O
of O
the O
mucocutaneous O
and O
cytoprotective O
properties O
of O
magnesium B-drug
is O
still O
valid O
, O
in O
cardioplegic B-drug
solutions I-drug
and O
for O
preservation O
of O
transplants O
particularly O
. O

Furosemide B-drug
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-drug
. O

efavirenz I-drug
concentration O

In O
a O
Phase O
I O
trial O
using O
escalating O
doses O
of O
TAXOL B-brand
( O
110-200 O
mg/m2 O
) O
and O
cisplatin B-drug
( O
50 O
or O
75 O
mg/m2 O
) O
given O
as O
sequential O
infusions O
, O
myelosuppression O
was O
more O
profound O
when O
TAXOL B-brand
was O
given O
after O
cisplatin B-drug
than O
with O
the O
alternate O
sequence O
( O
ie O
, O
TAXOL B-brand
before O
cisplatin B-drug
) O
. O

-adrenergic O
Blockers O
: O
-adrenergic O
blockers O
may O
weaken O
or O
antagonise O
the O
effect O
of O
FORADIL B-brand
. O

The O
key O
to O
maximizing O
therapy O
lies O
in O
individualizing O
it O
as O
much O
as O
possible O
. O

In O
clinical O
studies O
with O
PROPECIA B-brand
( O
finasteride B-drug
, O
1 O
mg O
) O
in O
men O
18-41 O
years O
of O
age O
, O
the O
mean O
value O
of O
serum O
prostate-specific O
antigen O
( O
PSA O
) O
decreased O
from O
0.7 O
ng/mL O
at O
baseline O
to O
0.5 O
ng/mL O
at O
Month O
12 O
. O

The O
patient O
had O
been O
receiving O
simvastatin B-drug
for O
approximately O
six O
months O
. O

Ergot-containing B-group
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
lasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

The O
concomitant O
use O
of O
alcohol B-drug
or O
other O
central B-group
nervous I-group
system I-group
depressants I-group
may O
have O
an O
additive O
effect O
. O

Antiarrhythmics B-drug
: O
Other O
antiarrhythmic B-drug
drugs O
, O
such O
as O
quinidine B-drug
, O
procainamide B-drug
, O
disopyramide B-drug
, O
and O
phenytoin B-drug
, O
have O
been O
used O
concurrently O
with O
amiodarone B-drug
. O

However O
, O
because O
nafarelin B-drug
acetate I-drug
is O
a O
peptide O
that O
is O
primarily O
degraded O
by O
peptidase O
and O
not O
by O
cytochrome O
P-450 O
enzymes O
, O
and O
the O
drug O
is O
only O
about O
80 O
% O
bound O
to O
plasma O
proteins O
at O
4 O
C O
, O
drug O
interactions O
would O
not O
be O
expected O
to O
occur O
. O

However O
, O
since O
there O
is O
an O
increased O
risk O
of O
bleeding O
with O
Xigris B-brand
, O
caution O
should O
be O
employed O
when O
Xigris B-brand
is O
used O
with O
other O
drugs O
that O
affect O
hemostasis O
. O

In O
addition O
, O
new O
cases O
of O
diabetes O
have O
been O
diagnosed O
during O
retinoid B-group
therapy O
, O
including O
diabetic O
ketoacidosis O
. O

On O
the O
contrary O
, O
neurotensin B-drug_n
and O
tuftsin B-drug_n
were O
agonists O
in O
induction O
of O
analgesia O
. O

A O
chemically O
similar O
drug O
in O
this O
class O
produced O
optic O
nerve O
degeneration O
( O
Wallerian O
degeneration O
of O
retinogeniculate O
fibers O
) O
in O
clinically O
normal O
dogs O
in O
a O
dose-dependent O
fashion O
at O
a O
dose O
that O
produced O
plasma O
drug O
levels O
about O
30 O
times O
higher O
than O
the O
mean O
drug O
level O
in O
humans O
taking O
the O
highest O
recommended O
dose O
. O

- O
Furazolidone B-drug
( O
e.g. O
, O
Furoxone B-brand
) O
or O

Concomitant O
administration O
of O
diltiazem B-drug
with O
carbamazepine B-drug
has O
been O
reported O
to O
result O
in O
elevated O
serum O
levels O
of O
carbamazepine B-drug
( O
40 O
% O
to O
72 O
% O
increase O
) O
, O
resulting O
in O
toxicity O
in O
some O
cases O
. O

In O
single O
and O
multiple O
dose O
studies O
in O
healthy O
subjects O
receiving O
both O
warfarin B-drug
and O
rofecoxib B-drug
, O
prothrombin O
time O
( O
measured O
as O
INR O
) O
was O
increased O
by O
approximately O
8 O
% O
to O
11 O
% O
. O

Pharmacokinetic O
studies O
indicate O
that O
administration O
of O
disulfiram B-drug
or O
diazepam B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
acamprosate B-drug
. O

Therefore O
, O
agents O
affecting O
sympathetic O
activity O
( O
e.g. O
, O
ganglionic B-group
blocking I-group
agents I-group
or O
adrenergic B-group
neuron I-group
blocking I-group
agents I-group
) O
should O
be O
used O
with O
caution O
. O

Reports O
in O
the O
literature O
suggest O
that O
plasma O
levels O
of O
doxorubicin B-drug
( O
and O
its O
active O
metabolite O
doxorubicinol B-drug_n
) O
may O
be O
increased O
when O
paclitaxel B-drug
and O
doxorubicin B-drug
are O
used O
in O
combination O
. O

The O
concomitant O
use O
of O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
with O
SPRYCEL B-brand
is O
not O
recommended O
. O

The O
results O
indicate O
that O
a O
statistically O
significant O
difference O
exists O
between O
the O
excreted O
levels O
of O
homocysteine O
in O
the O
urine O
of O
both O
control O
and O
levonorgestrel-treated B-drug
rats O
and O
the O
levels O
shown O
by O
rats O
treated O
with O
ethynyl B-drug
estradiol I-drug
. O

The O
IV O
methylprednisolone B-drug
dose O
should O
be O
reduced O
by O
approximately O
25 O
% O
, O
and O
the O
oral O
methylprednisolone B-drug
dose O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-drug
to O
achieve O
exposures O
of O
methylprednisolone B-drug
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-drug
. O

Simultaneous O
use O
of O
activated B-group
prothrombin I-group
complex I-group
concentrates I-group
or O
prothrombin B-group
complex I-group
concentrates I-group
should O
be O
avoided O
. O

Digoxin B-drug
did O
not O
affect O
BREVIBLOC B-brand
pharmacokinetics O
. O

Urinary B-drug
acidifying I-drug
agents O
decrease O
blood O
levels O
and O
increase O
excretion O
of O
amphetamines B-group
. O

Antibiotics B-group
( O
ampicillin B-drug
, O
tetracycline B-drug
) O
: O
Pregnancy O
has O
been O
reported O
following O
concomitant O
use O
, O
however O
, O
pharmacokinetic O
studies O
have O
not O
shown O
consistent O
effects O
with O
these O
antibiotics B-group
on O
plasma O
concentrations O
of O
synthetic B-group
steroids I-group
. O

The O
second O
pregnancy O
test O
( O
a O
confirmation O
test O
) O
should O
be O
done O
during O
the O
first O
5 O
days O
of O
the O
menstrual O
period O
immediately O
preceding O
the O
beginning O
of O
Accutane B-brand
therapy O
. O

However O
, O
total O
mucosal O
accumulation O
of O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
and O
that O
transferred O
to O
the O
body O
increase O
in O
a O
linear O
logarithmic O
fashion O
from O
0.05 O
to O
5 O
mm O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
. O

Information O
on O
concurrent O
usage O
of O
atenolol B-drug
and O
aspirin B-brand
is O
limited O
. O

In O
order O
to O
avoid O
the O
occurrence O
of O
severe O
hypersensitivity O
reactions O
, O
all O
patients O
treated O
with O
TAXOL B-brand
should O
be O
premedicated O
with O
corticosteroids B-group
( O
such O
as O
dexamethasone B-drug
) O
, O
diphen-hydramine O
and O
H2 B-group
antagonists I-group
( O
such O
as O
cimetidine B-drug
or O
ranitidine B-drug
) O
. O

Patients O
in O
a O
clinical O
study O
who O
were O
on O
established O
therapy O
with O
sulfasalazine B-drug
, O
to O
which O
ENBREL B-brand
was O
added O
, O
were O
noted O
to O
develop O
a O
mild O
decrease O
in O
mean O
neutrophil O
counts O
in O
comparison O
to O
groups O
treated O
with O
either O
ENBREL B-brand
CI O
or O
sulfasalazine B-drug
alone O
. O

It O
is O
concluded O
from O
these O
results O
that O
the O
modulatory O
effect O
of O
glycine B-drug
is O
evidently O
a O
later O
developmental O
acquisition O
( O
after O
day O
15 O
of O
incubation O
) O
in O
the O
embryogenesis O
of O
NMDA-ergic O
activation O
of O
spontaneous O
motility O
in O
chick O
embryos O
similarly O
as O
glycinergic O
inhibition O
. O

If O
TRANXENE B-brand
is O
to O
be O
combined O
with O
other O
drugs O
acting O
on O
the O
central O
nervous O
system O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
to O
be O
employed O
. O

Plasma O
concentrations O
of O
cyclosporine B-drug
should O
therefore O
be O
closely O
monitored O
, O
and O
its O
dosage O
reduced O
accordingly O
, O
in O
patients O
treated O
with O
nicardipine B-drug
. O

Excessive O
ethanol B-drug
ingestion O
should O
be O
avoided O
because O
a O
psychotic O
reaction O
has O
been O
reported O
. O

There O
is O
thus O
an O
enhancement O
effect O
of O
PGF2alpha B-drug
upon O
the O
reaction O
of O
placental O
vessels O
to O
oxytocin B-drug
in O
vitro O
. O

Azithromycin B-drug

or O
- O
over-the-counter O
cough O
, O
cold O
, O
allergy O
, O
or O
weight O
loss O
medications O
. O

DESIGN O
: O
Open-label O
, O
three-phase O
, O
sequential O
study O
. O

Adenosine B-drug
effects O
are O
potentiated O
by O
dipyridamole B-drug
. O

Aerosol O
particles O
of O
budesonide B-drug
were O
generated O
from O
an O
ethanol B-drug
solution O
, O
dried O
, O
and O
collected O
by O
a O
cascade O
impactor O
for O
characterization O
or O
by O
a O
liquid O
impinger O
for O
dissolution O
experiments O
. O

Colestipol B-drug

STUDY O
OBJECTIVE O
: O
To O
evaluate O
the O
effect O
of O
fluoxetine B-drug
on O
the O
pharmacokinetics O
and O
cardiovascular O
safety O
of O
cisapride B-drug
at O
steady O
state O
in O
healthy O
men O
. O

However O
, O
current O
evidence O
suggests O
that O
isoniazid B-drug
does O
induce O
P-450IIE1 O
, O
a O
mixed-function O
oxidase O
enzyme O
that O
appears O
to O
generate O
the O
toxic O
metabolites O
, O
in O
the O
liver O
. O

Nelfinavir B-drug
is O
an O
inhibitor O
of O
CYP3A O
( O
cytochrome O
P450 O
3A O
) O
. O

The O
vasodilating O
effects O
of O
nitroglycerin B-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

The O
hatching O
of O
miracidia O
from O
eggs O
was O
inhibited O
by O
concentrations O
of O
1000-10000 O
microg/l O
of O
single O
metals O
. O

Phenytoin B-drug
decreases O
serum O
amiodarone O
levels O
. O

The O
effect O
of O
orally O
ingested O
peginterferon B-drug
or O
ribavirin B-drug
from O
breast O
milk O
on O
the O
nursing O
infant O
has O
not O
been O
evaluated O
. O

Vardenafil B-drug
dose O
should O
not O
exceed O
a O
maximum O
of O
2.5 O
mg O
in O
a O
24-hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-drug
therapy O
. O

therefore O
, O
caution O
should O
be O
used O
when O
administering O
CYP3A4 O
inhibitors O
with O
IRESSA B-brand
. O

Therefore O
, O
the O
simultaneous O
administration O
of O
these O
drugs O
should O
be O
avoided O
. O

Non-selective B-group
MAO I-group
inhibitors I-group
including O
tranylcypromine B-drug
sulfate I-drug
, O
phenelzine B-drug
sulfate I-drug
, O
and O
pargyline B-drug
HC1 O
: O
Concomitant O
use O
of O
L-tyrosine B-drug
and O
non-selective O
MAO B-group
inhibitors I-group
may O
cause O
hypertension O
. O

Acetaminophen B-drug
had O
no O
effect O
on O
plasma O
levels O
of O
diflunisal B-drug
. O

However O
, O
in O
patients O
treated O
with O
oral O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
rare O
instances O
of O
drug O
interactions O
have O
occurred O
with O
high-dose O
salicylate B-drug
therapy O
. O

Immunosuppressive B-group
Drugs I-group
, O
Fibric B-group
Acid I-group
Derivatives I-group
, O
Niacin B-drug
( O
Nicotinic B-drug
Acid I-drug
, O
Erythromycin B-drug
, O
Azole B-group
Antifungals I-group
: O
Skeletal O
Muscle O
. O

Further O
, O
these O
results O
confirm O
that O
the O
diabetic O
Chinese O
hamster O
's O
alpha O
and O
beta O
cells O
respond O
normally O
to O
theophylline B-drug
, O
but O
are O
relatively O
insensitive O
to O
glucose B-drug
. O

Patients O
treated O
with O
acebutolol B-drug
plus O
catecholamine B-group
depletors I-group
should O
, O
therefore O
, O
be O
observed O
closely O
for O
evidence O
of O
marked O
bradycardia O
or O
hypotension O
which O
may O
present O
as O
vertigo O
, O
syncope/presyncope O
, O
or O
orthostatic O
changes O
in O
blood O
pressure O
without O
compensatory O
tachycardia O
. O

Thus O
, O
the O
hypothesis O
of O
Gibaldi O
et O
al O
. O

This O
has O
been O
observed O
with O
CLINITEST O
reagent O
tablets O

For O
patients O
with O
amenorrhea O
, O
the O
second O
test O
should O
be O
done O
at O
least O
11 O
days O
after O
the O
last O
act O
of O
unprotected O
sexual O
intercourse O
( O
without O
using O
2 O
effective O
forms O
of O
contraception O
) O
. O

No O
interactions O
have O
been O
observed O
with O
beta-receptor B-group
blockers I-group
, O
calcium B-group
antagonists I-group
, O
thiazide O
and O
loop B-group
diuretics I-group
and O
ACE B-group
inhibitors I-group
. O

These O
experiences O
have O
been O
characterized O
by O
flushing O
, O
rash O
, O
peripheral O
edema O
, O
nausea O
, O
and O
headache O
. O

Modification O
of O
toxin B-drug_n
A I-drug_n
with O
diethyl B-drug_n
pyrocarbonate I-drug_n
abolished O
both O
its O
cytotoxic O
activity O
and O
the O
ability O
of O
the O
toxin O
to O
bind O
Zn-Sepharose O
gel O
. O

Flurbiprofen B-drug
pretreatment O
attenuated O
the O
hypotensive O
effect O
of O
a O
single O
dose O
of O
propranolol B-drug
but O
not O
atenolol B-drug
. O

Conclusions O
and O
the O
types O
of O
studies O
which O
support O
these O
conclusions O
are O
given O
for O
each O
major O
section O
. O

Thiazide B-group
Diuretics I-group
: O
The O
reports O
that O
the O
concomitant O
use O
of O
allopurinol B-drug
and O
thiazide B-group
diuretics I-group
may O
contribute O
to O
the O
enhancement O
of O
allopurinol B-drug
toxicity O
in O
some O
patients O
have O
been O
reviewed O
in O
an O
attempt O
to O
establish O
a O
cause-and-effect O
relationship O
and O
a O
mechanism O
of O
causation O
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

For O
example O
, O
when O
vitamin B-group
K I-group
antagonists I-group
are O
administered O
concomitantly O
with O
nilutamide B-drug
, O
prothrombin O
time O
should O
be O
carefully O
monitored O
and O
if O
necessary O
, O
the O
dosage O
of O
vitamin B-group
K I-group
antagonists I-group
should O
be O
reduced O
. O

Theophylline B-drug
: O
Grepafloxacin B-drug
is O
a O
competitive O
inhibitor O
of O
the O
metabolism O
of O
theophylline B-drug
. O

However O
, O
the O
absolute O
number O
of O
alcohol-related B-drug
deaths O
is O
far O
greater O
than O
the O
number O
of O
deaths O
in O
amphetamine B-drug
or O
heroin B-drug_n
users O
. O

Phenytoin/Phenobarbital B-drug
: O
The O
coadministration O
of O
phenytoin B-drug
or O
phenobarbital B-drug
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-group
D I-group
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol/ergocalcitriol B-drug
by O
accelerating O
metabolism O
. O

In O
the O
presence O
of O
these O
methylxanthines B-group
, O
larger O
doses O
of O
adenosine B-drug
may O
be O
required O
or O
adenosine B-drug
may O
not O
be O
effective O
. O

Gastrointestinal O
: O
Nausea O
( O
4-12 O
% O
) O
, O
constipation O
( O
2-6 O
% O
) O
; O

If O
a O
diuretic B-group
is O
also O
used O
, O
the O
risk O
of O
lithium O
toxicity O
may O
be O
increased O
. O

The O
administration O
of O
epinephrine B-drug
should O
be O
avoided O
in O
the O
treatment O
of O
drug O
induced O
hypotension O
because O
of O
a O
possible O
reverse O
epinephrine B-drug
effect O
. O

The O
blood O
pressure O
( O
carotid O
cannulation O
) O
decreased O
along O
with O
the O
core O
temperature O
. O

The O
decrease O
in O
temperature O
began O
within O
20 O
minutes O
after O
ethanol B-drug
administration O
, O
reaching O
a O
maximal O
decrease O
between O
60 O
and O
120 O
minutes O
post O
ethanol B-drug
. O

Aripiprazole B-drug
dose O
should O
be O
reduced O
to O
one-half O
of O
its O
normal O
dose O
when O
concomitant O
administration O
of O
quinidine B-drug
with O
aripiprazole B-drug
occurs O
. O

Dose O
adjustment O
is O
not O
recommended.Levetiracetam B-drug
had O
no O
effect O
on O
plasma O
concentrations O
of O
carbamazepine B-drug
, O
valproate B-drug
, O
topiramate B-drug
, O
or O
lamotrigine B-drug
. O

Peripheral O
mononuclear O
cells O
were O
also O
collected O
for O
quantitation O
of O
phosphorylated O
zidovudine B-drug
. O

Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

In O
the O
present O
study O
, O
it O
is O
proposed O
that O
the O
opioids B-group
applied O
to O
supraspinal O
brain O
sites O
produced O
their O
analgesic O
effects O
by O
the O
activation O
of O
different O
descending O
pain O
inhibitory O
systems O
. O

Warfarin B-drug
: O
The O
effect O
of O
valdecoxib B-drug
on O
the O
anticoagulant O
effect O
of O
warfarin B-drug
( O
1 O
- O
8 O
mg/day O
) O
was O
studied O
in O
healthy O
subjects O
by O
coadministration O
of O
BEXTRA B-brand
40 O
mg O
BID O
for O
7 O
days O
. O

While O
mean O
INR O
values O
were O
only O
slightly O
increased O
with O
coadministration O
of O
valdecoxib B-drug
, O
the O
day-to-day O
variability O
in O
individual O
INR O
values O
was O
increased O
. O

The O
preservation O
of O
the O
microtubules O
was O
improved O
when O
D2O O
was O
present O
in O
the O
incubation O
medium O
. O

With O
simultaneous O
dosing O
of O
Vardenafil B-drug
10 O
mg O
and O
terazosin B-drug
10 O
mg O
, O
6 O
of O
8 O
subjects O
experienced O
a O
standing O
systolic O
blood O
pressure O
of O
less O
than O
85 O
mm O
Hg O
. O

Lithium B-drug
: O
Inhibition O
of O
renal O
lithium B-drug
clearance O
, O
leading O
to O
an O
increase O
in O
plasma O
lithium B-drug
concentration O
, O
has O
been O
reported O
with O
some O
prostaglandin O
synthesis-inhibiting O
drugs O
. O

Drugs O
that O
reduce O
the O
number O
of O
blood O
platelets O
by O
causing O
bone O
marrow O
depression O
( O
such O
as O
antineoplastic B-group
agents I-group
) O
or O
drugs O
which O
inhibit O
platelet O
function O
( O
eg O
, O
aspirin B-brand
and O
other O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
, O
dipyridamole B-drug
, O
hydrochloroquine B-drug
, O
clofibrate B-drug
, O
dextran B-drug
) O
may O
increase O
the O
bleeding O
tendency O
produced O
by O
anticoagulants B-group
without O
altering O
prothrombin O
time O
determinations O
. O

Monitoring O
for O
amiodarone B-drug
toxicity O
and O
serial O
measurement O
of O
amiodarone B-drug
serum O
concentration O
during O
concomitant O
protease B-group
inhibitor I-group
therapy O
should O
be O
considered O
. O

Interactions O
with O
Fruit O
Juices O
Fruit O
juices O
such O
as O
grapefruit O
, O
orange O
and O
apple O
may O
reduce O
the O
bioavailability O
and O
exposure O
of O
fexofenadine B-drug
. O

The O
effects O
of O
oral O
neomycin B-drug
on O
ACTH B-group
induced O
hypertension O
were O
examined O
in O
conscious O
sheep O
. O

Cardiovascular O
disease O
is O
a O
common O
comorbidity O
and O
a O
major O
cause O
of O
mortality O
in O
patients O
with O
chronic O
renal O
disease O
. O

Patients O
taking O
warfarin B-drug
or O
other O
coumarin-derivative B-group
anticoagulants I-group
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O

Risk O
of O
Anaphylactic O
Reaction O
: O
Although O
it O
is O
known O
that O
patients O
on O
beta-blockers B-group
may O
be O
refractory O
to O
epinephrine B-drug
in O
the O
treatment O
of O
anaphylactic O
shock O
, O
beta-blockers B-group
can O
, O
in O
addition O
, O
interfere O
with O
the O
modulation O
of O
allergic O
reaction O
and O
lead O
to O
an O
increased O
severity O
and/or O
frequency O
of O
attacks O
. O

- O
Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
leading O
to O
in-creased O
circulating O
total O
thyroid O
hormone O
; O

Serum O
digoxin B-drug
levels O
using O
an O
125I-labelled O
antigen O
: O
Validation O
of O
method O
and O
observations O
on O
cardiac O
patients O
. O

There O
are O
no O
known O
drug O
interactions O
with O
LEUSTATIN B-brand
Injection O
. O

This O
cluster O
of O
metabolic O
abnormalities O
has O
been O
termed O
the O
insulin O
resistance O
or O
cardiovascular O
dysmetabolic O
syndrome O
. O

Deferasirox B-drug
should O
be O
taken O
on O
an O
empty O
stomach O
30 O
minutes O
before O
eating O
. O

As O
DIFFERIN B-brand
Gel O
has O
the O
potential O
to O
produce O
local O
irritation O
in O
some O
patients O
, O
concomitant O
use O
of O
other O
potentially O
irritating O
topical O
products O
( O
medicated O
or O
abrasive O
soaps O
and O
cleansers O
, O
soaps O
and O
cosmetics O
that O
have O
a O
strong O
drying O
effect O
, O
and O
products O
with O
high O
concentrations O
of O
alcohol O
, O
astringents O
, O
spices O
or O
lime O
) O
should O
be O
approached O
with O
caution O
. O

To O
investigate O
the O
effects O
of O
antimicrobial O
combinations O
of O
GL B-drug_n
with O
four O
kinds O
of O
antibiotics B-group
( O
ampicillin B-drug
, O
cefazolin B-drug
, O
oxytetracycline B-drug
and O
chloramphenicol B-drug
) O
, O
the O
fractional O
inhibitory O
concentration O
index O
( O
FICI O
) O
was O
determined O
by O
checkerboard O
assay O
for O
each O
strain O
. O

Effect O
of O
Clonazepam B-drug
on O
the O
Pharmacokinetics O
of O
Other O
Drugs O
: O
Clonazepam B-drug
does O
not O
appear O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-drug
, O
carbamazepine B-drug
, O
or O
phenobarbital B-drug
. O

Excystment O
in O
vitro O
was O
only O
significantly O
affected O
by O
cercariae O
exposed O
to O
cadmium/zinc O
mixtures O
whilst O
encysting O
. O

Hypokalemia O
may O
increase O
susceptibility O
to O
cardiac O
arrhythmias O
in O
patients O
treated O
with O
digitalis B-group
. O

Lamivudine B-drug
: O
In O
vitro O
studies O
in O
peripheral O
blood O
mononuclear O
cells O
, O
U937 O
and O
Molt-4 O
cells O
revealed O
that O
lamivudine B-drug
significantly O
inhibited O
zalcitabine B-drug
phosphorylation O
in O
a O
dose O
dependent O
manner O
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

as O
judged O
by O
increased O
serum O
enzyme O
activities O
and O
increased O
incidence O
of O
hepatic O
necrosis O
. O

Caution O
should O
be O
exercised O
if O
an O
HMG-CoA B-group
reductase I-group
inhibitor I-group
is O
administered O
concomitantly O
with O
drugs O
that O
may O
decrease O
the O
levels O
or O
activity O
of O
endogenous O
steroid O
hormones O
, O
such O
as O
ketoconazole B-drug
, O
spironolactone B-drug
, O
and O
cimetidine B-drug
. O

Inhibitors O
of O
CYP2D6 O
: O
Because O
CYP2D6 O
is O
involved O
in O
duloxetine B-drug
metabolism O
, O
concomitant O
use O
of O
duloxetine B-drug
with O
potent O
inhibitors O
of O
CYP2D6 O
may O
result O
in O
higher O
concentrations O
of O
duloxetine B-drug
. O

Ketoconazole B-drug
: O
Co-administration O
of O
200 O
mg O
twice-daily O
ketoconazole B-drug
with O
aliskiren B-drug
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
plasma O
levels O
of O
aliskiren B-drug
. O

The O
pharmacokinetic O
variables O
for O
digoxin B-drug
were O
determined O
after O
a O
1.0 O
mg O
intravenous O
dose O
of O
digoxin B-drug
in O
each O
subject O
, O
before O
and O
after O
oral O
amiodarone B-drug
, O
400 O
mg O
daily O
for O
3 O
weeks O
. O

Drugs O
That O
Interfere O
With O
Hemostasis O
( O
NSAIDs B-group
, O
Aspirin B-brand
, O
Warfarin B-drug
, O
etc O
. O
) O

Rat O
kidney O
homogenates O
supplemented O
with O
coenzyme O
A O
, O
ATP O
, O
oxaloacetate O
, O
and O
Mg2+ O
converted O
1,3-difluoroacetone B-drug_n
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
in O
vitro O
. O

mefenamic B-drug
acid I-drug
; O

Genitourinary O
: O
Urinary O
frequency O
( O
2-6 O
% O
) O
; O

Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-drug
potently O
inhibits O
the O
metabolism O
of O
cisapride B-drug
resulting O
in O
a O
mean O
eight-fold O
increase O
in O
AUC O
of O
cisapride B-drug
. O

Ketoconazole B-drug
at O
400 O
mg O
daily O
( O
the O
maximum O
approved O
prescription O
dose O
) O
co-administered O
with O
TIKOSYN B-brand
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-drug
Cmax O
by O
53 O
% O
in O
males O
and O
97 O
% O
in O
females O
, O
and O
AUC O
by O
41 O
% O
in O
males O
and O
69 O
% O
in O
females O
. O

Any O
agent O
that O
alters O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
effect O
on O
target O
tissues O
, O
metabolism O
, O
or O
elimination O
may O
alter O
the O
optimal O
therapeutic O
dose O
of O
levothyroxine B-drug
sodium O
. O

Cysteine B-drug
conjugation O
at O
3.6 O
, O
5.3 O
and O
7.3 O
% O
( O
m/m O
) O
resulted O
in O
R-values O
of O
1.4 O
, O
1.7 O
and O
1.8 O
, O
respectively O
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
: O
Coadministration O
of O
moclobemide B-drug
resulted O
in O
a O
27 O
% O
decrease O
in O
almotriptan B-drug
clearance O
and O
an O
increase O
in O
Cmax O
of O
approximately O
6 O
% O
. O

GI O
Motility O
Agent O
: O
cisapride* B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

However O
, O
increasing O
use O
of O
such O
preparations O
to O
control O
symptoms O
indicates O
deterioration O
of O
asthma O
control O
and O
the O
need O
to O
reassess O
the O
patient O
s O
therapy O
. O

Concomitant O
administration O
of O
FACTIVE B-brand
and O
calcium B-drug
carbonate I-drug
, O
cimetidine B-drug
, O
omeprazole B-drug
, O
or O
an O
estrogen/progesterone B-group
oral O
contraceptive B-group
produced O
minor O
changes O
in O
the O
pharmacokinetics O
of O
gemifloxacin B-drug
, O
which O
were O
considered O
to O
be O
without O
clinical O
significance O
. O

Interaction O
with O
Food O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Metabolism O
. O

5-HT3 B-group
antagonists I-group
: O
In O
clinical O
drug O
interaction O
studies O
, O
aprepitant B-drug
did O
not O
have O
clinically O
important O
effects O
on O
the O
pharmacokinetics O
of O
ondansetron B-drug
or O
granisetron B-drug
. O

Use O
lowest O
possible O
dose O
of O
atorvastatin B-drug
with O
careful O
monitoring O
, O
or O
consider O
HMG-CoA B-group
reductase I-group
inhibitors I-group
that O
are O
not O
primarily O
metabolized O
by O
CYP3A4 O
, O
such O
as O
pravastatin B-drug
, O
fluvastatin B-drug
, O
or O
rosuvastatin B-drug
in O
combination O
with O
CRIXIVAN B-brand
. O

Patients O
who O
have O
been O
treated O
with O
MAO B-group
inhibitors I-group
within O
two O
to O
three O
weeks O
prior O
to O
the O
administration O
of O
dopamine B-drug
HCl I-drug
should O
receive O
initial O
doses O
of O
dopamine B-drug
HCl I-drug
no O
greater O
than O
one-tenth O
( O
1/10 O
) O
of O
the O
usual O
dose O
. O

There O
is O
considerable O
evidence O
suggesting O
that O
histaminergic O
and O
serotoninergic O
central O
pathways O
are O
involved O
in O
nociception O
and O
that O
antihistaminic B-group
drugs O
can O
modulate O
their O
responses O
( O
1 O
) O
. O

Glyburide B-drug
: O
Glyburide B-drug
is O
a O
CYP O
2C9 O
substrate O
. O

The O
concomitant O
use O
of O
nitrofurantoin B-drug
is O
not O
recommended O
since O
nitrofurantoin B-drug
may O
antagonize O
the O
antibacterial O
effect O
of O
Norfloxacin B-drug
in O
the O
urinary O
tract O
. O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

The O
hypotensive O
effect O
of O
sodium B-drug
nitroprusside I-drug
is O
augmented O
by O
that O
of O
most O
other O
hypotensive B-group
drugs I-group
, O
including O
ganglionic B-group
blocking I-group
agents I-group
, O
negative O
inotropic O
agents O
, O
and O
inhaled O
anesthetics B-group
. O

GABITRIL B-brand
is O
considered O
to O
be O
a O
non-enzyme O
inducing O
AED B-group
. O

The O
following O
drugs O
have O
been O
coadministered O
with O
Kerlone B-brand
and O
have O
not O
altered O
its O
pharmacokinetics O
: O
cimetidine B-drug
, O
nifedipine B-drug
, O
chlorthalidone B-drug
, O
and O
hydrochlorothiazide B-drug
. O

AUCss O
( O
0-12h O
) O
( O
Extent O
of O
systemic O
exposure O
) O

Although O
concomitant O
use O
of O
Clozapine B-drug
and O
carbamazepine B-drug
is O
not O
recommended O
, O
it O
should O
be O
noted O
that O
discontinuation O
of O
concomitant O
carbamazepine B-drug
administration O
may O
result O
in O
an O
increase O
in O
Clozapine B-drug
plasma O
levels O
. O

Sildenafil B-drug

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

Data O
from O
studies O
to O
date O
show O
that O
disease O
states O
, O
underlying O
conditions O
, O
and O
concomitantly O
administered O
highly O
protein-bound O
drugs O
have O
essentially O
no O
effect O
on O
etodolac B-drug
pharmacokinetics O
. O

Warfarin B-drug
: O
Increased O
INR O
( O
International O
Normalized O
Ratio O
) O
when O
ARAVA B-brand
and O
warfarin B-drug
were O
co-administered O
has O
been O
rarely O
reported O
. O

The O
mechanism O
for O
this O
interaction O
probably O
is O
adsorption O
of O
nitrofurantoin B-drug
onto O
the O
surface O
of O
magnesium B-drug
trisilicate I-drug
. O

An O
oral O
glucose B-drug
overload O
of O
1 O
ml O
of O
a O
50 O
% O
glucose B-drug
solution O
was O
given O
to O
rats O
and O
blood O
glucose O
was O
determined O
after O
30 O
, O
60 O
and O
90 O
min O
. O

Caution O
should O
be O
exercised O
when O
imipramine B-drug
hydrochloride I-drug
is O
used O
with O
agents O
that O
lower O
blood O
pressure O
. O

Rifampin B-drug

There O
is O
the O
possibility O
of O
precipitating O
anticonvulsant O
drug O
toxicity O
. O

Because O
of O
possible O
additive O
effects O
with O
other O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
concomitant O
use O
is O
not O
advisable O
. O

certain O
tetracyclic B-group
antidepressants I-group
( O
such O
as O
maprotiline B-drug
) O
; O

Nonsteroidal B-drug
Antiinflammatory I-drug
Agents O
: O
Aspirin B-drug
is O
contraindicated O
in O
patients O
who O
are O
hypersensitive O
to O
nonsteroidal B-drug
anti-inflammatory I-drug
agents O
. O

There O
are O
no O
data O
that O
conclusively O
establish O
whether O
the O
concomitant O
administration O
of O
Mefloquineuine O
and O
the O
above O
listed O
agents O
has O
an O
effect O
on O
cardiac O
function O
. O

especially O
if O
these O
patients O
are O
extensive O
metabolizers O
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel-blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

Thus O
, O
concentrations O
which O
have O
been O
obtained O
in O
vivo O
clinically O
in O
patients O
with O
normal O
renal O
function O
are O
considerably O
lower O
than O
the O
in O
vitro O
concentrations O
found O
to O
induce O
abnormalities O
in O
platelet O
function O
tests O
. O

In O
psoriatic O
arthritis O
clinical O
trials O
, O
concomitant O
medications O
included O
MTX B-drug
in O
approximately O
half O
of O
the O
patients O
as O
well O
as O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
folic B-drug
acid I-drug
and O
corticosteroids B-group
. O

Coadministration O
with O
valdecoxib B-drug
increased O
exposure O
of O
omeprazole B-drug
( O
AUC O
) O
by O
46 O
% O
. O

Coadministration O
in O
HIV-infected O
individuals O
with O
a O
history O
of O
injection O
drug O
use O
resulted O
in O
decreased O
plasma O
levels O
of O
methadone B-drug
and O
signs O
of O
opiate B-group
withdrawal O
. O

Saquinavir B-drug

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
is O
recommended O
when O
administering O
itraconazole B-drug
concurrently O
. O

Carbamazepine B-drug
: O
Felbatol B-brand
causes O
a O
decrease O
in O
the O
steady-state O
carbamazepine B-drug
plasma O
concentrations O
and O
an O
increase O
in O
the O
steady-state O
carbamazepine B-drug_n
epoxide I-drug_n
plasma O
concentration O
. O

Glucose O
: O
Some O
patients O
receiving O
Accutane B-brand
have O
experienced O
problems O
in O
the O
control O
of O
their O
blood O
sugar O
. O

Products O
containing O
calcium B-drug
and O
other O
multivalent O
cations O
( O
such O
as O
aluminum B-drug
, O
magnesium B-drug
, O
iron B-drug
) O
are O
likely O
to O
interfere O
with O
absorption O
of O
Ibandronate B-drug
. O

Antacids B-group
: O
The O
concomitant O
administration O
of O
antacids B-group
has O
no O
apparent O
effect O
on O
the O
extent O
of O
absorption O
of O
Lodine B-brand
. O

INDOCIN B-brand
and O
triamterene B-drug
should O
not O
be O
administered O
together O
. O

However O
, O
hydrocortisone B-drug
pretreatment O
did O
not O
affect O
any O
of O
the O
physiological O
, O
behavioral O
, O
or O
subjective O
effects O
of O
d-amphetamine B-drug
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8-fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA O
) O
. O

The O
resulting O
increase O
in O
nitrofurantoin B-drug
serum O
levels O
may O
increase O
toxicity O
, O
and O
the O
decreased O
urinary O
levels O
could O
lessen O
its O
efficacy O
as O
a O
urinary O
tract O
antibacterial B-group
. O

In O
pigeons O
, O
naloxone B-drug
did O
not O
systematically O
alter O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
. O

A O
group O
of O
patients O
who O
had O
had O
a O
new O
acute O
episode O
despite O
seemingly O
adequate O
treatment O
were O
selected O
. O

Hypotension O
was O
more O
likely O
to O
occur O
if O
the O
calcium B-group
antagonist I-group
were O
a O
dihydropyridine B-group
derivative I-group
, O
e.g. O
, O
nifedipine B-drug
, O
while O
left O
ventricular O
failure O
and O
AV O
conduction O
disturbances O
, O
including O
complete O
heart O
block O
, O
were O
more O
likely O
to O
occur O
with O
either O
verapamil B-drug
or O
diltiazem B-drug
. O

In O
the O
warfarin B-drug
study O
, O
vardenafil B-drug
had O
no O
effect O
on O
the O
prothrombin O
time O
or O
other O
pharmacodynamic O
parameters O
. O

In O
a O
chronic O
toxicity O
study O
, O
cynomolgus O
monkeys O
were O
dosed O
weekly O
for O
52 O
weeks O
with O
intravenous O
alefacept B-drug
at O
1 O
mg/kg/dose O
or O
20 O
mg/kg/dose O
. O

However O
, O
serious O
opportunistic O
infections O
have O
not O
been O
observed O
, O
and O
no O
complications O
have O
specifically O
been O
attributed O
to O
lymphocytopenia O
. O

Adenosine O
3':5'-cyclic O
phosphate O
in O
turn O
controls O
levels O
of O
free O
calcium O
ions O
in O
platelets O
and O
regulates O
calcium-dependent O
reactions O
. O

Accordingly O
, O
renal O
function O
should O
be O
closely O
monitored O
in O
these O
patients O
and O
, O
in O
the O
event O
of O
relevant O
significant O
changes O
in O
laboratory O
parameters O
, O
bezafibrate B-drug
should O
, O
if O
necessary O
, O
be O
discontinued O

Aspirin B-brand
: O
In O
normal O
volunteers O
, O
a O
small O
decrease O
in O
diflunisal B-drug
levels O
was O
observed O
when O
multiple O
doses O
of O
diflunisal B-drug
and O
aspirin B-brand
were O
administered O
concomitantly O
. O

Clonazepam B-drug
would O
be O
useful O
in O
cases O
with O
potential O
risk O
of O
hypoglycemia O
. O

6 O
. O

In O
vitro O
metabolism O
studies O
have O
demonstrated O
that O
tizoxanide B-drug
has O
no O
significant O
inhibitory O
effect O
on O
cytochrome O
P450 O
enzymes O
. O

This O
may O
indicate O
that O
ibuprofen B-drug
could O
enhance O
the O
toxicity O
of O
methotrexate B-drug
. O

FLEXERIL B-brand
may O
have O
life-threatening O
interactions O
with O
MAO B-group
inhibitors I-group
. O

acanthus O
. O

0.001 O
. O

In O
an O
in O
vitro O
study O
, O
cytochrome O
P450 O
isozymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
, O
and O
3A4 O
were O
not O
inhibited O
by O
exposure O
to O
cevimeline B-drug
. O

ZEBETA B-brand
should O
not O
be O
combined O
with O
other O
beta-blocking B-group
agents I-group
. O

The O
safety O
and O
efficacy O
of O
PROLEUKIN B-brand
in O
combination O
with O
any O
antineoplastic B-group
agents I-group
have O
not O
been O
established O
. O

Nevertheless O
, O
the O
effects O
of O
Mefloquine B-drug
on O
travelers O
receiving O
comedication O
, O
particularly O
diabetics O
or O
patients O
using O
anticoagulants B-group
, O
should O
be O
checked O
before O
departure O
. O

In O
contrast O
, O
nucleophosmin/B23 O
in O
serum-deprived O
ras-transformed O
( O
RAS-3T3 O
) O
cells O
was O
as O
stable O
as O
that O
in O
serum-supplemented O
NIH-3T3 O
or O
RAS-3T3 O
cells O
. O

Patients O
using O
CYP3A4 O
metabolized O
statins B-group
should O
have O
cholesterol O
levels O
monitored O
after O
TRACLEER B-brand
is O
initiated O
to O
see O
whether O
the O
statin B-group
dose O
needs O
adjustment O
. O

Due O
to O
its O
nephrotoxicity O
, O
gentamicin B-drug
may O
cause O
abnormal O
renal O
uptake O
to O
be O
seen O
on O
99mTc-MDP B-drug
bone O
scintigraphy O
. O

Paroxetine B-drug
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-drug
3 O
mg O
and O
paroxetine B-drug
20 O
mg O
daily O
for O
7 O
days O
produced O
no O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
. O

More O
than O
600 O
Parkinsons O
disease O
patients O
in O
clinical O
trials O
have O
used O
selegiline B-drug
in O
combination O
with O
entacapone B-drug
and O
levodopa/dopa B-drug
decarboxylase B-group
inhibitor I-group
. O

Lincomycin B-drug
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-group
blocking I-group
agents I-group
. O

Antacids B-group
, O
Sucralfate B-drug
, O
Metal O
Cations O
, O
Multivitamins B-group
Quinolones I-group
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metal O
cations O
. O

In O
vitro O
mixing O
of O
an O
aminoglycoside B-group
with O
beta-lactamtype O
antibiotics B-group
( O
penicillins B-group
or O
cephalosporins B-group
) O
may O
result O
in O
a O
significant O
mutual O
inactivation O
. O

When O
given O
in O
a O
dose O
of O
50 O
mg/kg O
, O
sandimmune B-brand
produced O
no O
statistically O
significant O
effect O
on O
the O
duration O
of O
hexanal-induced O
sleep O
in O
mice O
. O

Although O
trough O
citalopram B-drug
plasma O
levels O
were O
unaffected O
, O
given O
the O
enzyme-inducing O
properties O
of O
carbamazepine B-drug
, O
the O
possibility O
that O
carbamazepine B-drug
might O
increase O
the O
clearance O
of O
escitalopram B-drug
should O
be O
considered O
if O
the O
two O
drugs O
are O
coadministered O
. O

BREVIBLOC B-brand
concentrations O
were O
equivocally O
higher O
when O
given O
with O
warfarin B-drug
, O
but O
this O
is O
not O
likely O
to O
be O
clinically O
important O
. O

Propranolol B-drug
: O
In O
a O
single O
dose O
study O
in O
normal O
volunteers O
, O
coadministration O
of O
propranolol B-drug
had O
a O
small O
effect O
on O
the O
rate O
but O
no O
effect O
on O
the O
extent O
of O
isradipine B-drug
bioavailability O
. O

Antipsychotic B-group
drugs I-group
such O
as O
phenothiazines B-group
or O
haloperidol B-drug
; O

Sumatriptan B-drug
and O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
should O
not O
be O
taken O
within O
24 O
hours O
of O
each O
other.. O

Use O
With O
Ribavirin B-drug
Ribavirin I-drug
is O
genotoxic O
and O
mutagenic O
. O

Corticosteroids B-group
may O
also O
potentiate O
the O
replication O
of O
some O
organisms O
contained O
in O
live B-group
attenuated I-group
vaccines I-group
. O

If O
the O
TARCEVA B-brand
dose O
is O
adjusted O
upward O
, O
the O
dose O
will O
need O
to O
be O
reduced O
upon O
discontinuation O
of O
rifampicin B-drug
or O
other O
inducers O
. O

Dexamethasone B-drug
: O
Steady-state O
trough O
concentrations O
of O
albendazole B-drug
sulfoxide I-drug
were O
about O
56 O
% O
higher O
when O
8 O
mg O
dexamethasone B-drug
was O
coadministered O
with O
each O
dose O
of O
albendazole B-drug
( O
15 O
mg/kg/day O
) O
in O
eight O
neurocysticercosis O
patients O
. O

Dexbrompheniramine B-drug
can O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

COPEGUS B-brand
therapy O
is O
contraindicated O
in O
women O
who O
are O
pregnant O
and O
in O
the O
male O
partners O
of O
women O
who O
are O
pregnant O
. O

A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-group
, O
phenylbutazone B-drug
, O
phenytoin B-drug
sodium I-drug
, O
carbamazepine B-drug
, O
griseofulvin B-drug
, O
topiramate B-drug
, O
and O
possibly O
with O
ampicillin B-drug
and O
tetracyclines B-group
72 O
. O

In O
a O
parallel O
group O
drug O
interaction O
study O
comparing O
the O
intravenous O
prodrug O
form O
of O
valdecoxib B-drug
at O
40 O
mg O
BID O
( O
n=10 O
) O
vs O
placebo O
( O
n=9 O
) O
, O
valdecoxib B-drug
had O
no O
effect O
on O
in O
vitro O
aspirin-mediated B-brand
inhibition O
of O
arachidonate- O
or O
collagen-stimulated O
platelet O
aggregation O
. O

Protein O
Binding O
: O
Entacapone B-drug
is O
highly O
protein O
bound O
( O
98 O
% O
) O
. O

Patients O
taking O
warfarin B-drug
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O
. O

The O
potential O
effects O
of O
INDOCIN B-brand
and O
potassium-sparing B-group
diuretics I-group
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O

Indinavir B-drug

Rifampin B-drug
significantly O
decreased O
the O
AUC O
( O
ss O
) O
of O
amprenavir B-drug
by O
82 O
% O
, O
but O
amprenavir B-drug
had O
no O
effect O
on O
rifampin B-drug
pharmacokinetics O
. O

Similarly O
, O
ethanol B-drug
decreased O
the O
rate O
of O
elimination O
of O
Antizol B-brand
( O
by O
approximately O
50 O
% O
) O
by O
the O
same O
mechanism O
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
and O
Tricyclic B-group
Antidepressants I-group
: O
FORADIL B-brand
should O
be O
administered O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
because O
the O
action O
of O
formoterol B-drug
on O
the O
cardiovascular O
system O
may O
be O
potentiated O
by O
these O
agents O
. O

1200-2400 O
up O
to O
40 O
% O
increase3 O
[ O
CI O
: O
12 O
% O
increase O
, O
60 O
% O
increase O
] O

Drug O
interaction O
studies O
have O
not O
been O
performed O
with O
Soliris B-brand
. O

Itraconazole B-drug

Organic O
nitrates B-group
- O
L-arginine B-drug
supplements O
theoretically O
may O
potentiate O
the O
effects O
of O
organic O
nitrates B-drug
if O
taken O
concomitantly O
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

The O
tolerability O
of O
NNRTIs B-group
appears O
generally O
good O
with O
few O
individuals O
discontinuing O
in O
clinical O
studies O
as O
a O
result O
of O
adverse O
drug O
events O
. O

Drug/Laboratory O
Test O
Interactions O
: O
The O
administration O
of O
CEFOTAN B-brand
may O
result O
in O
a O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O

Coadministration O
of O
oral O
contraceptives B-group
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
18 O
% O
, O
decreased O
clearance O
by O
22 O
% O
, O
and O
increased O
half-life O
by O
29 O
% O
. O

The O
therapeutic O
efficacy O
of O
tricyclic B-group
antidepressants I-group
may O
be O
compromised O
in O
these O
patients O
when O
cimetidine B-drug
is O
discontinued O
. O

Drugs O
Metabolized O
by O
CYP2D6 O
: O
Duloxetine B-drug
is O
a O
moderate O
inhibitor O
of O
CYP2D6 O
. O


In O
renal O
and O
cardiac O
transplant O
recipients O
, O
a O
reduction O
of O
cyclosporine B-drug
dose O
ranging O
from O
15 O
% O
to O
48 O
% O
was O
necessary O
to O
maintain O
cyclosporine B-drug
trough O
concentrations O
similar O
to O
those O
seen O
prior O
to O
the O
addition O
of O
diltiazem B-drug
. O

Catecholamine-depleting O
drugs O
( O
e.g. O
, O
reserpine B-drug
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-drug
agents O
. O

Morphine B-drug
pharmacokinetic O
parameter O
values O
were O
not O
affected O
by O
administration O
of O
Neurontin B-brand
2 O
hours O
after O
morphine B-drug
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
and O
of O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

. O

If O
phenytoin B-drug
or O
other O
hepatic O
enzyme O
inducers O
are O
taken O
concurrently O
with O
Norpace B-brand
or O
Norpace B-brand
CR I-brand
, O
lower O
plasma O
levels O
of O
disopyramide B-drug
may O
occur O
. O

Ketoconazole B-drug
( O
200 O
mg O
once O
daily O
) O
produced O
a O
10-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
4-fold O
increase O
in O
Cmax O
when O
co-administered O
with O
Vardenafil B-drug
( O
5 O
mg O
) O
in O
healthy O
volunteers O
. O

As O
most O
entacapone B-drug
excretion O
is O
via O
the O
bile O
, O
caution O
should O
be O
exercised O
when O
drugs O
known O
to O
interfere O
with O
biliary O
excretion O
, O
glucuronidation O
, O
and O
intestinal O
beta-glucuronidase O
are O
given O
concurrently O
with O
entacapone B-drug
. O

Limited O
PK O
and/or O
PD O
studies O
investigating O
possible O
interactions O
between O
anagrelide B-drug
and O
other O
medicinal O
products O
have O
been O
conducted O
. O

Cimetidine B-drug
( O
300 O
mg O
qid O
) O
+103 O
% O
+ O
6 O
% O

Nursing O
Mothers O

Coadministration O
of O
NIZORAL B-brand
Tablets O
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O

CYP2D6 O
inhibitors O
- O
Atomoxetine B-drug
is O
primarily O
metabolized O
by O
the O
CYP2D6 O
pathway O
to O
4-hydroxyatomoxetine B-drug_n
. O

Antacid B-group
: O
When O
atorvastatin B-drug
and O
Maalox B-brand
TC I-brand
suspension O
were O
coadministered O
, O
plasma O
concentrations O
of O
atorvastatin B-drug
decreased O
approximately O
35 O
% O
. O

Erythromycin B-drug
and O
clarithromycin B-drug
( O
and O
possibly O
other O
macrolide B-group
antibiotics I-group
) O
and O
tetracycline B-drug
may O
increase O
digoxin B-drug
absorption O
in O
patients O
who O
inactivate O
digoxin B-drug
by O
bacterial O
metabolism O
in O
the O
lower O
intestine O
, O
so O
that O
digitalis B-group
intoxication O
may O
result O
. O

Concurrent O
administration O
of O
a O
TNF B-group
antagonist I-group
with O
ORENCIA B-brand
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
and O
no O
significant O
additional O
efficacy O
over O
use O
of O
the O
TNF B-group
antagonists I-group
alone O
. O

Central B-group
nervous I-group
system I-group
depressant I-group
( O
CNS O
) O
drugs O
including O
alcohol B-drug
, O
antidepressants B-group
, O
antihistamines B-group
, O
antipsychotics B-group
, O
blood O
pressure O
medications O
( O
reserpine B-drug
, O
methyldopa B-drug
, O
beta-blockers B-group
) O
, O
motion O
sickness O
medications O
, O
muscle B-group
relaxants I-group
, O
narcotics B-group
, O
sedatives B-group
, O
sleeping O
pills O
and O
tranquilizers B-group

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Patients O
receiving O
these O
drugs O
concurrently O
should O
be O
monitored O
for O
a O
potential O
drug O
interaction O
. O

Concomitant O
use O
of O
other O
5-HT1B/1D O
agonists O
within O
24 O
hours O
of O
FROVA B-brand
treatment O
is O
not O
recommended O
. O

This O
change O
was O
not O
considered O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
needed O
when O
ketoconazole B-drug
and O
VIRACEPT B-brand
are O
coadministered O
. O

Interactions O
for O
vitamin B-group
D I-group
analogues O
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

Considering O
that O
the O
involvement O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
has O
been O
implicated O
in O
the O
toxicity O
of O
various O
pesticides O
, O
this O
study O
was O
designed O
to O
investigate O
the O
possibility O
of O
oxidative O
stress O
induction O
by O
cypermethrin B-drug
, O
a O
Type B-drug_n
II I-drug_n
pyrethroid I-drug_n
. O

Digoxin B-drug
: O
Rofecoxib B-drug
75 O
mg O
once O
daily O
for O
11 O
days O
does O
not O
alter O
the O
plasma O
concentration O
profile O
or O
renal O
elimination O
of O
digoxin B-drug
after O
a O
single O
0.5 O
mg O
oral O
dose O
. O

Endocrine O
Function O
HMG-CoA B-group
reductase I-group
inhibitors I-group
interfere O
with O
cholesterol O
synthesis O
and O
theoretically O
might O
blunt O
adrenal O
and/or O
gonadal O
steroid O
production O
. O

Other O
Drugs O
: O
In O
small O
groups O
of O
patients O
( O
7-10/interaction O
study O
) O
, O
the O
concomitant O
administration O
of O
azathioprine B-drug
, O
gold B-group
, O
chloroquine B-drug
, O
D-penicillamine B-drug
, O
prednisolone B-drug
, O
doxycycline B-drug
, O
or O
digitoxin B-drug
did O
not O
significantly O
affect O
the O
peak O
levels O
and O
AUC O
values O
of O
diclofenac B-drug
. O

4 O
. O

In O
clinical O
studies O
, O
coadministration O
of O
WelChol B-brand
with O
atorvastatin B-drug
, O
lovastatin B-drug
, O
or O
simvastatin B-drug
did O
not O
interfere O
with O
the O
lipid-lowering O
activity O
of O
the O
HMG-CoA B-group
reductase I-group
inhibitor I-group
. O

The O
latency O
to O
loss O
of O
the O
righting O
reflex O
and O
duration O
of O
sleep O
time O
were O
recorded O
while O
the O
rats O
were O
kept O
in O
sound-attenuating O
chambers O
. O

The O
concurrent O
use O
of O
these O
drugs O
is O
not O
recommended O
. O

There O
are O
no O
known O
drug/drug O
interactions O
with O
chlorambucil B-drug
. O

In O
the O
first O
study O
, O
concomitant O
administration O
of O
0.2 O
mg O
cerivastatin B-drug
sodium I-drug
and O
12 O
g O
cholestyramine B-drug
resulted O
in O
decreases O
of O
more O
than O
22 O
% O
for O
AUC O
and O
40 O
% O
for O
Cmax O
when O
compared O
to O
dosing O
cerivastatin B-drug
sodium I-drug
alone O
. O

PTX B-drug_n
caused O
the O
release O
of O
norepinephrine O
from O
the O
muscle O
. O

Although O
glucocorticoids B-group
have O
been O
shown O
to O
reduce O
PROLEUKIN-induced B-brand
side O
effects O
including O
fever O
, O
renal O
insufficiency O
, O
hyperbilirubinemia O
, O
confusion O
, O
and O
dyspnea O
, O
concomitant O
administration O
of O
these O
agents O
with O
PROLEUKIN B-brand
may O
reduce O
the O
antitumor O
effectiveness O
of O
PROLEUKIN B-brand
and O
thus O
should O
be O
avoided O
. O
12 O
Beta-blockers B-group
and O
other O
antihypertensives B-group
may O
potentiate O
the O
hypotension O
seen O
with O
PROLEUKIN B-brand
. O

Combination O
therapy O
should O
be O
administered O
with O
caution O
, O
especially O
in O
immunocompromised O
patients O
. O

CPK O
: O
Some O
patients O
undergoing O
vigorous O
physical O
activity O
while O
on O
Accutane B-brand
therapy O
have O
experienced O
elevated O
CPK O
levels O
; O

We O
obtained O
evidence O
that O
increased O
stability O
of O
nucleophosmin/B23 O
is O
involved O
in O
antiapoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O

In O
a O
controlled O
clinical O
trial O
, O
a O
20 O
% O
reduction O
of O
the O
phenytoin B-drug
dose O
at O
the O
initiation O
of O
Felbatol B-brand
therapy O
resulted O
in O
phenytoin B-drug
levels O
comparable O
to O
those O
prior O
to O
Felbatol B-brand
administration O
. O

The O
percentage O
of O
drug O
binding O
in O
each O
preparation O
was O
calculated O
. O

Thus O
, O
the O
results O
suggest O
that O
cypermethrin B-drug
exposure O
of O
rats O
results O
in O
free O
radical-mediated O
tissue O
damage O
, O
as O
indicated O
by O
elevated O
cerebral O
and O
hepatic O
lipid O
peroxidation O
, O
which O
was O
prevented O
by O
allopurinol B-drug
and O
Vitamin B-drug
E I-drug
. O

Two O
retrospective O
studies O
were O
conducted O
in O
1992 O
( O
75 O
cases O
) O
and O
in O
1993 O
( O
51 O
cases O
) O
. O

use O
potassium B-drug
supplements O
if O
necessary O
. O

In O
addition O
, O
the O
beneficial O
effects O
of O
levodopa B-drug
in O
Parkinsons O
disease O
have O
been O
reported O
to O
be O
reversed O
by O
phenytoin B-drug
and O
papaverine B-drug
. O

No O
effects O
were O
evident O
on O
excystment O
rates O
of O
cyst-exposed O
parasites O
. O

These O
included O
seven O
cerebrovascular O
accidents O
, O
six O
sudden O
cardiac O
deaths O
, O
three O
cases O
of O
hyperpyrexia O
, O
eight O
poisonings O
of O
uncertain O
mechanism O
and O
seven O
cases O
of O
medical O
complications O
of O
intravenous O
injection O
; O

The O
interval O
between O
the O
administration O
of O
COLESTID B-brand
Tablets O
and O
any O
other O
medication O
should O
be O
as O
long O
as O
possible O
. O

Administration O
of O
diltiazem B-drug
hydrochloride I-drug
with O
digoxin B-drug
in O
24 O
healthy O
male O
subjects O
increased O
plasma O
digoxin B-drug
concentrations O
approximately O
20 O
% O
. O

positive O
antinuclear O

The O
atorvastatin B-drug
Cmax O
values O
were O
not O
significantly O
affected O
by O
fenofibrate B-drug
. O

None O
Reported O

one O
patient O
died O
with O
severe O
hypocalcemia O
. O

DIGOXIN B-drug
: O
Plasma O
digoxin B-drug
levels O
and O
digoxin B-drug
clearance O
at O
steady-state O
were O
not O
affected O
by O
co-administration O
of O
0.2 O
mg O
cerivastatin B-drug
sodium I-drug
. O

Tricyclic B-group
antidepressants I-group
( O
amitriptyline B-drug
, O
imipramine B-drug
, O
nortriptyline B-drug
) O
: O
Metabolism O
may O
be O
inhibited O
by O
combination B-group
hormonal I-group
contraceptives I-group
, O
increasing O
plasma O
levels O
of O
antidepressant B-group
; O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

Drugs O
Decreasing O
Heparin B-drug
Effect O
: O
Digitalis B-group
, O
tetracyclines B-group
, O
nicotine B-drug
, O
or O
antihistamines B-group
may O
partially O
counteract O
the O
anticoagulant O
action O
of O
heparin B-drug
sodium I-drug
. O

Lack O
of O
interaction O
between O
levofloxacin B-drug
and O
oxycodone B-drug
: O
pharmacokinetics O
and O
drug O
disposition O
. O

substrates O
, O
in O
vitro O
data O
suggest O
similar O
effects O
of O
grepafloxacin B-drug
in O
CYP3A4 O
mediated O
metabolism O
and O
theophylline B-drug
metabolism O
. O

Development O
and O
pharmacology O
of O
fluvastatin B-drug
. O

Choose O
particular O
low O
doses O
of O
these O
drugs O
. O

Treatment O
of O
both O
parental O
and O
resistant O
MCF-7 O
cells O
with O
TAM B-drug_n
induces O
apoptosis O
and O
clusterin O
. O

Phenothiazines B-group
and O
butyrophenones B-group
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-drug
. O

. O

No O
dose O
adjustment O
of O
bosentan B-drug
is O
necessary O
, O
but O
increased O
effects O
of O
bosentan B-drug
should O
be O
considered O
. O

Urinary O
alkalinizing O
agents O
( O
acetazolamide B-drug
, O
some O
thiazides B-group
) O
increase O
the O
concentration O
of O
the O
non-ionized O
species O
of O
the O
amphetamine B-drug
molecule O
, O
thereby O
decreasing O
urinary O
excretion O
. O

Cyclophosphamide B-drug

It O
is O
suggested O
that O
in O
patients O
receiving O
dopamine B-drug
HCl I-drug
, O
alternatives O
to O
phenytoin B-drug
should O
be O
used O
if O
anticonvulsant B-group
therapy O
is O
needed O
. O

Similarly O
, O
saquinavir B-drug
might O
also O
modify O
the O
pharmacokinetics O
of O
other O
drugs O
that O
are O
substrates O
for O
CYP3A4 O
or O
Pgp O
. O

5 O
. O

Hepatotoxicity O
Asymptomatic O
increases O
in O
liver O
transaminases O
have O
been O
observed O
in O
TARCEVA B-brand
treated O
patients O
; O

On O
the O
other O
hand O
, O
surprisingly O
, O
green B-drug
tea I-drug
gallocatechins I-drug
, O
( O
- O
) O
-epigallocatechin-3-O-gallate O
and O
theasinensin O
A O
, O
potently O
enhanced O
the O
promoter O
activity O
( O
182 O
and O
247 O
% O
activity O
at O
1 O
microM O
, O
respectively O
) O
. O

N=12 O
) O
administration O
. O

Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
saquinavir B-drug
may O
be O
required O
. O

In O
screening O
patients O
suspected O
of O
having O
a O
pheochromocytoma O
and O
being O
treated O
with O
labetalol B-drug
HCl I-drug
, O
a O
specific O
method O
, O
such O
as O
a O
high O
performance O
liquid O
chromatographic O
assay O
with O
solid O
phase O
extraction O
( O
e.g. O
, O
J O
Chromatogr O
385:241,1987 O
) O
should O
be O
employed O
in O
determining O
levels O
of O
catecholamines O
. O

MICs O
of O
vancomycin B-drug
against O
67 O
% O
of O
resistant O
clinical O
isolates O
and O
a O
type O
strain O
of O
enterococci O
were O
lowered O
from O
> O
250 O
microg O
mL O
( O
-1 O
) O
to O
1 O

however O
, O
14-OH O
metabolite O
concentrations O
were O
increased.Because O
clarithromycin B-drug
active O
metabolite O
has O
reduced O
activity O
against O
Mycobacteriumavium-intracellulare O
complex O
, O
overallactivity O
against O
this O
pathogen O
may O
bealtered O
. O

The O
magnitude O
of O
interaction O
at O
other O
doses O
is O
not O
known O
. O

Anastrozole B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
antipyrine B-drug
. O

The O
results O
of O
a O
study O
of O
coadministration O
of O
ethambutol B-drug
( O
50 O
mg/kg O
) O
with O
an O
aluminum B-drug
hydroxide I-drug
containing O
antacid B-group
to O
13 O
patients O
with O
tuberculosis O
showed O
a O
reduction O
of O
mean O
serum O
concentrations O
and O
urinary O
excretion O
of O
ethambutol B-drug
of O
approximately O
20 O
% O
and O
13 O
% O
, O
respectively O
, O
suggesting O
that O
the O
oral O
absorption O
of O
ethambutol B-drug
may O
be O
reduced O
by O
these O
antacid B-group
products I-group
. O

No O
formal O
studies O
to O
evaluate O
drug O
interactions O
with O
bexarotene B-drug
have O
been O
conducted O
. O

However O
, O
there O
has O
been O
one O
report O
of O
prolonged O
prothrombin O
time O
when O
buspirone B-drug
was O
added O
to O
the O
regimen O
of O
a O
patient O
treated O
with O
warfarin B-drug
. O

Interactions O
for O
vitamin B-group
D I-group
analogues I-group
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

- O
Drug/Laboratory O
Test O
Interactions O
: O
Thiazides B-group
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

Conversion O
could O
be O
affected O
by O
alterations O
in O
the O
level O
of O
phosphatase O
activity O
, O
but O
given O
the O
abundance O
and O
wide O
distribution O
of O
phosphatases O
in O
the O
body O
it O
is O
unlikely O
that O
drugs O
would O
affect O
this O
activity O
enough O
to O
affect O
conversion O
of O
fosphenytoin B-drug
to O
phenytoin B-drug
. O

For O
example O
, O
diuretics B-group
( O
e.g. O
, O
thiazides B-group
) O
may O
activate O
the O
renin-angiotensin-aldosterone O
system O
. O

Corticosteroids B-group
and O
Corticotropin B-drug
( O
ACTH B-group
) O
: O
may O
potentiate O
amphotericin B-drug
B- O
induced O
hypokalemia O
which O
may O
predispose O
the O
patient O
to O
cardiac O
dysfunction O
. O

Sedatives B-group
and O
tranquilizers B-group
( O
e.g. O
, O
diazepam B-drug
) O
. O

If O
these O
drugs O
are O
to O
be O
used O
in O
the O
initial O
treatment O
of O
severe O
malaria O
, O
Mefloquine B-drug
administration O
should O
be O
delayed O
at O
least O
12 O
hours O
after O
the O
last O
dose O
. O

Drug O
Name O

Because O
antacids B-group
may O
interfere O
with O
the O
absorption O
of O
anticholinergic B-group
agents I-group
, O
simultaneous O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

anemia O

Single O
doses O
of O
either O
cholestyramine B-drug
or O
colestipol B-drug
resins B-group
bind O
the O
hydrochlorothiazide B-drug
and O
reduce O
its O
absorption O
from O
the O
gastrointestinal O
tract O
by O
up O
to O
85 O
and O
43 O
percent O
, O
respectively O
. O

Differences O
in O
iron B-drug
balance O
were O
only O
observed O
between O
both O
dietary O
concentrations O
, O
showing O
a O
higher O
absolute O
but O
a O
lower O
relative O
absorption O
as O
well O
as O
retention O
in O
the O
groups O
fed O
further O
Fe B-drug
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Terfenadine B-drug
: O
No O
clinically O
significant O
changes O
occurred O
in O
heart O
rate O
or O
corrected O
QT O
intervals O
, O
or O
in O
terfenadine B-drug
metabolite O
or O
lomefloxacin B-drug
pharmacokinetics O
, O
during O
concurrent O
administration O
of O
lomefloxacin B-drug
and O
terfenadine B-drug
at O
steady-state O
in O
28 O
healthy O
males O
. O

No O
other O
drug O
interactions O
are O
known O
. O

Ketorolac B-drug
is O
highly O
bound O
to O
human O
plasma O
protein O
( O
mean O
99.2 O
% O
) O
. O

Although O
BETAGAN B-brand
used O
alone O
has O
little O
or O
no O
effect O
on O
pupil O
size O
, O
mydriasis O
resulting O
from O
concomitant O
therapy O
with O
BETAGAN B-brand
and O
epinephrine B-drug
may O
occur O
. O

Use O
of O
PRINIVIL B-brand
with O
potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
potassium-containing O
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O

Ketoconazole I-drug

Blood O
sampling O
for O
the O
pharmacokinetics O
of O
everolimus B-drug
and O
cyclosporine B-drug
was O
performed O
on O
day O
1 O
, O
on O
weeks O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
, O
and O
on O
months O
2 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
. O

No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
phenytoin B-drug
and O
Accutane B-brand
. O

Analysis O
of O
the O
concentration O
of O
budesonide B-drug
following O
ultracentrifugation O
indicated O
that O
there O
is O
rapid O
equilibration O
of O
budesonide B-drug
between O
the O
Survanta B-brand
and O
aqueous O
phase O
. O

The O
immediate O
release O
, O
but O
not O
the O
coat-core O
formulation O
of O
nisoldipine B-drug
increased O
plasma O
quinidine B-drug
concentrations O
by O
about O
20 O
% O
. O

Because O
busulfan B-drug
is O
eliminated O
from O
the O
body O
via O
conjugation O
with O
glutathione O
, O
use O
of O
acetaminophen B-drug
prior O
to O
( O
72 O
hours O
) O
or O
concurrent O
with O
BUSULFEX B-brand
may O
result O
in O
reduced O
busulfan B-drug
clearance O
based O
upon O
the O
known O
property O
of O
acetaminophen B-drug
to O
decrease O
glutathione O
levels O
in O
the O
blood O
and O
tissues O
. O

Response O
to O
Treatment O
for O
Anaphylactic O
Reaction O
: O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

Amphetamines B-group
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

If O
combination O
therapy O
is O
initiated O
or O
withdrawn O
in O
conjunction O
with O
propranolol B-drug
, O
an O
adjustment O
in O
the O
propranolol B-drug
dose O
may O
be O
warranted O
. O

Other O
than O
with O
probenecid B-drug
, O
no O
specific O
clinical O
drug O
interaction O
studies O
have O
been O
conducted O

Alternate O
or O
additional O
contraceptive O
measures O
should O
be O
used O
during O
therapy O
with O
VIRACEPT B-brand

Also O
, O
although O
minimal O
alterations O
of O
fluvastatin B-drug
clearance O
in O
patients O
with O
renal O
insufficiency O
are O
anticipated O
due O
to O
limited O
renal O
excretion O
( O
5 O
% O
) O
, O
a O
study O
in O
this O
patient O
group O
is O
currently O
underway O
to O
examine O
this O
further O
. O

However O
, O
neuromuscular O
paralysis O
may O
be O
potentiated O
by O
co-administration O
or O
overlapping O
administration O
of O
different O
botulinum B-group
toxin I-group
serotypes O
. O

The O
effects O
of O
ruthenium B-drug_n
red I-drug_n
( O
RR B-drug_n
) O
on O
inositol B-drug_n
1,4,5-trisphosphate I-drug_n
( O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
) I-drug_n
-induced O
responses O
were O
studied O
in O
rat O
bone O
marrow O
megakaryocytes O
with O
the O
patch-clamp O
whole-cell O
recording O
technique O
in O
combination O
with O
fura-2 O
microfluorometry O
. O

Extended O
Release O
Tablets O
: O
Administration O
of O
nifedipine B-drug
with O
digoxin B-drug
increased O
digoxin B-drug
levels O
in O
9 O
of O
12 O
normal O
volunteers O
. O

Other O
antihypertensive B-group
drugs I-group
: O
additive O
effect O
or O
potentiation O
. O

Unfortunately O
, O
folic B-drug
acid I-drug
will O
not O
correct O
changes O
in O
the O
nervous O
system O
that O
result O
from O
vitamin O
B12 O
deficiency O
. O

These O
effects O
not O
only O
improve O
insulin O
sensitivity O
and O
glycemic O
control O
with O
reduced O
insulin O
requirements O
, O
but O
also O
have O
potentially O
favorable O
effects O
on O
other O
components O
of O
the O
cardiovascular O
dysmetabolic O
syndrome O
. O

= O
increase O
; O

No O
rashes O
were O
reported O
in O
these O
patients O
. O

The O
data O
presented O
here O
demonstrate O
that O
with O
serial O
pharmacokinetic O
dosing O
of O
gentamicin B-drug
, O
the O
iatrogenic O
alteration O
caused O
by O
gentamicin B-drug
therapy O
can O
be O
avoided O
. O

Ritonavir B-drug
and O
indinavir B-drug
: O
Upon O
concomitant O
administration O
of O
5 O
mg O
of O
Vardenafil B-drug
with O
600 O
mg O
BID O
ritonavir B-drug
, O
the O
Cmax O
and O
AUC O
of O
ritonavir B-drug
were O
reduced O
by O
approximately O
20 O
% O
. O

These O
data O
raise O
the O
question O
of O
whether O
sertraline B-drug
is O
the O
best O
choice O
for O
prolonged O
use O
for O
diabetic O
individuals O
, O
because O
of O
its O
antihyperglycemic O
effects O
. O

Due O
to O
the O
considerable O
variability O
of O
these O
interactions O
, O
the O
dosage O
of O
digoxin B-drug
should O
be O
individualized O
when O
patients O
receive O
these O
medications O
concurrently O
. O

increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O

Tablet O
If O
a O
patient O
receiving O
clonidine B-drug
hydrochloride I-drug
is O
also O
taking O
tricyclic B-group
antidepressants I-group
, O
the O
effect O
of O
clonidine B-drug
may O
be O
reduced O
, O
thus O
necessitating O
an O
increase O
in O
dosage O
. O

As O
a O
consequence O
, O
when O
INDOCIN B-brand
and O
lithium B-drug
are O
given O
concomitantly O
, O
the O
patient O
should O
be O
carefully O
observed O
for O
signs O
of O
lithium B-drug
toxicity O
. O

Blood O
Sugar O
: O
Some O
patients O
receiving O
retinoids B-group
have O
experienced O
problems O
with O
blood O
sugar O
control O
. O

Antifungals B-group

avoid O
use O
if O
possible O
or O
closely O
monitor O
cardiovascular O
status O
at O
the O
end O
of O
drug O
interactions O

Caffeine B-drug
Theobromine I-drug
Grepafloxacin I-drug
, O
like O
other O
quinolones B-group
, O
may O
inhibit O
the O
metabolism O
of O
caffeine B-drug
and O
theobromine B-drug
. O

Clinical O
studies O
of O
PEGASYS B-brand
alone O
or O
in O
combination O
with O
COPEGUS B-brand
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
or O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

d-amphetamine B-drug
with O
desipramine B-drug
or O
protriptyline B-drug
and O
possibly O
other O
tricyclics B-group
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d-amphetamine B-drug
in O
the O
brain O
; O

RESULTS O
: O
Insulin B-drug
increased O
renal O
plasma O
flow O
and O
fundus O
pulsation O
amplitude O
but O
not O
the O
glomerular O
filtration O
rate O
. O

During O
concomitant O
therapy O
with O
NSAIDs B-group
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O

Mixtures O
should O
not O
be O
administered O
intravenously O
. O

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

The O
safety O
of O
using O
STADOL B-brand
NS I-brand
and O
IMITREX B-brand
( O
sumatriptan B-drug
) O
Nasal O
Spray O
during O
the O
same O
episode O
of O
migraine O
has O
not O
been O
established O
. O

Cevimeline B-drug
should O
be O
administered O
with O
caution O
to O
patients O
taking O
beta B-group
adrenergic I-group
antagonists I-group
, O
because O
of O
the O
possibility O
of O
conduction O
disturbances O
. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCAmay B-group
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

No O
interaction O
with O
the O
tricyclic B-group
antidepressant I-group
imipramine B-drug
was O
shown O
in O
a O
single-dose O
study O
with O
entacapone B-drug
without O
coadministered O
levodopa/dopa-decarboxylase B-drug
inhibitor B-group
. O

Drug/Laboratory O
Test O
Interactions O
Effect O
on O
Blood O
Coagulation O
: O
Diclofenac B-drug
increases O
platelet O
aggregation O
time O
but O
does O
not O
affect O
bleeding O
time O
, O
plasma O
thrombin O
clotting O
time O
, O
plasma O
fibrinogen O
, O
or O
factors O
V O
and O
VII O
to O
XII O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
the O
allergic O
reaction O
. O

This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O
) O

Morphine B-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
morphine B-drug
. O

This O
may O
potentiate O
and O
prolong O
hypnotic O
and O
sedative O
effects O
. O

Ketoconazole B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O

Each O
healthy O
subject O
( O
N O
= O
10 O
) O
received O
rofecoxib B-drug
( O
75 O
mg O
once O
daily O
) O
or O
placebo O
for O
11 O
days O
in O
a O
double-blind O
, O
randomized O
, O
balanced O
, O
two-period O
crossover O
study O
. O

Since O
colestipol B-drug
hydrochloride I-drug
is O
an O
anion B-group
exchange I-group
resin I-group
, O
it O
may O
have O
a O
strong O
affinity O
for O
anions O
other O
than O
the O
bile O
acids O
. O

In O
such O
cases O
of O
combined O
treatment O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Intracellular O
resistance O
to O
thyroid B-group
hormone I-group
is O
quite O
rare O
. O

Drugs O
that O
suppress O
the O
immune O
system O
are O
widely O
used O
. O

Saquinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
increased O
21 O
% O
, O
decreased O
19 O
% O
, O
and O
decreased O
48 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O

Anticholinergics B-group
antagonize O
the O
effects O
of O
antiglaucoma B-group
agents I-group
. O

The O
intake O
of O
furosemide B-drug
and O
sucralfate B-drug
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

Patients O
taking O
digoxin B-drug
should O
be O
monitored O
appropriately O
. O

For O
this O
reason O
the O
dose O
of O
adrenaline B-drug
should O
be O
restricted O
and O
an O
antiarrhythmic B-group
agent I-group
administered O
as O
appropriate O
. O

On O
the O
other O
hand O
, O
the O
density O
of O
D2 O
binding O
sites O
in O
the O
SST O
and O
the O
RBC O
mice O
in O
the O
STR O
was O
significantly O
increased O
in O
cocaine-treated B-drug
groups O
without O
change O
in O
Kd O
. O

This O
study O
investigated O
the O
role O
of O
neuronal O
uptake O
of O
norepinephrine B-drug
( O
uptake-1 O
) O
in O
human O
heart O
failure O
as O
a O
local O
factor O
for O
altering O
concentrations O
of O
norepinephrine O
at O
the O
cardiac O
myocyte O
membranes O
. O

In O
clinical O
trials O
, O
mean O
decreases O
of O
1 O
to O
2 O
mg/dL O
were O
observed O
in O
arthritic O
patients O
receiving O
etodolac B-drug
( O
600 O
mg O
to O
1000 O
mg/day O
) O
after O
4 O
weeks O
of O
therapy O
. O

Breakthrough O
bleeding O
has O
been O
reported O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

A O
variety O
of O
toxic O
neurological O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O

Postoperative O
respiratory O
depression O
may O
be O
enhanced O
or O
prolonged O
by O
these O
agents O
. O

Both O
groups O
of O
agents O
increase O
blood O
levels O
and O
therefore O
potentiate O
the O
actions O
of O
amphetamines B-group
. O

Therefore O
, O
monitoring O
of O
blood O
glucose O
is O
recommended O
when O
these O
agents O
are O
co-administered O
. O

Hypersensitivity O
reactions O
have O
been O
reported O
in O
patients O
receiving O
combination O
regimens O
containing O
sequential O
high O
dose O
PROLEUKIN B-brand
and O
antineoplastic B-group
agents I-group
, O
specifically O
, O
dacarbazine B-drug
, O
cis-platinum B-drug
, O
tamoxifen B-drug
and O
interferon-alfa B-drug
. O

Concurrent O
administration O
of O
oxyphenbutazone B-drug
and O
androgens B-group
may O
result O
in O
elevated O
serum O
levels O
of O
oxyphenbutazone B-drug
. O

Increased O
ectopic O
pacemaker O
activity O
can O
occur O
when O
pseudoephedrine B-drug
is O
used O
concomitantly O
with O
digitalis B-group
. O

When O
concomitant O
treatment O
with O
agents B-group
with I-group
b-blocking I-group
properties I-group
and O
clonidine B-drug
is O
to O
be O
terminated O
, O
the O
b-blocking B-group
agent I-group
should O
be O
discontinued O
first O
. O

Blunting O
of O
the O
antihypertensive O
effect O
of O
beta-adrenoceptor B-group
blocking I-group
agents I-group
by O
non-steroidal B-group
antiinflammatory I-group
drugs I-group
including O
INDOCIN B-brand
has O
been O
reported O
. O

Serious O
cardiac O
dysrhythmias O
, O
some O
resulting O
in O
death O
, O
have O
occurred O
in O
patients O
receiving O
terfenadine B-drug
concomitantly O
with O
other O
macrolide B-group
antibiotics I-group
. O

The O
growth O
of O
Pseudomonas O
aeruginosa O
, O
particularly O
serotype O
O11 O
, O
in O
pentazocine B-drug
and O
tripelennamine B-drug

There O
is O
strong O
evidence O
that O
insulin O
resistance O
is O
involved O
in O
the O
development O
of O
not O
only O
hyperglycemia O
, O
but O
also O
dyslipidemia O
, O
hypertension O
, O
hypercoagulation O
, O
vasculopathy O
, O
and O
ultimately O
atherosclerotic O
cardiovascular O
disease O
. O

Central B-group
Nervous I-group
System I-group
Depressants I-group
: O
The O
concomitant O
use O
of O
DURAGESIC B-brand
( O
fentanyl B-drug
transdermal O
system O
) O
with O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
including O
but O
not O
limited O
to O
other O
opioids B-group
, O
sedatives B-group
, O
hypnotics B-group
, O
tranquilizers B-group
( O
e.g. O
, O
benzodiazepines B-group
) O
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
skeletal B-group
muscle I-group
relaxants I-group
, O
and O
alcohol B-drug
, O
may O
cause O
respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
, O
or O
potentially O
result O
in O
coma O
or O
death O
. O

OBJECTIVE O
: O
Our O
objective O
was O
to O
examine O
the O
interaction O
between O
fluvoxamine B-drug
and O
tolbutamide B-drug
to O
confirm O
that O
fluvoxamine B-drug
inhibits O
CYP2C9 O
. O

Abciximab B-drug
has O
been O
administered O
to O
patients O
with O
ischemic O
heart O
disease O
treated O
concomitantly O
with O
a O
broad O
range O
of O
medications O
used O
in O
the O
treatment O
of O
angina O
myocardial O
infarction O
and O
hypertension O
. O

Patients O
receiving O
insulin B-drug
or O
oral O
hypoglycemics B-group
should O
be O
closely O
watched O
during O
initiation O
of O
thyroid O
replacement O
therapy O
. O

No O
data O
for O
saquinavir B-drug
. O

N=48 O
) O
decreases O
hydrocodone B-drug
( O
10 O
mg O
; O

Appropriate O
laboratory O
testing O
should O
be O
considered O
prior O
to O
initiating O
combination O
therapy O
with O
Amprenavir B-drug
and O
ritonavir B-drug
and O
at O
periodic O
intervals O
or O
if O
any O
clinical O
signs O
or O
symptoms O
of O
hyperlipidemia O
or O
elevated O
liver O
function O
tests O
occur O
during O
therapy O
. O

Griseofulvin B-drug
: O
Griseofulvin B-drug
may O
induce O
the O
metabolism O
of O
combination B-group
hormonal I-group
contraceptives I-group
causing O
menstrual O
changes O
; O

It O
is O
not O
known O
whether O
other O
progestational B-group
contraceptives I-group
, O
such O
as O
implants O
and O
injectables O
, O
are O
adequate O
methods O
of O
contraception O
during O
acitretin B-drug
therapy O
. O

Because O
heparin B-drug
, O
aspirin B-brand
, O
or O
Activase B-brand
may O
cause O
bleeding O
complications O
, O
careful O
monitoring O
for O
bleeding O
is O
advised O
, O
especially O
at O
arterial O
puncture O
sites O
. O

There O
is O
no O
pharmacokinetic O
interaction O
between O
ethanol B-drug
and O
flumazenil B-drug
. O

This O
is O
demonstrated O
for O
cigarette O
smokers O
and O
industrial O
workers O
involved O
in O
chemical O
waste O
incineration O
. O

Differences O
in O
clearance O
between O
patients O
on O
these O
medications O
( O
at O
any O
occasion O
in O
the O
study O
) O
and O
those O
off O
medications O
varied O
between O
-16 O
% O
and O
+3 O
% O
. O

The O
adverse O
effects O
of O
CAMPTOSAR B-brand
, O
such O
as O
myelosuppression O
and O
diarrhea O
, O
would O
be O
expected O
to O
be O
exacerbated O
by O
other O
antineoplastic B-group
agents I-group
having O
similar O
adverse O
effects O
. O

It O
is O
, O
however O
, O
possible O
that O
concomitant O
use O
of O
other O
known O
photosensitizing B-group
agents I-group
such O
as O
griseofulvin B-drug
, O
thiazide B-group
diuretics I-group
, O
sulfonylureas B-group
, O
phenothiazines B-group
, O
sulfonamides B-group
and O
tetracyclines B-group
might O
increase O
the O
photosensitivity O
reaction O
of O
actinic O
keratoses O
treated O
with O
the O
LEVULAN B-brand
KERASTICK I-brand
for O
Topical O
Solution O
. O

No O
evaluation O
of O
EXTRANEALs B-brand
effects O
on O
the O
cytochrome O
P450 O
system O
was O
conducted O
. O

These O
increases O
should O
be O
considered O
when O
selecting O
an O
oral O
contraceptive B-group
for O
a O
woman O
taking O
atorvastatin B-drug
. O

Cimetidine B-drug
: O
Cimetidine B-drug
has O
been O
reported O
to O
produce O
clinically O
significant O
fluctuations O
in O
steady-state O
serum O
concentrations O
of O
various O
tricyclic B-group
antidepressants I-group
. O

In O
patients O
on O
chronic O
warfarin B-drug
therapy O
, O
the O
prothrombin O
time O
( O
INR O
) O
should O
be O
closely O
monitored O
in O
the O
2-week O
period O
, O
particularly O
at O
7 O
to O
10 O
days O
, O
following O
initiation O
of O
the O
3-day O
regimen O
of O
Aprepitant B-drug
with O
each O
chemotherapy O
cycle O
. O

Therefore O
, O
a O
potent O
effect O
of O
etofibrate B-drug
on O
both O
chylomicron O
lipolysis O
and O
remnant O
removal O
was O
achieved O
, O
indicating O
that O
this O
drug O
can O
be O
used O
to O
improve O
this O
metabolism O
in O
future O
prospective O
studies O
. O

Antimycobacterial B-group
: O
rifampin B-drug

Patients O
already O
stabilized O
on O
valdecoxib B-drug
should O
be O
closely O
monitored O
for O
loss O
of O
symptom O
control O
with O
phenytoin B-drug
coadministration O
. O

There O
were O
26 O
PI O
with O
drugs O
of O
low O
intrinsic O
value O
( O
7.6 O
% O
; O
95 O
% O
CI O
, O
+/- O
2.8 O
) O
. O

Seizures O
have O
been O
reported O
in O
patients O
taking O
another O
quinolone B-group
class I-group
antimicrobial I-group
and O
the O
nonsteroidal B-group
anti-inflammatory I-group
drug I-group
fenbufen B-drug
concurrently O
. O

Monitoring O
of O
disopyramide B-drug
plasma O
levels O
is O
recommended O
in O
such O
concurrent O
use O
to O
avoid O
ineffective O
therapy O
. O

Available O
data O
are O
not O
sufficient O
, O
however O
, O
to O
predict O
the O
effects O
of O
concomitant O
medication O
on O
patients O
with O
impaired O
ventricular O
function O
or O
cardiac O
conduction O
abnormalities O
. O

Withdrawal O
of O
rifampin B-drug
decreased O
the O
warfarin B-drug
requirement O
by O
50 O
% O
. O

In O
patients O
who O
have O
received O
general O
anesthesia O
utilizing O
a O
volatile O
agent O
known O
to O
sensitize O
the O
myocardium O
to O
catecholamines O
, O
administration O
of O
doxapram B-drug
should O
be O
delayed O
until O
the O
volatile O
agent O
has O
been O
excreted O
in O
order O
to O
lessen O
the O
potential O
for O
arrhythmias O
, O
including O
ventricular O
tachycardia O
and O
ventricular O
fibrillation O
. O

This O
defect O
in O
the O
failing O
heart O
can O
be O
mimicked O
by O
the O
effects O
of O
uptake O
blocking O
agents O
, O
such O
as O
cocaine B-drug
and O
desipramine B-drug
, O
in O
the O
nonfailing O
heart O
only O
. O

Patients O
treated O
with O
Nalfon B-brand
may O
be O
resistant O
to O
the O
effects O
of O
loop B-group
diuretics I-group
. O

In O
Europe O
, O
Nimotop B-brand
was O
observed O
to O
occasionally O
intensify O
the O
effect O
of O
antihypertensive B-group
compounds I-group
taken O
concomitantly O
by O
patients O
suffering O
from O
hypertension O
; O

Inhibits O
CYP2D6 O
( O
weak O
) O
. O

Cholestyramine B-drug
, O
an O
anionic-binding O
resin O
, O
has O
a O
considerable O
effect O
in O
lowering O
the O
rate O
and O
extent O
of O
fluvastatin B-drug
bioavailability O
. O

Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-group
response O
, O
ie O
, O
decreased O
prothrom-bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-group
steroids I-group
; O

Certain O
concomitant O
medications O
( O
such O
as O
rifampin B-drug
, O
anticonvulsants B-group
, O
St O
. O

The O
authors O
investigated O
the O
possibility O
of O
a O
similar O
interaction O
between O
oxycodone B-drug
and O
levofloxacin B-drug
. O

The O
successive O
application O
of O
glycine B-drug
( O
5 O
or O
10 O
mg/kg O
egg O
weight O
( O
e.w O
. O
) O

Combinations O
of O
clindamycin B-drug
and O
gentamicin B-drug
were O
indifferent O
for O
16 O
and O
synergistic O
for O
11 O
of O
the O
resistant O
strains O
. O

Concurrent O
use O
of O
erythromycin B-drug
and O
ergotamine B-drug
or O
dihydroergotamine B-drug
has O
been O
associated O
in O
some O
patients O
with O
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O

Triazolam B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
titrated O
to O
40 O
mg/day O
for O
28 O
days O
) O
and O
the O
CYP3A4 O
substrate O
triazolam B-drug
( O
single O
dose O
of O
0.25 O
mg O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
either O
citalopram B-drug
or O
triazolam B-drug
. O

Aprepitant B-drug
is O
a O
substrate O
, O
a O
moderate O
inhibitor O
, O
and O
an O
inducer O
of O
CYP3A4 O
. O

Due O
to O
highintersubject O
variability O
, O
however O
, O
somepatients O
may O
experience O
large O
increases O
inrifabutin B-drug
exposure O
and O
may O
be O
at O
higher O
riskfor O
rifabutin O
toxicity O
. O

In O
eight O
experiments O
the O
perfusion O
medium O
contained O
oxytocin B-drug
. O

The O
anticoagulant O
effect O
of O
heparin B-drug
is O
enhanced O
by O
concurrent O
treatment O
with O
antithrombin B-drug
III I-drug
( O
human O
) O
in O
patients O
with O
hereditary O
antithrombin O
III O
deficiency O
. O


After O
multiple O
dosing O
, O
interferon B-drug
beta-1a I-drug
( O
AVONEX B-brand
30 O
mcg O
IM O
once O
weekly O
) O
reduced O
TYSABRI B-brand
clearance O
by O
approximately O
30 O
% O
. O

Drug O
interactions O
between O
NEUPOGEN B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

Fluconazole B-drug
, O
an O
inhibitor O
of O
P450 O
2C9 O
, O
decreased O
active O
metabolite O
concentration O
and O
increased O
losartan B-drug
concentration O
. O

A O
proposed O
mechanism O
for O
the O
potentiation O
of O
cAMP-mediated O
acid O
secretion O
by O
carbachol B-drug
. O

Renal O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-brand
in O
patients O
with O
impaired O
renal O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
serum O
creatinine O
concentration O
1.5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O

Limited O
clinical O
data O
in O
angina O
patients O
receiving O
concomitant O
bepridil B-drug
hydrochloride I-drug
and O
digoxin B-drug
therapy O
indicate O
no O
discernible O
changes O
in O
serum O
digoxin O
levels O
. O

FLEXERIL B-brand
may O
enhance O
the O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
, O
and O
other O
CNS B-group
depressants I-group
. O

Interactions O
of O
cobalt B-drug
and O
iron B-drug
in O
absorption O
and O
retention O
. O

Adenosine B-drug
: O
Dipyridamole B-drug
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
and O
cardiovascular O
effects O
of O
adenosine B-drug
. O

Cholestyramine B-drug
and O
colestipol B-drug
resins B-group
: O
Absorption O
of O
hydrochlorothiazide B-drug
is O
impaired O
in O
the O
presence O
of O
anionic B-group
exchange I-group
resins I-group
. O

Beta-adrenergic B-group
Blocking I-group
Agents I-group
: O
The O
effect O
of O
flurbiprofen B-drug
on O
blood O
pressure O
response O
to O
propranolol B-drug
and O
atenolol B-drug
was O
evaluated O
in O
men O
with O
mild O
uncomplicated O
hypertension O
( O
n O
= O
10 O
) O
. O

methyldopa B-drug
; O

Because O
the O
nitrosourea B-group
CCNU B-drug
is O
given O
exclusively O
by O
the O
oral O
route O
in O
man O
, O
we O
have O
carried O
out O
studies O
in O
mice O
on O
the O
antitumour O
activity O
, O
acute O
toxicity O
and O
pharmacokinetics O
of O
oral O
CCNU B-drug
, O
either O
alone O
or O
in O
combination O
with O
the O
chemosensitizer O
misonidazole B-drug_n
. O

Given O
the O
primary O
CNS O
effects O
of O
Anafranil B-brand
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS-active O
drugs O
. O

This O
may O
occur O
because O
diflunisal B-drug
competitively O
displaces O
coumarins B-group
from O
protein O
binding O
sites O
. O

In O
vivo O
studies O
: O
Cytochrome O
P450 O
Inhibitors O

These O
potential O
drug O
interactions O
are O
listed O
in O
Table O
4 O
. O

It O
is O
recommended O
not O
to O
exceed O
a O
single O
2.5 O
mg O
Vardenafil B-drug
dose O
in O
a O
24-hour O
period O
when O
used O
in O
combination O
with O
indinavir B-drug
. O

Because O
severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
oral O
miconazole B-drug
( O
an O
imidazole B-group
) O
and O
oral O
hypoglycemic B-group
agents I-group
, O
such O
a O
potential O
interaction O
involving O
the O
latter O
agents O
when O
used O
concomitantly O
with O
ketoconazole B-drug
tablets O
( O
an O
imidazole B-group
) O
can O
not O
be O
ruled O
out O
. O

The O
oral O
dexamethasone B-drug
doses O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-drug
, O
to O
achieve O
exposures O
of O
dexamethasone B-drug
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-drug
. O

Beta-Blocking O
Agents O
A O
pharmacokinetic O
study O
of O
felodipine B-drug
in O
conjunction O
with O
metoprolol B-drug
demonstrated O
no O
significant O
effects O
on O
the O
pharmacokinetics O
of O
felodipine B-drug
. O

ROMAZICON B-brand
blocks O
the O
central O
effects O
of O
benzodiazepines B-group
by O
competitive O
interaction O
at O
the O
receptor O
level O
. O

Serum O
Amylase O
An O
apparent O
decrease O
in O
serum O
amylase O
activity O
has O
been O
observed O
in O
patients O
administered O
EXTRANEAL B-brand
. O

Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
, O
and O
the O
patient O
's O
serum O
potassium O
should O
be O
monitored O
frequently O
. O

In O
addition O
, O
certain O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
many O
antidepressants B-group
( O
clozapine B-drug
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
, O
and O
others O
) O
, O
may O
inhibit O
the O
activity O
of O
this O
isozyme O
, O
and O
thus O
may O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
with O
regard O
to O
concomitant O
therapy O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
system O
, O
leading O
to O
drug O
interaction O
. O

increased O
alkaline O

Ethanol B-drug
or O
Triazolam B-drug
: O
No O
significant O
differences O
were O
observed O
in O
the O
pharmacokinetics O
of O
triazolam B-drug
( O
0.125 O
mg O
) O
and O
tiagabine B-drug
( O
10 O
mg O
) O
when O
given O
together O
as O
a O
single O
dose O
. O

Studies O
have O
demonstrated O
that O
pretreatment O
with O
isoniazid B-drug
potentiates O
a O
cetaminophen O
hepatoxicity O
in O
rats O
. O

Ibogaine B-drug_n
attenuates O
, O
but O
18-MC B-drug_n
potentiates O
, O
the O
acute O
locomotor O
effects O
of O
morphine B-drug
; O

The O
carbamazepine B-drug
steady-state O
Cmin O
decreased O
31 O
% O
to O
5 O
1 O
micrograms/mL O
when O
felbamate B-drug
( O
3000 O
mg/day O
, O
divided O
into O
three O
doses O
) O
was O
coadministered O
. O


Sodium B-drug
cephalothin I-drug
may O
enhance O
the O
nephrotoxicity O
of O
Coly-Mycin B-brand
M I-brand
Parenteral O
. O

magnesium B-drug
salts O
; O

The O
gradual O
withdrawal O
of O
guafacine B-drug
or O
a O
cardioselective B-group
beta-blocker I-group
could O
be O
substituted O
. O

Refer O
to O
the O
package O
insert O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
preparations O
with O
Hydrochlorothiazide B-drug
. O

Therefore O
, O
if O
theophylline B-drug
is O
co-administered O
with O
fluvoxamine B-drug
maleate I-drug
, O
its O
dose O
should O
be O
reduced O
to O
one O
third O
of O
the O
usual O
daily O
maintenance O
dose O
and O
plasma O
concentrations O
of O
theophylline B-drug
should O
to O
monitored O
. O

Caution O
in O
using O
concomitant O
drugs O
such O
as O
beta-blockers B-group
( O
ophthalmic O
and O
systemic O
) O
, O
anti-hypertensives B-group
and/or O
cardiac B-group
glycosides I-group
is O
advised O
. O

Beta-adrenergic B-group
blocking I-group
agents I-group
may O
also O
interact O
with O
sympathomimetics B-group
. O

EDECRIN B-brand
may O
increase O
the O
ototoxic O
potential O
of O
other O
drugs O
such O
as O
aminoglycoside B-group
and O
some O
cephalosporin B-group
antibiotics I-group
. O

A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedicts O
or O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
) O
, O
but O
not O
with O
enzyme-based O
tests O
for O
glycosuria O
( O
e.g. O
, O
CLINISTIX O
, O
TES-TAPE O
) O
. O

Immunosuppressants B-group
: O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
sirolimus B-drug

Pentamidine B-drug
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O

quinine B-drug
; O

This O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
hepatic O
cytochrome O
P- O
450 O
by O
cimetidine B-drug
, O
which O
could O
decrease O
first O
pass O
metabolism O
of O
nimodipine B-drug
. O

It O
is O
not O
known O
whether O
this O
potentiation O
of O
ampicillin B-drug
rashes O
is O
due O
to O
allopurinol B-drug
or O
the O
hyperuricemia O
present O
in O
these O
patients O
. O

Theophylline B-drug
: O
Following O
co-administration O
of O
two O
250-mg O
dirithromycin B-drug
tablets O
administered O
once O
daily O
with O
200-mg O
theophylline B-drug
tablets O
administered O
twice O
daily O
for O
10 O
days O
to O
14 O
healthy O
subjects O
, O
the O
steady-state O
plasma O
concentration O
of O
theophylline B-drug
was O
not O
significantly O
altered O
. O

These O
reactions O
have O
also O
been O
reported O
in O
patients O
who O
have O
discontinued O
that O
drug O
and O
have O
been O
started O
on O
a O
MAOI B-group
. O

Zidovudine B-drug
: O
There O
is O
no O
significant O
pharmacokinetic O
interaction O
between O
ZDV B-drug
and O
zalcitabine B-drug
which O
has O
been O
confirmed O
clinically O
. O

The O
concomitant O
use O
of O
transdermal O
fentanyl B-drug
with O
ritonavir B-drug
or O
other O
potent O
3A4 O
inhibitors O
such O
as O
ketoconazole B-drug
, O
itraconazole B-drug
, O
troleandomycin B-drug
, O
clarithromycin B-drug
, O
nelfinavir B-drug
, O
and O
nefazadone O
may O
result O
in O
an O
increase O
in O
fentanyl B-drug
plasma O
concentrations O
. O

Most O
( O
98 O
% O
) O
of O
plasma O
doxazosin B-drug
is O
protein O
bound O
. O

Tetracycline B-drug
, O
a O
bacteriostatic B-group
antibiotic I-group
, O
may O
antagonize O
the O
bactercidal O
effect O
of O
penicillin B-drug
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

Specific O
interaction O
studies O
have O
demonstrated O
the O
following O
: O
Cyclosporine B-drug
A I-drug
: O
During O
the O
first O
day O
of O
concomitant O
administration O
, O
trough O
concentrations O
of O
bosentan B-drug
were O
increased O
by O
about O
30-fold O
. O

This O
has O
been O
demonstrated O
in O
view O
, O
however O
, O
the O
clinical O
significance O
of O
this O
interaction O
is O
not O
well O
documented O
. O

Ketoconazole B-drug
( O
400 O
mg O
once O
daily O
) O

Conflicting O
results O
have O
been O
reported O
regarding O
the O
effects O
of O
EPA B-drug
supplements O
on O
glycemic O
control O
in O
non-diabetics O
with O
glucose O
intolerance O
, O
and O
those O
with O
type O
2 O
diabetes O
. O

Hematology O
: O
TAXOL B-brand
therapy O
should O
not O
be O
administered O
to O
patients O
with O
baseline O
neutrophil O
counts O
of O
less O
than O
1,500 O
cells/mm3 O
. O

However O
, O
another O
HMG-CoA B-group
reductase I-group
inhibitor I-group
has O
been O
found O
to O
produce O
a O
less O
than O
two-second O
increase O
in O
prothrombin O
time O
in O
healthy O
volunteers O
receiving O
low O
doses O
of O
warfarin B-drug
. O

Warfarin B-drug
: O
Co-administration O
of O
bosentan B-drug
500 O
mg O
b.i.d O
. O
for O
6 O
days O
decreased O
the O
plasma O
concentrations O
of O
both O
S-warfarin B-drug
( O
a O
CYP2C9 O
substrate O
) O
and O
R-warfarin B-drug
( O
a O
CYP3A4 O
substrate O
) O
by O
29 O
and O
38 O
% O
, O
respectively O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
or O
phenothiazines B-group
may O
produce O
severe O
, O
prolonged O
hypotension O
or O
hypertension O
. O

Acid O
secretion O
in O
isolated O
rabbit O
gastric O
glands O
was O
monitored O
by O
the O
accumulation O
of O
[ O
( O
14 O
) O
C O
] O
aminopyrine B-drug
. O

Antiarrhythmics B-group
: O
bepridil B-drug
, O
lidocaine B-drug
( O
systemic O
) O
and O
quinidine B-drug

Therefore O
, O
when O
INDOCIN B-brand
and O
INDOCIN B-brand
. O

decreased O
levels O
of O
anti-factor O
Xa O
and O
antithrombin B-drug
III I-drug
, O
decreased O
antithrombin B-drug
III I-drug
activity O
; O

Anticoagulant B-brand
therapy O
should O
be O
monitored O
, O
particularly O
during O
the O
first O
few O
weeks O
, O
after O
initiating O
therapy O
with O
BEXTRA B-brand
in O
patients O
receiving O
warfarin B-drug
or O
similar O
agents O
. O

Based O
on O
in O
vitro O
data O
, O
no O
interaction O
would O
be O
expected O
with O
drugs O
whose O
metabolism O
is O
dependent O
upon O
cytochrome O
P450 O
isozymes O
1A1 O
, O
1A2,2A6,2B6,2D6,2E1 O
, O
or O
3A4 O
. O

Ketoconazole B-drug
: O
Coadministration O
of O
ketoconazole B-drug
with O
VIRACEPT B-brand
resulted O
in O
a O
35 O
% O
increase O
in O
nelfinavir B-drug
plasma O
A.C O
. O

Moreover O
, O
additional O
interaction O
studies O
with O
niacin B-drug
and O
propranolol B-drug
have O
not O
demonstrated O
any O
effect O
on O
fluvastatin B-drug
plasma O
levels O
, O
and O
administration O
to O
a O
patient O
population O
chronically O
receiving O
digoxin B-drug
resulted O
in O
no O
difference O
in O
the O
extent O
of O
bioavailability O
of O
digoxin B-drug
relative O
to O
control O
data O
. O

The O
initiation O
of O
alcohol B-drug
or O
nicotine B-drug
use O
may O
be O
precipitated O
by O
similar O
personality O
characteristics O
in O
the O
user O
, O
such O
as O
impulsivity O
and O
sensation O
seeking O
. O

ZINECARD B-brand
does O
not O
influence O
the O
pharmacokinetics O
of O
doxorubicin B-drug
. O

FORADIL B-brand
should O
not O
be O
used O
as O
a O
substitute O
for O
oral O
or O
inhaled O
corticosteroids B-group
. O

dmPGE2 B-drug_n
( O
0.1-1.0 O
mg/kg O
, O
p.o O
. O
) O

A O
subset O
( O
3 O
% O
-10 O
% O
) O
of O
the O
population O
has O
reduced O
activity O
of O
certain O
drug O
metabolizing O
enzymes O
such O
as O
the O
cytochrome O
P450 O
isozyme O
P450 O
2D6 O
. O

It O
may O
also O
produce O
artifactually O
low O
results O
in O
dexamethasone O
or O
metyrapone O
tests O
. O

- O
Reduced O
response O
to O
metyrapone O
test O

Potential O
drug O
interactions O
for O
doxylamine B-drug
include O
, O
increased O
sedation O
if O
doxylamine B-drug
is O
combined O
with O
other O
CNS B-group
depressant I-group
drugs I-group
. O

Amprenavir B-drug
plus O
rifabutin B-drug
was O
poorly O
tolerated O
, O
and O
5 O
of O
11 O
subjects O
discontinued O
therapy O
. O

Concurrent O
administration O
of O
HEXALEN B-brand
and O
antidepressants B-group
of I-group
the I-group
MAO I-group
inhibitor I-group
class I-group
may O
cause O
severe O
orthostatic O
hypotension.Cimetidine B-drug
, O
an O
inhibitor O
of O
microsomal O
drug O
metabolism O
, O
increased O
altretamines B-drug
half-life O
and O
toxicity O
in O
a O
rat O
model O
. O

Anticholinesterases B-group
: O
Concomitant O
use O
of O
anticholinesterase B-group
agents I-group
and O
corticosteroids B-group
may O
produce O
severe O
weakness O
in O
patients O
with O
myasthenia O
gravis O
. O

Such O
information O
assists O
in O
development O
of O
safe O
dosing O
regimens O
, O
prediction O
of O
abnormal O
handling O
of O
drugs O
in O
states O
of O
disease O
and O
disorder O
and O
anticipation O
of O
drug O
interactions O
. O

The O
effect O
of O
administering O
different O
botulinum B-group
neurotoxin I-group
serotypes O
at O
the O
same O
time O
or O
within O
several O
months O
of O
each O
other O
is O
unknown O
. O

In O
some O
patients O
, O
the O
administration O
of O
a O
non- B-group
steroidal I-group
antiinflammatory I-group
agent I-group
can O
reduce O
the O
diuretic B-group
, I-group
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium- O
sparing O
and O
thiazide B-group
diuretics I-group
. O

Given O
the O
primary O
CNS O
effects O
of O
Clozapine B-drug
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS-active O
drugs O
or O
alcohol B-drug
. O

This O
suggests O
that O
an O
interaction O
of O
aripiprazole B-drug
with O
inhibitors O
or O
inducers O
of O
these O
enzymes O
, O
or O
other O
factors O
, O
like O
smoking O
, O
is O
unlikely O
. O

Animal O
reproduction O
studies O
, O
however O
, O
are O
not O
always O
predictive O
of O
human O
response O
and O
there O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant O
women O
. O

Increased O
plasma O
HDL O
and O
HDL2 O
cholesterol O
subfraction O
concentrations O
, O
reduced O
LDL O
cholesterol O
concentration O
, O
increased O
triglyceride O
levels O
. O

The O
urinary O
excretion O
of O
meclofenamate B-drug
sodium I-drug
is O
unaffected O
by O
aspirin B-brand
, O
indicating O
no O
change O
in O
meclofenamate B-drug
sodium I-drug
absorption O
. O

Renal O
function O
should O
be O
monitored O
carefully O
if O
high O
doses O
of O
aminoglycosides B-group
are O
to O
be O
administered O
with O
MAXIPIME B-brand
because O
of O
the O
increased O
potential O
of O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycoside B-group
antibiotics I-group
. O

Netilmicin B-drug
should O
not O
be O
administered O
concomitantly O
with O
potent O
loop B-group
diuretics I-group
such O
as O
furosemide B-drug
and O
ethacrynic B-drug
acid I-drug
as O
the O
potential O
for O
ototoxicity O
is O
enhanced O
by O
the O
combination O
. O

When O
warfarin B-drug
is O
co-administered O
with O
nevirapine B-drug
, O
anticoagulation O
levels O
should O
be O
monitored O
frequently O
. O

Sucralfate B-drug
administered O
2 O
hours O
before O
lomefloxacin B-drug
resulted O
in O
a O
slower O
absorption O
( O
mean O
C O
max O
decreased O
by O
30 O
% O
and O
mean O
T O
max O
increased O
by O
1 O
hour O
) O
and O
a O
lesser O
extent O
of O
absorption O
( O
mean O
AUC O
decreased O
by O
approximately O
25 O
% O
) O
. O

Medication O
is O
rarely O
needed O
. O

Liver O
Function O
Tests O
: O
Since O
elevations O
of O
liver O
enzymes O
have O
been O
observed O
during O
clinical O
trials O
, O
and O
hepatitis O
has O
been O
reported O
, O
pretreatment O
and O
follow-up O
liver O
function O
tests O
should O
be O
performed O
at O
weekly O
or O
biweekly O
intervals O
until O
the O
response O
to O
Accutane B-brand
has O
been O
established O

Renal O
function O
should O
be O
carefully O
monitored O
, O
especially O
if O
higher O
dosages O
of O
the O
aminoglycosides B-group
are O
to O
be O
administered O
or O
if O
therapy O
is O
prolonged O
, O
because O
of O
the O
potential O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycosidic B-group
antibiotics I-group
. O

A O
case O
report O
of O
one O
patient O
taking O
amiodarone B-drug
200 O
mg O
and O
indinavir B-drug
800 O
mg O
three O
times O
a O
day O
resulted O
in O
increases O
in O
amiodarone B-drug
concentrations O
from O
0.9 O
mg/L O
to O
1.3 O
mg/L O
. O

The O
addition O
of O
tiagabine B-drug
in O
a O
limited O
number O
of O
patients O
in O
three O
well-controlled O
studies O
caused O
no O
systematic O
changes O
in O
phenobarbital B-drug
or O
primidone B-drug
concentrations O
when O
compared O
to O
placebo O
. O

Therefore O
, O
injection O
of O
these O
agents O
into O
patients O
receiving O
thyroid B-group
preparations I-group
increases O
the O
risk O
of O
precipitating O
coronary O
insufficiency O
especially O
in O
patients O
with O
coronary O
artery O
disease O
. O

Here O
, O
we O
have O
examined O
whether O
METH B-drug
administration O
affects O
expression O
of O
an O
effector O
IEG O
arc O
( O
activity-regulated O
, O
cytoskeleton-associated O
) O
that O
encodes O
a O
protein O
with O
homology O
to O
spectrin O
. O

Lotensin B-brand
has O
been O
used O
concomitantly O
with O
beta-adrenergic-blocking B-group
agents I-group
, O
calcium-channel-blocking B-group
agents I-group
, O
diuretics B-group
, O
digoxin B-drug
, O
and O
hydralazine B-drug
, O
without O
evidence O
of O
clinically O
important O
adverse O
interactions O
. O

These O
pharmacokinetic O
effects O
seen O
during O
diltiazem B-drug
coadministration O
can O
result O
in O
increased O
clinical O
effects O
( O
e.g. O
, O
prolonged O
sodation O
) O
of O
both O
midazolam B-drug
and O
triazolam B-drug
. O

Combinations O
of O
clozapine B-drug
and O
phencyclidine B-drug_n
: O
effects O
on O
drug O
discrimination O
and O
behavioral O
inhibition O
in O
rats O
. O

No O
drug O
interaction O
studies O
were O
performed O
. O

RESULTS O
: O
Everolimus B-drug
steady O
state O
was O
reached O
on O
or O
before O
day O
7 O
, O
with O
a O
median O
3-fold O
accumulation O
of O
drug O
exposure O
compared O
with O
that O
after O
the O
first O
postoperative O
dose O
. O

The O
binding O
of O
thyroxine O
by O
thyroxine-binding O
prealbumin O
( O
TBPA O
) O
is O
inhibited O
by O
salicylates B-group

Warfarin B-drug
: O
Eszopiclone B-drug
3 O
mg O
administered O
daily O
for O
5 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
( O
R O
) B-drug
- I-drug
or I-drug
( I-drug
S I-drug
) I-drug
-warfarin I-drug
, O
nor O
were O
there O
any O
changes O
in O
the O
pharmacodynamic O
profile O
( O
prothrombin O
time O
) O
following O
a O
single O
25 O
mg O
oral O
dose O
of O
warfarin B-drug

The O
patient O
continued O
to O
receive O
intermittent O
hemodialysis O
until O
his O
death O
from O
infectious O
complications O
that O
occurred O
three O
months O
after O
admission O
. O

Pharmacoeconomic O
analyses O
indicate O
that O
olanzapine B-drug
does O
not O
significantly O
increase O
, O
and O
may O
even O
decrease O
, O
the O
overall O
direct O
treatment O
costs O
of O
schizophrenia O
, O
compared O
with O
haloperidol B-drug
. O

In O
spite O
of O
the O
absence O
of O
kidney O
function O
, O
the O
value O
of O
the O
elimination O
rate O
constant O
was O
significantly O
decreased O
in O
the O
presence O
of O
probenecid B-drug
( O
from O
0.326 O
to O
0.263/h O
) O
. O

Information O
on O
precautions O
and O
contraindications O
, O
indications O
, O
use O
instructions O
, O
and O
instructions O
for O
appropriate O
actions O
after O
missing O
a O
pill O
is O
appended O
. O

Alcohol B-drug
: O
Has O
a O
synergistic O
effect O
with O
aspirin B-brand
in O
causing O
gastrointestinal O
bleeding O
. O

Immunosuppressive B-group
drugs I-group
and O
their O
complications O
. O

Current O
immunosuppressive O
therapies O
are O
effective O
but O
can O
be O
associated O
with O
significant O
adverse O
reactions O
. O

In O
addition O
, O
there O
was O
no O
pharmacodynamic O
interaction O
as O
a O
result O
of O
coadministration O
of O
zaleplon B-drug
and O
venlafaxine B-drug
ER O
. O

Increases O
in O
plasma O
levels O
of O
tricyclic B-drug
antidepressants I-drug
, O
and O
in O
the O
frequency O
and O
severity O
of O
side O
effects O
, O
particularly O
anticholinergic B-drug
, O
have O
been O
reported O
when O
cimetidine B-drug
was O
added O
to O
the O
drug B-drug
regimen O
. O

The O
mechanism O
of O
resveratrol-induced B-drug_n
vasorelaxation O
differs O
in O
the O
mesenteric O
resistance O
arteries O
of O
lean O
and O
obese O
rats O
. O

clinical O
implications O
are O
unclear O
. O

When O
the O
muscle O
was O
exposed O
to O
the O
potassium-depleted O
solution O
, O
the O
first O
contractile O
response O
to O
PTX B-drug_n
was O
rather O
potentiated O
. O

Addition O
or O
deletion O
of O
any O
drug O
from O
the O
therapeutic O
regimen O
of O
patients O
receiving O
oral O
anticoagulants B-group
may O
affect O
patient O
response O
to O
the O
anticoagulant B-group
. O

Concomitant O
use O
of O
agents O
in O
the O
tricyclic B-group
antidepressant I-group
class I-group
( O
which O
includes O
Anafranil B-brand
) O
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
agent I-group
or O
the O
other O
drug O
. O

Patients O
receiving O
other O
narcotic B-group
analgesics O
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
sedative-hypnotics B-group
, O
tricyclic B-group
antidepressants I-group
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
concomitantly O
with O
DILAUDID B-brand
may O
exhibit O
an O
additive O
CNS O
depression O
. O

In O
vitro O
studies O
of O
human O
CYP O
enzymes O
showed O
that O
entacapone B-drug
inhibited O
the O
CYP O
enzymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A O
only O
at O
very O
high O
concentrations O
( O
IC50 O
from O
200 O
to O
over O
1000 O
uM O
; O

900 O

NSAIDs B-group
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
diclofenac B-drug
and O
ibuprofen B-drug
at O
concentrations O
in O
the O
clinical O
range O
. O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Hydrochlorothiazide B-drug
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-drug
and O
hydrochlorothiazide B-drug
resulted O
in O
significantly O
increased O
plasma O
levels O
of O
hydrochlorothiazide B-drug
. O

Enhanced O
theophylline B-drug
clearance O
secondary O
to O
phenytoin B-drug
therapy O
. O

Glyburide B-drug
: O
An O
increased O
risk O
of O
elevated O
liver O
aminotransferases O
was O
observed O
in O
patients O
receiving O
concomitant O
therapy O
with O
glyburide B-drug
. O

Concomitant O
administration O
of O
an O
aluminum-containing B-drug
antacid B-group
had O
no O
significant O
effect O
in O
the O
bioavailability O
of O
6MNA B-drug_n
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Although O
the O
interaction O
between O
almotriptan B-drug
and O
other O
potent O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
itraconazole B-drug
, O
ritonavir B-drug
, O
and O
erythromycin B-drug
) O
has O
not O
been O
studied O
, O
increased O
exposures O
to O
almotriptan B-drug
may O
be O
expected O
when O
almotriptan B-drug
is O
used O
concomitantly O
with O
these O
medications O
. O

Pretreatment O
and O
follow-up O
measurements O
should O
be O
obtained O
under O
fasting O
conditions O
. O

Ergotamine B-drug
or O
dihydroergotamine B-drug
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O

Interactions O
with O
Other O
CNS O
Agents O
: O
Concurrent O
use O
of O
Levo-Dromoran B-brand
with O
all O
central B-group
nervous I-group
system I-group
depressants I-group
( O
eg O
, O
alcohol B-drug
, O
sedatives B-group
, O
hypnotics B-group
, O
other O
opioids B-group
, O
general O
anesthetics B-group
, O
barbiturates B-group
, O
tricyclic B-group
antidepressants I-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
skeletal B-group
muscle I-group
relaxants I-group
and O
antihistamines B-group
) O
may O
result O
in O
additive O
central O
nervous O
system O
depressant O
effects O
. O

Propantheline B-drug
and O
diphenoxylate B-drug
, O
by O
decreasing O
gut O
motility O
, O
may O
increase O
digoxin B-drug
absorption O
. O

If O
taken O
1 O
hour O
before O
indinavir B-drug
( O
IDV B-drug
) O
, O
didanosine B-drug
does O
not O
affect O
IDV B-drug
exposure O
, O
despite O
persistent O
buffering O
effects O
. O

5 O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

The O
effect O
of O
concomitant O
administration O
of O
fluconazole B-drug
and O
glipizide B-drug
has O
been O
demonstrated O
in O
a O
placebo-controlled O
crossover O
study O
in O
normal O
volunteers O
. O

However O
, O
in O
the O
second O
study O
, O
administration O
of O
12 O
g O
cholestyramine B-drug
1 O
hour O
before O
the O
evening O
meal O
and O
0.3 O
mg O
cerivastatin B-drug
sodium I-drug
approximately O
4 O
hours O
after O
the O
same O
evening O
meal O
resulted O
in O
a O
decrease O
in O
the O
cerivastatin B-drug
AUC O
of O
less O
than O
8 O
% O
, O
and O
a O
decrease O
in O
Cmax O
of O
about O
30 O
% O
when O
compared O
to O
dosing O
cerivastatin B-drug
sodium I-drug
alone O
. O

These O
results O
suggest O
that O
the O
hepatoxicity O
of O
ethanol B-drug
in O
alcoholic O
beverages O
is O
enhanced O
by O
interaction O
with O
its O
congeners O
and O
acetaldehyde B-drug_n
; O

It O
is O
now O
clear O
that O
topoisomerase O
activity O
level O
is O
an O
important O
determinant O
of O
sensitivity O
to O
topo O
drugs O
. O

( O
See O
CLINICAL O
PHARMACOLOGY O
) O
Coadministration O
of O
Femara B-brand
and O
tamoxifen B-drug
20 O
mg O
daily O
resulted O
in O
a O
reduction O
of O
letrozole B-drug
plasma O
levels O
by O
38 O
% O
on O
average O
. O

however O
, O
the O
total O
amount O
of O
6MNA B-drug_n
in O
the O
plasma O
is O
unchanged O
. O

Therefore O
, O
amiodarone B-drug
has O
the O
potential O
for O
interactions O
with O
drugs O
or O
substances O
that O
may O
be O
substrates O
, O
inhibitors O
or O
inducers O
of O
CYP3A4 O
. O

Neither O
racemic O
warfarin B-drug
nor O
isradipine B-drug
binding O
to O
plasma O
proteins O
in O
vitro O
was O
altered O
by O
the O
addition O
of O
the O
other O
drug O
. O

These O
agents O
, O
including O
norfloxacin B-drug
, O
ciprofloxacin B-drug
, O
ofloxacin B-drug
, O
enoxacin B-drug
, O
and O
lomefloxacin B-drug
, O
have O
been O
extensively O
studied O
and O
have O
demonstrated O
efficacy O
and O
safety O
profiles O
comparable O
to O
those O
of O
other O
traditional O
agents O
for O
the O
treatment O
of O
complicated O
or O
uncomplicated O
urinary O
tract O
infections O
and O
prostatitis O
. O

Furosemide B-drug
: O
When O
aliskiren B-drug
was O
co-administered O
with O
furosemide B-drug
, O
the O
AUC O
and O
Cmax O
of O
furosemide B-drug
were O
reduced O
by O
about O
30 O
% O
and O
50 O
% O
, O
respectively O
. O

Treatment O
with O
antidepressant B-group
drugs I-group
can O
directly O
interfere O
with O
blood O
glucose O
levels O
or O
may O
interact O
with O
hypoglycemic B-group
agents I-group
. O

Ethinyl B-drug
Estradiol I-drug
and O
Norethindrone B-drug
: O
Coadministration O
of O
VIRACEPT B-brand
with O
OVCON-35 B-brand
resulted O
in O
a O
47 O
% O
decrease O
in O
ethinyl B-drug
estradiol I-drug
and O
an O
18 O
% O
decrease O
in O
norethindrone B-drug
plasma O
concentrations O
. O

- O
Sulfoxone B-drug
( O
e.g. O
, O
Diasone B-brand
) O
or O

The O
8.5 O
% O
incidence O
of O
akathisia O
, O
however O
, O
is O
within O
the O
range O
reported O
for O
use O
of O
prochlorperazine B-drug
when O
given O
as O
a O
premedication O
for O
other O
chemotherapies O
. O

- O
a O
nonsteroidal B-group
anti-inflammatory I-group
drug I-group
( O
NSAID B-group
) O
such O
as O
ibuprofen B-drug
( O
Motrin B-brand
, O
Advil B-brand
, O
Nuprin B-brand
, O
others O
) O
, O
ketoprofen B-drug
( O
Orudis B-brand
, O
Orudis B-brand
KT I-brand
, O
Oruvail B-brand
) O
, O
diclofenac B-drug
( O
Voltaren B-brand
, O
Cataflam B-brand
) O
, O
etodolac B-drug
( O
Lodine B-brand
) O
, O
indomethacin B-drug
( O
Indocin B-brand
) O
, O
nabumetone B-drug
( O
Relafen B-brand
) O
, O
oxaprozin B-drug
( O
Daypro B-brand
) O
, O
and O
naproxen B-drug
( O
Anaprox B-brand
, O
Naprosyn B-brand
, O
Aleve B-brand
) O
; O

However O
, O
when O
any O
additional O
drug O
, O
including O
INDOCIN B-brand
, O
is O
added O
to O
the O
treatment O
of O
patients O
on O
anticoagulant B-group
therapy O
, O
the O
patients O
should O
be O
observed O
for O
alterations O
of O
the O
prothrombin O
time O
. O

Lorazepam B-drug
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-drug
3 O
mg O
and O
lorazepam B-drug
2 O
mg O
did O
not O
have O
clinically O
relevant O
effects O
on O
the O
pharmacodynamics O
or O
pharmacokinetics O
of O
either O
drug O
. O

Drug O
Interaction O
During O
Pregnancy O
: O
Cromolyn B-drug
sodium I-drug
and O
isoproterenol B-drug
were O
studied O
following O
subcutaneous O
injections O
in O
pregnant O
mice O
. O

Symptoms O
resolved O
within O
a O
few O
hours O
. O

The O
threohydrobupropion B-drug_n
metabolite O
of O
bupropion B-drug
does O
not O
appear O
to O
be O
produced O
by O
the O
cytochrome O
P450 O
isoenzymes O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O

In O
the O
case O
that O
you O
are O
taking O
digoxin B-drug
while O
taking O
aminosalicylic B-drug
acid I-drug
, O
higher O
doses O
of O
digoxin B-drug
may O
be O
needed O
. O

no O
evidence O
of O
mutagenicity O
was O
observed O
. O

Further O
, O
in O
rabbits O
dosed O
at O
0.25 O
mg/kg/day O
( O
about O
one-half O
the O
human O
dose O
on O
BSA O
) O
, O
increases O
in O
placental O
weight O
and O
post-implantation O
loss O
were O
observed O
but O
, O
there O
were O
no O
observed O
effects O
on O
fetal O
development O
. O


The O
following O
are O
examples O
of O
substances O
that O
may O
reduce O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
: O
corticosteroids B-group
, O
danazol B-drug
, O
diuretics B-group
, O
sympathomimetic B-group
agents I-group
( O
e.g. O
, O
epinephrine B-drug
, O
albuterol B-drug
, O
terbutaline B-drug
) O
, O
isoniazid B-drug
, O
phenothiazine B-group
derivatives I-group
, O
somatropin B-drug
, O
thyroid B-group
hormones I-group
, O
estrogens B-group
, O
progestogens B-group
( O
e.g. O
, O
in O
oral O
contraceptives B-group
) O
. O

In O
order O
to O
monitor O
the O
occurrence O
of O
myelotoxicity O
, O
it O
is O
recommended O
that O
frequent O
peripheral O
blood O
cell O
counts O
be O
performed O
on O
all O
patients O
receiving O
TAXOL B-brand
. O

Acid-base O
and O
electrolyte O
alterations O
were O
not O
reported O
in O
the O
clinical O
trials O
with O
brinzolamide B-drug
. O

. O

Albendazole B-drug
sulfoxide I-drug
plasma O
concentrations O
were O
unchanged O
4 O
hours O
after O
dosing O
. O

HIV B-group
Antiviral I-group
Agents I-group

Drugs O
that O
inhibit O
or O
Induce O
CYP O
2D6 O
and O
CYP O
3A4 O
may O
affect O
the O
concentration O
on O
Aricept B-brand
. O

The O
optimal O
dosing O
interval O
for O
coadministration O
with O
VIDEX B-brand
should O
be O
determined O
by O
consulting O
the O
appropriate O
quinolone B-group
package O
insert O
. O

Itraconazole B-drug
decreases O
busulfan B-drug
clearance O
by O
up O
to O
25 O
% O
, O
and O
may O
produce O
AUCs O
1500 O
M O
min O
in O
some O
patients O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
antacids B-group
containing O
magnesium B-drug
or O
aluminum B-drug
with O
VIDEX B-brand
Chewable/Dispersible O
Buffered O
Tablets O
or O
Pediatric O
Powder O
for O
Oral O
Solution O
may O
potentiate O
adverse O
events O
associated O
with O
the O
antacid B-group
components O
. O

This O
article O
will O
describe O
the O
escalating O
use O
of O
herbal O
therapy O
and O
the O
hazards O
of O
herbal O
remedy O
use O
among O
patients O
. O

Nelfinavir B-drug

Interferon O
induction O
: O
tool O
for O
establishing O
interactions O
among O
homopolyribonucleotides O
. O

- O
Pressor O
amines O
( O
e.g. O
, O
norepinephrine B-drug
) O
: O
Possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O

This O
study O
demonstrated O
that O
the O
potent O
cytochrome O
P450 O
enzyme-inducer O
phenytoin B-drug
did O
indeed O
have O
a O
marked O
effect O
on O
the O
metabolism O
of O
quetiapine B-drug
, O
resulting O
in O
a O
5-fold O
increase O
in O
clearance O
when O
administered O
concomitantly O
to O
patients O
with O
DSM-IV-diagnosed O
schizophrenia O
, O
schizoaffective O
disorder O
, O
or O
bipolar O
disorder O
. O

Accordingly O
, O
when O
diflunisal B-drug
is O
administered O
with O
oral O
anticoagulants B-group
, O
the O
prothrombin O
time O
should O
be O
closely O
monitored O
during O
and O
for O
several O
days O
after O
concomitant O
drug O
administration O
. O

Imidazoles B-group
( O
e. O
g. O
, O
ketoconazole B-drug
, O
miconazole B-drug
, O
clotrimazole B-drug
, O
fluconazole B-drug
, O
etc O
. O
) O
: O
in O
vitro O
and O
animal O
studies O
with O
the O
combination O
of O
amphotericin B-drug
B I-drug
and O
imidazoles B-group
suggest O
that O
imidazoles B-group
may O
induce O
fungal O
resistance O
to O
amphotericin B-drug
B I-drug
. O

Phenobarbital B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-drug
; O

Benzodiazepines B-group

A O
study O
in O
rats O
to O
assess O
the O
carcinogenic O
potential O
of O
ribavirin B-drug
is O
ongoing O
. O

Although O
bupropion B-drug
is O
not O
metabolized O
by O
this O
isoenzyme O
, O
bupropion B-drug
and O
hydroxybupropion B-drug_n
are O
inhibitors O
of O
the O
CYP2D6 O
isoenzyme O
in O
vitro O
. O

Although O
there O
have O
been O
no O
formal O
interaction O
studies O
other O
than O
with O
antipyrine B-drug
, O
based O
on O
these O
in O
vivo O
and O
in O
vitro O
studies O
, O
it O
is O
unlikely O
that O
co-administration O
of O
a O
1 O
mg O
dose O
of O
ARIMIDEX B-brand
with O
other O
drugs O
will O
result O
in O
clinically O
significant O
drug O
inhibition O
of O
cytochrome O
P450-mediated O
metabolism O
of O
the O
other O
drugs O
. O

Probenecid B-drug
: O
Probenecid B-drug
, O
a O
renal O
tubular O
secretion O
blocking O
agent O
, O
administered O
at O
a O
dose O
of O
500 O
mg O
four O
times O
a O
day O
, O
did O
not O
change O
the O
pharmacokinetics O
of O
levetiracetam B-drug
1000 O
mg O
twice O
daily O
. O

18-MC B-drug_n
does O
not O
produce O
these O
effects O
. O

Plasma O
levels O
of O
flecainide B-drug
have O
been O
reported O
to O
increase O
in O
the O
presence O
of O
oral O
amiodarone B-drug
; O

No O
increase O
in O
mortality O
was O
observed O
in O
patients O
taking O
digoxin B-drug
as O
concomitant O
medication O
. O

However O
, O
if O
the O
patients O
thyroid O
gland O
has O
sufficient O
function O
, O
the O
decreased O
free O
thyroxine B-drug
will O
result O
in O
a O
compensatory O
increase O
in O
thyroxine O
output O
by O
the O
thyroid O
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
healthy O
adults O
and O
adult O
patients O
with O
epilepsy O
. O

Administration O
of O
repeat O
doses O
of O
FACTIVE B-brand
had O
no O
effect O
on O
the O
repeat O
dose O
pharmacokinetics O
of O
theophylline B-drug
, O
digoxin B-drug
or O
an O
ethinylestradiol/levonorgestrol B-drug
oral O
contraceptive B-group
product I-group
in O
healthy O
subjects O
. O

There O
was O
no O
change O
after O
a O
single O
dose O
of O
PGF2alpha B-drug
. O

Studies O
in O
vitro O
show O
that O
caspofungin B-drug
acetate I-drug
is O
not O
an O
inhibitor O
of O
any O
enzyme O
in O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
. O

Salicylates-Salicylates B-group
in O
large O
doses O
may O
inhibit O
vitamin O
K O
epoxide O
reductase O
resulting O
in O
vitamin O
K O
deficiency O
. O

During O
co-administration O
, O
systemic O
levels O
of O
TMP B-drug
and O
SMX B-drug
were O
essentially O
unchanged O
. O

After O
incubation O
at O
0 O
degrees O
C O
for O
4 O
h O
this O
number O
fell O
to O
2.3 O
plus O
or O
minus O
0.1 O
S.E.M O
. O

- O
Valproic B-drug
acid I-drug
( O
e.g. O
, O
Depakene B-brand
) O
Use O
of O
sulfapyridine B-drug
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O

Ketoconazole B-drug
tablets O
may O
alter O
the O
metabolism O
of O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
and O
methylprednisolone B-drug
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
drugs O
. O

- O
The O
action O
of O
sulphonylureas B-group
and O
insulin B-drug
may O
be O
enhanced O
by O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
. O

However O
, O
these O
studies O
did O
not O
show O
whether O
ginsenosides-induced B-drug_n
inhibition O
of O
Ca O
( O
2+ O
) O
currents O
discriminates O
among O
the O
various O
Ca O
( O
2+ O
) O
channel O
subtypes O
, O
although O
it O
is O
known O
that O
there O
are O
at O
least O
five O
different O
Ca O
( O
2+ O
) O
channel O
subtypes O
in O
neuronal O
cells O
. O

Concomitant O
administration O
of O
erythromycin B-drug
and O
digoxin B-drug
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-drug
serum O
levels O
. O

Differential O
actions O
of O
intrathecal O
naloxone B-drug
on O
blocking O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
beta-endorphin B-drug_n
and O
morphine B-drug
in O
rats O
. O

While O
taking O
beta B-group
blockers I-group
, O
patients O
with O
a O
history O
of O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
have O
a O
more O
severe O
reaction O
on O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
or O
therapeutic O
. O

Q4H O
, O
and O
levofloxacin B-drug
, O
500 O
mg O
p.o O
. O

Nonetheless O
, O
their O
relevance O
continues O
to O
be O
demonstrated O
by O
the O
dependence O
of O
each O
agent O
on O
intact O
liver O
blood O
flow O
and O
function O
for O
normal O
rates O
of O
elimination O
; O

However O
, O
in O
vitro O
studies O
have O
shown O
that O
at O
high O
concentrations O
( O
7.4 O
mMol/L O
or O
0.97 O
mg/mL O
and O
greater O
) O
EACA B-drug
inhibits O
ADP O
and O
collagen-induced O
platelet O
aggregation O
, O
the O
release O
of O
ATP O
and O
serotonin O
, O
and O
the O
binding O
of O
fibrinogen O
to O
the O
platelets O
in O
a O
concentration-response O
manner O
. O

Use O
with O
Allopurinol B-drug
: O
The O
principal O
pathway O
for O
detoxification O
of O
azathioprine B-drug
is O
inhibited O
by O
allopurinol B-drug
. O

Familial O
hyper- O
or O
hypo-thyroxine-binding-globulinemias O
have O
been O
described O
. O

Talk O
to O
your O
doctor O
if O
you O
are O
taking O
certain O
antibiotics B-group
such O
as O
erythromycin B-drug
, O
clarithromycin B-drug
or O
azithromycin B-drug
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Guardians O
of O
children O
who O
have O
been O
prescribed O
FORADIL B-brand
should O
be O
alerted O
to O
the O
general O
concern O
regarding O
asthma O
therapy O
compliance O
, O
especially O
neglect O
of O
anti-inflammatory O
therapy O
and O
overuse O
of O
short-acting B-group
beta2-agonists I-group
. O

Injection O
: O
Lorazepam B-drug
injection O
, O
like O
other O
injectable O
benzodiazepines B-group
, O
produces O
depression O
of O
the O
central O
nervous O
system O
when O
administered O
with O
ethyl B-drug
alcohol I-drug
, O
phenothiazines B-group
, O
barbiturates B-group
, O
MAO B-group
inhibitors I-group
, O
and O
other O
antidepressants.When B-group
scopolamine B-drug
is O
used O
concomitantly O
with O
injectable O
lorazepam B-drug
, O
an O
increased O
incidence O
of O
sedation O
, O
hallucinations O
, O
and O
irrational O
behavior O
has O
been O
observed O
. O

Acidifying B-group
agents I-group
: O
Gastrointestinal B-group
acidifying I-group
agents I-group
( O
guanethidine B-drug
, O
reserpine B-drug
, O
glutamic B-drug
acid I-drug
HCl I-drug
, O
ascorbic B-drug
acid I-drug
, O
fruit O
juices O
, O
etc O
. O
) O
lower O
absorption O
of O
amphetamines B-group
. O

Positive O
direct O
and O
indirect O
antiglobulin O
( O
Coombs O
) O
tests O
have O
occurred O
; O

Drugs O
highly O
bound O
to O
albumin O
could O
increase O
the O
unbound O
fraction O
of O
fosphenytoin B-drug
. O

The O
concomitant O
use O
of O
beta-adrenergic B-group
blocking I-group
agents I-group
with O
digitalis B-group
and O
calcium B-group
antagonists O
may O
have O
additive O
effects O
on O
prolonging O
atrioventricular O
conduction O
time O
. O

RESULTS O
: O
The O
two O
treatment O
groups O
were O
well O
matched O
with O
regard O
to O
patient O
demographics O
, O
NHL O
characteristics O
, O
HIV O
status O
, O
and O
treatment O
, O
i.e. O
, O
the O
number O
of O
cycles O
and O
chemotherapy O
dose O
. O

Avoid O
the O
concomitant O
use O
of O
chlorprothixene B-drug
and O
tramadol B-drug
( O
Ultram B-brand
) O
. O

Coadministration O
of O
NIZORAL B-brand
Tablets O
with O
midazolam B-drug
or O
triazolam B-drug
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O

This O
treatment O
arm O
was O
discontinued O
from O
the O
trial O
. O

No O
dose O
adjustment O
is O
necessary O
. O

An O
in O
vitro O
effect O
occurs O
when O
the O
medication O
interferes O
with O
the O
assay O
, O
and O
the O
result O
is O
erroneous O
and O
can O
not O
be O
interpreted O
. O

Ironically O
, O
benzodiazepines B-group
are O
often O
used O
in O
the O
treatment O
of O
heroin B-drug
addiction O
while O
they O
cause O
much O
more O
severe O
withdrawal O
symptoms O
. O

However O
, O
a O
crossover O
study O
in O
healthy O
subjects O
receiving O
either O
Tagamet B-brand
300 O
mg O
q.i.d O
. O
or O
800 O
mg O
h.s O
. O
concomitantly O
with O
a O
300 O
mg O
b.i.d O
. O
dosage O
of O
theophylline B-drug
( O
Theo-Dur B-brand
, O
Key O
Pharmaceuticals O
, O
Inc. O
) O
demonstrated O
less O
alteration O
in O
steady-state O
theophylline B-drug
peak O
serum O
levels O
with O
the O
800 O
mg O
h.s O
. O
regimen O
, O
particularly O
in O
subjects O
aged O
54 O
years O
and O
older O
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

cardiac B-group
glycosides I-group
; O

Specific O
studies O
have O
confirmed O
these O
effects O
with O
sevoflurane B-drug
, O
isoflurane B-drug
, O
propofol B-drug
, O
alfentanil B-drug
, O
and O
midazolam B-drug
. O

Anti-arrhythmics B-group
and O
tricyclic B-group
anti-depressants I-group
could O
exaggerate O
the O
prolongation O
of O
the O
QT O
interval O
observed O
with O
bepridil B-drug
hydrochloride I-drug
. O

It O
is O
assumed O
that O
increased O
interaction O
between O
3H-spiroperidol B-drug_n
and O
high O
affinity O
binding O
sites O
for O
apomorphine B-drug
on O
dopamine2- O
and O
serotonin2-receptors O
underlies O
the O
antipsychotic O
action O
of O
neuroleptics B-group
after O
their O
prolonged O
administration O
. O

The O
most O
commonly O
occurring O
drug O
interactions O
are O
listed O
below O
: O
- O
Drugs O
that O
may O
increase O
plasma O
phenytoin B-drug
concentrations O
include O
: O
acute O
alcohol B-drug
intake O
, O
amiodarone B-drug
, O
chboramphenicol O
, O
chlordiazepoxide B-drug
, O
cimetidine B-drug
, O
diazepam B-drug
, O
dicumarol B-drug
, O
disulfiram B-drug
, O
estrogens B-group
, O
ethosuximide B-drug
, O
fluoxetine B-drug
, O
H2-antagonists B-group
, O
halothane B-drug
, O
isoniazid B-drug
, O
methylphenidate B-drug
, O
phenothiazines B-group
, O
phenylbutazone B-drug
, O
salicylates B-group
, O
succinimides B-group
, O
sulfonamides B-group
, O
tolbutamide B-drug
, O
trazodone B-drug

If O
they O
do O
occur O
, O
the O
EPA B-drug
dose O
should O
be O
lowered O
or O
discontinued O
. O

For O
digoxin B-drug
AUC O
( O
0-infinity O
) O
, O
AUC O
( O
0-24 O
) O
, O
and O
Cmax O
, O
the O
geometric O
mean O
ratios O
( O
90 O
% O
confidence O
interval O
) O
for O
( O
rofecoxib B-drug
+ O
digoxin/placebo B-drug
+ O
digoxin B-drug
) O
were O
1.04 O
( O
0.94 O
, O
1.14 O
) O
, O
1.02 O
( O
0.94 O
, O
1.09 O
) O
, O
and O
1.00 O
( O
0.91 O
, O
1.10 O
) O
, O
respectively O
. O

washout O
( O
days O
7-13 O
) O
; O

In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
Kineret B-brand
and O
etanercept B-drug
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
etanercept B-drug
alone O
( O
0 O
% O
) O
. O

Because O
Nalfon B-brand
has O
not O
been O
shown O
to O
produce O
any O
additional O
effect O
beyond O
that O
obtained O
with O
aspirin B-brand
alone O
and O
because O
aspirin B-brand
increases O
the O
rate O
of O
excretion O
of O
Nalfon B-brand
, O
the O
concomitant O
use O
of O
Nalfon B-brand
and O
salicylates B-group
is O
not O
recommended O
. O

In O
that O
same O
study O
, O
aspirin B-brand
alone O
produced O
a O
marked O
inhibition O
in O
platelet O
aggregation O
ex O
vivo O
. O

When O
used O
concomitantly O
, O
anesthetics B-group
and O
calcium B-group
channel I-group
blockers I-group
should O
be O
titrated O
carefully O
. O

When O
estrogen B-group
therapy O
is O
initiated O
, O
a O
reduction O
in O
corticosteroid B-group
dosage O
may O
be O
required O
, O
and O
increased O
amounts O
may O
be O
required O
when O
estrogen B-group
is O
terminated O
. O

In O
neither O
case O
were O
the O
pharmacokinetics O
of O
sumatriptan B-drug
affected O
by O
coadministration O
with O
STADOL B-brand
NS I-brand
. O

Some O
cases O
presented O
with O
features O
resembling O
neuroleptic O
malignant O
syndrome O
. O

Therefore O
, O
intake O
of O
supplemental O
folic B-drug
acid I-drug
should O
not O
exceed O
1000 O
micrograms O
( O
g O
, O
sometimes O
mcg O
) O
per O
day O
to O
prevent O
folic B-drug
acid I-drug
from O
masking O
symptoms O
of O
vitamin O
B12 O
deficiency O
. O

Xigris B-brand
present O
in O
plasma O
samples O
does O
not O
interfere O
with O
one-stage O
factor O
assays O
based O
on O
the O
PT O
( O
such O
as O
factor O
II O
, O
V O
, O
VII O
, O
and O
X O
assays O
) O
. O

These O
compounds O
interfere O
with O
chemical O
color O
development O
essential O
to O
the O
analytical O
procedures O
. O

GI O
motility O
agents O
: O
cisapride B-drug

Amprenavir B-drug
is O
metabolized O
in O
the O
liver O
by O
the O
cytochrome O
P450 O
enzyme O
system O
. O

At O
least O
14 O
days O
should O
elapse O
between O
discontinuation O
of O
a O
MAO B-group
inhibitor I-group
and O
initiation O
of O
treatment O
with O
dexfenfluramine B-drug
. O

Phenytoin B-drug
is O
extensively O
bound O
to O
serum O
plasma O
proteins O
and O
is O
prone O
to O
competitive O
displacement O
. O

the O
third O
group O
( O
SH/EA O
) O
was O
treated O
with O
a O
hydroalcoholic O
solution O
of O
ethanol B-drug
; O

Administration O
of O
rifampin B-drug
concomitantly O
with O
oral O
amiodarone B-drug
has O
been O
shown O
to O
result O
in O
decreases O
in O
serum O
concentrations O
of O
amiodarone B-drug
and O
desethylamiodarone B-drug
. O

The O
fluoroquinolones B-group
are O
also O
extensively O
used O
in O
urologic O
surgery O
. O

Each O
serum O
without O
the O
other O
added O
drug O
as O
well O
as O
the O
serum O
supplemented O
with O
the O
other O
drug O
at O
the O
three O
concentrations O
was O
dialyzed O
against O
phosphate O
buffer O
. O

endocrine O
dysfunction O
; O

Quinolones B-group
have O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Therefore O
, O
concurrent O
use O
of O
Trileptal B-brand
with O
hormonal B-group
contraceptives I-group
may O
render O
these O
contraceptives B-group
less O
effective O
. O

In O
controlled O
clinical O
trials O
of O
AUGMENTIN B-brand
XR I-brand
, O
22 O
patients O
received O
concomitant O
allopurinol B-drug
and O
AUGMENTIN B-brand
XR I-brand
. O

Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Decreased O
By O
Co-administration O
With O
Nevirapine B-drug

Using O
calcium B-drug
acetate I-drug
with O
digitalis B-group
glycosides I-group
( O
heart O
medicine O
) O
may O
cause O
hypercalcemia O
( O
too O
much O
calcium B-drug
in O
the O
blood O
) O
, O
which O
could O
increase O
the O
chance O
of O
developing O
an O
irregular O
heartbeat O
. O

Fentanyl B-drug
Anesthesia O
: O
Severe O
hypotension O
has O
been O
reported O
during O
fentanyl B-drug
anesthesia O
with O
concomitant O
use O
of O
a O
beta B-group
blocker I-group
and O
a O
calcium B-group
channel I-group
blocker I-group
. O

Laboratory O
Tests O
If O
significant O
abnormal O
laboratory O
results O
are O
obtained O
, O
either O
dosage O
reduction O
with O
careful O
monitoring O
or O
treatment O
discontinuation O
is O
recommended O
, O
depending O
on O
clinical O
judgement O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Although O
ROMAZICON B-brand
exerts O
a O
slight O
intrinsic O
anticonvulsant O
effect O
, O
its O
abrupt O
suppression O
of O
the O
protective O
effect O
of O
a O
benzodiazepine B-group
agonist O
can O
give O
rise O
to O
convulsions O
in O
epileptic O
patients O
. O

In O
healthy O
volunteers O
, O
the O
pharmacokinetics O
of O
a O
1-mg O
dose O
of O
butorphanol B-drug
administered O
as O
STADOL B-brand
NS I-brand
were O
not O
affected O
by O
the O
coadministration O
of O
a O
single O
6-mg O
subcutaneous O
dose O
of O
sumatriptan B-drug
. O

In O
post-marketing O
experience O
, O
bleeding O
has O
been O
reported O
in O
patients O
on O
concomitant O
treatment O
with O
anticoagulants B-group
and O
INDOCIN B-brand
. O

Concurrent O
administration O
of O
low-dose O
dopamine B-drug
HCl I-drug
and O
diuretic B-group
agents I-group
may O
produce O
an O
additive O
or O
potentiating O
effect O
on O
urine O
flow O
. O

Maximal O
hypotension O
was O
found O
120 O
minutes O
post O
ethanol B-drug
, O
and O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-drug
. O

Since O
bacteriostatic O
drugs O
, O
such O
as O
the O
tetracycline B-group
class I-group
of O
antibiotics B-group
, O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillins B-group
, O
it O
is O
not O
advisable O
to O
administer O
these O
drugs O
concomitantly O
. O

In O
healthy O
volunteers O
, O
Exjade B-brand
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

Dexfenfluramine B-drug
should O
not O
be O
administered O
with O
other O
serotoninergic B-group
agents I-group
. O

Nevirapine I-drug

To O
prevent O
stomach O
irritation O
, O
subjects O
received O
rantidine B-drug
hydrochloride I-drug
before O
each O
experimental O
session O
. O

Amiodarone B-drug
is O
known O
to O
raise O
serum O
digoxin B-drug
levels O
. O

No O
formal O
drug O
interaction O
studies O
of O
Aranesp B-brand
have O
been O
performed O
. O

Deaths O
from O
severe O
enterocolitis O
, O
diarrhea O
, O
and O
dehydration O
have O
been O
reported O
in O
elderly O
patients O
receiving O
weekly O
leucovorin B-drug
and O
fluorouracil B-drug
. O

The O
response O
rates O
were O
similar O
between O
the O
two O
groups O
. O

Antacids B-group
and O
kaolin B-drug
: O
Antacids B-group
and O
kaolin B-drug
can O
reduce O
absorption O
of O
chloroquine B-drug
; O

However O
, O
the O
effects O
of O
stress O
and O
glucocorticoids B-group
on O
the O
subjective O
and O
behavioral O
effects O
of O
psychostimulants B-group
have O
not O
been O
well O
studied O
in O
humans O
. O

filipin B-drug_n
was O
more O
potent O
in O
lysing O
human O
red O
blood O
cells O
, O
whereas O
amphotericin B-drug
B I-drug
was O
more O
potent O
in O
inhibiting O
yeast O
cell O
growth O
; O


Oral O
contraceptives B-group
may O
be O
less O
effective O
while O
you O
are O
taking O
lymecycline B-drug
. O

AIMS/HYPOTHESIS O
: O
There O
is O
evidence O
that O
insulin B-drug
and O
glucose B-drug
cause O
renal O
and O
ocular O
vasodilation O
. O

Latent O
LCV O
infection O
is O
generally O
asymptomatic O
, O
but O
can O
lead O
to O
B-cell O
lymphomas O
when O
animals O
are O
immune O
suppressed O
. O

PEGASYS B-brand
should O
be O
assumed O
to O
have O
abortifacient O
potential O
. O

Adrenergic B-group
Agents I-group
: O
Some O
individuals O
receiving O
ZYVOX B-brand
may O
experience O
a O
reversible O
enhancement O
of O
the O
pressor O
response O
to O
indirect-acting O
sympathomimetic B-group
agents I-group
, O
vasopressor B-group
or O
dopaminergic B-group
agents I-group
. O

Effect O
of O
Other O
Drugs O
on O
the O
Pharmacokinetics O
of O
Clonazepam B-drug
: O
Literature O
reports O
suggest O
that O
ranitidine B-drug
, O
an O
agent O
that O
decreases O
stomach O
acidity O
, O
does O
not O
greatly O
alter O
clonazepam B-drug
pharmacokinetics O
. O

Substances O
that O
inhibit O
the O
cytochrome O
P450 O
isoenzyme O
( O
CYP3A4 O
) O
activity O
may O
decrease O
metabolism O
and O
increase O
imatinib B-drug
concentrations O
. O

However O
, O
in O
a O
well-controlled O
study O
of O
patients O
with O
lymphoma O
on O
combination O
therapy O
, O
allopurinol B-drug
did O
not O
increase O
the O
marrow O
toxicity O
of O
patients O
treated O
with O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
bleomycin B-drug
, O
procarbazine B-drug
and/or O
mechlorethamine B-drug
. O

Diabetic O
patients O
have O
a O
20 O
% O
higher O
risk O
of O
depression O
than O
the O
general O
population O
. O

Drug/Laboratory O
Test O
Interactions O
A O
false-positive O
reaction O
for O
ketones O
in O
the O
urine O
may O
occur O
with O
tests O
using O
nitroprusside B-drug
, O
but O
not O
with O
those O
using O
nitroferricyanide B-drug
. O

General O
No O
clinical O
drug O
interaction O
studies O
were O
performed O
. O

The O
interaction O
between O
lomefloxacin B-drug
and O
cimetidine B-drug
has O
not O
been O
studied O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
closely O
monitored O
. O


Beta B-group
blockers I-group
may O
exacerbate O
the O
hypertensive O
response O
seen O
with O
clonidine B-drug
withdrawl O
. O

Potential O
for O
reduction O
in O
anticonvulsant B-group
and/or O
efavirenz B-drug
plasma O
levels O
; O

Beta-blockers B-group
( O
metoprolol B-drug
, O
propranolol B-drug
) O
serum O
concentrations O
and O
pharmacologic O
effects O
may O
be O
increased O
. O

Aprepitant B-drug
is O
unlikely O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
the O
P-glycoprotein O
transporter O
, O
as O
demonstrated O
by O
the O
lack O
of O
interaction O
of O
Aprepitant B-drug
with O
digoxin B-drug
in O
a O
clinical O
drug O
interaction O
study O
. O

Hypotension O
: O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-drug
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
enalapril B-drug
or O
enalaprilat B-drug
. O

Warfarin B-drug
: O
No O
significant O
differences O
were O
observed O
in O
the O
steady-state O
pharmacokinetics O
of O
R-warfarin B-drug
or O
S-warfarin B-drug
with O
the O
addition O
of O
tiagabine B-drug
given O
as O
a O
single O
dose O
. O

In O
patients O
receiving O
FORADIL B-brand
, O
other O
inhaled O
medications O
should O
be O
used O
only O
as O
directed O
by O
the O
physician O
. O

With O
the O
exception O
of O
albuterol B-drug
, O
there O
are O
no O
formal O
studies O
fully O
evaluating O
the O
interaction O
effects O
of O
ATROVENT B-brand
Inhalation O
Aerosol O
and O
these O
drugs O
with O
respect O
to O
effectiveness O
. O

We O
demonstrate O
that O
the O
conversion O
of O
1,3-difluoro-2-propanol B-drug_n
to O
1,3-difluoroacetone B-drug_n
by O
an O
NAD+-dependent O
oxidation O
is O
the O
rate-limiting O
step O
in O
the O
synthesis O
of O
the O
toxic O
product O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
from O
1,3-difluoro-2-propanol B-drug_n
. O

These O
results O
suggest O
that O
exposure O
to O
environmental O
lead B-drug_n
may O
alter O
the O
biological O
and O
behavioral O
responsiveness O
of O
an O
animal O
to O
alcohol B-drug
. O

No O
drug O
interactions O
were O
detected O
except O
for O
an O
increase O
in O
symptomatic O
hypotension O
in O
patients O
receiving O
oral O
ACE B-group
inhibitors I-group
. O

Excessive O
neuromuscular O
weakness O
may O
be O
exacerbated O
by O
administration O
of O
another O
botulinum B-group
toxin I-group
prior O
to O
the O
resolution O
of O
the O
effects O
of O
a O
previously O
administered O
botulinum B-group
toxin I-group
. O

SINCE O
THE O
CONCOMITANT O
ADMINISTRATION O
OF O
THESE O
TWO O
DRUGS O
CAN O
LEAD O
TO O
PHENYTOIN B-drug
INTOXICATION O
, O
PRIOR O
TO O
ADMINISTERING O
DISULFIRAM B-drug
TO O
A O
PATIENT O
ON O
PHENYTOIN B-drug
THERAPY O
, O
A O
BASELINE O
PHENYTOIN B-drug
SERUM O
LEVEL O
SHOULD O
BE O
OBTAINED O
. O

Other O
CNS B-group
depressant I-group
drugs I-group
should O
be O
used O
with O
caution O
in O
patients O
taking O
fenfluramine B-drug
, O
since O
the O
effects O
may O
be O
additive O
. O

When O
taken O
concurrently O
with O
ethanol B-drug
, O
a O
pharmacological O
interaction O
may O
occur O
, O
potentiating O
the O
central O
nervous O
system O
depression O
produced O
by O
either O
drug O
. O

Cytochrome O
P-450 O
is O
not O
known O
to O
be O
involved O
in O
the O
metabolism O
of O
Plenaxis B-brand
. O

Diuretics B-group
: O
Patients O
on O
diuretics B-group
, O
especially O
those O
with O
intravascular O
volume O
depletion O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
fosinopril B-drug
sodium I-drug
. O

Drug/Laboratory O
Test O
Interactions O
Acetaminophen B-drug
may O
produce O
false-positive O
test O
results O
for O
urinary O
5-hydroxyindoleacetic O
acid O
. O

Some O
quinolone B-group
antibiotics I-group
would O
be O
expected O
to O
have O
similar O
effects O
and O
these O
combinations O
should O
be O
avoided O
. O

Colestipol-Concomitant B-drug
intake O
of O
colestipol B-drug
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Since O
fondaparinux B-drug
does O
not O
markedly O
inhibit O
CYP450s O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
or O
CYP3A4 O
) O
in O
vitro O
, O
fondaparinux B-drug
sodium I-drug
is O
not O
expected O
to O
significantly O
interact O
with O
other O
drugs O
in O
vivo O
by O
inhibition O
of O
metabolism O
mediated O
by O
these O
isozymes O
. O

Several O
studies O
indicate O
that O
olanzapine B-drug
has O
benefits O
against O
symptoms O
of O
aggression O
and O
agitation O
, O
while O
other O
studies O
strongly O
support O
the O
effectiveness O
of O
olanzapine B-drug
in O
the O
treatment O
of O
depressive O
symptomatology O
. O

In O
view O
of O
the O
potential O
risk O
of O
dehydration O
secondary O
to O
vomiting O
and/or O
diarrhea O
induced O
by O
CAMPTOSAR B-brand
, O
the O
physician O
may O
wish O
to O
withhold O
diuretics B-group
during O
dosing O
with O
CAMPTOSAR B-brand
and O
, O
certainly O
, O
during O
periods O
of O
active O
vomiting O
or O
diarrhea O
. O

Co-administration O
of O
bosentan B-drug
decreased O
the O
plasma O
concentrations O
of O
glyburide B-drug
by O
approximately O
40 O
% O
. O

Diltiazem B-drug
: O
In O
patients O
with O
mild O
to O
moderate O
hypertension O
, O
administration O
of O
aprepitant B-drug
once O
daily O
, O
as O
a O
tablet O
formulation O
comparable O
to O
230 O
mg O
of O
the O
capsule O
formulation O
, O
with O
diltiazem B-drug
120 O
mg O
3 O
times O
daily O
for O
5 O
days O
, O
resulted O
in O
a O
2-fold O
increase O
of O
aprepitant B-drug
AUC O
and O
a O
simultaneous O
1.7-fold O
increase O
of O
diltiazem B-drug
AUC O
. O

This O
increase O
is O
greatest O
in O
the O
evening O
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
INVIRASE/Ritonavir B-brand

Concomitant O
administration O
of O
drugs O
known O
to O
induce O
cytochrome O
P450 O
enzymes O
may O
decrease O
the O
plasma O
levels O
of O
clozapine B-drug
. O

Digoxin B-drug
is O
eliminated O
renally O
. O

However O
, O
LDL-C O
reduction O
was O
not O
altered O
. O

There O
was O
no O
apparent O
pharmacokinetic O
interaction O
between O
zaleplon B-drug
and O
ibuprofen B-drug
following O
single O
dose O
administration O
( O
10 O
mg O
and O
600 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O

In O
controlled O
clinical O
trials O
, O
however O
, O
beta B-drug
blockers I-drug
including O
metoprolol B-drug
were O
concurrently O
administered O
with O
felodipine B-drug
and O
were O
well O
tolerated O
. O

When O
amiodarone B-drug
is O
added O
to O
flecainide B-drug
therapy O
, O
plasma O
flecainide B-drug
levels O
may O
increase O
two-fold O
or O
more O
in O
some O
patients O
, O
if O
flecainide B-drug
dosage O
is O
not O
reduced O
. O

Digoxin B-drug
: O
Enoxacin B-drug
may O
raise O
serum O
digoxin B-drug
levels O
in O
some O
individuals O
. O

Cardiovascular O
collapse O
in O
patients O
treated O
simultaneously O
with O
varapamil O
and O
dantrolene B-drug
sodium I-drug
is O
rare O
. O

tolbutamide B-drug
; O

In O
such O
a O
case O
, O
the O
peripheral O
vascular O
resistance O
may O
increase O
. O

9 O
. O

The O
effects O
of O
diethyl B-drug_n
pyrocarbonate I-drug_n
could O
be O
reversed O
by O
hydroxylamine B-drug_n
treatment O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

both O
compounds O
attenuate O
morphine-induced B-drug
locomotion O
in O
morphine-experienced B-drug
rats O
. O

ACE B-group
Inhibitors I-group
and O
Angiotensin B-group
II I-group
Receptor I-group
Antagonists I-group
( O
Hypertension O
) O
- O
In O
clinical O
studies O
of O
patients O
with O
hypertension O
, O
the O
addition O
of O
INSPRA B-brand
50 O
to O
100 O
mg O
to O
ACE B-group
inhibitors I-group
and O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
increased O
mean O
serum O
potassium O
slightly O
( O
about O
0.09-0.13 O
mEq/L O
) O
. O

Although O
results O
have O
varied O
from O
study O
to O
study O
, O
effects O
have O
been O
shown O
on O
furosemide-stimulated B-drug
diuresis O
, O
natriuresis O
, O
and O
kaliuresis O
. O

The O
possibility O
of O
reduced O
statin B-group
efficacy O
should O
be O
considered O
. O

These O
data O
indicate O
that O
levetiracetam B-drug
does O
not O
influence O
the O
plasma O
concentration O
of O
other O
AEDs B-group
and O
that O
these O
AEDs B-group
do O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

Multiple-dose O
administration O
of O
the O
potent O
CYP3A4 O
inducer O
rifampin B-drug
( O
600 O
mg O
every O
24 O
hours O
, O
q24h O
, O
for O
14 O
days O
) O
, O
however O
, O
reduced O
zaleplon B-drug
Cmax O
and O
AUC O
by O
approximately O
80 O
% O
. O

. O

In O
vitro O
studies O
have O
indicated O
that O
colestipol B-drug
hydrochloride I-drug
binds O
a O
number O
of O
drugs O
. O

Combination O
hormonal B-group
contraceptives I-group
may O
also O
increase O
risk O
of O
thromboembolic O
disorders O
. O

( O
1968 O
, O
1970 O
) O
, O
the O
higher O
serum O
concentrations O
of O
penicillins B-group
and O
cephaloridine B-drug
reached O
after O
administration O
of O
probenecid B-drug
are O
due O
not O
only O
to O
slower O
renal O
elimination O
but O
also O
to O
an O
altered O
distribution O
in O
the O
body O
. O

Caution O
should O
also O
be O
applied O
for O
other O
sympathomimetics B-group
, O
and O
for O
aminophylline B-drug
and O
theophylline B-drug
and O
tricyclic B-group
antidepressants I-group
, O
which O
may O
also O
precipitate O
arrhythmias O
. O

CNS O
Drugs O
- O
Given O
the O
primary O
CNS O
effects O
of O
escitalopram B-drug
, O
caution O
should O
be O
used O
when O
it O
is O
taken O
in O
combination O
with O
other O
centrally O
acting O
drugs O
. O

nc1 O
40 O
% O
decrease O
[ O
CI O
: O
17 O
% O
decrease O
, O
57 O
% O
decrease O
] O

approximately O
one-hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
) O
, O
fulvestrant B-drug
caused O
a O
reversible O
reduction O
in O
female O
fertility O
, O
as O
well O
as O
effects O
on O
embryo/fetal O
development O
consistent O
with O
its O
anti-estrogenic O
activity O
. O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Morphine B-drug
analgesia O
and O
pupil O
constriction O
were O
unaffected O
by O
ADL B-drug
8-2698 I-drug
and O
differed O
from O
placebo O
( O
P O
< O
.002 O
) O
. O

Survanta B-brand
increased O
the O
extent O
of O
dissolution O
of O
budesonide B-drug
in O
proportion O
to O
the O
added O
concentration O
, O
which O
was O
also O
verified O
by O
equilibrium O
solubilization O
studies O
. O

Each O
volunteer O
was O
administered O
one O
400-mg O
ceftibuten B-drug
capsule O
. O

Other O
drugs O
have O
not O
been O
studied O
. O

Dimenhydrinate B-drug
may O
decrease O
emetic B-group
response O
to O
apomorphine B-drug
. O

Electrocardiograms O
were O
done O
at O
baseline O
and O
on O
the O
last O
day O
of O
the O
washout O
period O
and O
phase O
2 O
. O

Because O
of O
the O
variability O
of O
individual O
patient O
response O
, O
multiple O
interacting O
mechanisms O
with O
some O
drugs O
, O
the O
dependency O
of O
the O
extent O
of O
the O
interaction O
on O
the O
dosage O
and O
duration O
of O
therapy O
, O
and O
the O
possible O
administration O
of O
several O
interacting O
drugs O
simultaneously O
, O
it O
is O
difficult O
to O
predict O
the O
direction O
and O
degree O
of O
the O
ultimate O
effect O
of O
concomitant O
medications O
on O
anticoagulant B-group
response O
. O

However O
, O
caution O
should O
be O
exercised O
because O
there O
have O
been O
a O
few O
spontaneous O
reports O
of O
prolonged O
prothrombin O
times O
, O
with O
or O
without O
bleeding O
, O
in O
etodolac-treated B-drug
patients O
receiving O
concomitant O
warfarin B-drug
therapy O
. O

Doxepin B-drug
is O
primarily O
metabolized O
by O
CYP2D6 O
( O
with O
CYP1A2 O
and O
CYP3A4 O
as O
minor O
pathways O
) O
. O

Release O
of O
arachidonic O
acid O
from O
membrane O
phospholipids O
as O
well O
as O
subsequent O
synthesis O
and O
release O
of O
vasoconstrictor O
thromboxane O
A2 O
are O
also O
regulated O
by O
movement O
of O
calcium O
ions O
. O

DESIGN O
: O
Cross-sectional O
descriptive O
study O
. O

Finasteride B-drug
does O
not O
appear O
to O
affect O
the O
cytochrome O
P450-linked O
drug-metabolizing O
enzyme O
system O
. O

We O
have O
shown O
that O
MCF-7 O
cells O
treated O
with O
100 O
nM O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
exhibit O
characteristic O
apoptotic O
morphology O
( O
pyknotic O
nuclei O
, O
chromatin O
and O
cytoplasmic O
condensation O
, O
nuclear O
matrix O
protein O
reorganization O
) O
within O
48 O
h O
. O

Therefore O
, O
the O
potential O
exists O
for O
a O
drug O
interaction O
between O
WELLBUTRIN B-brand
and O
drugs O
that O
affect O
the O
CYP2B6 O
isoenzyme O
( O
e.g. O
, O
orphenadrine B-drug
and O
cyclophosphamide B-drug
) O
. O

Dose O
adjustment O
of O
Sensipar B-brand
may O
be O
required O
and O
PTH O
and O
serum O
calcium O
concentrations O
should O
be O
closely O
monitored O
if O
a O
patient O
initiates O
or O
discontinues O
therapy O
with O
a O
strong O
CYP3A4 O
inhibitor O
( O
e.g. O
, O
ketoconazole B-drug
, O
erythromycin B-drug
, O
itraconazole B-drug
; O

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
, O
achieving O
a O
maximum O
relaxation O
of O
> O
95 O
% O
at O
a O
concentration O
of O
35 O
micromol/l O
. O

It O
was O
concluded O
that O
, O
although O
gentamycin B-drug
did O
augment O
the O
neuromuscular O
blockade O
of O
atracurium B-drug
, O
the O
effect O
was O
minimal O
. O


Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
or O
vaginal O
preparations O
of O
miconazole B-drug
is O
not O
known O
. O

The O
mode O
of O
toxic O
action O
of O
the O
pesticide O
gliftor B-drug_n
: O
the O
metabolism O
of O
1,3-difluoroacetone B-drug_n
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
. O

. O

Rare O
cases O
of O
elevated O
plasma O
concentrations O
of O
digoxin B-drug
have O
been O
reported O
. O

At O
75 O
% O
recovery O
of O
fade O
, O
hoof O
twitch O
was O
87 O
+/- O
3 O
% O
for O
atracurium B-drug
alone O
and O
82 O
+/- O
4 O
% O
for O
atracurium B-drug
plus O
gentamycin B-drug
. O

CYP3A4 B-drug
Inhibitors O
Felodipine O
is O
metabolized O
by O
CYP3A4 B-drug
. O

therefore O
, O
if O
glucocorticoid B-group
replacement O
is O
needed O
, O
hydrocortisone B-drug
should O
be O
prescribed O
. O

Hepatic O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-brand
in O
patients O
with O
impaired O
liver O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
ALT O
and/or O
AST O
2.5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
and/or O
total O
bilirubin O
2 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O

Digoxin B-drug
: O
Studies O
of O
concomitant O
administration O
of O
flurbiprofen B-drug
and O
digoxin B-drug
to O
healthy O
men O
( O
n= O
14 O
) O
did O
not O
show O
a O
change O
in O
the O
steady O
state O
serum O
levels O
of O
either O
drug O
. O

Thus O
, O
when O
ibuprofen B-drug
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

Acarbose B-drug
may O
affect O
digoxin B-drug
bioavailabillty O
and O
may O
require O
dose O
adjustment O
of O
digoxin B-drug
by O
16 O
% O
( O
90 O
% O
confidence O
interval O
: O
8-23 O
% O
) O
, O
decrease O
mean O
C O
max O
digoxin B-drug
by O
26 O
% O
( O
90 O
% O
confidence O
interval O
: O
16-34 O
% O
) O
and O
decrease O
mean O
trough O
concentrations O
of O
digoxin B-drug
by O
9 O
% O
( O
90 O
% O
confidence O
limit O
: O
19 O
% O
decrease O
to O
2 O
% O
increase O
) O
. O

According O
to O
Gibaldi O
et O
al O
. O

Concurrent O
use O
of O
hydroxyurea B-drug
and O
other O
myelosuppressive O
agents O
or O
radiation O
therapy O
may O
increase O
the O
likelihood O
of O
bone O
marrow O
depression O
or O
other O
adverse O
events O
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-group
D I-group
. O

Due O
to O
the O
frequent O
occurrence O
of O
severe O
and O
prolonged O
thrombocytopenia O
, O
the O
potential O
benefits O
of O
medications O
which O
interfere O
with O
platelet O
function O
and/or O
anticoagulation O
should O
be O
weighed O
against O
the O
potential O
increased O
risks O
of O
bleeding O
and O
hemorrhage O
. O

Carbamazepine B-drug_n
epoxide I-drug_n
steady-state O
Cmin O
concentrations O
increased O
57 O
% O
from O
1.0 O
0.3 O
to O
1.6 O
0.4 O
micrograms/mL O
with O
the O
addition O
of O
felbamate B-drug
. O

LABORATORY O
TEST O
FINDINGS O
Asymptomatic O
, O
transitory O
changes O
in O
serum O
iron O
have O
been O
observed O
. O

In O
separate O
single O
or O
multiple O
dose O
pharmacokinetic O
interaction O
studies O
with O
chlorthalidone B-drug
, O
nifedipine B-drug
, O
propanolol B-drug
, O
hydrochlorothiazide B-drug
, O
cimetidine B-drug
, O
metoclopramide B-drug
, O
propantheline B-drug
, O
digoxin B-drug
, O
and O
warfarin B-drug
, O
the O
bioavailability O
of O
fosinoprilat B-drug_n
was O
not O
altered O
by O
coadministration O
of O
fosinopril B-drug
with O
any O
one O
of O
these O
drugs O
. O

Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-group
antidepressants I-group
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O

Caution O
should O
be O
exercised O
if O
tacrolimus B-drug
and O
bosentan B-drug
are O
used O
together O
. O

Patients O
taking O
isoniazid B-drug
when O
disulfiram B-drug
is O
given O
should O
be O
observed O
for O
the O
appearance O
of O
unsteady O
gait O
or O
marked O
changes O
in O
mental O
status O
; O


ADL-8-2698 B-drug
is O
a O
novel O
peripherally B-group
restricted I-group
opioid I-group
antagonist I-group
that O
may O
selectively O
prevent O
opioid-induced B-group
gastrointestinal O
effects O
without O
reversing O
analgesia O
. O

This O
was O
due O
to O
reductions O
in O
both O
renal O
clearance O
( O
from O
105 O
+/- O
39 O
to O
84 O
+/- O
15 O
ml/min O
) O
( O
p O
less O
than O
0.05 O
) O
and O
nonrenal O
clearance O
( O
from O
130 O
+/- O
38 O
to O
88 O
+/- O
20 O
ml/min O
) O
( O
p O
less O
than O
0.01 O
) O
. O

Use O
with O
caution O
. O

Diabetics O
should O
discuss O
the O
use O
of O
these O
supplements O
with O
their O
physicians O
and O
note O
if O
the O
supplements O
affect O
their O
glycemic O
control O
. O

Infusion O
of O
arginine B-drug
alone O
markedly O
decreased O
the O
amount O
of O
extractable O
pancreatic O
insulin O
and O
glucagon O
. O

Aspirin B-brand
: O
Vardenafil B-drug
( O
10 O
mg O
and O
20 O
mg O
) O
did O
not O
potentiate O
the O
increase O
in O
bleeding O
time O
caused O
by O
aspirin B-brand
( O
two O
81 O
mg O
tablets O
) O
. O

In O
a O
12-week O
endoscopy O
study O
conducted O
in O
OA O
patients O
there O
was O
no O
difference O
in O
the O
cumulative O
incidence O
of O
endoscopic O
gastroduodenal O
ulcers O
in O
patients O
taking O
low-dose O
( O
81 O
mg O
) O
enteric O
coated O
aspirin B-brand
plus O
VIOXX B-brand
25 O
mg O
daily O
, O
as O
compared O
to O
those O
taking O
ibuprofen B-drug
2400 O
mg O
daily O
alone O
. O

Patients O
receiving O
both O
drugs O
should O
be O
under O
careful O
observation O
. O

Cmax O
and O
AUC O
values O
are O
3 O
% O
to O
4 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
125 O
mg O
Neurontin B-brand
and O
21 O
% O
to O
22 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
500 O
mg O
Neurontin B-brand
. O

The O
concomitant O
use O
of O
INDOCIN B-brand
with O
other O
NSAIDs B-group
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O

Concomitant O
treatment O
with O
coumarin B-group
derivatives I-group
( O
vitamin B-group
K I-group
antagonists I-group
) O
and O
drugs O
that O
affect O
platelet O
function O
may O
also O
increase O
the O
risk O
of O
bleeding O
. O

1,25-Dihydroxycholecalciferol B-drug
D3 I-drug
( O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
) O
, O
the O
active O
metabolite O
of O
vitamin B-group
D I-group
, O
is O
a O
potent O
inhibitor O
of O
breast O
cancer O
cell O
growth O
both O
in O
vivo O
and O
in O
vitro O
. O

cmaxSS O
( O
Peak O
plasma O
concentration O
) O

Dexbrompheniramine B-drug
can O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

These O
reactions O
include O
fever O
, O
chills O
, O
nausea O
, O
vomiting O
, O
pruritus O
, O
rash O
, O
diarrhea O
, O
hypotension O
, O
edema O
, O
and O
oliguria O
. O

Increases O
of O
22 O
% O
with O
MHD B-drug_n
and O
47 O
% O
with O
oxcarbazepine B-drug
were O
observed O
. O

Interaction O
of O
the O
constituents O
of O
alcoholic O
beverages O
in O
the O
promotion O
of O
liver O
damage O
. O

Resistance O
was O
measured O
near O
the O
placental O
margin O
after O
spontaneous O
term O
delivery O
. O

Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-drug
with O
norfloxacin B-drug
. O

Warfarin B-drug

Geriatric O
Use O
Younger O
patients O
have O
higher O
virologic O
response O
rates O
than O
older O
patients O
. O

Rifampin B-drug

The O
magnitude O
and O
relative O
importance O
of O
the O
effects O
noted O
below O
are O
likely O
to O
be O
patient O
specific O
and O
may O
vary O
by O
such O
factors O
as O
age O
, O
gender O
, O
race O
, O
intercurrent O
illnesses O
, O
dose O
of O
either O
agent O
, O
additional O
concomitant O
medications O
, O
and O
timing O
of O
drug O
administration O
. O

Phenothiazine-related B-group
compounds I-group
and O
beta-adrenergic B-group
blocking I-group
agents I-group
may O
have O
additive O
hypotensite O
effects O
due O
to O
the O
inhibition O
of O
each O
other O
s O
metabolism O
. O

Lethargy O
and O
somnolence O
have O
been O
reported O
following O
doses O
of O
REVIA B-brand
and O
thioridazine B-drug
. O

Coadministration O
of O
amprenavir B-drug
and O
methadone B-drug
as O
compared O
to O
a O
non-matched O
historicalcontrol O
group O
resulted O
in O
a O
30 O
% O
, O
27 O
% O
, O
and O
25 O
% O
decrease O
in O
serum O
amprenavir B-drug
AUC O
, O
Cmax O
, O
andCmin O
, O
respectively O
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
( O
drying O
) O
effects O
of O
antihistamines B-group
. O

In O
vitro O
metabolism O
studies O
have O
suggested O
that O
decitabine B-drug
is O
not O
a O
substrate O
for O
the O
human O
liver O
cytochrome O
P450 O
enzymes O
. O

For O
the O
identification O
of O
" O
limit O
values O
" O
, O
it O
has O
generally O
been O
suggested O
in O
the O
literature O
that O
the O
possible O
effects O
deriving O
from O
multiple O
exposure O
be O
considered O
as O
additive O
. O

Cancer O
in O
the O
elderly O
: O
basic O
science O
and O
clinical O
aspects O
. O

Rare O
cases O
of O
serious O
cardiovascular O
adverse O
events O
, O
including O
electrocardiographic O
QT/QTc O
interval O
prolongation O
, O
cardiac O
arrest O
, O
torsades O
de O
pointes O
, O
and O
other O
ventricular O
arrhythmias O
have O
been O
observed O
. O

Other O
Agents O
: O
PRINIVIL B-brand
has O
been O
used O
concomitantly O
with O
nitrates B-group
and/or O
digoxin B-drug
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
2 O
drugs O
are O
given O
concomitantly O
. O

It O
is O
important O
that O
patients O
understand O
how O
to O
use O
FORADIL B-brand
( O
formoterol B-drug
fumarate I-drug
) O
capsules O
with O
the O
supplied O
AerolizerTM O
inhalation O
device O
and O
how O
it O
should O
be O
used O
in O
relation O
to O
other O
asthma O
or O
COPD O
medications O
they O
are O
taking O
. O

Coadministration O
of O
alosetron B-drug
and O
strong O
CYP3A4 O
inhibitors O
, O
such O
as O
clarithromycin B-drug
, O
telithromycin B-drug
, O
protease B-group
inhibitors I-group
, O
voriconazole B-drug
, O
and O
itraconazole B-drug
has O
not O
been O
evaluated O
but O
should O
be O
undertaken O
with O
caution O
because O
of O
similar O
potential O
drug O
interactions O
. O

In O
vitro O
studies O
suggest O
that O
coadministration O
of O
cytochrome O
P450 O
inhibitors O
to O
PMs O
will O
not O
increase O
the O
plasma O
concentrations O
of O
atomoxetine B-drug
. O

Effect O
of O
dofetillide B-drug
on O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

. O

miconazole B-drug
; O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Caution O
should O
be O
exercised O
when O
anticoagulants B-group
are O
given O
in O
conjunction O
with O
Atromid-S B-brand
. O

Because O
tetracyclines B-group
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-group
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-group
dosage O
. O

Caspofungin B-drug
is O
not O
a O
substrate O
for O
P-glycoprotein O
and O
is O
a O
poor O
substrate O
for O
cytochrome O
P450 O
enzymes O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
Acarbose B-drug
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
blood O
glucose O
control O
. O

Antacids B-group
containing O
aluminum B-drug
hydroxide I-drug
and O
magnesium B-drug
hydroxide I-drug
reduce O
the O
oral O
absorption O
of O
enoxacin B-drug
by O
75 O
% O
. O

Green B-drug
tea I-drug
polyphenols I-drug
as O
potent O
enhancers B-drug
of O
glucocorticoid-induced O
mouse O
mammary O
tumor O
virus O
gene O
expression O
. O

1- O
nc O
denotes O
a O
mean O
change O
of O
less O
than O
10 O
% O
2- O
Pediatrics O
3- O
Mean O
increase O
in O
adults O
at O
high O
Trileptal B-brand
doses O
In O
vivo O
, O
the O
plasma O
levels O
of O
phenytoin B-drug
increased O
by O
up O
to O
40 O
% O
, O
when O
Trileptal B-brand
was O
given O
at O
doses O
above O
1200 O
mg/day O
. O

- O
Androgens B-group
( O
male O
hormones O
) O
or O

Cimetidine B-drug
( O
400 O
mg O
b.i.d O
. O
) O
had O
no O
effect O
on O
vardenafil B-drug
bioavailability O
( O
AUC O
) O
and O
maximum O
concentration O
( O
Cmax O
) O
of O
vardenafil B-drug
when O
co-administered O
with O
20 O
mg O
Vardenafil B-drug
in O
healthy O
volunteers O
. O

Furosemide B-drug
: O
In O
normal O
volunteers O
, O
the O
concomitant O
administration O
of O
diflunisal B-drug
and O
furosemide B-drug
had O
no O
effect O
on O
the O
diuretic O
activity O
of O
furosemide B-drug
. O

While O
the O
effects O
of O
chronic O
phenytoin B-drug
or O
carbamazepine B-drug
therapy O
on O
the O
action O
of O
NIMBEX B-brand
are O
unknown O
, O
slightly O
shorter O
durations O
of O
neuromuscular O
block O
may O
be O
anticipated O
and O
infusion O
rate O
requirements O
may O
be O
higher O
. O

Animal O
toxicology O
studies O
showed O
increased O
DEET B-drug
toxicity O
when O
DEET B-drug
was O
included O
as O
proof O
of O
the O
formulation O
. O

Itraconazole B-drug
Ketoconazole I-drug
Erythromycin I-drug
Clarithromycin I-drug
Telithromycin I-drug
HIV B-group
protease I-group
inhibitors I-group
Nefazodone B-drug
Cyclosporine I-drug
Large O
quantities O
of O
grapefruit O
juice O
( O
1 O
quart O
daily O
) O

The O
fluoroquinolones B-group
for O
urinary O
tract O
infections O
: O
a O
review O
. O

A O
clinical O
study O
in O
healthy O
male O
volunteers O
( O
n=24 O
) O
demonstrated O
that O
mixing O
NovoLog B-brand
with O
NPH B-drug
human I-drug
insulin I-drug
immediately O
before O
injection O
produced O
some O
attenuation O
in O
the O
peak O
concentration O
of O
NovoLog B-brand
, O
but O
that O
the O
time O
to O
peak O
and O
the O
total O
bioavailability O
of O
NovoLog B-brand
were O
not O
significantly O
affected O
. O

Therefore O
, O
when O
INDOCIN B-brand
and O
digoxin B-drug
are O
used O
concomitantly O
, O
serum O
digoxin B-drug
levels O
should O
be O
closely O
monitored O
. O

Hyperglycaemia O
increased O
all O
the O
renal O
and O
ocular O
parameters O
studied O
. O

Increase O
daily O
dose O
of O
rifabutin B-drug
by O
50 O
% O
. O

After O
30 O
min O
, O
fasting O
glycemia O
was O
measured O
. O

Co-administration O
of O
celecoxib B-drug
with O
drugs O
that O
are O
known O
to O
inhibit O
2C9 O
should O
be O
done O
with O
caution O
. O

Potassium B-drug
Supplements O
and O
Potassium-Sparing B-group
Diuretics I-group
Lotensin O
can O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-group
diuretics I-group
. O

In O
case O
of O
theophylline B-drug
toxicity O
and/or O
elevated O
serum O
theophylline B-drug
levels O
, O
the O
dose O
of O
theophylline B-drug
should O
be O
reduced O
while O
the O
patient O
is O
receiving O
concomitant O
erythromycin B-drug
therapy O
. O

Phenytoin B-drug
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
reports O
of O
both O
increases O
and O
decreases O
in O
phenytoin B-drug
levels O
with O
dexamethasone B-drug
co-administration O
, O
leading O
to O
alterations O
in O
seizure O
control O
. O

In O
vitro O
binding O
studies O
with O
human O
serum O
proteins O
indicate O
that O
glipizide B-drug
binds O
differently O
than O
tolbutamide B-drug
and O
does O
not O
interact O
with O
salicylate B-group
or O
dicumarol B-drug
. O

It O
is O
not O
known O
if O
hormonal B-group
contraceptives I-group
differ O
in O
their O
effectiveness O
when O
used O
with O
Accutane B-brand
. O

Administration O
of O
dantrolene B-drug
may O
potentiate O
vecuronium-induced B-drug
neuromuscular O
block O
. O

This O
decrease O
in O
bioavailability O
was O
about O
5 O
% O
when O
gabapentin B-drug
was O
administered O
2 O
hours O
after O
Maalox B-brand
. O

Folic B-drug
acid I-drug
supplements O
can O
correct O
the O
anemia O
associated O
with O
vitamin O
B12 O
deficiency O
. O

Taking O
amyl B-drug
nitrite I-drug
after O
drinking O
alcohol B-drug
may O
worsen O
side O
effects O
and O
may O
cause O
severe O
hypotension O
and O
cardiovascular O
collapse O
. O

Indomethacin B-drug
was O
also O
ineffective O
in O
altering O
resveratrol B-drug_n
activity O
in O
arteries O
from O
both O
lean O
and O
dietary-obese O
rats O
. O

INDOCIN B-brand
given O
concomitantly O
with O
digoxin B-drug
has O
been O
reported O
to O
increase O
the O
serum O
concentration O
and O
prolong O
the O
half-life O
of O
digoxin B-drug
. O

Considerable O
caution O
should O
be O
exercised O
if O
PEGANONE B-brand
is O
administered O
concurrently O
with O
Phenurone B-brand
( O
phenacemide B-drug
) O
since O
paranoid O
symptoms O
have O
been O
reported O
during O
therapy O
with O
this O
combination O
. O

Paroxetine B-drug
produced O
only O
minor O
changes O
in O
the O
levels O
of O
clozapine B-drug
and O
its O
metabolites O
. O

Formulation O
of O
fluorescence O
labelled O
bacitracin B-drug
and O
insulin B-drug
in O
unconjugated O
NaCMC B-drug_n
( O
1 O
% O
m/v O
) O
did O
not O
significantly O
improve O
the O
permeation O
, O
however O
in O
the O
presence O
of O
1 O
% O
( O
m/v O
) O
CMC-Cys7.3 B-drug_n
a O
significantly O
improved O
permeation O
was O
observed O
( O
R= O
1.3 O
) O
. O

Interaction O
of O
ketamine B-drug
and O
halothane B-drug
in O
rats O
. O

Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O

PEGASYS B-brand
should O
be O
used O
with O
caution O
in O
patients O
with O
creatinine O
clearance O
50 O
mL/min O
and O
COPEGUS B-brand
should O
not O
be O
administered O
to O
patients O
with O
creatinine O
clearance O
50 O
mL/min O

Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
( O
i.e. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
) O
leading O
to O
increased O
total O
circulating O
corticosteroids B-group
and O
sex B-group
steroids I-group
, O
respectively O
. O

Decreases O
in O
TBg O
concentrations O
are O
observed O
in O
nephrosis O
, O
acromegaly O
and O
after O
androgen B-group
or O
corticosteroid B-group
therapy O
. O

Concomitant O
administration O
of O
clarithromycin B-drug
with O
pimozide B-drug
is O
contraindicated O
. O

In O
comparison O
with O
haloperidol B-drug
, O
the O
adverse O
events O
reported O
significantly O
more O
frequently O
with O
olanzapine B-drug
in O
> O
or O
= O
3.5 O
% O
of O
patients O
were O
dry O
mouth O
, O
bodyweight O
gain O
and O
increased O
appetite O
and O
compared O
with O
risperidone B-drug
, O
only O
bodyweight O
gain O
occurred O
significantly O
more O
frequently O
with O
olanzapine B-drug
. O

These O
medications O
have O
included O
heparin B-drug
, O
warfarin B-drug
, O
beta-adrenergic B-group
receptor I-group
blockers I-group
, O
calcium B-group
channel I-group
antagonists I-group
, O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
, O
intravenous O
and O
oral O
nitrates B-group
, O
ticlopidine B-drug
, O
and O
aspirin B-brand
. O

Pretreatment O
of O
rats O
with O
allopurinol B-drug
( O
100 O
mg/kg O
, O
ip O
) O
or O
Vitamin B-drug
E I-drug
( O
100 O
mg/kg O
per O
day O
, O
ig O
, O
for O
3 O
days O
and O
a O
dose O
of O
40 O
mg/kg O
on O
the O
4th O
day O
) O
provided O
significant O
protection O
against O
the O
elevation O
of O
TBARS O
levels O
in O
cerebral O
and O
hepatic O
tissues O
, O
induced O
by O
single O
high O
dose O
of O
oral O
cypermethrin B-drug
administration O
within O
4 O
h O
. O

These O
would O
include O
a O
variety O
of O
preparations O
which O
contain O
androgens B-group
, O
estrogens B-group
, O
progestins B-group
, O
or O
glucocorticoids B-group
. O

Theophylline B-drug
: O
Theophylline B-drug
clearance O
may O
decrease O
in O
hypothyroid O
patients O
and O
return O
toward O
normal O
when O
a O
euthyroid O
state O
is O
achieved O
. O

These O
data O
suggest O
that O
rofecoxib B-drug
may O
produce O
a O
modest O
inhibition O
of O
cytochrome O
P450 O
( O
CYP O
) O
1A2 O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
of O
the O
potential O
for O
serious O
adverse O
reactions O
from O
FASLODEX B-brand
in O
nursing O
infants O
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

A O
return O
to O
normal O
menstrual O
rhythm O
followed O
cessation O
of O
treatment O
. O

The O
higher O
verografine B-drug
and O
iodamide B-drug
excretion O
was O
due O
to O
their O
increased O
renal O
tubular O
secretion O
. O

Opioids B-group
are O
strong O
central B-group
nervous I-group
system I-group
depressants I-group
, O
but O
regular O
users O
develop O
physiological O
tolerance O
allowing O
gradually O
increased O
dosages O
. O

Calcium B-group
Channel I-group
Blockers I-group
, O
Dihydropyridine B-group
: O
e.g. O
, O
felodipine B-drug
, O
nifedipine B-drug
, O
nicardipine B-drug

Additionally O
, O
paroxetine B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
Sonata B-brand
, O
reflecting O
the O
absence O
of O
a O
role O
of O
CYP2D6 O
in O
zaleplon B-drug
s O
metabolism O
. O

Therefore O
, O
monitoring O
of O
plasma O
digoxin B-drug
levels O
may O
be O
indicated O
in O
patients O
receiving O
similar O
combination O
chemotherapy O
regimens O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

Dolasetron B-drug
has O
been O
safely O
coadministered O
with O
drugs O
used O
in O
chemotherapy O
and O
surgery O
. O

Phenobarbital B-drug
: O
Coadministration O
of O
felbamate B-drug
with O
phenobarbital B-drug
causes O
an O
increase O
in O
phenobarbital B-drug
plasma O
concentrations O
, O
In O
12 O
otherwise O
healthy O
male O
volunteers O
ingesting O
phenobarbital B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
phenobarbital B-drug
concentration O
was O
14.2 O
micrograms/mL O
. O

Antihypertensives B-group
: O
Amphetamines B-group
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-drug
. O

In O
these O
subjects O
, O
celecoxib B-drug
did O
not O
alter O
the O
anticoagulant O
effect O
of O
warfarin B-drug
as O
determined O
by O
prothrombin O
time O
. O

Repeating O
the O
study O
with O
6 O
healthy O
male O
volunteers O
in O
the O
absence O
of O
glibenclamide B-drug
did O
not O
detect O
an O
effect O
of O
acitretin B-drug
on O
glucose O
tolerance O
. O

Two O
weeks O
after O
bilateral O
ovariectomy O
, O
female O
rats O
received O
a O
s.c O
. O

( O
Effectiveness O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
because O
of O
alkalinization O
of O
the O
urine O
. O
) O

Although O
not O
studied O
with O
alosetron B-drug
, O
inhibition O
of O
N-acetyltransferase O
may O
have O
clinically O
relevant O
consequences O
for O
drugs O
such O
as O
isoniazid B-drug
, O
procainamide B-drug
, O
and O
hydralazine B-drug
. O

However O
, O
if O
Argatroban B-drug
is O
to O
be O
initiated O
after O
cessation O
of O
heparin B-drug
therapy O
, O
allow O
sufficient O
time O
for O
heparins O
effect O
on O
the O
aPTT O
to O
decrease O
prior O
to O
initiation O
of O
Argatroban B-drug
therapy O
. O

- O
Antidiabetics B-group
, O
oral O
( O
diabetes O
medicine O
you O
take O
by O
mouth O
) O
Use O
of O
oral O
antidiabetics B-group
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
blood O
and/or O
the O
side O
effects O
or O
oral O
antidiabetics B-group

Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-drug
and O
cisapride B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

If O
you O
are O
taking O
a O
tricyclic B-group
antidepressant I-group
, O
talk O
to O
your O
doctor O
before O
taking O
this O
medicine O
. O

Carbamazepine B-drug
: O
Isoniazid B-drug
is O
known O
to O
slow O
the O
metabolism O
of O
carbamazepine B-drug
and O
increase O
its O
serum O
levels O
Carbamazepine B-drug
levels O
should O
be O
determined O
prior O
to O
concurrent O
administration O
with O
isoniazid B-drug
, O
signs O
and O
symptoms O
of O
carbamazepine B-drug
toxicity O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustment O
of O
the O
anticonvulsant B-group
should O
be O
made O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Butyrophenones B-group
( O
such O
as O
haloperidol B-drug
) O
and O
phenothiazines B-group
can O
suppress O
the O
dopaminergic B-drug
renal O
and O
mesenteric O
vasodilation O
induced O
with O
low O
dose O
dopamine O
infusion O
. O

Erythromycin I-drug
( O
500 O
mg O
q8h O
) O
+ O
40 O
% O
+46 O
% O

Also O
, O
due O
to O
the O
potential O
for O
additive O
effects O
such O
as O
bradycardia O
and O
AV O
block O
, O
caution O
is O
warranted O
in O
patients O
receiving O
clonidine B-drug
with O
agents O
known O
to O
affect O
sinus O
node O
function O
or O
AV O
nodal O
conduction O
( O
e.g. O
, O
digitalis B-group
, O
calcium B-group
channel I-group
blockers I-group
, O
and O
beta-blockers B-group
. O
) O

The O
size O
of O
wheal O
and O
flare O
were O
significantly O
larger O
when O
fexofenadine B-drug
hydrochloride I-drug
was O
administered O
with O
either O
grapefruit O
or O
orange O
juices O
compared O
to O
water O
. O

Effects O
of O
Lapatinib B-drug
on O
Drug O
Metabolizing O
Enzymes O
and O
Drug O
Transport O
Systems O
Lapatinib B-drug
inhibits O
CYP3A4 O
and O
CYP2C8 O
in O
vitro O
at O
clinically O
relevant O
concentrations O
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Administration O
of O
epinephrine B-drug
to O
patients O
receiving O
cyclopropane B-drug
or O
halogenated B-group
hydrocarbon I-group
general I-group
anesthetics I-group
such O
as O
halothane B-drug
which O
sensitize O
the O
myocardium O
, O
may O
induce O
cardiac O
arrhythmia.. O

AZOPT B-brand
( O
brinzolamide B-drug
ophthalmic O
suspension O
) O
1 O
% O
contains O
a O
carbonic B-group
anhydrase I-group
inhibitor I-group
. O

All O
20 O
strains O
of O
enterococcus O
, O
three O
strains O
of O
Clostridium O
, O
three O
strains O
of O
Escherichia O
coli O
, O
and O
one O
strain O
of O
Proteus O
rettgeri O
were O
resistant O
to O
both O
clindamycin B-drug
( O
minimal O
inhibitory O
concentration O
greater O
than O
3.1 O
mug/ml O
) O
and O
gentamicin B-drug
( O
minimal O
inhibitory O
concentration O
greater O
than O
6.2 O
mug/ml O
) O
. O

In O
combination O
with O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
heroin B-drug_n
may O
still O
kill O
even O
experienced O
users O
, O
particularly O
if O
their O
tolerance O
to O
the O
drug O
has O
reduced O
or O
the O
strength O
of O
their O
usual O
dose O
has O
increased O
. O

Caution O
is O
advised O
when O
TRISENOX B-brand
is O
coadministered O
with O
other O
medications O
that O
can O
prolong O
the O
QT O
interval O
( O
e.g O
. O
certain O
antiarrhythmics B-group
or O
thioridazine B-drug
) O
or O
lead O
to O
electrolyte O
abnormalities O
( O
such O
as O
diuretics B-group
or O
amphotericin B-drug
B I-drug
) O
. O

Available O
data O
indicate O
that O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
are O
important O
factors O
in O
hemostasis O
and O
regulation O
of O
vascular O
tone O
. O

All O
patients O
in O
whom O
this O
effect O
was O
observed O
remained O
asymptomatic O
. O

Combination O
of O
amiodarone B-drug
with O
other O
antiarrhythmic B-drug
therapy O
should O
be O
reserved O
for O
patients O
with O
life-threatening O
ventricular O
arrhythmias O
who O
are O
incompletely O
responsive O
to O
a O
single O
agent O
or O
incompletely O
responsive O
to O
amiodarone B-drug
. O

RESULTS O
: O
During O
treatment O
with O
fluvoxamine B-drug
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
the O
median O
of O
the O
total O
clearance O
of O
tolbutamide B-drug
, O
from O
845 O
mL/h O
to O
688 O
mL/h O
, O
among O
the O
volunteers O
who O
received O
75 O
mg/d O
. O

Disopyramide B-drug
increases O
QT O
prolongation O
which O
could O
cause O
arrhythmia O
. O

When O
combined O
with O
ofloxacin B-drug
, O
KRM-1648 B-drug_n
exhibited O
strong O
synergistic O
activity O
while O
only O
additive O
effects O
were O
observed O
with O
the O
combination O
of O
rifampicin B-drug
( O
or O
rifabutin B-drug
) O
and O
ofloxacin B-drug
. O

Clarithromycin B-drug
exposure O
was O
significantly O
decreased O
by O
nevirapine B-drug
; O

Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-group
hormonal I-group
contraceptives I-group
who O
also O
used O
some O
form O
of O
St. O
Johns O
Wort O
. O

Patients O
currently O
receiving O
diltiazem B-drug
therapy O
should O
be O
carefully O
monitored O
for O
a O
change O
in O
pharmacological O
effect O
when O
initiating O
and O
discontinuing O
therapy O
with O
cimetidine B-drug
. O

Anticoagulants B-group
, O
oral O
: O
Co-administration O
of O
corticosteroids B-group
and O
warfarin B-drug
usually O
results O
in O
inhibition O
of O
response O
to O
warfarin B-drug
, O
although O
there O
have O
been O
some O
conflicting O
reports O
. O

- O
a O
phenothiazine B-group
such O
as O
chlorpromazine B-drug
( O
Thorazine B-brand
) O
, O
fluphenazine B-drug
( O
Prolixin B-brand
, O
Permitil B-brand
) O
, O
prochlorperazine B-drug
( O
Compazine B-brand
) O
, O
promethazine B-drug
( O
Phenergan B-brand
) O
, O
and O
others O
; O

Rifampin B-drug
: O
Following O
concomitant O
administration O
of O
a O
single O
dose O
of O
ARAVA B-brand
to O
subjects O
receiving O
multiple O
doses O
of O
rifampin B-drug
, O
M1 O
peak O
levels O
were O
increased O
( O
~40 O
% O
) O
over O
those O
seen O
when O
ARAVA B-brand
was O
given O
alone O
. O

sulfonamides B-group
, O
long O
acting O
; O

In O
both O
plasma O
and O
KHT O
tumour O
the O
peak O
concentration O
and O
" O
early O
" O

The O
monoamine O
oxidase O
inhibitory O
effects O
of O
Isocarboxazid B-drug
may O
persist O
for O
a O
substantial O
period O
after O
discontinuation O
of O
the O
drug O
, O
and O
this O
should O
be O
borne O
in O
mind O
when O
another O
drug O
is O
prescribed O
following O
Isocarboxazid B-drug
. O

When O
cholestyramine B-drug
resin B-group
is O
given O
for O
long O
periods O
of O
time O
, O
concomitant O
supplementation O
with O
water-miscible O
( O
or O
parenteral O
) O
forms O
of O
fat-soluble B-group
vitamins I-group
should O
be O
considered O
. O

Drugs O
That O
Induce O
CYP3A4 O
( O
Rifampicin B-drug
) O
Racemic O
zopiclone B-drug
exposure O
was O
decreased O
80 O
% O
by O
concomitant O
useof O
rifampicin B-drug
, O
a O
potent O
inducer O
of O
CYP3A4 O
. O

Prothrombin O
time O
was O
not O
affected O
. O

400-2000 O

The O
concomitant O
administration O
of O
rifampin B-drug
and O
warfarin B-drug
resulted O
in O
the O
need O
for O
an O
unusually O
high O
maintenance O
dose O
of O
warfarin B-drug
( O
20 O
mg O
per O
day O
) O
in O
order O
to O
produce O
a O
therapeutic O
effect O
. O

Cyclosporin B-drug
: O
After O
introduction O
of O
chloroquine B-drug
( O
oral O
form O
) O
, O
a O
sudden O
increase O
in O
serum O
cyclosporin B-drug
level O
has O
been O
reported O
. O

Although O
a O
dose O
adjustment O
of O
azithromycin B-drug
is O
not O
recommended O
when O
administered O
in O
combination O
with O
nelfinavir B-drug
, O
close O
monitoring O
for O
known O
side O
effects O
of O
azithromycin B-drug
, O
such O
as O
liver O
enzyme O
abnormalities O
and O
hearing O
impairment O
, O
is O
warranted O
. O

Special O
consideration O
should O
be O
given O
to O
the O
administration O
of O
ETHYOL B-brand
in O
patients O
receiving O
antihypertensive B-group
medications I-group
or O
other O
drugs O
that O
could O
cause O
or O
potentiate O
hypotension O
. O

Synergism O
between O
xanthine B-group
bronchodilators I-group
( O
e.g. O
, O
theophylline B-drug
) O
, O
ephedrine B-drug
, O
and O
other O
sympathomimetic B-group
bronchodilators I-group
has O
been O
reported O
. O

Promethazine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-drug
and O
promethazine B-drug
( O
10 O
and O
25 O
mg O
, O
respectively O
) O
resulted O
in O
a O
15 O
% O
decrease O
in O
maximal O
plasma O
concentrations O
of O
zaleplon B-drug
, O
but O
no O
change O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
. O

Although O
no O
specific O
drug O
interactions O
with O
topical O
glaucoma O
drugs O
or O
systemic O
medications O
were O
identified O
in O
clinical O
studies O
of O
IOPIDINE B-brand
0.5 O
% O
Ophthalmic O
Solution O
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-group
depressants I-group
( O
alcohol B-drug
, O
barbiturates B-group
, O
opiates B-group
, O
sedatives B-group
, O
anesthetics B-group
) O
should O
be O
considered O
. O

CONCLUSIONS O
: O
It O
is O
important O
to O
identify O
the O
medications O
most O
commonly O
involved O
in O
the O
PICR O
so O
as O
to O
establish O
corrective O
measures O
to O
minimise O
the O
risks O
arising O
from O
multiple O
medication O
. O

Lithium B-drug
: O
Lithium B-drug
toxicity O
has O
been O
reported O
in O
patients O
receiving O
lithium B-drug
concomitantly O
with O
drugs O
which O
cause O
elimination O
of O
sodium O
, O
including O
ACE B-group
inhibitors I-group
. O

Effect O
on O
Concentration O
of O
Nevirapine B-drug
or O
Concomitant O
Drug O

Additionally O
, O
higher O
than O
expected O
tricyclic B-group
antidepressant I-group
levels O
have O
been O
observed O
when O
they O
are O
begun O
in O
patients O
already O
taking O
cimetidine B-drug
. O

Interactions O
may O
occur O
between O
EPA B-drug
supplements O
and O
aspirin B-brand
and O
other O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
and O
herbs O
such O
as O
garlic O
( O
Allium O
sativum O
) O
and O
ginkgo B-drug
( O
Ginkgo B-drug
biloba I-drug
) O
. O

Theoretically O
, O
it O
may O
decrease O
hepatic O
toxicity O
in O
the O
case O
of O
other O
potential O
hepatotoxic O
drugs O
, O
as O
well O
. O

On O
the O
basis O
of O
the O
principles O
observed O
the O
concentrations O
fo O
these O
hormones O
were O
investigated O
in O
the O
plasma O
of O
dogs O
deprived O
of O
water O
for O
3 O
days O
and O
then O
allowed O
to O
drink O
. O

Ocupress B-brand
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
receiving O
a O
beta-adrenergic B-group
blocking I-group
agent I-group
orally O
because O
of O
the O
potential O
for O
additive O
effects O
on O
systemic O
beta-blockade O
. O

In O
diabetics O
, O
blood-sugar O
levels O
should O
be O
monitored O
very O
carefully O
. O

Ketoconazole B-drug
: O
Co-administration O
of O
bosentan B-drug
125 O
mg O
b.i.d O
. O
and O
ketoconazole B-drug
, O
a O
potent O
CYP3A4 O
inhibitor O
, O
increased O
the O
plasma O
concentrations O
of O
bosentan B-drug
by O
approximately O
2-fold O
. O

clarithromycin I-drug
concentration O
indinavir B-drug
concentration O

Further O
, O
no O
effects O
on O
either O
warfarin B-drug
levels O
or O
prothrombin O
times O
were O
observed O
in O
a O
study O
involving O
concomitant O
administration O
of O
warfarin B-drug
and O
fluvastatin B-drug
. O

The O
amplitude O
data O
from O
this O
study O
suggest O
that O
ethanol B-drug
's O
augmentation O
of O
component O
P2 O
may O
result O
, O
at O
least O
in O
part O
, O
from O
alterations O
in O
cholinergic O
functions O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
DOXIL B-brand
. O

The O
effect O
may O
be O
mediated O
by O
cimetidines B-drug
known O
inhibition O
of O
hepatic O
cytochrome O
P-450 O
, O
the O
enzyme O
system O
responsible O
for O
the O
first-pass O
metabolism O
of O
diltiazem B-drug
. O

Therefore O
, O
a O
lower O
total O
daily O
dosage O
of O
INDOCIN B-brand
may O
produce O
a O
satisfactory O
therapeutic O
effect O
. O

Drug O
interaction O
studies O
with O
decitabine B-drug
have O
not O
been O
conducted O
. O

It O
is O
recommended O
not O
to O
exceed O
a O
single O
5 O
mg O
dose O
of O
Vardenafil B-drug
in O
a O
24-hour O
period O
when O
used O
in O
combination O
with O
erythromycin B-drug
. O

The O
concomitant O
administration O
of O
griseofulvin B-drug
has O
been O
reported O
to O
reduce O
the O
efficacy O
of O
oral O
contraceptives B-group
and O
to O
increase O
the O
incidence O
of O
breakthrough O
bleeding O
. O

Fluvoxamine B-drug
is O
a O
known O
strong O
inhibitor O
of O
CYP1A2 O
and O
also O
inhibits O
CYP3A4 O
, O
CYP2C9 O
, O
and O
CYP2C19 O
. O

No O
information O
is O
available O
. O


Greater O
fecal O
blood O
loss O
results O
from O
concomitant O
administration O
of O
both O
drugs O
than O
from O
either O
drug O
alone O
. O

Concomitant O
use O
with O
other O
oxytocic B-group
agents I-group
is O
not O
recommended O

Data O
from O
in O
vitro O
studies O
of O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-drug
for O
the O
following O
: O
sertraline B-drug
and O
paroxetine B-drug
. O

Concurrent O
use O
of O
rifampin B-drug
increases O
the O
metabolic O
clearance O
of O
ZEBETA B-brand
, O
resulting O
in O
a O
shortened O
elimination O
half-life O
of O
ZEBETA B-brand
. O

Urinary O
Alkalinizers O
: O
Decrease O
aspirin B-brand
effectiveness O
by O
increasing O
the O
rate O
of O
salicylate B-group
renal O
excretion O
. O

When O
concomitant O
administration O
of O
ketoconazole B-drug
with O
aripiprazole B-drug
occurs O
, O
aripiprazole B-drug
dose O
should O
be O
reduced O
to O
one-half O
of O
its O
normal O
dose O
. O

Therefore O
, O
the O
dose O
of O
corticosteroid B-group
should O
be O
titrated O
to O
avoid O
steroid O
toxicity O
. O

In O
patients O
taking O
an O
anticonvulsant B-group
( O
eg O
, O
valproic B-drug
acid I-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
or O
phenytoin B-drug
) O
, O
the O
concomitant O
use O
of O
Mefloquine B-drug
may O
reduce O
seizure O
control O
by O
lowering O
the O
plasma O
levels O
of O
the O
anticonvulsant B-group
. O

Moreover O
, O
the O
mechanisms O
underlying O
the O
development O
of O
dependence O
may O
be O
similar O
for O
alcohol B-drug
and O
nicotine B-drug
. O

May O
interact O
with O
cefamandole B-drug
naftate I-drug
, O
cephalothin B-drug
sodium I-drug
, O
magnesium B-drug
sulfate I-drug
, O
prednisolone B-drug
sodium I-drug
succinate I-drug
, O
and O
prochlorperazine B-drug
edisylate I-drug
. O

- O
Etretinate B-drug
( O
e.g. O
, O
Tegison B-brand
) O
or O

In O
patients O
taking O
furosemide B-drug
, O
nifedipine B-drug
, O
diltiazem B-drug
, O
ACE B-group
inhibitors I-group
, O
verapamil B-drug
, O
glyburide B-drug
, O
propranolol B-drug
, O
and O
various O
chemotherapy O
agents O
, O
no O
effect O
was O
shown O
on O
the O
clearance O
of O
hydrodolasetron B-drug_n
. O

The O
depression O
of O
cardiac O
contractility O
, O
conductivity O
, O
and O
automaticity O
as O
well O
as O
the O
vascular O
dilation O
associated O
with O
anesthetics B-group
may O
be O
potentiated O
by O
calcium B-group
channel I-group
blockers I-group
. O

Nifedipine B-drug
did O
not O
alter O
the O
plasma O
levels O
of O
Vardenafil B-drug
when O
taken O
in O
combination O
. O

No O
evidence O
of O
interaction O
of O
PROCRIT B-brand
with O
other O
drugs O
was O
observed O
in O
the O
course O
of O
clinical O
trials O
. O

The O
drug O
interaction O
between O
warfarin B-drug
and O
rifampin B-drug
is O
not O
well O
known O
. O

However O
, O
due O
to O
possible O
pharmacodynamic O
interactions O
, O
when O
co-administered O
with O
PRECEDEX B-brand
, O
a O
reduction O
in O
dosage O
of O
PRECEDEX B-brand
on O
the O
concomitant O
anesthetic B-group
, O
sedative B-group
, O
hypnotic B-group
or O
opioid B-group
may O
be O
required O
. O

Drugs O
which O
inhibit O
this O
metabolic O
pathway O
may O
have O
a O
profound O
effect O
on O
the O
clearance O
of O
alprazolam B-drug
. O

Enoxacin B-drug
does O
not O
affect O
the O
clearance O
of O
the O
active O
S-isomer O
, O
and O
changes O
in O
clotting O
time O
have O
not O
been O
observed O
when O
enoxacin B-drug
and O
warfarin B-drug
were O
coadministered O
. O

Anticoagulants B-group
( O
Oral O
) O
: O
In O
patients O
receiving O
oral O
anticoagulants B-group
, O
the O
coagulation O
times O
were O
increased O
in O
some O
cases O
. O

AUC O
for O
total O
nitrosoureas B-group
were O
about O
1.4-1.5 O
fold O
greater O
for O
the O
oral O
compared O
to O
the O
i.p O
. O

Because O
the O
tetracyclines B-group
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-group
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-group
dosage O
. O

Oxytocin B-drug
or O
other O
oxytocics B-group
( O
concurrent O
use O
with O
dinoprost B-drug
may O
result O
in O
uterine O
hypertonus O
, O
possibly O
causing O
uterine O
rupture O
or O
cervical O
laceration O
, O
especially O
in O
the O
absence O
of O
adequate O
cervical O
dilatation O
; O

The O
single-dose O
nature O
of O
this O
study O
and O
the O
lack O
of O
correlation O
between O
glyburide B-drug
blood O
levels O
and O
pharmaco-dynamic O
effects O
, O
makes O
the O
clinical O
significance O
of O
this O
interaction O
uncertain O
. O

The O
incidence O
of O
TBg O
deficiency O
approximates O
1 O
in O
9000 O
. O

If O
midazolam B-drug
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O

Caffeine B-drug
: O
Enoxacin B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P-450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-group
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

Dexamethasone O
suppression O
test O
( O
DST O
) O
: O
False-negative O
results O
in O
the O
dexamethasone O
suppression O
test O
( O
DST O
) O
in O
patients O
being O
treated O
with O
indomethacin B-drug
have O
been O
reported O
. O

Use O
with O
Angiotensln B-group
Converting I-group
Enzyme I-group
Inhibitors I-group
: O
The O
use O
of O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
to O
control O
hypertension O
in O
patients O
on O
azathioprine B-drug
has O
been O
reported O
to O
induce O
severe O
leukopenia O
. O

In O
addition O
, O
other O
quinolones B-group
have O
been O
reported O
to O
decrease O
the O
CYP3A4-mediated O
metabolism O
of O
cyclosporine B-drug
. O


Imipramine B-drug
and O
clonazepam B-drug
did O
not O
change O
fasting O
or O
overload O
glycemia O
. O

The O
concurrent O
administration O
of O
allopurinol B-drug
and O
ampicillin B-drug
increases O
substantially O
the O
incidence O
of O
rashes O
in O
patients O
receiving O
both O
drugs O
as O
compared O
to O
patients O
receiving O
ampicillin B-drug
alone O
. O

The O
initial O
dose O
of O
levorphanol B-drug
should O
be O
reduced O
by O
approximately O
50 O
% O
or O
more O
when O
it O
is O
given O
to O
patients O
along O
with O
another O
drug O
affecting O
respiration O
. O

Cerivastatin B-drug
plasma O
concentrations O
were O
also O
not O
affected O
by O
co-administration O
of O
digoxin B-drug
. O

Betaseron B-brand
administration O
to O
three O
cancer O
patients O
over O
a O
dose O
range O
of O
0.025 O
mg O
to O
2.2 O
mg O
led O
to O
a O
dose-dependent O
inhibition O
of O
antipyrine B-drug
elimination.14 O
The O
effect O
of O
alternate-day O
administration O
of O
0.25 O
mg O
of O
Betaseron B-brand
on O
drug O
metabolism O
in O
MS O
patients O
is O
unknown O
. O

- O
Acetohydroxamic B-drug
acid I-drug
( O
e.g. O
, O
Lithostat B-brand
) O
or O

Indinavir B-drug
is O
metabolized O
by O
CYP3A4 O
. O

Plasma O
was O
analyzed O
for O
tolbutamide B-drug
, O
and O
urine O
was O
analyzed O
for O
tolbutamide B-drug
and O
its O
two O
metabolites O
, O
4-hydroxytolbutamide B-drug_n
and O
carboxytolbutamide B-drug_n
by O
means O
of O
HPLC O
. O

No O
clinically O
relevant O
drug-drug O
interactions O
have O
been O
observed O
with O
drugs O
likely O
to O
be O
co-administered O
with O
anidulafungin B-drug
. O

Nelfinavir B-drug
is O
metabolized O
in O
proof O
by O
C.P.A O
. O

. O

Curariform B-brand
muscle I-brand
relaxants I-brand
( O
eg O
, O
tubocurarine B-drug
) O
and O
other O
drugs O
, O
including O
ether O
, O
succinylcholine B-drug
, O
gallamine B-drug
, O
decamethonium B-drug
and O
sodium B-drug
citrate I-drug
, O
potentiate O
the O
neuromuscular O
blocking O
effect O
and O
should O
be O
used O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
Coly-Mycin B-brand
M I-brand
Parenteral O
. O

The O
MPTP-induced B-drug
neuronal O
damage O
produced O
a O
tolerance O
to O
the O
disruptive O
effects O
of O
amphetamine B-drug
and O
a O
supersensitivity O
to O
the O
disruptive O
effects O
of O
apomorphine B-drug
in O
rats O
responding O
in O
a O
schedule O
controlled O
paradigm O
. O

Since O
chronic O
dosing O
is O
required O
for O
therapeutic O
efficacy O
of O
antipsychotics B-group
, O
future O
studies O
should O
focus O
on O
investigation O
of O
chronic O
dosing O
effects O
of O
these O
drugs O
in O
combination O
with O
PCP B-drug_n
. O

When O
carbamazepine B-drug
is O
added O
to O
aripiprazole B-drug
therapy O
, O
aripiprazole B-drug
dose O
should O
be O
doubled O
. O

Effect O
of O
Probenecid B-drug
: O
Probenecid B-drug
is O
a O
blocker O
of O
renal O
tubular O
secretion O
. O

Post-marketing O
reports O
of O
changes O
in O
prothrombin O
measures O
have O
been O
received O
among O
patients O
on O
concomitant O
warfarin B-drug
and O
esomeprazole B-drug
therapy O
. O

To O
determine O
whether O
probenecid B-drug
has O
a O
direct O
effect O
on O
the O
distribution O
of O
cloxacillin B-drug
, O
the O
elimination O
and O
distribution O
of O
cloxacillin B-drug
was O
studied O
in O
six O
patients O
, O
five O
lacking O
kidney O
function O
and O
one O
with O
a O
partially O
impaired O
renal O
function O
, O
in O
the O
presence O
or O
absence O
of O
probenecid B-drug
. O

Accordingly O
, O
diazepam B-drug
and O
fluvoxamine B-drug
should O
not O
ordinarily O
be O
co-administered O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

Calcium B-drug
Supplements/Antacids B-group

Fluoxetine B-drug
and O
its O
active O
metabolite O
, O
norfluoxe-tine O
, O
have O
long O
half-lives O
( O
4 O
to O
16 O
days O
for O
norfluoxetine B-drug_n
) O
, O
that O
may O
affect O
strategies O
during O
conversion O
from O
one O
drug O
to O
the O
other O
. O

In O
vitro O
displacement O
studies O
with O
highly O
protein-bound O
drugs O
such O
as O
furosemide B-drug
, O
propranolol B-drug
, O
captopril B-drug
, O
nicardipine B-drug
, O
pravastatin B-drug
, O
glyburide B-drug
, O
warfarin B-drug
, O
phenytoin B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
tolbutamide B-drug
, O
and O
metformin B-drug
showed O
no O
influence O
on O
the O
extent O
of O
nateglinide B-drug
protein O
binding O
. O

In O
those O
patients O
in O
whom O
renal O
insufficiency O
was O
documented O
, O
however O
, O
the O
recommendation O
to O
lower O
the O
dose O
of O
allopurinol B-drug
was O
not O
followed O
. O

Serum O
potassium O
levels O
and O
cardiac O
function O
should O
be O
closely O
monitored O
and O
any O
deficit O
promptly O
corrected O
. O

More O
specific O
applications O
of O
the O
assay O
of O
thio O
compounds O
in O
urine O
allow O
development O
of O
selective O
methods O
that O
may O
be O
useful O
for O
biological O
monitoring O
. O

. O

In O
a O
small O
( O
n=30 O
) O
combination O
study O
of O
ARAVA B-brand
with O
methotrexate B-drug
, O
a O
2- O
to O
3-fold O
elevation O
in O
liver O
enzymes O
was O
seen O
in O
5 O
of O
30 O
patients O
. O

In O
the O
absence O
of O
formal O
clinical O
drug O
interaction O
studies O
, O
caution O
should O
be O
exercised O
when O
administering O
TAXOL B-brand
concomitantly O
with O
known O
substrates O
or O
inhibitors O
of O
the O
cytochrome O
P450 O
isoenzymes O
CYP2C8 O
and O
CYP3A4 O
. O

pentoxifylline B-drug
; O

and O
clinical O
implications O
. O

Sedative/hypnotics B-group
: O
midazolam B-drug
, O
triazolam B-drug

Other O
kits O
, O
such O
as O
the O
Coat-A-Count O
RIA O
Kit O
, O
may O
be O
used O
. O

The O
effects O
, O
if O
any O
, O
on O
the O
pituitary-gonadal O
axis O
in O
premenopausal O
women O
are O
unknown O
. O

The O
clinical O
significance O
of O
this O
increase O
in O
doxazosin B-drug
AUC O
is O
unknown O
. O

Ketoconazole B-drug
: O
Potential O
interaction O
of O
Ketoconazole B-drug
and O
Isoniazid B-drug
may O
exist O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
Anafranil B-brand
is O
administered O
with O
anticholinergic B-group
or O
sympathomimetic B-group
drugs I-group
. O

Prolonged O
recovery O
time O
may O
occur O
if O
barbiturates B-group
and/or O
narcotics B-group
are O
used O
concurrently O
with O
ketamine B-drug
. O

It O
was O
observed O
that O
contortrostatin B-drug_n
had O
a O
dramatic O
effect O
on O
the O
tyrosine O
phosphorylation O
status O
of O
several O
proteins O
in O
T24 O
human O
bladder O
cancer O
cells O
, O
including O
robust O
induction O
of O
phosphorylation O
of O
proteins O
in O
the O
range O
of O
120-140 O
kDa O
. O

The O
safety O
and O
efficacy O
of O
AMEVIVE B-brand
in O
pediatric O
patients O
have O
not O
been O
studied O
. O

Coadministration O
of O
glyburide B-drug
with O
doses O
higher O
than O
40 O
mg O
valdecoxib B-drug
( O
e.g. O
, O
40 O
mg O
BID O
) O
have O
not O
been O
studied O
. O

The O
dextrorotatory O
isomer O
, O
on O
the O
other O
hand O
, O
had O
effects O
similar O
to O
those O
of O
PCP B-drug_n
in O
both O
species O
. O

Antacids B-group
increase O
the O
rate O
of O
absorption O
of O
pseudoephedrine B-drug
, O
while O
kaolin B-drug
decreases O
it O
. O

Thyroid B-group
hormone I-group
activity O
may O
also O
be O
enhanced O
. O

Ritonavir B-drug

Methotrexate B-drug
Renal O
tubular O
transport O
of O
methotrexate B-drug
may O
be O
inhibited O
by O
concomitant O
administration O
of O
ciprofloxacin B-drug
, O
potentially O
leading O
to O
increased O
plasma O
levels O
of O
methotrexate B-drug
. O

A O
number O
of O
drugs O
, O
including O
ethacrynic B-drug
acid I-drug
, O
have O
been O
shown O
to O
displace O
warfarin B-drug
from O
plasma O
protein O
; O

Milk O
, O
milk O
products O
, O
and O
calcium-rich B-drug
foods O
or O
drugs O
may O
impair O
the O
absorption O
of O
EMCYT B-brand
. O

Anticoagulants B-group
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
or O
decrease O
the O
effects O
of O
coumarin B-group
derivatives I-group
. O

Concomitant O
administration O
of O
gemfibrozil B-drug
with O
Targretin B-brand
capsules O
is O
not O
recommended O
. O

No O
formal O
drug-drug O
interaction O
studies O
have O
been O
performed O
. O

Therefore O
, O
indomethacin B-drug
and O
diflunisal B-drug
should O
not O
be O
used O
concomitantly O
. O

Drug O
interaction O
studies O
with O
SUSTIVA B-brand
and O
these O
imidazole O
and O
triazole B-group
antifungals I-group
have O
not O
been O
conducted B-group
. I-group


In O
addition O
, O
administration O
of O
Sonata B-brand
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
should O
not O
cause O
transient O
increase O
in O
free O
concentrations O
of O
the O
other O
drug O
. O

When O
taken O
orally O
, O
imidazole B-group
compounds I-group
like O
ketoconazole B-drug
may O
enhance O
the O
anticoagulant O
effect O
of O
coumarin-like B-group
drugs O
. O

Anticholinergic B-group
agents I-group
may O
affect O
gastrointestinal O
absorption O
of O
various O
drugs O
, O
such O
as O
slowly O
dissolving O
dosage O
forms O
of O
digoxin B-drug
; O

However O
, O
no O
clinically O
or O
statistically O
significant O
differences O
in O
prothrombin O
time O
ratio O
or O
warfarin B-drug
enantiomer O
pharmacokinetics O
were O
observed O
in O
a O
small O
study O
of O
7 O
healthy O
males O
who O
received O
both O
warfarin B-drug
and O
lomefloxacin B-drug
under O
steady-state O
conditions O
. O

All O
of O
these O
also O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-drug
. O

Optimal O
designs O
for O
the O
individual O
and O
joint O
exposure O
general O
logistic O
regression O
models O
. O

The O
following O
drug O
interactions O
have O
been O
reported O
with O
etomidate B-drug
. O


The O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
and O
pulsatile O
choroidal O
blood O
flow O
were O
measured O
using O
the O
paraaminohippurate O
method O
, O
the O
inulin O
method O
and O
a O
laser O
interferometric O
measurement O
of O
fundus O
pulsation O
amplitude O
, O
respectively O
. O

Potassium-sparing B-group
diuretics I-group
such O
as O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
, O
or O
potassium B-drug
supplements O
should O
be O
given O
only O
for O
documented O
hypokalemia O
, O
and O
then O
with O
caution O
, O
since O
they O
may O
lead O
to O
a O
significant O
increase O
of O
serum O
potassium O
. O

Optimal O
conditions O
, O
kinetics O
, O
equilibrium O
, O
and O
the O
mechanism O
of O
this O
acid-catalyzed O
ethanolysis O
are O
reported O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

Dosage O
of O
the O
anticoagulant B-group
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O

The O
histology O
of O
the O
liver O
was O
altered O
in O
the O
three O
groups O
which O
were O
submitted O
to O
treatment O
with O
the O
hydroalcoholic O
solutions O
, O
with O
quantitative O
and O
qualitative O
differences O
between O
the O
groups O
. O

The O
following O
laboratory O
tests O
have O
been O
found O
to O
be O
abnormal O
in O
a O
few O
patients O
receiving O
baclofen B-drug
: O
increased O
SGOT O
, O
elevated O
alkaline O
phosphatase O
, O
and O
elevation O
of O
blood O
sugar O
. O

Analgesic O
effects O
of O
antihistaminics B-group
. O

Combined O
effects O
may O
induce O
serious O
cardiac O
arrhythmias O
. O

Oral O
Hypoglycemic B-group
Agents I-group
: O
In O
one O
study O
, O
flurbiprofen B-drug
was O
given O
to O
adult O
diabetics O
who O
were O
already O
receiving O
glyburide B-drug
( O
n=4 O
) O
, O
metformin B-drug
( O
n=2 O
) O
chlorpropamide B-drug
with O
phenformin B-drug
( O
n= O
3 O
) O
or O
glyburide B-drug
with O
phenformin B-drug
( O
n=6 O
) O
. O

CELEBREX B-brand
should O
be O
introduced O
at O
the O
lowest O
recommended O
dose O
in O
patients O
receiving O
fluconazole B-drug
. O

The O
incidence O
of O
akathisia O
in O
clinical O
trials O
of O
the O
weekly O
dosage O
schedule O
was O
greater O
( O
8.5 O
% O
, O
4/47 O
patients O
) O
when O
prochlorperazine B-drug
was O
administered O
on O
the O
same O
day O
as O
CAMPTOSAR B-brand
than O
when O
these O
drugs O
were O
given O
on O
separate O
days O
( O
1.3 O
% O
, O
1/80 O
patients O
) O
. O

To O
avoid O
phenytoin B-drug
intoxication O
, O
appropriate O
adjustment O
of O
the O
anticonvulsant B-group
should O
be O
made O
. O

however O
, O
no O
significant O
difference O
in O
the O
maximum O
concentration O
in O
plasma O
or O
the O
area O
under O
the O
concentration-time O
curve O
from O
time O
zero O
to O
8 O
h O
was O
observed O
. O

Orlistat-Orlistat B-drug
may O
decrease O
the O
absorption O
of O
vitamin B-group
K I-group
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

Clinical O
Comment O

When O
used O
in O
therapeutic O
doses O
, O
azithromycin B-drug
had O
a O
modest O
effect O
on O
the O
pharmacokinetics O
of O
atorvastatin B-drug
, O
carbamazepine B-drug
, O
cetirizine B-drug
, O
didanosine B-drug
, O
efavirenz B-drug
, O
fluconazole B-drug
, O
indinavir B-drug
, O
midazolam B-drug
, O
rifabutin B-drug
, O
sildenafil B-drug
, O
theophylline B-drug
( O
intravenous O
and O
oral O
) O
, O
triazolam B-drug
, O
trimethoprim/sulfamethoxazole B-drug
or O
zidovudine B-drug
. O

HMG-CoA B-group
Reductase I-group
Inhibitors I-group
: O
lovastatin B-drug
, O
simvastatin B-drug
WARNING O
potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O

In O
addition O
to O
established O
drug O
interactions O
, O
there O
may O
be O
potential O
pharmacokinetic O
interactions O
between O
nevirapine B-drug
and O
other O
drug O
classes O
that O
are O
metabolized O
by O
the O
cytochrome O
P450 O
system O
. O

Drug/Laboratory O
Test O
Interaction O
After O
treatment O
with O
ampicillin B-drug
, O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper B-drug_n
sulfate I-drug_n
tests O
( O
Benedicts O
solution O
, O
Fehlings O
solution O
, O
or O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme O
based O
tests O
such O
as O
Clinistix O
and O
Glucose O
Enzymatic O
Test O
Strip O
USP O
. O

Lovastatin B-drug
therapy O
has O
not O
been O
associated O
with O
bleeding O
or O
with O
changes O
in O
prothrombin O
time O
in O
patients O
not O
taking O
anticoagulants B-group
. O

. O

Note O
: O

Olanzapine B-drug
, O
a O
thienobenzodiazepine B-group
derivative I-group
, O
is O
a O
second B-group
generation I-group
( I-group
atypical I-group
) I-group
antipsychotic I-group
agent I-group
which O
has O
proven O
efficacy O
against O
the O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O

Other O
Drug O
Interaction O
Information O
Digoxin B-drug
: O
Studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-brand
does O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-group
antidepressants I-group
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O

Propanolol B-drug
: O
The O
pharmacokinetics O
of O
almotriptan B-drug
were O
not O
affected O
by O
coadministration O
of O
propranolol B-drug
. O

phase O
1 O
( O
days O
1-6 O
) O
: O
cisapride B-drug
10 O
mg O
4 O
times/day O
; O

Compared O
with O
risperidone B-drug
, O
olanzapine B-drug
has O
also O
been O
reported O
to O
decrease O
overall O
treatment O
costs O
, O
despite O
the O
several-fold O
higher O
daily O
acquisition O
cost O
of O
the O
drug O
. O

Alcohol B-drug
- O
Although O
LEXAPRO B-brand
did O
not O
potentiate O
the O
cognitive O
and O
motor O
effects O
of O
alcohol B-drug
in O
a O
clinical O
trial O
, O
as O
with O
other O
psychotropic B-group
medications I-group
, O
the O
use O
of O
alcohol B-drug
by O
patients O
taking O
LEXAPRO B-brand
is O
not O
recommended O
. O

- O
When O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
used O
concurrently O
with O
anion-exchange B-group
resins I-group
( O
e.g O
. O
cholestryramine B-drug
) O
, O
an O
interval O
of O
at O
least O
2 O
hours O
should O
be O
maintained O
between O
the O
two O
medicines O
, O
since O
the O
absorption O
of O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
impaired O

However O
, O
initial O
dose O
modification O
is O
generally O
not O
necessary O
. O

4 O
. O

These O
behavioral O
changes O
may O
be O
related O
with O
the O
negative O
symptoms O
of O
schizophrenia O
. O

metronidazole B-drug
; O

Other O
quinolones B-group
have O
demonstrated O
moderate O
to O
marked O
interference O
with O
the O
metabolism O
of O
caffeine B-drug
, O
resulting O
in O
a O
reduced O
clearance O
, O
a O
prolongation O
of O
plasma O
half-life O
, O
and O
an O
increase O
in O
symptoms O
that O
accompany O
high O
levels O
of O
caffeine B-drug
. O

METHODS O
: O
From O
the O
beginning O
of O
the O
experiment O
, O
rats O
were O
given O
10 O
weekly O
subcutaneous O
injections O
of O
AOM B-drug_n
( O
7.4 O
mg/kg O
body O
weight O
) O
and O
subcutaneous O
injections O
of O
bombesin B-drug_n
( O
40 O
microg/kg O
body O
weight O
) O
every O
other O
day O
, O
and O
from O
week O
16 O
, O
intraperitoneal O
injections O
of O
verapamil B-drug
( O
10 O
or O
20 O
mg/kg O
body O
weight O
) O
every O
other O
day O
until O
the O
end O
fo O
the O
experiment O
in O
week O
45 O
. O

The O
exact O
length O
of O
time O
may O
vary O
and O
is O
dependent O
upon O
the O
particular O
MAO B-group
inhibitor I-group
being O
used O
, O
the O
length O
of O
time O
it O
has O
been O
administered O
, O
and O
the O
dosage O
involved O
. O

Saquinavir B-drug

Interaction O
between O
lomefloxacin B-drug
and O
cyclosporine B-drug
has O
not O
been O
studied O
. O

this O
effect O
is O
at O
least O
balanced O
by O
decreased O
metabolism O
of O
corticosteroids B-group
. O

Although O
metoclopramide B-drug
may O
increase O
the O
bioavailability O
of O
levodopa B-drug
by O
increasing O
gastric O
emptying O
, O
metoclopramide B-drug
may O
also O
adversely O
affect O
disease O
control O
by O
its O
dopamine O
receptor O
antagonistic O
properties O
. O

This O
increase O
may O
be O
clinically O
relevant O
as O
adverse O
experiences O
are O
related O
to O
dose O
and O
exposure O
; O

Increasing O
the O
indinavir B-drug
dose O
to O
1000 O
mg O
every O
8 O
hours O
does O
not O
compensate O
for O
the O
increased O
indinavir B-drug
metabolism O
due O
to O
efavirenz B-drug
. O

Internal O
application O
of O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
( O
100 O
microM O
) O
increased O
intracellular O
Ca O
( O
2+ O
) O
concentration O
( O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
) O
and O
activated O
the O
Ca O
( O
2+ O
) O
-dependent O
K O
( O
+ O
) O
current O
. O

If O
treatment O
with O
inhibitors O
of O
CYP3A4 O
activity O
( O
such O
as O
ketoconazole B-drug
, O
intraconazole B-drug
, O
ritonavir B-drug
, O
indinavir B-drug
, O
saquinavir B-drug
, O
erythromycin B-drug
, O
etc O
. O
) O
is O
indicated O
, O
reduction O
of O
the O
budesonide B-drug
dose O
should O
be O
considered O
. O

The O
core O
temperature O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-drug
. O

St. O
Johns O
wort O
( O
Hypericum O
perforatum O
) O
may O
decrease O
SPRYCEL B-brand
plasma O
concentrations O
unpredictably O
. O

In O
a O
multiple O
dose O
study O
of O
theophylline B-drug
( O
400 O
mg O
once O
daily O
for O
3 O
days O
) O
and O
cetirizine B-drug
( O
20 O
mg O
once O
daily O
for O
3 O
days O
) O
, O
a O
16 O
% O
decrease O
in O
the O
clearance O
of O
cetirizine B-drug
was O
observed O
. O

Patients O
taking O
low-dose O
aspirin B-brand
plus O
ibuprofen B-drug
were O
not O
studied O
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

However O
, O
iloprost B-drug
has O
the O
potential O
to O
increase O
the O
hypotensive O
effect O
of O
vasodilators B-group
and O
antihypertensive B-group
agents I-group
. O

Specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
Levofloxacin B-drug
. O

These O
reports O
are O
more O
frequent O
for O
women O
who O
use O
only O
a O
single O
method O
of O
contraception O
. O

Other O
medicines O
- O
Although O
certain O
medicines O
should O
not O
be O
used O
together O
at O
all O
, O
in O
other O
cases O
two O
different O
medicines O
may O
be O
used O
together O
even O
if O
an O
interaction O
might O
occur O
. O

Most O
cases O
of O
serious O
or O
fatal O
adverse O
events O
involving O
Levo-Dromoran B-brand
reported O
to O
the O
manufacturer O
or O
the O
FDA O
have O
involved O
either O
the O
administration O
of O
large O
initial O
doses O
or O
too O
frequent O
doses O
of O
the O
drug O
to O
nonopioid O
tolerant O
patients O
, O
or O
the O
simultaneous O
administration O
of O
levorphanol B-drug
with O
other O
drugs O
affecting O
respiration O
. O

The O
results O
demonstrate O
a O
high O
degree O
of O
stereoselectivity O
in O
the O
behavioral O
effects O
of O
NANM B-drug_n
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type O
1C O
antiarrhythrnics O
propatenone O
and O
flecainide B-drug
) O
. O

The O
effect O
of O
ceftibuten B-drug
on O
the O
pharmacokinetics O
of O
theophylline B-drug
administered O
orally O
has O
not O
been O
investigated O
. O

Cimetidine B-drug

As O
a O
precursor O
to O
this O
effort O
, O
optimal O
and O
minimal O
experimental O
designs O
for O
the O
case O
in O
which O
a O
single O
compound O
is O
administered O
have O
also O
been O
developed O
. O

co-administration O
of O
phenobarbital B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

If O
used O
in O
combination O
with O
saquinavir B-drug
hard O
gelatin O
capsules O
at O
the O
recommended O
dose O
of O
600 O
mg O
tid O
, O
no O
dose O
adjustments O
are O
needed O
. O

It O
is O
not O
known O
if O
REGRANEX B-brand
Gel O
interacts O
with O
other O
topical O
medications O
applied O
to O
the O
ulcer O
site O
. O

. O

Possible O
extrarenal O
mechanisms O
of O
action O
of O
cimetidine B-drug
on O
verografine B-drug
and O
iodamide B-drug
transport O
were O
also O
examined O
. O

[ O
Hippocampus O
as O
interaction O
sites O
between O
cerebral O
memory O
systems O
] O
Most O
of O
the O
current O
theories O
assume O
that O
there O
are O
multiple O
forms O
of O
memory O
that O
are O
supported O
by O
separate O
brain O
systems O
and O
have O
different O
characteristics O
. O

Concomitant O
medications O
should O
be O
carefully O
assessed O
. O

Periodic O
measurement O
of O
serum O
PSA O
levels O
may O
also O
be O
considered O
. O

Recovery O
of O
hoof O
twitch O
from O
50 O
% O
to O
75 O
% O
took O
7.7 O
+/- O
0.7 O
min O
for O
atracurium B-drug
alone O
and O
11.5 O
+/- O
2.7 O
min O
for O
atracurium B-drug
plus O
gentamycin B-drug
( O
P O
= O
0.03 O
) O
. O

Inducers O
and O
Inhibitors O
of O
Hepatic O
Metabolism O
: O
Rifampin B-drug
reduced O
plasma O
concentrations O
of O
carvedilol B-drug
by O
about O
70 O
% O
. O

The O
fluoroquinolones B-group
are O
a O
rapidly O
growing O
class O
of O
antibiotics B-group
with O
a O
broad O
spectrum O
of O
activity O
against O
gram-negative O
and O
some O
gram-positive O
aerobic O
bacteria O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
of O
lithium B-drug
was O
decreased O
by O
19 O
% O
during O
this O
period O
of O
concomitant O
drug O
administration O
. O

Because O
escitalopram B-drug
is O
metabolized O
by O
multiple O
enzyme O
systems O
, O
inhibition O
of O
a O
single O
enzyme O
may O
not O
appreciably O
decrease O
escitalopram B-drug
clearance O
. O

Some O
drugs/substances B-drug
are O
known O
to O
accelerate O
the O
metabolism O
of O
amiodarone B-drug
by O
stimulating O
the O
synthesis O
of O
CYP3A4 B-drug
( O
enzyme O
induction O
) O
. O

Methotrexate B-drug
: O
HUMIRA B-brand
has O
been O
studied O
in O
rheumatoid O
arthritis O
patients O
taking O
concomitant O
MTX B-drug
. O

Some O
disorders O
unrelated O
to O
sexual O
dysfunction O
( O
eg O
, O
esophageal O
motility O
dysfunction O
) O
may O
also O
respond O
to O
sildenafil B-drug
. O

Co-administration O
of O
irbesartan B-drug
reduced O
aliskiren B-drug
Cmax O
up O
to O
50 O
% O
after O
multiple O
dosing O
. O

Disulfiram B-drug
alone O
in O
the O
rat O
s O
diet O
did O
not O
lead O
to O
such O
tumors O
. O

Platelet O
function O
studies O
in O
these O
patients O
have O
not O
demonstrated O
any O
significant O
platelet O
dysfunction O
. O

Paclitaxel B-drug
- O
In O
one O
report O
, O
L-glutamine B-drug
at O
a O
dose O
of O
10 O
grams O
three O
times O
daily O
, O
given O
24 O
hours O
after O
receiving O
paclitaxel B-drug
, O
appeared O
to O
prevent O
the O
development O
of O
myalgia O
and O
arthralgia O
, O
adverse O
reactions O
of O
paclitaxel B-drug
. O

METH B-drug
induced O
arc O
mRNA O
in O
layers O
IV O
and O
VI O
of O
the O
cortex O
which O
dopamine O
receptor O
are O
localized O
to O
. O

Carbamazepine B-drug
: O
Tiagabine B-drug
had O
no O
effect O
on O
the O
steady-state O
plasma O
concentrations O
of O
carbamazepine B-drug
or O
its O
epoxide O
metabolite O
in O
patients O
with O
epilepsy O
. O

Table O
4 O
Potential O
Drug O
Interactions O
: O
Use O
With O
Caution O
, O
Dose O
Adjustment O
of O
Co-administered O
Drug O
May O
Be O
Needed O
due O
to O
Possible O
Decrease O
in O
Clinical O
Effect O

Other O
concomitant O
therapies O
: O
In O
clinical O
trials O
, O
the O
safety O
profile O
in O
subjects O
treated O
with O
Acamprosate B-drug
concomitantly O
with O
anxiolytics B-group
, O
hypnotics B-group
and O
sedatives B-group
( O
including O
benzodiazepines B-group
) O
, O
or O
non-opioid B-group
analgesics I-group
was O
similar O
to O
that O
of O
subjects O
taking O
placebo O
with O
these O
concomitant O
medications O
. O

could O
not O
be O
confirmed O
for O
cloxacillin B-drug
in O
patients O
lacking O
kidney O
function O
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
- O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7-10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

Chapter O
3 O
covers O
pharmacology O
( O
pharmacokinetics O
, O
pharmacodynamics O
and O
potency O
, O
and O
clinical O
implications O
) O
. O

Slow-channel B-group
calcium I-group
blockers I-group
, O
such O
as O
verapamil B-drug
, O
diltiazem B-drug
and O
nifedipine B-drug
, O
inhibit O
platelet O
activation O
in O
vitro O
, O
and O
decrease O
platelet O
adhesion O
intravascularly O
. O

Magnesium- B-drug
and O
aluminum-containing B-drug
antacids B-group
, O
administered O
concomitantly O
with O
lomefloxacin B-drug
, O
significantly O
decreased O
the O
bioavailability O
( O
48 O
% O
) O
of O
lomefloxacin B-drug
. O

The O
regulation O
of O
topoisomerases O
is O
no O
doubt O
complex O
and O
multifaceted O
and O
is O
probably O
accomplished O
through O
redundancy O
at O
many O
control O
levels O
. O

clinical O
significance O
unknown O
. O

Narcotic B-group
analgesics I-group
may O
potentiate O
the O
hypotensive O
effects O
of O
clonidine B-drug
. O

Lithium B-drug
: O
Valdecoxib B-drug
40 O
mg O
BID O
for O
7 O
days O
produced O
significant O
decreases O
in O
lithium B-drug
serum O
clearance O
( O
25 O
% O
) O
and O
renal O
clearance O
( O
30 O
% O
) O
with O
a O
34 O
% O
higher O
serum O
exposure O
compared O
to O
lithium B-drug
alone O
. O

Clidinium B-drug
may O
decrease O
the O
effect O
of O
phenothiazines B-group
, O
levodopa B-drug
, O
and O
ketoconazole B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2-7 O
) O
) O
with O
glyburide B-drug
( O
10 O
mg O
glyburide B-drug
BID O
) O
resulted O
in O
21 O
% O
increase O
in O
glyburide B-drug
AUC0-12 O
and O
a O
16 O
% O
increase O
in O
glyburide B-drug
Cmax O
leading O
to O
a O
16 O
% O
decrease O
in O
glucose O
AUC0-24 O
. O

Nursing O
Mothers O
Fulvestrant B-drug
is O
found O
in O
rat O
milk O
at O
levels O
significantly O
higher O
( O
approximately O
12-fold O
) O
than O
plasma O
after O
administration O
of O
2 O
mg/kg O
. O

dose-dependently O
increased O
the O
number O
of O
defecation O
episodes O
and O
induced O
a O
soft O
and O
watery O
stool O
in O
cecectomized O
rats O
. O

Intermediate O
doses O
of O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
produced O
transient O
increases O
in O
FI O
responding O
in O
monkeys O
and O
sustained O
increases O
in O
FI O
responding O
in O
pigeons O
; O

The O
basal O
colonic O
fluid O
contents O
and O
transits O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O

Co-administration O
of O
nelfinavir B-drug
at O
steady-state O
with O
a O
single O
dose O
of O
azithromycin B-drug
( O
2 O
x O
600 O
mg O
tablets O
) O
results O
in O
increased O
azithromycin B-drug
serum O
concentrations O
. O

Drug O
monitoring O
may O
be O
of O
assistance O
in O
detecting O
alterations O
in O
carbamazepine B-drug
plasma O
concentrations O
. O

Pharmacological/Pharmacodynamic O
Interactions O
with O
Carbamazepine B-drug
Concomitant O
administration O
of O
carbamazepine B-drug
and O
lithium B-drug
may O
increase O
the O
risk O
of O
neurotoxic O
side O
effects O
. O

The O
reaction O
after O
norepinephrine B-drug
remained O
the O
same O
in O
both O
groups O
of O
experiments O
. O

CONCLUSIONS O
: O
Olanzapine B-drug
demonstrated O
superior O
antipsychotic O
efficacy O
compared O
with O
haloperidol B-drug
in O
the O
treatment O
of O
acute O
phase O
schizophrenia O
, O
and O
in O
the O
treatment O
of O
some O
patients O
with O
first-episode O
or O
treatment-resistant O
schizophrenia O
. O

In O
clinical O
studies O
where O
patients O
were O
on O
chronic O
theophylline B-drug
therapy O
, O
lomefloxacin B-drug
had O
no O
measurable O
effect O
on O
the O
mean O
distribution O
of O
theophylline B-drug
concentrations O
or O
the O
mean O
estimates O
of O
theophylline B-drug
clearance O
. O

No O
cases O
of O
rhabdomyolysis O
were O
reported O
in O
this O
trial O
. O

No O
information O
is O
available O
about O
the O
use O
of O
butorphanol B-drug
concurrently O
with O
MAO B-group
inhibitors I-group
. O

Cromolyn B-drug
sodium I-drug
alone O
in O
doses O
up O
to O
540 O
mg/kg/day O
( O
approximately O
340 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
did O
not O
cause O
significant O
increases O
in O
resorptions O
or O
major O
malformations O
. O

Caution O
is O
advised O
in O
patients O
receiving O
chronic O
concomitant O
therapy O
. O

Methamphetamine B-drug
, O
like O
MPTP B-drug_n
, O
produced O
depletions O
of O
striatal O
dopamine O
but O
these O
actions O
were O
potentiated O
by O
pargyline B-drug
pretreatment O
. O

Amiodarone B-drug
is O
metabolized O
to O
desethylamiodarone B-drug
by O
the O
cytochrome O
P450 O
( O
CYP450 O
) O
enzyme O
group O
, O
specifically O
cytochromes O
P450 O
3A4 O
( O
CYP3A4 O
) O
and O
CYP2C8 O
. O

Tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
blunt O
the O
hypotensive O
effect O
of O
systemic O
clonidine B-drug
. O

Antagonism O
was O
never O
observed O
. O

When O
coadministered O
with O
SUSTIVA B-brand
in O
treatment-naive O
patients O
, O
the O
recommended O
dose O
of O
atazanavir B-drug
is O
300 O
mg O
with O
ritonavir B-drug
100 O
mg O
and O
SUSTIVA B-brand
600 O
mg O
( O
all O
once O
daily O
) O
. O

Vaccines B-group
: O
Patients O
on O
corticosteroid B-group
therapy O
may O
exhibit O
a O
diminished O
response O
to O
toxoids O
and O
live O
or B-group
inactivated I-group
vaccines I-group
due O
to O
inhibition O
of O
antibody O
response O
. O

In O
rats O
, O
simultaneous O
ingestion O
of O
disulfiram B-drug
and O
nitrite B-drug
in O
the O
diet O
for O
78 O
weeks O
has O
been O
reported O
to O
cause O
tumors O
, O
and O
it O
has O
been O
suggested O
that O
disulfiram B-drug
may O
react O
with O
nitrites B-group
in O
the O
rat O
stomach O
to O
form O
a O
nitrosamine O
, O
which O
is O
tumorigenic O
. O

Therophylline O
: O
A O
recent O
study O
has O
shown O
that O
concomitan O
administration O
of O
isoniazid B-drug
and O
theophylline B-drug
may O
cause O
elevated O
plasma O
levels O
of O
theophylline B-drug
, O
and O
in O
some O
instances O
a O
slight O
decrease O
in O
the O
elimination O
of O
isoniazid B-drug
. O

and O
( O
ii O
) O
the O
effects O
of O
filipin B-drug_n
were O
more O
efficiently O
inhibited O
by O
added O
cholesterol O
, O
the O
major O
membrane O
sterol O
in O
human O
cells O
, O
whereas O
the O
effects O
of O
amphotericin B-drug
B I-drug
were O
more O
efficiently O
inhibited O
by O
ergosterol O
, O
the O
major O
membrane O
sterol O
in O
yeast O
. O

Some O
of O
the O
cases O
of O
collapse/respiratory O
arrest/cardiac O
arrest O
during O
initial O
treatment O
occurred O
in O
patients O
who O
were O
being O
administered O
benzodiazepines B-group
; O

For O
comprehensive O
information O
concerning O
laboratory O
test O
alterations O
associated O
with O
ritonavir B-drug
, O
physicians O
should O
refer O
to O
the O
complete O
prescribing O
information O
for O
NORVIR B-brand
( O
ritonavir B-drug
) O
. O

The O
effects O
of O
ERGOMAR B-brand
may O
be O
potentiated O
by O
triacetyloleandomycin B-drug
which O
inhibits O
the O
metabolism O
of O
ergotamine B-drug
. O

In O
2 O
separate O
studies O
, O
fexofenadine B-drug
hydrochloride I-drug
120 O
mg O
twice O
daily O
( O
240 O
mg O
total O
daily O
dose O
) O
was O
co-administered O
with O
either O
erythromycin B-drug
500 O
mg O
every O
8 O
hours O
or O
ketoconazole B-drug
400 O
mg O
once O
daily O
under O
steady-state O
conditions O
to O
healthy O
volunteers O
( O
n=24 O
, O
each O
study O
) O
. O

HMG-CoA B-group
Reductase I-group
inhibitors I-group
: O
lovastatin B-drug
, O
simvastatin B-drug

Oral O
Anticoagulants B-group
CAUTION O
SHOULD O
BE O
EXERCISED O
WHEN O
COUMARIN B-group
ANTICOAGULANTS I-group
ARE O
GIVEN O
IN O
CONJUNCTION O
WITH O
TRICOR B-brand
. O

High-dose O
cisplatin B-drug
with O
sodium B-drug
thiosulfate I-drug
protection O
. O

There O
have O
been O
rare O
reports O
of O
significant O
respiratory O
depression O
, O
stupor O
and/or O
hypotension O
with O
the O
concomitant O
use O
of O
loxapine B-drug
and O
lorazepam B-drug
. O

The O
latter O
might O
arise O
from O
a O
hit O
in O
a O
genetically O
initiated O
cell O
, O
the O
result O
of O
which O
is O
a O
more O
rapid O
progression O
in O
tumor O
type O
. O

Coadministration O
of O
CRIXIVAN B-brand
and O
other O
drugs O
that O
inhibit O
CYP3A4 O
may O
decrease O
the O
clearance O
of O
indinavir B-drug
and O
may O
result O
in O
increased O
plasma O
concentrations O
of O
indinavir B-drug
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactams B-group
, O
the O
renal O
excretion O
of O
cephalexin B-drug
is O
inhibited O
by O
probenecid B-drug
. O

Therefore O
, O
when O
using O
doses O
of O
Trileptal B-brand
greater O
than O
1200 O
mg/day O
during O
adjunctive O
therapy O
, O
a O
decrease O
in O
the O
dose O
of O
phenytoin B-drug
may O
be O
required O
. O

oxolinic B-drug
acid I-drug
; O

Cimetidine B-drug
: O
In O
the O
presence O
of O
cimetidine B-drug
at O
300 O
mg O
QID O
( O
N=12 O
) O
the O
mean O
apparent O
oral O
clearance O
of O
gabapentin B-drug
fell O
by O
14 O
% O
and O
creatinine O
clearance O
fell O
by O
10 O
% O
. O

The O
toxicity O
of O
cadmium O
, O
zinc B-drug
, O
and O
cadmium/zinc O
mixtures O
at O
concentrations O
ranging O
from O
10000 O
to O
10 O
microg/l O
was O
investigated O
. O

Vecuronium B-drug
: O
When O
used O
in O
the O
perioperative O
period O
, O
piperacillin B-drug
has O
been O
implicated O
in O
the O
prolongation O
of O
the O
neuromuscular O
blockade O
of O
vecuronium B-drug
. O

The O
agent O
was O
found O
to O
produce O
some O
inhibiting O
activity O
against O
hepatic O
microsomal O
7-ethoxycoumarine O
deethylase O
in O
male O
Wistar O
rats O
in O
vitro O
and O
in O
vivo O
experiments O
. O

Other O
strong O
inhibitors O
of O
CYP3A4 O
( O
itraconazole B-drug
) O
would O
be O
expected O
to O
have O
similar O
effects O
and O
need O
similar O
dose O
reductions O
; O

- O
a O
monoamine B-group
oxidase I-group
inhibitor I-group
( O
MAOI B-group
) O
such O
as O
isocarboxazid B-drug
( O
Marplan B-brand
) O
, O
tranylcypromine B-drug
( O
Parnate B-brand
) O
, O
or O
phenelzine B-drug
( O
Nardil B-brand
) O
; O

The O
mean O
percentage O
increase O
in O
the O
glipizide B-drug
AUC O
after O
fluconazole B-drug
administration O
was O
56.9 O
% O
( O
range O
: O
35 O
to O
81 O
) O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

Additive O
adverse O
effects O
resulting O
from O
cholinergic O
blockade O
may O
occur O
when O
LEVSIN B-brand
is O
administered O
concomitantly O
with O
other O
antimuscarinics B-group
, O
amantadine B-drug
, O
haloperidol B-drug
, O
phenothiazines B-group
, O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
or O
some O
antihistamines B-group
. O

Additional O
drugs O
that O
are O
not O
recommended O
for O
coadministration O
with O
INVIRASE B-brand
and O
ritonavir B-drug
are O
included O
below O
. O

The O
physician O
is O
advised O
to O
monitor O
plasma O
levels O
of O
phenytoin B-drug
and O
to O
decrease O
the O
dose O
if O
necessary O
. O

Benazepril B-drug
, O
like O
other O
ACE B-group
inhibitors I-group
, O
has O
had O
less O
than O
additive O
effects O
with O
beta-adrenergic B-group
blockers I-group
, O
presumably O
because O
both O
drugs O
lower O
blood O
pressure O
by O
inhibiting O
parts O
of O
the O
renin-angiotensin O
system O

Fifteen O
to O
30 O
minutes O
of O
exposure O
to O
1.25 O
MAC O
isoflurane B-drug
or O
enflurane B-drug
had O
minimal O
effects O
on O
the O
duration O
of O
action O
of O
initial O
doses O
of O
NIMBEX B-brand
and O
therefore O
, O
no O
adjustment O
to O
the O
initial O
dose O
should O
be O
necessary O
when O
NIMBEX B-brand
is O
administered O
shortly O
after O
initiation O
of O
volatile O
agents O
. O

In O
vitro O
studies O
with O
several O
drugs O
which O
may O
be O
administered O
concomitantly O
showed O
that O
the O
extent O
of O
flecainide B-drug
binding O
to O
human O
plasma O
proteins O
is O
either O
unchanged O
or O
only O
slightly O
less O
. O

N-methyllevallorphan B-drug_n
( O
5 O
mg/kg O
, O
s.c. O
) O
completely O
antagonized O
the O
inhibitory O
effect O
of O
loperamide B-drug
and O
partly O
antagonized O
the O
effect O
of O
morphine B-drug
. O

At O
a O
median O
follow-up O
of O
33 O
months O
, O
the O
combination O
of O
ARIMIDEX B-brand
and O
tamoxifen B-drug
did O
not O
demonstrate O
any O
efficacy O
benefit O
when O
compared O
with O
tamoxifen B-drug
in O
all O
patients O
as O
well O
as O
in O
the O
hormone O
receptor-positive O
subpopulation O
. O

The O
effect O
of O
dofetilide B-drug
on O
the O
steady-state O
pharmacokinetics O
of O
digoxin B-drug
was O
evaluated O
in O
a O
randomized O
, O
double-blind O
study O
. O

increased O
platelet O
count O
; O

The O
effects O
of O
DCG-IV B-drug_n
and O
L-CCG-1 B-drug_n
upon O
phencyclidine B-drug_n
( O
PCP B-drug_n
) O
-induced O
locomotion O
and O
behavioral O
changes O
in O
mice O
. O

Serious O
anticholinergic O
symptoms O
( O
severe O
dry O
mouth O
, O
urinary O
retention O
, O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-group
antidepressants I-group
when O
cimetidine B-drug
is O
added O
to O
the O
drug O
regimen O
. O

Concurrent O
use O
of O
butorphanol B-drug
with O
central B-group
nervous I-group
system I-group
depressants I-group
( O
e.g. O
, O
alcohol B-drug
, O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
antihistamines B-group
) O
may O
result O
in O
increased O
central B-group
nervous I-group
system I-group
depressant I-group
effects O
. O

Atromid-S B-brand
may O
displace O
acidic O
drugs O
such O
as O
phenytoin B-drug
or O
tolbutamide B-drug
from O
their O
binding O
sites O
. O

- O
Corticosteroids B-group
, O
ACTH B-drug
: O
Intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O

Because O
of O
the O
risk O
of O
serious O
ventricular O
arrhythmias O
and O
sudden O
death O
potentially O
associated O
with O
elevated O
plasma O
levels O
of O
thioridazine B-drug
, O
Duloxetine B-drug
and O
thioridazine B-drug
should O
not O
be O
co-administered O
. O

It O
is O
essentially O
completely O
metabolised O
, O
therefore O
little O
is O
excreted O
unchanged O
. O

Atazanavir B-drug

Alcohol B-drug
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
rare O
reports O
of O
adverse O
neuropsychiatric O
events O
or O
reduced O
alcohol B-drug
tolerance O
in O
patients O
who O
were O
drinking O
alcohol B-drug
during O
treatment O
with O
WELLBUTRIN B-brand
. O

Such O
an O
interaction O
can O
potentially O
lead O
to O
higher O
free O
fractions O
of O
either O
tiagabine B-drug
or O
the O
competing O
drug O
. O

PROSTIN B-brand
E2 I-brand
may O
augment O
the O
activity O
of O
other O
oxytocic B-group
drugs I-group
. O

Single O
dose O
bioavailability O
studies O
in O
normal O
volunteers O
have O
failed O
to O
wshow O
an O
effect O
of O
aspirin B-brand
on O
ibuprofen B-drug
blood O
levels O
. O

Ergot O
derivatives O
: O
dihydroergotamine B-drug
, O
ergonovine B-drug
, O
ergotamine B-drug
, O
methylergonovine B-drug

fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
. O

In O
vitro O
studies O
show O
significant O
inhibition O
of O
the O
formation O
of O
oxidized O
irbesartan O
metabolites O
with O
the O
known O
cytochrome O
CYP O
2C9 O
substrates/inhibitors O
sulphenazole B-drug
, O
tolbutamide B-drug
and O
nifedipine B-drug
. O

Other O
drugs O
that O
are O
specific O
substrates O
, O
inhibitors O
, O
or O
inducers O
of O
the O
enzyme O
system O
may O
have O
a O
significant O
impact O
on O
the O
efficacy O
and O
side O
effect O
profile O
of O
diltiazem B-drug
. O

[ O
Quantitative O
approach O
to O
treatment O
with O
incisive O
neuroleptics B-group
by O
therapeutic O
monitoring O
] O
; O
The O
problems O
encountered O
during O
the O
longterm O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-group
are O
illustrated O
by O
six O
typical O
case O
reports O
. O

The O
effect O
of O
BREVIBLOC B-drug
on O
the O
duration O
of O
succinylcholine-induced B-drug
neuromuscular O
blockade O
was O
studied O
in O
patients O
undergoing O
surgery O
. O

In O
treatment-experienced O
patients O
, O
available O
uncontrolled O
data O
suggest O
these O
agents O
contribute O
to O
regimen O
efficacy O
in O
NNRTI-na B-group
ve O
, O
treatment-experienced O
patients O
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
paroxetine B-drug
, O
and O
fluvoxamine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Haloperidol B-drug
: O
Haloperidol B-drug
blocks O
dopamine O
receptors O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
. O

No O
drug O
interactions O
have O
been O
reported O
between O
Prostin B-brand
VR I-brand
Pediatric I-brand
and O
the O
therapy O
standard O
in O
neonates O
with O
restricted O
pulmonary O
or O
systemic O
blood O
flow O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
procainamide B-drug
for O
less O
than O
seven O
days O
increases O
plasma O
concentrations O
of O
procainamide B-drug
and O
n-acetyl O
procainamide B-drug
by O
55 O
% O
and O
33 O
% O
, O
respectively O
. O

In O
some O
patients O
, O
the O
administration O
of O
INDOCIN B-brand
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive B-group
effects O
of O
loop O
, O
potassium-sparing O
, O
and O
thiazide B-group
diuretics I-group
. O

Improvements O
in O
general O
cognitive O
function O
seen O
with O
olanzapine B-drug
treatment O
in O
a O
1-year O
controlled O
study O
of O
patients O
with O
early-phase O
schizophrenia O
, O
were O
significantly O
greater O
than O
changes O
seen O
with O
either O
risperidone B-drug
or O
haloperidol B-drug
. O

Intravenous O
Pentamidine B-drug
: O
Treatment O
with O
HIVID B-drug
should O
be O
interrupted O
when O
the O
use O
of O
a O
drug O
that O
has O
the O
potential O
to O
cause O
pancreatitis O
is O
required O
. O

Studies O
to O
evaluate O
possible O
interactions O
between O
REVIA B-brand
and O
drugs O
other O
than O
opiates B-group
have O
not O
been O
performed O
. O

nalidixic B-drug
acid I-drug
; O

The O
findings O
suggest O
that O
the O
agent O
has O
slight O
effects O
on O
the O
tested O
activities O
. O

Drug O
Effect O

Aminosalicylic B-drug
acid I-drug
may O
decrease O
the O
amount O
of O
digoxin B-drug
( O
Lanoxin B-brand
, O
Lanoxicaps B-drug
) O
that O
gets O
absorbed O
into O
your O
body O
. O

Clinical O
Comment O

Quinidine B-drug
and O
procainamide O
doses O
should O
be O
reduced O
by O
one-third O
when O
either O
is O
administered O
with O
amiodarone B-drug
. O

However O
, O
halothane B-drug
anesthetic O
requirement O
( O
i.e. O
, O
MAC O
) O
was O
depressed O
in O
a O
dose-dependent O
fashion O
as O
much O
as O
56 O
% O
1-2 O
hours O
and O
as O
much O
as O
14 O
% O
5-6 O
hours O
after O
injection O
of O
ketamine B-drug
, O
50 O
mg/kg O
, O
im O
. O

CONCLUSIONS O
: O
The O
combination O
of O
CHOP O
plus O
HAART O
is O
feasible O
and O
may O
reduce O
the O
morbidity O
from O
OIs O
in O
HIV-NHL O
patients O
. O


The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
may O
produce O
severe O
, O
prolonged O
hypertension O
. O

Phenobarbital B-drug
: O
Decreases O
aspirin B-brand
effectiveness O
by O
enzyme O
induction O
. O

Orthostatic O
hypotension O
in O
patients O
taking O
clozapine B-drug
can O
, O
in O
rare O
cases O
( O
approximately O
1 O
case O
per O
3,000 O
patients O
) O
, O
be O
accompanied O
by O
profound O
collapse O
and O
respiratory O
and/or O
cardiac O
arrest O
. O

The O
use O
of O
dextromethorphan B-drug
hydrobromide I-drug
may O
result O
in O
additive O
CNS O
depressant O
effects O
when O
coadministered O
with O
alcohol B-drug
, O
antihistamines B-group
, O
psychotropics B-group
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

No O
inhibition O
of O
any O
of O
the O
other O
isoforms O
tested O
was O
observed O
at O
gabapentin B-drug
concentrations O
up O
to O
171 O
mg/mL O
( O
approximately O
15 O
times O
the O
Cmax O
at O
3600 O
mg/day O
) O
. O

Dose O
modification O
is O
recommended O
for O
patients O
who O
are O
also O
receiving O
a O
potent O
CYP O
3A4 O
inducer O
. O

Following O
a O
10 O
g O
bolus O
of O
AMICAR B-brand
, O
transient O
peak O
plasma O
concentrations O
of O
4.6 O
mMol/L O
or O
0.60 O
mg/mL O
have O
been O
obtained O
. O

Butalbital B-drug
, O
acetaminophen B-drug
and O
caffeine B-drug
may O
enhance O
the O
effects O
of O
: O
other O
narcotic B-group
analgesics O
, O
alcohol B-drug
, O
general O
anesthetics B-group
, O
tranquilizers B-group
such O
as O
chlordiazepoxide B-drug
, O
sedative-hypnotics B-group
, O
or O
other O
CNS B-group
depressants I-group
, O
causing O
increased O
CNS O
depression O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-drug
. O

Discontinuation O
of O
cimetidine B-drug
in O
well-controlled O
patients O
receiving O
tricyclic B-drug
antidepressants I-drug
and O
cimetidine B-drug
may O
decrease O
the O
plasma O
levels O
and O
efficacy O
of O
the O
antidepressants B-drug
. O

Nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
have O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-drug
and O
to O
potentiate O
its O
toxicity O
. O

Pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-drug
inhibits O
the O
metabolism O
of O
astemizole B-drug
, O
resulting O
in O
elevated O
plasma O
levels O
of O
astemizole B-drug
and O
its O
active O
metabolite O
desmethylastemizole B-drug_n
which O
may O
prolong O
QT O
intervals O
. O

Flurbiprofen B-drug
did O
not O
appear O
to O
affect O
the O
beta-blocker-mediated O
reduction O
in O
heart O
rate O
. O

In O
patients O
receiving O
HCTZ B-drug
alone O
, O
dofetilide B-drug
AUC O
increased O
by O
27 O
% O
and O
Cmax O
by O
21 O
% O
. O

descending O
epsilon O
and O
mu O
systems O
for O
beta-endorphin B-drug_n
and O
morphine B-drug
, O
respectively O
, O
are O
proposed O
. O

Both O
steady-state O
maximum O
concentration O
and O
AUC O
were O
dose O
proportional O
over O
the O
full O
dose O
range O
when O
assessed O
on O
day O
1 O
, O
as O
well O
as O
for O
the O
full O
duration O
of O
the O
study O
at O
steady O
state O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Agents I-group
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
, O
the O
co-administration O
of O
lisinopril B-drug
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O

Drugs O
which O
may O
potentiate O
the O
release O
of O
neutrophils O
, O
such O
as O
lithium B-drug
, O
should O
be O
used O
with O
caution O
. O

bone O
density O
; O

Treatment O
with O
entacapone B-drug
coadministered O
with O
levodopa/dopa B-drug
decarboxylase B-group
inhibitor I-group
does O
not O
change O
these O
effects O
. O

Pimozide B-drug
and O
Celexa B-brand
- O
In O
a O
controlled O
study O
, O
a O
single O
dose O
of O
pimozide B-drug
2 O
mg O
co-administered O
with O
racemic O
citalopram B-drug
40 O
mg O
given O
once O
daily O
for O
11 O
days O
was O
associated O
with O
a O
mean O
increase O
in O
QTc O
values O
of O
approximately O
10 O
msec O
compared O
to O
pimozide B-drug
given O
alone O
. O

Oral O
Contraceptives B-group
: O
Multiple O
dose O
administration O
of O
tiagabine B-drug
( O
8 O
mg/day O
monotherapy O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
oral O
contraceptives B-group
in O
healthy O
women O
of O
childbearing O
age O
. O

The O
clinical O
significance O
of O
this O
property O
is O
unknown O
. O

Cephalosporins B-group
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Loperamide B-drug
and O
morphine B-drug
( O
0.1 O
and O
1.0 O
mg/kg O
, O
s.c O
. O
) O

As O
with O
other O
cephalosporins B-group
, O
high O
concentrations O
of O
cefotetan B-drug
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
Jaffe O
reaction O
and O
produce O
false O
increases O
in O
the O
levels O
of O
creatinine O
reported O
. O

Profound O
hypotensive O
episodes O
may O
occur O
when O
diazoxide B-drug
infection O
and O
hydralazine B-drug
are O
used O
concomitantly O
. O

However O
, O
concomitant O
administration O
of O
5 O
mg O
b.i.d O
. O
isradipine B-drug
and O
40 O
mg O
b.i.d O
. O

Two O
groups O
( O
SH/DA O
; O
SH/FA O
) O
were O
submitted O
to O
daily O
treatment O
with O
synthetic O
hydroalcoholic O
solutions O
containing O
ethanol B-drug
, O
methanol B-drug_n
, O
higher O
alcohols B-drug_n
and O
acetaldehyde B-drug_n
in O
the O
same O
proportions O
as O
those O
found O
in O
most O
common O
distilled O
and O
fermented O
alcoholic O
beverages O
; O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
VIOXX B-brand
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

Esomeprazole B-drug
inhibits O
gastric O
acid O
secretion O
. O

Antihistamines B-group

Anesthetics B-group

Acetaminophen B-drug
: O
A O
report O
of O
severe O
acetaminophen B-drug
toxicity O
was O
reported O
in O
a O
patient O
receiving O
Isoniazid B-drug
. O

Interaction O
between O
glycine B-drug
and O
glutamate B-drug
in O
the O
development O
of O
spontaneous O
motility O
in O
chick O
embryos O
. O

The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O

The O
pharmacokinetics O
of O
theophylline B-drug
were O
not O
altered O
. O

b O
This O
table O
is O
not O
all-inclusive O
. O

Wait O
5 O
weeks O
after O
stopping O
escitalopram B-drug
before O
starting O
a O
non-selective B-group
MAO I-group
inhibitor I-group
. O

However O
, O
coadministration O
of O
escitalopram B-drug
( O
20 O
mg O
) O
and O
ritonavir B-drug
( O
600 O
mg O
) O
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
escitalopram B-drug
. O

This O
loss O
of O
microtubules O
on O
cooling O
the O
nerves O
and O
their O
reappearance O
on O
rewarming O
was O
a O
rapid O
process O
; O

The O
potential O
for O
increased O
sedation O
when O
guanfacine B-drug
is O
given O
with O
other O
CNS-depressant B-group
drug I-group
should O
be O
appreciated O
. O

The O
potential O
effects O
of O
increased O
plasma O
concentrations O
of O
midazolam B-drug
or O
other O
benzodiazepines B-group
metabolized O
via O
CYP3A4 O
( O
alprazolam B-drug
, O
triazolam B-drug
) O
should O
be O
considered O
when O
coadministering O
these O
agents O
with O
Aprepitant B-drug
. O

Oral O
anticoagulant B-group
agents I-group
: O
Pharmacokinetic O
drug-drug O
interactions O
between O
Argatroban B-drug
and O
warfarin B-drug
( O
7.5 O
mg O
single O
oral O
dose O
) O
have O
not O
been O
demonstrated O
. O

Drug/Laboratory O
Test-Interactions O
None O
observed O
. O

The O
ratios O
of O
the O
AUCs O
of O
unbound O
valproate B-drug
to O
the O
AUCs O
of O
the O
total O
valproate B-drug
were O
11.1 O
% O
, O
13.0 O
% O
, O
and O
11.5 O
% O
, O
with O
coadministration O
of O
0 O
, O
1200 O
, O
and O
2400 O
mg/day O
of O
Felbatol B-brand
, O
respectively O
. O

The O
results O
of O
the O
ERMBT O
after O
2 O
weeks O
of O
rifabutin B-drug
and O
rifampin B-drug
therapy O
were O
increased O
187 O
and O
156 O
% O
, O
respectively O
. O

Interations O

CANCIDAS B-brand
reduced O
the O
blood O
AUC0-12 O
of O
tacrolimus B-drug
by O
approximately O
20 O
% O
, O
peak O
blood O
concentration O
( O
Cmax O
) O
by O
16 O
% O
, O
and O
12-hour O
blood O
concentration O
( O
C12hr O
) O
by O
26 O
% O
in O
healthy O
subjects O
when O
tacrolimus B-drug
( O
2 O
doses O
of O
0.1 O
mg/kg O
12 O
hours O
apart O
) O
was O
administered O
on O
the O
10th O
day O
of O
CANCIDAS B-brand
70 O
mg O
daily O
, O
as O
compared O
to O
results O
from O
a O
control O
period O
in O
which O
tacrolimus B-drug
was O
administered O
alone O
. O

This O
combinational O
action O
in O
reversing O
vancomycin O
resistance O
of O
enterococci O
highlights O
novel O
drug O
targets O
and O
has O
importance O
in O
the O
design O
of O
new O
therapeutic O
regimes O
against O
resistant O
pathogens O
. O

Concurrent O
use O
of O
macrolides B-group
and O
warfarin B-drug
in O
clinical O
practice O
has O
been O
associated O
with O
increased O
anticoagulant O
effects O
. O


Serial O
plasma O
and O
urine O
samples O
for O
measurement O
of O
amprenavir B-drug
, O
rifabutin B-drug
, O
and O
rifampin B-drug
and O
their O
25-O-desacetyl B-drug_n
metabolites I-drug_n
, O
were O
measured O
by O
high-performance O
liquid O
chromatography O
. O

Nevirapine I-drug
and O
rifampin B-drug
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O
nevirapine B-drug
plasmaconcentrations O
may O
reduce O
the O
efficacy O
ofthe O
drug O
. O

Antibiotics B-group
: O
In O
vitro O
and/or O
in O
vivo O
data O
show O
that O
clarithromycin B-drug
, O
erythromycin B-drug
, O
and O
troleandomycin B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

The O
treatment O
of O
ewes O
with O
an O
intravenous O
( O
IV O
) O
injection O
of O
trichlorfon B-drug_n
, O
insufficient O
to O
produce O
significant O
inhibition O
of O
erythrocyte O
acetylcholinesterase O
( O
AChE O
) O
activity O
, O
appeared O
to O
produce O
additive O
effects O
with O
those O
produced O
by O
subsequent O
treatment O
with O
4 O
mg O
of O
coumaphos/kg/day B-drug_n
. O

Consequently O
, O
it O
is O
recommended O
not O
to O
exceed O
a O
single O
2.5 O
mg O
Vardenafil B-drug
dose O
in O
a O
72-hour O
period O
when O
used O
in O
combination O
with O
ritonavir B-drug
. O

Castor B-drug
oil I-drug
( O
4 O
ml/kg O
, O
p.o O
. O
) O

Probenecid B-drug
: O
Probenecid B-drug
increases O
both O
free O
and O
bound O
ketoprofen B-drug
by O
reducing O
the O
plasma O
clearance O
of O
ketoprofen B-drug
to O
about O
one-third O
, O
as O
well O
as O
decreasing O
its O
protein O
binding O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
coadministration O
of O
escitalopram B-drug
and O
drugs O
metabolized O
by O
CYP2D6 O
. O

Capsules O
INDOCIN B-brand
50 O
mg O
t.i.d O
. O
produced O
a O
clinically O
relevant O
elevation O
of O
plasma O
lithium B-drug
and O
reduction O
in O
renal O
lithium B-drug
clearance O
in O
psychiatric O
patients O
and O
normal O
subjects O
with O
steady O
state O
plasma O
lithium B-drug
concentrations O
. O

Therefore O
, O
increased O
monitoring O
of O
digoxin B-drug
is O
recommended O
when O
initiating O
, O
adjusting O
, O
or O
discontinuing O
COREG B-brand
. O

Cimetidine B-drug
, O
caffeine B-drug
, O
and O
erythromycin B-drug
may O
increase O
plasma O
levels O
of O
Clozapine B-drug
, O
potentially O
resulting O
in O
adverse O
effects O
. O

Analysis O
of O
16,16-dimethylprostaglandin B-drug_n
E2-induced O
diarrhea O
in O
cecectomized O
rats O
. O

Response O
to O
sympathomimetic B-group
agents I-group
may O
be O
enhanced O
by O
colchicine B-drug
. O

Therefore O
, O
digoxin B-drug
serum O
levels O
should O
be O
monitored O
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Increases O
in O
prothrombin O
time O
have O
been O
noted O
in O
patients O
receiving O
long- O
term O
warfarin B-drug
therapy O
after O
flutamide B-drug
was O
initiated O
. O

. O

Methotrexate B-drug
: O
Caution O
should O
be O
used O
if O
diflunisal B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

dosage O
adjustments O
may O
be O
necessary O
. O
) O

While O
all O
the O
selective O
serotonin B-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Fulvestrant B-drug
was O
not O
mutagenic O
or O
clastogenic O
in O
multiple O
in O
vitro O
tests O
with O
and O
without O
the O
addition O
of O
a O
mammalian O
liver O
metabolic O
activation O
factor O
( O
bacterial O
mutation O
assay O
in O
strains O
of O
Salmonella O
typhimurium O
and O
Escherichia O
coli O
, O
in O
vitro O
cytogenetics O
study O
in O
human O
lymphocytes O
, O
mammalian O
cell O
mutation O
assay O
in O
mouse O
lymphoma O
cells O
and O
in O
vivo O
micronucleus O
test O
in O
rat O
. O

Concomitantly O
given O
thiazide B-group
diuretics I-group
did O
not O
interfere O
with O
the O
absorption O
of O
a O
tablet O
of O
digoxin B-drug
. O

After O
1 O
h O
, O
atracurium B-drug
was O
discontinued O
and O
hoof O
twitch O
allowed O
to O
recover O
to O
75 O
% O
. O

Depression O
is O
reaching O
epidemic O
proportions O
in O
the O
western O
world O
. O

When O
these O
drugs O
are O
administered O
to O
or O
withdrawn O
from O
patients O
receiving O
Starlix B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
changes O
in O
glycemic O
control O
. O

When O
amiloride B-drug
HCl O
is O
administered O
concomitantly O
with O
an O
angiotensin-converting B-group
enzyme I-group
inhibitor I-group
, O
the O
risk O
of O
hyperkalemia O
may O
be O
increased O
. O

No O
interactions O
have O
been O
observed O
between O
nizatidine B-drug
and O
theophylline B-drug
, O
chlordiazepoxide B-drug
, O
lorazepam B-drug
, O
lidocaine B-drug
, O
phenytoin B-drug
, O
and O
warfarin B-drug
. O

Coadministration O
of O
valdecoxib B-drug
with O
doses O
higher O
than O
40 O
mg O
QD O
omeprazole B-drug
has O
not O
been O
studied O
. O

In O
the O
second O
experiment O
, O
non-diabetic O
and O
streptozotocin-induced O
diabetic O
rats O
were O
fasted O
, O
and O
the O
same O
procedures O
were O
followed O
for O
estimation O
of O
glucose B-drug
tolerance O
30 O
min O
after O
glucose B-drug
overload O
. O

Digoxin B-drug
, O
Methotrexate B-drug
, O
Cyclosporine B-drug
: O
Diclofenac B-drug
, O
like O
other O
NSAIDs B-group
, O
may O
affect O
renal O
prostaglandins O
and O
increase O
the O
toxicity O
of O
certain O
drugs O
. O

Studies O
have O
shown O
that O
the O
bioavailability O
of O
isoniazid B-drug
is O
reduced O
significantly O
when O
administered O
with O
food O
. O

Drug-Drug O
Interactions O
Albuterol B-drug
- O
STRATTERA B-brand
should O
be O
administered O
with O
caution O
to O
patients O
being O
treated O
with O
systemically-administered O
( O
oral O
or O
intravenous O
) O
albuterol B-drug
( O
or O
other O
beta2 B-group
agonists I-group
) O
because O
the O
action O
of O
albuterol B-drug
on O
the O
cardiovascular O
system O
can O
be O
potentiated O
resulting O
in O
increases O
in O
heart O
rate O
and O
blood O
pressure O
. O

Drugs O
Which O
Require O
a O
Dose O
Reduction O
When O
Coadminstered O
With O
VIRACEPT B-brand
Antimycobacterial B-group
agents I-group
: O
rifabutin B-drug

phosphokinase O

Acetaminophen B-drug
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-drug
and O
acetaminophen B-drug
resulted O
in O
an O
approximate O
50 O
% O
increase O
in O
plasma O
levels O
of O
acetaminophen B-drug
. O

In O
a O
single-dose O
crossover O
study O
examining O
lansoprazole B-drug
30 O
mg O
and O
omeprazole B-drug
20 O
mg O
each O
administered O
alone O
and O
concomitantly O
with O
sucralfate B-drug
1 O
gram O
, O
absorption O
of O
the O
proton B-group
pump I-group
inhibitors I-group
was O
delayed O
and O
their O
bioavailability O
was O
reduced O
by O
17 O
% O
and O
16 O
% O
, O
respectively O
, O
when O
administered O
concomitantly O
with O
sucralfate B-drug
. O

Pharmacokinetics O
. O

Saquinavir B-drug
: O
Coadministration O
of O
saquinavir B-drug
( O
using O
an O
experimental O
soft-gelatin O
capsule O
formulation O
of O
saquinavir B-drug
1200mg O
) O
with O
VIRACEPT B-brand
resulted O
in O
an O
18 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
4-fold O
increase O
in O
saquinavir B-drug
plasma O
A.C O
. O

This O
is O
based O
on O
the O
results O
from O
3 O
clinical O
studies O
using O
histamine B-drug
induced O
skin O
wheals O
and O
flares O
coupled O
with O
population O
pharmacokinetic O
analysis O
. O

CONCLUSIONS O
. O

Other O
: O
There O
appears O
to O
be O
no O
pharmacokinetic O
interaction O
between O
acitretin B-drug
and O
cimetidine B-drug
, O
digoxin B-drug
, O
or O
glyburide B-drug
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e. O
g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Substrate O
of O
CYP2D6 O
( O
minor O
) O
, O
3A4 O
( O
major O
) O
; O

this O
interaction O
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O

Other O
TNFa-blocking B-group
agents I-group
( O
including O
REMICADE B-brand
) O
used O
in O
combination O
with O
anakinra B-drug
may O
also O
result O
in O
similar O
toxicities O
. O

There O
have O
been O
reports O
of O
positive O
test O
results O
using O
the O
Bio-Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
in O
patients O
receiving O
piperacillin/tazobactam B-drug
injection O
who O
were O
subsequently O
found O
to O
be O
free O
of O
Aspergillus O
infection O
. O

MAO B-group
Inhibitors I-group
: O
DURAGESIC B-brand
is O
not O
recommended O
for O
use O
in O
patients O
who O
have O
received O
MAOI B-group
within O
14 O
days O
because O
severe O
and O
unpredictable O
potentiation O
by O
MAO B-group
inhibitors I-group
has O
been O
reported O
with O
opioid B-group
analgesics I-group

INDOCIN B-brand
reduces O
basal O
plasma O
renin O
activity O
( O
PRA O
) O
, O
as O
well O
as O
those O
elevations O
of O
PRA O
induced O
by O
furosemide B-drug
administration O
, O
or O
salt O
or O
volume O
depletion O
. O

In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
ENBREL B-brand
and O
anakinra B-drug
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
ENBREL B-brand
alone O
( O
0 O
% O
) O
. O

The O
antimicrobial O
effect O
of O
a O
benzoxazinorifamycin B-drug_n
, O
KRM-1648 B-drug_n
, O
either O
alone O
or O
in O
combination O
with O
ofloxacin B-drug
, O
was O
evaluated O
in O
vitro O
against O
two O
type O
strains O
and O
six O
clinical O
isolates O
of O
Mycobacterium O
ulcerans O
. O

The O
combination O
of O
therapeutic O
doses O
of O
intravenous O
dantrolene B-drug
sodium I-drug
and O
verapamil B-drug
in O
halothane B-drug
a-chloralose O
anesthetized O
swine O
has O
resulted O
in O
ventricular O
fibrillation O
and O
cardiovascular O
collapse O
in O
association O
with O
marked O
hyperkalemia O
. O

Phenylbutazone B-drug
: O
Phenylbutazone B-drug
causes O
increase O
( O
by O
about O
80 O
% O
) O
in O
the O
free O
fraction O
of O
etodolac B-drug
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phe-nothiazines O
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimet-ics O
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

Fulvestrant B-drug
caused O
an O
increased O
incidence O
of O
fetal O
abnormalities O
in O
rats O
( O
tarsal O
flexure O
of O
the O
hind O
paw O
at O
2 O
mg/kg/day O
IM O
; O

CIMETlDINE B-drug
: O
Cerivastatin B-drug
plasma O
concentrations O
were O
not O
affected O
by O
co-administration O
of O
cimetidine B-drug
. O

DIAMOX B-brand
modifies O
phenytoin B-drug
metabolism O
with O
increased O
serum O
levels O
of O
phenytoin B-drug
. O

In O
vitro O
studies O
indicate O
that O
, O
at O
therapeutic O
concentrations O
of O
salicylate B-group
( O
300 O
m O
g/mL O
) O
, O
the O
binding O
of O
ketorolac B-drug
was O
reduced O
from O
approximately O
99.2 O
% O
to O
97.5 O
% O
, O
representing O
a O
potential O
twofold O
increase O
in O
unbound O
ketorolac B-drug
plasma O
levels O
. O

increased O
norepinephrine-induced O
platelet O
aggregability O

Ergot-containing O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O

No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
systemic B-group
corticosteroids I-group
and O
Accutane B-brand
. O

Erythromycin B-drug
: O
In O
healthy O
individuals O
, O
plasma O
concentrations O
of O
atorvastatin B-drug
increased O
approximately O
40 O
% O
with O
coadministration O
of O
atorvastatin B-drug
and O
erythromycin B-drug
, O
a O
known O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
. O

to O
contend O
with O
. O

Cysteine B-drug
was O
covalently O
linked O
to O
carbodiimide O
activated O
NaCMC B-drug_n
. O

Warfarin B-drug
: O
Meclofenamate B-drug
sodium I-drug
enhances O
the O
effect O
of O
warfarin B-drug
. O

The O
mean O
changes O
were O
observed O
to O
be O
less O
than O
1 O
second O
in O
both O
instances O
, O
however O
, O
and O
are O
unlikely O
to O
be O
clinically O
important O
. O

SUBJECTS O
: O
Twelve O
healthy O
male O
volunteers O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
. O

Angiomax B-brand
should O
be O
used O
with O
caution O
in O
patients O
with O
disease O
states O
associated O
with O
an O
increased O
risk O
of O
bleeding O
. O

The O
syndrome O
requires O
immediate O
medical O
attention O
and O
may O
include O
one O
or O
more O
of O
the O
following O
symptoms O
: O
excitement O
, O
hypomania O
, O
restlessness O
, O
loss O
of O
consciousness O
, O
confusion O
, O
disorientation O
, O
anxiety O
, O
agitation O
, O
motor O
weakness O
, O
myoclonus O
, O
tremor O
, O
hemiballismus O
, O
hyperreflexia O
, O
ataxia O
, O
dysarthria O
, O
incoordination O
, O
hyperthermia O
, O
shivering O
, O
pupillary O
dilation O
, O
diaphoresis O
, O
emesis O
, O
and O
tachycardia O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
probenecid B-drug
inhibits O
the O
renal O
excretion O
of O
cefdinir B-drug
, O
resulting O
in O
an O
approximate O
doubling O
in O
A.C. O
a O
54 O
% O
increase O
in O
peak O
cefdinir B-drug
plasma O
levels O
, O
and O
a O
50 O
% O
prolongation O
in O
the O
apparent O
elimination O
half-life O
. O

Future O
trends O
are O
also O
predicted O
. O

Coadministration O
of O
Aprepitant B-drug
with O
these O
drugs O
or O
other O
drugs O
that O
are O
known O
to O
be O
metabolized O
by O
CYP2C9 O
, O
such O
as O
phenytoin B-drug
, O
may O
result O
in O
lower O
plasma O
concentrations O
of O
these O
drugs O
. O

efavirenz B-drug
concentration O

Indinavir I-drug

Lack O
of O
an O
effect O
of O
azithromycin B-drug
on O
the O
disposition O
of O
zidovudine B-drug
and O
dideoxyinosine B-drug
in O
HIV-infected O
patients O
. O

Although O
increased O
plasma O
concentrations O
( O
AUC O
0-24 O
hrs O
) O
of O
loratadine B-drug
and/or O
descarboethoxyloratadine B-drug
were O
observed O
following O
coadministration O
of O
loratadine B-drug
with O
each O
of O
these O
drugs O
in O
normal O
volunteers O
( O
n O
= O
24 O
in O
each O
study O
) O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
loratadine B-drug
, O
as O
assessed O
by O
electrocardiographic O
parameters O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O

The O
conjugates O
so O
formed O
often O
appear O
in O
the O
urine O
as O
mercapturic O
acids O
or O
other O
thioether O
products O
. O

Agents O
that O
have O
been O
found O
, O
or O
are O
expected O
to O
have O
decreased O
plasma O
levels O
in O
the O
presence O
of O
EQUETROTM B-brand
due O
to O
induction O
of O
CYP O
enzymes O
are O
the O
following O
: O
Acetaminophen B-drug
, O
alprazolam B-drug
, O
amitriptyline B-drug
, O
bupropion B-drug
, O
buspirone B-drug
, O
citalopram B-drug
, O
clobazam B-drug
, O
clonazepam B-drug
, O
clozapine B-drug
, O
cyclosporin B-drug
, O
delavirdine B-drug
, O
desipramine B-drug
, O
diazepam B-drug
, O
dicumarol B-drug
, O
doxycycline B-drug
, O
ethosuximide B-drug
, O
felbamate B-drug
, O
felodipine B-drug
, O
glucocorticoids B-group
, O
haloperidol B-drug
, O
itraconazole B-drug
, O
lamotrigine B-drug
, O
levothyroxine B-drug
, O
lorazepam B-drug
, O
methadone B-drug
, O
midazolam B-drug
, O
mirtazapine B-drug
, O
nortriptyline B-drug
, O
olanzapine B-drug
, O
oral O
contraceptives B-group
( O
3 O
) O
, O
oxcarbazepine B-drug
, O
Phenytoin B-drug
( O
4 O
) O
, O
praziquantel B-drug
, O
protease B-group
inhibitors I-group
, O
quetiapine B-drug
, O
risperidone B-drug
, O
theophylline B-drug
, O
topiramate B-drug
, O
tiagabine B-drug
, O
tramadol B-drug
, O
triazolam B-drug
, O
valproate B-drug
, O
warfarin B-drug
( O
5 O
) O
, O
ziprasidone B-drug
, O
and O
zonisamide B-drug
. O

The O
pharmacokinetics O
of O
nelfinavir B-drug
are O
not O
altered O
to O
a O
clinically O
significant O
degree O
when O
it O
is O
administered O
with O
a O
light O
meal O
1 O
hour O
after O
VIDEX B-brand
. O

. O

Caution O
should O
be O
used O
if O
naproxen B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

It O
is O
recommended O
to O
avoid O
concurrent O
administration O
of O
ethambutol B-drug
with O
aluminum B-drug
hydroxide I-drug
containing O
antacids B-group
for O
at O
least O
4 O
hours O
following O
ethambutol B-drug
administration O
. O

*Increased O
and O
decreased O
prothrombin O
time O
responses O
have O
been O
reported O
. O

Epinephrine B-drug
should O
be O
used O
cautiously O
in O
patients O
with O
hyperthyroidism O
, O
hypertension O
and O
cardiac O
arrhythmias O
. O

Atracurium B-drug
infusion O
was O
continued O
for O
a O
third O
hour O
, O
and O
then O
hoof O
twitch O
was O
again O
allowed O
to O
recover O
spontaneously O
to O
75 O
% O
. O

Patients O
should O
report O
to O
their O
practitioners O
any O
new O
rashes O
, O
itching O
, O
mouth O
sores O
, O
or O
unusual O
taste O
while O
taking O
auranofin B-drug
. O

and O
the O
remaining O
25.9 O
% O
( O
95 O
% O
CI O
, O
+/- O
9.3 O
) O
by O
monitoring O
and O
follow-up O
of O
patients O
. O

immunosuppressant B-group
agents I-group
concentration O

MAO B-group
inhibitors I-group
should O
be O
used O
with O
caution O
in O
patients O
receiving O
hydralazine B-drug
. O

In O
vitro O
studies O
have O
shown O
CASODEX B-brand
can O
displace O
coumarin B-group
anticoagulants O
, O
such O
as O
warfarin B-drug
, O
from O
their O
protein-binding O
sites O
. O

chlorpropamide B-drug
; O

The O
benzodiazepines B-group
, O
including O
alprazolam B-drug
, O
produce O
additive O
CNS O
depressant O
effects O
when O
co-administered O
with O
other O
psychotropic B-group
medications I-group
, O
anticonvulsants B-group
, O
antihistaminics B-group
, O
ethanol B-drug
, O
and O
other O
drugs O
which O
themselves O
produce O
CNS O
depression O
. O

Digitalis B-group
glycosides I-group
enhanced O
possibility O
of O
arrhythmias O
or O
digitalis B-group
toxicity O
associated O
with O
hypokalemia O
. O

In O
the O
presence O
of O
ouabain B-drug
( O
10 O
( O
-5 O
) O
M O
) O
, O
PTX B-drug_n
( O
10 O
( O
-8 O
) O
M O
) O
failed O
to O
cause O
the O
first O
contraction O
; O

no O
other O
specific O
drug O
interaction O
studies O
were O
performed O
. O

INFORMATION O
TO O
BE O
PROVIDED O
TO O
THE O
PATIENT O
OR O
GUARDIAN O
See O
illustrated O
Information O
For O
The O
Patient O
or O
Guardian O
section O
. O

Therefore O
, O
to O
maximize O
the O
effects O
of O
fexofenadine B-drug
, O
it O
is O
recommended O
that O
ALLEGRA B-brand
should O
be O
taken O
with O
water O

Patients O
were O
intravenously O
injected O
a O
chylomicron-like O
emulsion O
doubly O
labeled O
with O
14C-cholesteryl O
oleate O
and O
3H-triolein O
at O
baseline O
and O
after O
treatments O
. O

increased O
levels O
of O
fibrinogen B-drug
and O
fibrinogen B-drug
activity O
; O

Warfarin B-drug
: O
The O
effects O
of O
warfarin B-drug
and O
NSAIDs B-group
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
users O
of O
either O
drug O
alone O
. O

A O
greater O
understanding O
of O
pain O
mechanisms O
will O
aid O
in O
elucidating O
the O
role O
of O
antihistaminics B-group
in O
analgesia O
. O

In O
vitro O
, O
propranolol B-drug
appears O
to O
be O
displaced O
from O
its O
binding O
sites O
by O
diltiazem B-drug
. O

For O
example O
, O
the O
plasma O
nitrosourea B-group
AUC O
was O
reduced O
by O
factors O
of O
1.05 O
and O
9.6 O
for O
MEC O
values O
of O
1 O
and O
2 O
micrograms O
ml-1 O
respectively O
. O

Proquin B-brand
XR I-brand
should O
be O
administered O
at O
least O
4 O
hours O
before O
or O
2 O
hours O
after O
these O
products O
. O

Rifampin B-drug
markedly O
increases O
the O
metabolic O
clearance O
of O
amprenavir B-drug
, O
and O
coadministration O
is O
contraindicated O
. O

CNS-Active O
Drugs O
Ethanol B-drug
: O
Sonata B-brand
10 O
mg O
potentiated O
the O
CNS-impairing O
effects O
of O
ethanol B-drug
0.75 O
g/kg O
on O
balance O
testing O
and O
reaction O
time O
for O
1 O
hour O
after O
ethanol B-drug
administration O
and O
on O
the O
digit O
symbol O
substitution O
test O
( O
DSST O
) O
, O
symbol O
copying O
test O
, O
and O
the O
variability O
component O
of O
the O
divided O
attention O
test O
for O
2.5 O
hours O
after O
ethanol B-drug
administration O
. O

Additionally O
, O
BREVIBLOC B-brand
should O
not O
be O
used O
to O
control O
supraventricular O
tachycardia O
in O
the O
presence O
of O
agents O
which O
are O
vasoconstrictive O
and O
inotropic O
such O
as O
dopamine B-drug
, O
epinephrine B-drug
, O
and O
norepinephrine B-drug
because O
of O
the O
danger O
of O
blocking O
cardiac O
contractility O
when O
systemic O
vascular O
resistance O
is O
high O
. O

Digoxin B-drug
: O
The O
concomitant O
administration O
of O
DynaCirc B-brand
( O
isradipine B-drug
) O
and O
digoxin B-drug
in O
a O
single-dose O
pharmacokinetic O
study O
did O
not O
affect O
renal O
, O
nonrenal O
and O
total O
body O
clearance O
of O
digoxin B-drug
. O

In O
vitro O
studies O
indicate O
that O
valdecoxib B-drug
is O
a O
moderate O
inhibitor O
of O
CYP O
2C19 O
( O
IC50 O
= O
6 O
g/mL O
or O
19 O
M O
) O
and O
2C9 O
( O
IC50 O
= O
13 O
g/mL O
or O
41 O
M O
) O
, O
and O
a O
weak O
inhibitor O
of O
CYP O
2D6 O
( O
IC50 O
= O
31 O
g/mL O
or O
100 O
M O
) O
and O
3A4 O
( O
IC50 O
= O
44 O
g/mL O
or O
141 O
M O
) O
.. O

If O
the O
drugs O
are O
used O
together O
, O
caution O
should O
be O
exercised O
because O
unexpected O
hypotension O
could O
result O
from O
beta-blocker O
inhibition O
of O
the O
sympathetic O
reflex O
response O
to O
fenoldopam B-drug
. O

Because O
cholestyramine B-drug
binds O
bile O
acids O
, O
cholestyramine B-drug
resin B-group
may O
interfere O
with O
normal O
fat O
digestion O
and O
absorption O
and O
thus O
may O
prevent O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
such O
as O
A O
, O
D O
, O
E O
, O
and O
K O
. O

. O

Chapter O
5 O
focuses O
on O
metabolic O
effects O
, O
specifically O
lipid O
metabolism O
, O
carbohydrate O
metabolism O
and O
diabetes O
, O
coagulation O
factors O
, O
and O
blood O
pressure O
. O

Therapeutic O
concentrations O
of O
digoxin B-drug
, O
warfarin B-drug
, O
ibuprofen B-drug
, O
naproxen B-drug
, O
piroxicam B-drug
, O
acetaminophen B-drug
, O
phenytoin B-drug
andtolbutamide O
did O
not O
alter O
ketorolac B-drug
tromethamine I-drug
protein O
binding O
. O

6 O
. O

[ O
Importance O
of O
pharmacogenetics O
] O
; O
Pharmacogenetics O
deals O
with O
the O
differences O
in O
effect O
of O
drugs O
caused O
by O
genetic O
variation O
. O

INSPRA B-brand
should O
not O
be O
used O
with O
drugs O
described O
as O
strong O
inhibitors O
of O
CYP3A4 O
in O
their O
labeling O
. O

* O
No O
longer O
marketed O
in O
the O
US O
. O

The O
peripheral O
vasoconstriction O
caused O
by O
high O
doses O
of O
dopamine B-drug
HCl I-drug
is O
antagonized O
by O
alpha-adrenergic B-group
blocking I-group
agents I-group
. O

Dosage O
reduction O
of O
Cerubidine B-brand
may O
be O
required O
when O
used O
concurrently O
with O
other O
myelosuppressive O
agents O
. O

In O
amiodarone-treated B-drug
patients O
who O
require O
additional O
antiarrhythmic B-drug
therapy O
, O
the O
initial O
dose O
of O
such O
agents O
should O
be O
approximately O
half O
of O
the O
usual O
recommended O
dose O
. O

Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
, O
as O
measured O
by O
protein-bound O
iodine O
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O

Drug O
Interactions O
, O
General O
: O
Although O
there O
have O
been O
no O
formal O
interaction O
studies O
, O
intravenous O
fenoldopam B-drug
has O
been O
administered O
safely O
with O
drugs O
such O
as O
digitalis B-group
and O
sublingual O
nitroglycerin B-drug
. O

The O
AUC O
of O
ciprofloxacin B-drug
was O
decreased O
an O
average O
of O
15-fold O
in O
12 O
healthy O
subjects O
given O
ciprofloxacin B-drug
and O
didanosine-placebo B-drug
tablets O
concurrently O
. O

Allopurinol B-drug
: O
The O
AUC O
of O
didanosine B-drug
was O
increased O
about O
4-fold O
when O
allopurinol B-drug
at O
300 O
mg/day O
was O
coadministered O
with O
a O
single O
200-mg O
dose O
of O
VIDEX B-brand
to O
two O
patients O
with O
renal O
impairment O
( O
CLcr=15 O
and O
18 O
mL/min O
) O
. O

ulcerans O
was O
between O
0.012 O
and O
0.025 O
mg/l O
, O
while O
corresponding O
values O
for O
rifampicin B-drug
and O
rifabutin B-drug
were O
in O
the O
range O
of O
0.1-0.8 O
mg/l O
and O
0.1-0.4 O
mg/l O
respectively O
. O

Antibiotics B-group
( O
e.g. O
, O
erythromycin B-drug
, O
trimethoprim B-drug
and O
sulfamethoxazole B-drug
, O
amoxicillin B-drug
) O
. O

If O
such O
measurements O
are O
necessary O
, O
the O
use O
of O
other O
methods O
is O
recommended O
. O

The O
following O
information O
was O
obtained O
from O
studies O
in O
normal O
volunteers O
. O

. O

Few O
systemic O
data O
have O
been O
collected O
on O
the O
metabolism O
of O
WELLBUTRIN B-brand
following O
concomitant O
administration O
with O
other O
drugs O
or O
, O
alternatively O
, O
the O
effect O
of O
concomitant O
administration O
of O
WELLBUTRIN B-brand
on O
the O
metabolism O
of O
other O
drugs O
. O

While O
the O
recognition O
of O
drug O
toxicity O
resulting O
from O
interactions O
is O
of O
importance O
to O
all O
physciains O
, O
it O
is O
especially O
so O
for O
the O
clinician O
responsible O
for O
the O
welfare O
of O
those O
in O
the O
aerospace O
environment O
. O

The O
serum O
estrogen O
concentrations O
of O
estradiol B-drug
+ O
endotoxin-treated B-drug_n
rats O
decreased O
by O
50 O
% O
, O
while O
those O
of O
the O
endotoxin-treated B-drug_n
rats O
increased O
( O
2- O
to O
5-fold O
) O
. O

however O
, O
in O
a O
study O
of O
12 O
normal O
subjects O
, O
concurrent O
administration O
of O
aspirin B-brand
decreased O
ketoprofen B-drug
protein O
binding O
and O
increased O
ketoprofen B-drug
plasma O
clearance O
from O
0.07 O
L/kg/h O
without O
aspirin B-brand
to O
0.11 O
L/kg/h O
with O
aspirin B-brand
. O

Everolimus B-drug
dose-proportionality O
and O
stability O
over O
time O
were O
assessed O
in O
the O
context O
of O
linear O
regression O
and O
ANOVA O
models O
. O

Based O
on O
in O
vitro O
studies O
in O
human O
liver O
microsomes O
, O
des-ciclesonide B-drug
appears O
to O
have O
no O
inhibitory O
or O
induction O
potential O
on O
the O
metabolism O
of O
other O
drugs O
metabolized O
by O
CYP O
450 O
enzymes O
. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O

Cssmax O
of O
the O
metabolite O
, O
ucb O
L057 O
, O
was O
approximately O
doubled O
in O
the O
presence O
of O
probenecid B-drug
while O
the O
fraction O
of O
drug O
excreted O
unchanged O
in O
the O
urine O
remained O
the O
same O
. O

Severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
azole B-group
antifungal I-group
agents I-group
and O
oral O
hypoglycemic B-group
agents I-group
. O

Corticosteroids B-group
may O
increase O
the O
clearance O
of O
chronic O
high O
dose O
aspirin B-brand
. O

adjust O
salicylate B-group
dosage O
accordingly O
if O
effect O
is O
altered O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
TCAs B-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

Chapter O
2 O
considers O
the O
mode O
of O
action O
, O
including O
ovulation O
prevention O
; O

Diuretics B-group
: O
Patients O
on O
diuretics B-group
, O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
Lotensin B-brand
. O

Because O
of O
the O
increased O
risk O
of O
adverse O
reactions O
in O
patients O
who O
have O
been O
taking O
benzodiazepines B-group
on O
a O
regular O
basis O
, O
it O
is O
particularly O
important O
that O
physicians O
query O
patients O
or O
their O
guardians O
carefully O
about O
benzodiazepine B-group
, O
alcohol B-drug
and O
sedative B-group
use O
as O
part O
of O
the O
history O
prior O
to O
any O
procedure O
in O
which O
the O
use O
of O
ROMAZICON B-brand
is O
planned O
. O

+15 O
% O
+5 O
% O
+15 O
% O
+4 O
% O

the O
doses O
of O
naloxone B-drug
required O
to O
antagonize O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
were O
more O
than O
100 O
times O
higher O
than O
those O
required O
to O
antagonize O
the O
effects O
of O
morphine B-drug
. O

Among O
aspirin B-brand
or O
NSAID B-group
users O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
events O
in O
patients O
treated O
with O
ibandronate B-drug
2.5 O
mg O
daily O
( O
28.9 O
% O
) O
was O
similar O
to O
that O
in O
placebo-treated O
patients O
( O
30.7 O
% O
) O
. O

Warfarin B-drug
: O
The O
effect O
of O
celecoxib B-drug
on O
the O
anti-coagulant O
effect O
of O
warfarin B-drug
was O
studied O
in O
a O
group O
of O
healthy O
subjects O
receiving O
daily O
doses O
of O
2-5 O
mg O
of O
warfarin B-drug
. O

4 O
. O

Increased O
anticoagulation O
effects O
due O
to O
interactions O
of O
erythromycin B-drug
with O
various O
oral O
anticoagulents O
may O
be O
more O
pronounced O
in O
the O
elderly O
. O

Colchicine B-drug
may O
increase O
sensitivity O
to O
the O
CNS B-group
depressants I-group
. O

Phenytoin B-drug
increases O
the O
clearance O
of O
busulfan B-drug
by O
15 O
% O
or O
more O
, O
possibly O
due O
to O
the O
induction O
of O
glutathione-S-transferase O
. O

In O
clinical O
trials O
, O
doxazosin B-drug
mesylate I-drug
tablets O
have O
been O
administered O
to O
patients O
on O
a O
variety O
of O
concomitant O
medications O
; O

The O
evidence O
for O
a O
role O
for O
norepinephrine O
and O
dopamine O
and O
the O
effects O
of O
antihistaminics B-group
on O
them O
are O
less O
well O
established O
. O

H2 B-group
Blockers/Proton I-group
Pump I-group
Inhibitors I-group
: O
Long-term O
suppression O
of O
gastric O
acid O
secretion O
by O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
( O
eg O
, O
famotidine B-drug
and O
omeprazole B-drug
) O
is O
likely O
to O
reduce O
dasatinib B-drug
exposure O
. O

abnormal O
vaginal O
bleeding O
; O

Inhibitors O
or O
substrates O
of O
CYP2D6 O
( O
i.e. O
, O
quinidine B-drug
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
[ O
SSRIs B-group
] O
) O
may O
increase O
the O
plasma O
concentration O
of O
doxepin B-drug
when O
administered O
concomitantly O
. O

No O
volunteer O
showed O
hormonal O
evidence O
of O
ovulation O
, O
but O
one O
volunteer O
reported O
intermenstrual O
bleeding O
during O
felbamate B-drug
treatment O
. O

Paralytic O
ileus O
may O
occur O
in O
patients O
taking O
tricyclic B-drug
antidepressants I-drug
in O
combination O
with O
anticholinergic-type B-drug
drugs O
. O

Repeat O
Treatment O
Studies O
evaluating O
the O
use O
of O
repeated O
courses O
of O
Zmax B-brand
have O
not O
been O
conducted O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O

chloral B-drug
hydrate* O
; O

Chlorpropamide B-drug
: O
Chlorpropamides B-drug
plasma O
half-life O
may O
be O
prolonged O
by O
allopurinol B-drug
, O
since O
allopurinol B-drug
and O
chlorpropamide B-drug
may O
compete O
for O
excretion O
in O
the O
renal O
tubule O
. O

This O
is O
especially O
true O
in O
patients O
who O
may O
subject O
themselves O
to O
an O
overdosage O
of O
drugs O
. O

Colchicine B-drug
para-aminosalicylic I-drug
acid I-drug
and O
heavy O
alcohol B-drug
intake O
for O
longer O
than O
2 O
weeks O
may O
produce O
malabsorption O
of O
vitamin B-drug
B12 I-drug
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
beta-adrenergic B-group
receptor I-group
blocking I-group
agents I-group
: O
Anesthetics B-group
, O
general O
: O
exaggeration O
of O
the O
hypotension O
induced O
by O
general O
anesthetics B-group
. O

It O
has O
been O
reported O
that O
Itraconazole B-drug
enhances O
the O
anticoagulant O
effect O
of O
coumarin-like B-group
drugs O
. O

Cimetidine B-drug
at O
400 O
mg O
BID O
( O
the O
usual O
prescription O
dose O
) O
co-administered O
with O
TIKOSYN B-brand
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-drug
plasma O
levels O
by O
58 O
% O
. O

. O

Integumentary O

341 O
PI O
affecting O
197 O
patients O
( O
31.5 O
% O
, O
95 O
% O
CI O
, O
+/- O
3.6 O
) O
were O
identified O
. O

Because O
bupropion B-drug
is O
extensively O
metabolized O
, O
the O
coadministration O
of O
other O
drugs O
may O
affect O
its O
clinical O
activity O
. O

Nonsteroidal B-group
Anti-Inflammatory I-group
Drugs I-group
( O
NSAIDs B-group
) O
-A O
drug O
interaction O
study O
of O
eplerenone B-drug
with O
an O
NSAID B-group
has O
not O
been O
conducted O
. O

Steroids B-group
enhance O
the O
renal O
toxicity O
of O
edetate B-drug
calcium I-drug
disodium I-drug
in O
animals O
. O
7 O
Edetate B-drug
calcium I-drug
disodium I-drug
interferes O
with O
the O
action O
of O
zinc B-drug
insulin I-drug
preparations O
by O
chelating O
the O
zinc B-drug
. O
7 O

These O
effects O
are O
usually O
reversible O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues O
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

H1 O
and O
H2 B-group
Blockers I-group
- O
Although O
not O
reported O
, O
L-histidine B-drug
, O
via O
its O
metabolism O
to O
histamine O
, O
might O
decrease B-group
the I-group
efficacy O
of O
H1 O
and O
H2 B-group
blockers I-group
. O

Serious O
toxicity O
may O
result O
if O
dextromethorphan B-drug
is O
coadministered O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOIs B-group
) O
. O

Human O
pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-drug
markedly O
inhibits O
the O
metabolism O
of O
cisapride B-drug
, O
resulting O
in O
a O
mean O
eight-fold O
increase O
in O
AUC O
of O
cisapride B-drug
. O

Growth O
of O
M O
. O

Opiate B-group
agonists I-group

Maximum O
calculated O
theophylline B-drug
clearance O
ranged O
from O
2 O
1/2 O
to O
3 O
1/2 O
times O
baseline O
. O

Interactions O
may O
also O
occur O
with O
the O
following O
: O
anti-depressants/anti-anxiety B-group
drugs I-group
, O
drugs O
used O
to O
treat O
an O
overactive O
thyroid O
, O
beta-blockers B-group
( O
e.g. O
, O
propranolol B-drug
) O
, O
sparfloxacin B-drug
, O
grepafloxacin B-drug
, O
guanethidine B-drug
, O
guanadrel B-drug
, O
metrizamide B-drug
, O
cabergoline B-drug
, O
lithium B-drug
, O
narcotic B-group
pain O
medication O
( O
e.g. O
, O
codeine B-drug
) O
, O
drugs O
used O
to O
aid O
sleep O
, O
drowsiness-causing O
antihistamines B-group
( O
e.g. O
, O
diphenhydramine B-drug
) O
, O
any O
other O
drugs O
that O
may O
make O
you O
drowsy O
. O

however O
, O
there O
was O
extensive O
concomitant O
use O
of O
NSAIDs B-group
in O
clinical O
studies O
and O
no O
differential O
effect O
was O
observed O
. O

however O
, O
at O
lower O
concentrations O
only O
zinc B-drug
demonstrated O
toxicity O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Drugs O
that O
may O
decrease O
dasatinib B-drug
plasma O
concentrations O
CYP3A4 O
Inducers O
: O
Drugs O
that O
induce O
CYP3A4 O
activity O
may O
decrease O
dasatinib B-drug
plasma O
concentrations O
. O

Valproate I-drug
** O

In O
vitro O
studies O
have O
shown O
that O
precipitation O
occurs O
when O
eye O
drops O
containing O
thimerosal B-drug_n
are O
mixed O
with O
latanoprost B-drug
. O

plasma O
levels O
of O
several O
closely O
related O
tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
methylphenidate B-drug
or O
hepatic O
enzyme O
inhibitors O
( O
e.g. O
, O
cimetidine B-drug
, O
fluoxetine B-drug
) O
and O
decreased O
by O
the O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e.g. O
, O
barbiturates B-group
, O
phenytoin B-drug
) O
, O
and O
such O
an O
effect O
may O
be O
anticipated O
with O
CMI B-drug
as O
well O
. O

Therefore O
, O
interactions O
could O
occur O
following O
concomitant O
administration O
of O
psychotropic B-group
drugs I-group
( O
e.g. O
, O
narcotics B-group
, O
analgesics B-group
, O
antiemetics B-group
, O
sedatives B-group
, O
tranquilizers B-group
) O
. O

Although O
no O
clinical O
drug-drug O
interaction O
studies O
have O
been O
conducted O
to O
date O
, O
on O
the O
basis O
of O
the O
in O
vitro O
studies O
, O
cytochrome O
p450 O
inhibitors O
and O
inducers O
are O
unlikely O
to O
affect O
the O
metabolism O
of O
clofarabine B-drug
. O

ACE B-group
inhibitors I-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
. O

Due O
to O
its O


This O
conference O
reviews O
recent O
developments O
in O
these O
areas O
, O
examines O
the O
effects O
of O
drug O
use O
in O
the O
elderly O
and O
implications O
for O
management O
, O
and O
discusses O
current O
information O
on O
how O
age O
may O
influence O
the O
response O
of O
cancer O
to O
therapy O
. O

We O
incorporate O
the O
principles O
of O
recovery O
and O
define O
positive O
and O
constructive O
alternatives O
in O
dealing O
with O
cocaine O
hunger O
. O

Although O
a O
causal O
mechanism O
and O
a O
cause-and-effect O
relationship O
have O
not O
been O
established O
, O
current O
evidence O
suggests O
that O
renal O
function O
should O
be O
monitored O
in O
patients O
on O
thiazide B-group
diuretics I-group
and O
allopurinol B-drug
even O
in O
the O
absence O
of O
renal O
failure O
, O
and O
dosage O
levels O
should O
be O
even O
more O
conservatively O
adjusted O
in O
those O
patients O
on O
such O
combined O
therapy O
if O
diminished O
renal O
function O
is O
detected.. O

These O
effects O
were O
not O
considered O
clinically O
important O
. O

Drugs O
that O
have O
been O
associated O
with O
peripheral O
neuropathy O
include O
antiretroviral B-drug
nucleoside I-drug
analogues I-drug
, O
chloramphenicol B-drug
, O
cisplatin B-drug
, O
dapsone B-drug
, O
disulfiram B-drug
, O
ethionamide B-drug
, O
glutethimide B-drug
, O
gold B-drug
, O
hydralazine B-drug
, O
iodoquinol B-drug
, O
isoniazid B-drug
, O
metronidazole B-drug
, O
nitrofurantoin B-drug
, O
phenytoin B-drug
, O
ribavirin B-drug
, O
and O
vincristine B-drug
. O

. O

Concurrent O
use O
of O
phenothiazines B-group
may O
antagonize O
the O
anorectic O
effect O
of O
diethylpropion B-drug
. O

It O
is O
extensively O
metabolized O
, O
predominantly O
by O
cytochrome O
P450 O
3A4 O
. O

There O
are O
other O
agents O
that O
may O
result O
in O
serious O
and/or O
life-threatening O
drug O
interactions O
. O

In O
another O
report O
, O
nine O
patients O
with O
breast O
cancer O
were O
reported O
to O
have O
decreased O
symptoms O
of O
methotrexate-related B-drug
toxicity O
when O
given O
supplemental O
L-glutamine B-drug
at O
a O
dose O
of O
0.5 O
gram/kilogram/day O
. O

Other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
that O
inhibit O
prostaglandin O
synthesis O
have O
been O
shown O
to O
interfere O
with O
thiazide B-group
diuretics I-group
in O
some O
studies O
and O
with O
potassium-sparing B-group
diuretics I-group
. O

Both O
groups O
of O
agents O
lower O
blood O
levels O
and O
efficacy O
of O
amphetamines B-group
. O

- O
Carmustine B-drug
( O
e.g. O
, O
BiCNU B-brand
) O
or O

The O
mechanism O
of O
these O
interactions O
has O
been O
evaluated O
in O
in O
vitro O
, O
in O
situ O
, O
and O
in O
vivo O
animal O
models O
. O

Concomitant O
use O
of O
L-phenylalanine B-drug
and O
non-selective B-group
MAO I-group
inhibitors I-group
may O
cause O
hypertension O
. O

The O
safety O
of O
such O
concomitant O
use O
with O
Activase B-brand
for O
the O
management O
of O
acute O
ischemic O
stroke O
is O
unknown O
. O

Veratrum B-group
alkaloids I-group
: O
Amphetamines B-group
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-group
alkaloids I-group
. O

Rarely O
salicylate B-group
toxicity O
may O
occur O
in O
patients O
who O
discontinue O
steroids B-group
after O
concurrent O
high-dose O
aspirin B-brand
therapy O
. O

Since O
amiodarone B-drug
is O
a O
substrate O
for O
CYP3A4 O
and O
CYP2C8 O
, O
drugs/substances O
that O
inhibit O
these O
isoenzymes O
may O
decrease O
the O
metabolism O
and O
increase O
serum O
concentration O
of O
amiodarone B-drug
. O

. O

the O
dose O
of O
Prostigmin B-brand
may O
have O
to O
be O
increased O
accordingly O
. O

Accelerated O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet O
aggregation O
time O
; O

Concomitant O
administration O
of O
probenecid B-drug
doubled O
the O
AUC O
for O
cefprozil B-drug
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
that O
induces O
CYP3A4 O
. O

Digoxin B-drug
: O
Concomitant O
administration O
of O
erythromycin B-drug
and O
digoxin B-drug
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-drug
serum O
levels O
. O

The O
effect O
of O
TORADOL B-brand
on O
plasma O
lithium B-drug
has O
not O
been O
studied O
, O
but O
cases O
of O
increased O
lithium B-drug
plasma O
levels O
during O
TORADOL B-brand
therapy O
have O
been O
reported O
. O

These O
studies O
indicate O
that O
ketoconazole B-drug
or O
erythromycin B-drug
co-administration O
enhances O
fexofenadine B-drug
gastrointestinal O
absorption O
. O

Because O
prostaglandina O
play O
an O
important O
role O
in O
hemostasis O
and O
ketoprofen B-drug
has O
an O
effect O
on O
platelet O
function O
as O
well O
, O
concurent O
therapy O
with O
ketoprofen B-drug
and O
warfarin B-drug
requires O
close O
monitoring O
of O
patients O
on O
both O
drugs O
. O

Initial O
doses O
of O
adrenergic B-group
agents I-group
, O
such O
as O
dopamine B-drug
or O
epinephrine B-drug
, O
should O
be O
reduced O
and O
titrated O
to O
achieve O
the O
desired O
response O
. O

But O
it O
is O
now O
difficult O
to O
situate O
the O
exact O
place O
of O
the O
pharmacological O
indications O
of O
magnesium B-drug
. O

In O
the O
experiments O
reported O
here O
, O
we O
examined O
the O
interactions O
between O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
and O
the O
antiestrogen B-group
4-hydroxytamoxifen B-drug_n
( O
TAM B-drug_n
) O
, O
which O
also O
induces O
apoptosis O
in O
MCF-7 O
cells O
. O

Anti-HIV B-group
protease I-group
inhibitors I-group
: O
Saquinavir/ritonavir B-drug
combination O

Diethyl B-drug_n
pyrocarbonate I-drug_n
, O
at O
pH O
7.0 O
, O
was O
used O
to O
chemically O
modify O
exposed O
histidine O
residues O
on O
toxin B-drug_n
A I-drug_n
. O

in O
vitro O
data O
on O
metabolic O
interactions O
indicate O
that O
Keppra B-brand
is O
unlikely O
to O
produce O
, O
or O
be O
subject O
to O
, O
pharmacokinetic O
interactions O
. O

Estrogen B-group
increased O
levels O
of O
corticosteroid-binding O
globulin O
, O
thereby O
increasing O
the O
bound O
( O
inactive O
) O
fraction O
; O

AMEVIVE B-brand
underwent O
trans-placental O
passage O
and O
produced O
in O
utero O
exposure O
in O
the O
developing O
monkeys O
. O

No O
special O
precautions O
appear O
to O
be O
necessary O
when O
oral O
anticoagulant O
therapy O
is O
begun O
in O
a O
patient O
already O
stabilized O
on O
maintenance O
thyroid O
replacement O
therapy O
. O

Diagnostic O
, O
treatment O
and O
aftercare O
approaches O
to O
cocaine B-drug
abuse O
. O

Antidiabetic B-group
drugs I-group
: O
( O
oral O
agents O
and O
insulin B-drug
) O
- O
dosage O
adjustment O
of O
the O
antidiabetic B-group
drug I-group
may O
be O
required O
. O

Although O
studies O
designed O
to O
examine O
drug O
interactions O
have O
not O
been O
done O
, O
it O
was O
noted O
that O
corticosteroid B-group
or O
ACTH B-drug
treatment O
of O
relapses O
for O
periods O
of O
up O
to O
28 O
days O
has O
been O
administered O
to O
patients O
( O
N=180 O
) O
receiving O
Betaseron B-brand
. O

Indinavir I-drug
and O
didanosine B-drug
formulations O
containing O
buffer O
should O
be O
administered O
at O
least O
one O
hour O
apart O
on O
an O
empty O
stomach O
. O

OBJECTIVES O
: O
To O
examine O
the O
effects O
of O
acute O
hydrocortisone B-drug
pretreatment O
on O
the O
subjective O
and O
behavioral O
effects O
of O
d-amphetamine B-drug
. O

Efavirenz B-drug
has O
been O
shown O
in O
vivo O
to O
induce O
CYP3A4 O
. O

The O
beta-blocker B-group
should O
be O
withdrawn O
first O
. O

Although O
this O
interaction O
has O
not O
been O
reported O
with O
cinoxacin B-drug
, O
caution O
should O
be O
exercised O
when O
cinoxacin B-drug
is O
given O
concomitantly O
with O
caffeine-containing B-drug
products O
. O

It O
is O
probable O
that O
dexamethasone B-drug
, O
given O
as O
antiemetic O
prophylaxis O
, O
contributed O
to O
hyperglycemia O
in O
some O
patients O
. O

[ O
Drug O
treatment O
of O
erection O
disorders O
in O
patients O
with O
cardiovascular O
disease O
] O
Erectile O
dysfunction O
is O
a O
frequent O
condition O
in O
cardiovascular O
patients O
. O

Physostigmine B-drug
briefly O
reduced O
the O
amplitude O
of O
most O
components O
, O
including O
P2 O
. O

No O
specific O
studies O
in O
humans O
have O
been O
performed O
and O
caution O
is O
recommended O
. O

Coadministered O
Concentration O
Concentration O

Co-administration O
of O
lovastatin B-drug
, O
atenolol B-drug
, O
warfarin B-drug
, O
furosemide B-drug
, O
digoxin B-drug
, O
celecoxib B-drug
, O
hydrochlorothiazide B-drug
, O
ramipril B-drug
, O
valsartan B-drug
, O
metformin B-drug
and O
amlodipine B-drug
did O
not O
result O
in O
clinically O
significant O
increases O
in O
aliskiren B-drug
exposure O
. O

During O
administration O
of O
multiple O
oral O
doses O
of O
TAMBOCOR B-brand
to O
healthy O
subjects O
stabilized O
on O
a O
maintenance O
dose O
of O
digoxin B-drug
, O
a O
13 O
% O
-19 O
% O
increase O
in O
plasma O
digoxin B-drug
levels O
occurred O
at O
six O
hours O
postdose O
. O


Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

This O
report O
describes O
a O
recently O
identified O
case O
of O
interference O
of O
acetylcysteine B-drug
with O
the O
urine O
test O
for O
ketones O
and O
demonstrates O
the O
importance O
of O
a O
thorough O
medication O
review O
in O
evaluating O
abnormal O
laboratory O
tests O
. O

Nondepolarizing B-group
Muscle I-group
Relaxants I-group
: O
In O
postmarketing O
experience O
there O
have O
been O
reports O
of O
a O
possible O
interaction O
between O
TORADOLIV/IM O
and O
nondepolarizing B-group
muscle I-group
relaxants I-group
that O
resulted O
in O
apnea O
. O

Phenytoin B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenytoin B-drug
; O

faecalis O
ATCC O
51299 O
showed O
the O
flavonoids O
alone O
significantly O
lowered O
numbers O
of O
colony O
forming O
units O
( O
CFUs O
) O
. O

Catecholamine-depleting O
drugs O
( O
eg O
, O
reserpine B-drug
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-group
agents O
. O

in O
vitro O
, O
Gleevec B-brand
inhibits O
the O
cytochrome O
P450 O
isoenzyme O
CYP2D6 O
activity O
at O
similar O
concentrations O
that O
affect O
CYP3A4 O
activity O
. O

When O
the O
STADOL B-brand
NS I-brand
was O
administered O
30 O
minutes O
after O
the O
sumatriptan B-drug
nasal O
spray O
, O
the O
AUC O
of O
butorphanol B-drug
increased O
11 O
% O
and O
Cmax O
decreased O
18 O
% O
. O

Dosage O
adjustments O
of O
BROVANA B-brand
are O
not O
necessary O
when O
the O
drug O
is O
given O
concomitantly O
with O
potent O
CYP2D6 O
inhibitors O
. O

Other O
drugs O
Drug O
interactions O
have O
been O
reported O
with O
concomitant O
administration O
of O
erythromycin B-drug
and O
other O
medications O
, O
including O
cyclosporine B-drug
, O
hexobarbital B-drug
, O
carbamazepine B-drug
, O
alfentanil B-drug
, O
disopyramide B-drug
, O
phenytoin B-drug
, O
bromocriptine B-drug
, O
valproate B-drug
, O
astemizole B-drug
, O
and O
lovastatin B-drug
. O

Drug/Laboratory O
Test O
Interferences O
: O
Dicumarol B-drug
and O
indanedione B-group
anticoagulants I-group
, O
including O
anisindione B-drug
, O
or O
their O
metabolites O
may O
color O
alkaline O
urine O
red-orange O
, O
which O
may O
interfere O
with O
spectrophotometrically O
determined O
urinary O
laboratory O
tests O
. O

. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Antacids B-group
: O
In O
a O
single O
dose O
study O
( O
n=6 O
) O
, O
ingestion O
of O
an O
antacid B-group
containing O
1.7-gram O
of O
magnesium B-drug
hydroxide I-drug
with O
500-mg O
of O
mefenamic B-drug
acid I-drug
increased O
the O
Cmax O
and O
AUC O
of O
mefenamic B-drug
acid I-drug
by O
125 O
% O
and O
36 O
% O
, O
respectively O
. O
A O
number O
of O
compounds O
are O
inhibitors O
of O
CYP2C9 O
including O
fluconazole B-drug
, O
lovastatin B-drug
and O
trimethoprim B-drug
. O

When O
ouabain B-drug
was O
applied O
to O
the O
muscle O
in O
the O
presence O
of O
phentolamine B-drug
, O
both O
first O
and O
second O
contractile O
responses O
to O
PTX B-drug_n
were O
abolished O
. O

Studies O
in O
rats O
have O
shown O
that O
neomycin B-drug
administration O
attenuates O
certain O
types O
of O
adrenocortical B-group
steroid I-group
dependent O
hypertension O
, O
including O
ACTH B-drug
hypertension O
. O

If O
these O
agents O
are O
to O
be O
administered O
concurrently O
, O
cyclosporine B-drug
concentrations O
should O
be O
monitored O
, O
especially O
when O
diltiazem B-drug
therapy O
is O
initiated O
, O
adjusted O
, O
or O
discontinued O
. O

We O
conclude O
that O
ADL B-drug
8-2698 I-drug
prevents O
morphine-induced B-drug
increases O
in O
gastrointestinal O
transit O
time O
by O
means O
of O
selective O
peripheral O
opioid O
anitagonism O
without O
affecting O
central O
opioid O
analgesia O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
when O
taking O
delavirdine B-drug
400 O
mg O
three O
times O
a O
day O
. O

As O
with O
other O
drugs O
that O
block O
angiotensin O
II O
or O
its O
effects O
, O
concomitant O
use O
of O
potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
salt O
substitutes O
containing O
potassium O
may O
lead O
to O
increases O
in O
serum O
potassium O
. O

In O
healthy O
subjects O
, O
no O
significant O
drug-drug O
interaction O
was O
observed O
when O
Norpace B-brand
was O
coadministered O
with O
either O
propranolol B-drug
or O
diazepam B-drug
. O

Concomitant O
administration O
of O
alosetron B-drug
and O
fluvoxamine B-drug
is O
contraindicated O
. O

Interaction O
of O
GABITRIL B-brand
with O
Highly O
Protein O
Bound O
Drugs O
: O
In O
vitro O
data O
showed O
that O
tiagabine B-drug
is O
96 O
% O
bound O
to O
human O
plasma O
protein O
and O
therefore O
has O
the O
potential O
to O
interact O
with O
other O
highly O
protein O
bound O
compounds O
. O

Alternate O
treatments O
lacking O
CYP3A4 O
inducing O
activity O
should O
be O
considered O
. O

In O
many O
of O
these O
cases O
, O
buprenorphine B-drug
was O
misused O
by O
self-injection O
of O
crushed O
SUBUTEX B-brand
tablets O
. O

Sildenafil B-drug
citrate I-drug
- O
Theoretically O
, O
L-arginine B-drug
supplements O
taken O
concomitantly O
with O
sildenafil B-drug
citrate I-drug
, O
may O
potentiate O
the O
effects O
of O
the O
drug O
. O

. O

Agents O
Having O
Vasodilator O
Activity O
: O
Data O
on O
the O
effect O
of O
concomitant O
use O
of O
other O
vasodilators B-group
in O
patients O
receiving O
captopril B-drug
for O
heart O
failure O
are O
not O
available O
; O

The O
coadministration O
of O
a O
potent O
CYP3A4 O
enzyme O
inducer O
, O
although O
not O
posing O
a O
safety O
concern O
, O
thus O
could O
lead O
to O
ineffectiveness O
of O
zaleplon B-drug
. O

Lithium B-drug
serum O
concentrations O
should O
be O
monitored O
closely O
when O
initiating O
or O
changing O
therapy O
with O
BEXTRA B-brand
in O
patients O
receiving O
lithium B-drug
. O

Five O
, O
10 O
, O
20 O
, O
or O
50 O
mg/kg O
of O
ketamine B-drug
alone O
or O
20 O
, O
50 O
, O
or O
100 O
mg/kg O
of O
metabolite O
I O
alone O
produced O
less O
than O
10 O
minutes O
of O
hypnosis O
. O

Fluoxetine B-drug

Theophylline B-drug
alone O
caused O
identical O
insulin O
and O
glucagon O
release O
in O
diabetics O
and O
normals O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
be O
used O
. O

However O
, O
neither O
phenobarbital B-drug
nor O
diazepam B-drug
appears O
to O
affect O
Dantrium B-brand
metabolism O
. O

Bile B-group
acid I-group
binding I-group
resins I-group
may O
also O
interfere O
with O
the O
absorption O
of O
oral O
phosphate B-drug
supplements O
and O
hydrocortisone B-drug
. O

Cyclosporine B-drug
: O
Because O
cyclosporine B-drug
can O
produce O
nephrotoxicity O
with O
decreases O
in O
creatinine O
clearance O
and O
rises O
in O
serum O
creatinine O
, O
and O
because O
renal O
excretion O
is O
the O
primary O
elimination O
route O
of O
fibrate B-group
drugs I-group
including O
TRICOR B-brand
, O
there O
is O
a O
risk O
that O
an O
interaction O
will O
lead O
to O
deterioration O
. O

- O
Antithyroid B-group
agents I-group
( O
medicine O
for O
overactive O
thyroid O
) O
or O

In O
the O
digitalized O
patient O
, O
slow O
alterations O
in O
serum O
levels O
after O
oral O
administration O
appeared O
well O
correlated O
with O
, O
at O
least O
, O
the O
negative O
chronotropic O
effects O
of O
the O
drug O
. O

Potential O
for O
Other O
Drugs O
to O
Affect O
ABILIFY B-brand
Aripiprazole I-brand
is O
not O
a O
substrate O
of O
CYP1A1 O
, O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
or O
CYP2E1 O
enzymes O
. O

Coadministration O
of O
oral O
contraceptives B-group
, O
diazepam B-drug
, O
phenytoin B-drug
, O
or O
quinidine B-drug
did O
not O
seem O
to O
change O
the O
pharmacokinetic O
profile O
of O
esomeprazole B-drug
. O

DRUG/LABORATORY O
TEST O
INTERACTIONS O
1 O
. O

In O
several O
well-controlled O
studies O
, O
guanfacine B-drug
was O
administered O
together O
with O
diuretics B-group
with O
no O
drug O
interactions O
reported O
. O

Spermine B-drug
( O
0.5-2 O
mM O
) O
promoted O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
in O
a O
cell-free O
system O
derived O
from O
rat O
liver O
. O

Ethinyl B-drug
estradiol I-drug
and O
Norethindrone B-drug

Due O
to O
the O
potential O
for O
additive O
effects O
, O
caution O
and O
careful O
titration O
are O
warranted O
in O
patients O
receiving O
diltiazem B-drug
hydrochloride I-drug
concomitantly O
with O
other O
agents O
known O
to O
affect O
cardiac O
contractility O
and/or O
conduction O
. O

laryngeal O
edema O

Since O
Zarontin B-brand
( O
ethosuximide B-drug
) O
may O
interact O
with O
concurrently O
administered O
antiepileptic B-group
drugs I-group
, O
periodic O
serum O
level O
determinations O
of O
these O
drugs O
may O
be O
necessary O
( O
eg O
, O
ethosuximide B-drug
may O
elevate O
phenytoin B-drug
serum O
levels O
and O
valproic B-drug
acid I-drug
has O
been O
reported O
to O
both O
increase O
and O
decrease O
ethosuximide B-drug
levels O
) O
. O

Interactions O
with O
Mixed B-group
Agonist/Antagonist I-group
Opioid I-group
Analgesics I-group
: O
Agonist/antagonist B-group
analgesics I-group
( O
eg O
, O
pentazocine B-drug
, O
nalbuphine B-drug
, O
butorphanol B-drug
, O
dezocine B-drug
and O
buprenorphine B-drug
) O
should O
NOT O
be O
administered O
to O
a O
patient O
who O
has O
received O
or O
is O
receiving O
a O
course O
of O
therapy O
with O
a O
pure B-group
agonist I-group
opioid I-group
analgesic I-group
such O
as O
Levo-Dromoran B-brand
. O

Amphotericin B-drug
B I-drug
or O
Corticosteroids B-group
or O
Corticotropin B-drug
( O
ACTH B-drug
) O

If O
oral O
anticoagulants B-group
are O
also O
being O
given O
, O
compensatory O
increases O
in O
clotting O
factor O
synthesis O
are O
impaired O
. O

Because O
efficient O
labeling O
can O
be O
achieved O
with O
0.1 O
% O
biocytin O
with O
whole-cell O
recording O
, O
higher O
concentrations O
are O
contraindicated O
. O

Nevertheless O
, O
the O
possibility O
of O
additive O
negative O
inotropic O
effects O
of O
beta B-group
blockers I-group
and O
flecainide B-drug
should O
be O
recognized O
. O

Caution O
should O
be O
taken O
when O
ENABLEX B-brand
is O
used O
concomitantly O
with O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
which O
have O
a O
narrow O
therapeutic O
window O
, O
such O
as O
flecainide B-drug
, O
thioridazine B-drug
and O
tricyclic B-group
antidepressants I-group
( O
see O
CLINICAL O
PHARMACOLOGY O
) O
. O

These O
results O
show O
that O
lung B-group
surfactant I-group
has O
the O
potential O
of O
enhancing O
the O
rate O
and O
extent O
of O
dissolution O
of O
drugs O
administered O
to O
the O
lung O
. O

Inhibition O
of O
renal O
lithium B-drug
clearance O
leading O
to O
increases O
in O
plasma O
lithium B-drug
concentrations O
has O
also O
been O
reported O
. O

Effects O
of O
low O
temperatures O
on O
microtubules O
in O
the O
non-myelinated O
axons O
of O
post-ganglionic O
sympathetic O
nerves O
. O

However O
, O
LDL-C O
reduction O
was O
greater O
when O
atorvastatin B-drug
and O
colestipol B-drug
were O
coadministered O
than O
when O
either O
drug O
was O
given O
alone O
. O

therefore O
, O
VIRACEPT B-brand
should O
not O
be O
administered O
concurrently O
with O
terfenadine B-drug
because O
of O
the O
potential O
for O
serious O
and/or O
life-threatening O
cardiac O
arrhythmias O
. O

Results O
with O
warfarin B-drug
wshow O
no O
evidence O
of O
interaction O
with O
either O
single O
or O
repeated O
doses O
of O
Trileptal B-brand
. O

The O
magnitude O
of O
interaction O
with O
multiple O
doses O
of O
erythromycin B-drug
is O
unknown O
. O

In O
general O
, O
most O
patients O
treated O
with O
dirithromycin B-drug
who O
are O
receiving O
concomitant O
theophylline B-drug
therapy O
may O
not O
require O
empiric O
adjustment O
of O
theophylline B-drug
dosage O
or O
monitoring O
of O
theophylline B-drug
plasma O
concentrations O
. O

and O
glutamate B-drug
( O
15 O
mg/kg O
e.w O
. O
) O

Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-group
agents I-group
such O
as O
NIMBEX B-brand
include O
certain O
antibiotics B-group
( O
e. O
g. O
, O
aminoglycosides B-group
, O
tetracyclines B-group
, O
bacitracin B-drug
, O
polymyxins B-group
, O
lincomycin B-drug
, O
clindamycin B-drug
, O
colistin B-drug
, O
and O
sodium B-drug
colistemethate I-drug
) O
, O
magnesium B-group
salts O
, O
lithium B-drug
, O
local O
anesthetics B-group
, O
procainamide B-drug
, O
and O
quinidine B-drug
. O

diseases O
of O
the O
liver O
, O
gallbladder O
, O
and O
bowel O
; O

In O
in O
vivo O
studies O
, O
10- O
to O
30-mg/day O
doses O
of O
aripiprazole B-drug
had O
no O
significant O
effect O
on O
metabolism O
by O
CYP2D6 O
( O
dextromethorphan B-drug
) O
, O
CYP2C9 O
( O
warfarin B-drug
) O
, O
CYP2C19 O
( O
omeprazole B-drug
, O
warfarin B-drug
) O
, O
and O
CYP3A4 O
( O
dextromethorphan B-drug
) O
substrates O
. O

Lapatinib B-drug
did O
not O
significantly O
inhibit O
the O
following O
enzymes O
in O
human O
liver O
microsomes O
: O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
and O
CYP2D6 O
or O
UGT O
enzymes O
in O
vitro O
, O
however O
, O
the O
clinical O
significance O
is O
unknown O
. O

On O
the O
other O
hand O
, O
the O
enhanced O
secretion O
of O
colonic O
fluid O
by O
dmPGE2 B-drug_n
, O
given O
intraluminally O
, O
was O
only O
half O
of O
that O
in O
control O
rats O
, O
whereas O
the O
colonic O
transit-enhancing O
effect O
of O
dmPGE2 B-drug_n
in O
cecectomized O
rats O
was O
more O
pronounced O
than O
in O
control O
rats O
at O
15 O
but O
not O
at O
30 O
min O
after O
its O
administration O
. O

Increases O
in O
INR O
and O
prothrombin O
time O
may O
lead O
to O
abnormal O
bleeding O
and O
even O
death O
. O

A O
5-mg O
Vardenafil B-drug
dose O
should O
not O
be O
exceeded O
when O
used O
in O
combination O
with O
200 O
mg O
once O
daily O
ketoconazole B-drug
. O

Fluvoxamine B-drug
increased O
mean O
alosetron B-drug
plasma O
concentrations O
( O
AUC O
) O
approximately O
6-fold O
and O
prolonged O
the O
half-life O
by O
approximately O
3-fold O
. O

[ O
Stimulation O
by O
cerulein B-drug_n
-- O
an O
analog O
of O
the O
octapeptide O
cholecystokinin O
-- O
of O
3H-spiroperidol B-drug_n
binding O
after O
the O
long-term O
administration O
of O
neuroleptics B-group
] O
It O
has O
been O
established O
in O
experiments O
on O
white O
male O
rats O
that O
prolonged O
administration O
( O
twice O
a O
day O
for O
14 O
days O
) O
of O
haloperidol B-drug
( O
0.25 O
mg/kg O
) O
and O
pyreneperone B-drug_n
( O
0.25 O
mg/kg O
) O
resulted O
in O
the O
reduced O
interaction O
between O
3H-spiroperidol B-drug_n
and O
low O
affinity O
binding O
sites O
for O
apomorphine B-drug
in O
subcortical O
structures O
, O
whereas O
3H-spiroperidol B-drug_n
binding O
with O
high O
affinity O
binding O
sites O
for O
apomorphine B-drug
increased O
both O
in O
the O
frontal O
cortex O
and O
subcortical O
structures O
of O
the O
forebrain O
. O

Pulmonary O
granulomata O
, O
subacute O
hepatitis O
and O
other O
lesions O
resulting O
from O
intravenous O
drug O
use O
were O
common O
findings O
at O
autopsy O
. O

Blunting O
of O
the O
antihypertensive O
effect O
of O
beta-adrenoceptor B-group
blocking I-group
agents I-group
by O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
has O
been O
reported O
. O

Therefore O
, O
when O
heparin B-drug
sodium I-drug
is O
given O
with O
dicumarol B-drug
or O
warfarin B-drug
sodium I-drug
, O
a O
period O
of O
at O
least O
5 O
hours O
after O
the O
last O
intravenous O
dose O
or O
24 O
hours O
after O
the O
last O
subcutaneous O
dose O
should O
elapse O
before O
blood O
is O
drawn O
if O
a O
valid O
prothrombin O
time O
is O
to O
be O
obtained O
. O

The O
concurrent O
use O
of O
TORADOL B-brand
with O
muscle B-group
relaxants I-group
has O
not O
been O
formally O
studied O
. O

When O
increases O
in O
the O
dose O
of O
INDOCIN B-brand
are O
made O
, O
they O
should O
be O
made O
carefully O
and O
in O
small O
increments O
. O

In O
some O
patients O
, O
a O
disulfiram-like B-drug
reaction O
may O
be O
produced O
by O
the O
ingestion O
of O
alcohol B-drug
. O

+12 O
% O
+19 O
% O
-11 O
% O
-3 O
% O

Because O
both O
of O
these O
drugs O
have O
negative O
inotropic O
properties O
and O
the O
effects O
of O
coadministration O
with O
TAMBOCOR B-brand
are O
unknown O
, O
neither O
disopyramide B-drug
nor O
verapamil B-drug
should O
be O
administered O
concurrently O
with O
TAMBOCOR B-brand
unless O
, O
in O
the O
judgment O
of O
the O
physician O
, O
the O
benefits O
of O
this O
combination O
outweigh O
the O
risks O
. O

The O
20 O
% O
v/v O
solution O
of O
alcohol B-drug
was O
prepared O
in O
water O
from O
a O
stock O
solution O
of O
95 O
% O
ethanol B-drug
. O

The O
clinical O
significance O
of O
this O
interaction O
in O
preterm O
neonates O
is O
not O
known O
. O

Retrospective O
analysis O
of O
side O
effects O
in O
clinical O
trials O
showed O
that O
poor O
2D6 O
metabolizers O
had O
a O
higher O
rate O
of O
dizziness O
during O
up-titration O
, O
presumably O
resulting O
from O
vasodilating O
effects O
of O
the O
higher O
concentrations O
of O
the O
a-blocking O
R O
( O
+ O
) O
enantiomer O
. O

asthma O
drugs O
and O
antipsychotics B-group
. O

bone O
marrow O
hypoplasia O

( O
20 O
mg O
QD O
) O

Coadministration O
of O
entecavir B-drug
with O
lamivudine B-drug
, O
adefovir B-drug
dipivoxil I-drug
, O
or O
tenofovir B-drug
disoproxil I-drug
fumarate I-drug
did O
not O
result O
in O
significant O
drug O
interactions O
. O

Because O
of O
the O
possible O
additive O
effects O
of O
drugs O
that O
may O
depress O
the O
nervous O
system O
, O
ethanol B-drug
or O
triazolam B-drug
should O
be O
used O
cautiously O
in O
combination O
with O
tiagabine B-drug
. O

Aminoglutethimide B-drug
: O
Aminoglutethimide B-drug
may O
diminish O
adrenal O
suppression O
by O
corticosteroids B-group
. O

Atropine B-drug
, O
either O
alone O
or O
in O
combination O
with O
alcohol B-drug
, O
produced O
approximately O
the O
same O
degree O
of O
enhancement O
of O
component O
P2 O
. O

Animals O
studies O
on O
the O
various O
dual-memory O
theories O
have O
been O
carried O
out O
mainly O
on O
the O
basis O
of O
hippocampal O
system O
function O
. O

Sertraline B-drug

Potential O
Drug O
Interactions O
Dofetilide B-drug
is O
eliminated O
in O
the O
kidney O
by O
cationic O
secretion O
. O

was O
evaluated O
as O
a O
possible O
explanation O
for O
the O
association O
of O
deep-seated O
infection O
with O
this O
organism O
and O
abuse O
of O
these O
drugs O
. O

When O
Vardenafil B-drug
dosing O
was O
separated O
from O
terazosin B-drug
10 O
mg O
by O
6 O
hours O
, O
7 O
of O
28 O
subjects O
who O
received O
20 O
mg O
of O
Vardenafil B-drug
experienced O
a O
decrease O
in O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

However O
, O
reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
. O

The O
neurochemical O
and O
functional O
consequences O
following O
MPTP B-drug_n
administration O
to O
the O
rat O
were O
evaluated O
and O
compared O
to O
similar O
effects O
following O
methamphetamine B-drug
administration O
. O

Caffeine B-drug
administered O
concurrently O
with O
ketoprofen B-drug
reduced O
the O
urine O
volume O
in O
4 O
healthy O
volunteers O
. O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side-effects O
in O
patients O
on O
concomitant O
theophylline-quinolone B-drug
therapy O
. O

Non-steroidal B-group
anti-inflammatory I-group
drugs I-group
( O
but O
not O
aspirin B-brand
) O
: O
These O
drugs O
in O
combination O
with O
very O
high O
doses O
of O
quinolones B-group
have O
been O
shown O
to O
provoke O
convulsions O
in O
pre-clinical O
studies O
. O

In O
vitro O
human O
liver O
microsome O
studies O
and O
an O
in O
vivo O
metabolic O
probe O
study O
demonstrated O
that O
alosetron B-drug
did O
not O
inhibit O
CYP O
enzymes O
2D6 O
, O
3A4 O
, O
2C9 O
, O
or O
2C19 O
. O

In O
contrast O
to O
its O
enantiomer O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
failed O
to O
increase O
FI O
responding O
significantly O
in O
either O
species O
; O

The O
extent O
to O
which O
SSRI-TCAinteractions B-group
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

Thus O
, O
in O
addition O
to O
its O
proposed O
specific O
information O
processing O
functions O
( O
i.e. O
, O
relational O
) O
, O
the O
hippocampus O
would O
play O
a O
role O
in O
addressing O
information O
to O
the O
brain O
memory O
system O
that O
, O
in O
a O
given O
situation O
, O
has O
the O
best O
adaptive O
value O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

When O
INDOCIN B-brand
is O
given O
to O
patients O
receiving O
probenecid B-drug
, O
the O
plasma O
levels O
of O
indomethacin B-drug
are O
likely O
to O
be O
increased O
. O

Antihistamines B-group
: O
Amphetamines B-group
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-group
. O

Mixing O
of O
Insulins B-group

There O
was O
not O
a O
significant O
difference O
( O
p O
> O
0.05 O
) O
in O
AUC O
( O
48.59 O
+/- O
8.52 O
vs. O
49.9 O
+/- O
9.93 O
) O
, O
Cmax O
( O
7.73 O
+/- O
2.6 O
vs. O
6.6 O
+/- O
2.0 O
) O
, O
and O
tmax O
( O
1.1 O
+/- O
0.6 O
vs. O
1.6 O
+/- O
1.1 O
) O
for O
levofloxacin B-drug
versus O
levofloxacin/oxycodone B-drug
regimens O
. O


The O
thiazolidinediones B-group
( O
rosiglitazone B-drug
and O
pioglitazone B-drug
) O
, O
a O
new O
class O
of O
oral O
antidiabetic B-group
agents I-group
, O
are O
" O
insulin O
sensitizers O
" O

Although O
specific O
drug O
interaction O
studies O
in O
HIV-1 O
seropositive O
subjects O
have O
not O
been O
conducted O
for O
the O
classes O
of O
drugs O
listed O
in O
Table O
4 O
, O
additional O
clinical O
monitoring O
may O
be O
warranted O
when O
co-administering O
these O
drugs O
. O

In O
this O
situation O
, O
special O
patient O
care O
and O
observation O
are O
appropriate O
. O

Labetalol B-drug
HCl I-drug
has O
also O
been O
reported O
to O
produce O
a O
false O
positive O
test O
for O
amphetamine B-drug
when O
screening O
urine O
for O
the O
presence O
of O
drugs O
using O
the O
commercially O
available O
assay O
methods O
Toxi-Lab O
A O
( O
thin-layer O
chromatographic O
assay O
) O
and O
Emit-d.a.u O
. O
( O
radioenzymatic O
assay O
) O
. O

Therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
when O
EULEXIN B-brand
Capsules O
are O
administered O
concomitantly O
with O
warfarin B-drug
. O

The O
data O
inTables O
1 O
and O
3 O
are O
based O
on O
the O
results O
of O
drug O
interaction O
studies O
conducted O
in O
HIV-1 O
seropositive O
subjects O
unless O
otherwise O
indicated O
. O

Phenobarbital B-drug
toxicity O
has O
been O
reported O
to O
have O
occurred O
in O
a O
patient O
on O
chronic O
phenobarbital B-drug
treatment O
following O
the O
initiation O
of O
diclofenac B-drug
therapy O
. O

Hydrochlorothiazide B-drug
: O
A O
study O
in O
normal O
healthy O
volunteers O
has O
shown O
that O
concomitant O
administration O
of O
DynaCirc B-brand
( O
isradipine B-drug
) O
and O
hydrochlorothiazide B-drug
does O
not O
result O
in O
altered O
pharmacoktnetics O
of O
either O
drug O
. O

CANCIDAS B-brand
has O
no O
effect O
on O
the O
pharmacokinetics O
of O
itraconazole B-drug
, O
amphotericin B-drug
B I-drug
, O
or O
the O
active O
metabolite O
of O
mycophenolate O
. O

Antidepressants B-group
( O
tricyclic B-group
) O
, O
atropine B-drug
or O
other O
anticholinergic B-group
agents I-group
, O
or O
digitalis B-group
glycosides I-group
: O
concurrent O
use O
with O
arbutamine B-drug
may O
produce O
additive O
inotropic O
and/or O
chronotropic O
effects O
. O

This O
interaction O
appears O
to O
be O
clinically O
significant O
. O

Since O
bacteriostatic O
drugs O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillin B-drug
, O
it O
is O
advisable O
to O
avoid O
giving O
tetracyclines B-group
in O
conjunction O
with O
penicillin B-group
. O

The O
mean O
reduction O
of O
growth O
caused O
by O
the O
drugs O
was O
1,000-fold O
greater O
for O
49 O
Pseudomonas O
strains O
from O
normal O
subjects O
than O
for O
32 O
strains O
from O
drug O
addicts O
( O
4.2 O
vs. O
1.3 O
logs O
of O
reduction O
at O
2 O
hr O
, O
P O
less O
than O
.0005 O
) O
. O

Diazepam B-drug
: O
Diazepam B-drug
( O
Valium B-brand
) O
is O
a O
CYP O
3A4 O
and O
CYP O
2C19 O
substrate O
. O

INCREASED O
PHENYTOIN B-drug
LEVELS O
SHOULD O
BE O
TREATED O
WITH O
APPROPRIATE O
DOSAGE O
ADJUSTMENT O
. O


Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O

Drugs O
Metabolized O
by O
Cytochrome O
P4502D6 O
- O
In O
vitro O
studies O
did O
not O
reveal O
an O
inhibitory O
effect O
of O
escitalopram B-drug
on O
CYP2D6 O
. O

The O
concomitant O
administration O
of O
macrolide B-group
antibiotics I-group
and O
other O
hydroxymethylglutaryl B-group
coenzyme I-group
A I-group
( I-group
HMG-CoA I-group
) I-group
reductase I-group
inhibitors I-group
have O
resulted O
in O
previous O
reports O
of O
rhabdomyolysis O
. O

The O
pressor O
effects O
of O
ERGOMAR B-brand
and O
other O
vasoconstrictor B-group
drugs I-group
can O
combine O
to O
cause O
dangerous O
hypertension O
. O

A O
causal O
relationship O
between O
these O
events O
and O
the O
concomitant O
administration O
of O
lithium B-drug
and O
HALDOL B-brand
has O
not O
been O
established O
; O

Aortic O
rings O
with O
intact O
endothelium O
from O
the O
high-dose O
( O
4 O
mg/kg/day O
) O
estradiol B-drug
group O
were O
supersensitive O
to O
noradrenaline B-drug
compared O
to O
the O
vehicle O
or O
low-dose O
( O
10 O
microg/kg/day O
) O
estradiol O
groups O
( O
pD2 O
values O
= O
7.86+/-0.09 O
, O
7.30+/-0.11 O
and O
7.35+/-0.04 O
, O
respectively O
) O
. O

The O
concurrent O
use O
of O
two O
or O
more O
drugs O
with O
anticholinergic O
activity O
-- O
such O
as O
an O
antipsychotic B-group
drug I-group
( O
eg O
, O
chlorpromazine B-drug
) O
, O
an O
antiparkinsonian B-group
drug I-group
( O
eg O
, O
trihexyphenidyl B-drug
) O
, O
and/or O
a O
tricyclic B-group
antidepressant I-group
( O
eg O
, O
amitriptyline B-drug
) O
-- O
commonly O
results O
in O
excessive O
anticholinergic O
effects O
, O
including O
dry O
mouth O
and O
associated O
dental O
complications O
, O
blurred O
vision O
, O
and O
, O
in O
patients O
exposed O
to O
high O
temperature O
and O
humidity O
, O
hyperpyrexia O
. O

Although O
the O
pattern O
of O
use O
for O
oral O
allopurinol B-drug
includes O
longer O
term O
therapy O
, O
particularly O
for O
gout O
and O
renal O
calculi O
, O
the O
experience O
gained O
may O
be O
relevant O
. O

Similarly O
, O
in O
the O
1-year O
monthly O
comparison O
study O
, O
aspirin B-brand
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
were O
taken O
by O
39 O
% O
of O
the O
1602 O
patients O
. O

These O
factors O
, O
in O
concert O
with O
age-dependent O
alterations O
in O
immune O
function O
and O
host O
defense O
, O
may O
help O
to O
explain O
the O
increased O
risk O
of O
malignant O
disease O
in O
aged O
persons O
. O

Although O
there O
was O
a O
slight O
reduction O
in O
blood O
sugar O
concentrations O
during O
concomitant O
administration O
of O
flurbiprofen B-drug
and O
hypoglycemic B-group
agents I-group
, O
there O
were O
no O
signs O
or O
symptoms O
of O
hypoglycemia O
. O

Survival O
of O
miracidia O
was O
reduced O
by O
increasing O
metal O
concentration O
except O
at O
concentrations O
of O
10 O
microg/l O
for O
single O
metal O
toxicity O
where O
survival O
was O
increased O
above O
the O
control O
. O

- O
Antihypertensives B-group
: O
Bumetanide B-drug
may O
potentiate O
the O
effect O
of O
various O
antihypertensive B-group
drugs I-group
, O
necessitating O
a O
reduction O
in O
the O
dosage O
of O
these O
drugs O
. O

acetaminophen/theophylline B-drug
, O
lidocaine/quinidine B-drug
, O
phenobarbital/acetaminophen B-drug
, O
phenobarbital/valproic B-drug
acid I-drug
, O
quinidine/lidocaine B-drug
, O
theophylline/acetaminophen B-drug
, O
and O
valproic B-drug
acid/phenobarbital I-drug
. O

- O
Increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O

Enalapril B-drug
IV O
has O
been O
used O
concomitantly O
with O
digitalis B-group
without O
evidence O
of O
clinically O
significant O
adverse O
reactions O
. O

Administration O
of O
CMI B-drug
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
of O
phenobarbital B-drug
, O
if O
given O
concomitantly O
. O

eosinophilia O

Presumably O
, O
phenytoin B-drug
acts O
as O
a O
stimulator O
of O
coumarin B-group
metabolism O
and O
has O
been O
reported O
to O
cause O
decreased O
serum O
levels O
of O
the O
coumarin B-group
anticoagulants I-group
and O
increased O
prothrombin-proconvertin O
concentrations O
. O

Johns O
Wort O
) O
may O
significantly O
reduce O
exposure O
to O
Gleevec B-brand
. O

( O
Read O
circulars O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O
) O

The O
results O
indicate O
that O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
readily O
penetrates O
both O
the O
mucosal O
and O
serosal O
surfaces O
of O
the O
epithelial O
membrane O
. O

Clarithromycin B-drug

Aspirin/Nonsteroidal B-brand
Antiinflammatory B-group
Drugs O
( O
NSAIDs B-group
) O

thyroid B-drug
medication O
; O

Pharmacokinetic O
interaction O
studies O
with O
cetirizine B-drug
in O
adults O
were O
conducted O
with O
pseudoephedrine B-drug
, O
antipyrine B-drug
, O
ketoconazole B-drug
, O
erythromycin B-drug
and O
azithromycin B-drug
. O

When O
given O
i.p. O
, O
dmPGE2 B-drug_n
( O
0.3 O
mg/kg O
) O
induced O
a O
watery O
stool O
in O
cecectomized O
and O
control O
rats O
with O
the O
same O
efficacy O
, O
although O
these O
effects O
were O
short-lasting O
as O
compared O
to O
oral O
administration O
. O

Prior O
administration O
of O
4-methylpyrazole B-drug
( O
90 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
was O
shown O
to O
prevent O
the O
conversion O
of O
1,3-difluoro-2-propanol B-drug_n
( O
100 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
in O
vivo O
and O
to O
eliminate O
the O
fluoride O
and O
citrate O
elevations O
seen O
in O
1,3-difluoro-2-propanol-intoxicated B-drug_n
animals O
. O

Therefore O
, O
use O
of O
lamivudine B-drug
in O
combination O
with O
zalcitabine B-drug
is O
not O
recommended O

Echistatin B-drug_n
alone O
had O
no O
effect O
on O
tyrosine O
phosphorylation O
in O
T24 O
cells O
, O
but O
dose-dependently O
inhibits O
the O
effects O
of O
contortrostatin B-drug_n
when O
both O
are O
added O
simultaneously O
. O

Patients O
taking O
diuretics B-group
are O
at O
a O
greater O
risk O
of O
developing O
renal O
failure O
secondary O
to O
a O
decrease O
in O
renal O
blood O
flow O
caused O
by O
prostaglandin O
inhibition O
. O

Heparin B-drug
, O
other O
anticoagulants B-group
, O
thrombolytics B-group
, O
and O
anti B-group
platelet I-group
agents I-group
are O
associated O
with O
an O
increase O
in O
bleeding O
. O

- O
Ethotoin B-drug
( O
e.g. O
, O
Peganone B-brand
) O
or O

Further O
, O
they O
bring O
into O
question O
the O
utility O
of O
using O
PCP B-drug_n
combination O
procedures O
in O
animals O
to O
screen O
for O
antipsychotic O
potential O
. O

chloral B-drug
hydrate* O
; O


clofibrate B-drug
; O

Caution O
should O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
neurotoxic O
and/ O
or O
nephrotoxic O
drugs O
because O
of O
possible O
enhancement O
of O
the O
nephrotoxicity O
and/or O
ototoxicity O
of O
neomycin B-drug
. O

Lithium B-drug
: O
Ibuprofen B-drug
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
in O
a O
study O
of O
eleven O
normal O
volunteers O
. O

fenoprofen B-drug
; O

The O
genotypes O
of O
CYP2C9 B-drug
and O
2C19 O
, O
the O
enzymes O
responsible O
for O
phenytoin O
metabolism O
, O
were O
homozygous O
for O
the O
wild-type O
alleles O
( O
CYP2C9*1/*1 B-drug
and O
2C19*1/ O
*1 O
) O
. O

Gabapentin B-drug
had O
no O
effect O
on O
naproxen B-drug
pharmacokinetic O
parameters O
. O

Coadministration O
with O
valdecoxib B-drug
( O
40 O
mg O
BID O
for O
7 O
days O
) O
resulted O
in O
a O
significant O
increase O
in O
dextromethorphan B-drug
plasma O
levels O
suggesting O
that O
, O
at O
these O
doses O
, O
valdecoxib B-drug
is O
a O
weak O
inhibitor O
of O
2D6 O
. O

- O
Lofexidine B-drug
may O
enhance O
the O
effects O
of O
anti-hypertensive B-group
drug I-group
therapy O

Drug O
Interactions O
: O
The O
central O
anticholinergic B-group
syndrome O
can O
occur O
when O
anticholinergic O
agents O
such O
as O
AKINETON B-brand
are O
administered O
concomitantly O
with O
drugs O
that O
have O
secondary O
anticholinergic O
actions O
, O
e.g. O
, O
certain O
narcotic B-group
analgesics I-group
such O
as O
meperidine B-drug
, O
the O
phenothiazines B-group
and O
other O
antipsychotics B-group
, O
tricyclic B-group
antidepressants I-group
, O
certain O
antiarrhythmics B-group
such O
as O
the O
quinidine B-drug
salts O
, O
and O
antihistamines B-group
. O

unlike O
ibogaine B-drug_n
, O
18-MC B-drug_n
does O
not O
affect O
responding O
for O
a O
nondrug O
reinforcer O
( O
water O
) O
. O

INOmax B-brand
has O
been O
administered O
with O
tolazoline B-drug
, O
dopamine B-drug
, O
dobutamine B-drug
, O
steroids B-group
, O
surfactant B-drug
, O
and O
high-frequency O
ventilation O
. O

The O
clinical O
significance O
of O
this O
interaction O
with O
doxepin B-drug
has O
not O
been O
systematically O
evaluated O
. O

in O
vitro O
, O
Gleevec B-brand
inhibits O
acetaminophen O
O-glucuronidation O
( O
Ki O
value O
of O
58.5 O
M O
) O
at O
therapeutic O
levels O
. O

There O
were O
several O
factors O
that O
could O
have O
increased O
his O
risk O
for O
developing O
rhabdomyolysis O
, O
including O
chronic O
renal O
failure O
. O

These O
small O
changes O
are O
not O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
necessary O
. O

and O
diuretics B-group
, O
such O
as O
furosemide B-drug
. O

D O
. O

NovoSeven B-brand
should O
not O
be O
mixed O
with O
infusion O
solutions O
until O
clinical O
data O
are O
available O
to O
direct O
this O
use O
. O

Therefore O
, O
the O
combined O
use O
of O
lovastatin B-drug
with O
fibrates B-group
should O
generally O
be O
avoided O
. O

Gentamycin B-drug
reduced O
twitch O
strength O
from O
40 O
+/- O
1 O
% O
( O
mean O
+/- O
sem O
) O
to O
29 O
+/- O
4 O
% O
within O
7.0 O
+/- O
1.5 O
min O
( O
P O
= O
0.02 O
) O
. O

Therefore O
, O
co-administration O
of O
bupropion B-drug
with O
drugs O
that O
are O
metabolized O
by O
CYP2D6 O
isoenzyme O
including O
certain O
antidepressants B-group
( O
e.g. O
, O
nortriptyline B-drug
, O
imipramine B-drug
, O
desipramine B-drug
, O
paroxetine B-drug
, O
fluoxetine B-drug
, O
sertraline B-drug
) O
, O
antipsychotics B-group
( O
e.g. O
, O
haloperidol B-drug
, O
risperidone B-drug
, O
thioridazine B-drug
) O
, O
beta-blockers B-group
( O
e.g. O
, O
metoprolol B-drug
) O
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
) O
, O
should O
be O
approached O
with O
caution O
and O
should O
be O
initiated O
at O
the O
lower O
end O
of O
the O
dose O
range O
of O
the O
concomitant O
medication O
. O

The O
plasma O
and O
tumour O
total O
nitrosourea B-group
peak O
concentrations O
were O
reduced O
by O
1.5 O
and O
1.7 O
fold O
respectively O
. O

The O
clinical O
significance O
of O
this O
reduction O
is O
not O
known O
, O
hence O
zalcitabine B-drug
is O
not O
recommended O
to O
be O
ingested O
simultaneously O
with O
magnesium/aluminum-containing B-drug
antacids B-group
. O

phophatase O

Therefore O
, O
hormonal B-group
contraceptives I-group
, O
including O
oral O
, O
injectable O
, O
transdermal O
, O
and O
implantable O
forms O
, O
may O
not O
be O
reliable O
when O
TRACLEER B-brand
is O
co-administered O
. O

Calcium B-drug
Supplements O
: O
Uncontrolled O
intake O
of O
additional O
calcium-containing B-drug
preparations O
should O
be O
avoided O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes-Tape O
) O
be O
used O
. O

Corticosteroids B-group
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-group
D I-group
analogues I-group
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-group
, O
which O
inhibit O
calcium O
absorption O
. O

Infusion O
requirements O
of O
NIMBEX B-brand
in O
patients O
administered O
succinylcholine B-drug
prior O
to O
infusions O
of O
NIMBEX B-brand
were O
comparable O
to O
or O
slightly O
greater O
than O
when O
succinylcholine B-drug
was O
not O
administered O
. O

The O
potentiation O
resulted O
from O
a O
CNS O
pharmacodynamic O
interaction O
; O

Since O
fondaparinux B-drug
sodium I-drug
does O
not O
bind O
significantly O
to O
plasma O
proteins O
other O
than O
ATIII O
, O
no O
drug O
interactions O
by O
protein-binding O
displacement O
are O
expected O
. O

Adjustment O
of O
dosage O
of O
oral O
anticoagulants B-group
may O
be O
required O
. O

However O
, O
because O
bleeding O
has O
been O
reported O
when O
ibuprofen B-drug
and O
other O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
have O
been O
administered O
to O
patients O
on O
coumarin-type B-group
anticoagulants I-group
, O
the O
physician O
should O
be O
cautious O
when O
administering O
ibuprofen B-drug
to O
patients O
on O
anticoagulants B-group
. O

In O
vitro O
data O
suggest O
that O
itraconazole B-drug
also O
markedly O
inhibits O
the O
biotransformation O
system O
mainly O
responsible O
for O
the O
metabolism O
of O
cisapride B-drug
; O

fecal O
excretion O
, O
too O
, O
was O
increased O
by O
supplementary O
iron B-drug
; O

No O
statistically O
significant O
differences O
between O
treatment O
groups O
were O
observed O
for O
any O
of O
the O
calculated O
digoxin B-drug
pharmacokinetic O
parameters O
. O

Medications O
can O
cause O
in O
vivo O
effects O
when O
the O
concentration O
or O
activity O
of O
the O
analyte O
is O
altered O
before O
the O
analysis O
and O
therefore O
the O
assay O
result O
is O
true O
and O
accurate O
. O

tadalafil I-drug
concentration O

Neomycin B-drug
has O
no O
effect O
on O
the O
blood O
pressure O
or O
metabolic O
responses O
to O
ACTH B-group
in O
sheep O
. O

The O
concurrent O
use O
of O
anticholinergics B-group
with O
hydrocodone B-drug
may O
produce O
paralytic O
ileus O
. O

Modification O
of O
surface O
histidine O
residues O
abolishes O
the O
cytotoxic O
activity O
of O
Clostridium B-drug_n
difficile I-drug_n
toxin I-drug_n
A I-drug_n
. O

Induction O
of O
apoptosis O
in O
breast O
cancer O
cells O
in O
response O
to O
vitamin B-group
D I-group
and O
antiestrogens B-group
. O

These O
six O
volunteers O
received O
terfenadine B-drug
alone O
( O
60 O
mg O
twice O
daily O
) O
for O
8 O
days O
, O
followed O
by O
terfenadine B-drug
in O
combination O
with O
dirithromycin B-drug
( O
500 O
mg O
once O
daily O
) O
for O
10 O
days O
. O

However O
, O
there O
are O
limited O
in O
vivo O
data O
suggesting O
a O
modest O
CYP2D6 O
inhibitory O
effect O
for O
escitalopram B-drug
, O
i.e. O
, O
coadministration O
of O
escitalopram B-drug
( O
20 O
mg/day O
for O
21 O
days O
) O
with O
the O
tricyclic B-group
antidepressant I-group
desipramine B-drug
( O
single O
dose O
of O
50 O
mg O
) O
, O
a O
substrate O
for O
CYP2D6 O
, O
resulted O
in O
a O
40 O
% O
increase O
in O
Cmax O
and O
a O
100 O
% O
increase O
in O
AUC O
of O
desipramine B-drug
. O

Ketoconazole/Itraconazole B-drug
, O
Macrolides B-group
, O
Including O
Erythromycin B-drug

Transient O
and O
minor O
adverse O
events O
occurred O
with O
similar O
frequency O
on O
placebo O
and O
rofecoxib B-drug
treatments O
, O
and O
no O
treatment-related O
pattern O
was O
apparent O
. O

The O
following O
drug O
interactions O
were O
observed O
in O
some O
patients O
undergoing O
treatment O
with O
oral O
allopurinol B-drug
. O

. O

INDOCIN B-brand
and O
potassium-sparing B-group
diuretics I-group
each O
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O

Potassium-sparing B-group
diuretics I-group
( O
spironolactone B-drug
, O
amiloride B-drug
, O
triamterene B-drug
, O
and O
others O
) O
or O
potassium B-drug
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O

Therefore O
, O
erlotinib B-drug
exposure O
may O
be O
increased O
in O
patients O
with O
hepatic O
dysfunction O
. O

alone O
. O

Pregnancy O
Pregnancy O
Category O
D O
: O
. O

Nevirapine B-drug
is O
known O
to O
be O
an O
inducer O
of O
these O
enzymes O
. O

Therefore O
, O
in O
patients O
taking O
insulin B-drug
or O
oral O
hypoglycemics B-group
, O
regular O
monitoring O
of O
blood O
glucose O
is O
recommended O
. O

It O
is O
recommended O
that O
in O
patients O
taking O
anticoagulants B-group
, O
prothrombin O
time O
be O
determined O
before O
starting O
lovastatin B-drug
and O
frequently O
enough O
during O
early O
therapy O
to O
insure O
that O
no O
significant O
alteration O
of O
prothrombin O
time O
occurs O
. O

Similarly O
, O
there O
is O
currently O
little O
adequate O
evidence O
on O
either O
the O
presence O
or O
the O
absence O
of O
serious O
adverse O
reactions O
to O
such O
doses O
of O
ascorbic B-drug
acid I-drug
, O
although O
many O
such O
reactions O
have O
been O
hypothesized O
. O

These O
agents O
include O
medications O
such O
as O
: O
anticoagulants B-group
, O
platelet B-group
inhibitors I-group
including O
acetylsalicylic B-drug
acid I-drug
, O
sali-cylates O
, O
NSAIDs B-group
( O
including O
ketorolac B-drug
tromethamine I-drug
) O
, O
dipyridamole B-drug
, O
or O
sulfinpyrazone B-drug
. O

Diminished O
urinary O
excretion O
of O
norfloxacin B-drug
has O
been O
reported O
during O
the O
concomitant O
administration O
of O
probenecid B-drug
and O
norfloxacin B-drug
. O

Retention O
was O
calculated O
by O
the O
balance O
technique O
and O
by O
the O
comparative O
slaughter O
technique O
. O

St. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O

Either O
single O
( O
170 O
mg/kg O
) O
or O
repeated O
( O
75 O
mg/kg O
per O
day O
for O
5 O
days O
) O
oral O
administration O
of O
cypermethrin B-drug
was O
found O
to O
produce O
significant O
oxidative O
stress O
in O
cerebral O
and O
hepatic O
tissues O
of O
rats O
, O
as O
was O
evident O
by O
the O
elevation O
of O
the O
level O
of O
thiobarbituric O
acid O
reactive O
substances O
( O
TBARS O
) O
in O
both O
tissues O
, O
either O
4 O
or O
24 O
h O
after O
treatment O
. O

The O
use O
of O
REGRANEX B-brand
Gel O
with O
other O
topical O
drugs O
has O
not O
been O
studied O
. O

Histidine O
modification O
had O
no O
effect O
on O
the O
glucosyl O
transferase O
enzyme O
activity O
of O
toxin B-drug_n
A I-drug_n
. O

Hypotension O
, O
AV O
conduction O
disturbances O
, O
and O
left O
ventricular O
failure O
have O
been O
reported O
in O
some O
patients O
receiving O
beta-adrenergic B-group
blocking I-group
agents I-group
when O
an O
oral O
calcium B-group
antagonist I-group
was O
added O
to O
the O
treatment O
regimen O
. O

When O
a O
diuretic B-group
is O
added O
to O
the O
therapy O
of O
a O
patient O
receiving O
PRINIVIL B-brand
, O
an O
additional O
antihypertensive O
effect O
is O
usually O
observed O
. O

METHODS O
. O

These O
recommendations O
are O
based O
on O
either O
drug O
interaction O
studies O
or O
predicted O
interactions O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
events O
or O
loss O
of O
efficacy O
. O

free O
T4 O
concentration O
is O
unaltered O
: O
impaired O
glucose O
tolerance O
; O

The O
inhibition O
of O
CYP-2C19 O
by O
OXC B-drug
and O
MHD B-drug_n
, O
however O
, O
is O
clinically O
relevant O
. O

anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
- O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
diphenidol B-drug
; O

Lopinavir/Ritonavir B-drug

Other O
factors O
may O
increase O
the O
risk O
of O
this O
drug O
interaction O
, O
including O
the O
administration O
of O
other O
medications O
that O
are O
associated O
with O
myopathy O
, O
underlying O
renal O
insufficiency O
, O
and O
administration O
of O
high O
doses O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Other O
Drug O
Interactions O
Oral O
Contraceptives B-group
Keppra B-brand
( O
500 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
an O
oral O
contraceptive B-group
containing O
0.03 O
mg O
ethinyl B-drug
estradiol I-drug
and O
0.15 O
mg O
levonorgestrel B-drug
, O
or O
of O
the O
luteinizing O
hormone O
and O
progesterone O
levels O
, O
indicating O
that O
impairment O
of O
contraceptive O
efficacy O
is O
unlikely O
. O

Amitriptyline B-drug
: O
Concurrent O
administration O
of O
25 O
mg O
or O
100 O
mg O
cinacalcet B-drug
with O
50 O
mg O
amitriptyline B-drug
increased O
amitriptyline B-drug
exposure O
and O
nortriptyline B-drug_n
( O
active O
metabolite O
) O
exposure O
by O
approximately O
20 O
% O
in O
CYP2D6 O
extensive O
metabolizers O
. O

When O
patients O
being O
treated O
with O
labetalol B-drug
have O
a O
positive O
urine O
test O
for O
amphetamine B-drug
using O
these O
techniques O
confirmation O
should O
be O
made O
by O
using O
more O
specific O
methods O
such O
as O
a O
gas O
chromatographic-mass O
spectrometer O
technique O
. O

Cyclosporine B-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
inhibit O
the O
metabolism O
of O
cyclosporine B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
; O

Since O
indomethacin B-drug
and O
potassium-sparing B-group
diuretics I-group
, O
including O
MIDAMOR B-brand
, O
may O
each O
be O
associated O
with O
increased O
serum O
potassium O
levels O
, O
the O
potential O
effects O
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O

Some O
preliminary O
data O
suggest O
that O
calcium B-group
blockers I-group
also O
increase O
generation O
of O
vasodilator O
and O
platelet O
antiaggregant O
prostacyclin O
, O
which O
could O
contribute O
to O
decrease O
in O
platelet O
function O
. O

Hypotension O
Patients O
on O
Diuretic B-group
Therapy O
: O
Patients O
on O
diuretics B-group
and O
especially O
those O
in O
whom O
diuretic B-group
therapy O
was O
recently O
instituted O
, O
as O
well O
as O
those O
on O
severe O
dietary O
salt O
restriction O
or O
dialysis O
, O
may O
occasionally O
experience O
a O
precipitous O
reduction O
of O
blood O
pressure O
usually O
within O
the O
first O
hour O
after O
receiving O
the O
initial O
dose O
of O
captopril B-drug
. O

Theophylline B-drug
: O
Ethinyl B-drug
estradiol I-drug
may O
inhibit O
the O
metabolism O
of O
theophylline B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
. O

by O
the O
nonlinear O
kinetic O
characteristics O
for O
verapamil B-drug
and O
diltiazem B-drug
( O
and O
probably O
for O
nifedipine B-drug
, O
as O
well O
) O
and O
the O
derivative O
implications O
for O
decreased O
dosing O
frequency O
requirements O
; O

In O
eight O
HIV-infected O
patients O
, O
the O
steady-state O
AUC O
of O
ciprofloxacin B-drug
was O
decreased O
an O
average O
of O
26 O
% O
( O
95 O
% O
CI O
= O
14 O
% O
, O
37 O
% O
) O
when O
ciprofloxacin B-drug
was O
administered O
2 O
hours O
prior O
to O
a O
marketed O
chewable/dispersible O
tablet O
formulation O
of O
VIDEX B-brand
. O

Coadministration O
of O
gly-buride O
and O
metformin B-drug
did O
not O
result O
in O
any O
changes O
in O
either O
metformin B-drug
pharmacokinetics O
or O
pharmaco-dynamics O
. O

Patients O
who O
begin O
taking O
diclofenac B-drug
or O
who O
increase O
their O
diclofenac B-drug
dose O
or O
any O
other O
NSAID B-group
while O
taking O
digoxin B-drug
, O
methotrexate B-drug
, O
or O
cyclosporine B-drug
may O
develop O
toxicity O
characteristics O
for O
these O
drugs O
. O

Mercaptopurine/Azathioprine B-drug
: O
Allopurinol B-drug
inhibits O
the O
enzymatic O
oxidation O
of O
mercaptopurine B-drug
and O
azathioprine B-drug
to O
6-thiouric B-drug
acid I-drug
. O

There O
was O
a O
small O
increase O
in O
plasma O
concentrations O
of O
capecitabine B-drug
and O
one O
metabolite O
( O
5-DFCR B-drug_n
) O
; O

Concomitant O
oral O
administration O
of O
ketoconazole B-drug
( O
a O
known O
inhibitor O
of O
CYP3A4 O
activity O
in O
the O
liver O
and O
in O
the O
intestinal O
mucosa O
) O
caused O
an O
eight-fold O
increase O
of O
the O
systemic O
exposure O
to O
oral O
budesonide B-drug
. O

Probenecid B-drug
or O
Cimetidine B-drug
: O
Concomitant O
administration O
of O
probenecid B-drug
or O
cimetidine B-drug
decreases O
the O
elimination O
of O
zalcitabine B-drug
, O
most O
likely O
by O
inhibition O
of O
renal O
tubular O
secretion O
of O
zalcitabine B-drug
. O

There O
is O
no O
information O
on O
the O
effect O
of O
other O
highly O
plasma O
protein O
bound O
drugs O
on O
doxazosin B-drug
binding O
. O

sickle O
cell O
disease O
; O

Buprenorphine B-drug
is O
metabolized O
to O
norbuprenorphine B-drug_n
by O
cytochrome O
CYP O
3A4 O
. O

Patients O
receiving O
other O
narcotic B-group
analgesics I-group
, O
antipsychotics B-group
, O
antianxiety B-group
agents I-group
, O
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
concomitantly O
with O
hydrocodone B-drug
and O
acetaminophen B-drug
tablets O
may O
exhibit O
an O
additive O
CNS O
depression O
. O

Depending O
on O
the O
traction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O


Isoproterenol B-drug
alone O
at O
a O
dose O
of O
2.7 O
mg/kg/day O
( O
approximately O
7 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
increased O
both O
resorptions O
and O
malformations O
. O

This O
could O
facilitate O
the O
action O
of O
fatty O
acids O
and O
enable O
cells O
to O
increase O
their O
capacity O
for O
triacylglycerol O
synthesis O
to O
match O
an O
increased O
availability O
of O
fatty O
acids O
. O

Formal O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ORENCIA B-brand
. O

Benzylpenicillin B-drug
, O
ampicillin B-drug
, O
oxacillin B-drug
, O
chlortetracycline B-drug
, O
doxycycline B-drug
, O
cephalothin B-drug
, O
erythromycin B-drug
, O
and O
sulfamethoxazole B-drug
have O
no O
influence O
in O
vitro O
on O
the O
protein O
binding O
of O
diclofenac B-drug
in O
human O
serum O
. O

Cyclosporine B-drug
, O
hexobarbital B-drug
and O
phenytoin B-drug
concentrations O
. O

Anticholinergic B-group
agents I-group
: O
Although O
ipratropium B-drug
bromide I-drug
is O
minimally O
absorbed O
into O
the O
systemic O
circulation O
, O
there O
is O
some O
potential O
for O
an O
additive O
interaction O
with O
concomitantly O
used O
anticholinergic B-group
medications I-group
. O

Preliminary O
animal O
and O
human O
studies O
have O
shown O
that O
small O
quantities O
of O
systemically O
administered O
leucovorin B-drug
enter O
the O
CSF O
primarily O
as O
5-methyltetrahydro-folate O
and O
, O
in O
humans O
, O
remain O
1 O
to O
3 O
orders O
of O
magnitude O
lower O
than O
the O
usual O
methotrexate B-drug
concentrations O
following O
intrathecal O
administration O
. O

THE O
POTENTIATING O
ACTION O
OF O
HYDROXYZINE B-drug
MUST O
BE O
CONSIDERED O
WHEN O
THE O
DRUG O
IS O
USED O
IN O
CONJUNCTION O
WITH O
CENTRAL B-group
NERVOUS I-group
SYSTEM I-group
DEPRESSANTS I-group
SUCH O
AS O
NARCOTICS B-group
, O
NON-NARCOTIC B-group
ANALGESICS I-group
AND O
BARBITURATES B-group
. O

Cholestyramine B-drug
increases O
enterohepatic O
elimination O
of O
amiodarone B-drug
and O
may O
reduce O
its O
serum O
levels O
and O
t1/2 B-drug
. O

Patients O
receiving O
these O
drugs O
in O
combination O
with O
zalcitabine B-drug
should O
be O
monitored O
for O
signs O
of O
toxicity O
and O
the O
dose O
of O
zalcitabine B-drug
reduced O
if O
warranted O
. O

. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium B-drug
excretion O
in O
urine O
. O

The O
drugs O
may O
, O
however O
, O
be O
administered O
alternately O
provided O
a O
proper O
interval O
has O
elapsed O
between O
doses O
. O

Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-drug
and O
cisapride B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O


. O

The O
plasma O
concentration O
of O
CMI B-drug
has O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
haloperidol B-drug
; O

In O
vitro O
studies O
have O
shown O
that O
naproxen B-drug
anion O
, O
because O
of O
its O
affinity O
for O
protein O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
which O
are O
also O
albumin-bound O
. O

Caution O
should O
be O
exercised O
when O
these O
2 O
agents O
are O
coadministered O
. O

In O
the O
case O
of O
digoxin B-drug
, O
serum O
levels O
should O
be O
monitored O
. O

Ranitidine B-drug
150 O
mg O
twice O
daily O
did O
not O
interact O
significantly O
with O
nisoldipine B-drug
( O
AUC O
was O
decreased O
by O
15-20 O
% O
) O
. O

Therefore O
, O
in O
patients O
taking O
VIOXX B-brand
, O
antiplatelet O
therapies O
should O
not O
be O
discontinued O
and O
should O
be O
considered O
in O
patients O
with O
an O
indication O
for O
cardiovascular O
prophylaxis O
. O

Co-administration O
of O
bosentan B-drug
decreased O
the O
plasma O
concentrations O
of O
cyclosporine B-drug
A I-drug
( O
a O
CYP3A4 O
substrate O
) O
by O
approximately O
50 O
% O
. O

Diuretics B-group
: O
Diclofenac B-drug
and O
other O
NSAIDs B-group
can O
inhibit O
the O
activity O
of O
diuretics B-group
. O

Clinical O
experience O
with O
concomitant O
administration O
of O
bosentan B-drug
and O
warfarin B-drug
in O
patients O
with O
pulmonary O
arterial O
hypertension O
did O
not O
show O
clinically O
relevant O
changes O
in O
INR O
or O
warfarin B-drug
dose O
( O
baseline O
vs. O
end O
of O
the O
clinical O
studies O
) O
, O
and O
the O
need O
to O
change O
the O
warfarin B-drug
dose O
during O
the O
trials O
due O
to O
changes O
in O
INR O
or O
due O
to O
adverse O
events O
was O
similar O
among O
bosentan- B-drug
and O
placebo-treated O
patients O
. O

This O
included O
post O
myocardial O
infarction O
patients O
who O
were O
receiving O
intravenous O
or O
transdermal O
nitroglycerin B-drug
. O

Potentiation O
of O
the O
hypotensive O
effects O
of O
nitrates B-group
for O
patients O
with O
ischemic O
heart O
disease O
has O
not O
been O
evaluated O
, O
and O
concomitant O
use O
of O
Vardenafil B-drug
and O
nitrates B-group
is O
contraindicated O
. O

sulindac B-drug
; O

. O

No O
differences O
in O
safety O
or O
efficacy O
were O
observed O
between O
older O
and O
younger O
patients O
, O
but O
there O
were O
not O
sufficient O
data O
to O
exclude O
important O
differences O
. O

Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
levels O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
as O
measured O
by O
protein-bound O
iodine B-drug
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O

Bosentan B-drug
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
oral O
hypoglycemic B-group
agents I-group
that O
are O
predominantly O
metabolized O
by O
CYP2C9 O
or O
CYP3A4 O
. O

2 O
. O

In O
vitro O
data O
suggest O
that O
itraconazole B-drug
, O
when O
compared O
to O
ketoconazole B-drug
, O
has O
a O
less O
pronounced O
effect O
on O
the O
biotransformation O
system O
responsible O
for O
the O
metabolism O
of O
astemizole B-drug
. O

These O
data O
suggest O
the O
modified O
histidine O
residues O
on O
toxin B-drug_n
A I-drug_n
are O
critical O
to O
its O
cytotoxic O
activity O
. O

Misonidazole B-drug_n
has O
a O
complex O
effect O
on O
oral O
CCNU B-drug
pharmacokinetics O
. O

Free O
T4 O
and O
free O
T3 O
concentrations O
are O
unaltered O
. O

Alcohol B-drug
: O
It O
should O
be O
borne O
in O
mind O
that O
alcohol B-drug
ingestion O
may O
increase O
the O
danger O
inherent O
in O
any O
intentional O
or O
unintentional O
SINEQUAN B-brand
overdosage O
. O

A O
similar O
effect O
would O
be O
expected O
with O
eszopiclone B-drug
. O

Plasma O
concentrations O
decreased O
by O
SUSTIVA B-brand
; O

The O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
cimetidine B-drug
on O
hepatic O
cytochrome O
P-450 O
, O
the O
enzyme O
system O
probably O
responsible O
for O
the O
first-pass O
metabolism O
of O
nifedipine B-drug
. O

No O
formal O
drug-interaction O
studies O
have O
been O
performed O
, O
and O
a O
clinically O
significant O
interaction O
with O
other O
medications O
used O
in O
the O
treatment O
of O
hypoxic O
respiratory O
failure O
can O
not O
be O
excluded O
based O
on O
the O
available O
data O
. O

unreliable O
prothrombin O
time O
determinations O
; O

Since O
etodolac B-drug
has O
a O
well-defined O
pharmacokinetic-pharmacodynamic O
relationship O
, O
measurement O
of O
pharmacokinetic O
parameters O
is O
clinically O
relevant O
. O

Core O
temperature O
was O
decreased O
in O
rats O
in O
a O
dose-dependent O
manner O
when O
ethanol B-drug
was O
administered O
to O
rats O
treated O
with O
disulfiram B-drug
8 O
hours O
before O
the O
ethanol B-drug
challenge O
. O

Other O
drug O
interactions O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid O
products O
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

When O
you O
are O
using O
idoxuridine B-drug
, O
it O
is O
especially O
important O
that O
your O
health O
care O
professional O
know O
if O
you O
are O
using O
the O
following O
: O
Eye O
product O
containing O
boric B-drug
acid I-drug
. O

Rifabutin B-drug
did O
not O
significantly O
affect O
amprenavir B-drug
's O
pharmacokinetics O
. O

an O
oral O
200 O
mg O
dose O
achieves O
a O
highest O
level O
of O
approximately O
5 O
uM O
in O
people O
) O
; O

These O
drugs O
should O
not O
be O
given O
concomitantly O
. O

The O
mechanisms O
of O
metal O
toxicity O
to O
miracidia O
are O
briefly O
discussed O
. O

Dolasetron B-drug
does O
not O
influence O
anesthesia O
recovery O
time O
in O
patients O
. O

Co-administration O
of O
TIKOSYN B-brand
with O
verapamil B-drug
resulted O
in O
increases O
in O
dofetilide B-drug
peak O
plasma O
levels O
of O
42 O
% O
, O
although O
overall O
exposure O
to O
dofetilide B-drug
was O
not O
significantly O
increased O
. O

Theophylline B-drug
decreased O
the O
binding O
of O
acetaminophen B-drug
by O
a O
net O
change O
of O
6.8 O
% O
( O
percentage O
increase O
in O
FDF O
, O
8.8 O
% O
) O
at O
277.5 O
micromol/L O
; O

This O
small O
decrease O
in O
excretion O
of O
gabapentin B-drug
by O
cimetidine B-drug
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O

The O
average O
infusion O
rate O
requirement O
may O
be O
decreased O
by O
as O
much O
as O
30 O
% O
to O
40 O
% O
. O

This O
report O
describes O
two O
cases O
in O
which O
theophylline B-drug
clearance O
accelerated O
markedly O
with O
concomitant O
phenytoin B-drug
administration O
. O

Minimum O
inhibitory O
concentrations O
( O
MICs O
) O
and O
viable O
counts O
were O
determined O
in O
Iso-sensitest O
broth O
using O
a O
microtitre O
method O
. O

Consequently O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
REVIA B-brand
and O
other O
drugs O
is O
required O
. O

Sinus O
bradycardia O
has O
been O
reported O
with O
oral O
amiodarone B-drug
in O
combination O
with O
lidocaine B-drug
( O
CYP3A4 B-drug
substrate O
) O
given O
for O
local O
anesthesia B-drug
. O

Need O
for O
more O
inhalations O
than O
usual O
of O
short-acting B-group
, I-group
inhaled I-group
beta2-agonists I-group
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
. O

Cimetidine B-drug
at O
doses O
of O
100 O
mg O
BID O
( O
OTC O
dose O
) O
resulted O
in O
a O
13 O
% O
increase O
in O
dofetilide B-drug
plasma O
levels O
( O
500 O
mcg O
single O
dose O
) O
. O

Blood O
levels O
of O
hydrodolasetron B-drug_n
increased O
24 O
% O
when O
dolasetron B-drug
was O
coadministered O
with O
cimetidine B-drug
( O
nonselective O
inhibitor O
of O
cytochrome O
P-450 O
) O
for O
7 O
days O
, O
and O
decreased O
28 O
% O
with O
coadministration O
of O
rifampin B-drug
( O
potent O
inducer O
of O
cytochrome O
P-450 O
) O
for O
7 O
days O
. O

Rifabutin B-drug
, O
another O
rifamycin B-drug
, O
is O
structurally O
similar O
to O
rifampin B-drug
and O
may O
possibly O
have O
some O
of O
the O
same O
drug O
interactions O
as O
rifampin B-drug
. O

Binding O
to O
plasma O
proteins O
is O
reduced O
by O
warfarin B-drug
and O
clotibrate O
and O
increased O
by O
tolbutamide B-drug
. O

( O
600 O
mg O
Q12h O
) O

Cisapride B-drug
is O
metabolized O
mainly O
via O
the O
cytochrome O
P450 O
3A4 O
enzyme O
. O

The O
clinical O
significance O
of O
this O
increased O
bioavailability O
and O
whether O
similar O
increases O
will O
occur O
in O
patients O
given O
oral O
H2-antagonists B-group
is O
unknown O
; O

The O
clinical O
significance O
of O
this O
interaction O
is O
not O
known O
; O

Literature O
reports O
indicate O
that O
coadministration O
of O
indomethacin B-drug
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-drug
in O
some O
patients O
by O
inhibiting O
prostaglandin O
synthesis O
. O

Drug O
regimens O
in O
patients O
with O
cardiovascular O
disease O
are O
frequently O
complex O
and O
can O
be O
significantly O
affected O
by O
alterations O
in O
renal O
function O
. O

SUBUTEX B-brand
and O
SUBOXONE B-brand
should O
be O
prescribed O
with O
caution O
to O
patients O
on O
benzodiazepines B-group
or O
other O
drugs O
that O
act O
on O
the O
central O
nervous O
system O
, O
regardless O
of O
whether O
these O
drugs O
are O
taken O
on O
the O
advice O
of O
a O
physician O
or O
are O
taken O
as O
drugs O
of O
abuse O
. O

The O
effect O
of O
digoxin B-drug
on O
Exjade B-brand
pharmacokinetics O
has O
not O
been O
studied O
. O

The O
antimicrobial O
combinations O
of O
GL B-drug_n
with O
four O
antibiotics B-group
resulted O
in O
additive O
effect O
in O
most O
instances O
, O
synergism O
in O
two O
instances O
, O
and O
antagonism O
in O
two O
instances O
. O

The O
pharmacokinetics O
of O
a O
1-mg O
dose O
of O
butorphanol B-drug
administered O
as O
STADOL B-brand
NS I-brand
were O
not O
affected O
by O
the O
coadministration O
of O
cimetidine B-drug
( O
300 O
mg O
QID O
) O
. O

In O
post-marketing O
experience O
, O
bleeding O
events O
have O
been O
reported O
, O
predominantly O
in O
the O
elderly O
, O
in O
association O
with O
increases O
in O
prothrombin O
time O
in O
patients O
receiving O
VIOXX B-brand
concurrently O
with O
warfarin B-drug
. O

Interactions O
between O
treatments O
with O
coumaphos B-drug_n
, O
bishydroxycoumarin B-drug
( O
an O
anticoagulant B-group
) O
, O
trichlorfon B-drug_n
( O
an O
organophosphorous B-group
compound I-group
) O
, O
and O
phenobarbital B-drug
sodium I-drug
( O
an O
inducer O
of O
microsomal O
enzymes O
) O
were O
investigated O
in O
sheep O
. O

Clinical O
comments O
about O
possible O
dosage O
modifications O
based O
on O
these O
pharmacokinetic O
changes O
are O
listed O
in O
Table O
3 O
. O

In O
contrast O
, O
in O
isolated O
single O
pancreatic O
acinar O
cells O
, O
RR B-drug_n
had O
no O
effect O
on O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-induced O
responses O
. O

Other O
No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
Lotensin B-brand
was O
administered O
concomitantly O
with O
hydrochlorothiazide B-drug
, O
chlorthalidone B-drug
, O
furosemide B-drug
, O
digoxin B-drug
, O
propranolol B-drug
, O
atenolol B-drug
, O
naproxen B-drug
, O
or O
cimetidine B-drug
. O

These O
differences O
were O
reflected O
in O
the O
roughly O
twofold O
greater O
antitumour O
activity O
for O
the O
oral O
route O
. O

ISUPREL B-brand
should O
be O
used O
with O
caution O
, O
if O
at O
all O
, O
when O
potent O
inhalational O
anesthetics B-group
such O
as O
halothane B-drug
are O
employed O
because O
of O
potential O
to O
sensitize O
the O
myocardium O
to O
effects O
of O
sympathomimetic B-group
amines I-group
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

Conversely O
, O
the O
coumarin B-group
anticoagulants I-group
have O
been O
reported O
to O
increase O
the O
serum O
levels O
and O
prolong O
the O
serum O
half-life O
of O
phenytoin B-drug
by O
inhibiting O
its O
metabolism O
. O

Antinociception O
was O
measured O
by O
the O
hot-plate O
method O
. O

The O
possibility O
of O
worsened O
glucose O
control O
in O
patients O
using O
these O
agents O
should O
be O
considered O
. O

Catecholamine-depleting B-group
drugs I-group
, O
such O
as O
reserpine B-drug
, O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-group
agents I-group
. O

Antacids B-group
or O
H B-group
2 I-group
-receptor I-group
antagonists I-group
: O
The O
effect O
of O
increased O
gastric O
pH O
on O
the O
bioavailability O
of O
ceftibuten B-drug
was O
evaluated O
in O
18 O
healthy O
adult O
volunteers O
. O

In O
vitro O
and O
in O
vivo O
studies O
have O
shown O
that O
esomeprazole B-drug
is O
not O
likely O
to O
inhibit O
CYPs O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O

The O
use O
of O
antacids B-group
should O
be O
considered O
in O
place O
of O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
in O
patients O
receiving O
SPRYCEL B-brand
therapy O
. O

No O
significant O
drug O
interactions O
have O
been O
reported O
in O
studies O
of O
candesartan B-drug
cilexetil I-drug
given O
with O
other O
drugs O
such O
as O
glyburide B-drug
, O
nifedipine B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
hydrochlorothiazide B-drug
, O
and O
oral O
contraceptives B-group
in O
healthy O
volunteers O
, O
or O
given O
with O
enalapril B-drug
to O
patients O
with O
heart O
failure O
( O
NYHA O
class O
II O
and O
III O
) O
. O

Potential O
pharmacokinetic O
interactions O
were O
assessed O
in O
clinical O
pharmacokinetic O
studies O
( O
phenytoin B-drug
, O
valproate B-drug
, O
oral O
contraceptive B-group
, O
digoxin B-drug
, O
warfarin B-drug
, O
probenecid B-drug
) O
and O
through O
pharmacokinetic O
screening O
in O
the O
placebo-controlled O
clinical O
studies O
in O
epilepsy O
patients O
. O

N=13 O
) O
. O

Concomitant O
use O
of O
bupropion B-drug
with O
other O
drugs O
metabolized O
by O
CYP2D6 O
has O
not O
been O
formally O
studied O
. O

Warfarin B-drug
: O
The O
effects O
of O
warfarin B-drug
and O
NSAIDs B-group
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
that O
of O
users O
of O
either O
drug O
alone O
. O

Systemic O
exposure O
to O
acetaminophen B-drug
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec B-brand
. O

If O
such O
drugs O
are O
used O
they O
should O
be O
administered O
with O
an O
interval O
of O
at O
least O
5 O
minutes O
between O
applications O
. O

Others O
reported O
: O
Neuropsychiatric O
: O
Confusion O
( O
1-11 O
% O
) O
, O
headache O
( O
4-8 O
% O
) O
, O
insomnia O
( O
2-7 O
% O
) O
; O

Effects O
of O
sympathomimetics B-group
are O
increased O
with O
MAO B-group
inhibitors I-group
and O
beta B-group
adrenergic I-group
blockers I-group
. O

Other O
Cardiovascular O
Agents O
: O
Enalapril B-drug
and O
enalapril B-drug
IV O
have O
been O
used O
concomitantly O
with O
beta B-group
adrenergic-blocking I-group
agents I-group
, O
methyldopa B-drug
, O
nitrates B-group
, O
calcium-blocking B-group
agents I-group
, O
hydralazine B-drug
, O
prazosin B-drug
and O
digoxin B-drug
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

The O
co-administration O
of O
Natrecor B-brand
with O
IV O
vasodilators B-group
such O
as O
nitroglycerin B-drug
, O
nitroprusside B-drug
, O
milrinone B-drug
, O
or O
IV O
ACE B-group
inhibitors I-group
has O
not O
been O
evaluated O
( O
these O
drugs O
were O
not O
co-administered O
with O
Natrecor B-brand
in O
clinical O
trials O
) O
. O

Ketoconazole B-drug

The O
contribution O
of O
each O
of O
the O
treatments O
to O
this O
adverse O
reaction O
is O
unknown O
but O
the O
possibility O
of O
a O
drug O
interaction O
can O
not O
be O
excluded O
. O

v. O
Patients O
should O
be O
cautioned O
regarding O
potential O
adverse O
cardiovascular O
effects O
, O
such O
as O
palpitations O
or O
chest O
pain O
. O

Research O
has O
shown O
that O
herbal O
remedy O
use O
may O
be O
associated O
with O
acute O
renal O
failure O
. O

Because O
oral O
anticoagulants B-group
may O
interfere O
with O
the O
hepatic O
metabolism O
of O
phenytoin B-drug
, O
toxic O
levels O
of O
the O
anticonvulsant B-group
may O
occur O
when O
an O
oral O
anticoagulant B-group
and O
phenytoin B-drug
are O
administered O
concurrently O
. O

Irinotecan B-drug
concentrations O
were O
similar O
in O
patients O
receiving O
bolus-IFL O
alone O
and O
in O
combination O
with O
AVASTIN B-brand
. O

Possible O
drug O
interactions O
of O
HUMORSOL B-brand
with O
succinylcholine B-drug
or O
with O
other O
anticholinesterase B-group
agents I-group
. O

The O
interaction O
of O
Activase B-brand
with O
other O
cardioactive O
or O
cerebroactive O
drugs O
has O
not O
been O
studied O
. O

Concurrent O
use O
of O
tetracyclines B-group
with O
oral O
contraceptives B-group
may O
render O
oral O
contraceptives B-group
less O
effective O
. O

600-1800 O

Insulin B-drug
: O
A O
clinical O
study O
in O
6 O
insulin-dependent O
diabetic O
patients O
demonstrated O
no O
effect O
of O
EXTRANEAL B-brand
on O
insulin B-drug
absorption O
from O
the O
peritoneal O
cavity O
or O
on O
insulins B-drug
ability O
to O
control O
blood O
glucose O
when O
insulin B-drug
was O
administered O
intraperitoneally O
with O
EXTRANEAL B-brand
. O

indinavir I-drug
concentration O

Imipramine B-drug
( O
5 O
mg/kg O
) O
, O
moclobemide B-drug
( O
30 O
mg/kg O
) O
, O
clonazepam B-drug
( O
0.25 O
mg/kg O
) O
, O
fluoxetine B-drug
( O
20 O
mg/kg O
) O
sertraline B-drug
( O
30 O
mg/kg O
) O
or O
vehicle O
was O
administered O
. O

The O
LST O
mice O
did O
not O
show O
any O
changes O
in O
the O
Kd O
and O
Bmax O
in O
either O
the O
STR O
or O
the O
NAC O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O

There O
is O
evidence O
that O
the O
use O
of O
halofantrine B-drug
after O
Mefloquineuine O
causes O
a O
significant O
lengthening O
of O
the O
QTc O
interval O
. O

Systemic O
clonidine B-drug
may O
inhibit O
the O
production O
of O
catecholamines O
in O
response O
to O
insulin-induced O
hypoglycemia O
and O
mask O
the O
signs O
and O
symptoms O
of O
hypoglycemia O
. O

therefore O
, O
plasma O
concentrations O
of O
phenytoin B-drug
should O
also O
be O
monitored O
when O
it O
is O
given O
concurrently O
with O
Itraconazole B-drug
. O

While O
18-MC B-drug_n
and O
ibogaine B-drug_n
have O
similar O
affinities O
for O
kappa O
opioid O
and O
possibly O
nicotinic O
receptors O
, O
18-MC B-drug_n
has O
much O
lower O
affinities O
than O
ibogaine B-drug_n
for O
NMDA O
and O
sigma-2 O
receptors O
, O
sodium O
channels O
, O
and O
the O
5-HT O
transporter O
. O

The O
specific O
objectives O
of O
this O
study O
were O
to O
elucidate O
metal O
toxicity O
to O
hatching O
, O
survival O
and O
avoidance O
behaviour O
of O
Schistosoma O
mansoni O
miracidia O
. O

Although O
the O
relevance O
of O
these O
reports O
and O
any O
mechanism O
of O
coagulation O
alterations O
is O
unclear O
, O
patients O
on O
warfarin B-drug
should O
have O
their O
prothrombin O
time O
monitored O
. O

( O
Thiazide B-group
diuretics I-group
may O
raise O
the O
level O
of O
blood O
uric O
acid O
; O

A O
conservative O
approach O
to O
dosing O
felodipine B-drug
should O
be O
taken O
. O

the O
disulfiram B-drug
should O
be O
discontinued O
if O
such O
signs O
appear O
. O

This O
may O
increase O
or O
enhance O
the O
occurrence O
of O
osteomalacia O
in O
some O
patients O
receiving O
chronic O
phenytoin B-drug
therapy O
. O

Glucose B-drug
and O
insulin B-drug
exert O
additive O
ocular O
and O
renal O
vasodilator O
effects O
on O
healthy O
humans O
. O

The O
rate O
of O
metabolism O
and O
the O
leukopenic O
activity O
of O
cyclophosphamide B-drug
reportedly O
are O
increased O
by O
chronic O
administration O
of O
high O
doses O
of O
phenobarbital B-drug
. O


Exjade B-brand
should O
not O
be O
combined O
with O
other O
iron O
chelator O
therapies O
, O
as O
safety O
of O
such O
combinations O
has O
not O
been O
established O
. O

the O
remainder O
were O
of O
uncertain O
cause O
. O

In O
occasional O
susceptible O
patients O
or O
in O
those O
receiving O
anticholinergic B-group
drugs I-group
( O
including O
antiparkinsonism O
agents O
) O
in O
addition O
, O
the O
atropine-like O
effects O
may O
become O
more O
pronounced O
( O
e.g. O
, O
paralytic O
ileus O
) O
. O

Thioridazine B-drug
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-brand
20 O
mg O
and O
thioridazine B-drug
50 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O

Pharmacology O
and O
pharmacotherapy O
of O
cardiovascular O
drugs O
in O
patients O
with O
chronic O
renal O
disease O
. O

No O
drug O
interactions O
have O
been O
identified O
. O

Motility O
agents O

No O
Important O
Interactions O
To O
Date O
Levosimendan B-drug
does O
not O
have O
clinically O
important O
pharmacokinetic O
interactions O
with O
captopril B-drug
, O
beta-blockers B-group
, O
felodipine B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
isosorbide B-drug
mononitrate I-drug
, O
carvedilol B-drug
, O
ethanol B-drug
or O
itraconazole B-drug
. O

Selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HTv O
agonists O
. O

1 O
hour O
after O
starting O
the O
oxycodone B-drug
or O
levofloxacin B-drug
500 O
mg O
p.o O
. O

Vitamin B-group
A I-group
and O
oral O
retinoids B-group
: O
Concomitant O
administration O
of O
vitamin B-group
A I-group
and/or O
other O
oral O
retinoids B-group
with O
acitretin B-drug
must O
be O
avoided O
because O
of O
the O
risk O
of O
hypervitaminosis O
A O
. O

Drug/Laboratory O
Test O
Interactions O
: O
Amphetamines B-group
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid O
levels O
. O

In O
addition O
, O
higher-than O
expected O
steady-state O
serum O
concentrations O
of O
tricyclic B-group
antidepressants I-group
have O
been O
observed O
when O
therapy O
is O
initiated O
in O
patients O
already O
taking O
cimetidine B-drug
. O

However O
, O
higher O
plasma O
concentrations O
of O
AMICAR B-brand
may O
occur O
in O
patients O
with O
severe O
renal O
failure O
. O

During O
concomitant O
therapy O
with O
ibuprofen B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic B-group
efficacy O
. O

Antifungal B-group
Agents I-group

Cisapride B-drug
should O
not O
be O
used O
concomitantly O
with O
other O
drugs O
known O
to O
prolong O
the O
QT O
interval O
: O
certain O
antiarrhythmics B-group
, O
including O
those O
of O
Class O
IA O
( O
such O
as O
quinidine B-drug
and O
procainamide B-drug
) O
and O
Class O
III O
( O
such O
as O
sotalol B-drug
) O
; O

therefore O
, O
coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
strongly O
induce O
CYP3A4 O
activity O
( O
e.g. O
, O
rifampin B-drug
, O
carbamazepine B-drug
, O
phenytoin B-drug
) O
may O
result O
in O
reduced O
plasma O
concentrations O
of O
aprepitant B-drug
that O
may O
result O
in O
decreased O
efficacy O
of O
Aprepitant B-drug
. O

Warfarin B-drug
: O
Anticoagulant O
activity O
should O
be O
monitored O
, O
particularly O
in O
the O
first O
few O
days O
after O
initiating O
or O
changing O
VIOXX B-brand
therapy O
in O
patients O
receiving O
warfarin B-drug
or O
similar O
agents O
, O
since O
these O
patients O
are O
at O
an O
increased O
risk O
of O
bleeding O
complications O
. O

Although O
beta-adrenergic B-group
blockers I-group
or O
calcium B-group
channel I-group
blockers I-group
and O
digoxin B-drug
may O
be O
useful O
in O
combination O
to O
control O
atrial O
fibrillation O
, O
their O
additive O
effects O
on O
AV O
node O
conduction O
can O
result O
in O
advanced O
or O
complete O
heart O
block O
. O

subjects O
. O

No O
specific O
information O
available O

It O
is O
proposed O
that O
the O
phosphohydrolase O
becomes O
metabolically O
active O
when O
it O
combines O
with O
membranes O
and O
that O
polyamines O
might O
help O
to O
regulate O
this O
interaction O
. O

These O
results O
suggest O
that O
both O
dexamethasone B-drug
and O
retinyl B-drug
acetate I-drug
, O
and O
possibly O
other O
glucocorticoids B-group
and O
retinoids B-group
, O
may O
regulate O
the O
proliferation O
of O
prostate O
epithelium O
by O
a O
dose-dependent O
modification O
of O
the O
activity O
of O
insulin B-drug
and O
EGF B-drug_n
. O

Neurochemical O
and O
functional O
consequences O
following O
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine B-drug_n
( O
MPTP B-drug_n
) O
and O
methamphetamine B-drug
. O

There O
are O
few O
data O
regarding O
the O
coadministration O
of O
radiation O
therapy O
and O
epirubicin B-drug
. O

Cimetidine B-drug
increased O
the O
AUC O
of O
epirubicin B-drug
by O
50 O
% O
. O

TRACRIUM B-brand
should O
not O
be O
administered O
until O
a O
patient O
has O
recovered O
from O
succinylcholine-induced B-drug
neuromuscular O
block O
. O

We O
conclude O
that O
the O
prophylactic O
and O
antidotal O
properties O
of O
4-methylpyrazole B-drug
seen O
in O
animals O
treated O
with O
1,3-difluoro-2-propanol B-drug_n
derive O
from O
its O
capacity O
to O
inhibit O
the O
NAD+-dependent O
oxidation O
responsible O
for O
converting O
1,3-difluoro-2-propanol B-drug_n
to O
1,3-difluoroacetone B-drug_n
in O
the O
committed O
step O
of O
the O
toxic O
pathway O
. O

No O
drugs O
are O
known O
to O
interfere O
with O
the O
conversion O
of O
fosphenytoin B-drug
to O
phenytoin B-drug
. O

Patients O
receiving O
concomitant O
lovastatin B-drug
and O
erythromycin B-drug
should O
be O
carefully O
monitored O
; O

Combination O
Therapy O
: O
Any O
form O
of O
therapy O
which O
adds O
to O
the O
stress O
of O
the O
patient O
, O
interferes O
with O
nutrition O
or O
depresses O
bone O
marrow O
function O
will O
increase O
the O
toxicity O
of O
Floxuridine B-drug
. O

The O
1-year O
risk O
of O
relapse O
( O
rehospitalisation O
) O
was O
significantly O
lower O
with O
olanzapine B-drug
than O
with O
haloperidol B-drug
treatment O
. O

Vitamin B-group
A I-group
: O
Because O
of O
the O
relationship O
of O
Accutane B-brand
to O
vitamin B-group
A I-group
, O
patients O
should O
be O
advised O
against O
taking O
vitamin B-group
supplements I-group
containing O
vitamin B-group
A I-group
to O
avoid O
additive O
toxic O
effects O

similar O
events O
have O
been O
reported O
in O
patients O
taking O
other O
psychotropic B-group
drugs I-group
or O
even O
Clozapine B-drug
by O
itself O
. O

In O
EM O
individuals O
treated O
with O
paroxetine B-drug
or O
fluoxetine B-drug
, O
the O
AUC O
of O
atomoxetine B-drug
is O
approximately O
6- O
to O
8-fold O
and O
Css O
, O
max O
is O
about O
3- O
to O
4-fold O
greater O
than O
atomoxetine B-drug
alone O
. O

The O
risk O
of O
using O
bromocriptine B-drug
mesylate I-drug
in O
combination O
with O
other O
drugs O
has O
not O
been O
systematically O
evaluated O
, O
but O
alcohol B-drug
may O
potentiate O
the O
side O
effects O
of O
bromocriptine B-drug
mesylate I-drug
. O

Fatalities O
have O
been O
reported O
. O

However O
, O
retinyl B-drug
acetate I-drug
stimulated O
, O
but O
did O
not O
significantly O
inhibit O
, O
proliferation O
in O
the O
presence O
of O
insulin B-drug
. O

In O
a O
study O
in O
which O
the O
2 O
mg O
clonazepam B-drug
orally O
disintegrating O
tablet O
was O
administered O
with O
and O
without O
propantheline B-drug
( O
an O
anticholinergic B-group
agent I-group
with O
multiple O
effects O
on O
the O
GI O
tract O
) O
to O
healthy O
volunteers O
, O
the O
AUC O
of O
clonazepam B-drug
was O
10 O
% O
lower O
and O
the O
Cmax O
of O
clonazepam B-drug
was O
20 O
% O
lower O
when O
the O
orally O
disintegrating O
tablet O
was O
given O
with O
propantheline B-drug
compared O
to O
when O
it O
was O
given O
alone O
. O

Agents O
Increasing O
Serum O
Potassium O
: O
Enalapril B-drug
and O
enalapril B-drug
IV O
attenuate O
potassium O
loss O
caused O
by O
thiazide-type B-group
diuretics I-group
. O

4 O
. O

Protease B-group
inhibitors I-group
: O
Amprenavir B-drug
, O
lopinavir B-drug
, O
nelfinavir B-drug
, O
and O
ritonavir B-drug
have O
been O
shown O
to O
decrease O
plasma O
levels O
of O
combination B-group
hormonal I-group
contraceptives I-group
; O

The O
effect O
of O
a O
higher O
ketoconazole B-drug
dose O
( O
400 O
mg/day O
) O
has O
not O
been O
studied O
. O

Although O
clinical O
studies O
have O
not O
been O
performed O
, O
based O
on O
the O
involvement O
of O
the O
cytochrome O
P-450 O
3A O
family O
in O
clonazepam B-drug
metabolism O
, O
inhibitors O
of O
this O
enzyme O
system O
, O
notably O
oral O
antifungal B-group
agents I-group
, O
should O
be O
used O
cautiously O
in O
patients O
receiving O
clonazepam B-drug
. O

Carbamazepine B-drug
, O
clonazepam B-drug
, O
ethosuximide B-drug

As O
a O
result O
, O
when O
giving O
these O
drugs O
concomitantly O
, O
plasma O
warfarin B-drug
levels O
may O
change O
with O
the O
potential O
for O
increases O
in O
coagulation O
time O
. O

Ritonavir B-drug
: O
Coadministration O
of O
ritonavir B-drug
with O
VIRACEPT B-brand
resulted O
in O
a O
152 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
very O
little O
change O
in O
ritonavir B-drug
plasma O
A.C O
. O

These O
usually O
clear O
within O
a O
week O
, O
leaving O
only O
the O
" O
drug O
hunger O
" O

- O
Although O
not O
a O
true O
drug O
interaction O
, O
tricyclic B-group
antidepressants I-group
may O
precipitate O
seizures O
in O
susceptible O
patients O
and O
Cerebyx B-brand
dosage O
may O
need O
to O
be O
adjusted O

Selective B-group
Serotonin I-group
Reuptake I-group
Inhibitors I-group
( O
SSRIs B-group
) O
: O
SSRIs B-group
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
rarely O
reported O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HT1 B-group
agonists I-group
. O

Lamivudine B-drug
is O
predominantly O
eliminated O
in O
the O
urine O
by O
active O
organic O
cationic O
secretion O
. O

Because O
prostaglandins O
play O
an O
important O
role O
in O
hemostasis O
, O
and O
NSAIDs B-group
affect O
platelet O
function O
as O
well O
, O
concurrent O
therapy O
with O
all O
NSAIDs B-group
, O
including O
diclofenac B-drug
, O
and O
warfarin B-drug
requires O
close O
monitoring O
of O
patients O
to O
be O
certain O
that O
no O
change O
in O
their O
anticoagulant B-group
dosage O
is O
required O
. O

Cytosine B-drug
arabinoside I-drug
, O
a O
cytostatic B-group
agent I-group
, O
has O
been O
reported O
to O
inactivate O
the O
antifungal O
activity O
of O
flucytosine B-drug
by O
competitive O
inhibition O
. O

Administration O
of O
eszopiclone B-drug
3 O
mg O
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein-bound O
would O
not O
be O
expected O
to O
cause O
an O
alteration O
in O
the O
free O
concentration O
of O
either O
drug O
. O

Pyrazolone B-group
Derivatives I-group
( O
phenylbutazone B-drug
, O
oxyphenbutazone B-drug
, O
and O
possibly O
dipyrone B-drug
) O
: O
Concomitant O
administration O
with O
aspirin B-drug
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
. O

18-MC B-drug_n
, O
a O
novel O
iboga O
alkaloid O
congener O
, O
is O
being O
developed O
as O
a O
potential O
treatment O
for O
multiple O
forms O
of O
drug O
abuse O
. O

Drugs O
With O
A O
Narrow O
Therapeutic O
Index O
Digoxin B-drug
A O
single O
dose O
of O
eszopiclone B-drug
3 O
mg O
did O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-drug
measured O
at O
steady O
state O
following O
dosing O
of O
0.5 O
mg O
twice O
daily O
for O
one O
day O
and O
0.25 O
mg O
daily O
for O
the O
next O
6 O
days O
. O

Mineral B-drug_n
Oil-Concomitant O
intake O
of O
mineral B-drug_n
oil I-drug_n
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Lithium B-drug
carbonate I-drug
: O
The O
anorectic O
and O
stimulatory O
effects O
of O
amphetamines B-group
may O
be O
inhibited O
by O
lithium B-drug
carbonate I-drug
. O

400-2800 O

Studies O
with O
famotidine B-drug
in O
man O
, O
in O
animal O
models O
, O
and O
in O
vitro O
have O
shown O
no O
significant O
interference O
with O
the O
disposition O
of O
compounds O
metabolized O
by O
the O
hepatic O
microsomal O
enzymes O
, O
e.g. O
, O
cytochrome O
P450 O
system O
. O

Agents O
with O
Increased O
Levels O
in O
the O
Presence O
of O
Carbamazepine B-drug
: O
EQUETROTM B-brand
increases O
the O
plasma O
levels O
of O
the O
following O
agents O
: O
Clomipramine B-drug
HCl I-drug
, O
Phenytoin B-drug
( O
6 O
) O
, O
and O
primidone B-drug
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
the O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
decrease O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O

These O
doses O
were O
6 O
to O
11 O
times O
( O
mouse O
) O
and O
8 O
to O
16 O
times O
( O
rat O
) O
the O
human O
AUC O
( O
0-24 O
) O
based O
on O
the O
maximum O
recommended O
human O
dose O
of O
80 O
mg/day O
. O

In O
some O
patients O
the O
combined O
use O
of O
indomethacin B-drug
and O
diflunisal B-drug
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O

FLUOTHANE B-brand
may O
augment O
the O
hypotension O
caused O
by O
the O
ganglionic-blocking O
effect O
of O
tubocurarine B-drug
. O

Specific O
studies O
with O
ibandronate B-drug
have O
not O
been O
performed O
. O

Acetazolamide B-drug
may O
elevate O
cyclosporine B-drug
levels O
. O

Similarly O
, O
of O
over O
1600 O
patients O
enrolled O
in O
a O
study O
comparing O
once-monthly O
with O
daily O
dosing O
regimens O
of O
ibandronate B-drug
, O
14 O
% O
of O
patients O
used O
anti-peptic O
agents O
. O

In O
vitro O
interaction O
of O
prostaglandin B-drug
F2alpha I-drug
and O
oxytocin B-drug
in O
placental O
vessels O
. O

These O
effects O
may O
be O
due O
to O
a O
relatively O
specific O
blockade O
of O
diverse O
potassium O
channel O
types O
. O

250-500 O

Patients O
taking O
both O
flurbiprofen B-drug
and O
a O
beta-blocker B-group
should O
be O
monitored O
to O
ensure O
that O
a O
satisfactory O
hypotensive O
effect O
is O
achieved O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O

In O
patients O
receiving O
mercaptopurine B-drug
( O
Purinethol B-brand
) O
or O
azathioprine B-drug
( O
Imuran B-brand
) O
, O
the O
concomitant O
administration O
of O
300-600 O
mg O
of O
allopurinol B-drug
per O
day O
will O
require O
a O
reduction O
in O
dose O
to O
approximately O
one-third O
to O
one-fourth O
of O
the O
usual O
dose O
of O
mercaptopurine B-drug
or O
azathioprine B-drug
. O

In O
a O
study O
of O
schizophrenic O
patients O
who O
received O
clozapine B-drug
under O
steady O
state O
conditions O
, O
fluvoxamine B-drug
or O
paroxetine B-drug
was O
added O
in O
16 O
and O
14 O
patients O
, O
respectively O
. O

Longitudinal O
assessment O
of O
everolimus B-drug
in O
de O
novo O
renal O
transplant O
recipients O
over O
the O
first O
post-transplant O
year O
: O
pharmacokinetics O
, O
exposure-response O
relationships O
, O
and O
influence O
on O
cyclosporine B-drug
. O

Nevertheless O
, O
plasma O
lithium B-drug
levels O
should O
be O
monitored O
with O
appropriate O
adjustment O
to O
the O
lithium B-drug
dose O
in O
accordance O
with O
standard O
clinical O
practice O
. O

Because O
the O
small O
magnitude O
and O
the O
direction O
of O
the O
effect O
on O
theophylline B-drug
clearance O
, O
this O
interaction O
is O
unlikely O
to O
be O
clinical O
concern O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

No O
drug-drug O
interaction O
studies O
in O
human O
subjects O
have O
been O
conducted O
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8-fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

With O
combined O
use O
, O
clinicians O
should O
be O
aware O
, O
when O
phenytoin B-drug
is O
added O
, O
of O
the O
potential O
for O
reexacerbation O
of O
pulmonary O
symptomatology O
due O
to O
lowered O
serum O
theophylline B-drug
concentrations O
. O

There O
is O
one O
reported O
case O
of O
a O
patient O
with O
acute O
delirium O
associated O
with O
the O
simultaneous O
use O
of O
fluphenazine B-drug
and O
oral O
clonidine B-drug
. O

Sublingual O
nitroglycerin B-drug
may O
be O
taken O
if O
necessary O
for O
the O
control O
of O
acute O
angina O
attacks O
during O
Bepridil B-drug
therapy O
. O

Ketoconazole B-drug
( O
200 O
mg O
q12h O
) O
+307 O
% O
+73 O
% O

Studies O
with O
other O
oral O
or O
implant O
contraceptives B-group
have O
not O
been O
conducted O
. O

Effect O
of O
coadministered O
drugs O
and O
ethanol B-drug
on O
the O
binding O
of O
therapeutic O
drugs O
to O
human O
serum O
in O
vitro O
. O

A O
possible O
drug O
interaction O
of O
FOSCAVIR B-brand
and O
intravenous O
pentamidine B-drug
has O
been O
described O
. O

Caution O
should O
also O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
aminoglycosides B-group
and O
polymyxins B-group
because O
they O
may O
enhance O
neomycin O
s O
nephrotoxicity O
and/or O
ototoxicity O
and O
potentiate O
neomycin B-drug
sulfate I-drug
neuromuscular O
blocking O
effects O
. O

In O
nine O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
carbamazepine B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
carbamazepine B-drug
concentration O
was O
8 O
2 O
micrograms/mL O
. O

The O
mean O
AUC O
values O
of O
EE O
were O
decreased O
by O
48 O
% O
[ O
90 O
% O
CI O
: O
22-65 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
38-52 O
] O
in O
another O
study O
[ O
1,2 O
] O
. O

Barbiturates B-group
, O
phenytoin B-drug
, O
or O
rifampin B-drug
increased O
metabolic O
clearance O
of O
fludrocortisone B-drug
acetate I-drug
because O
of O
the O
induction O
of O
hepatic O
enzymes O
. O

There O
have O
been O
rare O
reports O
of O
reddish O
stools O
in O
patients O
who O
have O
received O
cefdinir B-drug
in O
Japan O
. O

Beta-blockers B-group
, O
clonidine B-drug
, O
lithium B-drug
salts O
, O
and O
alcohol B-drug
may O
either O
potentiate O
or O
weaken O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
. O

Aspirin B-brand
: O
When O
Lodine B-brand
is O
administered O
with O
aspirin B-brand
, O
its O
protein O
binding O
is O
reduced O
, O
although O
the O
clearance O
of O
free O
etodolac B-drug
is O
not O
altered O
. O

The O
behavioral O
effects O
of O
these O
two O
drugs O
differ O
, O
and O
they O
do O
not O
act O
on O
the O
same O
target O
sites O
in O
the O
brain O
, O
although O
they O
may O
share O
, O
or O
partly O
share O
, O
certain O
properties O
. O

The O
extent O
of O
plasma O
protein O
binding O
of O
atovaquone B-drug
in O
human O
plasma O
is O
not O
affected O
by O
the O
presence O
of O
therapeutic O
concentrations O
of O
phenytoin B-drug
( O
15 O
mcg/ O
mL O
) O
, O
nor O
is O
the O
binding O
of O
phenytoin B-drug
affected O
by O
the O
presence O
of O
atovaquone B-drug
. O

Inhibitors O
of O
renal O
cationic O
secretion O
are O
contraindicated O
with O
TIKOSYN B-brand
. O

Nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
NSAIDS B-group
) O
: O
Concomitant O
use O
of O
aspirin B-brand
( O
or O
other O
nonsteroidal B-group
antiinflammatory I-group
agents I-group
) O
and O
corticosteroids B-group
increases O
the O
risk O
of O
gastrointestinal O
side O
effects O
. O

Consider O
doubling O
the O
rifabutin B-drug
dose O
in O
regimens O
where O
rifabutin B-drug
is O
given O
2 O
or O
3 O
times O
a O
week O
. O

Diflunisal B-drug
decreased O
the O
hyperuricemic O
effect O
of O
hydrochlorothiazide B-drug
. O

Patients O
who O
are O
concomitantly O
receiving O
VELCADE B-brand
and O
drugs O
that O
are O
inhibitors O
or O
inducers O
of O
cytochrome O
P450 O
3A4 O
should O
be O
closely O
monitored O
for O
either O
toxicities O
or O
reduced O
efficacy O
. O

Bosentan B-drug
is O
an O
inducer O
of O
CYP3A4 O
and O
CYP2C9 O
. O

therefore O
, O
the O
efficacy O
of O
oral O
contraceptives B-group
during O
administration O
of O
Aprepitant B-drug
may O
be O
reduced O
. O

The O
effects O
of O
concomitant O
phenytoin B-drug
administration O
on O
the O
steady-state O
pharmacokinetics O
of O
quetiapine B-drug
. O

It O
is O
unknown O
whether O
the O
concomitant O
administration O
of O
proton B-group
pump I-group
inhibitors I-group
affects O
duloxetine B-drug
absorption O
. O

Routine O
administration O
of O
vaccines B-group
or O
toxoids O
should O
be O
deferred O
until O
corticosteroid B-group
therapy O
is O
discontinued O
if O
possible O
. O

While O
it O
is O
not O
known O
whether O
this O
interaction O
occurs O
with O
fibrates B-group
other O
than O
gemfibrozil B-drug
, O
myopathy O
and O
rhabdomyolysis O
have O
occasionally O
been O
associated O
with O
the O
use O
of O
fibrates B-group
alone O
, O
including O
clofibrate B-drug
. O

Clarithromycin B-drug

The O
minimal O
inhibitory O
concentration O
as O
well O
as O
minimal O
bactericidal O
concentration O
of O
KRM-1648 B-drug_n
against O
M O
. O

In O
vitro O
studies O
indicate O
that O
the O
binding O
is O
not O
easily O
removed O
. O

There O
are O
rare O
reports O
, O
however O
, O
from O
marketing O
experiences O
, O
of O
changes O
in O
effects O
of O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
in O
the O
presence O
of O
diclofenac B-drug
that O
necessitated O
changes O
in O
the O
doses O
of O
such O
agents O
. O

Consequently O
, O
interactions O
with O
other O
drugs O
which O
are O
highly O
protein O
bound O
( O
e.g. O
, O
anticoagulants B-group
) O
would O
not O
be O
expected O
. O

No O
significant O
drug-drug O
pharmacokinetic O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
cimetidine B-drug
and O
phenobarbital B-drug
. O

Calcium B-drug
Supplements O
: O
Uncontrolled O
intake O
of O
additional O
calcium-containing B-drug
preparations O
should O
be O
avoided O
. O

DOSTINEX B-brand
should O
not O
be O
administered O
concurrently O
with O
D2-antagonists O
, O
such O
as O
phenothiazines B-group
, O
butyrophenones B-group
, O
thioxanthines B-group
, O
or O
metoclopramide B-drug
. O

Interference O
with O
the O
absorption O
of O
oral O
phosphate B-drug_n
supplements O
has O
been O
observed O
with O
another O
positively-charged O
bile O
acid O
sequestrant O
. O

Warfarin B-drug
: O
In O
a O
short-term O
controlled O
study O
in O
14 O
normal O
volunteers O
, O
ketoprofen B-drug
did O
not O
significantly O
interfere O
with O
the O
effect O
of O
warfarin B-drug
on O
prothrombin O
time O
. O

Co-administration O
: O
Concomitant O
use O
of O
Argatroban B-drug
with O
antiplatelet B-group
agents I-group
, O
thrombolytics B-group
, O
and O
other O
anticoagulants B-group
may O
increase O
the O
risk O
of O
bleeding O
. O

Corresponding O
values O
for O
free O
valproate B-drug
Cmin O
concentrations O
were O
7 O
3 O
, O
9 O
4 O
, O
and O
11 O
6 O
micrograms/mL O
for O
0 O
, O
1200 O
, O
and O
2400 O
mg/day O
Felbatol B-brand
, O
respectively O
. O

Indinavir B-drug
is O
an O
inhibitor O
of O
the O
cytochrome O
P450 O
isoform O
CYP3A4 O
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

structural O
heart O
disease O
is O
a O
known O
risk O
factor O
for O
arrhythmia O
. O

Ergot B-group
alkaloids I-group

Magnesium/Aluminum-containing B-drug
Antacid B-group
Products I-group
: O
Absorption O
of O
zalcitabine B-drug
is O
moderately O
reduced O
( O
approximately O
25 O
% O
) O
when O
coadministered O
with O
magnesium/aluminum-containing B-drug
antacid B-group
products I-group
. O

This O
increase O
is O
greatest O
in O
the O
evening O
. O

Pressor O
amines O
( O
e.g. O
, O
norepinephrine B-drug
) O
: O
possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O
. O

Antihistamines B-group
( O
e.g. O
, O
chlorpheniramine B-group
) O
. O

Ranitidine B-drug
produced O
smaller O
, O
non-significant O
increases O
. O


Increased O
plasma O
concentrations O
of O
terfenadine B-drug
, O
astemizole B-drug
, O
and O
cisapride B-drug
cause O
QT O
prolongation O
and O
have O
been O
associated O
with O
torsades O
de O
pointes-type O
ventricular O
tachycardia O
, O
sometimes O
fatal O
. O

Aspirin B-brand
: O
Animal O
studies O
wshow O
that O
aspirin B-brand
given O
with O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
including O
ibuprofen B-drug
, O
yields O
a O
net O
decrease O
in O
anti-inflammatory O
activity O
with O
lowered O
blood O
levels O
of O
the O
non-aspirin O
drug O
. O

Furthermore O
, O
rifampin B-drug
, O
phenytoin B-drug
, O
phenobarbital B-drug
, O
and O
other O
inducers O
of O
cytochrome O
P450 O
3A4 O
may O
cause O
a O
reduction O
in O
plasma O
bexarotene B-drug
concentrations O
. O

Reduced O
levels O
( O
up O
to O
20 O
% O
) O
of O
total O
glutathione O
( O
total O
GSH O
) O
, O
and O
elevation O
of O
conjugated O
dienes O
( O
approximately O
60 O
% O
in O
liver O
by O
single O
dose O
at O
4 O
h O
) O
also O
indicated O
the O
presence O
of O
an O
oxidative O
insult O
. O

General O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
demonstrated O
no O
evidence O
of O
cytochrome O
P450-mediated O
drug O
interactions O
that O
are O
likely O
to O
be O
of O
clinical O
relevance O
. O

Correlative O
clinical O
studies O
have O
not O
been O
performed O
. O

This O
interaction O
, O
which O
has O
not O
been O
investigated O
using O
higher O
doses O
of O
fluvoxamine B-drug
, O
may O
be O
more O
pronounced O
if O
a O
300 O
mg O
daily O
dose O
is O
co-administered O
, O
particularly O
since O
fluvoxamine B-drug
exhibits O
non-linear O
pharmacokinetics O
over O
the O
dosage O
range O
100-300 O
mg O
. O
If O
alprazolam B-drug
is O
co-administered O
with O
Fluvoxamine B-drug
Tablets O
, O
the O
initial O
alprazolam B-drug
dosage O
should O
be O
at O
least O
halved O
and O
titration O
to O
the O
lowest O
effective O
dose O
is O
recommended O
. O

Both O
of O
these O
strategies O
will O
become O
more O
feasible O
as O
specific O
molecular O
differences O
between O
tumor O
and O
normal O
cells O
are O
being O
rapidly O
identified O
and O
new O
combination O
therapies O
that O
take O
advantage O
of O
these O
differences O
are O
being O
designed O
and O
tested O
. O

Hypothermia O
as O
an O
index O
of O
the O
disulfiram-ethanol B-drug
reaction O
in O
the O
rat O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post-marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

In O
dogs O
, O
cimetidine B-drug
unchanged O
the O
secretion O
of O
cardiotrast B-drug
, O
a O
test O
agent O
for O
anionic O
transport O
. O

This O
effect O
of O
aspirin B-brand
( O
which O
also O
lowers O
serum O
concentrations O
of O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
given O
with O
it O
) O
has O
been O
demonstrated O
in O
patients O
with O
rheumatoid O
arthritis O
( O
n= O
15 O
) O
as O
well O
as O
normal O
volunteers O
( O
n= O
16 O
) O
. O

In O
extremely O
acidic O
conditions O
, O
Duloxetine B-drug
, O
unprotected O
by O
the O
enteric O
coating O
, O
may O
undergo O
hydrolysis O
to O
form O
naphthol O
. O

Amprenavir B-drug
inhibits O
CYP3A4 O
. O

Anticoagulants B-group
: O
There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-drug
and O
oral O
anticoagulants B-group
were O
used O
concomitantly O
. O


Oral O
neomycin B-drug
sulfate I-drug
may O
enhance O
the O
effect O
of O
coumarin B-group
in O
anticoagulants B-group
by O
decreasing O
vitamin O
K O
availability O
. O

The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
cyclophosphamide B-drug
even O
though O
cyclophosphamide B-drug
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O

Among O
fifteen O
species O
of O
bacteria O
tested O
, O
the O
antimicrobial O
activity O
of O
GL B-drug_n
was O
the O
most O
potent O
against O
Micrococcus O
luteus O
( O
MIC O
, O
0.75 O
mg/ml O
) O
. O

Aprepitant I-drug
is O
a O
substrate O
for O
CYP3A4 O
; O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
a O
prolongation O
of O
its O
plasma O
half-life O
. O

Aripiprazole B-drug
also O
does O
not O
undergo O
direct O
glucuronidation O
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

Vitamin B-drug
D3 I-drug
administration O
to O
rachitic O
chicks O
was O
effective O
in O
significantly O
elevating O
duodenal O
arsenate B-drug_n
absorption O
, O
acting O
primarily O
to O
enhance O
serosal O
transport O
. O

TBg O
may O
also O
be O
increased O
during O
infectious O
hepatitis O
. O

. O

The O
plasma O
concentrations O
of O
bosentan B-drug
were O
also O
decreased O
by O
approximately O
30 O
% O
. O

Drugs O
that O
induce O
hepatic O
enzymes O
such O
as O
phenobarbital B-drug
, O
phenytoin B-drug
and O
rifampin B-drug
may O
increase O
the O
clearance O
of O
corticosteroids B-group
and O
may O
require O
increases O
in O
corticosteroid B-group
dose O
to O
achieve O
the O
desired O
response O
. O

Amiodarone B-drug
: O
Amiodarone B-drug
therapy O
alone O
can O
cause O
hypothyroidism O
or O
hyperthyroidism O
. O

Higher O
concentrations O
of O
dexamethasone B-drug
( O
10 O
( O
-8 O
) O
- O
10 O
( O
-6 O
) O
M O
) O
or O
retinyl B-drug
acetate I-drug
( O
3 O
X O
10 O
( O
-8 O
) O
- O
10 O
( O
-7 O
) O
M O
) O
enhance O
the O
mitogenic O
activity O
of O
EGF B-drug_n
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Recent O
studies O
and O
consensus O
reports O
have O
expanded O
our O
understanding O
of O
its O
efficacy O
, O
safety O
, O
contraindications O
, O
and O
drug O
interactions O
. O

Drugs O
That O
Inhibit O
CYP3A4 O
( O
Ketoconazole B-drug
) O
CYP3A4 O
is O
a O
major O
metabolic O
pathway O
for O
elimination O
of O
eszopiclone B-drug
. O

A O
pharmacokinetic O
study O
evaluating O
the O
administration O
of O
a O
single O
dose O
of O
INSPRA B-brand
100 O
mg O
with O
ketoconazole B-drug
200 O
mg O
BID O
, O
a O
potent O
inhibitor O
of O
the O
CYP3A4 O
pathway O
, O
showed O
a O
1.7-fold O
increase O
in O
Cmax O
of O
eplerenone B-drug
and O
a O
5.4-fold O
increase O
in O
AUC O
of O
eplerenone B-drug
. O

Caution O
should O
be O
exercised O
and O
dose O
reduction O
of O
the O
concomitant O
substrate O
drug O
should O
be O
considered O
when O
dosing O
lapatinib B-drug
concurrently O
with O
medications O
with O
narrow O
therapeutic O
windows O
that O
are O
substrates O
of O
CYP3A4 O
or O
CYP2C8 O
. O

As O
with O
other O
agents B-group
with I-group
b-blocking I-group
properties I-group
, O
if O
COREG B-brand
is O
to O
be O
administered O
orally O
with O
calcium B-group
channel I-group
blockers I-group
of O
the O
verapamil B-drug
or O
diltiazem B-drug
type O
, O
it O
is O
recommended O
that O
ECG O
and O
blood O
pressure O
be O
monitored O
. O

No O
formal O
assessments O
of O
drug-drug O
interactions O
between O
Vidaza B-brand
and O
other O
agents O
have O
been O
conducted O

Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-group
hormonal I-group
contraceptives I-group
who O
also O
used O
some O
form O
of O
St. O
Johns O
Wort O
. O

Phenobarbital B-drug

Specific O
drug O
interaction O
studies O
have O
not O
been O
performed O
with O
SUSTIVA B-brand
and O
NRTIs B-group
other O
than O
lamivudine B-drug
and O
zidovudine B-drug
. O

Concomitant O
administration O
of O
Norpace B-brand
and O
quinidine B-drug
resulted O
in O
slight O
increases O
in O
plasma O
disopyramide B-drug
levels O
and O
slight O
decreases O
in O
plasma O
quinidine B-drug
levels O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
rhabdomyolysis O
resulting O
from O
concomitant O
use O
of O
clarithromycin B-drug
and O
simvastatin B-drug
. O

Drugs O
with O
a O
Narrow O
Therapeutic O
Index O
Digoxin B-drug
: O
Sonata B-brand
( O
10 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetic O
or O
pharmacodynamic O
profile O
of O
digoxin B-drug
( O
0.375 O
mg O
q24h O
for O
8 O
days O
) O
. O

Coadministration O
with O
compounds O
that O
are O
potent O
inducers O
of O
CYP3A4 O
( O
eg O
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
carbamazepine B-drug
) O
may O
result O
in O
decreased O
plasma O
levels O
of O
saquinavir B-drug
. O

Warfarin B-drug
: O
Quinolones B-group
, O
including O
enoxacin B-drug
, O
decrease O
the O
clearance O
of O
R-warfarin B-drug
, O
the O
less O
active O
isomer O
of O
racemic O
warfarin B-drug
. O

Drug/Laboratory O
Test O
Interactions O
Phenytoin B-drug
may O
decrease O
serum O
concentrations O
of O
14 O
. O

Combination O
hormonal B-group
contraceptives I-group
may O
also O
decrease O
the O
plasma O
concentration O
of O
acetaminophen B-drug
. O

Digoxin B-drug
: O
When O
multiple O
doses O
of O
atorvastatin B-drug
and O
digoxin B-drug
were O
coadministered O
, O
steady-state O
plasma O
digoxin B-drug
concentrations O
increased O
by O
approximately O
20 O
% O
. O

Oxcarbazepine B-drug
was O
evaluated O
in O
human O
liver O
microsomes O
to O
determine O
its O
capacity O
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
responsible O
for O
the O
metabolism O
of O
other O
drugs O
. O

In O
studies O
with O
finasteride B-drug
, O
no O
clinically O
meaningful O
changes O
in O
luteinizing O
hormone O
( O
LH O
) O
, O
follicle-stimulating O
hormone O
( O
FSH O
) O
or O
prolactin O
were O
detected O
. O

Phenytoin B-drug

Amiodarone B-drug
caused O
a O
three- O
to O
fivefold O
increase O
in O
serum O
reverse O
triiodothyronine O
levels O
, O
but O
changes O
in O
thyroid O
function O
were O
not O
quantitatively O
related O
to O
the O
changes O
in O
digoxin B-drug
pharmacokinetics O
. O

The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
; O

Additive O
CNS O
depression O
may O
occur O
when O
antihistamines B-group
are O
administered O
concomitantly O
with O
other O
CNS B-group
depressants I-group
including O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
alcohol B-drug
. O

This O
article O
looks O
at O
five O
commonly O
used O
immunosuppressive B-group
drugs I-group
in O
turn O
( O
corticosteroids B-group
, O
cyclosporin B-drug
, O
azathioprine B-drug
, O
methotrexate B-drug
, O
cyclophosphamide B-drug
) O
, O
discussing O
the O
main O
, O
non-infection O
, O
unwanted O
effects O
, O
ways O
to O
avoid O
them O
and O
what O
to O
do O
if O
problems O
arise O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
TCAs B-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

No O
pharmacokinetic-based O
drug-drug O
interaction O
studies O
have O
been O
conducted O
with O
SYNAREL B-brand
. O

Prescribers O
are O
advised O
to O
consult O
the O
package O
insert O
of O
medication O
administered O
concomitantly O
with O
hormonal B-group
contraceptives I-group
, O
since O
some O
medications O
may O
decrease O
the O
effectiveness O
of O
these O
birth O
control O
products O
. O

Co-administration O
of O
anastrozole B-drug
and O
tamoxifen B-drug
resulted O
in O
a O
reduction O
of O
anastrozole B-drug
plasma O
levels O
by O
27 O
% O
compared O
with O
those O
achieved O
with O
anastrozole B-drug
alone O
. O

The O
mechanism O
of O
this O
pharmacodynamic O
interaction O
is O
not O
known O
. O

Patients O
receiving O
high O
doses O
of O
salicylates B-group
concomitantly O
with O
furosemide B-drug
, O
as O
in O
rheumatic O
disease O
, O
may O
experience O
salicylate B-group
toxicity O
at O
lower O
doses O
because O
of O
competitive O
renal O
excretory O
sites O
. O

When O
lansoprazole B-drug
was O
administered O
concomitantly O
with O
theophylline B-drug
( O
CYP1A2 O
, O
CYP3A O
) O
, O
a O
minor O
increase O
( O
10 O
% O
) O
in O
the O
clearance O
of O
theophylline B-drug
was O
seen O
. O

Caution O
is O
advised O
in O
using O
Duloxetine B-drug
in O
patients O
with O
conditions O
that O
may O
slow O
gastric O
emptying O
( O
e.g. O
, O
some O
diabetics O
) O
. O

Diuretic B-group
agents I-group
reduce O
the O
renal O
clearance O
of O
lithium B-drug
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-group
. O

These O
cells O
express O
the O
vitamin O
D O
receptor O
and O
exhibit O
doubling O
times O
comparable O
to O
the O
parental O
MCF-7 O
cells O
, O
even O
when O
grown O
in O
100 O
mM O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
. O

Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

The O
concomitant O
administration O
of O
uricosuric B-group
agents I-group
and O
allopurinol B-drug
has O
been O
associated O
with O
a O
decrease O
in O
the O
excretion O
of O
oxypurines O
( O
hypoxanthine O
and O
xanthine O
) O
and O
an O
increase O
in O
urinary O
uric O
acid O
excretion O
compared O
with O
that O
observed O
with O
allopurinol B-drug
alone O
. O

TAMBOCOR B-brand
has O
been O
used O
in O
a O
large O
number O
of O
patients O
receiving O
diuretics B-group
without O
apparent O
interaction O
. O

Drugs O
That O
Inhibit O
Aldehyde O
Oxidase O
The O
aldehyde O
oxidase O
enzyme O
system O
is O
less O
well O
studied O
than O
the O
cytochrome O
P450 O
enzyme O
system O
. O

A O
study O
in O
eight O
healthy O
volunteers O
has O
shown O
a O
50 O
% O
increase O
in O
mean O
peak O
nimodipine B-drug
plasma O
concentrations O
and O
a O
90 O
% O
increase O
in O
mean O
area O
under O
the O
curve O
, O
after O
a O
one O
week O
course O
of O
cimetidine B-drug
at O
1,000 O
mg/day O
and O
nimodipine B-drug
at O
90 O
mg/day O
. O

We O
have O
selected O
a O
subclone O
of O
MCF-7 O
cells O
resistant O
to O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
( O
MCF-7D3Res O
) O
. O

Antagonism O
between O
lincomycin B-drug
and O
erythromycin B-drug
in O
vitro O
has O
been O
demonstrated O
. O


The O
data O
suggest O
that O
the O
histidine O
residues O
may O
be O
crucial O
to O
the O
receptor-binding O
activity O
of O
toxin B-drug_n
A I-drug_n
. O

The O
following O
precautions O
should O
be O
kept O
in O
mind O
in O
the O
treatment O
of O
anticholinesterase O
poisoning O
although O
they O
do O
not O
bear O
directly O
on O
the O
use O
of O
atropine B-drug
and O
pralidoxime B-drug
. O

Drug/Laboratory O
Test O
Interactions O
None O
known O
. O

Other O
Chemotherapy O
Agents O
In O
a O
separate O
study O
, O
concomitant O
administration O
of O
lapatinib B-drug
with O
capecitabine B-drug
did O
not O
meaningfully O
alter O
the O
pharmacokinetics O
of O
either O
agent O
( O
or O
the O
metabolites O
of O
capecitabine B-drug
) O
. O

Labetalol B-drug
HCl I-drug
blunts O
the O
reflex O
tachycardia O
produced O
by O
nitroglycerin B-drug
without O
preventing O
its O
hypotensive O
effect O
. O

It O
is O
advisable O
to O
check O
coagulation O
time O
within O
the O
first O
few O
days O
after O
the O
start O
and O
discontinuation O
of O
cisapride B-drug
therapy O
, O
with O
an O
appropriate O
adjustment O
of O
the O
anticoagulant B-group
dose O
, O
if O
necessary O
. O

This O
is O
especially O
important O
in O
patients O
who O
may O
use O
alcohol B-drug
excessively O
. O

It O
is O
likely O
that O
use O
of O
epirubicin B-drug
with O
radiotherapy O
may O
sensitize O
tissues O
to O
the O
cytotoxic O
actions O
of O
irradiation O
. O

Carbamazepine B-drug
overdose O
recognized O
by O
a O
tricyclic B-group
antidepressant I-group
assay O
. O

The O
concomitant O
use O
of O
vasopressors B-group
, O
vasoconstricting O
agents O
( O
such O
as O
ergonovine B-drug
) O
and O
some O
oxytocic B-group
drugs I-group
may O
result O
in O
severe O
hypertension O
. O

Concurrent O
use O
with O
general O
anesthetics B-group
may O
result O
in O
arrhythmias O
. O

Thrombolytic B-group
agents I-group
: O
The O
safety O
and O
effectiveness O
of O
Argatroban B-drug
with O
thrombolytic B-group
agents I-group
have O
not O
been O
established O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Agents I-group
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
the O
co-administration O
of O
enalapril B-drug
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O

This O
indicates O
that O
tiagabine B-drug
does O
not O
cause O
induction O
or O
inhibition O
of O
the O
hepatic O
microsomal O
enzyme O
systems O
responsible O
for O
the O
metabolism O
of O
antipyrine B-drug
. O

indinavir I-drug
concentration O

Cimetidine B-drug
: O
Co-administration O
with O
high O
doses O
of O
cimetidine B-drug
[ O
800 O
mg O
twice O
daily O
] O
increased O
the O
Cmax O
of O
rofecoxib B-drug
by O
21 O
% O
, O
the O
AUC0-120hr O
by O
23 O
% O
and O
the O
t1/2 O
by O
15 O
% O
. O

Other O
drug O
interactions O
Cimetidine B-drug
, O
erythromycin B-drug
and O
dextropropoxyphene B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
MHD B-drug_n
. O

Standard O
monitoring O
of O
methotrexate-related B-drug
toxicity O
should O
be O
continued O
if O
VIOXX B-brand
and O
methotrexate B-drug
are O
administered O
concomitantly O
. O

Risk O
of O
Anaphylactic O
Reaction O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

In O
healthy O
volunteers O
, O
treatment O
with O
finasteride B-drug
did O
not O
alter O
the O
response O
of O
LH O
and O
FSH O
to O
gonadotropin-releasing O
hormone O
indicating O
that O
the O
hypothalamic-pituitary-testicular O
axis O
was O
not O
affected O
. O

Rifabutin I-drug

The O
prior O
administration O
of O
succinylcholine B-drug
does O
not O
enhance O
the O
duration O
, O
but O
quickens O
the O
onset O
and O
may O
increase O
the O
depth O
, O
of O
neuromuscular O
block O
induced O
by O
TRACRIUM B-brand
. O

ranitidine* B-drug
; O

The O
appropriate O
interval O
between O
administration O
of O
these O
agents O
and O
dexfenfluramine B-drug
has O
not O
been O
established O
. O

The O
half-life O
increased O
from O
4.0 O
to O
4.8 O
hours O
. O

There O
is O
no O
pharmacokinetic O
interaction O
between O
zaleplon B-drug
and O
diphenhydramine B-drug
following O
the O
administration O
of O
a O
single O
dose O
( O
10 O
mg O
and O
50 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O

saquinavir I-drug
concentration O

The O
adverse O
experience O
profile O
seen O
with O
KEMSTROTM B-brand
was O
similar O
to O
that O
seen O
with O
baclofen B-drug
tablets O
. O

Agents O
that O
are O
CYP3A4 O
inhibitors O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
increase O
plasma O
levels O
of O
EQUETROTM B-brand
are O
the O
following O
: O
Acetazolamide B-drug
, O
azole B-group
antifungals I-group
, O
cimetidine B-drug
, O
clarithromycin B-drug
( O
1 O
) O
, O
dalfopristin B-drug
, O
danazol B-drug
, O
delavirdine B-drug
, O
diltiazem B-drug
, O
erythromycin B-drug
( O
1 O
) O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
grapefruit O
juice O
, O
isoniazid B-drug
, O
itraconazole B-drug
, O
ketoconazole B-drug
, O
loratadine B-drug
, O
nefazodone B-drug
, O
niacinamide B-drug
, O
nicotinamide B-drug
, O
protease B-group
inhibitors I-group
, O
propoxyphene B-drug
, O
quinine B-drug
, O
quinupristin B-drug
, O
troleandomycin B-drug
, O
valproate B-drug
( O
1 O
) O
, O
verapamil B-drug
, O
zileuton B-drug
. O

In O
three O
separate O
controlled O
, O
parallel O
group O
clinical O
pharmacology O
studies O
, O
desloratadine B-drug
at O
the O
clinical O
dose O
of O
5 O
mg O
has O
been O
coadministered O
with O
azithromycin B-drug
500 O
mg O
followed O
by O
250 O
mg O
once O
daily O
for O
4 O
days O
( O
n=18 O
) O
or O
with O
fluoxetine B-drug
20 O
mg O
once O
daily O
for O
7 O
days O
after O
a O
23 O
day O
pretreatment O
period O
with O
fluoxetine B-drug
( O
n=18 O
) O
or O
with O
cimetidine B-drug
600 O
mg O
every O
12 O
hours O
for O
14 O
days O
( O
n=18 O
) O
under O
steady O
state O
conditions O
to O
normal O
healthy O
male O
and O
female O
volunteers O
. O

Concomitant O
use O
of O
digoxin B-drug
and O
sympathomimetics B-group
increases O
the O
risk O
of O
cardiac O
arrhythmias O
. O

Olanzapine B-drug
is O
associated O
with O
significantly O
fewer O
extrapyramidal O
symptoms O
than O
haloperidol B-drug
and O
risperidone B-drug
. O

lithium B-drug
; O

Drugs O
which O
impair O
glomerular O
filtration O
may O
prolong O
the O
biological O
half-life O
of O
flucytosine B-drug
. O

Meperidine B-drug
: O
Amphetamines B-group
potentiate O
the O
analgesic O
effect O
of O
meperidine B-drug
. O

- O
Dantrolene B-drug
( O
e.g. O
, O
Dantrium B-brand
) O
or O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
drug-laboratory O
test O
interactions O
. O

Lodine B-brand
treatment O
is O
associated O
with O
a O
small O
decrease O
in O
serum O
uric O
acid O
levels O
. O

Immediate O
and O
Extended O
Release O
Tablets O
The O
hypoglycemic O
action O
of O
sulfonylureas B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
some O
azoles B-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

CYP3A4 O
inducers O
: O
CYP3A4 O
inducers O
may O
decrease O
the O
levels/effects O
of O
ethinyl B-drug
estradiol I-drug
. O

Aprepitant I-drug
, O
when O
given O
as O
a O
regimen O
of O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
, O
increased O
the O
AUC O
of O
methylprednisolone B-drug
, O
a O
CYP3A4 O
substrate O
, O
by O
1.34-fold O
on O
Day O
1 O
and O
by O
2.5-fold O
on O
Day O
3 O
, O
when O
methylprednisolone B-drug
was O
coadministered O
intravenously O
as O
125 O
mg O
on O
Day O
1 O
and O
orally O
as O
40 O
mg O
on O
Days O
2 O
and O
3 O
. O

Catecholamine-depleting O
drugs O
( O
e.g. O
, O
reserpine B-drug
) O
: O
additive O
effect O
; O

Doxazosin B-drug
mesylate I-drug
tablets O
have O
been O
used O
with O
the O
following O
drugs O
or O
drug O
classes O
: O
1 O
. O

Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
AXERT B-brand
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
. O

Miracidia O
demonstrated O
a O
rapid O
avoidance O
behaviour O
when O
briefly O
exposed O
to O
heavy O
metals O
. O

Carbamazepine B-drug
: O
In O
healthy O
subjects O
receiving O
the O
CYP3A4 O
inducer O
, O
carbamazepine B-drug
, O
at O
100 O
mg O
twice O
daily O
for O
3 O
days O
and O
200 O
mg O
twice O
daily O
for O
17 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-drug
was O
decreased O
approximately O
72 O
% O
. O

The O
aim O
of O
this O
paper O
was O
to O
study O
the O
interaction O
between O
neurotensin B-drug_n
and O
both O
enkephalins B-drug_n
or O
its O
synthetic O
analogue O
D-Ala2-metenkephalinamide B-drug_n
, O
or O
tuftsin B-drug_n
, O
on O
the O
antinonciceptive O
effect O
of O
these O
peptides O
in O
mice O
after O
intracisternal O
injection O
. O

Coadministration O
of O
this O
oral O
contraceptive B-group
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

The O
magnitude O
of O
interaction O
within O
the O
recommended O
dose O
ranges O
of O
either O
drug O
is O
not O
known O
. O

Treatment O
of O
toxin B-drug_n
A I-drug_n
with O
[ O
( O
14 O
) O
C O
] O
-diethyl B-drug_n
pyrocarbonate I-drug_n
revealed O
concentration O
dependent O
labelling O
of O
histidine O
residues O
on O
the O
toxin O
molecules O
. O

Cross-reactions O
with O
non-Aspergillus O
polysaccharides O
and O
polyfuranoses O
with O
the O
Bio-Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
have O
been O
reported O
. O

Drug/Laboratory O
Test O
Interactions O
: O
A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedict O
s O
or O
Fehling O
s O
solution O
or O
with O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme-based O
tests O
for O
glycosuria O
. O

Grapefruit O
juice O
should O
not O
be O
taken O
during O
treatment O
with O
oral O
amiodarone O
. O

monitor O
cyclosporine B-drug
levels O
. O

Table O
3 O
Established O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O

Anagrelide B-drug
is O
an O
inhibitor O
of O
cyclic O
AMP O
PDE O
III O
. O

Cyclosporine B-drug
: O
Concomitant O
administration O
of O
nicardipine B-drug
and O
cyclosporine B-drug
levels O
. O

This O
interaction O
may O
result O
in O
myopathy O
and O
rhabdomyolysis O
, O
particularly O
in O
patients O
with O
renal O
insufficiency O
or O
those O
who O
are O
concurrently O
taking O
medications O
associated O
with O
myopathy O
. O

FLUOTHANE B-brand
augments O
the O
action O
of O
non-depolarising B-group
muscle I-group
relaxants O
and O
the O
muscle O
relaxant O
effects O
of O
aminoglycosides B-group
. O

Twelve O
strains O
of O
Staphylococcus O
aureus O
( O
a O
frequent O
cause O
of O
infection O
in O
heroin B-drug_n
, O
but O
not O
in O
pentazocine B-drug
and O
tripelennamine B-drug
, O
addicts O
) O
were O
completely O
inhibited O
by O
the O
drug O
combination O
. O

Recovery O
programs O
should O
be O
flexible O
and O
involve O
individual O
and O
family O
education O
on O
recovery O
and O
the O
nature O
of O
addictive O
disease O
. O

- O
Skeletal B-group
muscle I-group
relaxants I-group
, O
nondepolarizing O
( O
e.g. O
, O
tubocurarine B-drug
) O
: O
Possible O
increased O
responsiveness O
to O
the O
muscle B-group
relaxant I-group

Continued O
admistration O
of O
the O
drug O
is O
required O
to O
maintain O
barpress O
response O
in O
this O
strain O
of O
dogs O
. O

A O
dose O
increase O
of O
lopinavir/ritonavir B-drug
to O
533/133 O
mg O
twice O
daily O
with O
food O
isrecommended O
in O
combination O
with O
nevirapine B-drug
. O

Nevertheless O
, O
caution O
should O
be O
used O
in O
patients O
receiving O
concomitant O
treatment O
with O
other O
drugs O
that O
are O
either O
inhibitors O
or O
inducers O
of O
these O
enzymes O
. O

Permanent O
nerve O
damage O
could O
theoretically O
occur O
if O
vitamin O
B12 O
deficiency O
is O
not O
treated O
. O

- O
Carbamazepine B-drug
( O
e.g. O
, O
Tegretol B-brand
) O
or O

Anagrelide B-drug
is O
metabolized O
at O
least O
in O
part O
by O
CYP1A2 O
. O

If O
the O
usual O
amounts O
of O
nondepolarizing O
relaxants O
are O
given O
, O
the O
time O
for O
recovery O
from O
neuromuscular O
blockade O
will O
be O
longer O
in O
the O
presence O
of O
Enflurane B-drug
than O
when O
halothane B-drug
or O
nitrous B-drug
oxide I-drug
with O
a O
balanced O
technique O
are O
used O
. O

Although O
not O
studied O
systematically O
in O
clinical O
trials O
, O
no O
drug O
interactions O
were O
observed O
when O
vecuronium B-drug
, O
pancuronium B-drug
, O
or O
atracurium B-drug
were O
administered O
following O
varying O
degrees O
of O
recovery O
from O
single O
doses O
or O
infusions O
of O
NIMBEX B-brand
. O

Free O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
; O

In O
both O
periods O
, O
blood O
and O
urine O
were O
sampled O
at O
regular O
intervals O
. O

Interest O
in O
administering O
compounds O
in O
combination O
lies O
both O
in O
enhancing O
efficacious O
effects O
and O
in O
limiting O
adverse O
effects O
. O

May O
interact O
with O
addictive O
medications O
, O
especially O
central B-group
nervous I-group
system I-group
( I-group
CNS I-group
) I-group
depressants I-group
with O
habituating O
potential O
( O
prolonged O
concurrent O
use O
may O
increase O
the O
risk O
of O
habituation O
) O
, O
alcohol B-drug
or O
CNS O
depression O
producing O
medications O
( O
concurrent O
use O
may O
increase O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
ethinamate B-drug
) O
. O

There O
were O
no O
significant O
differences O
among O
the O
pD2 O
values O
for O
noradrenaline B-drug
in O
aortic O
rings O
without O
endothelium O
. O

Consequently O
, O
concomitant O
administration O
of O
Aprepitant B-drug
with O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
nefazodone B-drug
, O
troleandomycin B-drug
, O
clarithromycin B-drug
, O
ritonavir B-drug
, O
nelfinavir B-drug
) O
should O
be O
approached O
with O
caution O
. O

Additional O
animals O
in O
both O
dose O
groups O
developed O
B-cell O
hyperplasia O
of O
the O
spleen O
and O
lymph O
nodes O
. O

When O
the O
CYP2D6 O
inhibitor O
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-drug
dose O
should O
then O
be O
increased O
. O

( O
Indomethacin B-drug
) O
diuretics B-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

Preliminary O
studies O
indicate O
that O
the O
concomitant O
use O
of O
dobutamine B-drug
and O
nitroprusside B-drug
results O
in O
a O
higher O
cardiac O
output O
and O
, O
usually O
, O
a O
lower O
pulmonary O
wedge O
pressure O
than O
when O
either O
drug O
is O
used O
alone O
. O

In O
order O
to O
use O
the O
pharmacological O
properties O
of O
induced O
therapeutic O
hypermagnesaemia O
, O
high O
oral O
doses O
of O
magnesium B-drug
( O
> O
10 O
mg/kg/day O
) O
are O
advisable O
for O
chronic O
indications O
and O
the O
parenteral O
route O
is O
suitable O
for O
acute O
indications O
. O

insulin B-drug
requirements O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O
) O

The O
CYP3A4 O
isoenzyme O
is O
present O
in O
both O
the O
liver O
and O
intestines O
. O

No O
information O
available O

DIDREX B-brand
should O
not O
be O
used O
concomitantly O
with O
other O
CNS B-group
stimulants I-group
. O

however O
, O
as O
with O
other O
NSAIDs B-group
, O
concomitant O
administration O
of O
Lodine B-brand
and O
aspirin B-brand
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O

Therefore O
, O
when O
hydroflumethiazide B-drug
and O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O
) O

In O
such O
cases O
, O
therefore O
, O
more O
frequent O
dosing O
may O
be O
required O
to O
achieve O
or O
maintain O
the O
desired O
hypotensive O
response O
. O

Gabapentin B-drug
is O
not O
appreciably O
metabolized O
nor O
does O
it O
interfere O
with O
the O
metabolism O
of O
commonly O
coadministered O
antiepileptic B-group
drugs I-group
. O

Drugs O
that O
Inhibit O
or O
Induce O
Cytochrome O
P450 O
3A4 O
Enzymes O
Lapatinib B-drug
undergoes O
extensive O
metabolism O
by O
CYP3A4 O
, O
and O
concomitant O
administration O
of O
strong O
inhibitors O
or O
inducers O
of O
CYP3A4 O
alter O
lapatinib B-drug
concentrations O
significantly O
. O

When O
initiating O
a O
multi-day O
course O
of O
grepafloxacin B-drug
in O
a O
patient O
maintained O
on O
theophylline B-drug
, O
the O
theophylline B-drug
maintenance O
dose O
should O
be O
halved O
for O
the O
period O
of O
concurrent O
use O
of O
grepafloxacin B-drug
and O
monitoring O
of O
serum O
theophylline B-drug
concentrations O
should O
be O
initiated O
as O
a O
guide O
to O
further O
dosage O
adjustments O
. O

ZEBETA B-brand
should O
be O
used O
with O
care O
when O
myocardial B-group
depressants I-group
or O
inhibitors O
of O
AV O
conduction O
, O
such O
as O
certain O
calcium B-group
antagonists I-group
( O
particularly O
of O
the O
phenylalkylamine B-group
[ O
verapamil B-drug
] O
and O
benzothiazepine B-group
[ O
diltiazem B-drug
] O
classes O
) O
, O
or O
antiarrhythmic B-group
agents I-group
, O
such O
as O
disopyramide B-drug
, O
are O
used O
concurrently O
. O

Elevated O
cyclosporine B-drug
serum O
levels O
have O
been O
reported O
with O
the O
concomitant O
use O
of O
quinolones B-group
and O
cyclosporine B-drug
. O

Cytotoxic B-group
Agents I-group
: O
Enhanced O
bone O
marrow O
suppression O
by O
cyclophosphamide B-drug
and O
other O
cytotoxic B-group
agents I-group
has O
been O
reported O
among O
patients O
with O
neoplastic O
disease O
, O
except O
leukemia O
, O
in O
the O
presence O
of O
allopurinol B-drug
. O

100-150 O

Once O
a O
stable O
prothrombin O
time O
has O
been O
documented O
, O
prothrombin O
times O
can O
be O
monitored O
at O
the O
intervals O
usually O
recommended O
for O
patients O
on O
coumarin B-group
anticoagulants I-group
. O

It O
is O
recommended O
that O
serum O
lithium B-drug
levels O
be O
monitored O
frequently O
if O
enalapril B-drug
is O
administered O
concomitantly O
with O
lithium B-drug
. O

- O
Non-steroidal B-group
Anti-inflammatory I-group
Drugs I-group
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-drug
diuretics I-drug
. O

The O
reluctance O
to O
treat O
aggressively O
is O
understandable O
because O
the O
geriatric O
population O
is O
susceptible O
to O
adverse O
drug O
reactions O
. O

Leukocyte B-drug_n
transfusions I-drug_n
: O
acute O
pulmonary O
toxicity O
has O
been O
reported O
in O
patients O
receiving O
intravenous O
amphotericin B-drug
B I-drug
and O
leukocyte B-drug_n
transfusions I-drug_n
. O

The O
effect O
of O
corticosteroids B-group
on O
oral O
anticoagulants B-group
is O
variable O
. O

The O
levorotatory O
isomer O
had O
opioid-antagonist O
and O
non-opioid O
agonist O
effects O
in O
pigeons O
and O
mixed O
opioid O
agonist-antagonist O
effects O
in O
monkeys O
. O

The O
interaction O
is O
a O
consequence O
of O
blocking O
hepatic O
metabolism O
of O
vardenafil B-drug
by O
ritonavir B-drug
, O
a O
highly O
potent O
CYP3A4 O
inhibitor O
, O
which O
also O
inhibits O
CYP2C9 O
. O

Samples O
for O
plasma O
and O
urine O
immunoreactive O
digoxin B-drug
concentrations O
were O
collected O
through O
120 O
hours O
following O
the O
digoxin B-drug
dose O
. O

. O

The O
pharmacokinetics O
of O
irbesartan B-drug
were O
not O
affected O
by O
coadministration O
of O
nifedipine B-drug
or O
hydrochlorothiazide B-drug

griseofulvin B-drug
; O

Praziquantel B-drug
: O
In O
the O
fed O
state O
, O
praziquantel B-drug
( O
40 O
mg/kg O
) O
increased O
mean O
maximum O
plasma O
concentration O
and O
area O
under O
the O
curve O
of O
albendazole B-drug
sulfoxide I-drug
by O
about O
50 O
% O
in O
healthy O
subjects O
( O
n=10 O
) O
compared O
with O
a O
separate O
group O
of O
subjects O
( O
n=6 O
) O
given O
albendazole B-drug
alone O
. O

Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-drug
, O
dextromethorphan B-drug
, O
and O
the O
tricyclic B-group
antidepressants I-group
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
monitored O
. O

- O
Anticoagulants B-group
: O
Interaction O
studies O
in O
humans O
have O
shown O
bumetanide B-drug
to O
have O
no O
effect O
on O
warfarin B-drug
metabolism O
or O
on O
plasma O
prothrombin O
activity O
. O

Both O
studies O
used O
12 O
subjects O
. O

Lithium B-drug
: O
Nonsteroidal B-group
anti-inflammatory I-group
agents I-group
have O
been O
reported O
to O
increase O
steadystate O
plasma O
lithium B-drug
levels O
. O

After O
etofibrate B-drug
treatment O
, O
there O
was O
decrease O
of O
total O
cholesterol O
and O
triglyceride O
plasma O
levels O
and O
a O
trend O
to O
increase O
high-density O
lipoprotein O
cholesterol O
plasma O
levels O
. O

nc1,2 O
30 O
% O
decrease O
[ O
CI O
: O
3 O
% O
decrease O
, O
48 O
% O
decrease O
] O

Patients O
receiving O
hydantoins B-group
, O
sulfonamides B-group
, O
or O
sulfonylureas B-group
should O
be O
observed O
for O
increased O
activity O
of O
these O
drugs O
and O
, O
therefore O
, O
signs O
of O
toxicity O
from O
these O
drugs O
. O

In O
vitro O
drug O
metabolism O
studies O
indicate O
that O
Starlix B-brand
is O
predominantly O
metabolized O
by O
the O
cytochrome O
P450 O
isozyme O
CYP2C9 O
( O
70 O
% O
) O
and O
to O
a O
lesser O
extent O
CYP3A4 O
( O
30 O
% O
) O
. O

zaleplon B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
ethanol B-drug
. O

Dofetilide B-drug
is O
not O
an O
inhibitor O
of O
CYP3A4 O
nor O
of O
other O
cytochrome O
P450 O
isoenzymes O
( O
e.g. O
, O
CYP2C9 O
, O
CYP2D6 O
) O
and O
is O
not O
expected O
to O
increase O
levels O
of O
drugs O
metabolized O
by O
CYP3A4 O
. O

Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg/day O
to O
1200 O
mg/day O
ketoconazole B-drug
for O
a O
week O
to O
healthy O
men O
. O

n-Octyl O
and O
n-cetyl O
gallate O
also O
showed O
good O
inhibition O
, O
while O
gallic O
acid O
itself O
was O
not O
so O
active O
, O
suggesting O
that O
the O
presence O
of O
hydrophobic O
side O
chain O
is O
important O
for O
the O
suppressive O
effect O
. O

These O
agents O
should O
not O
be O
used O
in O
patients O
treated O
with O
Itraconazole B-drug
. O

18-Methoxycoronaridine B-drug_n
( O
18-MC B-drug_n
) O
and O
ibogaine B-drug_n
: O
comparison O
of O
antiaddictive O
efficacy O
, O
toxicity O
, O
and O
mechanisms O
of O
action O
. O

Conjugation O
at O
NaCMC B-drug_n
with O
cysteine B-drug
moieties O
significantly O
improves O
the O
intestinal O
permeation O
of O
the O
hydrophilic O
molecule O
NaFlu B-drug
and O
the O
model O
peptide O
drugs O
bacitracin B-drug
and O
insulin B-drug
in O
vitro O
, O
therefore O
this O
conjugated O
system O
maybe O
useful O
for O
peroral O
administration O
of O
peptide O
drugs O
in O
the O
future O
. O

Reproductive O
toxicology O
studies O
have O
been O
performed O
in O
cynomolgus O
monkeys O
at O
doses O
up O
to O
5 O
mg/kg/week O
( O
about O
62 O
times O
the O
human O
dose O
based O
on O
body O
weight O
) O
and O
have O
revealed O
no O
evidence O
of O
impaired O
fertility O
or O
harm O
to O
the O
fetus O
due O
to O
AMEVIVE B-brand
. O

Since O
both O
alcohol B-drug
and O
organoleads O
are O
present O
in O
the O
environment O
and O
seem O
to O
influence O
limbic O
integration O
, O
the O
interaction O
of O
these O
two O
compounds O
was O
assessed O
in O
the O
present O
experiment O
. O

Interactions O
between O
theraputic O
agents O
have O
been O
recognized O
as O
increasingly O
important O
causes O
of O
drug O
at O
their O
usual O
recommended O
dose O
may O
, O
under O
certain O
conditions O
, O
produce O
toxicity O
of O
life-endangering O
proportions O
. O

We O
examined O
the O
effect O
of O
exogenous O
estradiol B-drug
on O
the O
changes O
in O
serum O
steroid O
hormone O
levels O
induced O
by O
a O
nonlethal O
dose O
of O
Escherichia O
coli O
endotoxin B-drug_n
in O
male O
rats O
and O
the O
deaths O
due O
to O
nonlethal O
and O
lethal O
doses O
of O
endotoxin B-drug_n
. O

Therefore O
, O
it O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
such O
agents O
. O


Meperidine B-drug
: O
Amphetamines B-group
potentiate O
the O
analgesic O
effect O
of O
meperidine B-drug
. O

A O
direct O
causal O
relationship O
has O
not O
been O
established O
, O
but O
physicians O
should O
consider O
the O
possibility O
that O
diclofenac B-drug
may O
alter O
a O
diabetic O
patient O
s O
response O
to O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
decrease O
extracellular O
levels O
of O
dopamine O
in O
the O
nucleus O
accumbens O
, O
but O
only O
ibogaine B-drug_n
increases O
extracellular O
levels O
of O
serotonin O
in O
the O
nucleus O
accumbens O
. O

Before O
prescribing O
a O
symptomatic O
( O
pharmaceutical O
) O
treatment O
for O
patients O
with O
an O
erection O
disorder O
, O
attention O
should O
be O
given O
tot O
the O
sexological O
, O
psychological O
and O
medical O
backgrounds O
of O
the O
disorder O
. O

In O
a O
study O
in O
36 O
patients O
with O
mild O
to O
moderate O
hypertension O
where O
the O
antihypertensive O
effects O
of O
PRINIVIL B-brand
alone O
were O
compared O
to O
PRINIVIL B-brand
given O
concomitantly O
with O
indomethacin B-drug
, O
the O
use O
of O
indomethacin B-drug
was O
associated O
with O
a O
reduced O
antihypertensive O
effect O
, O
although O
the O
difference O
between O
the O
two O
regimens O
was O
not O
significant O
. O

In O
this O
study O
we O
investigated O
the O
effect O
of O
ginsenosides B-drug_n
on O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
channel O
subtypes O
using O
their O
selective B-group
Ca I-group
( I-group
2+ I-group
) I-group
channel I-group
blockers I-group
nimodipine B-drug
( O
L-type O
) O
, O
omega-conotoxin B-drug_n
GVIA I-drug_n
( O
N-type O
) O
, O
or O
omega-agatoxin B-drug_n
IVA I-drug_n
( O
P-type O
) O
in O
bovine O
chromaffin O
cells O
. O

Dose O
reduction O
or O
interruption O
of O
TARCEVA B-brand
should O
be O
considered O
if O
changes O
in O
liver O
function O
are O
severe O
. O

Trimethoprim B-drug
Alone O
or O
in O
Combination O
with O
Sulfamethoxazole B-drug
: O
Concomitant O
use O
of O
trimethoprim B-drug
alone O
or O
in O
combination O
with O
sulfamethoxazole B-drug
is O
contraindicated O
. O

This O
paper O
critically O
reviews O
the O
suitability O
of O
the O
urinary O
thioether O
assay O
as O
a O
method O
for O
the O
detection O
of O
exposure O
to O
electrophilic O
agents O
or O
their O
precursors O
. O

clinical O
implications O
are O
unclear O
. O

Nabilone B-drug
has O
been O
shown O
to O
have O
an O
additive O
CNS O
depressant O
effect O
when O
given O
with O
either O
diazepam B-drug
, O
secobarbitone B-brand
sodium I-brand
, O
alcohol B-drug
or O
codeine B-drug
. O

The O
interaction O
may O
be O
a O
result O
of O
inhibition O
of O
both O
CYP2C9 B-drug
and O
2C19 O
by O
fluvoxamine B-drug
. O

Other O
nephrotoxic O
medications O
: O
agents O
such O
as O
aminoglycosides B-group
, O
cyclosporine B-drug
, O
and O
pentamidine B-drug
may O
enhance O
the O
potential O
for O
drug-induced O
renal O
toxicity O
, O
and O
should O
be O
used O
concomitantly O
only O
with O
great O
caution O
. O

Methotrexate B-drug
: O
An O
increased O
risk O
of O
hepatitis O
has O
been O
reported O
to O
result O
from O
combined O
use O
of O
methotrexate B-drug
and O
etretinate B-drug
. O

certain O
antipsychotic B-group
medications I-group
( O
such O
as O
sertindole B-drug
) O
; O

Phenytoin B-drug
, O
phenobarbital B-drug
and O
carbamazepine B-drug
are O
ge O
nerally O
classified O
as O
enzyme O
inducers O
; O

Sertraline B-drug
neutralized O
the O
increase O
of O
glycemia O
induced O
by O
oral O
glucose B-drug
overload O
. O

Drug/ O
Laboratory O
Test O
Interactions O
Certain O
endocrine O
and O
liver O
function O
tests O
may O
be O
affected O
by O
estrogen-containing B-group
oral O
contraceptives B-group
. O

- O
Divalproex B-drug
( O
e.g. O
, O
Depakote B-brand
) O
or O

This O
is O
especially O
important O
for O
drugs O
associated O
with O
serious O
toxicity O
, O
such O
as O
other O
antiarrhythmics B-group
. O

In O
a O
study O
in O
hypertensive O
patients O
, O
addition O
of O
isradipine B-drug
to O
existing O
hydrochlorothiazide B-drug
therapy O
did O
not O
result O
in O
any O
unexpected O
adverse O
effects O
, O
and O
isradipine B-drug
had O
an O
additional O
antihypertensive O
effect O
. O

Acarbose B-drug
did O
not O
interfere O
with O
the O
absorption O
or O
disposition O
of O
the O
sulfonylurea B-drug
glyburide I-drug
in O
diabetic O
patients O
. O

These O
effects O
are O
usually O
reversible O
. O

Inhibitors O
Of O
Endogenous O
Prostaglandin O
Synthesis O
It O
has O
been O
reported O
that O
indomethacin B-drug
may O
reduce O
the O
antihypertensive O
effect O
of O
captopril B-drug
, O
especially O
in O
cases O
of O
low O
renin O
hypertension O
. O

Pregnancy O
( O
Category O
B O
) O

Therefore O
, O
diflunisal B-drug
and O
INDOCIN B-brand
should O
not O
be O
used O
concomitantly O
. O

Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Drug-Drug O
Interactions O
Between O
Keppra B-brand
And O
Other O
Antiepileptic B-group
Drugs I-group
( O
AEDs B-group
) O
Phenytoin B-drug
Keppra B-brand
( O
3000 O
mg O
daily O
) O
had O
no O
effect O
on O
the O
pharmacokinetic O
disposition O
of O
phenytoin B-drug
in O
patients O
with O
refractory O
epilepsy O
. O

The O
benefits O
of O
Mefloquine B-drug
therapy O
should O
be O
weighed O
against O
the O
possibility O
of O
adverse O
effects O
in O
patients O
with O
cardiac O
disease O
. O

Each O
treatment O
period O
was O
separated O
by O
14 O
to O
21 O
days O
. O

Zimelidine B-drug_n
etomidate B-drug
antagonism O

In O
these O
cases O
, O
your O
doctor O
may O
want O
to O
change O
the O
dose O
, O
or O
other O
precautions O
may O
be O
necessary O
. O

Other O
significant O
inhibitors O
of O
CYP2D6 O
, O
such O
as O
fluoxetine B-drug
or O
paroxetine B-drug
, O
would O
be O
expected O
to O
have O
similar O
effects O
and O
, O
therefore O
, O
should O
be O
accompanied O
by O
similar O
dose O
reductions O
. O

Patients O
with O
major O
psychotic O
disorders O
, O
treated O
with O
neuroleptics B-group
, O
should O
be O
treated O
with O
dopamine B-group
agonists I-group
only O
if O
the O
potential O
benefits O
outweigh O
the O
risks O
. O

Nine O
additional O
patients O
who O
had O
initial O
positive O
tests O
were O
negative O
on O
repeat O
testing O
. O

Antiepileptic B-group
Drugs I-group
: O
Sporadic O
cases O
of O
seizures O
have O
been O
reported O
during O
concomitant O
use O
of O
TORADOL B-brand
and O
antiepileptic B-group
drugs I-group
( O
phenytoin B-drug
, O
carbamazepine B-drug
) O
. O

Concomitant O
Drug O

- O
Plicamycin B-drug
( O
e.g. O
, O
Mithracin B-brand
) O
or O

Digoxin B-drug
: O
When O
Starlix B-brand
120 O
mg O
before O
meals O
was O
administered O
in O
combination O
with O
a O
single O
1-mg O
dose O
of O
digoxin B-drug
to O
healthy O
volunteers O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

Additional O
interactions O

Therefore O
, O
inhibitors O
of O
these O
enzymes O
are O
expected O
to O
reduce O
vardenafil B-drug
clearance O
. O

Ketoconazole B-drug
: O
In O
healthy O
subjects O
receiving O
ketoconazole B-drug
, O
a O
CYP3A4 O
inhibitor O
, O
at O
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-drug
was O
increased O
to O
approximately O
3.6-fold O
of O
control O
and O
half-life O
increased O
to O
1.7-fold O
of O
control O
. O

Guidelines O
are O
provided O
to O
assist O
the O
clinician O
in O
his O
logical O
approach O
to O
the O
identification O
of O
drug O
interactions O
when O
serious O
drug O
toxicity O
is O
encountered O
in O
a O
pateint O
. O

Because O
of O
foscarnets B-drug
tendency O
to O
cause O
renal O
impairment O
, O
the O
use O
of O
FOSCAVIR B-brand
should O
be O
avoided O
in O
combination O
with O
potentially O
nephrotoxic O
drugs O
such O
as O
aminoglycosides B-group
, O
amphotericin B-drug
B I-drug
and O
intravenous O
pentamidine B-drug
unless O
the O
potential O
benefits O
outweigh O
the O
risks O
to O
the O
patient O
. O

Epinephrine B-drug
may O
antagonize O
the O
neuron O
blockade O
produced O
by O
guanethidine B-drug
resulting O
in O
decreased O
antihypertensive O
effect O
and O
requiring O
increased O
dosage O
of O
the O
latter O
. O

Because O
CYP O
3A4 O
inhibitors O
may O
increase O
plasma O
concentrations O
of O
buprenorphine B-drug
, O
patients O
already O
on O
CYP O
3A4 O
inhibitors O
such O
as O
azole B-group
antifungals I-group
( O
e.g O
. O

With O
each O
successive O
generation O
more O
people O
are O
becoming O
more O
severely O
depressed O
at O
a O
younger O
age O
. O

saquinavir I-drug
concentration O

Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-group
channel I-group
blockers I-group
and O
organic B-group
nitrates I-group
were O
used O
in O
combination O
. O

Thus O
no O
dosing O
adjustments O
are O
necessary O
during O
concomitant O
use O
with O
these O
agents O
. O

Concomitant O
administration O
of O
Sonata B-brand
( O
10 O
mg O
) O
and O
cimetidine B-drug
( O
800 O
mg O
) O
produced O
an O
85 O
% O
increase O
in O
the O
mean O
Cmax O
and O
AUC O
of O
zaleplon B-drug
. O

This O
antagonistic O
effect O
of O
probenecid B-drug
on O
bumetanide B-drug
natriuresis O
is O
not O
due O
to O
a O
direct O
action O
on O
sodium O
excretion O
but O
is O
probably O
secondary O
to O
its O
inhibitory O
effect O
on O
renal O
tubular O
secretion O
of O
bumetanide B-drug
. O

For O
information O
on O
the O
pharmacokinetics O
of O
Gemzar B-brand
and O
cisplatin B-drug
in O
combination O
, O
see O
Drug O
Interactions O
under O
CLINICAL O
PHARMACOLOGY O
section O
. O

Caffeine-related B-drug
adverse O
effects O
have O
occurred O
in O
patients O
consuming O
caffeine B-drug
while O
on O
therapy O
with O
enoxacin B-drug
. O

Cholestyramine B-drug
: O
Cholestyramine B-drug
may O
increase O
the O
clearance O
of O
corticosteroids B-group
. O

Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-drug
150 O
mg O
once O
monthly O
was O
similar O
to O
that O
in O
patients O
treated O
with O
Ibandronate B-drug
2.5 O
mg O
once O
daily O
. O

Ampicillin B-drug
: O
In O
a O
study O
of O
healthy O
volunteers O
, O
chloroquine B-drug
significantly O
reduced O
the O
bioavailability O
of O
ampicillin B-drug
. O

Metal O
mixtures O
had O
no O
effect O
on O
egg B-drug
hatching O
. O

Because O
of O
its O
primary O
CNS O
effect O
, O
caution O
should O
be O
used O
when O
EQUETROTM B-brand
is O
taken O
with O
other O
centrally B-group
acting I-group
drugs I-group
and O
alcohol B-drug
. O

Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-group
inhibitors I-group
, O
including O
lisinopril B-drug
. O

Thus O
agents O
likely O
to O
be O
concomitantly O
administered O
with O
Chirocaine B-brand
that O
are O
metabolized O
by O
this O
isoenzyme O
family O
may O
potentially O
interact O
with O
Chirocaine B-brand
. O

These O
individuals O
may O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
when O
given O
usual O
doses O
. O

In O
order O
to O
approximate O
the O
steady O
state O
level O
, O
serum O
digoxin B-drug
levels O
should O
be O
drawn O
either O
before O
or O
at O
least O
six O
hours O
following O
the O
administration O
of O
an O
oral O
tablet O
. O

The O
use O
of O
herbal O
remedies O
is O
becoming O
increasingly O
popular O
in O
the O
United O
States O
. O

Drugs O
that O
may O
decrease O
imatinib B-drug
plasma O
concentrations O
: O
Substances O
that O
are O
inducers O
of O
CYP3A4 O
activity O
may O
increase O
metabolism O
and O
decrease O
imatinib B-drug
plasma O
concentrations O
. O

This O
inhibition O
can O
result O
in O
unexpectedly O
high O
plasma O
levels O
of O
other O
drugs B-drug
which O
are O
metabolized O
by O
those O
CYP450 O
enzymes O
. O

In O
a O
study O
in O
diabetics O
with O
microalbuminuria O
INSPRA B-brand
200 O
mg O
combined O
with O
the O
ACE B-group
inhibitor I-group
enalapril B-drug
10 O
mg O
increased O
the O
frequency O
of O
hyperkalemia O
( O
serum O
potassium O
5.5 O
mEq/L O
) O
from O
17 O
% O
on O
enalapril B-drug
alone O
to O
38 O
% O
. O

Tumor O
phenotype O
and O
susceptibility O
to O
progression O
as O
an O
expression O
of O
subpopulations O
of O
initiated O
murine O
cells O
. O

Rifampin B-drug
and O
warfarin B-drug
: O
a O
drug O
interaction O
. O

When O
catecholamines B-group
are O
administered O
, O
dilute O
solutions O
should O
be O
used O
and O
blood O
pressure O
should O
be O
monitored O
closely O
. O

Iodine B-drug
or O
iodine B-drug
excess O
may O
decrease O
the O
effect O
of O
Carbimazole B-drug
, O
and O
an O
iodine B-drug
deficiency O
can O
increase O
the O
effect O
of O
Carbimazole B-drug
. O

Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
the O
concomitant O
use O
of O
some O
quinolones B-group
and O
cyclosporine B-drug
. O

See O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
. O

Acetazolamide B-drug
increases O
lithium B-drug
excretion O
and O
the O
lithium B-drug
may O
be O
decreased O
. O

Drugs O
that O
may O
increase O
dasatinib B-drug
plasma O
concentrations O
CYP3A4 O
Inhibitors O
: O
Dasatinib B-drug
is O
a O
CYP3A4 O
substrate O
. O

No O
significant O
interaction O
has O
been O
found O
with O
broad-spectrum O
antibiotics B-group
. O

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

Differential O
regulation O
of O
tyrosine O
phosphorylation O
in O
tumor O
cells O
by O
contortrostatin B-drug_n
, O
a O
homodimeric O
disintegrin O
, O
and O
monomeric O
disintegrins O
echistatin B-drug_n
and O
flavoridin B-drug_n
. O

Usually O
, O
this O
has O
been O
observed O
in O
patients O
with O
a O
history O
of O
diabetes O
mellitus O
or O
evidence O
of O
glucose O
intolerance O
prior O
to O
administration O
of O
CAMPTOSAR B-brand
. O

. O

Salt O
substitutes O
containing O
potassium B-drug
should O
also O
be O
used O
with O
caution O
. O

In O
TAMBOCOR B-brand
clinical O
trials O
, O
patients O
who O
were O
receiving O
beta B-group
blockers I-group
concurrently O
did O
not O
experience O
an O
increased O
incidence O
of O
side O
effects O
. O

Benzodiazepines B-group
: O
Combination O
hormonal B-group
contraceptives I-group
may O
decrease O
the O
clearance O
of O
some O
benzodiazepines B-group
( O
alprazolam B-drug
, O
chlordiazepoxide B-drug
, O
diazepam B-drug
) O
and O
increase O
the O
clearance O
of O
others O
( O
lorazepam B-drug
, O
oxazepam B-drug
, O
temazepam B-drug
) O
. O

All O
animals O
in O
the O
study O
were O
positive O
for O
an O
endemic O
primate O
gammaherpes O
virus O
also O
known O
as O
lymphocryptovirus O
( O
LCV O
) O
. O

Cyclosporine B-drug
- O
L-arginine B-drug
may O
counteract O
the O
antinaturetic O
effect O
of O
cyclosporin B-drug
. O

Although O
, O
it O
is O
unknown O
whether O
this O
could O
result O
in O
clinically O
significant O
effects O
, O
caution O
is O
advised O
when O
administering O
Cerebyx B-brand
with O
other O
drugs O
that O
significantly O
bind O
to O
serum O
albumin O
. O

Coingestion O
of O
acetaminophen B-drug
with O
theophylline B-drug
, O
phenobarbital B-drug
with O
acetaminophen B-drug
, O
and O
valproic B-drug
acid I-drug
with O
phenobarbital B-drug
at O
high O
to O
toxic O
concentrations O
decreases O
the O
binding O
of O
the O
target O
drug O
. O

Alosetron B-drug
does O
not O
appear O
to O
induce O
the O
major O
cytochrome O
P450 O
( O
CYP O
) O
drug O
metabolizing O
enzyme O
3A O
. O

3 O
. O

antacids B-group
; O

N=12 O
) O
are O
identical O
whether O
the O
drugs O
are O
administered O
alone O
or O
together O
. O

Erythromycin B-drug
( O
500 O
mg O
t.i.d O
) O
produced O
a O
4-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
3-fold O
increase O
in O
Cmax O
when O
co-administered O
with O
Vardenafil B-drug
5 O
mg O
in O
healthy O
volunteers O
. O

HMG-CoA B-group
Reductase I-group
Inhibitor I-group
: O
atorvastatin B-drug

These O
results O
would O
seem O
to O
dictate O
against O
the O
clinical O
use O
of O
methotrexate B-drug
with O
ELSPAR B-brand
, O
or O
during O
the O
period O
following O
ELSPAR B-brand
therapy O
when O
plasma O
asparagine O
levels O
are O
below O
normal O
. O

Gastrointestinal O
transit O
time O
( O
lactulose O
hydrogen O
breath O
test O
) O
was O
measured O
in O
14 O
volunteers O
with O
oral O
and O
intravenous O
placebo O
, O
oral O
placebo O
and O
intravenous O
morphine B-drug
( O
0.05 O
mg O
x O
kg O
( O
-1 O
) O
) O
, O
and O
oral O
ADL B-drug
8-2698 I-drug
( O
4 O
mg O
) O
and O
intravenous O
morphine B-drug
( O
0.05 O
mg O
x O
kg O
( O
-1 O
) O
) O
in O
a O
double O
blind O
, O
cross-over O
study O
. O

Also O
, O
bleeding O
and/or O
increased O
prothrombin O
time O
have O
been O
reported O
in O
a O
few O
patients O
taking O
coumarin B-group
anticoagulants O
concomitantly O
with O
lovastatin B-drug
. O

The O
acceleration O
of O
gastric O
emptying O
by O
cisapride B-drug
could O
affect O
the O
rate O
of O
absorption O
of O
other O
drugs O
. O

In O
a O
study O
of O
15 O
male O
subjects O
( O
ages O
19 O
to O
35 O
years O
) O
who O
were O
extensive O
metabolizers O
of O
the O
CYP2D6 O
isoenzyme O
, O
daily O
doses O
of O
bupropion B-drug
given O
as O
150 O
mg O
twice O
daily O
followed O
by O
a O
single O
dose O
of O
50 O
mg O
desipramine B-drug
increased O
the O
Cmax O
, O
AUC O
, O
and O
t1/2 O
of O
desipramine B-drug
by O
an O
average O
of O
approximately O
2- O
, O
5- O
and O
2-fold O
, O
respectively O
. O

Quinolones B-group
, O
including O
cinoxacin B-drug
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-group
, O
such O
as O
warfarin B-drug
or O
its O
derivatives O
. O

The O
selection O
of O
drugs O
and O
their O
dosages O
may O
be O
improved O
, O
and O
the O
number O
of O
adverse O
effects O
reduced O
by O
pharmacogenetic O
investigations O
. O

Chlorthalidone B-drug
and O
related O
drugs O
may O
increase O
the O
responsiveness O
to O
tubocurarine B-drug
. O

Although O
a O
3-day O
regimen O
of O
Aprepitant B-drug
given O
concomitantly O
with O
oral O
contraceptives B-group
has O
not O
been O
studied O
, O
alternative O
or O
back-up O
methods O
of O
contraception O
should O
be O
used O
. O

Caffeine B-drug
: O
Two O
hundred O
mg O
of O
caffeine B-drug
( O
equivalent O
to O
1 O
to O
3 O
cups O
of O
American O
coffee O
) O
was O
administered O
to O
16 O
normal O
, O
healthy O
volunteers O
who O
had O
achieved O
steady-state O
blood O
concentrations O
of O
lomefloxacin B-drug
after O
being O
dosed O
at O
400 O
mg O
qd O
. O

Their O
concurrent O
use O
should O
be O
avoided O
. O

Metoclopramide B-drug
: O
When O
coadministered O
with O
MONUROL B-brand
, O
metoclopramide B-drug
, O
a O
drug O
which O
increases O
gastrointestinal O
motility O
, O
lowers O
the O
serum O
concentration O
and O
urinary O
excretion O
of O
fosfomycin B-drug
. O

Dosage O
of O
the O
anticoagulant B-group
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O

Among O
the O
proteins O
that O
undergo O
tyrosine O
phosphorylation O
in O
response O
to O
contortrostatin B-drug_n
treatment O
is O
CAS O
, O
a O
130 O
kDa O
adapter O
protein O
involved O
in O
integrin O
signaling O
. O

Careful O
observation O
is O
required O
. O

The O
presence O
of O
food O
in O
the O
stomach O
does O
not O
alter O
the O
bioavailability O
of O
PRINIVIL B-brand
. O

Epidural O
clonidine B-drug
may O
prolong O
the O
duration O
of O
pharmacologic O
effects O
of O
epidural O
local O
anesthetics B-group
, O
including O
both O
sensory O
and O
motor O
blockade O
. O

Esomeprazole B-drug
is O
extensively O
metabolized O
in O
the O
liver O
by O
CYP2C19 O
and O
CYP3A4 O
. O

also O
induced O
diarrhea O
, O
but O
did O
not O
produce O
a O
watery O
stool O
in O
cecectomized O
rats O
. O

( O
Concurrent O
use O
with O
thiazide B-group
diuretics I-group
is O
not O
recommended O
, O
as O
they O
may O
provoke O
lithium B-drug
toxicity O
because O
of O
reduced O
renal O
clearance O
. O
) O

Coadministration O
of O
astemizole B-drug
with O
ketoconazole B-drug
tablets O
is O
therefore O
contraindicated O
. O

Based O
on O
the O
literature O
reports O
, O
the O
same O
effects O
may O
be O
extrapolated O
to O
other O
fruit O
juices O
such O
as O
apple O
juice O
. O

Drugs O
possessing O
beta-blocking O
properties O
can O
blunt O
the O
bronchodilator O
effect O
of O
beta-receptor B-group
agonist I-group
drugs I-group
in O
patients O
with O
bronchospasm O
; O

Ritonavir B-drug

- O
Dapsone B-drug
or O

A O
study O
in O
six O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
diltiazem B-drug
plasma O
levels O
( O
58 O
% O
) O
and O
AUC O
( O
53 O
% O
) O
after O
a O
1-week O
course O
of O
cimetidine B-drug
1200 O
mg/day O
and O
a O
single O
dose O
of O
diltiazem B-drug
60mg O
. O

The O
pathophysiologic O
consequences O
could O
be O
an O
increased O
synaptic O
concentration O
of O
norepinephrine B-drug
predisposing O
to O
adenylyl O
cyclase O
desensitization O
. O

However O
, O
a O
significantly O
higher O
proportion O
of O
neurons O
fired O
spontaneous O
action O
potentials O
with O
either O
0.05-0.2 O
or O
1 O
% O
biocytin O
compared O
to O
no O
biocytin O
. O

The O
Factrel B-brand
test O
should O
be O
conducted O
in O
the O
absence O
of O
other O
drugs O
which O
directly O
affect O
the O
pituitary O
secretion O
of O
the O
gonadotropins O
. O

Cimetidine O
Co-administration O
of O
felodipine B-drug
with O
cimetidine B-drug
( O
a O
non-specific O
CYP-450 O
inhibitor O
) O
resulted O
in O
an O
increase O
of O
approximately O
50 O
% O
in O
the O
AUC O
and O
the O
Cmax O
, O
of O
felodipine B-drug
. O

triclofos B-drug
sodium I-drug
; O

Metal O
mixture O
toxicity O
investigation O
was O
undertaken O
with O
equal O
concentrations O
of O
the O
metals O
. O

A O
pharmacokinetic O
interaction O
between O
diltiazem B-drug
and O
cyclosporine B-drug
has O
been O
observed O
during O
studies O
involving O
renal O
and O
cardiac O
transplant O
patients O
. O

Reversal O
of O
the O
block O
with O
edrophonium B-drug
and O
subsequent O
recovery O
of O
the O
horses O
from O
anaesthesia O
were O
uneventful O
. O

Mean O
number O
of O
drugs O
per O
MAC O
was O
4 O
( O
95 O
% O
CI O
, O
+/- O
0.2 O
) O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O

Patients O
undergoing O
systemic O
anticholinesterase O
treatment O
should O
be O
warned O
of O
the O
possible O
additive O
effects O
of O
Phospholine B-drug
Iodide I-drug
. O

The O
presence O
of O
the O
radiopharmaceutical B-group
in O
the O
kidneys O
, O
along O
with O
an O
increase O
in O
renal O
retention O
, O
tend O
to O
produce O
scintigraphic O
results O
that O
falsely O
identify O
characteristics O
related O
to O
diseases O
such O
as O
renal O
vascular O
, O
or O
urinary O
tract O
obstruction O
, O
and O
even O
renal O
cancer O
. O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-group
diuretics I-group
. O

Concomitant O
use O
with O
other O
oxytocic B-group
agents I-group
is O
not O
recommended O
. O

Anticonvulsants B-group
: O
Phenytoin B-drug
Phenobarbital I-drug
Carbamazepine I-drug

decreased O
pharmacologic O
effect O
of O
aspirin B-brand
. O

The O
inhibiting O
effects O
of O
anticholinergic B-group
drugs I-group
on O
gastric O
hydrochloric O
acid O
secretion O
are O
antagonized O
by O
agents O
used O
to O
treat O
achlorhydria O
and O
those O
used O
to O
test O
gastric O
secretion O
. O

The O
possibility O
of O
interactions O
with O
other O
drugs O
administered O
concurrently O
should O
be O
considered O
, O
particularly O
when O
their O
main O
route O
of O
elimination O
is O
active O
renal O
secretion O
via O
the O
organic O
cationic O
transport O
system O
( O
e.g. O
, O
trimethoprim B-drug
) O
. O

The O
following O
information O
was O
obtained O
from O
the O
literature O
. O

Co-administration O
of O
warfarin B-drug
and O
cerivastatin B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
cerivastatin B-drug
sodium I-drug
. O

However O
, O
the O
antagonism O
of O
the O
theophylline-induced B-drug
anxiogenic O
effects O
by O
CGS21680 B-drug_n
was O
only O
observed O
in O
the O
time O
spent O
in O
the O
light O
zone O
, O
and O
DPCPX-induced B-drug_n
anxiogenic O
effects O
were O
neither O
reversed O
by O
CGS B-drug
21680 I-drug
nor O
by O
CPA B-drug_n
. O

No O
clinical O
or O
drug O
interaction O
study O
was O
conducted O
with O
dolasetron B-drug
. O

Although O
other O
hormonal B-group
contraceptives I-group
are O
highly O
effective O
, O
there O
have O
been O
reports O
of O
pregnancy O
from O
women O
who O
have O
used O
combined B-group
oral I-group
contraceptives I-group
, O
as O
well O
as O
topical/injectable/implantable/insertable O
hormonal O
birth O
control O
products O
. O

Anticoagulants B-group
: O
Warfarin B-drug

METHODS O
: O
The O
study O
was O
carried O
out O
as O
an O
open O
, O
randomized O
, O
crossover O
design O
with O
14 O
healthy O
participants O
. O

7 O
. O

However O
, O
in O
a O
single O
in O
vivo O
rodent O
study O
denileukin B-drug
diftitox I-drug
had O
no O
effect O
on O
P450 O
levels O
. O

If O
hypotension O
occurs O
, O
the O
patient O
should O
be O
placed O
in O
a O
supine O
position O
and O
, O
if O
necessary O
, O
receive O
an O
intravenous O
infusion O
of O
normal O
saline O
. O

There O
have O
been O
no O
formal O
studies O
of O
the O
interaction O
of O
LEVULAN B-brand
KERASTICK I-brand
for O
Topical O
Solution O
with O
any O
other O
drugs O
, O
and O
no O
drug-specific O
interactions O
were O
noted O
during O
any O
of O
the O
controlled O
clinical O
trials O
. O

In O
addition O
, O
the O
use O
of O
herbal O
remedies O
may O
be O
detrimental O
for O
the O
patient O
with O
compromised O
renal O
function O
. O

This O
may O
result O
in O
increased O
risk O
of O
theophylline-related B-drug
adverse O
reactions O
. O

The O
pharmacokinetics O
of O
estazolam B-drug
( O
Cmax O
and O
AUC O
) O
were O
not O
affected O
during O
multiple-dose O
fluoxetine B-drug
, O
suggesting O
no O
clinically O
significant O
pharmacokinetic O
interaction O
. O

Even O
so O
dextromethorphan B-drug
plasma O
concentrations O
in O
the O
presence O
of O
high O
doses O
of O
valdecoxib B-drug
were O
almost O
5-fold O
lower O
than O
those O
seen O
in O
CYP O
2D6 O
poor O
metabolizers O
suggesting O
that O
dose O
adjustment O
is O
not O
necessary O
. O

CNS O
Acting O
Drugs O
: O
Given O
the O
primary O
CNS O
effects O
of O
Duloxetine B-drug
, O
it O
should O
be O
used O
with O
caution O
when O
it O
is O
taken O
in O
combination O
with O
or O
substituted O
for O
other O
centrally O
acting O
drugs O
, O
including O
those O
with O
a O
similar O
mechanism O
of O
action O
. O

Slow O
chylomicron O
intravascular O
catabolism O
has O
been O
associated O
with O
coronary O
artery O
disease O
and O
screening O
for O
drugs O
that O
can O
speed-up O
this O
process O
can O
be O
important O
. O

Pretreatment O
of O
healthy O
volunteers O
with O
multiple O
doses O
of O
rifampin B-drug
followed O
by O
a O
single O
dose O
of O
Gleevec B-brand
, O
increased O
Gleevec B-brand
oral-dose O
clearance O
by O
3.8-fold O
, O
which O
significantly O
( O
p O
0.05 O
) O
decreased O
mean O
cmax O
and O
AUC O
( O
0-8 O
) O
. O

sertraline I-drug
concentration O

Coadministration O
of O
almotriptan B-drug
and O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-drug
( O
400 O
mg O
q.d O
. O
for O
3 O
days O
) O
resulted O
in O
an O
approximately O
60 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
and O
maximal O
plasma O
concentrations O
of O
almotriptan B-drug
. O

Delavirdine B-drug

Because O
pregnancy O
could O
not O
be O
maintained O
in O
the O
rabbit O
following O
doses O
of O
fulvestrant B-drug
of O
1 O
mg/kg/day O
and O
above O
, O
this O
study O
was O
inadequate O
to O
fully O
define O
the O
possible O
adverse O
effects O
on O
fetal O
development O
at O
clinically O
relevant O
exposures O
. O

HMG-CoA B-group
reductase I-group
inhibitors I-group
: O
The O
combined O
use O
of O
TRICOR B-brand
and O
HMG-CoA B-group
reductase I-group
inhibitors I-group
should O
be O
avoided O
unless O
the O
benefit O
of O
further O
alterations O
in O
lipid O
levels O
is O
likely O
to O
outweigh O
the O
increased O
risk O
of O
this O
drug O
combination O
. O

Coadministration O
of O
diltiazem B-drug
with O
rifampin B-drug
or O
any O
known O
CYP3A4 O
inducer O
should O
be O
avoided O
when O
possible O
, O
and O
alternative O
therapy O
considered O
. O

Acellular O
, O
live O
and O
live-attenuated B-group
vaccines I-group
should O
not O
be O
administered O
during O
RAPTIVA B-brand
treatment O
. O

Drugs O
Highly O
Bound O
to O
Plasma O
Protein O
Zaleplon B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
fraction O
bound O
60 O
% O
15 O
% O
) O
; O

The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
may O
produce O
severe O
, O
prolonged O
hypertension O
. O

Skeletal B-group
muscle I-group
relaxants I-group
: O
amphotericin B-drug
B-induced O
hypokalemia O
may O
enhance O
the O
curariform O
effect O
of O
skeletal B-group
muscle I-group
relaxants I-group
( O
e.g. O
, O
tubocurarine B-drug
) O
. O

[ O
2 O
epidemics O
of O
arsenical O
encephalopathy O
in O
the O
treatment O
of O
trypanosomiasis O
, O
Uganda O
, O
1992-1993 O
] O
Since O
1988 O
, O
the O
french O
non-governmental O
organisation O
M O
decins O
Sans O
Fronti O
res O
is O
running O
a O
control O
program O
of O
human O
african O
trypanosomiasis O
in O
the O
district O
of O
Moyo O
, O
North-Uganda O
. O

There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-drug
and O
oral O
anticoagulants B-group
were O
used O
concomitantly O
. O

Verapamil B-drug
also O
significantly O
decreased O
the O
incidence O
of O
lymphatic O
invasion O
of O
adenocarcinomas O
, O
which O
was O
enhanced O
by O
bombesin B-drug_n
. O

However O
, O
high O
doses O
of O
leucovorin B-drug
may O
reduce O
the O
efficacy O
of O
intrathecally O
administered O
methotrexate B-drug
. O

Other O
factors O
, O
such O
as O
tolerance O
and O
sensitization O
to O
the O
drugs O
' O
actions O
and O
the O
development O
of O
withdrawal O
symptoms O
, O
may O
also O
contribute O
to O
dependence O
. O

epilepsy O
; O

Cisplatin B-drug
was O
administered O
over O
the O
last O
two O
hours O
of O
the O
thiosulfate B-drug
infusion O
. O

Determinants O
of O
cellular O
sensitivity O
to O
topoisomerase-targeting B-group
antitumor I-group
drugs I-group
. O

Care O
should O
be O
given O
when O
administering O
this O
drug O
to O
patients O
with O
symptoms O
of O
myasthenic O
weakness O
who O
are O
also O
on O
anticholinesterase B-group
drugs I-group
. O

The O
concomitant O
administration O
of O
Exjade B-brand
and O
vitamin B-drug
C I-drug
has O
not O
been O
formally O
studied O
. O

it O
was O
independent O
of O
the O
influence O
of O
the O
nueronal O
cell O
body O
and O
of O
protein O
synthesis O
within O
the O
axon O
. O

An O
altered O
biodistribution O
may O
provide O
misleading O
information O
that O
can O
either O
mask O
or O
mimic O
certain O
disease O
symptoms O
. O

Such O
data O
are O
discussed O
herein O
, O
with O
emphasis O
on O
those O
aspects O
that O
impact O
on O
the O
clinical O
use O
of O
the O
calcium-entry B-group
antagonists I-group
. O

Anticoagulants B-group
: O
Ten O
patients O
who O
were O
stabilized O
on O
oral O
anticoagulants B-group
were O
given O
guanfacine B-drug
, O
1-2 O
mg/day O
, O
for O
4 O
weeks O
. O

Concurrent O
use O
with O
probenecid B-drug
or O
other O
drugs O
significantly O
eliminated O
by O
active O
renal O
tubular O
secretion O
may O
result O
in O
increased O
plasma O
concentrations O
of O
penciclovir B-drug
. O

Fenbufen B-drug
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O

TAXOL B-brand
contains O
dehydrated O
alcohol O
USP O
, O
396 O
mg/mL O
; O

Another O
oral O
azole B-group
antifungal I-group
, O
ketoconazole B-drug
, O
inhibits O
the O
metabolism O
of O
astemizole B-drug
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
astemizole B-drug
and O
its O
active O
metabolite O
desmethylastermizole B-drug_n
which O
may O
prolong O
QT O
intervals O
. O

Lansoprazole B-drug
has O
also O
been O
shown O
to O
have O
no O
clinically O
significant O
interaction O
with O
amoxicillin B-drug
. O

Potential O
drug O
interactions O
between O
Keppra B-brand
and O
other O
AEDs B-group
( O
carbamazepine B-drug
, O
gabapentin B-drug
, O
lamotrigine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
primidone B-drug
and O
valproate B-drug
) O
were O
also O
assessed O
by O
evaluating O
the O
serum O
concentrations O
of O
levetiracetam B-drug
and O
these O
AEDs B-group
during O
placebo-controlled O
clinical O
studies O
. O

These O
data O
suggest O
that O
ginsenosides B-drug_n
are O
negatively O
coupled O
to O
three O
types O
of O
calcium O
channels O
in O
bovine O
chromaffin O
cell O
, O
including O
an O
omega-conotoxin B-drug_n
GVIA-sensitive O
( O
N-type O
) O
channel O
, O
an O
omega-agatoxin B-drug_n
IVA-sensitive O
( O
P-type O
) O
channel O
and O
nimodipine/omega-conotoxin B-drug
GVIA/omega-agatoxin B-drug_n
VIA-resistant O
( O
presumptive O
Q-type O
) O
channel O
. O

Drug O
Interactions O
with O
Beta-Blockers B-group
: O
Concomitant O
use O
of O
fenoldopam B-drug
with O
beta-blockers B-group
should O
be O
avoided O
. O

Morphine B-drug
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
.005 O
) O
; O
this O
was O
prevented O
by O
ADL B-drug
8-2698 I-drug
( O
P O
= O
.004 O
) O
. O

Oral O
Contraceptives B-group
: O
Coadministration O
of O
atorvastatin B-drug
and O
an O
oral O
contraceptive B-group
increased O
AUC O
values O
for O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
by O
approximately O
30 O
% O
and O
20 O
% O
. O

Caution O
should O
be O
used O
if O
INDOCIN B-brand
is O
administered O
simultaneously O
with O
methotrexate B-drug
. O

exfoliative O
dermatitis O

Therefore O
, O
it O
would O
be O
expected O
that O
a O
dosing O
schedule O
of O
cerivastatin B-drug
sodium I-drug
given O
at O
bedtime O
and O
cholestyramine B-drug
given O
before O
the O
evening O
meal O
would O
not O
result O
in O
a O
significant O
decrease O
in O
the O
clinical O
effect O
of O
cerivastatin B-drug
sodium I-drug
. O

However O
, O
there O
were O
16 O
% O
and O
32 O
% O
increases O
in O
the O
AUC O
and O
Cmax O
, O
respectively O
, O
of O
the O
combined O
moieties O
of O
threohydrobupropion B-drug_n
and O
erythrohydrobupropion B-drug_n
. O

The O
permeability O
of O
the O
cell O
membrane O
was O
changed O
as O
evidenced O
by O
the O
leakage O
of O
260-nm O
absorbing O
materials O
, O
amino O
acids O
, O
proteins O
, O
and O
inorganic O
cations O
. O

Therefore O
, O
caution O
should O
be O
used O
when O
administering O
nitazoxanide B-drug
concurrently O
with O
other O
highly O
plasma O
protein-bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
( O
e.g. O
, O
warfarin B-drug
) O
. O

The O
plasma O
maximum O
concentration O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
of O
diltiazem B-drug
, O
desacetyldiltiazem B-drug_n
, O
and O
desmethyldiltiazem B-drug_n
were O
unchanged O
after O
coadministration O
of O
sirolimus B-drug
, O
and O
no O
potentiation O
of O
the O
effects O
of O
diltiazem B-drug
on O
diastolic O
or O
systolic O
blood O
pressure O
or O
on O
the O
electrocardiographic O
parameters O
was O
seen O
. O

Prothrombin O
time O
was O
not O
affected O
by O
levetiracetam B-drug
. O

Noncardioselective B-group
beta-blockers I-group
( O
nadolol B-drug
, O
porpranolol O
, O
timolol B-drug
) O
may O
exacerbate O
rebound O
hypertension O
when O
guanfacine B-drug
is O
withdrawn O
. O

**No O
significant O
effect O
. O

Data O
from O
in O
vitro O
studies O
of O
benzodiazepines B-group
other O
than O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
for O
the O
following O
: O
ergotamine B-drug
, O
cyclosporine B-drug
, O
amiodarone B-drug
, O
nicardipine B-drug
, O
and O
nifedipine B-drug
. O

An O
interacting O
drug O
which O
leads O
to O
a O
decrease O
in O
prothrombin O
time O
necessitating O
an O
increased O
dose O
of O
oral O
anticoagulant B-group
to O
maintain O
an O
adequate O
degree O
of O
anticoagulation O
may O
, O
if O
abruptly O
discontinued O
, O
increase O
the O
risk O
of O
subsequent O
bleeding O
. O

Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-drug
was O
similar O
to O
that O
in O
placebo-treated O
patients O
. O

Corticosteroids B-group
, O
Methylxanthines B-group
and O
Diuretics B-group
: O
Concomitant O
treatment O
with O
xanthine B-group
derivatives I-group
, O
steroids B-group
, O
or O
diuretics B-group
may O
potentiate O
a O
possible O
hypokalemic O
effect O
of O
beta2-agonists B-group
. I-group

Drug/Laboratory O
Test O
Interactions O
The O
presence O
of O
labetalol O
metabolites O
in O
the O
urine O
may O
result O
in O
falsely O
elevated O
levels O
of O
urinary O
catecholamines O
, O
metanephrine O
, O
normetanephrine O
and O
vanillylmandelic O
acid O
when O
measured O
by O
fluorimetric O
or O
photometric O
methods O
. O

Eight O
healthy O
volunteers O
were O
randomized O
in O
an O
open-label O
, O
two-way O
crossover O
study O
to O
receive O
oxycodone B-drug
, O
5 O
mg O
p.o O
. O

Patients O
taking O
coumarin-derivative B-group
anticoagulants I-group
concomitantly O
with O
capecitabine B-drug
should O
be O
monitored O
regularly O
for O
alterations O
in O
their O
coagulation O
parameters O
( O
PT O
or O
INR O
) O
. O

Cytokines B-group
( O
interferon B-group
, O
interleukin B-group
) O
: O
Cytokines B-group
have O
been O
reported O
to O
induce O
both O
hyperthyroidism O
and O
hypothyroidism O
. O

Corticotropin B-drug
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-drug
therapy O
. O

Because O
of O
the O
low O
dietary O
cobalt B-drug
concentration O
as O
compared O
to O
the O
iron B-drug
contents O
of O
the O
diets O
, O
no O
effect O
of O
cobalt B-drug
on O
iron B-drug
absorption O
and O
excretion O
occurred O
. O

Tricyclic B-group
Antidepressants I-group
: O
Concurrent O
use O
may O
increase O
the O
therapeutic O
and O
toxic O
effects O
of O
both O
drugs O
, O
possibly O
due O
to O
increased O
catecholamine O
sensitivity O
. O

Drug-Drug O
Interactions O
: O
The O
pharmacokinetic O
and O
pharmacodynamic O
interactions O
between O
UROXATRAL B-brand
and O
other O
alpha-blockers B-group
have O
not O
been O
determined O
. O

The O
administration O
of O
SUPRAX B-brand
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
** O
, O
Benedict O
s O
solution O
, O
or O
Fehling O
s O
solution O
. O

thyroid B-group
drugs I-group
; O

No O
formal O
drug-drug O
interaction O
studies O
, O
however O
, O
have O
been O
conducted O
. O

The O
reduction O
in O
MAC O
was O
correlated O
with O
brain O
levels O
of O
ketamine B-drug
or O
metabolite O
I O
, O
suggesting O
a O
ketamine B-drug
: O
metabolite O
I O
potency O
ration O
of O
3:1 O
. O

In O
vitro O
studies O
demonstrated O
no O
evidence O
of O
incompatibility O
of O
heparin B-drug
with O
EXTRANEAL B-brand
. O

The O
action O
of O
colchicine B-drug
is O
potentiated O
by O
alkalinizing B-group
agents I-group
. O

In O
male O
Sprague-Dawley O
rats O
fasted O
for O
18 O
h O
, O
concomitant O
administration O
of O
caffeine B-drug
( O
0.1 O
g/kg O
, O
i.p O
. O
) O

If O
combination O
therapy O
is O
needed O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
all O
agents O
to O
be O
used O
. O

Zalcitabine B-drug
inhibited O
lamivudine B-drug
phosphorylation O
at O
high O
concentration O
ratios O
( O
10 O
and O
100 O
) O
; O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Valdecoxib B-drug
caused O
a O
statistically O
significant O
increase O
in O
plasma O
exposures O
of O
R-warfarin B-drug
and O
S-warfarin B-drug
( O
12 O
% O
and O
15 O
% O
, O
respectively O
) O
, O
and O
in O
the O
pharmacodynamic O
effects O
( O
prothrombin O
time O
, O
measured O
as O
INR O
) O
of O
warfarin B-drug
. O

Lithium B-drug
: O
NSAIDs B-group
have O
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
. O

Mutagenicity O
studies O
were O
conducted O
in O
vitro O
and O
in O
vivo O
; O

The O
relative O
risk O
of O
myocardial O
infarction O
during O
sexual O
activity O
is O
not O
significantly O
higher O
than O
for O
healthy O
persons O
. O

Those O
for O
which O
effectiveness O
is O
reported O
includes O
diphenhydramine B-drug
, O
hydroxyzine B-drug
, O
orphenadrine B-drug
, O
pyrilamine B-drug
, O
phenyltoloxamine B-drug_n
, O
promethazine B-drug
, O
methdilazine B-drug
, O
and O
tripelennamine B-drug
. O

Heart O
rate O
increased O
initially O
and O
returned O
to O
normal O
40 O
minutes O
after O
ethanol B-drug
challenge O
. O

The O
concentration O
of O
AMICAR B-brand
necessary O
to O
maintain O
inhibition O
of O
fibrinolysis O
is O
0.99 O
mMol/L O
or O
0.13 O
mg/mL O
. O

Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Pharmacokinetic O
data O
suggest O
that O
absorption O
, O
metabolism O
, O
and O
elimination O
of O
each O
of O
these O
drugs O
are O
unchanged O
when O
they O
are O
used O
together O
. O

Short-Acting B-group
beta2-agonists I-group
: O
Aerosol O
bronchodilators B-group
of O
the O
short-acting O
adrenergic O
stimulant O
type O
may O
be O
used O
for O
relief O
of O
breakthrough O
symptoms O
while O
using O
formoterol B-drug
. O

It O
is O
recommended O
that O
gabapentin B-drug
be O
taken O
at O
least O
2 O
hours O
following O
Maalox B-brand
administration O
. O

ethacrynic B-drug
acid I-drug
; O

Warfarin B-drug
: O
When O
healthy O
subjects O
were O
administered O
Starlix B-brand
120 O
mg O
three O
times O
daily O
before O
meals O
for O
four O
days O
in O
combination O
with O
a O
single O
dose O
of O
warfarin B-drug
30 O
mg O
on O
day O
2 O
, O
there O
were O
no O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

Cerubidine B-brand
should O
not O
be O
used O
in O
patients O
who O
have O
previously O
received O
the O
recommended O
maximum O
cumulative O
doses O
of O
doxorubicin B-drug
or O
Cerubidine B-brand
. O

However O
, O
L-NAME B-drug_n
( O
100 O
and O
300 O
micromol/l O
) O
did O
not O
alter O
the O
effects O
of O
reseveratrol B-drug_n
on O
arteries O
from O
dietary-obese O
rats O
, O
giving O
superimposed O
concentration-responses O
curves O
. O

- O
a O
sulfa-based O
drug O
such O
as O
sulfamethoxazole-trimethoprim B-drug
( O
Bactrim B-brand
, O
Septra B-brand
) O
, O
sulfisoxazole B-drug
( O
Gantrisin B-brand
) O
, O
or O
sulfasalazine B-drug
( O
Azulfidine B-brand
) O
; O

Concomitant O
use O
of O
SPRYCEL B-brand
and O
drugs O
that O
inhibit O
CYP3A4 O
( O
eg O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
clarithromycin B-drug
, O
ritonavir B-drug
, O
atazanavir B-drug
, O
indinavir B-drug
, O
nefazodone B-drug
, O
nelfinavir B-drug
, O
saquinavir B-drug
, O
telithromycin B-drug
) O
may O
increase O
exposure O
to O
dasatinib B-drug
and O
should O
be O
avoided O
. O


Patients O
should O
be O
cautioned O
against O
engaging O
in O
hazardous O
activities O
requiring O
complete O
mental O
alertness O
such O
as O
operating O
machinery O
or O
driving O
a O
motor O
vehicle O
. O

If O
a O
diuretic B-group
is O
also O
used O
, O
the O
risk O
of O
lithium B-drug
toxicity O
may O
be O
increased O
. O

Insulin B-drug
or O
Oral O
Hypoglycemics B-group
: O
Agents B-group
with I-group
b-blocking I-group
properties I-group
may O
enhance O
the O
blood-sugar-reducing O
effect O
of O
insulin B-drug
and O
oral O
hypoglycemics B-group
. O

The O
following O
drug O
interactions O
were O
studied O
with O
ketoprofen B-drug
doses O
of O
200 O
mg/day O
. O

The O
gonadotropin O
levels O
may O
be O
transiently O
elevated O
by O
spironolactone B-drug
, O
minimally O
elevated O
by O
levodopa B-drug
, O
and O
suppressed O
by O
oral O
contraceptives B-group
and O
digoxin B-drug
. O

Careful O
observations O
on O
hepatotoxicity O
are O
suggested O
when O
acetaminophen B-drug
is O
prescribed O
with O
caffeine B-drug
. O

Lipids O
: O
Pretreatment O
and O
follow-up O
blood O
lipids O
should O
be O
obtained O
under O
fasting O
conditions O
. O

This O
effect O
should O
be O
kept O
in O
mind O
when O
bleeding O
times O
are O
determined O
. O

Trecator B-brand
may O
potentiate O
the O
adverse O
effects O
of O
other O
antituberculous B-group
drugs I-group
administered O
concomitantly O
. O

Immunodeficiency-associated O
lymphocyte O
disorders O
( O
plasmacytic O
hyperplasia O
, O
polymorphic O
proliferation O
, O
and O
B-cell O
lymphomas O
) O
occur O
in O
patients O
who O
have O
congenital O
or O
acquired O
immunodeficiencies O
including O
those O
resulting O
from O
immunosuppressive B-group
therapy O
. O

Prescribing O
. O

- O
Hydroxychloroquine B-drug
( O
e.g. O
, O
Plaquenil B-brand
) O
or O

The O
risk O
of O
myopathy O
is O
also O
increased O
by O
the O
following O
lipid-lowering O
drugs O
that O
are O
not O
potent O
CYP3A4 O
inhibitors O
, O
but O
which O
can O
cause O
myopathy O
when O
given O
alone O
. O

Codeine B-drug
in O
combination O
with O
other O
narcotic B-group
analgesics I-group
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
sedative-hypnotics B-group
, O
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
has O
additive O
depressant O
effects O
. O

Potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O

Heparin B-drug
: O
Since O
heparin B-drug
is O
contraindicated O
in O
patients O
with O
heparin-induced B-drug
thrombocytopenia O
, O
the O
co-administration O
of O
Argatroban B-drug
and O
heparin B-drug
is O
unlikely O
for O
this O
indication O
. O

If O
these O
products O
are O
needed O
, O
they O
should O
be O
given O
at O
least O
2 O
hours O
before O
cimetidine B-drug
administration O
. O

Terfenadine B-drug
: O
Administration O
of O
terfenadine B-drug
with O
VIRACEPT B-brand
resulted O
in O
the O
appearance O
of O
unchanged O
terfenadine B-drug
in O
plasma O
; O

increased O
levels O
of O
fibrinogen O
and O
fibrinogen O
activity O
; O

Probenecid B-drug
: O
Probenecid B-drug
is O
known O
to O
interact O
with O
the O
metabolism O
or O
renal O
tubular O
excretion O
of O
many O
drugs O
( O
e.g. O
, O
acetaminophen B-drug
, O
acyclovir B-drug
, O
angiotensin-converting B-group
enzyme I-group
inhibitors I-group
, O
aminosalicylic B-drug
acid I-drug
, O
barbiturates B-group
, O
benzodiazepines B-group
, O
bumetanide B-drug
, O
clofibrate B-drug
, O
methotrexate B-drug
, O
famotidine B-drug
, O
furosemide B-drug
, O
nonsteroidal B-group
anti-inflammatory I-group
agents O
, O
theophylline B-drug
, O
and O
zidovudine B-drug
) O
. O

The O
data O
suggest O
that O
18-MC B-drug_n
has O
a O
narrower O
spectrum O
of O
actions O
and O
will O
have O
a O
substantially O
greater O
therapeutic O
index O
than O
ibogaine B-drug_n
. O

Cyclopentolate B-drug
may O
interfere O
with O
the O
anti-glaucoma O
action O
of O
carbachol B-drug
or O
pilocarpine B-drug
; O

Anticonvulsants B-group
( O
carbamazepine B-drug
, O
felbamate B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
topiramate B-drug
) O
: O
Increase O
the O
metabolism O
of O
ethinyl B-drug
estradiol I-drug
and/or O
some O
progestins B-group
, O
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O

Anticoagulants B-group
: O
While O
studies O
have O
not O
shown O
diclofenac B-drug
to O
interact O
with O
anticoagulants B-group
of I-group
the I-group
warfarin I-group
type I-group
, O
caution O
should O
be O
exercised O
, O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
NSAIDs B-group
. O

Methenamine B-drug
therapy O
Urinary O
excretion O
of O
amphetamines B-group
is O
increased O
, O
and O
efficacy O
is O
reduced O
by O
acidifying O
agents O
used O
in O
methenamine B-drug
therapy O
. O

Dose O
adjustment O
of O
lapatinib B-drug
should O
be O
considered O
for O
patients O
who O
must O
receive O
concomitant O
strong O
inhibitors O
or O
concomitant O
strong O
inducers O
of O
CYP3A4 O
enzymes O
. O

Short-term O
controlled O
studies O
failed O
to O
show O
that O
taking O
the O
drug O
significantly O
affects O
prothrombin O
times O
when O
administered O
to O
individuals O
on O
coumarin-type B-group
anticoagulants I-group
. O

Monitoring O
of O
plasma O
phenytoin B-drug
concentrations O
may O
be O
helpful O
when O
possible O
drug O
interactions O
are O
suspected O
. O

SUSTIVAhas O
the O
potential O
to O
decrease O
serum O
concentrations O
of O
amprenavir B-drug
. O

Interaction O
of O
gentamycin B-drug
and O
atracurium B-drug
in O
anaesthetised O
horses O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Although O
not O
observed O
in O
this O
study O
, O
adverse O
effects O
could O
potentially O
arise O
from O
co-administration O
of O
cephalexin B-drug
and O
metformin B-drug
by O
inhibition O
of O
tubular O
secretion O
via O
organic O
cationic O
transporter O
systems O
. O

In O
bioavailability O
studies O
with O
normal O
subjects O
, O
the O
concurrent O
administration O
of O
antacids B-group
at O
therapeutic O
levels O
did O
not O
significantly O
influence O
the O
bioavailability O
of O
TRANXENE B-brand
tablets O
. O

Nitroglycerin B-drug
: O
DynaCirc B-brand
( O
isradipine B-drug
) O
has O
been O
safely O
coadministered O
with O
nitroglycerin B-drug
. O

Even O
though O
such O
interactions O
were O
not O
seen O
during O
clinical O
studies O
with O
nicardipine B-drug
HCl I-drug
, O
an O
increased O
volume O
of O
circulating O
fluids O
might O
be O
required O
if O
such O
an O
interaction O
were O
to O
occur O
. O

Patients O
receiving O
concurrent O
administration O
of O
substrates O
of O
C.P.A O
. O
were O
not O
excluded O
from O
clinical O
trials O
of O
grepafloxacin B-drug
. O

Warfarin B-drug
Keppra B-brand
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
R O
and O
S B-drug
warfarin I-drug
. O

Hepatotoxic O
Drugs O
Increased O
side O
effects O
may O
occur O
when O
leflunomide B-drug
is O
given O
concomitantly O
with O
hepatotoxic O
substances O
. O

Physicians O
needing O
to O
treatpatients O
co-infected O
with O
tuberculosis O
andusing O
a O
nevirapine B-drug
containing O
regimen O
mayuse O
rifabutin B-drug
instead O
. O

In O
a O
pharmacokinetic O
study O
, O
38 O
healthy O
female O
subjects O
received O
ketoconazole B-drug
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
with O
coadministration O
of O
alosetron B-drug
1 O
mg O
on O
the O
last O
day O
. O

ketoconazole B-drug
) O
, O
macrolide B-group
antibiotics I-group
( O
e.g O
. O
erythromycin B-drug
) O
, O
and O
HIV B-group
protease I-group
inhibitors I-group
( O
e.g O
. O
ritonavir B-drug
, O
indinavir B-drug
and O
saquinavir B-drug
) O
should O
have O
their O
dose O
of O
SUBUTEX B-brand
or O
SUBOXONE B-brand
adjusted O
. O

It O
may O
be O
necessary O
to O
adjust O
the O
dosage O
of O
oral O
anticoagulants B-group
upon O
beginning O
or O
stopping O
disulfiram B-drug
. O
since O
disulfiram B-drug
may O
prolong O
prothrombin O
time O
. O

Caution O
is O
advised O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
nonsteroidal O
agents O
of O
this O
class O
. O

The O
simplest O
inference O
is O
that O
the O
toxicity O
and O
effectiveness O
of O
polyenes O
are O
determined O
by O
their O
relative O
avidities O
for O
the O
predominant O
sterol O
in O
cell O
membranes O
. O

In O
Study O
1 O
, O
patients O
receiving O
bolus-IFL O
plus O
AVASTIN B-brand
had O
a O
higher O
incidence O
of O
Grade O
3-4 O
diarrhea O
and O
neutropenia O
. O


Plasma O
TCA B-group
concentrations O
may O
need O
to O
be O
monitored O
and O
the O
dose O
of O
the O
TCA B-group
may O
need O
to O
be O
reduced O
if O
a O
TCA B-group
is O
co-administered O
with O
Duloxetine B-drug
. O

Although O
there O
is O
little O
risk O
for O
loss O
of O
contraceptive O
efficacy O
, O
the O
clinical O
significance O
of O
these O
increased O
exposures O
in O
terms O
of O
safety O
is O
not O
known O
. O

Additional O
clinical O
experience O
may O
reveal O
other O
drugs O
affected O
by O
the O
concomitant O
administration O
of O
Tagamet B-brand
. O

Tricyclic B-group
Antidepressants I-group
: O
Use O
of O
thyroid B-group
products I-group
with O
imipramine B-drug
and O
other O
tricyclic B-group
antidepressants I-group
may O
increase O
receptor O
sensitivity O
and O
enhance O
antidepressant O
activity O
transient O
cardiac O
arrhythmias O
have O
been O
observed O
. O

Effects O
of O
Felbatol B-brand
on O
Low-Dose O
Combination B-group
Oral I-group
Contraceptives I-group
A O
group O
of O
24 O
nonsmoking O
, O
healthy O
white O
female O
volunteers O
established O
on O
an O
oral O
contraceptive B-group
regimen O
containing O
30 O
mg O
ethinyl B-drug
estradiol I-drug
and O
75 O
mg O
gestodene B-drug
for O
at O
least O
3 O
months O
received O
2400 O
mg/day O
of O
felbamate B-drug
from O
midcycle O
( O
day O
15 O
) O
to O
midcycle O
( O
day O
14 O
) O
of O
two O
consecutive O
oral O
contraceptive B-group
cycles O
. O

The O
median O
survival O
for O
CHOP-HAART O
patients O
was O
not O
reached O
, O
whereas O
the O
medial O
survival O
of O
CHOP O
patients O
was O
7 O
months O
( O
P O
= O
0.03 O
) O
. O

increased O
platelet O
count O
; O

Tadalafil B-drug

Cisapride B-drug
was O
well O
tolerated O
when O
administered O
alone O
or O
with O
fluoxetine B-drug
. O

H2 B-group
Blockers I-group
and O
Proton B-group
Pump I-group
Inhibitors I-group
( O
PPIs B-group
) O

Antihistamines B-group
may O
partially O
counteract O
the O
anticoagulation O
effects O
of O
heparin B-drug
or O
warfarin B-drug
. O

Since O
FOSCAVIR B-brand
decreases O
serum O
concentrations O
of O
ionized O
calcium O
, O
concurrent O
treatment O
with O
other O
drugs O
known O
to O
influence O
serum O
calcium O
concentrations O
should O
be O
used O
with O
particular O
caution O
. O

Beta-adrenergic B-group
blocking I-group
drugs I-group
add O
some O
further O
antihypertensive O
effect O
to O
captopril B-drug
, O
but O
the O
overall O
response O
is O
less O
than O
additive O
. O

chymotrypsin B-drug
; O

In O
vitro O
studies O
in O
human O
liver O
microsomes O
indicate O
that O
ertapenem B-drug
does O
not O
inhibit O
metabolism O
mediated O
by O
any O
of O
the O
following O
six O
cytochrome O
p450 O
( O
CYP O
) O
isoforms O
: O
1A2 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O

These O
events O
required O
medical O
intervention O
in O
some O
patients O
. O

- O
Digoxin B-drug
: O
Interaction O
studies O
in O
humans O
have O
shown O
no O
effect O
on O
digoxin B-drug
blood O
levels O
. O

Potassium-depleting B-group
diuretics I-group
are O
a O
major O
contributing O
factor O
to O
digitalis B-group
toxicity O
. O

Rhabdomyolysis O
has O
been O
observed O
in O
patients O
receiving O
HMG-CoA B-group
reductase I-group
inhibitors I-group
administered O
alone O
( O
at O
recommended O
dosages O
) O
or O
concomitantly O
with O
immunosuppressive B-group
drugs I-group
including O
cyclosporine B-drug
. O

Magnesium B-drug
and O
therapeutics O
. O

Interactions O
with O
lipid-lowering O
drugs O
that O
can O
cause O
myopathy O
when O
given O
alone O
. O

Geriatric O
Use O

Quetiapine B-drug
fumarate I-drug
( O
'Seroquel B-brand
' O
) O
is O
a O
newly O
introduced O
atypical B-group
antipsychotic I-group
with O
demonstrated O
efficacy O
in O
the O
treatment O
of O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O

glucagon B-drug
; O

In O
the O
case O
of O
severe O
neutropenia O
( O
500 O
cells/mm3 O
for O
seven O
days O
or O
more O
) O
during O
a O
course O
of O
TAXOL B-brand
therapy O
, O
a O
20 O
% O
reduction O
in O
dose O
for O
subsequent O
courses O
of O
therapy O
is O
recommended O
. O

Based O
on O
adult O
data O
, O
lower O
doses O
of O
caffeine B-drug
may O
be O
needed O
following O
coadministration O
of O
drugs O
which O
are O
reported O
to O
decrease O
caffeine B-drug
elimination O
( O
e.g. O
, O
cimetidine B-drug
and O
ketoconazole B-drug
) O
and O
higher O
caffeine B-drug
doses O
may O
be O
needed O
following O
coadministration O
of O
drugs O
that O
increase O
caffeine B-drug
elimination O
( O
e.g. O
, O
phenobarbital B-drug
and O
phenytoin B-drug
) O
. O

- O
Disulfiram B-drug
( O
e.g. O
, O
Antabuse B-brand
) O
or O

Rifampin B-drug
: O
Coadministration O
of O
rifampin B-drug
and O
MEPRON B-brand
Suspension O
results O
in O
a O
significant O
decrease O
in O
average O
steady- O
state O
plasma O
atovaquone B-drug
concentrations O
. O

When O
digoxin B-drug
and O
BREVIBLOC B-brand
were O
concomitantly O
administered O
intravenously O
to O
normal O
volunteers O
, O
there O
was O
a O
10-20 O
% O
increase O
in O
digoxin B-drug
blood O
levels O
at O
some O
time O
points O
. O

Grapefruit O
juice O
increases O
ethinyl B-drug
estradiol I-drug
concentrations O
and O
would O
be O
expected O
to O
increase O
progesterone B-drug
serum O
levels O
as O
well O
; O

Rifabutin B-drug

Acetazolamide B-drug
and O
sodium B-drug
bicarbonate I-drug
used O
concurrently O
increases O
the O
risk O
of O
renal O
calculus O
formation O
. O

Efavirenz I-drug

Moreover O
, O
the O
basal O
and O
dmPGE2-induced B-drug_n
jejunal O
net O
fluid O
transfers O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O

Antacids B-group
: O
In O
a O
clinical O
pharmacology O
study O
, O
coadministration O
of O
an O
antacid B-group
( O
aluminum B-drug
hydroxide I-drug
, O
magnesium B-drug
hydroxide I-drug
, O
and O
simethicone B-drug
) O
with O
fosinopril B-drug
reduced O
serum O
levels O
and O
urinary O
excretion O
of O
fosinoprilat B-drug_n
as O
compared O
with O
fosinopril B-drug
administered O
alone O
, O
suggesting O
that O
antacids B-group
may O
impair O
absorption O
of O
fosinopril B-drug
. O

The O
renal O
effects O
of O
nephrotoxic O
compounds O
may O
be O
potentiated O
by O
Carboplatin B-drug
. O

Further O
, O
in O
clinical O
studies O
with O
PROSCAR B-brand
( O
finasteride B-drug
, O
5 O
mg O
) O
when O
used O
in O
older O
men O
who O
have O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
, O
PSA O
levels O
are O
decreased O
by O
approximately O
50 O
% O
. O

Amiodarone B-drug
may O
suppress O
certain O
CYP450 O
enzymes O
, O
including O
CYP1A2 B-drug
, O
CYP2C9 B-drug
, O
CYP2D6 B-drug
, O
and O
CYP3A4 B-drug
. O

Influence O
of O
estradiol B-drug
and O
progesterone B-drug
on O
the O
sensitivity O
of O
rat O
thoracic O
aorta O
to O
noradrenaline B-drug
. O

Use O
of O
Cerubidine B-brand
in O
a O
patient O
who O
has O
previously O
received O
doxorubicin B-drug
increases O
the O
risk O
of O
cardiotoxicity O
. O

Because O
Anafranil B-brand
is O
highly O
bound O
to O
serum O
protein O
, O
the O
administration O
of O
Anafranil B-brand
to O
patients O
taking O
other O
drugs O
that O
are O
highly O
bound O
to O
protein O
( O
e.g. O
, O
warfarin B-drug
, O
digoxin B-drug
) O
may O
cause O
an O
increase O
in O
plasma O
concentrations O
of O
these O
drugs O
, O
potentially O
resulting O
in O
adverse O
effects O
. O

Olanzapine B-drug
: O
Coadministration O
of O
eszopiclone B-drug
3 O
mg O
and O
olanzapine B-drug
10 O
mg O
produced O
a O
decrease O
in O
DSST O
scores O
. O

METHOD O
: O
This O
study O
was O
a O
multicenter O
randomized O
double-blind O
study O
of O
101 O
patients O
who O
were O
randomly O
assigned O
1:1:1 O
to O
receive O
everolimus B-drug
tablets O
at O
doses O
of O
0.5 O
mg O
, O
1 O
mg O
, O
or O
2 O
mg O
twice O
daily O
with O
cyclosporine B-drug
and O
prednisone B-drug
. O

The O
onset O
of O
symptoms O
usually O
occurred O
within O
hours O
( O
most O
commonly O
1 O
to O
4 O
hours O
) O
following O
the O
administration O
of O
contrast O
media O
. O

The O
coadministration O
of O
aspirin B-brand
decreases O
the O
biologic O
half-life O
of O
fenoprofen B-drug
because O
of O
an O
increase O
in O
metabolic O
clearance O
that O
results O
in O
a O
greater O
amount O
of O
hydroxylated B-drug_n
fenoprofen I-drug_n
in O
the O
urine O
. O

If O
NovoLog B-brand
is O
mixed O
with O
NPH B-drug
human I-drug
insulin I-drug
, O
NovoLog B-brand
should O
be O
drawn O
into O
the O
syringe O
first O
. O

The O
fraction O
of O
STADOL B-brand
NS I-brand
absorbed O
is O
unaffected O
by O
the O
concomitant O
administration O
of O
a O
nasal B-group
vasoconstrictor I-group
( O
oxymetazoline B-drug
) O
, O
but O
the O
rate O
of O
absorption O
is O
decreased O
. O

Minor O
symptoms O
such O
as O
flushing O
, O
skin O
reactions O
, O
dyspnea O
, O
hypotension O
, O
or O
tachycardia O
do O
not O
require O
interruption O
of O
therapy O
. O

Spermine B-drug
, O
and O
to O
a O
lesser O
extent O
, O
spermidine B-drug_n
, O
enhanced O
the O
translocating O
action O
of O
oleate O
and O
increased O
its O
effectiveness O
in O
transferring O
the O
phosphohydrolase O
from O
the O
soluble O
to O
the O
microsomal O
fraction O
. O

Carcinogenesis O
, O
Mutagenesis O
and O
Impairment O
of O
Fertility O
A O
two-year O
carcinogenesis O
study O
was O
conducted O
in O
female O
and O
male O
rats O
, O
at O
intramuscular O
doses O
of O
15 O
mg/kg/30 O
days O
, O
10 O
mg/rat/30 O
days O
and O
10 O
mg/rat/15 O
days O
. O

Although O
in O
vivo O
studies O
have O
not O
been O
done O
to O
see O
if O
etodolac B-drug
clearance O
is O
changed O
by O
coadministration O
of O
phenylbutazone B-drug
, O
it O
is O
not O
recommended O
that O
they O
be O
coadministered O
. O

Products O
containing O
calcium B-drug
and O
other O
multivalent B-drug
cations I-drug
likely O
will O
interfere O
with O
absorption O
of O
alendronate B-drug
. O

Enoxaparin B-drug
dosed O
as O
a O
1.0 O
mg/kg O
subcutaneous O
injection O
q12h O
for O
four O
doses O
did O
not O
alter O
the O
pharmacokinetics O
of O
eptifibatide B-drug
or O
the O
level O
of O
platelet O
aggregation O
in O
healthy O
adults O
. O

These O
results O
indicate O
that O
the O
pancreatic O
alpha O
cell O
of O
the O
diabetic O
Chinese O
hamster O
responds O
excessively O
to O
arginine B-drug
, O
as O
is O
seen O
in O
the O
human O
diabetic O
. O

The O
mean O
AUC O
values O
of O
LNG O
were O
decreased O
by O
32 O
% O
[ O
90 O
% O
CI O
: O
20-45 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
42-52 O
] O
in O
another O
study O
. O

Cohort O
1 O
then O
received O
amprenavir B-drug
plus O
rifabutin B-drug
for O
10 O
days O
, O
and O
cohort O
2 O
received O
amprenavir B-drug
plus O
rifampin B-drug
for O
4 O
days O
. O

Protease B-group
Inhibitors I-group
: O
In O
vitro O
data O
indicate O
that O
indinavir B-drug
and O
ritonavir B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

Death O
due O
to O
fulminant O
pancreatitis O
possibly O
related O
to O
intravenous O
pentamidine B-drug
and O
HIVID B-drug
has O
been O
reported O
. O

These O
findings O
should O
be O
taken O
into O
account O
for O
proper O
interpretation O
of O
serum O
PSA O
when O
evaluating O
men O
treated O
with O
finasteride B-drug
. O

The O
dosage O
of O
these O
medications O
should O
not O
be O
changed O
and O
they O
should O
not O
be O
stopped O
without O
consulting O
the O
physician O
, O
even O
if O
the O
patient O
feels O
better O
after O
initiating O
treatment O
with O
FORADIL B-brand
. O

Diuretic B-group
agents I-group
reduce O
the O
renal O
clearance O
of O
lithium B-drug
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

The O
action O
of O
the O
benzodiazepines B-group
may O
be O
potentiated O
by O
anticonvulsants B-group
, O
antihistamines B-group
, O
alcohol B-drug
, O
barbiturates B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
narcotics B-group
, O
phenothiazines B-group
, O
psychotropic B-group
medications I-group
, O
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

Although O
there O
is O
no O
documentation O
of O
such O
, O
a O
similar O
interaction O
between O
ethotoin B-drug
and O
the O
coumarin B-group
anticoagulants I-group
may O
occur O
. O

if O
necessary O
, O
amiodarone B-drug
can O
continue O
to O
be O
used O
after O
insertion O
of O
a O
pacemaker O
in O
patients O
with O
severe O
bradycardia O
or O
sinus O
arrest O
. O

Although O
neither O
dexamethasone B-drug
nor O
retinyl B-drug
acetate I-drug
affected O
the O
proliferation O
of O
prostatic O
epithelium O
in O
RPMI1640 O
containing O
transferrin B-drug_n
alone O
, O
they O
modify O
the O
mitogenic O
effect O
of O
EGF B-drug_n
and O
insulin B-drug
. O

Barbiturates B-group
and O
glutethimide B-drug
should O
not O
be O
administered O
to O
patients O
receiving O
coumarin B-group
drugs I-group
. O

If O
pregnancy O
occurs O
while O
taking O
AMEVIVE B-brand
, O
continued O
use O
of O
the O
drug O
should O
be O
assessed O
. O

drugs O
affecting O
blood O
elements O
; O

Electrolyte O
Disturbances O
Patients O
with O
hypokalemia O
or O
hypomagnesemia O
should O
have O
the O
condition O
corrected O
whenever O
possible O
before O
being O
treated O
with O
Cordarone B-drug
I.V. I-drug
, O
as O
these O
disorders O
can O
exaggerate O
the O
degree O
of O
QTc O
prolongation O
and O
increase O
the O
potential O
for O
TdP O
. O

Potentially O
fatal O
drug O
interactions O
may O
occur O
when O
coadministered O
with O
digoxin B-drug
, O
as O
this O
may O
enhance O
cardiovascular O
depression O
and O
bradyarrhythmias O
may O
occur O
. O

Interacts O
with O
valproic B-drug
acid I-drug

Furthermore O
, O
arsenate B-drug_n
and O
phosphate B-drug
do O
not O
appear O
to O
share O
a O
common O
transport O
pathway O
in O
the O
duodenum O
and O
no O
evidence O
was O
obtained O
for O
any O
interaction O
between O
the O
two O
at O
this O
level O
. O

Ingestion O
of O
diclofenac B-drug
may O
increase O
serum O
concentrations O
of O
digoxin B-drug
and O
methotrexate B-drug
and O
increase O
cyclosporine B-drug
s O
nephrotoxicity O
. O

No O
dose O
adjustment O
is O
necessary O
when O
Simulect B-brand
is O
added O
to O
triple-immunosuppression O
regimens O
including O
cyclosporine B-drug
, O
corticosteroids B-group
, O
and O
either O
azathioprine B-drug
or O
mycophenolate B-drug
mofetil I-drug
. O

Inhibition O
of O
the O
other O
isozymes O
evaluated O
( O
CYPs O
2A1 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
, O
and O
3E1 O
) O
was O
0-16 O
% O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
site O
of O
the O
inhibitory O
action O
of O
RR B-drug_n
is O
at O
the O
InsP O
( O
3 O
) O
receptor O
, O
or O
its O
closely O
associated O
proteins O
. O

Iodometric O
titration O
of O
the O
polymer O
conjugates O
was O
used O
to O
determine O
the O
extent O
of O
immobilised O
cysteine B-drug
. O

The O
duration O
of O
the O
period O
following O
treatment O
with O
AMEVIVE B-brand
before O
one O
should O
consider O
starting O
other O
immunosuppressive B-group
therapy O
has O
not O
been O
evaluated O
. O

Plasma O
membrane O
and O
intracellular O
mobilization O
of O
calcium O
ions O
are O
intimately O
related O
to O
platelet O
activation O
and O
release O
of O
platelet O
contents O
. O

Prior O
administration O
of O
succinylcholine B-drug
had O
no O
effect O
on O
the O
duration O
of O
neuromuscular O
block O
following O
initial O
or O
maintenance O
bolus O
doses O
of O
NIMBEX B-brand
. O

- O
Increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Patients O
receiving O
flurbiprofen B-drug
and O
furosemide B-drug
or O
other O
diuretics B-group
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
is O
obtained O
. O

Quinolones B-group
, O
including O
nalidixic B-drug
acid I-drug
, O
may O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
or O
its O
derivatives O
. O

Coadministration O
of O
Itraconazole B-drug
and O
cyclosporine B-drug
, O
tacrolimus B-drug
or O
digoxin B-drug
has O
led O
to O
increased O
plasma O
concentrations O
of O
the O
latter O
three O
drugs O
. O

The O
administration O
of O
other O
potassium-sparing B-group
antihypertensives I-group
with O
NSAIDs B-group
has O
been O
shown O
to O
reduce O
the O
antihypertensive O
effect O
in O
some O
patients O
and O
result O
in O
severe O
hyperkalemia O
in O
patients O
with O
impaired O
renal O
function O
. O

Anastrozole B-drug
inhibited O
in O
vitro O
metabolic O
reactions O
catalyzed O
by O
cytochromes O
P450 O
1A2 O
, O
2C8/9 O
, O
and O
3A4 O
but O
only O
at O
relatively O
high O
concentrations O
. O

( O
Effects O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
; O

Chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
interact O
pharmacologically O
with O
orally O
administered O
anticoagulant B-group
agents I-group
, O
but O
the O
effect O
is O
not O
clinically O
significant O
. O

Standard O
therapy O
includes O
antibiotics B-group
, O
such O
as O
penicillin B-drug
and O
gentamicin B-drug
; O

This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
prostaglandin O
synthesis O
. O

Leucovorin B-drug
: O
The O
concentration O
of O
5-fluorouracil B-drug
is O
increased O
and O
its O
toxicity O
may O
be O
enhanced O
by O
leucovorin B-drug
. O

Caution O
is O
warranted O
and O
therapeutic O
concentration O
monitoring O
is O
recommended O
for O
antiarrhythmics B-group
when O
coadministered O
with O
CRIXIVAN B-brand
. O

This O
slowing O
potentiates O
amphetamines B-group
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O

The O
majority O
of O
these O
reports O
concerned O
variable O
elevations O
in O
prothrombin O
times O
without O
clinically O
significant O
sequelae O
. O

Effects O
of O
Antacids B-group
on O
Felbatol B-brand
The O
rate O
and O
extent O
of O
absorption O
of O
a O
2400 O
mg O
dose O
of O
Felbatol B-brand
as O
monotherapy O
given O
as O
tablets O
was O
not O
affected O
when O
coadministered O
with O
antacids B-group
. O

There O
has O
been O
too O
little O
experience O
with O
the O
coadministration O
of O
TAMBOCOR B-brand
with O
nifedipine B-drug
or O
diltiazem B-drug
to O
recommend O
concomitant O
use O
. O

Because O
of O
the O
risk O
of O
increased O
exposure O
tonevirapine B-drug
, O
caution O
should O
be O
used O
inconcomitant O
administration O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
nevirapine-associated O
adverse O
events O
. O

Cardiac B-group
Glycosides I-group
: O
In O
a O
study O
of O
young O
healthy O
male O
subjects O
no O
evidence O
of O
a O
direct O
pharmacokinetic O
captopril-digoxin B-drug
interaction O
could O
be O
found O
. O

Monitor O
cardiovascular O
status O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

methadone I-drug
concentration O

There O
is O
no O
information O
regarding O
the O
effect O
on O
lamivudine B-drug
pharmacokinetics O
of O
higher O
doses O
of O
TMP/SMX B-drug
such O
as O
those O
used O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
. O

Based O
on O
known O
metabolic O
profiles O
, O
clinically O
significant O
drug O
interactions O
are O
not O
expected O
between O
VIRACEPT B-brand
and O
dapsone B-drug
, O
trimethoprim/sulfamethoxazole B-drug
, O
clarithromycin B-drug
, O
erythromycin B-drug
, O
itraconazole B-drug
or O
fluconazole B-drug
. O

Therefore O
, O
close O
monitoring O
of O
serum O
cyclosporin B-drug
level O
is O
recommended O
and O
, O
if O
necessary O
, O
chloroquine B-drug
should O
be O
discontinued O
. O

Lapatinib B-drug
inhibits O
human O
P-glycoprotein O
. O

Oral O
anticoagulants B-group
may O
potentiate O
the O
hypoglycemic O
action O
of O
hypoglycemic B-group
agents I-group
, O
eg O
, O
tolbutamide B-drug
and O
chlorpropamide B-drug
, O
by O
inhibiting O
their O
metabolism O
in O
the O
liver O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

No O
formal O
drug/drug O
interaction O
studies O
with O
Plenaxis B-brand
were O
performed O
. O

Coadministration O
of O
warfarin B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

All O
antagonists O
decreased O
the O
time O
spent O
in O
the O
light O
zone O
in O
this O
test O
, O
which O
suggested O
that O
these O
compounds O
have O
anxiogenic O
effects O
. O

iv O
. O

Nucleoside O
Analogues O
Didanosine B-drug
Co-administration O
of O
COPEGUS B-brand
and O
didanosine B-drug
is O
not O
recommended O
. O

Glutathione-S-transferase O
( O
GST O
) O
activity O
, O
however O
, O
did O
not O
differ O
from O
control O
values O
for O
any O
dose O
or O
at O
any O
time O
point O
in O
cerebral O
and O
hepatic O
tissues O
. O

Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
of O
EQUETROTM B-brand
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
or O
epoxide O
hydrolase O
inhibitors O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
reduction O
for O
EQUETROTM B-brand
may O
be O
necessary O
. O

In O
a O
ten-subject O
study O
, O
coadministration O
of O
diltiazem B-drug
( O
120 O
mg O
bid O
) O
with O
lovastatin B-drug
resulted O
in O
a O
3-4 O
times O
increase O
in O
mean O
lovastatin B-drug
AUC O
and O
Cmax O
vs. O
lovastatin B-drug
alone O
; O

. O

In O
clinical O
trials O
in O
patients O
undergoing O
PTCA/PCI O
, O
co-administration O
of O
Angiomax B-brand
with O
heparin B-drug
, O
warfarin B-drug
, O
thrombolytics B-group
or O
glycoprotein O
IIb/IIIa O
inhibitors O
was O
associated O
with O
increased O
risks O
of O
major O
bleeding O
events O
compared O
to O
patients O
not O
receiving O
these O
concomitant O
medications O
. O

Drug/Laboratory O
Test O
Interactions O
The O
urine O
of O
patients O
who O
take O
Lodine B-brand
can O
give O
a O
false-positive O
reaction O
for O
urinary O
bilirubin O
( O
urobilin O
) O
due O
to O
the O
presence O
of O
phenolic O
metabolites O
of O
etodolac B-drug
. O

Hormonal B-group
Contraceptives I-group
: O
It O
has O
not O
been O
established O
if O
there O
is O
a O
pharmacokinetic O
interaction O
between O
acitretin B-drug
and O
combined B-group
oral I-group
contraceptives I-group
. O

Beta-blockers B-group
not O
only O
block O
the O
therapeutic O
effects O
of O
beta-agonists B-group
, O
but O
may O
produce O
severe O
bronchospasm O
in O
COPD O
patients O
. O

A O
smaller O
24-week O
study O
has O
suggested O
nevirapine B-drug
may O
be O
superior O
to O
the O
PI B-group
nelfinavir B-drug
. O

Therefore O
, O
monitoring O
of O
theophylline B-drug
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-drug
adjusted O
as O
required O
. O

